PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Yu, XQ; Kanost, MR				Yu, XQ; Kanost, MR			Immulectin-2, a lipopolysaccharide specific lectin from an insect, Manduca sexta, is induced in response to gram-negative bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; C-TYPE LECTIN; BETA-1,3-GLUCAN RECOGNITION PROTEIN; PERIPLANETA LECTIN; HYPHANTRIA-CUNEA; CDNA CLONING; COCKROACH; PURIFICATION; HEMOLYMPH; SILKWORM	A lipopolysaccharide-specific lectin, immulectin-2, was isolated from plasma of the tobacco hornworm, Manduca sexta. Immulectin-2 has specificity for xylose, glucose, lipopolysaccharide, and mannan, A cDNA clone encoding immulectin-2 was isolated from an Escherichia coli-induced M. sexta larval fat body cDNA library. The cDNA is 1253 base pairs long, with an open reading frame of 981 base pairs, encoding a 327-residue polypeptide, Immulectin-2 is a member of the C-type lectin superfamily, It consists of two carbohydrate recognition domains, which is similar to the organization of M, sexta immulectin-1, Immulectin-8 was present at a constitutively low level in plasma of control larvae and increased 3-4-fold after injection of Gram negative bacteria or lipopolysaccharide, Immulectin-2 mRNA was detected in fat body of control larvae, and its level increased dramatically after injection of E. coli. The concentration of immulectin-2 in plasma did not change significantly after injection of Gram-positive bacteria or yeast, even though its mRNA level was increased by these treatments. Compared with immulectin-1, immulectin-2 has a more restricted specificity for binding to Gram-negative bacteria. Immulectin-2 at low physiological concentrations agglutinated E, coli in a calcium-dependent manner. It also bound to immobilized lipopolysaccharide from E, coli, Binding of immulectin-2 to lipopolysaccharide stimulated phenol oxidase activation in plasma. The properties of immulectin-2 are consistent with its function as a pattern recognition receptor for detection and defense against Gram-negative bacterial infection in M. sexta.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu	YU, XIAO-QIANG/AAL-1797-2021; YU, XiaoQiang/GRJ-1077-2022	YU, XIAO-QIANG/0000-0003-1419-9009; Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R29GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashida Masaaki, 1998, P135; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Chen CL, 1999, COMP BIOCHEM PHYS B, V122, P309, DOI 10.1016/S0305-0491(99)00020-6; CHEN CL, 1993, BIOCHEM J, V294, P181, DOI 10.1042/bj2940181; CHEN CL, 1995, BIOCHEM J, V310, P23, DOI 10.1042/bj3100023; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Haq S, 1996, J BIOL CHEM, V271, P20213, DOI 10.1074/jbc.271.33.20213; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jiang H, 1996, INSECT MOL BIOL, V5, P31, DOI 10.1111/j.1365-2583.1996.tb00038.x; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; JOMORI T, 1992, FEBS LETT, V296, P283, DOI 10.1016/0014-5793(92)80305-Z; JOMORI T, 1990, EUR J BIOCHEM, V190, P201, DOI 10.1111/j.1432-1033.1990.tb15565.x; Kawasaki K, 1996, INSECT BIOCHEM MOLEC, V26, P355, DOI 10.1016/0965-1748(95)00101-8; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; KUBO T, 1993, DEV BIOL, V156, P381, DOI 10.1006/dbio.1993.1085; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Matsushita M, 1996, MICROBIOL IMMUNOL, V40, P887, DOI 10.1111/j.1348-0421.1996.tb01156.x; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Shin SW, 2000, FEBS LETT, V467, P70, DOI 10.1016/S0014-5793(00)01127-3; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Vilmos P, 1998, IMMUNOL LETT, V62, P59, DOI 10.1016/S0165-2478(98)00023-6; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wilson R, 1999, J IMMUNOL, V162, P1590; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3	46	225	242	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37373	37381		10.1074/jbc.M003021200	http://dx.doi.org/10.1074/jbc.M003021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954704	hybrid			2022-12-25	WOS:000165618700011
J	Marcu, MG; Chadli, A; Bouhouche, I; Catelli, M; Neckers, LM				Marcu, MG; Chadli, A; Bouhouche, I; Catelli, M; Neckers, LM			The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90 MOLECULAR CHAPERONE; CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; DNA GYRASE; IN-VITRO; GELDANAMYCIN; KINASE; SITE; HETEROCOMPLEX; CONFORMATION	Heat shock protein 90 (Hsp90), one of the most abundant chaperones in eukaryotes, participates in folding and stabilization of signal-transducing molecules including steroid hormone receptors and protein kinases, The amino terminus of Hsp90 contains a non-conventional nucleotide-binding site, related to the ATP-binding motif of bacterial DNA gyrase. The anti-tumor agents geldanamycin and radicicol bind specifically at this site and induce destabilization of Hsp90-dependent client proteins. We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-l, and p185(ExbB2). In the present study we used deletion/mutation analysis to identify the site of interaction of novobiocin with Hsp90, and we demonstrate that the novobiocin-binding site resides in the carboxyl terminus of the chaperone. Surprisingly, this motif also recognizes ATP, and ATP and novobiocin efficiently compete with each other for binding to this region of Hsp90. Novobiocin interferes with association of the cochaperones Hsc70 and p23 with Hsp90. These results identify a second site on Hsp90 where the binding of small molecule inhibitors can significantly impact the function of this chaperone, and they support the hypothesis that both amino- and carboxyl-terminal domains of Hsp90 interact to modulate chaperone activity.	NCI, Dept Cell & Canc Biol, Med Branch, NIH, Rockville, MD 20850 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; CNRS, UPR Cochin Port Royal, F-75014 Paris, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Centre National de la Recherche Scientifique (CNRS)	Neckers, LM (corresponding author), NCI, Dept Cell & Canc Biol, Med Branch, NIH, Rockville, MD 20850 USA.				NATIONAL CANCER INSTITUTE [Z01SC010074, ZIASC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chavany C, 1996, J BIOL CHEM, V271, P4974; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Jibard N, 1999, EXP CELL RES, V247, P461, DOI 10.1006/excr.1998.4375; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Soti C, 1998, EUR J BIOCHEM, V255, P611, DOI 10.1046/j.1432-1327.1998.2550611.x; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	37	420	447	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37181	37186		10.1074/jbc.M003701200	http://dx.doi.org/10.1074/jbc.M003701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10945979	hybrid			2022-12-25	WOS:000165577700099
J	Gonzalez, E; Fernandez, MR; Larroy, C; Sola, L; Pericas, MA; Pares, X; Biosca, JA				Gonzalez, E; Fernandez, MR; Larroy, C; Sola, L; Pericas, MA; Pares, X; Biosca, JA			Characterization of a (2R,3R)-2,3-butanediol dehydrogenase as the Saccharomyces cerevisiae YAL060W gene product - Disruption and induction of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ALCOHOL-DEHYDROGENASE; BACILLUS-STEAROTHERMOPHILUS; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; ACETOIN REDUCTASE; BREWERS-YEAST; DNA-SEQUENCE; 2,3-BUTANEDIOL; PURIFICATION; FORMALDEHYDE	The completion of the Saccharomyces cerevisiae genome project-in 1996 showed that almost 60% of the potential open reading frames of the genome had no experimentally determined function. Using a conserved sequence motif present in the zinc-containing medium-chain alcohol dehydrogenases, we found several potential alcohol dehydrogenase genes with no defined function. One of these, YAL060W, was overexpressed using a multicopy inducible vector, and its protein product was purified to homogeneity. The enzyme was found to be a homodimer that, in the presence of NAD(+), but not of NADP, could catalyze the stereospecific oxidation of (2R,3R)-2,3-butanediol (K(m) = 14 mM, k(cat) = 78,000 min(-1)) and meso-butanediol (K(m) = 65 mM, k(cat) = 46,000 min(-1)) to (3R)-acetoin and (SS)-acetoin, respectively. It was unable, however, to further oxidize these acetoins to diacetyl, In the presence of NADH, it could catalyze the stereospecific reduction of racemic acetoin ((3R/3S)acetoin K(m) = 4.5 mM, k(cat) = 98,000 min(-1)) to (2R,3R)-2,3-butanediol and meso-butanediol, respectively. The substrate stereospecificity was determined by analysis of products by gas-liquid chromatography, The YALOGOW gene product can therefore be classified as an NAD-dependent (2R,3R)-2,3-butanediol dehydrogenase (BDH). S. cerevisiae could grow on 2,3-butanediol as the sole carbon and energy source. hTnder these conditions, a 3.5-fold: increase in (2R,3R)-2,3-butanediol dehydrogenase activity was observed in the total cell extracts. The isoelectric focusing pattern of the induced enzyme coincided with that of the pure BDH (pI 6.9). The disruption of the YALOGOW gene was not lethal for the yeast under laboratory conditions. The disrupted strain could also grow on 2,3-butanediol, although attaining a lesser cell density than the wild-type strain. Taking into consideration the substrate specificity of the YALOGOW gene product, we propose the name of BDH for this gene. The corresponding enzyme is the first eukaryotic (2R,3R)2,3-butanediol dehydrogenase characterized of the medium-chain dehydrogenase/reductase family.	Univ Autonoma Barcelona, Fac Sci, Dept Biochem & Mol Biol, E-08193 Bellaterra, Barcelona, Spain; Univ Barcelona, Dept Quim Organ, Unitat Recerca Sintesi Asimetr, E-08028 Barcelona, Spain	Autonomous University of Barcelona; University of Barcelona	Pares, X (corresponding author), Univ Autonoma Barcelona, Fac Sci, Dept Biochem & Mol Biol, E-08193 Bellaterra, Barcelona, Spain.	xavier.pares@uab.es	Pericàs, Miquel A./B-1085-2009; Larroy, Carol/AAB-3170-2021; Fernandez, Maria Rosario R/F-4015-2016; Biosca, Josep/G-3137-2013; Pares, Xavier/K-8228-2017	Pericàs, Miquel A./0000-0003-0195-8846; Larroy, Carol/0000-0002-4717-5612; Fernandez, Maria Rosario R/0000-0002-1750-7786; Biosca, Josep/0000-0003-2794-3124; Pares, Xavier/0000-0002-5071-9465; Gonzalez-Roca, Eva/0000-0002-1126-0321				ARONSON BD, 1989, J BIOL CHEM, V264, P5226; ATRIAN S, 1990, GENE, V93, P205, DOI 10.1016/0378-1119(90)90226-H; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLOMQVIST K, 1991, APPL ENVIRON MICROB, V57, P2796, DOI 10.1128/AEM.57.10.2796-2803.1991; BLOMQVIST K, 1993, J BACTERIOL, V175, P1392, DOI 10.1128/JB.175.5.1392-1404.1993; Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259; CHAOCHEN G, 1984, BIOCHEMISTRY-US, V23, P3576; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DREWKE C, 1988, BIOCHIM BIOPHYS ACTA, V950, P54, DOI 10.1016/0167-4781(88)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FERNANDEZ MR, 1995, FEBS LETT, V370, P23; Fernandez MR, 1999, J BIOL CHEM, V274, P37869, DOI 10.1074/jbc.274.53.37869; FERNANDEZ MR, 1998, THESIS U AUTONOMA BA; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; Giovannini PP, 1996, TETRAHEDRON, V52, P1669, DOI 10.1016/0040-4020(95)00995-7; Giovannini PP, 1996, BIOORGAN MED CHEM, V4, P1197; HEIDLAS J, 1990, EUR J BIOCHEM, V188, P165, DOI 10.1111/j.1432-1033.1990.tb15384.x; HEIDLAS J, 1990, ARCH MICROBIOL, V154, P267, DOI 10.1007/BF00248966; HOOG JO, 1993, ENZYMOLOGY MOL BIOL, V4, P439; HUANG M, 1994, FEMS MICROBIOL LETT, V124, P141, DOI 10.1111/j.1574-6968.1994.tb07276.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JORNVALI H, 1977, EUR J BIOCHEM, V16, P25; JORNVALL H, 1993, ENZYMOLOGY MOL BIOL, V4, P533; JORNVALL H, 1994, MOL BASIS ALCOHOL US, P221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebs P., 1969, Nahrung, V13, P455, DOI 10.1002/food.19690130602; NEISH AC, 1950, CAN J RES B, V28, P660, DOI 10.1139/cjr50b-079; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PERSSON B, 1993, FEBS LETT, V324, P9, DOI 10.1016/0014-5793(93)81522-2; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; PLAPP BV, 1991, ADV EXP MED BIOL, V284, P241; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; Richard P, 1999, FEBS LETT, V457, P135, DOI 10.1016/S0014-5793(99)01016-9; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; ROMANO P, 1993, FEMS MICROBIOL LETT, V108, P23; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SARTHY AV, 1994, GENE, V140, P121, DOI 10.1016/0378-1119(94)90741-2; Smania AM, 1997, GENE, V197, P231, DOI 10.1016/S0378-1119(97)00267-9; STIVERS JT, 1993, BIOCHEMISTRY-US, V32, P13472, DOI 10.1021/bi00212a012; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; SUOMALAINEN H, 1968, NATURE, V220, P792, DOI 10.1038/220792a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITTEL D, 1979, MONAT BRAUEREI, V32, P260; Ui S, 1997, J FERMENT BIOENG, V84, P185, DOI 10.1016/S0922-338X(97)82052-1; Ui S, 1998, J FERMENT BIOENG, V86, P290, DOI 10.1016/S0922-338X(98)80132-3; VERDUYN C, 1988, YEAST, V4, P127, DOI 10.1002/yea.320040206; VERDUYN C, 1988, YEAST, V4, P135, DOI 10.1002/yea.320040207; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; Wilkin JM, 1999, EUR J BIOCHEM, V262, P299, DOI 10.1046/j.1432-1327.1999.00369.x; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; WILLS C, 1979, EUR J BIOCHEM, V99, P323, DOI 10.1111/j.1432-1033.1979.tb13260.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; YOUNG ET, 1985, MOL CELL BIOL, V5, P3024, DOI 10.1128/MCB.5.11.3024	60	107	139	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35876	35885		10.1074/jbc.M003035200	http://dx.doi.org/10.1074/jbc.M003035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10938079	hybrid			2022-12-25	WOS:000165382000035
J	Tcherkasskaya, O; Bychkova, VE; Uversky, VN; Gronenborn, AM				Tcherkasskaya, O; Bychkova, VE; Uversky, VN; Gronenborn, AM			Multisite fluorescence in proteins with multiple tryptophan residues - Apomyoglobin natural variants and site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREQUENCY-DOMAIN FLUOROMETRY; MOLTEN GLOBULE INTERMEDIATE; SPERM WHALE APOMYOGLOBINS; STRUCTURAL CHARACTERIZATION; CONFORMATIONAL PROPERTIES; FOLDING REACTIONS; ESCHERICHIA-COLI; ENERGY-TRANSFER; MYOGLOBIN; STATE	Time-resolved fluorescence experiments were carried out on a variety of apomyoglobins with one or two tryptophan (Trp) residues located at invariant positions 7 and 14 in the primary sequence. In all cases, the Trp fluorescence kinetics were resolved adequately into two discrete lifetime domains, and decay-associated spectra (DAS) were obtained for each decay component. The DAS resolved for unfolded proteins were indistinguishable by position of the emission maxima and the spectral shapes. The folded proteins revealed noticeable differences in the DAS, which relate to the diverse local environments around the Trp residues in the individual proteins. Furthermore, the DAS of wild-type protein possessing two Trp residues were simulated well by that of one Trp mutants either in the native, molten globule, or unfolded states. Overall, employing Trp fluorescence and site-directed mutagenesis allowed us to highlight the conformational changes induced by the single amino acid replacement and generate novel structural information on equilibrium folding intermediates. Specifically, it was found that conformational fluctuations in the local cluster around the evolutionarily conserved Trp(14) are very similar in the native and molten globule states of apomyoglobins, This result indicates that residues in the E and B helices contributing to this cluster are most likely involved in the stabilization of the overall architecture of the structured molten globule intermediate.	NCI, Lab Expt & Computat Biol, NIH, Bethesda, MD 20892 USA; Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; University of California System; University of California Santa Cruz; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Tcherkasskaya, O (corresponding author), NCI, Lab Expt & Computat Biol, NIH, Bethesda, MD 20892 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Gronenborn, Angela M/0000-0001-9072-3525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1970, BIOCHEMISTRY-US, V9, P4723, DOI 10.1021/bi00826a015; BALESTRIERI C, 1978, COMP BIOCHEM PHYS B, V60, P195, DOI 10.1016/0305-0491(78)90130-X; Ballew RM, 1996, NAT STRUCT BIOL, V3, P923, DOI 10.1038/nsb1196-923; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BISMUTO E, 1989, BIOCHEMISTRY-US, V28, P1508, DOI 10.1021/bi00430a013; BISMUTO E, 1994, J MOL BIOL, V241, P103, DOI 10.1006/jmbi.1994.1477; BOENS N, 1990, P SPIE C TIME RESOLV, V2, P456; Chang Y, 1997, BIOCHEMISTRY-US, V36, P7652, DOI 10.1021/bi970197g; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; COCCO MJ, 1990, BIOCHEMISTRY-US, V29, P11067, DOI 10.1021/bi00502a008; Demchenko A. P., 1992, TOPICS FLUORESCENCE, V3, P65; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; EFTINK MR, 1987, BIOCHEMISTRY-US, V26, P8338, DOI 10.1021/bi00399a047; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hudson BS, 1999, J PHYS CHEM A, V103, P2227, DOI 10.1021/jp983585g; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IRACE G, 1981, BIOCHEMISTRY-US, V20, P792, DOI 10.1021/bi00507a022; JANES SM, 1987, BIOPHYS J, V51, P653, DOI 10.1016/S0006-3495(87)83390-8; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kay MS, 1996, NAT STRUCT BIOL, V3, P439, DOI 10.1038/nsb0596-439; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1999, PRINCIPLES FLUROESCE, P487; LATTMAN EE, 1971, J MOL BIOL, V60, P271, DOI 10.1016/0022-2836(71)90293-2; Lecomte JTJ, 1999, PROTEIN SCI, V8, P1484, DOI 10.1110/ps.8.7.1484; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; Morawetz H, 1999, J POLYM SCI POL CHEM, V37, P1725, DOI 10.1002/(SICI)1099-0518(19990615)37:12<1725::AID-POLA1>3.0.CO;2-D; Park SH, 1999, NAT STRUCT BIOL, V6, P943, DOI 10.1038/13311; POKALSKY C, 1995, J BIOL CHEM, V270, P3809, DOI 10.1074/jbc.270.8.3809; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P223, DOI 10.1111/j.1432-1033.1991.tb16005.x; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ptitsyn OB, 1999, J MOL BIOL, V291, P671, DOI 10.1006/jmbi.1999.2920; Rischel C, 1996, J MOL BIOL, V257, P877, DOI 10.1006/jmbi.1996.0208; Sillen A, 1999, PROTEINS, V37, P253, DOI 10.1002/(SICI)1097-0134(19991101)37:2<253::AID-PROT10>3.0.CO;2-J; Sillen A, 2000, PROTEIN SCI, V9, P158; Sirangelo I, 2000, BBA-PROTEIN STRUCT M, V1476, P173, DOI 10.1016/S0167-4838(99)00257-5; Sirangelo I, 1998, EUR BIOPHYS J BIOPHY, V27, P27, DOI 10.1007/s002490050107; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; Tanio M, 1999, BIOPHYS J, V77, P431, DOI 10.1016/S0006-3495(99)76901-8; Tcherkasskaya O, 2000, BIOCHEMISTRY-US, V39, P1879, DOI 10.1021/bi992117+; Tcherkasskaya O, 1999, FEBS LETT, V455, P325, DOI 10.1016/S0014-5793(99)00792-9; Tcherkasskaya O, 1999, PROTEIN ENG, V12, P485, DOI 10.1093/protein/12.6.485; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; WASYLEWSKI Z, 1988, EUR J BIOCHEM, V172, P719, DOI 10.1111/j.1432-1033.1988.tb13948.x; [No title captured]	55	28	28	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36285	36294		10.1074/jbc.M003008200	http://dx.doi.org/10.1074/jbc.M003008200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948189	hybrid			2022-12-25	WOS:000165382000091
J	Peirce, M; Metzger, H				Peirce, M; Metzger, H			Detergent-resistant microdomains offer no refuge for proteins phosphorylated by the IgE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BASOPHILIC LEUKEMIA-CELLS; HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; ACTIVATION; PHOSPHATASES; MECHANISM	When the high affinity receptor for IgE and related receptors become aggregated, they emigrate to specialized microdomains of the plasma membrane that are enriched in certain lipids and lipid-anchored proteins. Among the latter are the kinases that initiate signaling cascade(s) by phosphorylating the receptors. In studying the IgE receptor, we explored whether, in addition to their potential role in enhancing the initiation of signaling by the kinase(s), the microdomains might augment the stimulation by excluding phosphatases. In vitro assessment of phosphatase activity, using either a relevant or irrelevant substrate, suggested that the microdomains were deficient in phosphatase activity, but, in vivo, proteins confined to the microdomains were found to be no less vulnerable to dephosphorylation than those outside such domains. In the course of our experiments, we observed that the procedures routinely used to isolate the detergent-resistant domains dissociated the receptor for IgE, thereby artificially accentuating the observed preferential distribution of phosphorylated subunits in the microdomains.	NIAMS, Arthritis & Rheumatism Branch, Sect Chem Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Metzger, H (corresponding author), NIAMS, Arthritis & Rheumatism Branch, Sect Chem Immunol, NIH, Bldg 10,Rm 9N-228,10 Ctr Dr,MSC-1820, Bethesda, MD 20892 USA.		Peirce, Matthew/ABB-9577-2021	Peirce, Matthew/0000-0003-3648-5639	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ALBER G, 1992, J IMMUNOL, V149, P2428; ALCARAZ G, 1984, J BIOL CHEM, V259, P4922; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Baird B, 1999, BIOPHYS CHEM, V82, P109, DOI 10.1016/S0301-4622(99)00110-6; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; EISEMAN E, 1992, NATURE, V355, P78; FEWTRELL C, 1980, J IMMUNOL, V125, P701; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Grucza RA, 1999, BIOCHEMISTRY-US, V38, P5024, DOI 10.1021/bi9829938; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; Kimura T, 1997, J IMMUNOL, V159, P4426; KINET JP, 1985, BIOCHEMISTRY-US, V24, P4117, DOI 10.1021/bi00336a046; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LIU FT, 1980, J IMMUNOL, V124, P2728; Mao SY, 1997, J BIOL CHEM, V272, P14067, DOI 10.1074/jbc.272.22.14067; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RIVNAY B, 1982, J BIOL CHEM, V257, P2800; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Stephan V, 1997, CELL SIGNAL, V9, P65, DOI 10.1016/S0898-6568(96)00093-9; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792	42	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34976	34982		10.1074/jbc.M005819200	http://dx.doi.org/10.1074/jbc.M005819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956655	hybrid			2022-12-25	WOS:000165422800022
J	Kasahara, K; Watanabe, K; Takeuchi, K; Kaneko, H; Oohira, A; Yamamoto, T; Sanai, Y				Kasahara, K; Watanabe, K; Takeuchi, K; Kaneko, H; Oohira, A; Yamamoto, T; Sanai, Y			Involvement of gangliosides in glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule TAG-1 signaling in lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; PROTEIN-TYROSINE KINASE; CHONDROITIN SULFATE PROTEOGLYCAN; ENRICHED MEMBRANE SUBDOMAINS; CAVEOLAE-LIKE DOMAINS; MELANOMA B16 CELLS; FC-EPSILON-RI; IMMUNOGLOBULIN SUPERFAMILY; PLASMA-MEMBRANE; NERVOUS-SYSTEM	The association of ganglioside GD3 with TAG-1, a glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule, was examined by coimmunoprecipitation experiments. Previously, we have shown that the anti-ganglioside GD3 antibody (R24) immunoprecipitated the Src family kinase Lyn from the rat cerebellum, and R24 treatment of primary cerebellar cultures induced Lyn activation and rapid tyrosine phosphorylation of an 80-kDa protein (p80), We now report that R24 coimmunoprecipitates a 135-kDa protein (p135) from primary cerebellar cultures. Treatment with phosphatidylinositol-specific phospholipase C revealed that p135 was glycosylphosphatidylinositol-anchored to the membrane. It was identified as TAG-1 by sequential immunoprecipitation with an anti-TAG-1 antibody. Antibody-mediated cross-linking of TAG-1 induced Lyn activation and rapid tyrosine phosphorylation of p80. Selective inhibitor for Src family kinases reduced the tyrosine phosphorylation of p80. Sucrose density gradient analysis revealed that the TAG-1 and tyrosine-phosphorylated p80 in cerebellar cultures were present in the lipid raft fraction. These data show that TAG-1 transduces signals via Lyn to p80 in the lipid rafts of the cerebellum. Furthermore, degradation of cell-surface glycosphingolipids by endoglycoceramidase induced an alteration of TAG-1 distribution on an OptiPrep gradient and reduced the TAG-1-mediated Lyn activation and tyrosine phosphorylation of p80, These observations suggest that glycosphingolipids are involved in TAG-1-mediated signaling in lipid rafts.	Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Gerontol, Dept Cell Recognit, Itabashi Ku, Tokyo 1730015, Japan; Inst Dev Res, Dept Perinatol & Neuroglycosci, Kasugai, Aichi 4800392, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1080071, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Gerontology; University of Tokyo	Kasahara, K (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, 3-18-22 Honkagome, Tokyo 1138613, Japan.	kasahara@rinshoken.or.jp	Takeuchi, Kosei/AAV-3577-2021	Takeuchi, Kosei/0000-0001-6397-2243; Kasahara, Kohji/0000-0001-7010-8365				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buttiglione M, 1998, J NEUROSCI, V18, P6853; Chen S, 1996, DEV BRAIN RES, V92, P140, DOI 10.1016/0165-3806(95)00208-1; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Draberova L, 1996, IMMUNOLOGY, V87, P141; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Henke RC, 1997, J NEUROSCI RES, V49, P655, DOI 10.1002/(SICI)1097-4547(19970915)49:6<655::AID-JNR1>3.3.CO;2-0; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; ITO M, 1991, J BIOL CHEM, V266, P7919; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kasahara K, 1999, BIOPHYS CHEM, V82, P121, DOI 10.1016/S0301-4622(99)00111-8; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; KNIEP B, 1994, BIOCHEM BIOPH RES CO, V203, P1069, DOI 10.1006/bbrc.1994.2291; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; KUHAR SG, 1993, DEVELOPMENT, V117, P97; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; Levi G., 1989, DISSECTION TISSUE CU, P211; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; PURPURA DP, 1978, NATURE, V276, P520, DOI 10.1038/276520a0; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1999, MOL BIOL CELL, V10, P3187, DOI 10.1091/mbc.10.10.3187; SKAPER SD, 1985, DEV BRAIN RES, V23, P19, DOI 10.1016/0165-3806(85)90003-3; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Surviladze Z, 1998, EUR J IMMUNOL, V28, P1847, DOI 10.1002/(SICI)1521-4141(199806)28:06<1847::AID-IMMU1847>3.0.CO;2-O; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMAKAWA T, 1978, TRENDS BIOCHEM SCI, V3, P128, DOI 10.1016/S0968-0004(78)80031-0; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; YOSHIHARA Y, 1995, J NEUROBIOL, V28, P51, DOI 10.1002/neu.480280106; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	77	131	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34701	34709		10.1074/jbc.M003163200	http://dx.doi.org/10.1074/jbc.M003163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944523	hybrid			2022-12-25	WOS:000165095300094
J	Perrin, RJ; Woods, WS; Clayton, DF; George, JM				Perrin, RJ; Woods, WS; Clayton, DF; George, JM			Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids - Structural analysis using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-SYSTEM ATROPHY; GLIAL CYTOPLASMIC INCLUSIONS; ALZHEIMERS-DISEASE; LEWY BODIES; SECONDARY STRUCTURE; PRECURSOR PROTEIN; AMPHIPATHIC HELIX; NERVOUS-SYSTEM; VESICLES; MUTATION	alpha -Synuclein has been centrally implicated in neurodegenerative disease, and a normal function in developmental synaptic plasticity has been suggested by studies in songbirds. A variety of observations suggest the protein partitions between membrane and cytosol, a behavior apparently conferred by a conserved structural similarity to the exchangeable apolipoproteins. Here we show that the capacity to bind lipids is broadly distributed across exons 3, 4, and 5 (encoding residues 1-102), Binding to phosphatidylserine-containing vesicles requires the presence of all three exons, while binding to phosphatidic acid can be mediated by any one of the three. Consistent with a "class A2" helical binding mechanism, lipid association is disrupted by introduction of charged residues along the hydrophobic face of the predicted cu-helix and also by biotinylation of conserved lysines (which line the interfacial region). Circular dichroism spectroscopy reveals a general correlation between the amount of lipid-induced alpha -helix content and the degree of binding to PS-containing vesicles. Two point mutations associated with Parkinson's disease have little (A30P) or no (A53T) effect on lipid binding or a-helicity. These results are consistent with the hypothesis that alpha -synuclein's normal functions depend on an ability to undergo a large conformational change in the presence of specific phospholipids.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	George, JM (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin, Urbana, IL 61801 USA.		Clayton, David/B-2190-2008; George, Julia M/B-2169-2008; Woods, Wendy/B-6602-2008	Clayton, David/0000-0002-6395-3488; George, Julia M/0000-0001-6194-6914; 	NIA NIH HHS [1R01 AG13762] Funding Source: Medline; NIGMS NIH HHS [5T32GM07143-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013762] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; Dittman JS, 1998, J NEUROSCI, V18, P6147; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gomis A, 1999, J NEUROSCI, V19, P6309; GREEN N. M., 1970, Methods in Enzymology, V18A, P418, DOI 10.1016/0076-6879(71)18342-5; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; HUANG KP, 1993, NEUROCHEM INT, V22, P417, DOI 10.1016/0197-0186(93)90037-6; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6	42	338	343	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34393	34398		10.1074/jbc.M004851200	http://dx.doi.org/10.1074/jbc.M004851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952980	hybrid			2022-12-25	WOS:000165095300054
J	Schuler-Metz, A; Knochel, S; Kaufmann, E; Knochel, W				Schuler-Metz, A; Knochel, S; Kaufmann, E; Knochel, W			The homeodomain transcription factor Xvent-2 mediates autocatalytic regulation of BMP-4 expression in Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-4; HOMEOBOX GENE; HEMATOPOIETIC MESODERM; VENTRALIZING FACTOR; INDUCTION; DROSOPHILA; PROMOTER; LAEVIS; DEFINES; SUPPRESSION	Like other genes of the transforming growth factor-p family, the BMP-4 gene is regulated by an autocatalytic loop. In Xenopus embryos this loop can be ectopically induced by injection of BMP-2 RNA. However, cycloheximide treatment subsequent to BMP-2 overexpression revealed that BMP signaling is not direct but requires additional factor(s), As putative mediator we have identified Xvent-2 which is activated by BMP-2/4 signaling and, in turn, activates BMP-4 transcription. Using promoter/reporter assays we have delineated Xvent-2 responsive elements within the BMP-4 gene. We further demonstrate that Xvent-2 which has recently been characterized as a transcriptional repressor can also act, context dependent, as an activator binding two copies of a 5'-CTAATT-3' motif in the second intron of the BMP-4 gene. Replacement of Xvent-2 target sites within the goosecoid (gsc) promoter by the BMP-4 enhancer converts Xvent-2 caused repression of gse to strong activation. This switch is obviously due to adjacent nucleotides probably binding a transcriptional co-activator interacting with Xvent-2, A model is presented describing the mechanism of BMP-4 gene activation in Xenopus embryos at the early gastrula stage.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Ulm University	Knochel, W (corresponding author), Univ Ulm, Biochem Abt, Albert Einstein Allee 11, D-89081 Ulm, Germany.							Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; CLEMENT JH, 1995, MECH DEVELOP, V52, P357, DOI 10.1016/0925-4773(95)00413-U; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Friedle H, 1998, EMBO J, V17, P2298, DOI 10.1093/emboj/17.8.2298; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARPER JW, 1993, CELL, V75, P805; Hild M, 1999, DEVELOPMENT, V126, P2149; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HURSH DA, 1993, DEVELOPMENT, V117, P1211; JACKSON PD, 1994, DEV DYNAM, V199, P28, DOI 10.1002/aja.1001990104; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; Kim J, 1998, BIOCHEM BIOPH RES CO, V250, P516, DOI 10.1006/bbrc.1998.9280; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KURIHARA T, 1993, BIOCHEM BIOPH RES CO, V192, P1049, DOI 10.1006/bbrc.1993.1523; LADHER R, 1996, DEVELOPMENT, V122, P1769; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Melby AE, 1999, DEV BIOL, V211, P293, DOI 10.1006/dbio.1999.9296; Metz A, 1998, MECH DEVELOP, V74, P29, DOI 10.1016/S0925-4773(98)00059-8; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Papalopulu N, 1996, DEV BIOL, V174, P104, DOI 10.1006/dbio.1996.0055; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; Shapira E, 2000, MECH DEVELOP, V90, P77, DOI 10.1016/S0925-4773(99)00283-X; SHODA A, 1993, GROWTH FACTORS, V8, P165, DOI 10.3109/08977199309011019; Shore EM, 1998, CALCIFIED TISSUE INT, V63, P221, DOI 10.1007/s002239900518; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Sykes TG, 1998, DEVELOPMENT, V125, P4595; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; Trindade M, 1999, DEV BIOL, V216, P442, DOI 10.1006/dbio.1999.9507; Ueno N, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046927; vandenWijngaard A, 1996, BIOCHEM BIOPH RES CO, V219, P789, DOI 10.1006/bbrc.1996.0312; YAMAJI N, 1994, BIOCHEM BIOPH RES CO, V205, P1944, DOI 10.1006/bbrc.1994.2898	49	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34365	34374		10.1074/jbc.M003915200	http://dx.doi.org/10.1074/jbc.M003915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938274	hybrid			2022-12-25	WOS:000165095300051
J	Zhang, YL; Yao, ZJ; Sarmiento, M; Wu, L; Burke, TR; Zhang, ZY				Zhang, YL; Yao, ZJ; Sarmiento, M; Wu, L; Burke, TR; Zhang, ZY			Thermodynamic study of ligand binding to protein-tyrosine phosphatase 1B and its substrate-trapping mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTHALPY-ENTROPY COMPENSATION; SOLID-PHASE SYNTHESIS; TITRATION CALORIMETRY; O-PHOSPHOTYROSINE; TRANSITION-STATE; INSULIN-RECEPTOR; CRYSTAL-STRUCTURE; INHIBITOR DESIGN; FOCAL ADHESIONS; SIGNATURE MOTIF	The binding of several phosphonodifluoromethyl phenylalanine (F(2)Pmp)-containing peptides to protein-tyrosine phosphatase 1B (PTP1B) and its substrate-trapping mutants (C215S and D181A) has been studied using isothermal titration calorimetry. The binding of a high affinity ligand, Ac-Asp-Ala-Asp-Glu-F(2)Pmp-Leu-NH2, to PTP1B (K-d = 0.24 muM) is favored by both enthalpic and entropic contributions. Disruption of ionic interactions between the side chain of Arg-47 and the N-terminal acidic residues reduces the binding affinity primarily through the reduction of the T DeltaS term. The role of Arg-47 may be to maximize surface contact between PTP1B and the peptide, which contributes to high affinity binding. The active site Cys-215-->Ser mutant PTP1B binds ligands with the same affinity as the wild-type enzyme. However, unlike wild-type PTP1B, peptide binding to C215S is predominately driven by enthalpy change, which likely results from the elimination of the electrostatic repulsion between the thiolate anion and the phosphonate group. The increased enthalpic contribution is offset by reduction in the binding entropy, which may be the result of increased entropy of the unbound protein caused by this mutation. The general acid-deficient mutant D181A binds the peptide 5-fold tighter than the C215S mutant, consistent with the observation that the Asp to Ala mutant is a better "substrate-trapping" reagent than C215S, The increased binding affinity for D181A as compared with the wildtype PTP1B results primarily from an increase in the DeltaH of binding in the mutant, which may be related to decreased electrostatic repulsion between the phosphate moiety and PTP1B, These results have important implications for the design of high affinity PTP1B inhibitors.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; NCI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Burke, Terrence R/N-2601-2014	Burke, Terrence/0000-0001-9925-8586	NIGMS NIH HHS [5T32-GM-07491, GM-55242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491, R01GM055242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Alhambra C, 1998, J AM CHEM SOC, V120, P3858, DOI 10.1021/ja972578n; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CONNELLY PR, 1990, BIOCHEMISTRY-US, V29, P6108, DOI 10.1021/bi00477a031; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Glover NR, 1999, BIOCHEMISTRY-US, V38, P5256, DOI 10.1021/bi9825450; GORDEEV MF, 1994, TETRAHEDRON LETT, V35, P7585, DOI 10.1016/S0040-4039(00)78349-3; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HINTZ HJ, 1983, ANNU REV BIOPHYS BIO, V12, P285; Hoff RH, 1999, J AM CHEM SOC, V121, P9514, DOI 10.1021/ja992361o; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JUSZEZAK LJ, 1997, BIOCHEMISTRY-US, V26, P2227; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SIGURSKJOLD BW, 1994, BIOCHEMISTRY-US, V33, P10191, DOI 10.1021/bi00199a048; SMYTH MS, 1994, TETRAHEDRON LETT, V35, P551, DOI 10.1016/S0040-4039(00)75835-7; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wang F, 1998, BIOCHEMISTRY-US, V37, P15289, DOI 10.1021/bi981481q; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wrobel J, 1999, J MED CHEM, V42, P3199, DOI 10.1021/jm990260v; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	63	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34205	34212		10.1074/jbc.M004490200	http://dx.doi.org/10.1074/jbc.M004490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952978	hybrid			2022-12-25	WOS:000165095300030
J	Lee, SH; Schloss, DJ; Swain, JL				Lee, SH; Schloss, DJ; Swain, JL			Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; NUCLEAR-LOCALIZATION; TARGETED EXPRESSION; TRANSGENIC MICE; IN-VITRO; FGF; ANGIOGENESIS; TRANSDUCTION; VASCULOGENESIS; FAMILY	Basic fibroblast growth factor (FGF)-2 is important for vessel formation and/or maintenance of vascular integrity in the embryo. FGF signaling may be mediated through transmembrane tyrosine kinase receptors or directly through intracellular pathways that do not involve receptor activation. To determine the role of receptor-mediated signaling in endothelial cells, an adenovirus encoding truncated FGF receptor (FGFR)-1, under the control of the cytomegalovirus promoter, was expressed in endothelial cells. FGF signaling was impaired, as indicated by inhibition of MAPK phosphorylation, Functional consequences included inhibition of endothelial cell migration and induction of apoptosis. To address the role of endothelial FGFR signaling in vascular development, recombinant adenovirus encoding a dominant-negative FGFR was injected into the sinus venosus of embryonic day 9.0 cultured mouse embryos. Previous studies demonstrated that transgenes delivered via adenovirus, under the control of the cytomegalovirus promoter, are expressed selectively in the developing vasculature, Embryos expressing a control adenovirus developed normally, whereas those expressing the FGFR-1 mutant exhibited abnormal embryonic and extra-embryonic vascular development. These data demonstrate that FGF, by signaling through the FGFR, plays a pivotal role in the development and maintenance of a mature vascular network in the embryo.	Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford University	Swain, JL (corresponding author), Stanford Univ, Dept Med, Sch Med, S-102,300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026831, T32HL007708, R01HL026831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26831, T32 HL07708] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Baldwin HS, 1997, GENE THER, V4, P1142, DOI 10.1038/sj.gt.3300525; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BIKALVI A, 1995, J CELL BIOL, V129, P233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FLAMME I, 1993, ANAT REC, V237, P49, DOI 10.1002/ar.1092370106; FLAMME I, 1992, DEVELOPMENT, V116, P435; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HERBERT JM, 1994, CELL, V78, P1017; Hogan B, 1994, MANIPULATING MOUSE E; HUANG L, 1995, MOL CELL BIOL, V16, P1349; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; Leconte I, 1998, DEV DYNAM, V213, P421, DOI 10.1002/(SICI)1097-0177(199812)213:4<421::AID-AJA7>3.0.CO;2-B; Levine JE, 1995, NEUROIMMUNOMODULAT, V2, P290, DOI 10.1159/000097208; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MINA T, 1995, P NATL ACAD SCI USA, V92, P467; Miyamoto T, 1998, J CELL PHYSIOL, V177, P58, DOI 10.1002/(SICI)1097-4652(199810)177:1<58::AID-JCP6>3.0.CO;2-D; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scata KA, 1999, EXP CELL RES, V250, P10, DOI 10.1006/excr.1999.4506; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; STRUM K, 1993, METHOD ENZYMOL, V225, P164; UENO H, 1992, J BIOL CHEM, V267, P1470; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; YAMAGUCHI TP, 1994, GENE DEV, V8, P3022; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	58	71	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33679	33687		10.1074/jbc.M004994200	http://dx.doi.org/10.1074/jbc.M004994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930413	hybrid			2022-12-25	WOS:000090104600070
J	Pena, MMO; Puig, S; Thiele, DJ				Pena, MMO; Puig, S; Thiele, DJ			Characterization of the Saccharomyces cerevisiae high affinity copper transporter Ctr3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MAC1; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; SECRETORY PATHWAY; QUALITY-CONTROL; IRON TRANSPORT; YEAST; PROTEIN; GENE; EXPRESSION	Copper is an essential nutrient required for the activity of a number of enzymes with diverse biological roles, In the bakers' yeast Saccharomyces cerevisiae, copper is transported into cells by two high affinity copper transport proteins, Ctr1 and Ctr3. Although Ctr1 and Ctr3 are functionally redundant, they bear little homology at the amino acid sequence level, In this report, me characterize Ctr3 with respect to its localization, assembly, and post-transcriptional regulation. Ctr3 is an integral membrane protein that assembles as a trimer to form a competent copper uptake permease at the plasma membrane, Whereas the CTR1 and CTR3 genes are similarly regulated at the transcriptional level in response to copper, post-transcriptional regulation of these proteins is distinct, Unlike Ctr1, the Ctr3 transporter is neither regulated at the level of protein degradation nor endocytosis as a function of elevated copper levels. Our studies suggest that Ctr3 constitutes a fundamental module found in all eukaryotic high affinity copper transporters to date, which is sufficient for copper uptake but lacks elements for post-transcriptional regulation by copper.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018089, R01GM041840] Funding Source: NIH RePORTER; NIGMS NIH HHS [5F32GM18089, GM41840] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder M, 1991, BIOCH COPPER; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rolfs A, 1999, J PHYSIOL-LONDON, V518, P1, DOI 10.1111/j.1469-7793.1999.0001r.x; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711	44	147	150	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33244	33251		10.1074/jbc.M005392200	http://dx.doi.org/10.1074/jbc.M005392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924521	hybrid			2022-12-25	WOS:000090104600012
J	Wong, J; Ishiai, M; Kurosaki, T; Chan, AC				Wong, J; Ishiai, M; Kurosaki, T; Chan, AC			Functional complementation of BLNK by SLP-76 and LAT linker proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; TYROSINE-PHOSPHORYLATED SLP-76; ANTIGEN RECEPTOR; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; EXCHANGE FACTOR; RAS PATHWAY; B-CELLS; ACTIVATION	Recent studies have demonstrated a requirement for the SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa) and LAT (linker for activation of cells) adaptor/linker proteins in T cell antigen receptor activation and T cell development as well as the BLNK. (B cell linker) linker protein in B cell antigen receptor (BCR) signal transduction and B cell development. Whereas the SLP-76 and LAT adaptor proteins are expressed in T, natural killer, and myeloid cells and platelets, BLNK is preferentially expressed in B cells and monocytes, Although BLNK is structurally homologous to SLP-76, BLNK interacts with a variety of downstream signaling proteins that interact directly with both SLP-76 and LAT, Here, we demonstrate that neither SLP-76 nor LAT alone is sufficient to restore the signaling deficits observed in BLNK-deficient B cells. Conversely, the coexpression of SLP-76 and LAT together restored BCR-inducible calcium responses as well as activation of all three families of mitogen-activated protein kinases, Together, these data suggest functional complementation of SLP-76 and LAT in T cell antigen receptor function with BLNK in BCR function.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Nephrol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Rheumatol, Dept Internal Med & Pathol, St Louis, MO 63110 USA; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Kansai Medical University	Chan, AC (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,POB 8022, St Louis, MO 63110 USA.	achan@im.wustl.edu	Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X	NIAID NIH HHS [R01AI42787, K08AI0168702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001687, R01AI042787] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Musci MA, 1997, J IMMUNOL, V159, P1639; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33116	33122		10.1074/jbc.M004467200	http://dx.doi.org/10.1074/jbc.M004467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934198	hybrid			2022-12-25	WOS:000090003800100
J	Verastegui, C; Bille, K; Ortonne, JP; Ballotti, R				Verastegui, C; Bille, K; Ortonne, JP; Ballotti, R			Regulation of the microphthalmia-associated transcription factor gene by the Waardenburg syndrome type 4 gene, SOX10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; MUTATIONS; MITF; PROTEIN; LEF-1	The absence of melanocytes from the cochlea and epidermis is responsible of deafness and hypopigmentation, two symptoms shared by the four Waardenburg syndrome (WS) subtypes, Microphthalmia-associated transcription factor (MITF) controls melanocyte survival and differentiation. Mutations, which impair MITF function or expression, result in an abnormal melanocyte development leading to the WS2, WS1 and WS3 are caused by mutation in the gene encoding the transcription factor Pax3, which regulates MITF expression. Recently, mutations in SOX10, a gene encoding a SRY-related transcription factor, have been reported in patients with WS4, However, the molecular basis of the defective melanocyte development in these patients remained to be elucidated. In the present report, we demonstrate that Sox10 is a strong activator of the MITF promoter, and we identify a Sox10 binding site between -264 and -266 of the MITF promoter. Finally, we show that three SOX10 mutations found in WS4 abolish the transcriptional activity of the resulting Sox10 proteins toward the MITF promoter. Taken together, our observations bring new and meaningful information concerning the molecular process that leads to a defective melanocyte development in WS4 patients with SOX10 mutations.	Fac Med, INSERM, U385, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice, France.	ballotti@unice.fr	BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; UDONO T, 2000, BIOCHIM BIOPHYS ACTA, V149, P2005; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283	20	135	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30757	30760		10.1074/jbc.C000445200	http://dx.doi.org/10.1074/jbc.C000445200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10938265	hybrid			2022-12-25	WOS:000089762700004
J	Marchio, AS; Pineau, P; Meddeb, M; Terris, B; Tiollais, P; Bernheim, A; Dejean, A				Marchio, AS; Pineau, P; Meddeb, M; Terris, B; Tiollais, P; Bernheim, A; Dejean, A			Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients	ONCOGENE			English	Article						HCC; HBV; non-B; non-C; losses; amplifications	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN HEPATOCELLULAR CARCINOMAS; SQUAMOUS-CELL CARCINOMA; GENETIC CHANGES; TUMOR-SUPPRESSOR; ALLELIC LOSSES; SOLID TUMORS; SHORT ARM; HETEROZYGOSITY; DELETIONS	To discriminate among the chromosomal abnormalities associated with the etiology of hepatocellular carcinoma (HCC), we performed a comparative genomic hybridization (CGH) analysis on 34 HCCs resected on noncirrhotic livers from patients serologically negative for both hepatitis B (HBV) and C (HCV) viruses. The results mere compared to those of a previous analysis of 50 HCCs selected on the basis of their positivity for HBV infection, The majority of the abnormalities found in the HBV positive cases (losses of chromosome arms 1p, 8p, 6q, 13q and 14q and gains of 1q, 8q, 6p and 17q) were similarly detected in the virus negative specimens. In contrast, a significant decrease (40% on average) was observed for losses at 4q, 16q and 17p in non-viral HCC samples, suggesting that these abnormalities are tightly associated with HBV infection. Thus, in addition to a common pathway towards malignancy, a subset of alterations may preferentially contribute to virus-induced carcinogenesis. In a parallel CGH study of 10 fibrolamellar carcinomas, a rare subtype of HCC, me found in sis out of the seven informative cases, gains of chromosome arm Iq, This region, which is also preferentially amplified in non fibrolamellar tumors (58%), may contain an essential proto-oncogene commonly implicated in liver carcinogenesis.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, Paris, France; Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, CNRS, URA 1967, Villejuif, France; Hop Beaujon, Anat Pathol Lab, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Dejean, A (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, Paris, France.		Terris, Benoit/P-1497-2017; Pineau, Pascal/AAP-5614-2020; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				Arribas R, 1999, LAB INVEST, V79, P111; Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; Boige V, 1997, CANCER RES, V57, P1986; CRAIG JR, 1980, CANCER, V46, P372, DOI 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S; Duff EK, 1998, BRIT J CANCER, V78, P1615, DOI 10.1038/bjc.1998.731; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5; El-Rifai W, 1997, LAB INVEST, V77, P699; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kato A, 1998, DIGEST DIS SCI, V43, P1, DOI 10.1023/A:1018838731634; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lee DJ, 1997, CLIN CANCER RES, V3, P501; LEREBOURS F, 1999, GENE CHROMOSOME CANC, V2, P145; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; MERTENS F, 1994, GENE CHROMOSOME CANC, V10, P221, DOI 10.1002/gcc.2870100402; Mertens F, 1997, CANCER RES, V57, P2765; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Orsatti G, 1997, LIVER, V17, P152; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Puisieux A, 1997, PATHOL BIOL, V45, P864; RADFORD DM, 1995, CANCER RES, V55, P5180; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Rumpel CA, 1999, AM J PATHOL, V154, P1329, DOI 10.1016/S0002-9440(10)65386-2; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; Sambrook J., 2002, MOL CLONING LAB MANU; Schullerus D, 1999, INT J CANCER, V80, P22, DOI 10.1002/(SICI)1097-0215(19990105)80:1<22::AID-IJC5>3.0.CO;2-S; Schwerdtle RF, 1997, CANCER RES, V57, P5009; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; ZHANG X, 1994, CANCER RES, V54, P4177	39	89	94	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3733	3738		10.1038/sj.onc.1203713	http://dx.doi.org/10.1038/sj.onc.1203713			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949927				2022-12-25	WOS:000088568400005
J	O'Neill, S; Robinson, A; Deering, A; Ryan, M; Fitzgerald, DJ; Moran, N				O'Neill, S; Robinson, A; Deering, A; Ryan, M; Fitzgerald, DJ; Moran, N			The platelet integrin alpha(IIb)beta(3) has an endogenous thiol isomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BINDING-SITE; CYTOPLASMIC TAIL; CELL-ADHESION; LIGAND; CONFORMATION; AGGREGATION; ACTIVATION; THIOREDOXIN; BETA(1)	Integrins are cysteine-rich heterodimeric cell-surface adhesion molecules that alter their affinity for ligands in response to cellular activation. The molecular mechanisms involved in this activation of integrins are not understood. Treatment with the thiol-reducing agent, dithiothreitol, can induce an activation-like state in many integrins suggesting that cysteine-cysteine dithiol bonds are important for the receptor's tertiary structure and may be involved in activation-induced conformational changes. Here we demonstrate that the platelet-specific integrin, alpha (IIb)beta (3), contains an endogenous thiol isomerase activity, predicted from the presence of the tetrapeptide motif, CXXC, in each of the cysteine-rich repeats of the beta (3) polypeptide. This motif comprises the active site in enzymes involved in disulfide exchange reactions, including protein-disulfide isomerase (EC 5.3.4.1) and thioredoxin. Intrinsic thiol isomerase activity is also observed in the related integrin, alpha (v)beta (3), which shares a common beta -subunit. Thiol isomerase activity within alpha (IIb)beta (3) is time dependent and saturable, and is inhibited by the protein-disulfide isomerase inhibitor, bacitracin. Furthermore, this activity is calcium-sensitive and is regulated in the EDTA-stabilized conformation of the integrin. This novel demonstration of an enzymatic activity associated with an integrin subunit suggests that altered thiol bonding within the integrin or its substrates may be locally modified during alpha (IIb)beta (3) activation.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin	Moran, N (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, 123 St Stephens Green, Dublin 2, Ireland.	nmoran@rcsi.ie	Moran, Niamh/F-4188-2012; O'Neill, Sarah/C-8041-2012	Moran, Niamh/0000-0002-8614-3242; 				BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; Calvete JJ, 1999, P SOC EXP BIOL MED, V222, P29, DOI 10.1111/j.1525-1373.1999.09993.x; CHEN K, 1995, BRIT J HAEMATOL, V90, P425, DOI 10.1111/j.1365-2141.1995.tb05169.x; CHEW CC, 1995, BIOCHEM SOC T, V23, pS394, DOI 10.1042/bst023394s; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DAVIS GE, 1993, J IMMUNOL, V151, P7138; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; GoferDadosh N, 1997, BIOCHEM BIOPH RES CO, V232, P724, DOI 10.1006/bbrc.1997.6201; GULINO D, 1992, J BIOL CHEM, V267, P1001; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Huang EM, 1997, BLOOD, V89, P3205, DOI 10.1182/blood.V89.9.3205; KOEDAM JA, 1994, BIOCHEM BIOPH RES CO, V198, P1225, DOI 10.1006/bbrc.1994.1173; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1994, BLOOD, V84, P1108; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; Liu CY, 1998, BLOOD, V92, p344A; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; Mou YL, 1998, J IMMUNOL, V161, P6323; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; ONEILL S, 1998, IRISH J MED SCI, V167, P197; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pariser HP, 1998, DEV BRAIN RES, V111, P1, DOI 10.1016/S0165-3806(98)00113-8; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; Peter K, 1996, BLOOD COAGUL FIBRIN, V7, P233, DOI 10.1097/00001721-199603000-00031; PHILLIPS DR, 1992, METHOD ENZYMOL, V215, P244; Pierini LM, 2000, BLOOD, V95, P2471; PIGIET VP, 1988, P NATL ACAD SCI U S, V83, P7643; Ruan J, 1999, BRIT J HAEMATOL, V105, P523, DOI 10.1111/j.1365-2141.1999.01376.x; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Takagi J, 1997, J BIOCHEM, V121, P914; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Wang RG, 1997, BLOOD, V90, P1718, DOI 10.1182/blood.V90.4.1718.1718_1718_1719; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	46	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36984	36990		10.1074/jbc.M003279200	http://dx.doi.org/10.1074/jbc.M003279200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10942760	hybrid			2022-12-25	WOS:000165577700075
J	Saez-Vasquez, J; Pikaard, CS				Saez-Vasquez, J; Pikaard, CS			RNA polymerase I holoenzyme-promoter interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; GENE-TRANSCRIPTION; YEAST; IDENTIFICATION; PURIFICATION; COMPONENTS; SUBUNITS; MOUSE	In plants and animals, RNA polymerase I (pol I) can be purified in a form that is self-sufficient for accurate rRNA gene promoter-dependent transcription and that has biochemical properties suggestive of a single complex, or holoenzyme, In this study, we examined the promoter binding properties of a highly purified Brassica pol I holoenzyme activity. DNase I footprinting revealed protection of the core promoter region from similar to -30 to +20, in good agreement with the boundaries of the minimal promoter defined by deletion analyses (-33 to +6), Using conventional polyacrylamide electrophoretic mobility shift assays (EMSA), protein-DNA complexes were mostly excluded from the gel. However, agarose EMSA revealed promoter-specific binding activity that co purified with promoter-dependent transcription activity. Titration, time-course, and competition experiments revealed the formation or dissociation of a single protein-DNA complex, This protein-DNA complex could be labeled by incorporation of radioactive ribonucleotides into RNA in the presence of rw-amanitin, suggesting that the polymerase I enzyme is part of the complex. Collectively, these results suggest that transcriptionally competent pol I holoenzymes can associate with rRNA gene promoters in a single DNA binding event.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pikaard, CS (corresponding author), Washington Univ, Dept Biol, Campus Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.	pikaard@biology.wustl.edu	Pikaard, Craig S/K-8772-2012; Saez-Vasquez, Julio/HDO-3375-2022	Pikaard, Craig S/0000-0001-8204-7459; Saez-Vasquez, Julio/0000-0002-2717-7995	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050910] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert AC, 1999, MOL CELL BIOL, V19, P796; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DOELLING JH, 1995, PLANT J, V8, P683, DOI 10.1046/j.1365-313X.1995.08050683.x; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; GUILFOYLE TJ, 1980, BIOCHEMISTRY-US, V19, P5966, DOI 10.1021/bi00567a004; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hannan Katherine M., 1998, Frontiers in Bioscience, V3, pD376; Hannan RD, 1999, NUCLEIC ACIDS RES, V27, P3720, DOI 10.1093/nar/27.18.3720; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Larkin RM, 1996, GENE, V172, P211, DOI 10.1016/0378-1119(96)00030-3; Larkin RM, 1999, GENE, V231, P41, DOI 10.1016/S0378-1119(99)00090-6; LOBO SM, 1994, TRANSCRIPTION MECH R, V3, P127; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; SaezVasquez J, 1997, P NATL ACAD SCI USA, V94, P11869, DOI 10.1073/pnas.94.22.11869; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Seither P, 1998, J MOL BIOL, V275, P43, DOI 10.1006/jmbi.1997.1434; SERIZAWA H, 1994, RAV S MOL C, V3, P27; SONG CZ, 1994, J BIOL CHEM, V269, P26976; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	32	16	17	2	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37173	37180		10.1074/jbc.M006057200	http://dx.doi.org/10.1074/jbc.M006057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10940310	hybrid			2022-12-25	WOS:000165577700098
J	Shimasaki, NB; Kane, CM				Shimasaki, NB; Kane, CM			Structural basis for the species-specific activity of TFIIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR TFIIS; TISSUE-SPECIFIC EXPRESSION; PROMOTE READ-THROUGH; FACTOR-S-II; TRANSCRIPTION ELONGATION; FACTOR-SII; TERMINATION SITES; INTRINSIC BLOCKS; ZINC-FINGER	Many proteins involved in eukaryotic transcription are similar in function and in sequence between organisms. Despite the sequence similarities, there are many factors that do not function across species. For example, transcript elongation factor TFIIS is highly conserved among eukaryotes, and yet the TFIIS protein from Saccharomyces cerevisiae cannot function with mammalian RNA polymerase II and vice versa. To determine the reason for this species specificity, chimeras were constructed linking three structurally independent regions of the TFIIS proteins from yeast and human cells. Two independently folding domains, II and III, have been examined previously using NMR (1-3). Yeast domain II alone is able to bind yeast RNA polymerase II with the same affinity as the full-length TFIIS protein, and this domain was expected to confer the species selectivity. Domain III has previously been shown to be readily exchanged between mammalian and yeast factors. However, the results presented here indicate that domain II is insufficient to confer species selectivity, and a primary determinant lies in a 30-amino acid highly conserved linker region connecting domain II with domain III. These 30 amino acids may physically orient domains II and III to support functional interactions between TFIIS and RNA polymerase II.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Kane, CM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	kanecm@uclink4.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; [Anonymous], 1991, Methods Enzymol, V194, P1; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; Booth V, 2000, J BIOL CHEM, V275, P31266, DOI 10.1074/jbc.M002595200; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CHRISTIE KR, 1995, THESIS U CALIFORNIA; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; Ishiguro A, 2000, MOL CELL BIOL, V20, P1263, DOI 10.1128/MCB.20.4.1263-1270.2000; Ito T, 1996, FEBS LETT, V385, P21, DOI 10.1016/0014-5793(96)00340-7; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KANE CM, 1994, TRANSCRIPTION MECH R, pCH16; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; Koulich D, 1998, J MOL BIOL, V276, P379, DOI 10.1006/jmbi.1997.1545; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kulish D, 2000, J BIOL CHEM, V275, P12789, DOI 10.1074/jbc.275.17.12789; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1994, TRANSCRIPTION MECH R, pCH15; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWADOGO M, 1980, BIOCHEM BIOPH RES CO, V96, P258, DOI 10.1016/0006-291X(80)91208-5; Shaw SP, 1996, MOL CELL BIOL, V16, P3651; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; Shimoaraiso M, 1997, J BIOL CHEM, V272, P26550, DOI 10.1074/jbc.272.42.26550; SIKORSKI RS, 1989, GENETICS, V122, P19; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Taira Y, 1998, GENES CELLS, V3, P289, DOI 10.1046/j.1365-2443.1998.00188.x; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; Weaver ZA, 1997, GENOMICS, V46, P516, DOI 10.1006/geno.1997.5073; Williams LA, 1996, YEAST, V12, P227, DOI 10.1002/(SICI)1097-0061(19960315)12:3<227::AID-YEA905>3.3.CO;2-0; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Wu JS, 1996, P NATL ACAD SCI USA, V93, P11552, DOI 10.1073/pnas.93.21.11552; XU QH, 1994, J BIOL CHEM, V269, P3100; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	58	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36541	36549		10.1074/jbc.M005834200	http://dx.doi.org/10.1074/jbc.M005834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10940308	hybrid			2022-12-25	WOS:000165577700013
J	Giampuzzi, M; Botti, G; Di Duca, M; Arata, L; Ghiggeri, G; Gusmano, R; Ravazzolo, R; Di Donato, A				Giampuzzi, M; Botti, G; Di Duca, M; Arata, L; Ghiggeri, G; Gusmano, R; Ravazzolo, R; Di Donato, A			Lysyl oxidase activates the transcription activity of human collagene III promoter - Possible involvement of Ku antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; DNA-BINDING; CROSS-LINKING; MESSENGER-RNA; UP-REGULATION; BETA-AMINOPROPIONITRILE; ADRIAMYCIN NEPHROPATHY; INTERSTITIAL FIBROSIS; V(D)J RECOMBINATION	Lysyl oxidase is an extracellular enzyme that controls the maturation of collagen and elastin, Lysyl oxidase and collagen III often show similar expression patterns in fibrotic tissues. Therefore, we investigated the influence of lysyl oxidase overexpression on the promoter activity of human COL3A1 gene. Our results showed that when COS-7 cells overexpressed the mature form of lysyl oxidase, the activity of the human COL3A1 promoter was increased up to an average of 12 times when tested by luciferase reporter assay. The effect was specific, because other promoters were not affected. Moreover, lysyl oxidase effect was abolished by beta -aminopropionitrile, a specific inhibitor of its catalytic activity. Electrophoretic mobility shift assay showed a binding activity in the region from -101 to -77 that was significantly increased by lysyl oxidase overexpression, The binding was specifically competed by the cold probe, and the mutagenesis of this region abolished both the binding activity in gel retardation and lysyl oxidase stimulation of COL3A1 promoter in transfection experiments. We identified the binding activity as Ku antigen in its two components: Ku80 and Ku70. This study suggests a new coordinated mechanism by which lysyl oxidase might control the development of fibrosis.	Gaslini Childrens Hosp, Dept Nephrol, Genoa, Italy; Gaslini Childrens Hosp, Fondo Malattie Renali Bambino, Genoa, Italy; Gaslini Childrens Hosp, Mol Genet Lab, Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16147 Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Di Donato, A (corresponding author), Ist Giannina Gaslini, Lab Nephrol, Largo G Gaslini 5, I-16147 Genoa, Italy.		Di Duca, Marco/AAB-4531-2021; Ghiggeri, Gian Marco/N-4712-2015	Di Duca, Marco/0000-0001-8456-7706; Ghiggeri, Gian Marco/0000-0003-3659-9062				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BARRESI R, 1994, GENE, V140, P195, DOI 10.1016/0378-1119(94)90544-4; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BERTANI T, 1986, KIDNEY INT, V30, P488, DOI 10.1038/ki.1986.212; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgman P, 1997, CANCER RES, V57, P2847; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; CHANOKI M, 1995, BRIT J DERMATOL, V133, P710; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; Decitre M, 1998, LAB INVEST, V78, P143; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DIMACULANGAN DD, 1994, DIFFERENTIATION, V58, P47, DOI 10.1046/j.1432-0436.1994.5810047.x; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GREEN RS, 1995, LAB INVEST, V73, P476; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; Jeggo P, 1999, CR ACAD SCI III-VIE, V322, P109, DOI 10.1016/S0764-4469(99)80031-6; JEGGO PA, 1994, INT J RADIAT BIOL, V66, P573, DOI 10.1080/09553009414551651; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; JONES CL, 1991, KIDNEY INT, V40, P1012; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1980, J BIOL CHEM, V255, P3656; KAGAN HM, 1991, AM J RESP CELL MOL B, V5, P296; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; Koike M, 1999, J CELL SCI, V112, P4031; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUIVANIEMI H, 1985, AM J HUM GENET, V37, P798; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUNCIO GS, 1991, KIDNEY INT, V39, P550, DOI 10.1038/ki.1991.63; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langenau DM, 1999, J MOL ENDOCRINOL, V23, P137, DOI 10.1677/jme.0.0230137; LEROMANCER M, 1993, CR ACAD SCI III-VIE, V316, P1283; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LEVENE CI, 1985, BIOCHEM J, V232, P293, DOI 10.1042/bj2320293; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; MARTIN JE, 1991, VIRCHOWS ARCH A, V419, P403, DOI 10.1007/BF01605074; MURAWAKI Y, 1991, HEPATOLOGY, V14, P1167, DOI 10.1002/hep.1840140635; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; OKUDA S, 1986, KIDNEY INT, V29, P502, DOI 10.1038/ki.1986.28; Oleggini R, 2000, NEPHROL DIAL TRANSPL, V15, P778, DOI 10.1093/ndt/15.6.778; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Petroski MD, 1998, J VIROL, V72, P8181, DOI 10.1128/JVI.72.10.8181-8190.1998; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; QUAGLINO D, 1993, MATRIX, V13, P481, DOI 10.1016/S0934-8832(11)80114-9; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; RILEY DJ, 1982, AM REV RESPIR DIS, V125, P67; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; ROYCE PM, 1980, BIOCHEM J, V192, P576; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA AK, 1993, KIDNEY INT, V44, P774, DOI 10.1038/ki.1993.312; Sharma R, 1997, BIOSCIENCE REP, V17, P409, DOI 10.1023/A:1027361418200; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Shieh B, 1997, INT IMMUNOL, V9, P1885, DOI 10.1093/intimm/9.12.1885; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SIEGEL RC, 1978, P NATL ACAD SCI USA, V75, P2945, DOI 10.1073/pnas.75.6.2945; SOMMER P, 1993, LAB INVEST, V69, P460; TAMAKI K, 1994, KIDNEY INT, V45, P525, DOI 10.1038/ki.1994.68; Tan RSP, 1996, CANCER RES, V56, P2417; Torrance H, 1998, J BIOL CHEM, V273, P20810, DOI 10.1074/jbc.273.33.20810; Trivedy C, 1999, J ORAL PATHOL MED, V28, P246; VAHERI A, 1965, VIROLOGY, V27, P434, DOI 10.1016/0042-6822(65)90126-1; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662; Wheldon TE, 1998, RADIOTHER ONCOL, V48, P5, DOI 10.1016/S0167-8140(98)00022-X; Woudstra EC, 1999, RADIAT RES, V152, P214, DOI 10.2307/3580096	80	104	113	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36341	36349		10.1074/jbc.M003362200	http://dx.doi.org/10.1074/jbc.M003362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942761	hybrid			2022-12-25	WOS:000165382000098
J	Osborne, A; Thorneley, RNF; Abell, C; Bornemann, S				Osborne, A; Thorneley, RNF; Abell, C; Bornemann, S			Studies with substrate and cofactor analogues provide evidence for a radical mechanism in the chorismate synthase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN MONONUCLEOTIDE; NEUROSPORA-CRASSA; INTERMEDIATE; ENZYME; PHOSPHATE; PATHWAY; BINDING; MODEL; ASSAY; ACID	Chorismate synthase catalyzes the conversion of 5-enolpyruvylshikimate 3-phosphate (EPSP) to chorismate. The strict requirement for a reduced FMN cofactor and a trans-1,4-elimination are unusual. (6R)-6-Fluoro-EPSP was shown to be converted to chorismate stoichiometrically with enzyme-active sites in the presence of dithionite. This conversion was associated with the oxidation of FMN to give a stable flavin semiquinone. The IC,, of the fluorinated substrate analogue was 0.5 and 250 muM with the Escherichia coli enzyme, depending on whether it was preincubated with the enzyme or not. The lack of dissociation of the flavin semiquinone and chorismate from the enzyme appears to be the basis of the essentially irreversible inhibition by this analogue. A dithionite-dependent transient formation of flavin semiquinone during turnover of (6S)-6-fluoro-EPSP has been observed. These reactions are best rationalized by radical chemistry that is strongly supportive of a radical mechanism occurring during normal turnover. The lack of activity with 5-deaza-FMN provides additional evidence for the role of flavin in catalysis by the E. coli enzyme.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Univ Cambridge, Chem Lab, Dept Chem, Cambridge CB2 1EW, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Cambridge	Bornemann, S (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.		Bornemann, Stephen/K-2938-2012	Bornemann, Stephen/0000-0001-5930-9473				BALASUBRAMANIAN S, 1995, BIOCHEMISTRY-US, V34, P341, DOI 10.1021/bi00001a042; BALASUBRAMANIAN S, 1991, J AM CHEM SOC, V113, P8945, DOI 10.1021/ja00023a051; BARTLETT PA, 1989, BCPC MONOGRAPH, V42, P155; BORNEMANN S, 1995, BIOCHEM J, V305, P707, DOI 10.1042/bj3050707; BORNEMANN S, 1995, J BIOL CHEM, V270, P22811, DOI 10.1074/jbc.270.39.22811; Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Bornemann S, 2000, BIOORG CHEM, V28, P191, DOI 10.1006/bioo.2000.1174; Bornemann S, 1996, BIOCHEM SOC T, V24, P84, DOI 10.1042/bst0240084; COPLEY SD, 1987, J AM CHEM SOC, V109, P5008, DOI 10.1021/ja00250a040; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; FLOSS HG, 1972, J BIOL CHEM, V247, P736; GIBSON F, 1964, BIOCHEM J, V90, P256, DOI 10.1042/bj0900256; GIESE B, 1994, TETRAHEDRON LETT, V35, P1677, DOI 10.1016/0040-4039(94)88317-3; HEMMERICH P, 1977, FEBS LETT, V84, P5, DOI 10.1016/0014-5793(77)81047-8; HILL RK, 1969, J AM CHEM SOC, V91, P5893, DOI 10.1021/ja01049a045; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAUHON CT, 1994, BIOCHEMISTRY-US, V33, P14100, DOI 10.1021/bi00251a019; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1999, PLANTA, V207, P325, DOI 10.1007/s004250050489; Macheroux P, 1998, BIOCHEM J, V335, P319, DOI 10.1042/bj3350319; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MACHEROUX P, 1997, FLAVINS FLAVOPROTEIN, P113; MORELL H, 1967, J BIOL CHEM, V242, P82; MULLER F, 1972, EUR J BIOCHEM, V25, P573, DOI 10.1111/j.1432-1033.1972.tb01730.x; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; RAMJEE MN, 1992, J AM CHEM SOC, V114, P3151, DOI 10.1021/ja00034a079; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; SUTHERLAND JK, 1989, J CHEM SOC CHEM COMM, P1386, DOI 10.1039/c39890001386; Theoclitou ME, 1996, BIOORG MED CHEM LETT, V6, P1285, DOI 10.1016/0960-894X(96)00217-X; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313	34	31	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35825	35830		10.1074/jbc.M005796200	http://dx.doi.org/10.1074/jbc.M005796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956653	hybrid			2022-12-25	WOS:000165382000028
J	Eto, B; Puzon-McLaughlin, W; Sheppard, D; Sehara-Fujisawa, A; Zhang, XP; Takada, Y				Eto, B; Puzon-McLaughlin, W; Sheppard, D; Sehara-Fujisawa, A; Zhang, XP; Takada, Y			RGD-independent binding of integrin alpha(9)beta(1) to the ADAM-12 and-15 disintegrin domains mediates cell-cell interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELTRIN-ALPHA; III REPEAT; IN-VIVO; METALLOPROTEASE; SUBUNIT; METARGIDIN; EXPRESSION; ADHESION; SEQUENCE; PROTEIN	ADAMs (a disintegrin and metalloproteases) mediate several important processes (e.g. tumor necrosis factor-cy:release, fertilization, and myoblast fusion). The ADAM disintegrin domains generally lack RGD motifs, and their receptors are virtually unknown. Here we show that integrin alpha (9)beta (1) specifically interacts with the recombinant ADAMs-12 and -15 disintegrin domains in an RGD-independent manner. We also show that interaction between ADAM-12 or -15 and alpha (9)beta (1) supports cell-cell interaction Interestingly, the cation requirement and integrin activation status required for alpha (9)beta (1)/ADAM-mediated cell adhesion and cell-cell interaction is similar to those required for known integrin-extracellular matrix interaction. These results are quite different from recent reports that ADAM-2/alpha (6)beta (1) interaction during sperm/egg fusion requires an integrin activation status distinct from that for extracellular matrix interaction. These results suggest that alpha (9)beta (1) may be a major receptor for ADAMs that lack RGD motifs, and that, considering a wide distribution of ADAMs and alpha (9)beta (1), this interaction may be of potential biological and pathological significance.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Ctr Occupat & Environm Hlth,Lung Biol Ctr, San Francisco, CA 94143 USA; Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Scripps Research Institute; University of California System; University of California San Francisco; Tokyo Metropolitan Institute of Medical Science	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,CAL-10, La Jolla, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047175, R01GM049899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47175, GM49899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bohm BB, 1999, ARTHRITIS RHEUM, V42, P1946, DOI 10.1002/1529-0131(199909)42:9<1946::AID-ANR21>3.0.CO;2-E; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EVANS JP, 1995, J CELL SCI, V108, P3267; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Nath D, 1999, J CELL SCI, V112, P579; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Takahashi H, 2000, J BIOL CHEM, V275, P23589, DOI 10.1074/jbc.M003526200; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; WANG A, 1995, DEV DYNAM, V204, P421, DOI 10.1002/aja.1002040408; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	42	183	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34922	34930		10.1074/jbc.M001953200	http://dx.doi.org/10.1074/jbc.M001953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944520				2022-12-25	WOS:000165422800015
J	McManus, MJ; Boerner, JL; Danielsen, AJ; Wang, Z; Matsumura, F; Maihle, NJ				McManus, MJ; Boerner, JL; Danielsen, AJ; Wang, Z; Matsumura, F; Maihle, NJ			An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; RET PROTOONCOGENE; ACTIVATION; TYROSINE; DOMAIN; ACTIN; PHOSPHORYLATION; TRANSFORMATION; MUTATIONS; PROTEINS	Many ligand-independent receptor tyrosine kinases are tumorigenic. The biochemical signals that mediate ligand-independent transformation of cells by these transmembrane receptors are poorly defined. In this report, we demonstrate that a constitutively activated mutant epidermal growth factor receptor (v-ErbB) induces the formation of a transformation-specific signaling module that complexes with myosin II. The components:of this signaling complex include the signal adapter proteins Shc, Grb2, and Nck, and tyrosine-phosphorylated forms of p21-activated kinase (Pak), caldesmon, and myosin light chain kinase. Transformation specific, tyrosine phosphorylation of Pak enhances the catalytic activity of this serine/threonine kinase. Furthermore, the tyrosine phosphorylation of Pak is Rho-, but not Ras-, Rac-, or Cdc42-dependent. These results demonstrate :that a ligand-independent epidermal growth factor receptor mutant can transduce oncogenic signals that are distinct from ligand-dependent, mitogenic signals. In addition, these data provide evidence for-the coupling of oncogenic receptor tyrosine kinases with the actomyosin molecular motor. This myosin-associated signaling module may mediate some of the biochemical changes of myosin found in v-ErbB-transformed fibroblasts, thereby contributing to the regulation of the mechanical forces governing cellular adhesion, cytoskeletal tension, and, hence, anchorage-independent cell growth.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Tumor Biol Program, Rochester, MN 55905 USA; Rutgers State Univ, Nelson Labs, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Mayo Clinic; Mayo Clinic; Rutgers State University New Brunswick	Maihle, NJ (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.			Matsumura, Fumio/0000-0002-8204-153X	NATIONAL CANCER INSTITUTE [T32CA075926, R01CA079808, R29CA075238] Funding Source: NIH RePORTER; NCI NIH HHS [CA75238, CA75926, CA79808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Biscardi JS, 1999, ADV CANCER RES, V76, P61; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; Boerner JL, 2000, J CELL SCI, V113, P935; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Cai S, 1998, AM J PHYSIOL-CELL PH, V275, pC1349, DOI 10.1152/ajpcell.1998.275.5.C1349; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; POLLARD TD, 1974, ANAL BIOCHEM, V60, P258, DOI 10.1016/0003-2697(74)90152-3; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; Tu H, 1999, MOL CELL BIOL, V19, P602; Wang Z, 1999, J BIOL CHEM, V274, P33807, DOI 10.1074/jbc.274.47.33807; WATTERSON DM, 1995, FEBS LETT, V373, P217; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	40	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35328	35334		10.1074/jbc.M005399200	http://dx.doi.org/10.1074/jbc.M005399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954714	hybrid			2022-12-25	WOS:000165422800067
J	Safadi, F; Reddy, VS; Reddy, ASN				Safadi, F; Reddy, VS; Reddy, ASN			A pollen-specific novel calmodulin-binding protein with tetratricopeptide repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-FREE CALCIUM; TUBE GROWTH; PLANT-CELLS; SIGNAL-TRANSDUCTION; TIP GROWTH; ARABIDOPSIS-THALIANA; LILIUM-LONGIFLORUM; EXTRACELLULAR CALMODULIN; GLCNAC TRANSFERASE; ANGIOSPERM POLLEN	Calcium is essential for pollen germination and pollen tube growth. A large body of information has established a link between elevation of cytosolic Ca2+ at the pollen tube tip and its growth. Since the action of Ca2+ is primarily mediated by Ca2+-binding proteins such as calmodulin (CaM), identification of CaM-binding proteins in pollen should provide insights into the mechanisms by which Ca2+ regulates pollen germination and tube growth. In this study, a CaM-binding protein from maize pollen (maize pollen calmodulin-binding protein, MPCBP) was isolated in a protein-protein interaction-based screening using S-35-labeled CaM as a probe, MPCBP has a molecular mass of about 72 kDa and contains three tetratricopeptide repeats (TPR) suggesting that it is a member of the TPR family of proteins. MPCBP protein shares a high sequence identity with two hypothetical TPR-containing proteins from Arabidopsis, Using gel overlay assays and CaM-Sepharose binding, we show that the bacterially expressed MPCBP binds to bovine CaM and three CaM isoforms from Arabidopsis in a Ca2+-dependent manner. To map the CaM-binding domain several truncated versions of the MPCBP were expressed in bacteria and tested for their ability to bind CaM, Based on these studies, the CaM-binding domain was mapped to an 18-amino acid stretch between the first and second TPR regions. Gel and fluorescence shift assays performed with CaM and a CaM-binding synthetic peptide further confirmed MPCBP binding to CaM, Western, Northern, and reverse transcriptase-polymerase chain reaction analysis have shown that MPCBP expression is specific to pollen. MPCBP was detected in both soluble and microsomal proteins. Immunoblots showed the presence of MPCBP in mature and germinating pollen. Pollen-specific expression of MPCBP, its CaM-binding properties, and the presence of TPR motifs suggest a role for this protein in Ca2+-regulated events during pollen germination and growth.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.		Safadi, Fayez/AAU-8699-2021	Reddy, Anireddy/0000-0002-4038-4091				BEDNARSKA E, 1995, FOLIA HISTOCHEM CYTO, V33, P43; Bednarska E., 1989, Sexual Plant Reproduction, V2, P53, DOI 10.1007/BF00190119; Bibikova TN, 1997, PLANTA, V203, P495, DOI 10.1007/s004250050219; Bibikova TN, 1999, PLANT J, V17, P657, DOI 10.1046/j.1365-313X.1999.00415.x; BREWBAKE JL, 1963, AM J BOT, V50, P859, DOI 10.2307/2439772; Broadwater Anne H., 1994, P538; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cai G, 1997, TRENDS PLANT SCI, V2, P86, DOI 10.1016/S1360-1385(96)10057-1; Calder GM, 1997, BIOCHEM BIOPH RES CO, V234, P690, DOI 10.1006/bbrc.1997.6514; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DERKSEN J, 1995, ACTA BOT NEERL, V44, P93; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Franklin-Tong VE, 1999, PLANT CELL, V11, P727, DOI 10.1105/tpc.11.4.727; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUSSER I, 1984, PLANTA, V162, P33, DOI 10.1007/BF00397418; Hepler PK, 1997, TRENDS PLANT SCI, V2, P79, DOI 10.1016/S1360-1385(97)88385-9; HERNANDEZ TJ, 1995, PLANT MOL BIOL, V27, P1221; HERTH W, 1990, TIP GROWTH PLANT FUN, P91; HESLOPHARRISON J, 1989, J CELL SCI, V94, P319; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HoldawayClarke TL, 1997, PLANT CELL, V9, P1999, DOI 10.1105/tpc.9.11.1999; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; JAFFE LA, 1975, J CELL BIOL, V67, P488, DOI 10.1083/jcb.67.2.488; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KUHTREIBER WM, 1990, J CELL BIOL, V110, P1565, DOI 10.1083/jcb.110.5.1565; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; Liao BR, 1995, METHOD CELL BIOL, V49, P487, DOI 10.1016/S0091-679X(08)61475-2; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; Ma LG, 1997, PLANTA, V202, P336, DOI 10.1007/s004250050135; Ma LG, 1999, PLANT CELL, V11, P1351, DOI 10.1105/tpc.11.7.1351; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MALHO R, 1994, PLANT J, V5, P331, DOI 10.1111/j.1365-313X.1994.00331.x; Malho R, 1996, PLANT CELL, V8, P1935, DOI 10.1105/tpc.8.11.1935; MALHO R, 1995, PLANT CELL, V7, P1173, DOI 10.1105/tpc.7.8.1173; MASCARENHAS JP, 1964, PLANT PHYSIOL, V39, P70, DOI 10.1104/pp.39.1.70; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Messerli MA, 1999, J CELL SCI, V112, P1497; MILLER DD, 1992, J CELL SCI, V101, P7; Moutinho A, 1998, SEX PLANT REPROD, V11, P131, DOI 10.1007/s004970050130; OBERMEYER G, 1991, EUR J CELL BIOL, V56, P319; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PICTON JM, 1985, PLANTA, V163, P20, DOI 10.1007/BF00395892; PICTON JM, 1983, PROTOPLASMA, V115, P11, DOI 10.1007/BF01293575; PIERSON ES, 1990, J EXP BOT, V41, P1461, DOI 10.1093/jxb/41.11.1461; PIERSON ES, 1992, INT REV CYTOL, V140, P73, DOI 10.1016/S0074-7696(08)61094-3; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; POLITO VS, 1983, POLLEN BIOL IMPLICAT, P53; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; RASICALDOGNO F, 1989, PLANT PHYSIOL, V90, P1429, DOI 10.1104/pp.90.4.1429; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; REDDY ASN, 2001, IN PRESS INT REV CYT; REDDY ASN, 2000, IN PRESS HDB PLANT C; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; REISS HD, 1985, PLANTA, V163, P84, DOI 10.1007/BF00395901; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Rozwadowski K, 1999, PLANT PHYSIOL, V120, P787, DOI 10.1104/pp.120.3.787; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; Tirlapur Uday K., 1994, Zygote, V2, P63; TIRLAPUR UK, 1992, ANN BOT-LONDON, V69, P503, DOI 10.1093/oxfordjournals.aob.a088379; TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Venolia L, 1999, CELL MOTIL CYTOSKEL, V42, P163, DOI 10.1002/(SICI)1097-0169(1999)42:3&lt;163::AID-CM1&gt;3.0.CO;2-E; Vucich VA, 1996, MOL GEN GENET, V252, P510, DOI 10.1007/BF02172397; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	87	38	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35457	35470		10.1074/jbc.M002720200	http://dx.doi.org/10.1074/jbc.M002720200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956642	hybrid			2022-12-25	WOS:000165422800083
J	Tabata, H; Matsuoka, T; Endo, F; Nishimura, Y; Matsushita, S				Tabata, H; Matsuoka, T; Endo, F; Nishimura, Y; Matsushita, S			Ligation of HLA-DR molecules on B cells induces enhanced expression of IgM heavy chain genes in association with SyK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; PROTEIN-TYROSINE KINASE; MEDIATED SIGNAL-TRANSDUCTION; SRC FAMILY KINASES; LYMPHOCYTES-B; MONOCLONAL-ANTIBODIES; SELECTIVE INHIBITOR; CYTOPLASMIC DOMAIN; IMMUNOGLOBULIN-M; SECRETING CELLS	Signals transmitted by class II major histocompatibility complex are important regarding cell function related to antigen presentation. We examined effects of DR-mediated signaling on Ig production from B cells. Cross-linking HLA-DR molecules on B cells by solid-phase anti-HLA-DR monoclonal antibodies, led to an increased production of IgM, without proliferation or apoptosis. This event was accompanied by an enhanced expression of both membrane- and secretory-type IgM heavy chain mRNA. When peptide-pulsed B cells were co-incubated with an HLA-DR-restricted T cell clone treated by the protein synthesis inhibitor emetine, peptide-induced de novo expression of lymphokines and cell-surface molecules on T cells can be neglected. CD40-CD154 interaction was not involved in IgM enhancement,: in such a system. The protein-tyrosine kinase inhibitors and the Syk inhibitor piceatannol, but not the Src inhibitor PP2 had a marked inhibitory effect on IgM secretion. Furthermore, ligation of HLA-DR on B cells using the F(ab')B fragment of anti-DR monoclonal antibody, enhanced Syk activity. Our data suggest that HLA-DR on B cells not only present antigenic peptides to T cells, but also up-regulate IgM production, in association with Syk activation and without the involvement of Src kinases, hence the possible physiological relevance of Src-independent Syk activation.	Kumamoto Univ, Grad Sch Med Sci, Dept Neurosci & Immunol, Div Immunogenet, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Pediat, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Matsushita, S (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Neurosci & Immunol, Div Immunogenet, Kumamoto 8600811, Japan.							AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSSON J, 1977, CELL, V10, P27, DOI 10.1016/0092-8674(77)90136-2; AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; BISHOP GA, 1991, J IMMUNOL, V147, P1107; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Greer SF, 1998, J BIOL CHEM, V273, P11970, DOI 10.1074/jbc.273.19.11970; HAMANO T, 1990, J IMMUNOL, V144, P811; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARTON JA, 1993, J IMMUNOL, V151, P5282; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; KANNER SB, 1995, TISSUE ANTIGENS, V46, P145, DOI 10.1111/j.1399-0039.1995.tb03113.x; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONDO N, 1992, CLIN EXP IMMUNOL, V88, P35; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LANE PJL, 1990, J IMMUNOL, V144, P3684; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; LAW CL, 1994, J BIOL CHEM, V269, P12310; MARKOWITZ JS, 1993, J IMMUNOL, V150, P1223; Matsuoka T, 1999, FASEB J, V13, pA275; Matsuoka T, 1996, J IMMUNOL, V157, P4837; Matsushita S, 1997, J IMMUNOL, V158, P5685; MEHINDATE K, 1995, J EXP MED, V182, P1573, DOI 10.1084/jem.182.5.1573; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; MOURAD W, 1989, J EXP MED, V170, P2011, DOI 10.1084/jem.170.6.2011; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PALACIOS R, 1983, P NATL ACAD SCI-BIOL, V80, P3456, DOI 10.1073/pnas.80.11.3456; Randall TD, 1998, IMMUNITY, V8, P733, DOI 10.1016/S1074-7613(00)80578-6; Rich T, 1997, J IMMUNOL, V159, P3792; ROBBINS PA, 1987, HUM IMMUNOL, V18, P301, DOI 10.1016/0198-8859(87)90077-2; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SONE T, 1985, J IMMUNOL, V135, P1288; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUMAN JP, 1994, INT IMMUNOL, V6, P887, DOI 10.1093/intimm/6.6.887; TSOI MS, 1978, J IMMUNOL, V120, P1485; TSUJI K, 1992, HLA 1991 P 11 INT HI, V1; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Wang BH, 1998, PLANTA MED, V64, P195, DOI 10.1055/s-2006-957407; WEAVER CT, 1986, J IMMUNOL, V137, P3868; Xu R, 1999, J IMMUNOL, V163, P1110; Zoller KE, 1997, J IMMUNOL, V158, P1650	60	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34998	35005		10.1074/jbc.M002089200	http://dx.doi.org/10.1074/jbc.M002089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948188	hybrid			2022-12-25	WOS:000165422800025
J	Wang, XY; Moore, SC; Laszckzak, M; Ausio, J				Wang, XY; Moore, SC; Laszckzak, M; Ausio, J			Acetylation increases the alpha-helical content of the histone tails of the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CORE PARTICLE; CIRCULAR-DICHROISM; MODEL PEPTIDES; CHROMATIN; DNA; BINDING; H4; TRIFLUOROETHANOL; TRANSCRIPTION	The nature of the structural changes induced by histone acetylation at the different levels of chromatin organization has been very elusive. At the histone level, it has been proposed on several occasions that acetylation may induce an alpha -helical conformation of their acetylated N-terminal domains (tails). In an attempt to provide experimental support for this hypothesis, we have purified and characterized the tail of histone H4 in its native and mono-, di-, tri-, and tetra- acetylated form. The circular dichroism analysis of these peptides shows conclusively that acetylation does increase their alpha -helical content. Furthermore, the same spectroscopic analysis shows that this is also true for both the acetylated nucleosome core particle and the whole histone octamer in solution. In contrast to the native tails in which the alpha -helical organization appears to be dependent upon interaction of these histone regions with DNA, the acetylated tails show an increase in alpha -helical content that does not depend on such an interaction.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,Petch Bldg 220, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						ALDER AJ, 1974, J BIOL CHEM, V249, P2911; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; Baneres JL, 1997, J MOL BIOL, V273, P503, DOI 10.1006/jmbi.1997.1297; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRADBURY EM, 1975, BIOCHEMISTRY-US, V14, P1876, DOI 10.1021/bi00680a012; CANDIDO EPM, 1971, J BIOL CHEM, V246, P3182; CARLOS S, 1993, J BIOL CHEM, V268, P185; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Creighton T.E., 1996, PROTEINS; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FASMAN GD, 1976, BIOPHYS J, V16, P1201, DOI 10.1016/S0006-3495(76)85768-2; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Georgieva EI, 1999, ANAL BIOCHEM, V269, P399, DOI 10.1006/abio.1999.4050; GILBRAT JF, 1987, J MOL BIOL, V198, P425; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HONG L, 1993, J BIOL CHEM, V268, P305; Howe LW, 1998, MOL CELL BIOL, V18, P1156, DOI 10.1128/MCB.18.3.1156; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; Peng HF, 1997, BIOCHEMISTRY-US, V36, P12371, DOI 10.1021/bi971046g; PERRY M, 1981, J BIOL CHEM, V256, P3313; PREVELIGE PE, 1987, BIOCHEMISTRY-US, V26, P2944, DOI 10.1021/bi00384a041; Puig OM, 1998, BBA-GENE STRUCT EXPR, V1397, P79, DOI 10.1016/S0167-4781(98)00008-6; SEGAWA S, 1991, BIOPOLYMERS, V31, P497, DOI 10.1002/bip.360310505; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; VERDAGUER N, 1993, EUR J BIOCHEM, V214, P879, DOI 10.1111/j.1432-1033.1993.tb17991.x; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; XU XB, 1995, BIOPOLYMERS, V35, P93, DOI 10.1002/bip.360350110; YAGER TD, 1984, J BIOL CHEM, V259, P4212; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	64	141	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35013	35020		10.1074/jbc.M004998200	http://dx.doi.org/10.1074/jbc.M004998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938086	hybrid			2022-12-25	WOS:000165422800027
J	Willemoes, M; Hove-Jensen, B; Larsen, S				Willemoes, M; Hove-Jensen, B; Larsen, S			Steady state kinetic model for the binding of substrates and allosteric effecters to Escherichia coli phosphoribosyl-diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; NUCLEOTIDE BINDING; RAT-LIVER; SYNTHETASE; INHIBITION; MECHANISM; SITE; GENE; PYROPHOSPHATE; PURIFICATION	A steady state kinetic investigation of the P-i activation of 5-phospho-D-ribosyl alpha -1-diphosphate synthase from Escherichia coli suggests that P-i can bind randomly to the enzyme either before or after an ordered addition-of free Mg2+ and substrates. Unsaturation with ribose 5-phosphate increased the apparent cooperativity of P-i activation. At unsaturating P-i concentrations partial substrate inhibition by ribose 5-phosphate was observed. Together these results suggest that saturation of the enzyme with P-i directs the subsequent ordered binding of Mg2+ and substrates via a fast pathway, whereas saturation with ribose B-phosphate leads to the binding of Mg2+ and substrates via a slow pathway where P-i binds to the enzyme last. The random mechanism for P-i binding was further supported by studies with competitive inhibitors of Mg2+, MgATP, and ribose 5-phosphate that all appeared noncompetitive when varying P-i at either saturating or unsaturating ribose B-phosphate concentrations. Furthermore, none of the inhibitors induced inhibition at increasing P-i concentrations. Results from ADP inhibition of P-i activation suggest that these effectors compete for binding to a common regulatory site.	Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, Ctr Enzyme Res, DK-1307 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Willemoes, M (corresponding author), Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, Univiersitetsparken 5, DK-2100 Copenhagen, Denmark.	martin@xray.ki.ku.dk	Willemoës, Martin/K-4359-2014; Larsen, Sine/A-4487-2017	Willemoës, Martin/0000-0003-1689-2712; Larsen, Sine/0000-0003-3848-1789				ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BOWER SG, 1988, J BACTERIOL, V170, P3243, DOI 10.1128/jb.170.7.3243-3248.1988; BOWER SG, 1989, J BIOL CHEM, V264, P10287; Cleland W W, 1979, Methods Enzymol, V63, P500; Eriksen TA, 2000, NAT STRUCT BIOL, V7, P303; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FOX IH, 1972, J BIOL CHEM, V247, P2126; FRY DW, 1995, MOL PHARMACOL, V47, P810; GIBSON KJ, 1982, J BIOL CHEM, V257, P2391; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; KHORANA HG, 1958, J BIOL CHEM, V230, P941; Krath BN, 1999, BBA-PROTEIN STRUCT M, V1430, P403, DOI 10.1016/S0167-4838(99)00022-9; Krath BN, 1999, PLANT PHYSIOL, V119, P497, DOI 10.1104/pp.119.2.497; Lundegaard C, 1999, BIOCHEMISTRY-US, V38, P3327, DOI 10.1021/bi982279q; MILLER GA, 1975, ARCH BIOCHEM BIOPHYS, V171, P732, DOI 10.1016/0003-9861(75)90086-7; Neet K E, 1980, Methods Enzymol, V64, P139; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Parry RJ, 1996, BIOORGAN MED CHEM, V4, P1077, DOI 10.1016/0968-0896(96)00090-9; ROTH DG, 1974, J BIOL CHEM, V249, P291; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; SCHUBERT KR, 1975, J BIOL CHEM, V250, P7492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RM, 1956, J AM CHEM SOC, V78, P2376, DOI 10.1021/ja01592a009; Sonoda T, 1998, BBA-PROTEIN STRUCT M, V1387, P32, DOI 10.1016/S0167-4838(98)00106-X; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; SWITZER RL, 1969, J BIOL CHEM, V244, P2854; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; WELLS BD, 1976, J THEOR BIOL, V60, P209, DOI 10.1016/0022-5193(76)90165-X; White RH, 1996, BIOCHEMISTRY-US, V35, P3447, DOI 10.1021/bi952308m; Willemoes M, 1996, BIOCHEMISTRY-US, V35, P8181, DOI 10.1021/bi9528560; Willemoes M, 1997, BIOCHEMISTRY-US, V36, P5078, DOI 10.1021/bi962610a; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i	36	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35408	35412		10.1074/jbc.M006346200	http://dx.doi.org/10.1074/jbc.M006346200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954724	hybrid			2022-12-25	WOS:000165422800077
J	Zhang, YJ; Sugiura, R; Lu, YB; Asami, M; Maeda, T; Itoh, T; Takenawa, T; Shuntoh, H; Kuno, T				Zhang, YJ; Sugiura, R; Lu, YB; Asami, M; Maeda, T; Itoh, T; Takenawa, T; Shuntoh, H; Kuno, T			Phosphatidylinositol 4-phosphate 5-kinase its3 and calcineurin Ppb1 coordinately regulate cytokinesis in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; ALPHA-ACTININ; KINASE; 4,5-BISPHOSPHATE; PROTEIN; ORGANIZATION; PHOSPHATASE; EXPRESSION; INTEGRITY	The ppb1(+) gene encodes a fission yeast homologue of the mammalian calcineurin. We have recently shown that Ppb1 is essential for chloride ion homeostasis, and acts antagonistically with Pmk1 mitogen-activated protein kinase pathway. In an attempt to identify genes that share an essential function with calcineurin, we screened for mutations that confer sensitivity to the calcineurin inhibitor FR506 and high temperature, and isolated a mutant, its3-1. its3(+) was shown to be an essential gene encoding a functional homologue of phosphatidylinositol-4-phosphate 5-kinase (PI(4)P5K), The temperature:upshift or addition of FK506 induced marked disorganization of actin patches and dramatic increase in the frequency of septation in the its3-1 mutants but not in: the wild-type cells. Expression of a green fluorescent protein-tagged Its3 and the phospholipase C delta pleckstrin homology domain indicated plasma membrane localization of PI(4)P5K and phosphatidylinositol 4,5-bisphosphate. These green fluorescent protein-tagged proteins were concentrated at the septum of dividing cells, and the mutant Its3 was no longer localized to the plasma membrane. These data suggest that fission yeast PI(4)P5K Its3 functions coordinately with calcineurin and plays a key role in cytokinesis, and that the plasma membrane localization of Its3 is the crucial event in:cytokinesis.	Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Kobe, Hyogo 6540142, Japan	Kobe University; University of Tokyo; Kobe University	Kuno, T (corresponding author), Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@kobe-u.ac.jp						Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HELM R, 1995, NATURE, V373, P663; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JOCHOVA J, 1991, CELL BIOL INT REP, V15, P607, DOI 10.1016/0309-1651(91)90007-6; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MARKS J, 1986, J CELL SCI, P229; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PLOCHOCKAZULINSKA D, 1995, J BIOL CHEM, V270, P24794, DOI 10.1074/jbc.270.42.24794; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toda T, 1996, MOL CELL BIOL, V16, P6752; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Vancurova I, 1999, J BIOL CHEM, V274, P1147, DOI 10.1074/jbc.274.2.1147; YOSHIDA T, 1994, J CELL SCI, V107, P1725	35	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35600	35606		10.1074/jbc.M005575200	http://dx.doi.org/10.1074/jbc.M005575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950958	hybrid			2022-12-25	WOS:000165422800101
J	Komatsu, S; Yano, T; Shibata, M; Tuft, RA; Ikebe, M				Komatsu, S; Yano, T; Shibata, M; Tuft, RA; Ikebe, M			Effects of the regulatory light chain phosphorylation of myosin II on mitosis and cytokinesis of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PROTEIN KINASE-C; MITOTIC SPINDLE; MONOCLONAL-ANTIBODY; CLEAVAGE FURROW; CULTURED-CELLS; SURFACE IG; ACTIN; DICTYOSTELIUM; DISRUPTION	Myosin plays an important role in mitosis, especially during cytokinesis. Although it has been assumed that phosphorylation of regulatory light chain of myosin (RLC) controls motility of mammalian non-muscle cells, the functional significance of RLC phosphorylation remains uninvestigated. To address this problem, we have produced unphosphorylatable RLC (T18A/S19A RLC) and overexpressed it in COS-7 cells and normal rat kidney cells. Overexpression of T18A/S19A RLC but not wild type RLC almost completely abolished concanavalin A-induced receptor cap formation. The results indicate that myosin phosphorylation is critical for concanavalin A-induced gathering of surface receptors, T18A/S19A RLC overexpression resulted in the production of multinucleated cells, suggesting the failure of proper cell division in these cells. Video microscopic observation revealed that cells expressing T18A/S19A RLC showed abnormalities during mitosis in two respects. One is that the cells produced abnormal cleavage furrows, resulting in incomplete cytokinesis, which suggests that myosin phosphorylation is important for the normal recruitment of myosin molecules into the contractile ring structure. The other is that separation of chromosomes from the metaphase plate is disrupted in T18A/S19A RLC expressing cells, thus preventing proper transition hom metaphase to anaphase, These results suggest that, in addition to cytokinesis, myosin and myosin phosphorylation play a role in the karyokinetic process.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Biomed Imaging Grp, Worcester, MA 01655 USA; Med & Biol Labs, Nagano 396, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NHLBI NIH HHS [HL60831, HL56218] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056218, R01HL060831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AUBIN JE, 1979, EXP CELL RES, V124, P93, DOI 10.1016/0014-4827(79)90260-X; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BOURGUIGNON LYW, 1980, CELL BIOL INT REP, V4, P541, DOI 10.1016/0309-1651(80)90019-3; BOURGUIGNON LYW, 1978, J CELL PHYSIOL, V95, P239, DOI 10.1002/jcp.1040950302; BOURGUIGNON LYW, 1977, P NATL ACAD SCI USA, V74, P5031, DOI 10.1073/pnas.74.11.5031; BOURGUIGNON LYW, 1981, J CELL BIOL, V91, P889, DOI 10.1083/jcb.91.3.889; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CONDEELIS J, 1979, J CELL BIOL, V80, P751, DOI 10.1083/jcb.80.3.751; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; FLANAGAN J, 1978, NATURE, V273, P278, DOI 10.1038/273278a0; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HIGHASHIHARA M, 1989, J BIOL CHEM, V264, P5218; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Komatsu S, 1996, BIOCHEM BIOPH RES CO, V223, P741, DOI 10.1006/bbrc.1996.0966; KORN ED, 1978, P NATL ACAD SCI USA, V75, P588, DOI 10.1073/pnas.75.2.588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUPIN P, 1986, J ULTRA MOL STRUCT R, V94, P92, DOI 10.1016/0889-1605(86)90055-8; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SANGER JM, 1989, CELL MOTIL CYTOSKEL, V14, P201, DOI 10.1002/cm.970140207; SCHREINER GF, 1977, J EXP MED, V145, P1393, DOI 10.1084/jem.145.5.1393; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Shuster CB, 1999, J CELL BIOL, V146, P981, DOI 10.1083/jcb.146.5.981; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; Smith JL, 1996, P NATL ACAD SCI USA, V93, P12321, DOI 10.1073/pnas.93.22.12321; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	54	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34512	34520		10.1074/jbc.M003019200	http://dx.doi.org/10.1074/jbc.M003019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944522	hybrid			2022-12-25	WOS:000165095300070
J	Oikonomakos, NG; Schnier, JB; Zographos, SE; Skamnaki, VT; Tsitsanou, KE; Johnson, LN				Oikonomakos, NG; Schnier, JB; Zographos, SE; Skamnaki, VT; Tsitsanou, KE; Johnson, LN			Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; GLUCOSE ANALOG INHIBITORS; STRUCTURAL BASIS; POTENT INHIBITION; IN-VIVO; CAFFEINE; DESIGN; SPIROHYDANTOIN; GLUCOPYRANOSE; L86-8275	Flavopiridol (L86-8275) ((-)-cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-[4-(3-hydroxy-1-methyl) -piperidinyl]-4H-benzopyran-4-one), a potential antitumor drug, currently in phase II trials, has been shown to be an inhibitor of muscle glycogen phosphorylase (GP) and to cause glycogen accumulation in A549 non-small cell lung carcinoma cells (Kaiser, A, Nishi, a, Gorin, F.A., Walsh, D.A., Bradbury, E. M., and Schnier, J. B., unpublished data). Kinetic experiments reported here show that flavopiridol inhibits GPb with an IC50 = 15.5 muM The inhibition is synergistic with glucose resulting in a reduction of IC50 for flavopiridol to 2.3 muM and mimics the inhibition of caffeine. In order to elucidate the structural basis of inhibition, we determined the structures of GPb complexed with flavopiridol, GPb complexed with caffeine, and GPa complexed with both glucose and flavopiridol at 1.76-, 2.30-, and 2.23-Angstrom resolution, and refined to crystallographic R values of 0.216 (R-free, = 0.247), 0.189 (R-free = 0.219), and 0.195 (R-free = 0.252), respectively. The structures provide a rational for flavopiridol potency and synergism with glucose inhibitory action. Flavopiridol binds at the allosteric inhibitor site, situated at the entrance to the catalytic site, the site where caffeine binds. Flavopiridol intercalates between the two aromatic rings of Phe(285) and Tyr(613). Both flavopiridol and glucose promote the less active T-state through localization of the closed position of the 280s loop which blocks access to the catalytic site, thereby explaining their synergistic inhibition. The mode of interactions of flavopiridol with GP is different from that of des-chloro-flavopiridol with CDK2, illustrating how different functional parts of the inhibitor can be used to provide specific and potent binding to two different enzymes.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England	National Hellenic Research Foundation; University of California System; University of California Davis; University of Oxford	Oikonomakos, NG (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vas Constantinou Ave, Athens 11635, Greece.	ngo@eie.gr	Zographos, Spyros/H-9058-2013	Zographos, Spyros/0000-0001-8455-2352; E. Tsitsanou, Katerina/0000-0001-9657-1390				Acharya K.R., 1991, GLYCOGEN PHOSPHORYLA, V2nd; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BICHARD CJF, 1995, TETRAHEDRON LETT, V36, P2145, DOI 10.1016/0040-4039(95)00197-K; BRUNGER AT, 1996, XPLOR VERSION 3 8 DE; CZECH J, 1995, INT J ONCOL, V6, P31; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Drees M, 1997, CLIN CANCER RES, V3, P273; ErcanFang N, 1997, J PHARMACOL EXP THER, V280, P1312; FISCHER EH, 1962, METHOD ENZYMOL, V5, P369, DOI 10.1016/S0076-6879(62)05243-X; Gregoriou M, 1998, PROTEIN SCI, V7, P915; HELMREICH E, 1964, P NATL ACAD SCI USA, V51, P131, DOI 10.1073/pnas.51.1.131; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HUBBARD SJ, 1993, NACCESS DEP BIOL MOL; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KASVINSKY PJ, 1981, CAN J BIOCHEM CELL B, V59, P387, DOI 10.1139/o81-054; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P9102; Kim S H, 1996, Prog Cell Cycle Res, V2, P137; Lommerse JPM, 1996, J AM CHEM SOC, V118, P3108, DOI 10.1021/ja953281x; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADSEN NB, 1983, BIOCHEMISTRY-US, V22, P4460, DOI 10.1021/bi00288a017; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MARTIN JL, 1991, BIOCHEMISTRY-US, V30, P10101, DOI 10.1021/bi00106a006; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; Noble MEM, 1999, PHARMACOL THERAPEUT, V82, P269, DOI 10.1016/S0163-7258(98)00051-5; Oikonomakos NG, 1999, PROTEIN SCI, V8, P1930, DOI 10.1110/ps.8.10.1930; OIKONOMAKOS NG, 1995, PROTEIN SCI, V4, P2469, DOI 10.1002/pro.5560041203; Oikonomakos NG, 2000, STRUCTURE, V8, P575, DOI 10.1016/S0969-2126(00)00144-1; OIKONOMAKOS NG, 1985, BIOCHIM BIOPHYS ACTA, V832, P248, DOI 10.1016/0167-4838(85)90257-2; OIKONOMAKOS NG, 1992, POST TRANSLATIONAL M, P81; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sausville EA, 1999, PHARMACOL THERAPEUT, V82, P285, DOI 10.1016/S0163-7258(98)00062-X; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Segel I. H, 1975, ENZYME KINETICS, P465; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; SPRANG S, 1982, BIOCHEMISTRY-US, V21, P2036, DOI 10.1021/bi00538a010; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; WATSON KA, 1994, BIOCHEMISTRY-US, V33, P5745, DOI 10.1021/bi00185a011; WATSON KA, 1995, ACTA CRYSTALLOGR D, V51, P458, DOI 10.1107/S090744499401348X; Zographos SE, 1997, STRUCTURE, V5, P1413, DOI 10.1016/S0969-2126(97)00292-X	48	117	121	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34566	34573		10.1074/jbc.M004485200	http://dx.doi.org/10.1074/jbc.M004485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924512	hybrid			2022-12-25	WOS:000165095300077
J	Yao, M; Ose, T; Sugimoto, H; Horiuchi, A; Nakagawa, A; Wakatsuki, S; Yokoi, D; Murakami, T; Honma, M; Tanaka, I				Yao, M; Ose, T; Sugimoto, H; Horiuchi, A; Nakagawa, A; Wakatsuki, S; Yokoi, D; Murakami, T; Honma, M; Tanaka, I			Crystal structure of 1-aminocyclopropane-1-carboxylate deaminase from Hartsenula saturnus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ACID DEAMINASE; PROTEIN CRYSTALLOGRAPHY; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; PSEUDOMONAS SP; ENZYME; CRYSTALLIZATION; REPLACEMENT; RESOLUTION	The pyridoxal 5'-phosphate (PLP)-dependent enzyme 1-aminocyclopropane-1-carboxylate deaminase (ACCD) catalyzes a reaction that involves a ring opening of cyclopropanoid amino acid, yielding alpha -ketobutyrate and ammonia. Unlike other PUP-dependent enzymes, this enzyme has no alpha -hydrogen atom in the substrate. Thus, a unique mechanism for the bond cleavage is expected. The crystal structure of ACCD from Hansenula saturnus has been determined at 2.0 Angstrom resolution by the multiple wavelength anomalous diffraction method using mercury atoms as anomalous scatterers. The model was built on the electron density map, which was obtained by the density averaging of multiple crystal forms. The final model was refined to an R-factor of 22.5% and an R-free-factor of 26.8%. The ACCD folds into two domains, each of which has an open twisted alpha/beta structure similar to the beta -subunit of tryptophan synthase, However, in ACCD, unlike in other members of the beta family of PLP-dependent enzymes, PLP is buried deep in the molecule, The structure provides the first view of the catalytic center of the cyclopropane ring opening.	Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Agr, Sapporo, Hokkaido 0608589, Japan; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Hokkaido University; Hokkaido University; European Synchrotron Radiation Facility (ESRF)	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan.		Sugimoto, Hiroshi/AAR-5442-2021; Nakagawa, Atsushi/D-4329-2009; yao, min/F-5287-2011; Sugimoto, Hiroshi/K-4041-2017; Ose, Toyoyuki/AAW-7821-2020; Nakagawa, Atsushi/M-5731-2019	Nakagawa, Atsushi/0000-0002-1700-7861; yao, min/0000-0003-1687-5904; Sugimoto, Hiroshi/0000-0002-3140-8362; Ose, Toyoyuki/0000-0002-2001-9388; Nakagawa, Atsushi/0000-0002-1700-7861; Wakatsuki, Soichi/0000-0001-5896-7968				Abola EE, 1997, METHOD ENZYMOL, V277, P556, DOI 10.1016/S0076-6879(97)77031-9; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; BURROUGHS LF, 1957, NATURE, V179, P360, DOI 10.1038/179360a0; Clausen T, 2000, EMBO J, V19, P831, DOI 10.1093/emboj/19.5.831; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HONMA M, 1985, AGR BIOL CHEM TOKYO, V49, P567, DOI 10.1080/00021369.1985.10866774; HONMA M, 1979, AGR BIOL CHEM TOKYO, V43, P1677, DOI 10.1080/00021369.1979.10863687; HONMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1825, DOI 10.1080/00021369.1978.10863261; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNIGHT S, 1989, THESIS SWEDISH U AGR; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li KQ, 1996, J AM CHEM SOC, V118, P8763, DOI 10.1021/ja960822p; Minami R, 1998, J BIOCHEM, V123, P1112; Murakami T, 1997, BIOSCI BIOTECH BIOCH, V61, P506, DOI 10.1271/bbb.61.506; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reed AJ, 1996, J AGR FOOD CHEM, V44, P388, DOI 10.1021/jf9504071; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHEEHY RE, 1991, J BACTERIOL, V173, P5260, DOI 10.1128/jb.173.17.5260-5265.1991; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; WALSH C, 1981, BIOCHEMISTRY-US, V20, P7509, DOI 10.1021/bi00529a028; YAO M, 1995, PROTEIN PEPTIDE LETT, V2, P305; YAO M, 1994, J STRUCT BIOL, V113, P251, DOI 10.1006/jsbi.1994.1060	40	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34557	34565		10.1074/jbc.M004681200	http://dx.doi.org/10.1074/jbc.M004681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938279	hybrid, Green Published			2022-12-25	WOS:000165095300076
J	Grzesiak, A; Krokoszynska, I; Krowarsch, D; Buczek, O; Dadlez, M; Otlewski, J				Grzesiak, A; Krokoszynska, I; Krowarsch, D; Buczek, O; Dadlez, M; Otlewski, J			Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KUNITZ DOMAIN INHIBITORS; X-RAY STRUCTURE; TICK ANTICOAGULANT PEPTIDE; FACTOR PATHWAY INHIBITOR; FACTOR-FACTOR VIIA; TISSUE FACTOR; CRYSTAL-STRUCTURE; PHAGE DISPLAY; ACTIVE-SITE; ITERATIVE OPTIMIZATION	series of 12 bovine pancreatic trypsin inhibitor variants mutated in the P-4 and P-3 positions of the canonical binding loop containing additional R15R and M52L mutations mere used to probe the role of single amino acid substitutions on binding to bovine trypsin and to the following human proteinases involved in blood clotting: plasmin, plasma kallikrein, factors X-a and XIIa, thrombin, and protein C. The mutants were expressed in Escherichia coli as fusion proteins with the LE1413 hydrophobic polypeptide and purified from inclusion bodies; these steps were followed by CNBr cleavage and oxidative refolding, The mutants inhibited the blood-clotting proteinases with association constants in the range of 10(3)-10(10) M-1. Inhibition of plasma kallikrein, factors X-a and XIIa, thrombin, and protein C could be improved by up to 2 orders of magnitude by the K15R substitution The highest increase in the association constant for P-3 mutant was measured for factor XIIa; P13S substitution increased the K-a value 58-fold, Several other substitutions at P-3 resulted in about 10-fold increase for factor X-a, thrombin, and protein C. The cumulative P-3 and P-1 effects on K-alpha values for the strongest mutant compared with the wild type bovine pancreatic trypsin inhibitor were in the range of 2,2- (plasmin) to 4,000-fold (factors XIIa and X-a). The substitutions at the P-4 site always caused negative effects (a decrease in the range from over 1.000- to 1.3-fold) on binding to all studied enzymes, including trypsin, Thermal stability studies showed a very large decrease of the denaturation temperature (about 22 degreesC) for all P-4 mutants, suggesting that substitution of the mild type Gly-12 residue leads to a change in the binding loop conformation manifesting itself in non-optimal binding to the proteinase active site.	Univ Wroclaw, Inst Biochem & Mol Biol, Lab Prot Engn, PL-50137 Wroclaw, Poland; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	University of Wroclaw; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Otlewski, J (corresponding author), Univ Wroclaw, Inst Biochem & Mol Biol, Lab Prot Engn, Tamka 2, PL-50137 Wroclaw, Poland.	otlewski@bf.uni.wroc.pl	Otlewski, Jacek/B-6340-2008	Dadlez, Michal/0000-0001-8811-5176				Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRINKMANN T, 1991, EUR J BIOCHEM, V202, P95, DOI 10.1111/j.1432-1033.1991.tb16348.x; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; DROHAN WN, 1994, ADVANCES IN BIOPROCESS ENGINEERING, P501; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; Grzesiak A, 2000, J MOL BIOL, V301, P205, DOI 10.1006/jmbi.2000.3935; HARDY JF, 1992, CAN J ANAESTH, V39, P353, DOI 10.1007/BF03009046; Helland R, 1999, ACTA CRYSTALLOGR D, V55, P139, DOI 10.1107/S090744499801052X; HOFMANN KJ, 1992, BIOCHEM J, V287, P943, DOI 10.1042/bj2870943; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; Katoh T, 1997, BIOSCI BIOTECH BIOCH, V61, P389, DOI 10.1271/bbb.61.389; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; Kraunsoe JAE, 1996, BIOCHEMISTRY-US, V35, P9090, DOI 10.1021/bi953013b; Krokoszynska I, 1998, J MOL BIOL, V275, P503, DOI 10.1006/jmbi.1997.1460; Krowarsch D, 1999, J MOL BIOL, V289, P175, DOI 10.1006/jmbi.1999.2757; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lapatto R, 1997, EMBO J, V16, P5151, DOI 10.1093/emboj/16.17.5151; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; MAKHATADZE GI, 1993, PROTEIN SCI, V2, P2028, DOI 10.1002/pro.5560021204; Markland W, 1996, BIOCHEMISTRY-US, V35, P8058, DOI 10.1021/bi952629y; Markland W, 1996, BIOCHEMISTRY-US, V35, P8045, DOI 10.1021/bi9526286; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MOSES E, 1983, J MOL BIOL, V170, P765, DOI 10.1016/S0022-2836(83)80130-2; NEEPER MP, 1990, J BIOL CHEM, V265, P17746; OTLEWSKI J, 1994, BIOCHEMISTRY-US, V33, P200, DOI 10.1021/bi00167a026; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; PRADO ES, 1986, BIOL CHEM H-S, V367, P199, DOI 10.1515/bchm3.1986.367.1.199; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; STASSEN JM, 1995, THROMB HAEMOSTASIS, V74, P646; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSCHESCHE H, 1987, BIOCHIM BIOPHYS ACTA, V913, P97, DOI 10.1016/0167-4838(87)90238-X; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; WENZEL HR, 1982, FEBS LETT, V140, P53, DOI 10.1016/0014-5793(82)80519-X; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	53	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33346	33352		10.1074/jbc.M006085200	http://dx.doi.org/10.1074/jbc.M006085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930417	hybrid			2022-12-25	WOS:000090104600026
J	Hashimoto, K; Zanger, K; Hollenberg, AN; Cohen, LE; Radovick, S; Wondisford, FE				Hashimoto, K; Zanger, K; Hollenberg, AN; Cohen, LE; Radovick, S; Wondisford, FE			cAMP response element-binding protein-binding protein mediates thyrotropin-releasing hormone signaling on thyrotropin subunit genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1/GHF-1; KINASE-C; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; GLYCOPROTEIN HORMONES; PITUITARY-CELLS; ALPHA-GENE; EXPRESSION; PIT-1; CBP; ACTIVATION	Transcription of pituitary alpha -glycoprotein hormone subunit (alpha -GSU) and thyrotropin beta subunit (TSH-beta) genes is stimulated by thyrotropin-releasing hormone (TRH). Since cAMP response element-binding protein (CREB)-binding protein (CBP) integrates a number of cell signaling pathways, we investigated whether CBP is important for TRH stimulation of the TSH subunit genes. Cotransfection of E1A in GH(3) cells completely blocked TRH stimulation of the TSH subunit genes, suggesting that CBP is a key factor for TRH signaling in the pituitary. CBP and Pit-1 acted synergistically in TRH stimulation of the TSH-beta promoter, and amino acids 1-450 of CBP were sufficient for the TRH effect. In contrast, on the human alpha -GSU promoter, CREB and P-Lim mediated TRH signaling. Intriguingly, CREB was phosphorylated upon TRH stimulation, leading to CBP recruitment to the alpha -GSU promoter. CBP also interacted with P-Lim in a TRH-dependent manner, suggesting that P-Lim is an important factor for non-cAMP response element-mediated TRH stimulation of this promoter. Distinct domains of CBP were required for TRH signaling by CREB and P-Lim on the alpha -GSU promoter, amino acids 450-700 and 1-450, respectively. Thus, the amino terminus of CBP plays a critical role in TRH signaling in the anterior pituitary via both Pit-1-dependent and -independent pathways, yielding differential regulation of pituitary gene products.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Thyroid Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School	Wondisford, FE (corresponding author), Univ Chicago, Dept Med, Endocrinol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.	fwondisf@medicine.bsd.uchicago.edu						ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; CARR FE, 1993, ENDOCRINOLOGY, V133, P1700, DOI 10.1210/en.133.4.1700; CARR FE, 1991, BIOCHEMISTRY-US, V30, P3721, DOI 10.1021/bi00229a019; CARR FE, 1989, MOL ENDOCRINOL, V3, P717, DOI 10.1210/mend-3-4-717; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cohen LE, 1999, J CLIN INVEST, V104, P1123, DOI 10.1172/JCI7308; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; GERSHENGORN MC, 1989, ANN NY ACAD SCI, V553, P191; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P679, DOI 10.1089/dna.1988.7.679; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KIM DS, 1994, MOL ENDOCRINOL, V8, P528, DOI 10.1210/me.8.4.528; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; KOURIDES IA, 1984, RECENT PROG HORM RES, V40, P79; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LICHT P, 1990, PROG CLIN BIOL RES, V342, P427; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; PENNATHUR S, 1993, MOL ENDOCRINOL, V7, P797, DOI 10.1210/me.7.6.797; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUPNIK MA, 1992, MOL ENDOCRINOL, V6, P43, DOI 10.1210/me.6.1.43; SHUPNIK MA, 1986, J BIOL CHEM, V261, P2675; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Steinfelder HJ, 1997, EXP CLIN ENDOCR DIAB, V105, P196, DOI 10.1055/s-0029-1211751; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	49	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33365	33372		10.1074/jbc.M006819200	http://dx.doi.org/10.1074/jbc.M006819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931853	hybrid			2022-12-25	WOS:000090104600028
J	Kusmierczyk, AR; Martin, J				Kusmierczyk, AR; Martin, J			High salt-induced conversion of Escherichia coli GroEL into a fully functional thermophilic chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CRYSTAL-STRUCTURE; HYDROPHOBIC SURFACES; ATPASE ACTIVITY; CENTRAL CAVITY; ALPHA-LACTALBUMIN; BINDING; HYDROLYSIS; PURIFICATION; INTERMEDIATE	The GroE chaperonin system can adapt to and function at various environmental folding conditions. To examine chaperonin-assisted protein folding at high salt concentrations, we characterized Escherichia coli GroE chaperonin activity in 1.2 M ammonium sulfate, Our data are consistent with GroEL undergoing a conformational change at this salt concentration, characterized by elevated ATPase activity and increased exposure of hydrophobic surface, as indicated by increased binding of the fluorophore bis-(5,5')-8-anilino-1-naphthalene sulfonic acid to the chaperonin, The presence of the salt results in increased substrate stringency and dependence on the full GroE system for release and productive folding of substrate proteins. Surprisingly, GroEL is fully functional as a thermophilic chaperonin in high concentrations of ammonium sulfate and is stable at temperatures up to 75 degreesC, At these extreme conditions, GroEL can suppress aggregation and mediate refolding of non-native proteins.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Brown University	Martin, J (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Box G-J2, Providence, RI 02912 USA.			Kusmierczyk, Andrew/0000-0001-6363-7437	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54534] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andra S, 1998, EUR J BIOCHEM, V255, P93, DOI 10.1046/j.1432-1327.1998.2550093.x; BOHNERT JL, 1982, BIOCHEMISTRY-US, V21, P5570, DOI 10.1021/bi00265a029; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; Brazil BT, 1998, J BIOL CHEM, V273, P3257, DOI 10.1074/jbc.273.6.3257; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Clark AC, 1998, METHOD ENZYMOL, V290, P100; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; DESCHAMPS JR, 1995, PROTEIN EXPRES PURIF, V6, P555, DOI 10.1006/prep.1995.1073; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FREIFELDER D, 1982, BIOPHYSICAL CHEM APP, pCH15; Furutani M, 1998, J BIOL CHEM, V273, P28399, DOI 10.1074/jbc.273.43.28399; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Gutsche I, 2000, CURR BIOL, V10, P405, DOI 10.1016/S0960-9822(00)00421-8; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LUO GX, 1994, J BIOL CHEM, V269, P32151; Ma JP, 1998, P NATL ACAD SCI USA, V95, P8502, DOI 10.1073/pnas.95.15.8502; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Martin J, 1998, J BIOL CHEM, V273, P7351, DOI 10.1074/jbc.273.13.7351; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Mendoza JA, 1996, BIOCHEM BIOPH RES CO, V229, P271, DOI 10.1006/bbrc.1996.1791; Minuth T, 1998, EUR J BIOCHEM, V258, P837, DOI 10.1046/j.1432-1327.1998.2580837.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; TAKII Y, 1992, APPL MICROBIOL BIOT, V38, P243, DOI 10.1007/BF00174476; TIMASHEFF SN, 1997, PROTEIN STRUCTURE PR, pCH14; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997	54	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33504	33511		10.1074/jbc.M006256200	http://dx.doi.org/10.1074/jbc.M006256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945996	hybrid, Green Published			2022-12-25	WOS:000090104600046
J	Mizushina, Y; Kamisuki, S; Mizuno, T; Takemura, M; Asahara, H; Linn, S; Yamaguchi, T; Matsukage, A; Hanaoka, F; Yoshida, S; Saneyoshi, M; Sugawara, F; Sakaguchi, K				Mizushina, Y; Kamisuki, S; Mizuno, T; Takemura, M; Asahara, H; Linn, S; Yamaguchi, T; Matsukage, A; Hanaoka, F; Yoshida, S; Saneyoshi, M; Sugawara, F; Sakaguchi, K			Dehydroaltenusin, a mammalian DNA polymerase alpha inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; PRIMASE COMPLEX; SELECTIVE-INHIBITION; ESCHERICHIA-COLI; 4 SUBUNITS; MOUSE; CELLS; BETA; PURIFICATION; REPLICATION	Dehydroaltenusin was found to be an inhibitor of mammalian DNA polymerase alpha (pol alpha) in vitro. Surprisingly, among the polymerases and DNA metabolic enzymes tested, dehydroaltenusin inhibited only mammalian pol alpha. Dehydroaltenusin did not influence the activities of the other replicative DNA polymerases, such as delta and epsilon; it also showed no effect even on the pol alpha activity from another vertebrate (fish) or plant species. The inhibitory effect of dehydroaltenusin on mammalian pol alpha was dose-dependent, and 50% inhibition was observed at a concentration of 0.5 muM. Dehydroaltenusin-induced inhibition of mammalian pol alpha activity was competitive with the template-primer and non-competitive with the dNTP substrate. BIAcore analysis demonstrated that dehydroaltenusin bound to the core domain of the largest subunit, p180, of mouse pol alpha, which has catalytic activity, but did not bind to the smallest subunit or the DNA primase p46 of mouse pol alpha. These results suggest that the dehydroaltenusin molecule competes with the template primer molecule on its binding site of the catalytic domain of mammalian pol alpha, binds to the site, and simultaneously disturbs dNTP substrate incorporation into the template-primer.	Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Nagoya Univ, Sch Med, Res Inst Dis Mechanism & Control, Lab Canc Cell Biol, Nagoya, Aichi 4668550, Japan; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Teikyo Univ Sci & Technol, Dept Biol Sci, Yamanashi 4090193, Japan; Japan Womens Univ, Dept Chem & Biol Sci, Bunkyo Ku, Tokyo 1128681, Japan	Tokyo University of Science; RIKEN; Nagoya University; University of California System; University of California Berkeley; Japan Womens University	Sakaguchi, K (corresponding author), Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan.							CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Chui GSJ, 1995, METHOD ENZYMOL, V262, P93; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P461; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOIZUMI KT, 1997, BIOCHEM MOL BIOL INT, V41, P1179; KORNBERG A, 1992, DNA REPLICATION, P197; LU BC, 1991, J BIOL CHEM, V266, P21060; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; Mizuno T, 1999, MOL CELL BIOL, V19, P7886; Mizuno T, 1996, J CELL SCI, V109, P2627; Mizushina Y, 1999, J BIOL CHEM, V274, P25599, DOI 10.1074/jbc.274.36.25599; Mizushina Y, 1998, BIOCHEM J, V330, P1325, DOI 10.1042/bj3301325; Mizushina Y, 1997, BBA-GEN SUBJECTS, V1336, P509, DOI 10.1016/S0304-4165(97)00067-6; Mizushina Y, 1996, BBA-GENE STRUCT EXPR, V1308, P256, DOI 10.1016/0167-4781(96)00121-2; NAKANISHI S, 1995, BIOSCI BIOTECH BIOCH, V59, P1333, DOI 10.1271/bbb.59.1333; NAKAYAMA C, 1985, J BIOCHEM-TOKYO, V97, P1385, DOI 10.1093/oxfordjournals.jbchem.a135192; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; OGURO M, 1979, EUR J BIOCHEM, V97, P603, DOI 10.1111/j.1432-1033.1979.tb13149.x; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; SAKAGUCHI K, 1980, CELL STRUCT FUNCT, V5, P323, DOI 10.1247/csf.5.323; SHOJIKAWAGUCHI M, 1995, J BIOCHEM-TOKYO, V117, P1095, DOI 10.1093/oxfordjournals.jbchem.a124812; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; SUZUKI M, 1989, J BIOL CHEM, V264, P10065; TAKADATAKAYAMA R, 1990, BIOCHEM BIOPH RES CO, V170, P589, DOI 10.1016/0006-291X(90)92132-J; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; THOMAS R, 1971, J CHEM SOC CHEM COMM, V8, P393; Tomikawa A, 1998, NUCLEOS NUCLEOT NUCL, V17, P487, DOI 10.1080/07328319808005193; Ueno T, 2000, BIOCHEMISTRY-US, V39, P5995, DOI 10.1021/bi992661i	35	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33957	33961		10.1074/jbc.M006096200	http://dx.doi.org/10.1074/jbc.M006096200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942777	hybrid			2022-12-25	WOS:000090104600107
J	Sudoh, M; Yamazaki, T; Masubuchi, K; Taniguchi, M; Shimma, N; Arisawa, M; Yamada-Okabe, H				Sudoh, M; Yamazaki, T; Masubuchi, K; Taniguchi, M; Shimma, N; Arisawa, M; Yamada-Okabe, H			Identification of a novel inhibitor specific to the fungal chitin synthase - Inhibition of chitin synthase 1 arrests the cell growth, but inhibition of chitin synthase 1 and 2 is lethal in the pathogenic fungus Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; EXPRESSION; YEAST	As in Saccharomyces cerevisiae, the pathogenic fungus Candida albicans harbors three chitin synthases called CaChs1p, CaChs2p, and CaChs3p, which are structurally and functionally analogous to the S. cerevisiae ScChs2p, ScChs1p, and ScChs3p, respectively. In S. cerevisiae, ScCHS1, ScCHS2, and ScCHS3 are all nonessential genes; only the simultaneous disruption of ScCHS2 and ScCHS3 is lethal. The fact that a null mutation of the CaCHS1 is impossible, however, implies that CaCHS1 is required for the viability of C. albicans. To gain more insight into the physiological importance of CaCHS1, we identified and characterized a novel inhibitor that was highly specific to CaChs1p. RO-09-3143 inhibited CaChs1p with a K-i value of 0.55 nM in a manner that was non-competitive to the substrate UDP-N-acetylglucosamine. RO-09-3143 also hampered the growth of the C. albicans cells with an MIC50 value of 0.27 muM. In the presence of RO-09-3143, the C. albicans cells failed to form septa and displayed an aberrant morphology, confirming the involvement of the C. albicans Chs1p in septum formation. Although the effect of RO-09-3143 on the wild-type C. albicans was fungistatic, it caused cell death in the cachs2 Delta null mutants but not in the cachs3 Delta null mutants. Thus, it appears that in C. albicans, inhibition of CaChs1p causes cell growth arrest, but simultaneous inhibition of CaChs1p and CaChs2p is lethal.	Nippon Roche Res Ctr, Dept Mycol & Oncol, Kamakura, Kanagawa 2478530, Japan; Nippon Roche Res Ctr, Dept Chem, Kamakura, Kanagawa 2478530, Japan	Roche Holding; Roche Holding	Yamada-Okabe, H (corresponding author), Nippon Roche Res Ctr, Dept Oncol, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	hisafumi.okabe@roche.com						AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BULAWA C, 1995, P NATL ACAD SCI USA, V92, P6216; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1991, ANTIMICROB AGENTS CH, V35, P170, DOI 10.1128/AAC.35.1.170; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; DURAN A, 1978, J BIOL CHEM, V253, P4419; FONZI WA, 1993, GENETICS, V134, P717; GAUGHRAN JP, 1994, J BACTERIOL, V176, P5857, DOI 10.1128/JB.176.18.5857-5860.1994; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; Masubuchi K, 2000, BIOORG MED CHEM LETT, V10, P1459, DOI 10.1016/S0960-894X(00)00257-2; Mio T, 1996, J BACTERIOL, V178, P2416, DOI 10.1128/jb.178.8.2416-2419.1996; MOTOYAMA T, 1994, BIOSCI BIOTECH BIOCH, V58, P1685, DOI 10.1271/bbb.58.1685; Munro CA, 1998, MICROBIOL-SGM, V144, P391, DOI 10.1099/00221287-144-2-391; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Newbery G, 1928, J CHEM SOC, P3046, DOI 10.1039/jr9280003046; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SBURLATI A, 1986, J BIOL CHEM, V261, P5147; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SILVERMAN SJ, 1988, P NATL ACAD SCI USA, V85, P4735, DOI 10.1073/pnas.85.13.4735; STGEORGIEV V, 1998, INFECT DIS IMMUNOCOM, P739; SUDOH M, 1995, MICROBIOL-UK, V141, P2673, DOI 10.1099/13500872-141-10-2673; SUDOH M, 1993, MOL GEN GENET, V241, P351, DOI 10.1007/BF00284688; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101	24	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32901	32905		10.1074/jbc.M003634200	http://dx.doi.org/10.1074/jbc.M003634200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930406	hybrid			2022-12-25	WOS:000090003800072
J	Zhang, Y; Chen, Q				Zhang, Y; Chen, Q			Changes of matrilin forms during endochondral ossification - Molecular basis of oligomeric assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; HELICAL COILED-COIL; C-TERMINAL DOMAIN; EXTRACELLULAR-MATRIX; FILAMENTOUS NETWORK; X COLLAGEN; CARTILAGE; PROTEIN; EXPRESSION; FAMILY	To understand the molecular properties of matrilin-3, a newly discovered member of the novel extracellular matrix protein family, we cloned a MAT-3 cDNA from developing chicken sterna. Real time quantitative reverse-transcription polymerase chain reaction indicates that MAT-3 mRNA is mainly expressed in the proliferation zone of a growth plate. It is also expressed in the maturation zone, overlapping with that of the mature chondrocyte-abundant matrilin-1 mRNA This suggests that matrilin-3 may self-assemble in the proliferation zone, in addition to its co-assembly with matrilin-1 during endochondral ossification. Transfection of a MAT-3 cDNA into COS-7 cells shows that MAT-3 predominantly forms a homotetramer but also a trimer and a dimer. Co-transfection of both MAT-3 and MAT-I cDNAs results in three major matrilins as follows: (MAT-1)(3), (MAT-3)(4), and (MAT-1)(2)(MAT-3)(2), Thus matrilin-3 may assemble into both homotypic and heterotypic oligomers, Our analysis shows that the assembly of MAT-3 does not depend on the number of epidermal growth factor repeats within the molecule, but the presence of Cys(412) and Cys(414) within the coiled-coil domain, which form covalent disulfide linkage responsible for both homooligomerization of MAT-3 and hetero-oligomerization of MAT-3 and MAT-1. Our data suggest that the varying synthetic levels of matrilins in different zones of a growth plate may result in a change of matrilin oligomeric forms during endochondral ossification.	Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Cell & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, Q (corresponding author), Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA.		Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG014399, R01AG014399] Funding Source: NIH RePORTER; NIA NIH HHS [AG14399, AG00811] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; Deak F, 1997, J BIOL CHEM, V272, P9268; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; KISS I, 1989, J BIOL CHEM, V264, P8126; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Sambrook J., 2002, MOL CLONING LAB MANU; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	20	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32628	32634		10.1074/jbc.M002594200	http://dx.doi.org/10.1074/jbc.M002594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930403	hybrid			2022-12-25	WOS:000090003800036
J	Hu, SM; Yang, XL				Hu, SM; Yang, XL			dFADD, a novel death domain-containing adapter protein for the Drosophila caspase DREDD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; APOPTOSIS; ACTIVATION; OLIGOMERIZATION; CED-4; PROCASPASE-9; INTERACTS; GENETICS; PATHWAY	Apoptotic cell death occurs through activation of procaspases, the precursors of a group of aspartate-specific cysteine proteases known as caspases. Procaspase activation is mediated by death adapter proteins such as the mammalian proteins FADD and Apaf-1 and the Caenorhabditis elegans protein CED-4. These adapters bind to procaspases and facilitate oligomerization and subsequent auto-proteolytic processing of the zymogens, Here we report cloning and characterization of dFADD, a FADD homologue in Drosophila. dFADD contains a death domain that is highly homologous to the FADD death domain, and it also shares a novel domain with;a Drosophila caspase DREDD, which we call death-inducing domain, dFADD binds to DREDD through the death-inducing domain and enhances the cell death activity and proteolytic processing of DREDD. dFADD and DREDD are stabilized by their interaction. The structural and functional similarities between dFADD and FADD suggest the existence of a FADD-like apoptosis pathway in Drosophila.	Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA	University of Pennsylvania	Yang, XL (corresponding author), Univ Penn, Sch Med, Dept Mol & Cellular Engn, 421 Curie Blvd,610 BRBII-III, Philadelphia, PA 19104 USA.		Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	31	102	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30761	30764		10.1074/jbc.C000341200	http://dx.doi.org/10.1074/jbc.C000341200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10934188	hybrid			2022-12-25	WOS:000089762700005
J	Arama, E; Dickman, D; Kimchie, Z; Shearn, A; Lev, Z				Arama, E; Dickman, D; Kimchie, Z; Shearn, A; Lev, Z			Mutations in the beta-propeller domain of the Drosophila brain tumor (brat) protein induce neoplasm in the larval brain	ONCOGENE			English	Article						invertebrate; tumorigenesis; tumor suppressor; neuroblastoma; plasmid rescue; NHL repeats	RNA-POLYMERASE-III; DECARBOXYLASE GENE-CLUSTER; RETINOBLASTOMA PROTEIN; SUPPRESSOR GENE; DOPA-DECARBOXYLASE; HUMAN HOMOLOG; RING FINGER; ZINC-FINGER; CAENORHABDITIS-ELEGANS; MALIGNANT NEOPLASMS	Inactivation of both alleles of the fruit fly D. melanogaster brain tumor (brat) gene results in the production of a tumor-like neoplasm in the larval brain, and lethality in the Larval third instar and pupal stages. We cloned the brat gene from a transposon-tagged allele and identified its gene product. hr nt encodes for an 1037 amino acid protein with an N-terminal B-box1 zinc finger followed ba a B-box2 zinc finger, a coiled-coil domain, and a C-terminal beta-propeller domain with six blades. All these motifs are known to mediate protein-protein interactions. Sequence analysis of four br at alleles revealed that all of them are mutated at the beta-propeller domain. The clustering of mutations in this domain strongly suggests that it has a crucial role in the normal function of Brat, and defines a novel protein motif involved in tumor suppression activity. The brat gene is expressed in the embryonic central and peripheral nervous systems including the embryonic brain. In third instar larva br nt expression was detected in the Larval central nervous sa stem including the brain and the ventral ganglion, in two glands - the ring gland and the salivary gland, and in parts of the foregut - the gastric caecae and the proventriculus. A second brat-like gene was found in D, melanogaster, and homologs were identified in the nematode, mouse, rat, and human. Accumulated data suggests that Brat may regulate proliferation and differentiation by secretion/transport mediated processes.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Technion Israel Institute of Technology; Johns Hopkins University	Lev, Z (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Arama, Eli/GYJ-0491-2022					Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CLINE TW, 1976, GENETICS, V83, pS16; DERENZINI M, 1991, VIRCHOWS ARCH B, V61, P1; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Frank DJ, 1998, J CELL BIOL, V140, P1321, DOI 10.1083/jcb.140.6.1321; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Gateff E, 1996, IN VIVO, V10, P211; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Gateff E., 1978, GENETICS BIOL DROS B, V2b, P181; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; Hartenstein V., 1993, ATLAS DROSOPHILA DEV; HEDGECOCK EM, 1995, GENETICS, V141, P989; INOUYE S, 1986, EUR J BIOCHEM, V154, P417, DOI 10.1111/j.1432-1033.1986.tb09414.x; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Larson RE, 1996, BRAZ J MED BIOL RES, V29, P309; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McNellis TW, 1996, PLANT CELL, V8, P1491, DOI 10.1105/tpc.8.9.1491; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBERTSON HM, 1988, GENETICS, V118, P461; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; SMETANA K, 1970, CANCER RES, V30, P1149; Spradling AC, 1999, GENETICS, V153, P135; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; STATHAKIS DG, 1995, GENETICS, V141, P629; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; TOROK T, 1993, GENETICS, V135, P71; WATSON KL, 1994, J CELL SCI, P19; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WRIGHT TRF, 1981, CHROMOSOMA, V83, P45, DOI 10.1007/BF00286015; WRIGHT TRF, 1976, GENETICS, V84, P287; Wright TRF, 1996, J HERED, V87, P175, DOI 10.1093/oxfordjournals.jhered.a022983	62	92	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3706	3716		10.1038/sj.onc.1203706	http://dx.doi.org/10.1038/sj.onc.1203706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949924				2022-12-25	WOS:000088568400002
J	Gorlach, A; Brandes, RP; Bassus, S; Kronemann, N; Kirchmaier, CM; Busse, R; Schini-Kerth, VB				Gorlach, A; Brandes, RP; Bassus, S; Kronemann, N; Kirchmaier, CM; Busse, R; Schini-Kerth, VB			Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets	FASEB JOURNAL			English	Article						NAD(P)H oxidase; reactive oxygen species; platelet-derived products; vascular injury; antisense technique	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NADPH OXIDASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; MESSENGER-RNA; FREE-RADICALS; GROWTH; THROMBIN	Vascular injury after balloon angioplasty results in the rapid activation of platelets leading to the release of growth factors and vasoactive substances, In addition, up-regulation of tissue factor (TF) and an increased production of reactive oxygen species (ROS) have been detected at sites of vascular injury. We investigated whether platelet-derived products (PDP) released from activated human platelets increase ROS production, resulting in the induction of TF expression in vascular smooth muscle cells (SMC). PDP induced a time- and concentration-dependent increase in ROS generation in cultured SMC that was mediated mainly by PDGF-AB and TGF-beta 1 and impaired by the flavin inhibitor diphenylene iodonium. Increased ROS formation was associated with enhanced mRNA levels of the small NAD(P)H oxidase subunit p22phox or its smooth muscle isoform. Transient transfection with a p22phox antisense vector decreased PDP-induced ROS generation. PDP up-regulated TF mRNA expression, which was redox sensitive and reduced by transfection of the p22phox antisense vector. In addition, PDP-stimulated reporter gene activity of two TF promoter constructs was decreased by coexpression of the p22phox antisense vector. These results indicate that activated platelets up-regulate TF expression and that this response involves ROS generation and a p22phox-containing NAD(P)H oxidase in SMC.	Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, D-60590 Frankfurt, Germany; Fachbereich Hamostaseol, Stiftung Deutsch Klin Diagnost, D-65191 Wiesbaden, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Gorlach, A (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Gorlach, Agnes/B-3494-2013; Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Ambrosio G, 1997, CARDIOVASC RES, V34, P445, DOI 10.1016/S0008-6363(97)00101-6; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Braun M, 1999, CARDIOVASC RES, V41, P395, DOI 10.1016/S0008-6363(98)00302-2; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fandrey J, 1997, KIDNEY INT, V51, P492, DOI 10.1038/ki.1997.68; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; Gallo R, 1998, CIRCULATION, V97, P581; Gardemann A, 1999, ATHEROSCLEROSIS, V145, P315, DOI 10.1016/S0021-9150(99)00083-0; GASPERETTI CM, 1993, CIRCULATION, V88, P2728, DOI 10.1161/01.CIR.88.6.2728; Gong KW, 1996, J VASC RES, V33, P42, DOI 10.1159/000159130; GORLACH A, 1993, BIOCHEM J, V290, P771; HAMON M, 1995, EUR HEART J, V16, P33, DOI 10.1093/eurheartj/16.suppl_I.33; Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; Inoue N, 1998, CIRCULATION, V97, P135, DOI 10.1161/01.CIR.97.2.135; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MARMUR JD, 1994, J AM COLL CARDIOL, V24, P1484, DOI 10.1016/0735-1097(94)90144-9; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; Marumo T, 1997, CIRCULATION, V96, P2361; McNamara CA, 1996, SEMIN THROMB HEMOST, V22, P139, DOI 10.1055/s-2007-999001; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Nunes GL, 1997, CIRCULATION, V96, P3593; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RUGGERI ZM, 1994, SEMIN HEMATOL, V31, P229; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; Schecter AD, 1997, J CLIN INVEST, V100, P2276, DOI 10.1172/JCI119765; SchiniKerth VB, 1997, CIRCULATION, V96, P3888; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Umemura K, 1996, THROMB HAEMOSTASIS, V76, P799; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; WILCOX JN, 1994, CIRC RES, V75, P1029, DOI 10.1161/01.RES.75.6.1029; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	47	100	103	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1518	1528		10.1096/fj.14.11.1518	http://dx.doi.org/10.1096/fj.14.11.1518			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928986				2022-12-25	WOS:000088627800006
J	Kardinal, C; Konkol, B; Schulz, A; Posern, G; Lin, H; Adermann, K; Eulitz, M; Estrov, Z; Talpaz, M; Arlinghaus, RB; Feller, SM				Kardinal, C; Konkol, B; Schulz, A; Posern, G; Lin, H; Adermann, K; Eulitz, M; Estrov, Z; Talpaz, M; Arlinghaus, RB; Feller, SM			Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients	FASEB JOURNAL			English	Article						CRKL; adapter protein; Bcr-Abl; MAP kinase (MAPK)	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; BCR-ABL ONCOGENE; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; TYROSINE KINASE; CRK; BINDING; MODEL	Bcr-Abl contributes prominently to the development of most chronic myeloid leukemias (CMLs). Prior work has identified the adapter protein CRKL as a major substrate of the Bcr-Abl tyrosine kinase. CRKL can also bind via its first SH3 domain [SH3(1)] to specific sequences in Bcr-Abl. Cell-penetrating peptides were developed that bind with high affinity and selectivity to the SH3(1) domain of CRKL. They disrupt Bcr-Abl-CRKL complexes and strongly reduce the proliferation of primary CML blast cells and cell lines established from Bcr-Abl-positive patients. Activation-specific antibodies against phosphorylated MAP kinase (MAPK) showed that MAPK activity is down-regulated in blast cells treated with the CRKLSH3(1) blocker peptides. We conclude that the Bcr-Abl-CRKL complexes are largely dependent on the CRKLSH3(1) domain, that the central mitogenic cascade is down-regulated as a consequence of the disruption of CRKLSH3(1) interactions, and that CRKL therefore contributes to the proliferation of CML blast cells.	Univ Wurzburg, MSZ, Oncol Mol Lab, D-97078 Wurzburg, Germany; GSF, Klin Mol Biol & Tumorgenet, Munich, Germany; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Texas System; UTMD Anderson Cancer Center	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Oncol Mol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.			Talpaz, Moshe/0000-0003-3361-3981				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Groffen J, 1997, BAILLIERE CLIN HAEM, V10, P187, DOI 10.1016/S0950-3536(97)80002-9; Hoyle C, 1998, BLOOD, V92, P3318, DOI 10.1182/blood.V92.9.3318.421k39_3318_3327; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Schulz A, 2000, TETRAHEDRON, V56, P3889, DOI 10.1016/S0040-4020(00)00305-7; Senechal K, 1996, MOL MED TODAY, V2, P503, DOI 10.1016/S1357-4310(97)81454-2; SKORSKI T, 1992, FOLIA HISTOCHEM CYTO, V30, P91; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Xu QH, 1999, BIOCHEMISTRY-US, V38, P3491, DOI 10.1021/bi982744j; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	36	39	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1529	1538		10.1096/fj.14.11.1529	http://dx.doi.org/10.1096/fj.14.11.1529			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928987				2022-12-25	WOS:000088627800007
J	Ohki, R; Nemoto, J; Murasawa, H; Oda, E; Inazawa, J; Tanaka, N; Taniguchi, T				Ohki, R; Nemoto, J; Murasawa, H; Oda, E; Inazawa, J; Tanaka, N; Taniguchi, T			Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G(2) phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-1; IFN-BETA-GENE; DNA-DAMAGE; DIFFERENTIAL DISPLAY; P53-INDUCIBLE GENE; P53; APOPTOSIS; PROTEIN; EXPRESSION; CHECKPOINT	A novel gene, Reprimo, in which induction in cells exposed to X-irradiation is dependent on p53 expression, has been isolated. Ectopic p53 expression results in the induction of its mRNA. Reprimo is a highly glycosylated protein and, when ectopically expressed, it is localized in the cytoplasm and induces G(2) arrest of the cell cycle. In the arrested cells, both Cdc2 activity and nuclear translocation of cyclin El are inhibited, suggesting the involvement of Reprimo in the Cdc2.cyclin B1 regulation pathway. Thus, Reprimo may be a new member involved in the regulation of p53-dependent G(2) arrest of the cell cycle.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU)	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		MURASAWA, Hideki/AAP-9514-2021	MURASAWA, Hideki/0000-0003-4897-1239; Tanaka, Nobuyuki/0000-0002-6373-2220				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; ITO T, 1994, FEBS LETT, V351, P231, DOI 10.1016/0014-5793(94)00867-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TAKITA J, 1995, ONCOGENE, V11, P1829; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	39	145	150	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22627	22630		10.1074/jbc.C000235200	http://dx.doi.org/10.1074/jbc.C000235200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930422	hybrid			2022-12-25	WOS:000088419400006
J	Wittemann, S; Mark, MD; Rettig, J; Herlitze, S				Wittemann, S; Mark, MD; Rettig, J; Herlitze, S			Synaptic localization and presynaptic function of calcium channel beta(4)-subunits in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; ALPHA(1C) SUBUNIT; NERVOUS-SYSTEM; EXPRESSION; MODULATION; SYNAPTOBREVIN; TRAFFICKING; RECEPTOR	Neurotransmitter release is triggered by the influx of Ca2+ into the presynaptic terminal through voltage gated Ca2+-channels. The shape of the presynaptic Ca2+ signal largely determines the amount of released quanta and thus the size of the synaptic response, Ca2+-channel function is modulated in particular by the auxiliary beta -subunits that interact intracellularly with the pore-forming alpha (1)-subunit, Using retrovirus-mediated gene transfer in cultured hippocampal neurons, we demonstrate that functional GFP-beta (4) constructs colocalize with the synaptic vesicle marker synaptobrevin II and endogenous P/Q-type channels, indicating that beta (4)-subunits are localized to synaptic sites. Costaining with the dendritic marker MAPS revealed that the beta (4)-subunit is transported to dendrites as well as axons, The nonconserved amino- and carboxyl-termini of the beta (2)-subunit were found to target the protein to the synapse. Physiological measurements in autaptic hippocampal neurons infected with green fluorescent protein (GFP)-beta (4) revealed an increase in both excitatory post-synaptic current amplitude and paired pulse facilitation ratio, whereas the GFP-beta (4) mutant, GFP-beta (4)(Delta 50-407), which demonstrated a cytosolic localization pattern, did not alter these synaptic properties. In summary, our data suggest a presynaptic function of the Ca2+-channel beta (4)-subunit in synaptic transmission.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Herlitze, S (corresponding author), Univ Tubingen, Dept Physiol 2, Heimmelreich 7, D-72074 Tubingen, Germany.		Rettig, Jens/K-5103-2013; Mark, Melanie/ABF-9102-2020	Rettig, Jens/0000-0001-6160-3954; Mark, Melanie/0000-0002-2788-6003				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bogdanov Y, 2000, EUR J NEUROSCI, V12, P894, DOI 10.1046/j.1460-9568.2000.00981.x; Bradke F, 1998, BBA-MOL CELL RES, V1404, P245, DOI 10.1016/S0167-4889(98)00060-3; Brody DL, 2000, J NEUROSCI, V20, P889, DOI 10.1523/JNEUROSCI.20-03-00889.2000; Caddick SJ, 1999, J NEUROPHYSIOL, V81, P2066, DOI 10.1152/jn.1999.81.5.2066; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Day NC, 1998, MOL BRAIN RES, V60, P259, DOI 10.1016/S0169-328X(98)00186-7; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Keller P, 1997, J CELL SCI, V110, P3001; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Li JY, 1996, J NEUROSCI, V16, P137; Lie AA, 1999, NEUROSCIENCE, V93, P449, DOI 10.1016/S0306-4522(99)00162-1; Lin FH, 1999, MOL BRAIN RES, V71, P1, DOI 10.1016/S0169-328X(99)00141-2; Ludwig A, 1997, J NEUROSCI, V17, P1339; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; McEnery MW, 1998, J BIOL CHEM, V273, P21435, DOI 10.1074/jbc.273.34.21435; Qian J, 2000, J NEUROSCI, V20, P163, DOI 10.1523/JNEUROSCI.20-01-00163.2000; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Volsen SG, 1997, NEUROSCIENCE, V80, P161, DOI 10.1016/S0306-4522(97)00115-2; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; West AE, 1997, J CELL BIOL, V139, P917, DOI 10.1083/jcb.139.4.917; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	41	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37807	37814		10.1074/jbc.M004653200	http://dx.doi.org/10.1074/jbc.M004653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10931840	hybrid			2022-12-25	WOS:000165618700068
J	Geva, A; Lassere, TB; Lichtarge, O; Pollitt, SK; Baranski, TJ				Geva, A; Lassere, TB; Lichtarge, O; Pollitt, SK; Baranski, TJ			Genetic mapping of the human C5a receptor - Identification of transmembrane amino acids critical for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHEROMONE RESPONSE PATHWAY; NEUROKININ-1 RECEPTOR; PLASMA-MEMBRANE; BINDING-SITE; RHODOPSIN; ACTIVATION; YEAST; SELECTIVITY; HELICES	Many hormones and sensory stimuli signal through a superfamily of seven transmembrane-spanning receptors to activate heterotrimeric G proteins, How the seven transmembrane segments of the receptors (a molecular architecture of bundled cu-helices conserved from yeast to man) work as "on/off' switches remains unknown. Previously, we used random saturation mutagenesis coupled with a genetic selection in yeast to determine the relative importance of amino acids in four of the seven transmembrane segments of the human C5a receptor (Baranski, T, J., Herzmark, P,, Lichtarge, O,, Gerber, B, O,, Trueheart, J,, Meng, E, C,, Iiri, T., Sheikh, S, P., and Bourne, H, R, (1999) J, Bioh Chen, 274, 15757-15765). In this study, we evaluate helices I, II, and TV,thereby furnishing a complete mutational map of the seven transmembrane helices of the human C5a receptor. Our analysis identified 19 amino acid positions resistant to non-conservative substitutions. When combined with the 25 essential residues previously identified in helices III and V-VII, they delineate two distinct components of the receptor switch: a ligand-binding surface at or near the extracellular surface of the helix bundle and a core cluster in the cytoplasmic half of the bundle. In addition, we found critical amino acids in the first and second helices that are predicted to face the lipid membrane. These residues form an extended surface that might mediate interactions with lipids and other membrane proteins or function as an oligomerization domain with other receptors.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Washington University (WUSTL); Washington University (WUSTL); Baylor College of Medicine; University of California System; University of California San Francisco	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, POB 8103,660 S Euclid Ave, St Louis, MO 63110 USA.							AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5, P353; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1994, J BIOL CHEM, V269, P14957; GERARD C, 1985, J BIOL CHEM, V260, P2613; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GU WX, 1995, ENDOCRINOLOGY, V136, P3146, DOI 10.1210/en.136.7.3146; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Javitch JA, 1999, BIOCHEMISTRY-US, V38, P7961, DOI 10.1021/bi9905314; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MERY L, 1994, J BIOL CHEM, V269, P3457; MIN KC, 1993, J BIOL CHEM, V268, P9400; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WONG SKF, 1990, J BIOL CHEM, V265, P6219	54	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35393	35401		10.1074/jbc.M005602200	http://dx.doi.org/10.1074/jbc.M005602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952985	hybrid			2022-12-25	WOS:000165422800075
J	Donate, F; Yanez, AJ; Iriarte, A; Martinez-Carrion, M				Donate, F; Yanez, AJ; Iriarte, A; Martinez-Carrion, M			Interaction of the precursor to mitochondrial aspartate aminotransferase and its presequence peptide with model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; SIGNAL SEQUENCE; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; BINDING-PROPERTIES; PENETRATION DEPTH; ESCHERICHIA-COLI; PARALLAX METHOD; ALPHA-HELICES	The possible contribution of the mature portion of a mitochondrial precursor protein to its interaction with membrane lipids is unclear. To address this issue, we examined the interaction of the precursor to mitochondrial aspartate aminotransferase (pmAAT) and of a synthetic peptide corresponding to the 29-residue presequence peptide (mAAT-pp) with anionic phospholipid vesicles. The affinity of mAAT-pp and pmAAT for anionic vesicles is nearly identical. Results obtained by analyzing the effect of mAAT-pp or full-length pmAAT on either the permeability or microviscosity of the phospholipid vesicles are consistent with only a shallow insertion of the presequence peptide in the bilayer. Analysis of the quenching of Trp-17 fluorescence by brominated phospholipids reveals that this presequence residue inserts to a depth of approximately 9 Angstrom hom the center of the bilayer, Furthermore, in membrane-bound pmAAT or mAAT-pp, both Arg-8 and Arg-28 are accessible to the solvent. These results suggest that the presequence segment lies close to the surface of the membrane and that the mature portion of the precursor protein has little effect on the affinity or mode of binding of the presequence to model membranes. Tn the presence of vesicles, mAAT-pp adopts considerable a-helical structure. Hydrolysis by trypsin after Arg-g results in the dissociation of the remaining 21-residue C-terminal peptide fragment from the membrane bilayer, suggesting that the N-terminal portion of the presequence is essential for membrane binding. Based on these results, we propose that the presequence peptide may contain dual recognition elements for both the lipid and import receptor components of the mitochondrial membrane.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Austral Chile, Fac Ciencias, Inst Bioquim, Valdivia, Chile	University of Missouri System; University of Missouri Kansas City; Universidad Austral de Chile	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd, Kansas City, MO 64110 USA.	martinezcm@umkc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Barlett G.R., 1959, J BIOL CHEM, V234, P466; Berezov A, 1996, ARCH BIOCHEM BIOPHYS, V336, P173, DOI 10.1006/abbi.1996.0546; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; CHATTOPADHYAY A, 1991, BIOCHEMISTRY-US, V30, P7159, DOI 10.1021/bi00243a017; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Donate F, 1998, PROTEIN SCI, V7, P1811, DOI 10.1002/pro.5560070817; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; ENDO T, 1989, FEBS LETT, V249, P173, DOI 10.1016/0014-5793(89)80618-0; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x; HORKOVICSKOVATS S, 1990, BIOCHEMISTRY-US, V29, P8652, DOI 10.1021/bi00489a022; HOYT DW, 1991, J BIOL CHEM, V266, P14406; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; HOYT DW, 1991, J BIOL CHEM, V266, P21693; IRIARTE A, 1990, ENZYMES DEPENDENT PR; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; Keller RCA, 1996, BIOCHEMISTRY-US, V35, P3063, DOI 10.1021/bi951870+; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Lain B, 1998, J BIOL CHEM, V273, P4406, DOI 10.1074/jbc.273.8.4406; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; MCKNIGHT CJ, 1991, P NATL ACAD SCI USA, V88, P5799, DOI 10.1073/pnas.88.13.5799; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NISHI T, 1989, J BIOL CHEM, V264, P6044; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Schleiff E, 1999, FEBS LETT, V461, P9, DOI 10.1016/S0014-5793(99)01415-5; Schleiff E, 1998, BIOCHEMISTRY-US, V37, P13052, DOI 10.1021/bi980746y; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WEINSTEIN S, 1979, P NATL ACAD SCI USA, V76, P4230, DOI 10.1073/pnas.76.9.4230; YU YG, 1994, BIOCHEMISTRY-US, V33, P14221, DOI 10.1021/bi00251a034	57	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34147	34156		10.1074/jbc.M004494200	http://dx.doi.org/10.1074/jbc.M004494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938277	hybrid			2022-12-25	WOS:000165095300023
J	Feschenko, MS; Stevenson, E; Sweadner, KJ				Feschenko, MS; Stevenson, E; Sweadner, KJ			Interaction of protein kinase C and cAMP-dependent pathways in the phosphorylation of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; ALPHA-SUBUNIT; INTACT-CELLS; CATALYTIC SUBUNIT; EPITHELIAL-CELLS; STRUCTURAL BASIS; PLASMA-MEMBRANE; XENOPUS OOCYTES; CHOROID-PLEXUS; NA+,K+-ATPASE	To test the hypothesis that there is cross-talk between the protein kinase C (PKC) and protein kinase A (PKA) pathways in the regulation of the Na,K-ATPase, we measured its phosphorylation in mammalian cell cultures. Phosphorylation of the PKC site, Ser-18, appeared to be due to the activation of the a isoform of the kinase. In NRK-52E and L6 cells, this phosphorylation was reduced by prior activation of a cAMP-dependent signaling pathway with forskolin. In principle this would be consistent with direct interaction between the two phosphorylation sites, but further investigation suggested a more indirect mechanism. First, phosphorylation of Ser-938, the PKA site, could not be detected despite the presence of active PKA. Second, there was a major reduction in the phosphorylation of unrelated phosphoproteins as a consequence of elevation of cAMP, suggesting generalized reduction of kinase activity or activation of phosphatase activity. In NRK-52E and L6, phosphorylation of the Na,K-ATPase at Ser-18 paralleled this global change. In C6 cells, in contrast, there was no cAMP effect on Na,K-ATPase phosphorylation at Ser-18 and no global cAMP effect on other phosphoproteins. The cross-talk is evidently mediated by events occurring at the cellular level.	Massachusetts Gen Hosp, Lab Membrane Biol, Ctr Neurosci, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Sweadner, KJ (corresponding author), Massachusetts Gen Hosp, Lab Membrane Biol, Ctr Neurosci, Charlestown, MA 02129 USA.	sweadner@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS27653] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; Arystarkhova E, 1997, J BIOL CHEM, V272, P22405, DOI 10.1074/jbc.272.36.22405; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Beguin P, 1996, AM J PHYSIOL-CELL PH, V270, pC131, DOI 10.1152/ajpcell.1996.270.1.C131; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Belusa R, 1997, J BIOL CHEM, V272, P20179, DOI 10.1074/jbc.272.32.20179; Beron J, 1997, MOL BIOL CELL, V8, P387, DOI 10.1091/mbc.8.3.387; BERTORELLO A, 1990, AM J PHYSIOL, V259, pF924, DOI 10.1152/ajprenal.1990.259.6.F924; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; Canfield VA, 1996, BIOCHEMISTRY-US, V35, P14165, DOI 10.1021/bi961851f; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; Carranza ML, 1996, FEBS LETT, V396, P309, DOI 10.1016/0014-5793(96)01121-0; Carranza ML, 1998, J PHYSIOL-LONDON, V511, P235, DOI 10.1111/j.1469-7793.1998.235bi.x; Cheng SXJ, 1999, J PHYSIOL-LONDON, V518, P37, DOI 10.1111/j.1469-7793.1999.0037r.x; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1981, DOI 10.1152/ajpcell.1997.273.6.C1981; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC893, DOI 10.1152/ajpcell.1997.273.3.C893; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; COHEN P, 1989, J BIOL CHEM, V264, P21435; Cornelius F, 1996, FEBS LETT, V380, P277, DOI 10.1016/0014-5793(96)00032-4; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; Feraille E, 2000, MOL BIOL CELL, V11, P39, DOI 10.1091/mbc.11.1.39; Feschenko MS, 1997, ANN NY ACAD SCI, V834, P479, DOI 10.1111/j.1749-6632.1997.tb52306.x; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Fisone G, 1998, MOL MED, V4, P258, DOI 10.1007/BF03401922; FISONE G, 1994, J BIOL CHEM, V269, P9368; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kiroytcheva M, 1999, KIDNEY INT, V55, P1819, DOI 10.1046/j.1523-1755.1999.00414.x; Li DL, 1998, AM J PHYSIOL-RENAL, V275, pF863, DOI 10.1152/ajprenal.1998.275.6.F863; Li DL, 1999, AM J PHYSIOL-HEART C, V276, pH2109, DOI 10.1152/ajpheart.1999.276.6.H2109; Liang MY, 1999, AM J PHYSIOL-RENAL, V277, pF859, DOI 10.1152/ajprenal.1999.277.6.F859; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; Muscella A, 2000, J NEUROCHEM, V74, P1325; Nestor NB, 1997, ANN NY ACAD SCI, V834, P579, DOI 10.1111/j.1749-6632.1997.tb52324.x; Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x; Nowicki S, 1997, J CLIN INVEST, V99, P1224, DOI 10.1172/JCI119279; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; ROBINSON JD, 1980, BIOCHIM BIOPHYS ACTA, V598, P543, DOI 10.1016/0005-2736(80)90034-6; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; Sweeney G, 1998, DIABETOLOGIA, V41, P1199, DOI 10.1007/s001250051052; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRIA E, 1974, BIOCHIM BIOPHYS ACTA, V343, P297, DOI 10.1016/0304-4165(74)90094-4; Vasilets LA, 1997, CELL PHYSIOL BIOCHEM, V7, P1, DOI 10.1159/000154847; YOON KL, 1994, J BIOL CHEM, V269, P28249; Zaheer A, 1997, J BIOL CHEM, V272, P5183, DOI 10.1074/jbc.272.8.5183	58	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34693	34700		10.1074/jbc.M005869200	http://dx.doi.org/10.1074/jbc.M005869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940309	hybrid			2022-12-25	WOS:000165095300093
J	Zhang, J; Tamilarasu, N; Hwang, SW; Garber, ME; Huq, I; Jones, KA; Rana, TM				Zhang, J; Tamilarasu, N; Hwang, SW; Garber, ME; Huq, I; Jones, KA; Rana, TM			HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; PHOTO-CROSS-LINKING; FACTOR P-TEFB; TRANSCRIPTIONAL ACTIVATION; BINDING DOMAIN; PHAGE-LAMBDA; DNA-BINDING; IN-VITRO; PROTEIN; COMPLEX	Human immunodeficiency virus, type 1 (HIV-1), Tat activates elongation of RNA polymerase II transcription at the HIV-1 promoter through interaction with the cyclin T1 (CycT1) subunit of the positive transcription elongation factor complex, P-TEFb, Binding of Tat to CycT1 induces cooperative binding of the beta -TEFb complex onto nascent HIV-1 TAR RNA. Here the specific interaction between Tat protein, human cyclin T1, and HIV-1 TAR RNA was analyzed by fluorescence resonance energy transfer, using fluorescein-labeled TAR RNA and a rhodamine-labeled Tat protein synthesized through solid-phase chemistry. We find that CycT1 remodels the structure of Tat to enhance its affinity for TAR RNA and that TAR RNA further enhances the interaction between Tat and CycT1, We conclude that TAR RNA nucleates the formation of the Tat.beta -TEFb complex through an induced fit mechanism.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Salk Institute	Rana, TM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041404, R56AI041404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; NEENHOLD HR, 1995, BIOCHEMISTRY-US, V34, P6303, DOI 10.1021/bi00019a007; Ping YH, 1997, RNA, V3, P850; Shah K, 1996, BIOCONJUGATE CHEM, V7, P283, DOI 10.1021/bc960023w; SHAH K, 1994, BIOCONJUGATE CHEM, V5, P508, DOI 10.1021/bc00030a005; Su LL, 1997, GENE DEV, V11, P2214, DOI 10.1101/gad.11.17.2214; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; Wang ZY, 1996, BIOCHEMISTRY-US, V35, P6491, DOI 10.1021/bi960037p; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang MS, 1997, METHOD ENZYMOL, V278, P417; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	35	57	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34314	34319		10.1074/jbc.M006804200	http://dx.doi.org/10.1074/jbc.M006804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944537	hybrid			2022-12-25	WOS:000165095300044
J	Zhou, WL; Carpenter, G				Zhou, WL; Carpenter, G			Heregulin-dependent trafficking and cleavage of ErbB-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; AMYLOID PRECURSOR PROTEIN; FACTOR RECEPTOR ACTIVATION; ALPHA-SECRETASE CLEAVAGE; MEMBRANE DOMAINS; SIGNALING NETWORK; CARDIAC MYOCYTES; BREAST-CANCER; MESSENGER-RNA; MAMMARY-GLAND	Heregulin was shown to promote the proteolytic cleavage of its receptor, ErbB-4, in several cell lines. The growth factor also rapidly promoted the transient translocation of ErbB-4 to a detergent-insoluble fraction, in which the receptor was hyper-tyrosine-phosphorylated compared with the receptor present in the detergent-soluble pool. However, an 80-kDa proteolytic fragment of ErbB-4 was found in the detergent soluble fraction, but not in the detergent-insoluble fraction. Although the heregulin-induced cleavage of ErbB-4 produced a fragment of ErbB-4 very similar to that induced by 12-O-tetradecanoylphorbol-13-acetate or pervanadate teach of which is blocked by metalloprotease inhibitors), the growth factor-induced cleavage was not sensitive to these inhibitors under the same conditions. The heregulin-induced cleavage of ErbB-4 could be blocked by conditions that prevent clathrin-coated pit formation, suggesting that heregulin-mediated ErbB-4 cleavage occurs subsequent to internalization. When reagents that prevent acidification of endosomes were employed, heregulin-induced ErbB-4 cleavage was sensitive to metalloprotease inhibitors. The results imply that during ligand-dependent receptor trafficking, activated ErbB-4 receptors are subject to proteolytic cleavage involving an intracellular metalloprotease.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem, 647 Light Hall,23rd Ave S Pierce, Nashville, TN 37232 USA.				NCI NIH HHS [CA24071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baulida J, 1996, J BIOL CHEM, V271, P5251; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Codony-Servat J, 1999, CANCER RES, V59, P1196; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; Drose S., 1996, J EXP BIOL, V200, P1; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2; Harlow E., 1988, ANTIBODIES LAB MANUA; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P17146; QUINTART J, 1979, J CELL BIOL, V82, P644, DOI 10.1083/jcb.82.3.644; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Solomon KA, 1997, J IMMUNOL, V159, P4524; Sorkin Alexander, 1998, Frontiers in Bioscience, V3, pD729; SRIHAVASAN R, 1998, J PATHOL, V185, P126; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vogt U, 1998, GENE, V223, P375, DOI 10.1016/S0378-1119(98)00454-5; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YABBOWITZ R, 1997, BLOOD, V90, P706; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870; Zhao YY, 1999, CIRC RES, V84, P1380	59	80	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34737	34743		10.1074/jbc.M003756200	http://dx.doi.org/10.1074/jbc.M003756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944525	hybrid			2022-12-25	WOS:000165095300098
J	Huse, JT; Pijak, DS; Leslie, GJ; Lee, VMY; Doms, RW				Huse, JT; Pijak, DS; Leslie, GJ; Lee, VMY; Doms, RW			Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme - The Alzheimer's disease beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; ENDOCYTIC PATHWAY; NT2N CELLS; RECEPTOR; CLEAVAGE; CATENIN; COMPARTMENT; COMPLEX; INTERNALIZATION; LYSOSOMES	The amyloidogenic A beta peptide is liberated from the amyloid precursor protein (APP) by two proteolytic activities, beta -secretase and gamma -secretase. Recently, a type I membrane protein termed RACE (beta -site APP cleaving enzyme) with characteristics of an aspartyl protease has been identified as the beta -secretase. We undertook a series of biochemical and morphological investigations designed to characterize the basic properties of this protein. Initial studies indicated that RACE undergoes N-linked glycosylation at three of four potential sites. Metabolic pulse-chase experiments revealed that after core glycosylation, RACE is rapidly and efficiently transported to the Gels apparatus and distal secretory pathway. RACE was also found to be quite stable, being turned over with a t(1/2) of similar to 16 h. Retention of RACE in the endoplasmic reticulum by introduction of a C-terminal dilysine motif prevented complex carbohydrate processing and demonstrated that propeptide cleavage occurs after exit from this organelle. RACE exhibited intramolecular disulfide bonding but did not form oligomeric structures by standard SDS-polyacrylamide gel electrophoresis analysis and sedimented as a monomer in sucrose velocity gradients. Immunofluorescence studies showed a largely vesicular staining pattern for RACE that colocalized web with endosomal, but not lysosomal, markers. Measurable levels of RACE were also detected on the plasma membrane by both immunostaining and cell surface biotinylation, and cycling of the protein between the cell membrane and the endosomes was documented. A cytoplasmic dileucine motif was found to be necessary for normal targeting of RACE to the endosomal system and accumulation of the protein in this intracellular site.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Doms, RW (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 806 Abramson Bldg,34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	doms@mail.med.upenn.edu			NIA NIH HHS [P01 AG11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kang DE, 1999, J NEUROSCI, V19, P4229; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KOO EH, 1994, J BIOL CHEM, V269, P17386; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 1999, J CLIN INVEST, V104, P1169, DOI 10.1172/JCI8508; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	42	368	386	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33729	33737		10.1074/jbc.M004175200	http://dx.doi.org/10.1074/jbc.M004175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924510	hybrid			2022-12-25	WOS:000090104600076
J	Wang, SL; Shi, Y; Gorshkova, I; Schwarz, FP				Wang, SL; Shi, Y; Gorshkova, I; Schwarz, FP			RNA polymerase-cNMP-ligated cAMP receptor protein (CRP) mutant interactions in the enhancement of transcription by CRP mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DNA COMPLEX; ESCHERICHIA-COLI; ACTIVATOR PROTEIN; LAC PROMOTER; BINDING; MUTATIONS; IDENTIFICATION; PURIFICATION; POSITION-127; OPERON	The enhancement of the transcription of three synthetic promoters by cNMP-ligated cAMP receptor protein (CRP)/mutant complexes was determined from the transcription yields of a short AAUU transcript in an abortive initiation in vitro transcription assay, The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP, The transcriptional activation of a 152-base pair lacUV5 promoter (synlac promoter) with a CRP consensus binding site sequence (syncon promoter) was enhanced by an average factor of 12.3 +/- 0.5 with the cAMP-ligated complexes of CRP/mutants and cGMP-ligated T127L, although their promoter binding site affinities varied by a factor of 5. However, in the presence of bound RNA polymerase, the binding affinities only ranged from 0.8 +/- 0.2 x 10(7) M-1 for cAMP-ligated CRP* to 1.8 +/- 0.3 x 10(7) M-1 for cAMP-ligated CRP, indicating that the CRP/mutant interacts with the bound RNA polymerase, which would account for the near constancy of the enhancement factors. The corresponding enhancement factors for the synlac promoter and a promoter with a different CRP binding site sequence (syngal promoter) were also nearly the same, 7.2 +/- 0.7 and 6 +/- 1, respectively, The binding reaction of the syncon promoter to the RNA polymerase is exothermic, with a binding constant (K-b) = 2.1 +/- 0.2 x 10(7) m(-1).	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	National Institute of Standards & Technology (NIST) - USA	Schwarz, FP (corresponding author), NIST, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.							ANDERSON W, 1971, J BIOL CHEM, V246, P5926; Baichoo N, 1999, J MOL BIOL, V290, P37, DOI 10.1006/jmbi.1999.2858; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BRUNNER M, 1987, EMBO J, V6, P3139, DOI 10.1002/j.1460-2075.1987.tb02624.x; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Leu SF, 1999, BIOCHEMISTRY-US, V38, P6222, DOI 10.1021/bi982938z; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; MOORE JL, 1993, THESIS G WASHINGTON; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; RYU S, 1994, P NATL ACAD SCI USA, V91, P8582, DOI 10.1073/pnas.91.18.8582; SAMBROOK J, 1989, MOL CLONING LAB MANU, pE5; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shi Y, 1999, J BIOL CHEM, V274, P6946, DOI 10.1074/jbc.274.11.6946; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; YANG CP, 1990, MICROCAL DATA ORIGIN, P66; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	27	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33457	33463		10.1074/jbc.M004877200	http://dx.doi.org/10.1074/jbc.M004877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934201	hybrid			2022-12-25	WOS:000090104600040
J	Frankel, A; Clarke, S				Frankel, A; Clarke, S			PRMT3 is a distinct member of the protein arginine N-methyltransferase family - Conferral of substrate specificity by a zinc-finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; BINDING PROTEINS; RNA RECOGNITION; K-PROTEIN; METHYLATION; IDENTIFICATION; YEAST; PURIFICATION; INTERACTS; HRMT1L1	S-Adenosyl-L-methionine-dependent protein arginine N-methyltransferases (PRMTs) catalyze the methylation of arginine residues within a variety of proteins. At least four distinct mammalian family members have now been described, including PRMT1, PRMT3, CARM1/PRMT4, and JBP1/PRMT5. To more fully define the physiological role of PRMT3, we characterized its unique putative zinc-finger domain and how it can affect its enzymatic activity. Here we show that PRMT3 does contain a single zinc-finger domain in its amino terminus. Although the zinc-liganded form of this domain is not required for methylation of an artificial substrate such as the glutathione S-transferase-fibrillarin amino-terminal fusion protein (GST-GAR), it is required for the enzyme to recognize RNA-associated substrates in RAT1 cell extracts. The recombinant form of PRMT3 is inhibited by high concentrations of ZnCl2 as well as N-ethylmaleimide, reagents that can modify cysteine sulfhydryl groups. We found that we could distinguish PRMT family members by their sensitivity to these reagents; JBP1/PRMT5 and HsI7 methyltransferases were inhibited in a similar manner as PRMT3, whereas Rmt1, PRMT1, and CARM1/PRMT4 were not affected. We were also able to define differences in these enzymes by their sensitivity to inhibition by Tris and free arginine. Finally, we found that the treatment of RAT1 cell extracts with N-ethylmaleimide leads to a loss of the major PRMT1-associated activity that was immune to inhibition under the same conditions as a GST fusion protein. These results suggest that native forms of PRMTs can have different properties than their GST-catalytic chain fusion protein counterparts, which may lack associated noncatalytic subunits.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biochem & Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, 611 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM26020, T32 GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020, T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yoo BC, 1999, AMINO ACIDS, V17, P391, DOI 10.1007/BF01361664	41	91	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32974	32982		10.1074/jbc.M006445200	http://dx.doi.org/10.1074/jbc.M006445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931850	hybrid			2022-12-25	WOS:000090003800082
J	Garcia-Martinez, C; Morenilla-Palao, C; Planells-Cases, R; Merino, JM; Ferrer-Montiel, A				Garcia-Martinez, C; Morenilla-Palao, C; Planells-Cases, R; Merino, JM; Ferrer-Montiel, A			Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ION-CHANNEL; CAPSAICIN-RECEPTOR; CA2+ CHANNEL; BINDING SITE; AFFINITY; NOCICEPTORS; CYSTEINES; CALCIUM; HEAT	Vanilloid receptor subunit 1 (VR1) is a nonselective cation channel that integrates multiple pain-producing stimuli. VR1 channels are blocked with high efficacy by the well established noncompetitive antagonist ruthenium red and exhibit high permeability to divalent cations. The molecular determinants that define these functional properties remain elusive. We have addressed this question and evaluated by site-specific neutralization the contribution on pore properties of acidic residues located in the putative VR1 pore region; Mutant receptors expressed in Xenopus oocytes exhibited capsaicin-operated ionic currents akin to those of wild type channels. Incorporation of glutamine residues at Glu(648) and Glu(651) rendered minor effects on VR1 pore attributes, while Glu(636) slightly modulated pore blockade. In contrast, replacement of Asp(646) by asparagine decreased 10-fold ruthenium red blockade efficacy and reduced 1-fold the relative permeability of the divalent cation Mg2+ with respect to Na+ without changing the selectivity of monovalent cations, At variance with wild type channels and E636Q, E648Q, and E651Q mutant receptors, ruthenium red blockade of D646N mutants was weakly sensitive to extracellular pH acidification. Collectively, our results suggest that Asp(646) is a molecular determinant of VR1 pore properties and imply that this residue may form a ring of negative charges that structures a high affinity binding site for cationic molecules at the extracellular entryway.	Univ Miguel Hernandez, Ctr Biol Mol & Celular, Alicante 03202, Spain; Univ Extremadura, Dept Bioquim & Biol Mol, Badajoz 06071, Spain	Universidad Miguel Hernandez de Elche; Universidad de Extremadura	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Ctr Biol Mol & Celular, Avda Ferrocarril S-N,Elche, Alicante 03202, Spain.	aferrer@umh.es	Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Merino, Jaime M./0000-0002-5316-9200; Morenilla-Palao, Cruz/0000-0002-8159-1206				BASH H, 1992, CHEM ACID DERIV 1 SB, V2, P1; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Ferrer-Montiel Antonio V., 1994, Methods (Orlando), V6, P60, DOI 10.1006/meth.1994.1008; Ferrer-Montiel AV, 2000, EUR J NEUROSCI, V12, P124; Ferrer-Montiel AV, 1999, METH MOL B, V128, P167; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FerrerMontiel AV, 1996, BIOPHYS J, V71, P749, DOI 10.1016/S0006-3495(96)79274-3; Fersht A., 1985, ENZYME STRUCTURE MEC; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jung J, 1999, J NEUROSCI, V19, P529; Klockner U, 1996, J BIOL CHEM, V271, P22293; LEWIS CA, 1979, J PHYSL, V286, P501; MILEDI R, 1985, J PHYSL, V357, P173; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Premkumar LS, 1996, NEURON, V16, P869, DOI 10.1016/S0896-6273(00)80107-5; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Seifert R, 1999, EMBO J, V18, P119, DOI 10.1093/emboj/18.1.119; Sterner O, 1999, TRENDS PHARMACOL SCI, V20, P459, DOI 10.1016/S0165-6147(99)01393-0; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Williams M, 1999, J MED CHEM, V42, P1481, DOI 10.1021/jm9805034; Williamson AV, 1999, BIOPHYS J, V77, P2575, DOI 10.1016/S0006-3495(99)77092-X; Wood J, 1993, CAPSAICIN STUDY PAIN; ZALAWESKI RI, 1992, CHEM ACID DERIVAT SB, V2, P305; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	35	145	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32552	32558		10.1074/jbc.M002391200	http://dx.doi.org/10.1074/jbc.M002391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931826	hybrid			2022-12-25	WOS:000090003800025
J	Kaldis, P; Cheng, AY; Solomon, MJ				Kaldis, P; Cheng, AY; Solomon, MJ			The effects of changing the site of activating phosphorylation in CDK2 from threonine to serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; RING FINGER PROTEIN; CELL-CYCLE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; STRUCTURAL BASIS; CDC28 MUTATION; IN-VITRO; CAK	Cyclin-dependent kinases (CDKs) that control cell, cycle progression are regulated in many ways, including activating phosphorylation of a conserved threonine residue. This essential phosphorylation is carried out by the CDK-activating kinase (CAK). Here we examine the effects of replacing this threonine residue in human CDK2 by serine. We found that cyclin A bound equally well to wild-type CDK2 (CDK2(Thr-160)) or to the mutant CDK2 (CDK2(Ser-160)). I, the absence of activating phosphorylation, CDK2(Ser-160)-cyclin A complexes were more active than wild-type CDK2(Thr-160)-cyclin A complexes. In contrast, following activating phosphorylation, CDK2(Ser-160)-cyclin A complexes were less active than phosphorylated CDK2(Thr-160)-cyclin A complexes, reflecting a much smaller effect of activating phosphorylation on CDK2(Ser-160). The kinetic parameters for phosphorylating histone H1 were similar for mutant and wild-type CDK2, ruling out a general defect in catalytic activity. Interestingly, the CDK2(Ser-160) mutant was selectively defective in phosphorylating a peptide derived from the C-terminal domain of RNA polymerase II. CDK2(Ser-160) was efficiently phosphorylated by CAKs, both human p40(MO15)(CDK7)-cyclin H and budding yeast Caklp. In fact, the k(cat) values for phosphorylation of CDK2(Ser-160) were significantly higher than for phosphorylation of CDK2(Thr-160), indicating that CDK2(Ser-160) is actually phosphorylated more efficiently than wild-type CDK2. In contrast, dephosphorylation proceeded more slowly with CDK2(Ser-160) than with wild-type CDK2, either in HeLa cell extract or by purified PP2C beta. Combined with the more efficient phosphorylation of CDK2(Ser-160) by CAK, we suggest that one reason for the conservation of threonine as the site of activating phosphorylation may be to favor unphosphorylated CDKs following the degradation of cyclins.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Kaldis, P (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Bldg 560,W 7th St, Frederick, MD 21702 USA.	kaldis@ncifcrf.gov	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Egan EA, 1998, MOL CELL BIOL, V18, P3659, DOI 10.1128/MCB.18.7.3659; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Iavarone A, 1997, NATURE, V387, P417; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kimmelman J, 1999, MOL CELL BIOL, V19, P4774; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	59	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32578	32584		10.1074/jbc.M003212200	http://dx.doi.org/10.1074/jbc.M003212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931829	hybrid			2022-12-25	WOS:000090003800029
J	Petronzelli, F; Riccio, A; Markham, GD; Seeholzer, SH; Stoerker, J; Genuardi, M; Yeung, AT; Matsumoto, Y; Bellacosa, A				Petronzelli, F; Riccio, A; Markham, GD; Seeholzer, SH; Stoerker, J; Genuardi, M; Yeung, AT; Matsumoto, Y; Bellacosa, A			Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; BASE EXCISION-REPAIR; G-A MISPAIRS; ENDONUCLEASE-III; MAMMALIAN-CELLS; GUANINE BASES; HELA-CELLS; METHYLATION; BINDING; GENE	The human protein MED1 (also known as MBD4) was previously isolated in a two-hybrid screening using the mismatch repair protein MLH1 as a bait, and shown to have homology to bacterial base excision repair DNA N-glycosylases/lyases. To define the mechanisms of action of MED1, we implemented a sensitive glycosylase assay amenable to kinetic analysis. We show that MED1 functions as a mismatch-specific DNA N-glycosylase active on thymine, uracil, and 5-fluorouracil when these bases are opposite to guanine, MED1 lacks uracil glycosylase activity on single-strand DNA and abasic site lyase activity. The glycosylase activity of MED1 prefers substrates containing a G:T mismatch within methylated or unmethylated CpG sites; since G:T mismatches can originate via deamination of 5-methylcytosine to thymine, MED1 may act as a caretaker of genomic fidelity at CpG sites. A kinetic analysis revealed that MED1 displays a fast first cleavage reaction followed by slower subsequent reactions, resulting in biphasic time course; this is due to the tight binding of MED1 to the abasic site reaction product rather than a consequence of enzyme inactivation. Comparison of kinetic profiles revealed that the MED1 5-methylcytosine binding domain and methylation of the mismatched CpG site are not required for efficient catalysis.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Cattolica Sacro Cuore, Sch Med, Dept Med Genet, I-00168 Rome, Italy; Bruker Daltonics Inc, Billerica, MA 01821 USA	Fox Chase Cancer Center; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Bruker Corporation	Bellacosa, A (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	a_bellacosa@fccc.edu	Genuardi, Maurizio/K-3049-2018	Genuardi, Maurizio/0000-0002-7410-8351; Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL CANCER INSTITUTE [R01CA078412, R01CA071426, R29CA078412, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71426, CA78412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird AP, 1996, CANCER SURV, V28, P87; BOLT HM, 1988, CRIT REV TOXICOL, V18, P299, DOI 10.3109/10408448809037469; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HCIKSON ID, 1997, BASE EXCISION REPAIR, P1; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Horst JP, 1996, EMBO J, V15, P5459, DOI 10.1002/j.1460-2075.1996.tb00929.x; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; Kleihues P, 1997, AM J PATHOL, V150, P1; Krokan HE, 1997, BIOCHEM J, V325, P1; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Saparbaev M, 1999, IARC SCI PUBL, P249; Sard L, 1997, GENOMICS, V44, P222, DOI 10.1006/geno.1997.4843; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; Schmutte C, 1998, BIOL CHEM, V379, P377; Schmutte C, 1997, CANCER RES, V57, P3010; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	48	147	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32422	32429		10.1074/jbc.M004535200	http://dx.doi.org/10.1074/jbc.M004535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930409	hybrid			2022-12-25	WOS:000090003800008
J	Huang, XY; Raushel, FM				Huang, XY; Raushel, FM			Restricted passage of reaction intermediates through the ammonia tunnel of carbamoyl phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRYPTOPHAN SYNTHASE; GLUTAMINE; SUBSTRATE; SITE	The x-ray crystal structure of the heterodimeric carbamoyl phosphate synthetase from Escherichia coli has identified an intermolecular tunnel that connects the glutamine binding site within the small amidotransferase subunit to the two phosphorylation sites within the large synthetase subunit, The tunneling of the ammonia intermediate through the interior of the protein has been proposed as a mechanism for the delivery of the ammonia from the small subunit to the large subunit. A series of mutants created within the ammonia tunnel were prepared by the placement of a constriction via site-directed mutagenesis. The degree of constriction within the ammonia tunnel of these enzymes was found to correlate to the extent of the uncoupling of the partial reactions, the diminution of carbamoyl phosphate formation, and the percentage of the internally derived ammonia that is channeled through the ammonia tunnel. NMR spectroscopy and a radiolabeled probe were used to detect and identify the enzymatic synthesis of N-amino carbamoyl phosphate and N-hydroxy carbamoyl phosphate from hydroxylamine and hydrazine, The kinetic results indicate that hydroxylamine, derived from the hydrolysis of gamma-glutamyl hydroxamate, is channeled through the ammonia tunnel to the large subunit. Discrimination between the passage of ammonia and hydroxylamine was observed among some of these tunnel-impaired enzymes. The overall results provide biochemical evidence for the tunneling of ammonia within the native carbamoyl phosphate synthetase.	Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Texas A&M Univ, Dept Chem, POB 30012, College Stn, TX 77843 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIDDK NIH HHS [DK 30343] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK030343, R01DK030343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN CM, 1966, CURRENT ASPECTS BIOC, P401; ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; Cleland W. W, 1970, ENZYMES, V2, P1; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; FASMAN GD, 1975, HDB BIOCH MOL BIOL, P307; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; Huang XY, 2000, BIOCHEMISTRY-US, V39, P3240, DOI 10.1021/bi9926173; LICHTER RL, 1970, J AM CHEM SOC, V93, P5218; MAREYA SM, 1994, BIOCHEMISTRY-US, V33, P2945, DOI 10.1021/bi00176a026; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; MCKINLEY S, 1967, J BIOL CHEM, V242, P3381; Miles BW, 2000, BIOCHEMISTRY-US, V39, P5051, DOI 10.1021/bi992772h; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mullins LS, 1999, J AM CHEM SOC, V121, P3803, DOI 10.1021/ja990063l; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Raushel FM, 1998, BIOCHEMISTRY-US, V37, P10272, DOI 10.1021/bi980753m; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; SNODGRASS PJ, 1969, J LAB CLIN MED, V73, P940; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; WANG TT, 1972, J BIOL CHEM, V247, P4437; WELLNER VP, 1973, BIOCHEMISTRY-US, V12, P2061, DOI 10.1021/bi00735a006; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	34	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26233	26240		10.1074/jbc.275.34.26233	http://dx.doi.org/10.1074/jbc.275.34.26233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10950966	hybrid			2022-12-25	WOS:000088999700049
J	Bauer, CB; Holden, HM; Thoden, JB; Smith, R; Rayment, I				Bauer, CB; Holden, HM; Thoden, JB; Smith, R; Rayment, I			X-ray structures of the apo and MgATP-bound states of Dictyostelium discoideum myosin motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN; MUSCLE-CONTRACTION; CRYSTAL-STRUCTURE; ACTIVE-SITE; COMPLEX; SUBFRAGMENT-1; MGADP; CONFORMATION; HYDROLYSIS; RESOLUTION	Myosin is the most comprehensively studied molecular motor that converts energy from the hydrolysis of MgATP into directed movement. Its motile cycle consists of a sequential series of interactions between myosin, actin, MgATP, and the products of hydrolysis, where the affinity of myosin for actin is modulated by the nature of the nucleotide bound in the active site. The first step in the contractile cycle occurs when ATP binds to actomyosin and releases myosin from the complex. We report here the structure of the motor domain of Dictyostelium discoideum myosin II both in its nucleotide-free state and complexed with MgATP. The structure with MgATP was obtained by soaking the crystals in substrate. These structures reveal that both the apo form and the MgATP complex are very similar to those previously seen with MgATP gammaS and MgAMP-PNP. Moreover, these structures are similar to that of chicken skeletal myosin subfragment-l, The crystallized protein is enzymatically active in solution, indicating that the conformation of myosin observed in chicken skeletal myosin subfragment-l is unable to hydrolyze ATP and most likely represents the pre-hydrolysis structure for the myosin head that occurs after release from actin.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35186] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; Brust-Mascher I, 1999, BIOCHEMISTRY-US, V38, P12607, DOI 10.1021/bi9905967; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOODY RS, 1975, PROTEIN LIGAND INTER, P109; GREENE LE, 1980, J BIOL CHEM, V255, P543; Gulick AM, 2000, J BIOL CHEM, V275, P398, DOI 10.1074/jbc.275.1.398; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HENRY GD, 1993, BIOCHEMISTRY-US, V32, P10451, DOI 10.1021/bi00090a022; HOLMES KC, 1997, CURR BIOL, V7, P112; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park S, 1997, BIOCHEMISTRY-US, V36, P3368, DOI 10.1021/bi9624999; Phan BC, 1996, BIOPHYS CHEM, V59, P341, DOI 10.1016/0301-4622(95)00127-1; PONOMAREV MA, 1995, FEBS LETT, V371, P261, DOI 10.1016/0014-5793(95)00898-J; Ramachandran S, 1999, BIOCHEMISTRY-US, V38, P9097, DOI 10.1021/bi9902945; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Resetar AM, 1995, BIOCHEMISTRY-US, V34, P16039, DOI 10.1021/bi00049a018; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Rostkova EV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P875; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4	37	104	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38494	38499		10.1074/jbc.M005585200	http://dx.doi.org/10.1074/jbc.M005585200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10954715	hybrid			2022-12-25	WOS:000165739800049
J	Ferguson, GD; Chen, XN; Korenberg, JR; Herschman, HR				Ferguson, GD; Chen, XN; Korenberg, JR; Herschman, HR			The human synaptotagmin IV gene defines an evolutionary break point between syntenic mouse and human chromosome regions but retains ligand inducibility and tissue specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SYNAPTIC FUNCTION; MESSENGER-RNA; SCHIZOPHRENIA; BRAIN; BINDING; DOMAIN; RAT; DEPOLARIZATION; VESICLES	Rat synaptotagmin IV (SYT IV) is a depolarization-inducible synaptic vesicle protein. SYT IV homozygous mutant mice are viable and have deficits in fine motor coordination and some forms of memory. In this study, we report the identification of a human SPT IV orthologue. The predicted amino acid sequence of the human SYT IV clone is nearly 90% identical to the rat and mouse SYT TV proteins. In addition, human SYT IV has a characteristic serine for aspartate substitution within the first C2 domain that is conserved among Drosophila, Caenorhabditis elegans, mouse, and rat SYT IV sequences. The human SYT IV gene maps to chromosome band 18912.3, a region that defines a break point in the synteny with mouse chromosome 18 and has been implicated by associated markers in two human psychiatric disorders. In the human neuroblastoma cell line SK-N-SH, SYT IV is an immediate-early gene inducible by elevated intracellular calcium and by forskolin, an activator of adenylyl cyclase. Expression of human SPT IV mRNA is restricted to brain and is not detectable in non-neuronal tissues. Within brain, human SYT IV mRNA is most highly expressed in hippocampus, with lower levels present in amygdala and thalamus. These results suggest a role for SYT TV in human brain function and in human neurological disease.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Ctr Med Genet Birth Defects, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Mol Biol, 341 Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD033113] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028660] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33113, HD17449] Funding Source: Medline; NINDS NIH HHS [NS28660] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; Berrettini WH, 2000, BIOL PSYCHIAT, V47, P245, DOI 10.1016/S0006-3223(99)00226-7; Berton F, 1997, J NEUROSCI, V17, P1206; Berton F, 2000, EUR J NEUROSCI, V12, P1294, DOI 10.1046/j.1460-9568.2000.00013.x; Calzolari E, 1996, AM J MED GENET, V67, P154, DOI 10.1002/(SICI)1096-8628(19960409)67:2<154::AID-AJMG5>3.3.CO;2-H; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Crispino M, 1998, MOL BRAIN RES, V59, P178, DOI 10.1016/S0169-328X(98)00143-0; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Denovan-Wright EM, 1998, MOL BRAIN RES, V55, P350, DOI 10.1016/S0169-328X(98)00042-4; Feldman JD, 2000, J NEUROCHEM, V74, P1838, DOI 10.1046/j.1471-4159.2000.0741838.x; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Ferguson GD, 2000, P NATL ACAD SCI USA, V97, P5598, DOI 10.1073/pnas.100104597; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GOLD JM, 1992, J ABNORM PSYCHOL, V101, P487, DOI 10.1037/0021-843X.101.3.487; GOLD JM, 1992, CLIN NEUROPSYCHOL, V6, P367; Hampson RM, 1999, PSYCHIATR GENET, V9, P161, DOI 10.1097/00041444-199909000-00010; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Jeljeli M, 1999, BEHAV BRAIN RES, V102, P61, DOI 10.1016/S0166-4328(98)00162-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Keshavan MS, 1999, J PSYCHIATR RES, V33, P513, DOI 10.1016/S0022-3956(99)00033-3; KORENBERG JR, 1995, CYTOGENET CELL GENET, V69, P196, DOI 10.1159/000133962; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Kugaya A, 2000, ANN NUCL MED, V14, P1, DOI 10.1007/BF02990472; Laruelle M, 1999, J PSYCHOPHARMACOL, V13, P358, DOI 10.1177/026988119901300405; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Preisig M, 2000, AM J PSYCHIAT, V157, P948, DOI 10.1176/appi.ajp.157.6.948; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Thomas DM, 1999, MOL BIOL CELL, V10, P2285, DOI 10.1091/mbc.10.7.2285; Ujike H, 1999, Nihon Shinkei Seishin Yakurigaku Zasshi, V19, P47; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; Van Broeckhoven C, 1999, AM J MED GENET, V88, P263, DOI 10.1002/(SICI)1096-8628(19990618)88:3<263::AID-AJMG10>3.3.CO;2-X; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WAGNER JA, 1985, J NEUROCHEM, V45, P1244, DOI 10.1111/j.1471-4159.1985.tb05549.x; Yamamoto J, 1997, PSYCHOPHARMACOLOGY, V131, P379, DOI 10.1007/s002130050306; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	46	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36920	36926		10.1074/jbc.M005801200	http://dx.doi.org/10.1074/jbc.M005801200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10938284	hybrid			2022-12-25	WOS:000165577700067
J	Bertram, PG; Choi, JH; Carvalho, J; Ai, WD; Zeng, CB; Chan, TF; Zheng, XFS				Bertram, PG; Choi, JH; Carvalho, J; Ai, WD; Zeng, CB; Chan, TF; Zheng, XFS			Tripartite regulation of Gln3p by TOR, Ure2p, and phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; RAPAMYCIN; YEAST; PROTEINS; DOMAIN; IDENTIFICATION; TRANSCRIPTION; GENE; SEQUENCE	Gln3p is a GATA-type transcription factor responsive to different nitrogen nutrients and starvation in yeast Saccharomyces cerevisiae, Recent evidence has linked TOR signaling to Gln3p. Rapamycin causes dephosphorylation and nuclear translocation of Gln3p, thereby activating nitrogen catabolite repressible-sensitive genes. However, a detailed mechanistic understanding of this process is lacking, In this study, we show that Tor1p physically interacts with Gln3p, An intact TOR kinase domain is essential for the phosphorylation of Gln3p, inhibition of Gln3p nude ar entry and repression of Gln3p-dependent transcription. In contrast, at least two distinct protein phosphatases, Pph3p and the Tap42p-dependent phosphatases, are involved in the activation of Gln3p. The yeast pro-prion protein Ure2p binds to both hyper- and hypo-phosphorylated Gln3p. In contrast to the free Gln3p, the Ure2p-bound Gln3p is significantly resistant to dephosphorylation, Taken together, these results reveal. a tripartite regulatory mechanism by which the phosphorylation of Gln3p is regulated.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Mol Genet Program, St Louis, MO 63110 USA; Washington Univ, Sch Med, Mol Cell Biol Program, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.		Chan, TingFung/A-6161-2013	Chan, TingFung/0000-0002-0489-3884				ADAMS A, 1997, METHODS YEAST GENETI, P137; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Brachmann CB, 1998, YEAST, V14, P115; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Coffman JA, 1997, J BACTERIOL, V179, P3416, DOI 10.1128/jb.179.11.3416-3429.1997; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; James P, 1996, GENETICS, V144, P1425; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KURNUVILLA F, 1999, CHEM BIOL, V6, pR129; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	35	182	189	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35727	35733		10.1074/jbc.M004235200	http://dx.doi.org/10.1074/jbc.M004235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940301	hybrid			2022-12-25	WOS:000165382000014
J	Pearlstone, JR; Chandra, M; Sorenson, MM; Smillie, LB				Pearlstone, JR; Chandra, M; Sorenson, MM; Smillie, LB			Biological function and site IICa2+-induced opening of the regulatory domain of skeletal troponin C are impaired by invariant site I or II Glu mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING SITES; MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; CARDIAC TROPONIN; CA2+ BINDING; ANGSTROM RESOLUTION; N-DOMAIN; MUSCLE-CONTRACTION; CIRCULAR-DICHROISM; STRUCTURAL-CHANGES; PROMOTER PLASMIDS	To investigate the roles of site I and II invariant Glu residues 41 and 77 in the functional properties and calcium-induced structural opening of skeletal muscle troponin C (TnC) regulatory domain, we have replaced them by Ala in intact F29W TnC and in wild-type and F29W N domains (TnC residues 1-90). Reconstitution of intact E41A/F29W and E77A/F29W mutants into TnC-depleted muscle skinned fibers showed that Ca2+-induced tension is greatly reduced compared with the F29W control. Circular dichroism measurements of wild-type N domain as a function of pCa (= -log[Ca2+]) demonstrated that similar to 90% of the total change in molar ellipticity at 222 nm ([theta](222 nm)) could be assigned to site II Ca2+ binding. With E41A, E77A, and cardiac TnC N domains this [theta](222 nm) change attributable to site II was reduced to less than or equal to 40% of that seen with wild type, consistent with their structures remaining closed in +Ca2+. Furthermore, the Ca2+-induced changes in fluorescence, near UV CD, and UV difference spectra observed with intact F29W are largely abolished with E41A/F29W and E77A/F29W TnCs. Taken together, the data indicate that the major structural change in N domain, including the closed to open transition, is triggered by site II Ca2+ binding, all interpretation relevant to the energetics of the skeletal muscle TnC and cardiac TnC systems.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Fed Rio de Janeiro, ICB, Dept Bioquim Med, CCS, BR-21941590 Rio De Janeiro, Brazil	University of Alberta; Universidade Federal do Rio de Janeiro	Smillie, LB (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.							BABU A, 1992, J BIOL CHEM, V267, P15469; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; Foguel D, 1996, P NATL ACAD SCI USA, V93, P10642, DOI 10.1073/pnas.93.20.10642; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P777; GAHLMANN R, 1988, J MOL BIOL, V201, P379, DOI 10.1016/0022-2836(88)90145-3; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HANNON JD, 1992, CIRC RES, V71, P984, DOI 10.1161/01.RES.71.4.984; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IIDA S, 1988, J BIOCHEM-TOKYO, V103, P482, DOI 10.1093/oxfordjournals.jbchem.a122296; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; MANNING MC, 1989, J PHARMACEUT BIOMED, V7, P1103, DOI 10.1016/0731-7085(89)80049-4; MAUNE JF, 1992, J BIOL CHEM, V267, P2586; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; MCKAY RT, 1999, THESIS U ALBERTA, P148; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATYSHUR KA, 1994, ACTA CRYSTALLOGR D, V50, P40, DOI 10.1107/S090744499300798X; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; Spyracopoulos L, 1998, BIOCHEMISTRY-US, V37, P18032, DOI 10.1021/bi9816960; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; SZCYESNA D, 1996, J BIOL CHEM, V271, P8381; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Yu A, 1999, BBA-PROTEIN STRUCT M, V1431, P53, DOI 10.1016/S0167-4838(99)00043-6; Yu A, 1999, NATO ADV SCI I E-APP, V358, P515; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	72	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35106	35115		10.1074/jbc.M001000200	http://dx.doi.org/10.1074/jbc.M001000200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952969	hybrid			2022-12-25	WOS:000165422800039
J	Samuel, D; Kumar, TKS; Srimathi, T; Hsieh, H; Yu, C				Samuel, D; Kumar, TKS; Srimathi, T; Hsieh, H; Yu, C			Identification and characterization of an equilibrium intermediate in the unfolding pathway of an all beta-barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLTEN GLOBULE STATE; BINDING; BOVINE	The guanidinium hydrochloride (GdnHCl)-induced unfolding of an all beta -sheet protein, the human acidic fibroblast growth factor (hFGF-1), is studied using a variety of biophysical techniques including multidimensional NMR. spectroscopy. The unfolding of hFGF-1 in GdnHCl is shown to involve the formation of a stable equilibrium intermediate. Size exclusion chromotagraphy using fast protein liquid chromatography shows that the intermediate accumulates maximally at 0.96 hz GdnHCl, 1-Anilinonapthalene 8-sulfonate binding, one-dimensional H-1 NMR, and limited proteolytic digestion experiments suggest that the intermediate has characteristics resembling a molten globule state. Chemical shift: perturbation and hydrogen-deuterium exchange monitored by H-1-N-15 heteronuclear single quantum coherence spectra reveal that profound structural changes in the intermediate state (in 0.96 M GdnHCl) occur in the C-terminal, heparin binding region of the protein molecule, Additionally, results of the stopped flow fluorescence experiments suggest that the kinetic refolding of hFGF-1 proceeds through the accumulation of an intermediate at low concentrations of the denaturant. To our knowledge, the present study is the first report wherein an equilibrium intermediate is characterized in detail in an all beta -barrel protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan	National Tsing Hua University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BHUYAN AK, 1997, BIOCHEMISTRY-US, V38, P9158; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CARLSSON U, 1995, CURR OPIN STRUC BIOL, V5, P482, DOI 10.1016/0959-440X(95)80032-8; DABORA JM, 1996, J MOL BIOL, V285, P279; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; Jones S, 2000, BIOCHEMISTRY-US, V39, P5672, DOI 10.1021/bi9923959; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KUMAR TKS, 1995, BIOCHEM BIOPH RES CO, V207, P536, DOI 10.1006/bbrc.1995.1221; KUMAR TKS, 1994, J BIOL CHEM, V269, P12620; LIU ZP, 1994, BIOCHEMISTRY-US, V33, P134, DOI 10.1021/bi00167a017; Lozano RM, 2000, BIOCHEMISTRY-US, V39, P4982, DOI 10.1021/bi992544n; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MIERLO CPM, 2000, PROTEIN SCI, V9, P145; Mizuguchi M, 2000, J MOL BIOL, V298, P985, DOI 10.1006/jmbi.2000.3705; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Park SH, 1997, BIOCHEMISTRY-US, V36, P14277, DOI 10.1021/bi971914+; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; Sanz JM, 1997, EUR J BIOCHEM, V246, P328, DOI 10.1111/j.1432-1033.1997.00328.x; Schonbrunner N, 1997, BIOCHEMISTRY-US, V36, P9057, DOI 10.1021/bi970594r; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Sivaraman T, 1997, BIOCHEM J, V321, P457, DOI 10.1042/bj3210457; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1992, FEBS LETT, V314, P89, DOI 10.1016/0014-5793(92)81468-2; WANG L, 1998, PROTEIN SCI, V7, P2360; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	38	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34968	34975		10.1074/jbc.M005147200	http://dx.doi.org/10.1074/jbc.M005147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950956	hybrid			2022-12-25	WOS:000165422800021
J	Zhang, J; Billingsley, ML; Kincaid, RL; Siraganian, RP				Zhang, J; Billingsley, ML; Kincaid, RL; Siraganian, RP			Phosphorylation of Syk activation loop tyrosines is essential for Syk function - An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; SIGNAL-TRANSDUCTION; KINASE P72(SYK); SH2 DOMAINS; MAST-CELLS; NEGATIVE REGULATION; IMMUNOGLOBULIN-E; FAMILY KINASES	Syk is an important protein-tyrosine kinase in immunoreceptor signaling. Fc epsilon RI aggregation in mast cells induces tyrosine phosphorylation and increased enzymatic activity of Syk. The two adjacent tyrosines in the Syk activation loop are thought to be important for the propagation of Fc epsilon RI signaling. To evaluate the phosphorylation of these tyrosines in vivo and further understand the relationship of Syk tyrosine phosphorylation with its function, an antibody was developed specific for phosphorylated tyrosines in the activation loop of Syk. Fc epsilon RI aggregation on mast cells induced the phosphorylation of both tyrosine residues of the activation loop. The kinase activity of Syk played the major role in phosphorylating its activation loop tyrosines both in vivo and in vitro. In Fc epsilon RI-stimulated mast cells, the total Syk tyrosine phosphorylation paralleled the phosphorylation of its activation loop tyrosines and downstream propagation of signals for histamine release. In contrast,:the cell surface binding of anti-ganglioside monoclonal antibody AA4 induced only strong general tyrosine: phosphorylation of Syk and minimal histamine release and weak phosphorylation of activation loop tyrosines. These results demonstrate that phosphorylation:of the activation loop tyrosines is important for mediating receptor signaling and is a better marker of Syk function than is total Syk tyrosine phosphorylation.	NIDCR, RAST Sect, OIIB, NIH, Bethesda, MD 20892 USA; Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhang, J (corresponding author), NIDCR, RAST Sect, OIIB, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.				NIDCR NIH HHS [N01-DE-62614] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [N01DE062614, Z01DE000696] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Costello PS, 1996, ONCOGENE, V13, P2595; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Fitzer-Attas CJ, 1998, J IMMUNOL, V160, P145; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, MOL CELL BIOL, V16, P1471; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Sada K, 2000, J IMMUNOL, V164, P338, DOI 10.4049/jimmunol.164.1.338; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; Zhang J, 1999, J IMMUNOL, V163, P2508; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhang J, 1998, J IMMUNOL, V161, P4366; Zoller KE, 1997, J IMMUNOL, V158, P1650	49	129	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35442	35447		10.1074/jbc.M004549200	http://dx.doi.org/10.1074/jbc.M004549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931839	hybrid			2022-12-25	WOS:000165422800081
J	Buxton, DB; Adelstein, RS				Buxton, DB; Adelstein, RS			Calcium-dependent threonine phosphorylation of nonmuscle myosin in stimulated RBL-2H3 mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; II HEAVY-CHAIN; BASOPHILIC LEUKEMIA-CELLS; SPHINGOSINE KINASE; HISTAMINE-RELEASE; ANTIGEN; EXOCYTOSIS; SECRETION; RECEPTOR; MTS1	Stimulation of RBL-2H3 mi mast cells through the IgE receptor with antigen, or through a G protein-coupled receptor with carbachol, leads to the rapid appearance of phosphothreonine in nonmuscle myosin heavy chain ZI-A (NMHC-IIA). We demonstrate that this results from phosphorylation of Thr-1940 by calcium/calmodulin-dependent protein kinase II (CaM kinase II), activated by increased intracellular calcium. The phosphorylation site in rodent NMHC-IIA was localized to the carboxyl terminus of NMHC-IIA distal to the coiled-coil region, and,identified as Thr-1940 by site-directed mutagenesis. A fusion protein containing the NMHC-IIA carboxyl terminus was phosphorylated by GaM kinase II in vitro, while mutation of Thr-1940 to Ala eliminated phosphorylation. In contrast to rodents, in humans Thr-1940 is replaced by Ala, and human NMHC-IIA fusion protein was not phosphorylated by CaM kinase II unless Ala-->1940 was mutated to Thr, Similarly, co-transfected Ala-->Thr-1940 human NMHC-IIA was phosphorylated by activated CaM: kinase II in HeLa cells, while wild type was not. In RBL-2H3 mi cells, inhibition of CaM kinase II decreased Thr-1940 phosphorylation, and inhibited release of the secretory granule marker hexosaminidase in response to carbachol but not to antigen. These data indicate a role for CaM kinase stimulation and resultant threonine phosphorylation of NMHC-IIA in RBL-2H3 mi cell activation.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Buxton, DB (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr, Bethesda, MD 20892 USA.			Buxton, Denis/0000-0003-3077-6435; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004230, Z01HL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An J, 1999, AM J PHYSIOL-ENDOC M, V277, pE862, DOI 10.1152/ajpendo.1999.277.5.E862; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; BURGOYNE RD, 1987, BIOSCIENCE REP, V7, P281, DOI 10.1007/BF01121449; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; CHOI OH, 1993, J IMMUNOL, V151, P5586; Choi OH, 1996, NATURE, V380, P634; CROSS RA, 1986, FEBS LETT, V200, P355, DOI 10.1016/0014-5793(86)81168-1; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Heist EK, 1998, CELL CALCIUM, V23, P103; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; IKEBE M, 1991, J BIOL CHEM, V266, P7030; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; Miralem T, 1998, BIOCHEM J, V330, P651, DOI 10.1042/bj3300651; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SPUDICH A, 1994, CELL MOTIL CYTOSKEL, V29, P345, DOI 10.1002/cm.970290407; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; SUN P, 1994, GENE DEV, V8, P227; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Waters WW, 1998, NEUROENDOCRINOLOGY, V67, P145, DOI 10.1159/000054309; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Wilson JR, 1999, DIABETES, V48, P2383, DOI 10.2337/diabetes.48.12.2383	40	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34772	34779		10.1074/jbc.M004996200	http://dx.doi.org/10.1074/jbc.M004996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945986	hybrid			2022-12-25	WOS:000165095300103
J	Grewal, SS; Fass, DM; Yao, H; Ellig, CL; Goodman, RH; Stork, PJS				Grewal, SS; Fass, DM; Yao, H; Ellig, CL; Goodman, RH; Stork, PJS			Calcium and cAMP signals differentially regulate cAMP-responsive element-binding protein function via a Rap1-extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NERVE GROWTH-FACTOR; MAP KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR CREB; CYCLIC-AMP; B-RAF; CBP; NUCLEAR	Two major intracellular signals that regulate neuronal function are calcium and cAMP, In many cases, the actions of these two second messengers involve long term changes in gene expression. One well studied target of both calcium and cAMP signaling is the transcription factor cAMP-responsive element-binding protein (CREB), Multiple signaling pathways have been shown to contribute to the regulation of CREB-dependent transcription, including both protein kinase A (PKA)- and mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK)-dependent kinase cascades. We have previously described a mechanism by which cAMP and calcium influx may stimulate ERKs in neuronal cells, This pathway involves the PKA-dependent activation of the Ras-related small G-protein, Rap1, and subsequent stimulation of the neuronal Raf isoform, B-Raf, In this study, we examined the contribution of the Rap1-ERK pathway to the control of gene transcription by calcium influx and cAMP, Using the PC12 cell model system, we found that both calcium influx and cAMP stimulated CREB-dependent transcription via a Rap1-ERK pathway, but this regulation occurred through distinct mechanisms. Calcium-mediated phosphorylation of CREB through the PKA-Rap1-ERK pathway. In contrast, cAMP phosphorylated CREB via PKA directly but required a Rap1-ERK pathway to activate a component downstream of CREB phosphorylation and CREB-binding protein recruitment, These data suggest that the Rap 1/B-Raf signaling pathway may have an important role in the regulation of CREB-dependent gene expression.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474,SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Roberson ED, 1999, J NEUROSCI, V19, P4337; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P1031; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	58	120	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34433	34441		10.1074/jbc.M004728200	http://dx.doi.org/10.1074/jbc.M004728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10950954	hybrid			2022-12-25	WOS:000165095300059
J	Kleifeld, O; Van den Steen, PE; Frenkel, A; Cheng, F; Jiang, HL; Opdenakker, G; Sagi, I				Kleifeld, O; Van den Steen, PE; Frenkel, A; Cheng, F; Jiang, HL; Opdenakker, G; Sagi, I			Structural characterization of the catalytic active site in the latent and active natural gelatinase B from human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; C-TERMINAL DOMAIN; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; CYSTEINE SWITCH; ZINC CONTENT; BINDING; STROMELYSIN-1; MECHANISM	Matrix metalloproteinases are endopeptidases that have a leading role in the catabolism of the macromolecular components of the extracellular matrix in a variety of normal and pathological processes. Human gelatinase B is a zinc-dependent proteinase and a member of the matrix metalloproteinase family that is involved in inflammation, tissue remodeling, and cancer. We have conducted x-ray absorption spectroscopy, atomic emission, and quantum mechanics studies of natural and activated human gelatinase B. Our results show that the natural enzyme contains one catalytic zinc ion that is central to catalysis. In addition, upon enzyme activation, the catalytic zinc site exhibits a conformation change that results in the expansion of the bond distances around the zinc ion and the replacement of one sulfur with oxygen. Interestingly, quantum mechanics calculations show that oxygen ligation at the catalytic zinc ion exhibits a greater affinity to the binding of an oxygen from an amino acid residue rather than from an external water molecule. These results suggest that the catalytic zinc ion plays a key role in both substrate binding and catalysis.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Illinois, Mat Res Lab, Urbana, IL 61801 USA; Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Meteria Med, Shanghai 200031, Peoples R China	Weizmann Institute of Science; KU Leuven; University of Illinois System; University of Illinois Urbana-Champaign; Chinese Academy of Sciences	Sagi, I (corresponding author), Weizmann Inst Sci, Dept Biol Struct, POB 26, IL-76100 Rehovot, Israel.	irit.sagi@weizmann.ac.il	Cheng, Feng/A-9760-2009; Opdenakker, Ghislain/V-8562-2019; Van den Steen, Philippe E/K-5132-2012; Opdenakker, Ghislain/Q-3130-2017; Frenkel, Anatoly/D-3311-2011; Kleifeld, Oded/G-7304-2012	Cheng, Feng/0000-0003-3619-8090; Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe E/0000-0002-7334-9145; Opdenakker, Ghislain/0000-0003-1714-2294; Frenkel, Anatoly/0000-0002-5451-1207; 				BAUSCHLICHER CW, 1995, CHEM PHYS LETT, V246, P40, DOI 10.1016/0009-2614(95)01089-R; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dubois B, 1999, ACTA NEUROL BELG, V99, P53; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; HENNING B, 1995, CURR OPIN CELL BIOL, V7, P728; HOLTHAUSEN MC, 1995, CHEM PHYS LETT, V240, P245, DOI 10.1016/0009-2614(95)00535-C; Kiyama R, 1999, J MED CHEM, V42, P1723, DOI 10.1021/jm980514x; Kleifeld O, 2000, BIOCHEMISTRY-US, V39, P7702, DOI 10.1021/bi0002030; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIOTTA LA, 1983, LAB INVEST, V49, P636; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MASURE S, 1990, BIOCHIM BIOPHYS ACTA, V1054, P317, DOI 10.1016/0167-4889(90)90103-K; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Norga K, 1996, CLIN RHEUMATOL, V15, P31, DOI 10.1007/BF02231681; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OPDENAKKER G, 1991, LYMPHOKINE CYTOK RES, V10, P317; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Parr R. G., 1989, DENSITY FUNCTIONAL T; RAO JS, 1993, CANCER RES, V53, P2208; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RICCA A, 1995, THEOR CHIM ACTA, V92, P123; Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e; Ryde U, 1999, BIOPHYS J, V77, P2777, DOI 10.1016/S0006-3495(99)77110-9; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SOLER D, 1994, BIOCHEM BIOPH RES CO, V201, P917, DOI 10.1006/bbrc.1994.1789; SPRINGMAN EB, 1995, BIOCHEMISTRY-US, V34, P15713, DOI 10.1021/bi00048a016; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STERN EA, 1995, PHYSICA B, V208, P117, DOI 10.1016/0921-4526(94)00826-H; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Strong RK, 1998, ACTA CRYSTALLOGR D, V54, P93, DOI 10.1107/S0907444997010615; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; Van den Steen P, 1998, BBA-GEN SUBJECTS, V1425, P587, DOI 10.1016/S0304-4165(98)00113-5; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILLENBROCK F, 1995, FEBS LETT, V358, P189, DOI 10.1016/0014-5793(94)01421-V; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995	55	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34335	34343		10.1074/jbc.M005714200	http://dx.doi.org/10.1074/jbc.M005714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938090	hybrid			2022-12-25	WOS:000165095300047
J	Li, XJ; Marians, KJ				Li, XJ; Marians, KJ			Two distinct triggers for cycling of the lagging strand polymerase at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; DNA-POLYMERASE; III HOLOENZYME; SLIDING CLAMPS; PRIMASE; HELICASE; TEMPLATE; PROTEIN	There are two modes of DNA synthesis at a replication fork. The leading strand is synthesized in a continuous fashion in lengths that in Escherichia coli can be in excess of 2 megabases. On the other hand, the lagging strand is synthesized in relatively short stretches of 2 kilobases. Nevertheless, identical assemblies of the DNA polymerase In: core tethered to the beta sliding clamp account for both modes of DNA synthesis. Yet the same lagging strand polymerase accounts for the synthesis of all Okazaki fragments at a replication fork, cycling repeatedly every 1 or 2 s from the S'-end of the just-completed fragment to the 3'-end of the new primer. Several models have been invoked to account for the rapid cycling of a polymerase complex that can remain bound to the template for upward of 40 min. By using isolated replication protein-DNA template complexes, we have tested these models and show here that cycling of the lagging strand polymerase can be triggered by either the action of primase binding to the replisome and synthesizing a primer or by collision of the lagging strand polymerase with the 5' end of the previous Okazaki fragment.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Li, XJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034557, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5267; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; SWART JR, 1993, J BIOL CHEM, V268, P12970; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	35	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34757	34765		10.1074/jbc.M006556200	http://dx.doi.org/10.1074/jbc.M006556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10948202	hybrid			2022-12-25	WOS:000165095300101
J	LaDu, MJ; Shah, JA; Reardon, CA; Getz, GS; Bu, G; Hu, JR; Guo, L; Van Eldik, LJ				LaDu, MJ; Shah, JA; Reardon, CA; Getz, GS; Bu, G; Hu, JR; Guo, L; Van Eldik, LJ			Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; E MESSENGER-RNA; LIPOPROTEIN-RECEPTOR; ALZHEIMERS-DISEASE; PROTEIN LRP; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; 39-KDA PROTEIN; APOE RECEPTOR	We have previously shown that beta -amyloid (A beta) induces astrocyte activation in vitro and that this reaction is attenuated by the addition of exogenous apolipoprotein E (apoE)-containing particles. However, the effects of A beta on endogenous apoE and apoJ levels and the potential role of apoE receptors in astrocyte activation have not been addressed. Three activating stimuli (lipopolysaccharide, dibutyryl cAMP, and aged A beta 1-42) were used to induce activation of rat astrocyte cultures, as assessed by changes in morphology and an increase in interleubin-1 beta. However, only A beta also induced similar to 50% reduction in the amount of released apoE and apoJ and an 8-fold increase in the levels of cell-associated apoE and apoJ, Experiments using two concentrations of receptor-associated protein, an inhibitor of apoE receptors with a differential affinity for the low density lipoprotein receptor (LDLR) and the LDLR-related protein (LRP), suggest that LRP mediates A beta -induced astrocyte activation, whereas LDLR mediates the A beta -induced changes in apoE levels. Receptor-associated protein had no effect on apoJ levels or on activation by either dibutyryl cAMP or lipopolysaccharide. These data suggest that apoE receptors translate the presence of extracellular A beta into cellular responses, both initiating and modulating the inflammatory response induced by A beta.	Northwestern Univ, Sch Med, NW Drug Discovery Program, Chicago, IL 60611 USA; Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Northwestern Univ, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; University of Chicago; Washington University (WUSTL); Washington University (WUSTL); Northwestern University	Van Eldik, LJ (corresponding author), Northwestern Univ, Sch Med, NW Drug Discovery Program, 303 E Chicago Ave,Ward 4-202, Chicago, IL 60611 USA.	vaneldik@northwestern.edu	Shah, Javeed/J-4906-2017; Shah, Javeed/J-2716-2019	Shah, Javeed/0000-0002-2997-7988; Shah, Javeed/0000-0002-2997-7988; LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL INSTITUTE ON AGING [R37AG013939, P01AG015501, R01AG013939] Funding Source: NIH RePORTER; NIA NIH HHS [AG16776, AG15501, AG13939] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Beffert U, 1998, J NEUROCHEM, V70, P1458; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1994, J BIOL CHEM, V269, P18521; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; ElKhoury J, 1996, NATURE, V382, P716; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Hu JR, 1998, J NEUROCHEM, V71, P1626; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Jordan J, 1998, J NEUROSCI, V18, P195; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Narita M, 1997, J NEUROCHEM, V69, P1904; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Puttfarcken PS, 1997, J NEUROCHEM, V68, P760; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Smith MA, 1997, J NEUROSCI, V17, P2653; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun YL, 1998, J NEUROSCI, V18, P3261; Tolar M, 1997, J NEUROSCI, V17, P5678; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	61	76	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33974	33980		10.1074/jbc.M000602200	http://dx.doi.org/10.1074/jbc.M000602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940295	hybrid			2022-12-25	WOS:000090104600110
J	Lan, KL; Zhong, HL; Nanamori, M; Neubig, RR				Lan, KL; Zhong, HL; Nanamori, M; Neubig, RR			Rapid kinetics of regulator of G-protein signaling (RGS)-mediated G alpha(i) and G alpha(o) deactivation - G alpha specificity of RGS4 and RGS7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; SACCHAROMYCES-CEREVISIAE; INTRINSIC FLUORESCENCE; TRANSITION-STATE; BINDING; SUBUNITS; FAMILY; TRANSDUCIN; HYDROLYSIS	Regulator of G-protein signaling (RGS) proteins accelerate GTP hydrolysis by G alpha subunits speeding deactivation. Ga deactivation kinetics mediated by RGS are too fast to be directly studied using conventional radiochemical methods. We describe a stopped-flow spectroscopic approach to visualize these rapid kinetics by measuring the intrinsic tryptophan fluorescence decrease of G alpha accompanying GTP hydrolysis and G alpha deactivation on the millisecond time scale. Basal k(cat) values for G alpha (o), G alpha (i1), and G alpha (i2) at 20 degreesC were similar (0.025-0.033 s(-1)). Glutathione S-transferase fusion proteins containing RGS4 and an RGS7 box domain (amino acids 305-453) enhanced the rate of G alpha deactivation in a manner Linear with RGS concentration. RGS4 stimulated rates could be measured up to 5 s(-1) at 3 muM, giving a catalytic efficiency of 1.7-2.8 x 10(6) M-1 s(-1) for all three Ga subunits. In contrast, RGS7 showed catalytic efficiencies of 0.44, 0.10, and 0.02 x 10(6) M-1 s(-1) toward G alpha (o), G alpha (i2), and G alpha (i1), respectively. Thus RGS7 is a weaker GTPase activating protein than RGS4 toward all Ga subunits tested, but it is specific for G alpha (o) over G alpha (i1) or G alpha (i2) Furthermore, the specificity of RGS7 for G alpha (o) does not depend on N- or C-terminal extensions or a G beta (5) subunit but resides in the RGS domain itself.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	RNeubig@umich.edu		Neubig, Richard/0000-0003-0501-0008	NIGMS NIH HHS [GM-39561] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Lan KL, 1998, BIOCHEMISTRY-US, V37, P837, DOI 10.1021/bi972122i; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SZABO G, 1989, TRENDS PHARMACOL SCI, P46; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	46	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33497	33503		10.1074/jbc.M005785200	http://dx.doi.org/10.1074/jbc.M005785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942773	hybrid			2022-12-25	WOS:000090104600045
J	Ransamy, TA; Neville, TAM; Chauhan, BM; Aggarwal, D; Sparks, DL				Ransamy, TA; Neville, TAM; Chauhan, BM; Aggarwal, D; Sparks, DL			Apolipoprotein A-I regulates lipid hydrolysis by hepatic lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HEPARAN-SULFATE PROTEOGLYCANS; TRIGLYCERIDE LIPASES; POSTPRANDIAL LIPEMIA; PLASMA-LIPOPROTEINS; MOLECULAR-BIOLOGY; DIETARY-FAT; LPA-I; LIPOLYSIS	Association of hepatic Lipase (HL) with pure heparan sulfate proteoglycans (HSPG) has little effect on hydrolysis of high density lipoprotein (HDL) particles, but significantly inhibits (>80%) the hydrolysis of low (LDL) and very low density lipoproteins (VLDL). Lipolytic inhibition is associated with a differential ability of the lipoproteins to remove HL from the HSPG. LDL and VLDL are unable to displace HL, whereas HDL readily displaces HL from the HSPG, These data show that HSPG-bound HL is inactive. Purified apolipoprotein (apo) A-I is more efficient than HDL at liberating HL from HSPG, and HL displacement is associated with the direct binding of apoA-I to HSPG. However, displacement of HL by apoA-I does not enhance hydrolysis of VLDL particles. This appears due to the direct inhibition of HL by apoA-I, Both apoA-I and HDL are able to inhibit VLDL lipid hydrolysis by up to 60%. Inhibition of VLDL hydrolysis is associated with the binding of apoA-I to the surface of the VLDL particle and a concomitant decreased affinity for HL. These data show that apoA-I can regulate lipid hydrolysis by HL by liberating! activating the enzyme from cell surface proteoglycans and by directly modulating lipoprotein binding and hydrolysis.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Sparks, DL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.							ASSMANN G, 1973, J BIOL CHEM, V248, P7184; Bensadoun A, 1996, CURR OPIN LIPIDOL, V7, P77, DOI 10.1097/00041433-199604000-00005; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CARDIN AD, 1989, INT J BIOL MACROMOL, V11, P59, DOI 10.1016/0141-8130(89)90042-1; CASTRO GR, 1984, J LIPID RES, V25, P58; CHEVREUIL O, 1993, ARTERIOSCLER THROMB, V13, P1391, DOI 10.1161/01.ATV.13.10.1391; CHOI SSY, 1994, J LIPID RES, V35, P848; CLARK AB, 1985, J BIOL CHEM, V260, P4778; Coffill CR, 1997, J LIPID RES, V38, P2224; de Man FHAF, 1997, J LIPID RES, V38, P2465; Ehnholm C, 1986, Methods Enzymol, V129, P716; EHNHOLM C, 1975, J BIOL CHEM, V250, P6756; EISENBERG S, 1979, J LIPID RES, V20, P614; GRESSNER AM, 1991, EUR J CLIN CHEM CLIN, V29, P293; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; Hahn PF, 1943, SCIENCE, V98, P19, DOI 10.1126/science.98.2531.19; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hime NJ, 1998, J BIOL CHEM, V273, P27191, DOI 10.1074/jbc.273.42.27191; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; JANSEN H, 1974, H-S Z PHYSIOL CHEM, V355, P1212; JI ZS, 1994, J BIOL CHEM, V269, P13429; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; KIRCHMAIR R, 1995, BAILLIERE CLIN ENDOC, V9, P705, DOI 10.1016/S0950-351X(95)80081-6; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; Millar JS, 1998, CURR OPIN LIPIDOL, V9, P197, DOI 10.1097/00041433-199806000-00003; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P277, DOI 10.1016/0005-2760(79)90029-8; MUSLINER TA, 1988, J LIPID RES, V29, P349; MUSLINER TA, 1991, J LIPID RES, V32, P917; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PHILLIPS MC, 1992, INTERACTIONS APOLIPO, P185; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Plump AS, 1997, J LIPID RES, V38, P1033; POSNER I, 1983, ARCH BIOCHEM BIOPHYS, V226, P306, DOI 10.1016/0003-9861(83)90297-7; REA TJ, 1993, J LIPID RES, V34, P1901; RITTER MC, 1977, J BIOL CHEM, V252, P1208; Sanan DA, 1997, J LIPID RES, V38, P1002; SCHAEFER EJ, 1978, J LIPID RES, V19, P667; Sparks DL, 1998, BBA-LIPID LIPID MET, V1390, P160, DOI 10.1016/S0005-2760(97)00172-0; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; Swift LL, 1996, J BIOL CHEM, V271, P31491; WAITE M, 1978, BIOCHIM BIOPHYS ACTA, V530, P292, DOI 10.1016/0005-2760(78)90014-0; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253	49	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33480	33486		10.1074/jbc.M005436200	http://dx.doi.org/10.1074/jbc.M005436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944531	hybrid			2022-12-25	WOS:000090104600043
J	Sivasothy, P; Dafforn, TR; Gettins, PGW; Lomas, DA				Sivasothy, P; Dafforn, TR; Gettins, PGW; Lomas, DA			Pathogenic alpha(1)-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; SERPIN-PROTEINASE COMPLEX; POLYMERIZATION; MECHANISM; ANTITHROMBIN; ALPHA-1-ANTITRYPSIN; CONFORMATION; ANGSTROM; DISEASE; LIVER	alpha (1)-Antitrypsin is the most abundant circulating protease inhibitor and the archetype of the serine protease inhibitor or serpin superfamily, Members of this family may be inactivated by point mutations that favor transition to a polymeric conformation. This polymeric conformation underlies diseases as diverse as alpha (1)-antitrypsin deficiency-related cirrhosis, thrombosis, angioedema, and dementia, The precise structural linkage within a polymer has been the subject of much debate with evidence for reactive loop insertion into beta -sheet A or C or as strand 7A. We have used site directed cysteine mutants and fluorescence resonance energy transfer (FRET) to measure a number of distances between monomeric units in polymeric alpha (1)-antitrypsin, We have then used a combinatorial approach to compare distances determined from FRET with distances obtained from 2.9 x 10(6) different possible orientations of the alpha (1)-antitrypsin polymer. The closest matches between experimental FRET measurements and theoretical structures show conclusively that polymers of alpha (1)-antitrypsin form by insertion of the reactive loop into beta -sheet A.	Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Med,Resp Med Unit, Cambridge CB2 2XY, England; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Cambridge; University of Cambridge; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dafforn, TR (corresponding author), Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Haematol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	td214@cus.cam.ac.uk	Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679				AULAK KS, 1993, J BIOL CHEM, V268, P18088; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Fairclough R H, 1978, Methods Enzymol, V48, P347; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Lakowitcz J.R, 1999, PRINCIPLES FLUORESCE, P237, DOI DOI 10.1007/978-1-4757-3061-6_8; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MIKI M, 1984, BIOCHIM BIOPHYS ACTA, V790, P201, DOI 10.1016/0167-4838(84)90023-2; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHERWIN SS, METHODS ENZYMOL, V49, P222; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	34	118	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33663	33668		10.1074/jbc.M004054200	http://dx.doi.org/10.1074/jbc.M004054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924508	hybrid			2022-12-25	WOS:000090104600068
J	Chandel, NS; Vander Heiden, MG; Thompson, CB; Schumacker, PT				Chandel, NS; Vander Heiden, MG; Thompson, CB; Schumacker, PT			Redox regulation of p53 during hypoxia	ONCOGENE			English	Article						mitochondria; reactive oxygen species; hydrogen peroxide; apoptosis; cell cycle	INNER MEMBRANE; OXYGEN; MITOCHONDRIA; TUMOR; CARDIOMYOCYTES; PROLIFERATION; METABOLISM; APOPTOSIS; PROTEIN; DEATH	The transcription factor p53 can induce growth arrest or death in cells, Tumor cells that develop mutations in p53 demonstrate a diminished apoptotic potential, which may contribute to growth and tumor metastasis. Cellular levels of p53 are stabilized during hypoxia. The present study tested the hypothesis that reactive oxygen species (ROS) released from mitochondria regulate the cytosolic redox state and are required for the stabilization of p53 protein levels in response to hypoxia. Our results indicate that hypoxia (1.5% O-2) increases mitochondrial ROS generation and increases p53 protein levels in human breast carcinoma MCF-7 cells and in normal human diploid fibroblast IMR-90 cells. MCF-7 cells depleted of their mitochondrial DNA (rho degrees cells) failed to stabilize p53 protein levels during hypoxia. The antioxidant N-acetylcysteine and the Cu/Zn superoxide dismutase inhibitor diethyldithiocarbamic acid abolished the hypoxia-induced increases in ROS and p53 levels. Rotenone, an inhibitor of mitochondrial complex I, and 4,4'-diisothiocyanato-stilbene-2,2'-disulfonate, a mitochondrial anion channel inhibitor, also abolished the increase in ROS signal and p53 levels during hypoxia. The p53-dependent gene p21(WAF1/CIP1) was also induced by hypoxia in both MCF-7 and IMR-90 cells without affecting the growth rate of either cell line. In contrast, both cell lines exhibited increases in p21(WAF1/CIP1) expression and growth arrest after gamma irradiation. Primary chick cardiac myocytes and murine embryonic fibroblasts also showed an increase in p53 protein levels in response to hypoxia without cell death or growth arrest. These results indicate that mitochondria regulate p53 protein levels during hypoxia through a redox-dependent mechanism involving ROS, Despite p53-induction, hypoxia alone does not cause either growth arrest or cell death.	Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	Northwestern University; University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Chandel, NS (corresponding author), Northwestern Univ, Dept Med, Div Pulm & Crit Care, Tarry Bldg 14-707,300 E Super St, Chicago, IL 60611 USA.		Rodríguez, Ferran A. A/H-4892-2011	Rodríguez, Ferran A. A/0000-0002-2280-8962; Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL35440, HL32646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ballarin C, 1996, J BIOENERG BIOMEMBR, V28, P125, DOI 10.1007/BF02110642; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; BASS DA, 1983, J IMMUNOL, V130, P1910; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Colombini M, 1996, Ion Channels, V4, P169; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; ELDEIRY WS, 1993, CELL, V75, P217; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; JONES DP, 1978, J BIOL CHEM, V253, P4874; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; MISRA HP, 1979, J BIOL CHEM, V254, P1623; Ravi R, 2000, GENE DEV, V14, P34; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P485, DOI 10.1016/0003-9861(79)90375-8	34	142	145	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3840	3848		10.1038/sj.onc.1203727	http://dx.doi.org/10.1038/sj.onc.1203727			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951577				2022-12-25	WOS:000088614300002
J	Lee, TH; Chuang, LY; Hung, WC				Lee, TH; Chuang, LY; Hung, WC			Induction of p21(WAF1) expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells	ONCOGENE			English	Article						tamoxifen; p21(WAF1); protein kinase A; estrogen receptor	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR SP1; SIGNAL-TRANSDUCTION; WAF1/CIP1 GENE; BREAST-CANCER; DNA-BINDING; GROWTH; PHOSPHORYLATION; ACTIVATION; INHIBITION	Although originally synthesized as an anti-estrogen, tamoxifen (Tam) was found to be able to inhibit proliferation of estrogen receptor (ER)-negative cancer cells in vitro. However, the molecular basis of such ER-independent growth inhibition is largely unknown. We have previously demonstrated that Tam induces p21(WAF1) and p27(KIP1) expression in human lung cancer cells which lack ER-alpha and -beta. We found that Tam induced p21(WAF1) expression via transcriptional activation. In order to determine the molecular mechanism responsible for p21(WAF1) induction by Tam, we performed a deletion analysis on the p21(WAF1) promoter. The minimal region in the p21(WAF1) promoter required for Tam-activated induction mas mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site. Our results showed that transcription factor Sp1 and Sp3 bound to this GC-rich region and mutation of Sp1-binding sites dramatically attenuated Tam-induced p21(WAF1) promoter activity. We also tried to elucidate the signaling pathway that mediated the activation of p21(WAF1) by Tam, Inhibition of mitogen-activated protein kinase pathways did not block Tam-induced p21(WAF1). Similarly, protein kinase C inhibitor calphostin C could not suppress Tam-induced p21(WAF1). Conversely, pretreatment of a specific protein kinase A inhibitor H89 significantly attenuated the induction of p21(WAF1) by Tam, Furthermore, PKA activators forskolin and dibutyryl-cAMP activated p21(WAF1) promoter activity and increased p21(WAF1) protein level in lung cancer cells. Taken together, these results demonstrate that Tam activates the p21(WAF1) promoter via Sp1-binding sites and suggest that PKA may be involved in the induction of p21(WAF1) by Tam in ER-negative Lung cancer cells.	Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Biochem, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, No 100 Shih-Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chuang, Lea-Yea/C-7450-2009					Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; ANDREW NC, 1991, NUC ACIDS RES, V19, P6418; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Caputi M, 1998, AM J RESP CELL MOL, V18, P213, DOI 10.1165/ajrcmb.18.2.2937m; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Catzavelos C, 1999, CANCER RES, V59, P684; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; DUHL JL, 1997, PHARMACEUT RES, V14, P186; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Menard S, 2000, CANCER RES, V60, P273; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; White LA, 1997, J NEUROSCI RES, V47, P242, DOI 10.1002/(SICI)1097-4547(19970201)47:3<242::AID-JNR2>3.0.CO;2-I; Yatabe Y, 1998, CANCER RES, V58, P1042; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	48	58	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3766	3773		10.1038/sj.onc.1203715	http://dx.doi.org/10.1038/sj.onc.1203715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949931				2022-12-25	WOS:000088568400009
J	Sun, XX; Wang, CC				Sun, XX; Wang, CC			The N-terminal sequence (residues 1-65) is essential for dimerization, activities, and peptide binding of Escherichia coli DSbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CHAPERONE-LIKE ACTIVITY; REDOX PROPERTIES; BOND FORMATION; DEHYDROGENASE; THIOREDOXIN; SUBSTRATE; ISOMERIZATION; DOMAINS; FAMILY	Limited proteolysis of DsbC with trypsin resulted in a compact and stable C-terminal fragment (residues 66-216), fDsbC, which retains the active site sequence, -Cys(98)-Gly-Tyr-Cys(101)-, and shows only minor differences in conformation compared with that of the intact molecule. The pK(a) of active site thiol and the K-SS with glutathione are very close to that of DsbC, respectively; however, fDsbC is inactive as an isomerase in catalyzing the formation of correct disulfide bonds in scrambled RNase A and denatured and reduced bovine pancreatic trypsin inhibitor and shows only 13% thiol-protein oxidoreductase activity (TPOR) of DsbC. In contrast to the dimeric DsbC, fDsbC exists as a monomer and has no chaperone activity in assisting the reactivation of denatured D-glyceraldehyde-3-phosphate dehydrogenase. The heterodimer of DsbC with the inactive DsbC carboxymethylated at both active site thiols shows about 50% TPOR activity of DsbC but no isomerase activity, indicating that the DsbC subunit in the heterodimer displays full TPOR activity but little, if any, isomerase activity. It is concluded that the N-terminal sequence (residues 1-65) is essential for dimer formation and chaperone activity of DsbC. The active sites in both subunits of the dimeric DsbC appear to be essential for its isomerase activity.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; Frishman D, 1996, BIOCHEM BIOPH RES CO, V219, P686, DOI 10.1006/bbrc.1996.0295; GIROUX E, 1994, J BIOL CHEM, V269, P31404; Grant GA, 1999, J BIOL CHEM, V274, P5357, DOI 10.1074/jbc.274.9.5357; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHEEK RM, 1982, METHOD ENZYMOL, V89, P305; Sone M, 1997, J BIOL CHEM, V272, P10349; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	30	64	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22743	22749		10.1074/jbc.M002406200	http://dx.doi.org/10.1074/jbc.M002406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930424	hybrid			2022-12-25	WOS:000088419400022
J	Szekeres, CK; Tang, KQ; Trikha, M; Honn, KV				Szekeres, CK; Tang, KQ; Trikha, M; Honn, KV			Eicosanoid activation of extracellular signal-regulated kinase 1/2 in human epidermoid carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LIPOXIN A(4) RECEPTOR; SMOOTH-MUSCLE CELLS; 12(S)-HYDROXYEICOSATETRAENOIC ACID; TYROSINE-KINASE; MELANOMA-CELLS; LIPOXYGENASE METABOLITE; PHOSPHOLIPASE-C; ANGIOTENSIN-II; CANCER METASTASIS	12(S)-Hydroxyeicosatetraenoic acid (12(S)-HETE), a 12-lipoxygenase metabolite of arachidonic acid, has multiple effects on tumor and endothelial cells, including stimulation of invasion and angiogenesis. However, the signaling mechanisms controlling these physiological processes are poorly understood. In a human epidermoid carcinoma cell fine (i.e. A431), 12(S)-HETE activates extracellular signal-regulated kinases 1/2 (ERK1/2), which is mediated by upstream kinases MEK and Raf. 12(S)-HETE stimulates phosphorylation of phospholipase C gamma1 and activity of protein kinase C alpha (PKC alpha). In addition, independent of PKC 12(S)-HETE increases tyrosine phosphorylation of Shc, and Grb2, stimulates association between Shc and Src, and increases the activity of Ras, via Src family kinases. Furthermore, at low (10-100 nM) concentrations 12(S)-HETE counteracts epidermal growth factor-stimulated activation of ERK1/2 via stimulating protein tyrosine phosphatases. We also present evidence that 12(S)-HETE stimulates ERK1/2 via G proteins and that A431 cells have multiple binding sites for 12(S)-HETE. Finally, inhibition of 12-lipoxygenase induced apoptosis of A431 cells, which was reversed by addition of exogenous 12(S)-HETE. Collectively we demonstrate that the activation of ERK1/2 by 12(S)-HETE may be regulated by multiple receptors triggering PKC-dependent and PKC-independent pathways in A431 cells.	Wayne State Univ, Dept Radiat Oncol, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Karmanos Canc Inst, Detroit, MI 48202 USA	Wayne State University; Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute	Honn, KV (corresponding author), Wayne State Univ, Dept Radiat Oncol, 431 Chem Bldg, Detroit, MI 48202 USA.				NATIONAL CANCER INSTITUTE [R01CA029997] Funding Source: NIH RePORTER; NCI NIH HHS [CA29997] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beindl W, 1996, MOL PHARMACOL, V50, P415; Bleich D, 1997, BIOCHEM BIOPH RES CO, V230, P448, DOI 10.1006/bbrc.1996.5981; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; CHEN YQ, 1994, CANCER RES, V54, P1574; CHOPRA H, 1991, INT J CANCER, V49, P774, DOI 10.1002/ijc.2910490524; COSTELLO PB, 1991, INFLAMMATION, V15, P269, DOI 10.1007/BF00917312; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; GAO X, 1995, UROLOGY, V46, P227, DOI 10.1016/S0090-4295(99)80198-8; GOPALAKRISHNA R, 1988, P NATL ACAD SCI USA, V85, P612, DOI 10.1073/pnas.85.2.612; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Gronroos E, 1996, BIOCHEM J, V316, P239; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hagmann W, 1996, EXP CELL RES, V228, P197, DOI 10.1006/excr.1996.0317; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herbertsson H, 1998, J LIPID RES, V39, P237; HONN KV, 1994, CANCER METAST REV, V13, P365, DOI 10.1007/BF00666105; HONN KV, 1994, EXP CELL RES, V214, P120, DOI 10.1006/excr.1994.1240; HONN KV, 1994, CANCER RES, V54, P565; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Katan M, 1996, CANCER SURV, V27, P199; KEVIN R, 1999, NATURE, V399, P789; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kurahashi Y, 2000, P NATL ACAD SCI USA, V97, P5779, DOI 10.1073/pnas.97.11.5779; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Lindsay MA, 1998, J LEUKOCYTE BIOL, V64, P555, DOI 10.1002/jlb.64.4.555; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LIU B, 1991, CELL REGUL, V2, P1045, DOI 10.1091/mbc.2.12.1045; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; LIU B, 1994, LAB INVEST, V70, P314; Liu XH, 1996, CLIN EXP METASTAS, V14, P145, DOI 10.1007/BF00121211; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONG S, 1990, MOL PHARMACOL, V37, P60; Nie D, 1998, CANCER RES, V58, P4047; PERKINS RS, 1995, BIOCHEM J, V310, P795, DOI 10.1042/bj3100795; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rice RL, 1998, INT J CANCER, V77, P271, DOI 10.1002/(SICI)1097-0215(19980717)77:2<271::AID-IJC17>3.0.CO;2-E; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SILLETTI S, 1994, CANCER RES, V54, P5752; SJOLANDER A, 1994, ANN NY ACAD SCI, V744, P155, DOI 10.1111/j.1749-6632.1994.tb52732.x; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; SUGDEN PH, 1999, CELL SIGNAL, V5, P337; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; Tang DG, 1997, ADV EXP MED BIOL, V400, P349; TANG DG, 1995, J CELL SCI, V108, P2629; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang KQ, 2000, BIOCHEMISTRY-US, V39, P3185, DOI 10.1021/bi992664v; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TIMAR J, 1992, INT J CANCER, V52, P594, DOI 10.1002/ijc.2910520418; TIMAR J, 1993, INT J CANCER, V55, P1; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zakaroff-Girard A, 1999, LIFE SCI, V64, P2135, DOI 10.1016/S0024-3205(99)00164-2	65	51	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38831	38841		10.1074/jbc.M002673200	http://dx.doi.org/10.1074/jbc.M002673200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952974	hybrid			2022-12-25	WOS:000165739800094
J	Schumacher, A; Koetsier, PA; Hertz, J; Doerfler, W				Schumacher, A; Koetsier, PA; Hertz, J; Doerfler, W			Epigenetic and genotype-specific effects on the stability of de Novo imposed methylation patterns in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL GENE-EXPRESSION; DNA METHYLATION; DENOVO METHYLATION; FOREIGN DNA; DETERMINES METHYLATION; CELLULAR MOSAICISM; HAMSTER-CELLS; MOUSE EMBRYO; SEQUENCES; EMBRYOGENESIS	The chloramphenicol acetyltransferase gene under the control of the late E2A promoter of adenovirus type 2 (Ad2) was introduced as transgene into the B6D2F1 mouse strain with mixed genetic background and became extensively de novo methylated. The methylation of this pAd2E2AL-CAT (7-1A) transgene was regulated in a strain-specific manner apparently depending on the site of integration. Transmission of the 7-1A transgene into an inbred DBA/2, 129/sv, or FVB/N genetic background led to a significant loss of methylation in the transgene, whereas C57BL/6, CB20, and Balb/c backgrounds favored the de novo methylation in very specific patterns. The newly established patterns of de novo methylation were transmitted to the offspring and remained stable for many generations, regardless of the heterozygosity of strain-specific DNA sequences present in these mouse strains. Segregation analyses showed a non-mendelian transmission of methylation phenotypes and suggested the involvement of dominant modifiers of methylation. The genotype-specific modifications of the transgene were followed for 11 backcross generations. These observations reflect an evolutionarily conserved mechanism directed against foreign, e.g. viral or bacterial, DNA at least in the chromosomal location of the 7-1A transgene, In seven additional mouse lines carrying the same transgene in different chromosomal locations, strain-specific alterations of methylation patterns were not observed.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany	University of Cologne	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.	doerfler@scan.genetik.uni-koeln.de	Schumacher, Axel/C-6612-2008					Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAILLET JR, 1995, GENE DEV, V9, P1177, DOI 10.1101/gad.9.10.1177; DELOIA JA, 1990, DEVELOPMENT, P73; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; DOERFLER W, 1999, FOREIGN DNA MAMMALIA; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; Engler P, 1998, P NATL ACAD SCI USA, V95, P10763, DOI 10.1073/pnas.95.18.10763; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LACY E, 1983, CELL, V34, P343, DOI 10.1016/0092-8674(83)90369-0; LATHAM KE, 1991, DEVELOPMENT, V113, P561; Latham KE, 1995, DIFFERENTIATION, V59, P269; LETTMANN C, 1991, NUCLEIC ACIDS RES, V19, P7131, DOI 10.1093/nar/19.25.7131; MARTIN CC, 1995, GENET RES, V65, P21, DOI 10.1017/S0016672300032973; MCGOWAN R, 1989, GENE DEV, V3, P1669, DOI 10.1101/gad.3.11.1669; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MONK M, 1987, DEVELOPMENT, V99, P371; MULLER U, 1987, J VIROL, V61, P3710; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; REIK W, 1990, DEVELOPMENT, P99; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1990, DEVELOPMENT, P107; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; Schweizer J, 1998, DNA CELL BIOL, V17, P427, DOI 10.1089/dna.1998.17.427; Solter D, 1998, INT J DEV BIOL, V42, P951; SURANI MA, 1990, DEVELOPMENT, P89; SUTTER D, 1979, COLD SPRING HARB SYM, V44, P565, DOI 10.1101/SQB.1980.044.01.058; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; SUTTER D, 1978, CELL, V14, P569, DOI 10.1016/0092-8674(78)90243-X; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; VARDIMON L, 1980, NUCLEIC ACIDS RES, V8, P2461, DOI 10.1093/nar/8.11.2461; Weichman K, 1997, MOL CELL BIOL, V17, P5269, DOI 10.1128/MCB.17.9.5269; WU X, 1992, MECH EUKARYOTIC DNA, P69; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	51	36	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37915	37921		10.1074/jbc.M004839200	http://dx.doi.org/10.1074/jbc.M004839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954710	hybrid			2022-12-25	WOS:000165618700082
J	Xia, RH; Stangler, T; Abramson, JJ				Xia, RH; Stangler, T; Abramson, JJ			Skeletal muscle ryanodine receptor is a redox sensor with a well defined redox potential that is sensitive to channel modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; SULFHYDRYL OXIDATION; GLUTATHIONE; DISULFIDE; REAGENTS; PURIFICATION; BINDING	Hyperreactive sulfhydryl groups associated with the Ca2+ release protein from sarcoplasmic reticulum are shown to have a well defined reduction potential that is sensitive to the cellular environment. Ca2+ channel activators lower the redox potential of the ryanodine receptor, which favors the oxidation of thiols and the opening of the Ca2+ release protein. In contrast, channel inhibitors increase the redox potential, which favors the reduction of disulfides and the closure of the release protein. Modulation of redox potential of reactive thiols may be a general control mechanism by which sarcoplasmic/endoplasmic reticulum, ryanodine receptors/IP3 receptors, control cytoplasmic Ca2+ concentrations.	Portland State Univ, Dept Phys, Portland, OR 97207 USA	Portland State University	Abramson, JJ (corresponding author), Portland State Univ, Dept Phys, POB 751, Portland, OR 97207 USA.							ABRAMSON JJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P396, DOI 10.1006/abbi.1993.1162; ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Anzai K, 1998, BIOCHEM BIOPH RES CO, V249, P938, DOI 10.1006/bbrc.1998.9244; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2000, BIOPHYS J, V78, p123A; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INUI M, 1987, J BIOL CHEM, V262, P1740; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; LIU GH, 1994, MOL PHARMACOL, V45, P189; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Morad M, 2000, ANTIOXID REDOX SIGN, V2, P1, DOI 10.1089/ars.2000.2.1-1; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	27	112	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36556	36561		10.1074/jbc.M007613200	http://dx.doi.org/10.1074/jbc.M007613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10952995	hybrid			2022-12-25	WOS:000165577700015
J	Christmann, M; Kaina, B				Christmann, M; Kaina, B			Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; DNA-DAMAGE TOLERANCE; MAMMALIAN-CELLS; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHROMOSOMAL INSTABILITY; METHYLATING AGENTS; ESCHERICHIA-COLI; GENOTOXIC AGENTS; BINDING-ACTIVITY; GENE-EXPRESSION	Mammalian:mismatch repair has been implicated in mismatch correction, the prevention of mutagenesis and cancer, and the induction of genotoxicity and apoptosis.:sere, we show that treatment of cells specifically with agents inducing O(6)-methylguanine in DNA, such as N-methyl-N'-nitro-N-nitrosoguanidine and N-methyl-N-nitrosourea, elevates the level of MSH2 and MSH6 and increases GT mismatch binding activity in the nucleus. This inducible response occurs immediately after alkylation, is long-lasting and dose-dependent, and results from translocation of the preformed MutS alpha complex (composed of MSHS and MSH6) from the cytoplasm into the nucleus. It is not caused by an increase in MSH2 gene activity. Cells expressing the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MG:MT), thus having the ability to repair O(6)-methylguanine, showed no translocation of MutSa, whereas inhibition of MGMT by O(6)-benzylguanine provoked the translocation. The results demonstrate that O(6)-methylguanine lesions are,involved in triggering nuclear accumulation of MSH2 and MSH6. The finding that treatment of cells with O(6)-methylguanine-generating mutagens results in an increase of MutS alpha and GT binding activity in the nucleus:indicates a novel type of genotoxic stress response.	Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher 67, D-55131 Mainz, Germany.	Kaina@mail.uni-mainz.de						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Belloni M, 1999, J NEUROCHEM, V72, P974, DOI 10.1046/j.1471-4159.1999.0720974.x; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BRENNAND J, 1986, CARCINOGENESIS, V7, P185, DOI 10.1093/carcin/7.1.185; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; Dosch J, 1996, ONCOGENE, V13, P1927; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Herrlich P, 1997, BIOL CHEM, V378, P1217; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kaina B, 1999, NATO ASI 2, V55, P289; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Korabiowska M, 1999, ONCOL REP, V6, P921; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; Marra G, 1996, ONCOGENE, V13, P2189; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SEDGWICK B, 1983, MOL GEN GENET, V191, P466, DOI 10.1007/BF00425764; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	49	85	86	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36256	36262		10.1074/jbc.M005377200	http://dx.doi.org/10.1074/jbc.M005377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954713	hybrid			2022-12-25	WOS:000165382000087
J	Lambrechts, A; Kwiatkowski, AV; Lanier, LM; Bear, JE; Vandekerckhove, J; Ampe, C; Gertler, FB				Lambrechts, A; Kwiatkowski, AV; Lanier, LM; Bear, JE; Vandekerckhove, J; Ampe, C; Gertler, FB			cAMP-dependent protein kinase phosphorylation of EVL, a mena/VASP relative, regulates its interaction with actin and SH3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; PROLINE-RICH SEQUENCES; ABL TYROSINE KINASE; HUMAN PLATELETS; FOCAL ADHESION; LISTERIA-MONOCYTOGENES; MONOCLONAL-ANTIBODY; BINDING PROPERTIES; ENA/VASP FAMILY; EVH1 DOMAIN	Proteins of the Ena/VASP family are implicated in processes that require dynamic actin remodeling such as axon guidance and platelet activation. In this work, we explored some of the pathways that likely regulate actin dynamics in part via EVL (Ena/VASP-like protein). Two isoforms, EVL and EVL-I, were highly expressed in hematopoietic cells of thymus and spleen. In CDS-activated T-cells, EVL was found in F-actin-rich patches and at the distal tips of the microspikes that formed on the activated side of the T-cells. Like the other family members, EVL localized to focal adhesions and the leading edge of lamellipodia when expressed in fibroblasts. EVL was a substrate for the cAMP-dependent protein kinase, and this phosphorylation regulated several of the interactions between EVL and its ligands. Unlike VASP, EVL nucleated actin polymerization under physiological conditions, whereas phosphorylation of both EVL and VASP decreased their nucleating activity. EVL bound directly to the Abl, Lyn, and nSrc SH3 domains; the FE65 WW domain; and profilin, likely via its proline-rich core. Binding of Abl and nSrc SH3 domains, but not profilin or other SH3 domains, was abolished by cAMP-dependent protein kinase phosphorylation of EVL. We show strong cooperative binding of two profilin dimers on the polyproline sequence of EVL, Additionally, profilin competed with the SH3 domains for binding to partially overlapping binding sites. These data suggest that the function of EVL could be modulated in a complex manner by its interactions with multiple ligands and through phosphorylation by cyclic nucleotide dependent kinases.	MIT, Dept Biol, Cambridge, MA 02139 USA; State Univ Ghent VIB, Fac Med, Dept Med Prot Chem, B-9000 Ghent, Belgium	Massachusetts Institute of Technology (MIT); Flanders Institute for Biotechnology (VIB); Ghent University	Gertler, FB (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,68-270, Cambridge, MA 02139 USA.	fgertler@mit.edu	Ampe, Christophe/B-5534-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058801] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58801] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BUTT E, 1994, J BIOL CHEM, V269, P14509; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; LAMBRECHTS A, 1995, EUR J BIOCHEM, V230, P281, DOI 10.1111/j.1432-1033.1995.0281i.x; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NIEBUHR K, 1997, IMMUNOLOGY METHODS M, P798; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pawson T, 2000, GENE DEV, V14, P1027; Pigino G, 1997, J CELL SCI, V110, P257; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RKAUSE M, 2000, J CELL BIOL, V149, P181; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SELLIAH N, 1995, J NEUROIMMUNOL, V56, P107, DOI 10.1016/0165-5728(94)00142-B; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Zhang J, 1998, J IMMUNOL, V161, P2930	61	142	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36143	36151		10.1074/jbc.M006274200	http://dx.doi.org/10.1074/jbc.M006274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945997	hybrid			2022-12-25	WOS:000165382000071
J	Yamage, M; Debrabant, A; Dwyer, DM				Yamage, M; Debrabant, A; Dwyer, DM			Molecular characterization of a hyperinducible, surface membrane-anchored, class I nuclease of a trypanosomatid parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI PROMASTIGOTES; AMINO-ACID-SEQUENCE; 3'-NUCLEOTIDASE NUCLEASE; CRITHIDIA-LUCILIAE; PENICILLIUM-CITRINUM; ASPERGILLUS-ORYZAE; PURINE STARVATION; MESSENGER-RNAS; GENE; PROTEIN	The 3'-nucleotidase/nuclease (5'-NT/NU) is a surface enzyme unique to trypanosomatid parasites. These organisms lack the pathway for de novo purine biosynthesis and thus are entirely dependent upon their hosts to supply this nutrient for their survival, growth, and multiplication. The 3'-NT/NU is involved in the salvage of preformed purines via the hydrolysis of either 3'-nucleotides or nucleic acids. In Crithidia luciliae, this enzyme is highly inducible. For example, in these organisms purine starvation triggers an similar to 1000-fold up-expression of 3'-NT/NU activity. In the present study, we cloned and characterized a gene encoding this intriguing enzyme from C. luciliae (Cl). Sequence analysis showed that the Cl 3'-NT/NU deduced protein possessed five regions, which we defined here as being characteristic of members of the class I nuclease family. Further, we demonstrated that the Cl 3'-NT/NU-expressed protein possessed both 3'-nucleotidase and nuclease activities. Moreover, we showed that the dramatic up-expression of 5'-NT/NU activity in response to purine starvation of C. luciliae was concomitant with the similar to 100-fold elevation in steady-state mRNA specific for this gene. Finally, results of our nuclear run-on analyses demonstrated that such up-regulation in 3'-NT/NU enzyme activity was mediated at the posttranscriptional level.	NIAID, Div Intramural Res, Parasit Dis Lab, Cell Biol Sect,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dwyer, DM (corresponding author), NIAID, Div Intramural Res, Parasit Dis Lab, Cell Biol Sect,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000745, Z01AI000745, Z01AI000162] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Alleman MM, 1995, EXP PARASITOL, V81, P519, DOI 10.1006/expr.1995.1145; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoyagi S, 1998, FEBS LETT, V429, P134, DOI 10.1016/S0014-5793(98)00563-8; Bates P.A., 1991, P537; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; BATES PA, 1993, FEMS MICROBIOL LETT, V107, P53, DOI 10.1111/j.1574-6968.1993.tb06003.x; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRYANT C, 1989, BIOCH ADAPTATION PAR, P71; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; CAMPBELL TA, 1991, MOL BIOCHEM PARASIT, V47, P109, DOI 10.1016/0166-6851(91)90153-W; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; Croan D, 1996, MOL BIOCHEM PARASIT, V79, P97, DOI 10.1016/0166-6851(96)02629-1; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; DESCOTEAUX A, 1994, METH MOL G, V3, P22; DOYLE PS, 1993, EXP PARASITOL, V77, P435, DOI 10.1006/expr.1993.1103; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; FRASER MJ, 1993, NUCLEASES, P171; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOTTLIEB M, 1989, PARASITOL TODAY, V5, P257, DOI 10.1016/0169-4758(89)90259-7; GOTTLIEB M, 1985, SCIENCE, V227, P72, DOI 10.1126/science.2981117; GOTTLIEB M, 1988, EXP PARASITOL, V66, P108, DOI 10.1016/0014-4894(88)90055-0; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HASSAN HF, 1987, MOL BIOCHEM PARASIT, V23, P285, DOI 10.1016/0166-6851(87)90035-1; IWAMATSU A, 1991, J BIOCHEM-TOKYO, V110, P151, DOI 10.1093/oxfordjournals.jbchem.a123534; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee BR, 1995, APPL MICROBIOL BIOT, V44, P425; Lewin B., 2000, GENES; MAEKAWA K, 1991, EUR J BIOCHEM, V200, P651, DOI 10.1111/j.1432-1033.1991.tb16228.x; Mahmood R, 1998, J BIOL CHEM, V273, P23729, DOI 10.1074/jbc.273.37.23729; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEUBERT TA, 1990, J BIOL CHEM, V265, P7236; Pogue GP, 1996, MOL BIOCHEM PARASIT, V81, P27, DOI 10.1016/0166-6851(96)02697-7; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHNEIDER A, 1993, J BIOL CHEM, V268, P21868; Shishido K, 1982, NUCLEASES, P155; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; Sullivan JT, 1998, P NATL ACAD SCI USA, V95, P5145, DOI 10.1073/pnas.95.9.5145; SUNO M, 1973, J BIOCHEM-TOKYO, V73, P1291, DOI 10.1093/oxfordjournals.jbchem.a130203; TABATA N, 1991, AGR BIOL CHEM TOKYO, V55, P461, DOI 10.1080/00021369.1991.10870590; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *UNDP WHO WORLD BA, 1997, TROP RES PROGR 1995; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0	53	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36369	36379		10.1074/jbc.M004036200	http://dx.doi.org/10.1074/jbc.M004036200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945983	hybrid			2022-12-25	WOS:000165382000101
J	Yamamura, Y; Hua, XX; Bergelson, S; Lodish, HF				Yamamura, Y; Hua, XX; Bergelson, S; Lodish, HF			Critical role of Smads and AP-1 complex in transforming growth factor-beta-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; TGF-BETA; C-JUN; TRANSCRIPTION FACTORS; LEUKEMIA CELLS; FAS LIGAND; B-CELLS; ACTIVATION; INDUCTION; RECEPTOR	Transforming growth factor-beta1 (TGF-beta1) induces not only cell growth inhibition but also apoptosis in hepatocytes, myeloid cells, and epithelial cells. Although Smad proteins are identified as key signal transducers in TGF-beta1 dependent growth inhibition, their roles in the induction of apoptosis are unclear. We show here that both Smad proteins and AP-1 complex are involved in TGF-beta1 signaling for apoptosis. Overexpression of a dominant-negative Smad3 mutant or Smad7, both of which impair Smad-mediated signal transduction, inhibits TGF-beta1-dependent apoptosis. Only the JunD-FosB form of the AP-1 complex is markedly activated during TGF-beta1-dependent apoptosis, FosB substantially enhances Smad3.Smad4-dependent transcription, and dominant-negative FosB blocks TGF-beta1-dependent apoptosis but not growth inhibition. Expression of JunD.FosB enhances induction of apoptosis by TGF-beta1. Moreover, JunD.FosB binds to the 12-O-tetradecanoyl-13-acetate-responsive gene promoter element and recruits Smad3.Smad4 to form a multicomponent complex. These results suggest that Smad proteins and AP-1 complex synergize to mediate TGF-beta1-dependent apoptosis.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tokyo Medical & Dental University (TMDU)	Yamamura, Y (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Altieri P, 1998, J CELL PHYSIOL, V177, P214, DOI 10.1002/(SICI)1097-4652(199811)177:2<214::AID-JCP3>3.3.CO;2-Y; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Brodin G, 1999, CANCER RES, V59, P2731; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIM SJ, 1990, MOL CELL BIOL, V12, P5015; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN JK, 1992, CANCER RES, V52, P385; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Takiya S, 1995, J CLIN PATHOL, V48, P1093, DOI 10.1136/jcp.48.12.1093; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	39	162	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36295	36302		10.1074/jbc.M006023200	http://dx.doi.org/10.1074/jbc.M006023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942775	hybrid			2022-12-25	WOS:000165382000092
J	Drugan, JK; Rogers-Graham, K; Gilmer, T; Campbell, S; Clark, GJ				Drugan, JK; Rogers-Graham, K; Gilmer, T; Campbell, S; Clark, GJ			The Ras/p120 GTPase-activating protein (GAP) interaction is regulated by the p120 GAP pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BRUTON TYROSINE KINASE; HIGH-AFFINITY BINDING; RAS-GTPASE; PHOSPHOINOSITIDE BINDING; PH DOMAIN; TRANSFORMATION; IDENTIFICATION; SPECIFICITY; GENE	Pleckstrin homology domains are structurally conserved functional domains that can undergo both protein/protein and protein/lipid interactions. Pleckstrin homology domains can mediate inter- and intra-molecular binding events to regulate enzyme activity. They occur in numerous proteins including many that interact with Pas superfamily members, such as p120 GAP, The pleckstrin homology domain of p120 GAP is located in the NH2-terminal, noncatalytic region of p120 GAP. Overexpression of the noncatalytic domains of p120 GAP may modulate Pas signal transduction pathways. Here, we demonstrate that expression of the isolated pleckstrin homology domain of p120 GAP specifically inhibits Pas-mediated signaling and transformation but not normal cellular growth. Furthermore, we show that the pleckstrin homology domain binds the catalytic domain of p120 GAP and interferes with the Ras/GAP interaction. Thus, we suggest that the pleckstrin homology domain of p120 GAP may specifically regulate the interaction of Pas with p120 GAP via competitive intramolecular binding.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Glaxo Wellcome Inc, Dept Cell Biol, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr, Rockville, MD 20850 USA.			campbell, sharon/0000-0003-0311-409X	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010279] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA070308, R29CA072644, R29CA064569] Funding Source: NIH RePORTER; NCI NIH HHS [CA72644-10, CA70308, CA64569] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1992, CANCER BIOL, V3, P199; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CARLIER MF, 1987, BIOCHEMISTRY-US, V26, P4428, DOI 10.1021/bi00388a036; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RUGGIERI R, 1994, MOL BIOL CELL, V5, P173, DOI 10.1091/mbc.5.2.173; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Srinivasan N, 1996, BIOCHEM BIOPH RES CO, V220, P697, DOI 10.1006/bbrc.1996.0467; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752	42	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35021	35027		10.1074/jbc.M004386200	http://dx.doi.org/10.1074/jbc.M004386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954709	hybrid			2022-12-25	WOS:000165422800028
J	Fong, NM; Jensen, TC; Shah, AS; Parekh, NN; Saltiel, AR; Brady, MJ				Fong, NM; Jensen, TC; Shah, AS; Parekh, NN; Saltiel, AR; Brady, MJ			Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PHOSPHATASE 1; CATALYTIC SUBUNIT; KINASE INHIBITION; ACTIVATION; INSULIN; PHOSPHORYLATION; SYNTHASE; TRANSLOCATION; DOMAINS	The activation of protein phosphastase-1 (PP1) by insulin-plays a critical role in the regulation of glycogen metabolism. PTG is a PP1 glycogen-targeting protein, which also binds the PP1 substrates glycogen synthase, glycogen phosphorylase, and phosphorylase kinase (Printen, J.:A,, Brady, M. J., and Saltiel, A. R. (1997) Science 275, 1475-1478). Through a combination of deletion analysis and site-directed mutagenesis, the regions on PTG responsible for binding PP1 and its substrates have been delineated. Mutagenesis of Val-62 and Phe-64 in the highly conserved (K/R)VXF PP1-binding motif to alanine was sufficient to ablate PP1 binding to PTG. Phosphorylase kinase, glycogen synthase, and phosphorylase binding all mapped to the same C-terminal region of PTG. Mutagenesis of Asp-225 and Glu-228 to alanine completely blocked the interaction between PTG and these three enzymes, without affecting PP1 binding. Disruption of either PP1 or substrate binding to PTG blocked the stimulation of PP1 activity in vitro against phosphorylase, indicating that both binding sites may be important in PTG action. Transient overexpression of wild type PTG in Chinese hamster ovary cells overexpressing the insulin receptor caused a 50-fold increase in glycogen levels. Expression of PTG mutants that do not bind PP1 had no effect on glycogen accumulation, indicating that PP1 targeting is essential for PTG function. Likewise, expression of the PTG mutants that do not bind PP1 substrates did not increase glycogen levels, indicating that PP1 targeting glycogen is not sufficient for the metabolic effects of PTG, These results cumulatively demonstrate that PTG serves as a molecular scaffold, allowing PP1 to recognize its substrates at the glycogen particle.	Pfizer Global Res & Dev, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Brady, MJ (corresponding author), Pfizer Global Res & Dev, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Berndt Norbert, 1999, Frontiers in Bioscience, V4, pD22, DOI 10.2741/Berndt; Bork P, 1998, J MOL MED-JMM, V76, P77, DOI 10.1007/s001090050194; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1999, TRENDS ENDOCRIN MET, V10, P408, DOI 10.1016/S1043-2760(99)00201-5; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; BRADY MJ, IN PRESS RECENT PROG; Cohen P, 1978, Curr Top Cell Regul, V14, P117; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GomezLechon MJ, 1996, ANAL BIOCHEM, V236, P296, DOI 10.1006/abio.1996.0170; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; TANG PM, 1991, J BIOL CHEM, V266, P15782; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	38	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35034	35039		10.1074/jbc.M005541200	http://dx.doi.org/10.1074/jbc.M005541200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938087	hybrid			2022-12-25	WOS:000165422800030
J	Gual, A; Camacho, AG; Alonso, JC				Gual, A; Camacho, AG; Alonso, JC			Functional analysis of the terminase large subunit, G2P, of Bacillus subtilis bacteriophage SPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PACKAGING ENZYME; KINETIC CHARACTERIZATION; NUCLEOPROTEIN COMPLEX; ENDONUCLEASE ACTIVITY; NUCLEOTIDE-SEQUENCE; LAMBDA TERMINASE; SITE PAC; PROTEIN; INITIATION; MECHANISM	The terminase of bacteriophage SPP1, constituted by a large (G2P) and a small (GIP) subunit, is essential for the initiation of DNA packaging. A hexa-histidine G2P (H6-G2P), which is functional in vivo, possesses endonuclease, ATPase, and double-stranded DNA binding activities. H6-G2P introduces a cut with preference at the 5'-RCGG down arrow CW-3' sequence. Distamycin A, which is a minor groove binder that mimics the architectural structure generated by G1P at pac, enhances the specific cut at both bona fide 5'-CTATTGCGG down arrow C-3' sequences within pacC of SPP1 and SF6 phages, H6-G2P hydrolyzes rATP or dATP to the corresponding rADP or dADP and Pi, H6-G2P interacts with two discrete G1P domains (I and II). Full-length GIP and G1P Delta N62 (lacking domain I) stimulate 3,5- and 1,9-fold, respectively, the ATPase activity of H6-G2P. The results presented suggest that a DNA structure, artificially promoted by distamycin A or facilitated by the assembly of GIP at pact and/or pacR, stimulates H6-G2P cleavage at both target sites within pacC. In the presence of two GIP decamers per H6-G2P monomer, the H6-G2P endonuclease is repressed, and the ATPase activity stimulated. Based on these results, we propose a model that can account for the role of terminase in headful packaging.	CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Alonso, JC (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.		Alonso, Juan Carlos/D-2595-2009	Alonso, Juan Carlos/0000-0002-5178-7179				Alonso JC, 1997, GENE, V204, P201, DOI 10.1016/S0378-1119(97)00547-7; ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; ALONSO JC, 1986, EMBO J, V5, P3723, DOI 10.1002/j.1460-2075.1986.tb04706.x; Ayora S, 1996, J MOL BIOL, V256, P301, DOI 10.1006/jmbi.1996.0087; BLACK LW, 1995, BIOESSAYS, V17, P1025, DOI 10.1002/bies.950171206; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BRAVO A, 1990, NUCLEIC ACIDS RES, V18, P2881, DOI 10.1093/nar/18.10.2881; Casjens S, 1985, VIRUS STRUCTURE ASSE, P75; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; CHAI S, 1992, J MOL BIOL, V224, P87, DOI 10.1016/0022-2836(92)90578-8; CHAI SH, 1994, VIROLOGY, V202, P930, DOI 10.1006/viro.1994.1415; Chai SH, 1997, GENE, V184, P251, DOI 10.1016/S0378-1119(96)00609-9; CHAI SH, 1995, J MOL BIOL, V252, P386, DOI 10.1006/jmbi.1995.0505; Chai SH, 1996, NUCLEIC ACIDS RES, V24, P282, DOI 10.1093/nar/24.2.282; COREN JS, 1995, J MOL BIOL, V249, P176, DOI 10.1006/jmbi.1995.0287; DEICHELBOHRER I, 1982, J VIROL, V42, P83, DOI 10.1128/JVI.42.1.83-90.1982; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gual A, 1998, VIROLOGY, V242, P279, DOI 10.1006/viro.1997.9017; Hwang Y, 1996, J MOL BIOL, V261, P524, DOI 10.1006/jmbi.1996.0480; Leffers G, 1996, J MOL BIOL, V258, P839, DOI 10.1006/jmbi.1996.0291; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; SKORUPSKI K, 1994, J MOL BIOL, V243, P268, DOI 10.1006/jmbi.1994.1653; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P8070, DOI 10.1073/pnas.87.20.8070; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Tavares P, 1996, J MOL BIOL, V264, P954, DOI 10.1006/jmbi.1996.0689; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	35	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35311	35319		10.1074/jbc.M004309200	http://dx.doi.org/10.1074/jbc.M004309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10930407	hybrid, Green Submitted			2022-12-25	WOS:000165422800065
J	Keller, C; Krude, T				Keller, C; Krude, T			Requirement of cyclin/Cdk2 and protein phosphatase 1 activity for chromatin assembly factor 1-dependent chromatin assembly during DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL NUCLEAR ANTIGEN; REPLICATION INVITRO; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; BINDING DOMAINS; PURINE ANALOGS; FACTOR-I; CYCLE; PCNA	The influence of reversible protein phosphorylation on nucleosome assembly during DNA replication was analyzed in extracts from human cells. Inhibitor studies and add-back: experiments indicated requirements of cyclin A/Cdk2, cyclin E/Cdk2, and protein phosphatase type 1 (PP1) activities for nucleosome assembly during DNA synthesis by chromatin assembly factor 1 (CAF-1). The p60 subunit of CAF-1 is a molecular target for reversible phosphorylation by cyclin/Cdk complexes and PP1 during nucleosome assembly and DNA synthesis in vitro. Purified p60 can be directly phosphorylated by purified:cyclin A/Cdk2, cyclin E/Cdk2, and cyclin B1/Cdk1, but not by cyclin D/CdkB4 complexes in vitro. Cyclin B1/Cdk1:triggers hyperphosphorylation of p60 in the presence of additional cytosolic factors. CAF-1 containing hyperphosphorylated p60 prepared from mitotic cells is inactive in nucleosome assembly and becomes activated by dephosphorylation in vitro. These data provide:functional evidence for a requirement of the cell cycle machinery for nucleosome assembly by CAF-1 during DNA replication.	Univ Cambridge, CRC, Wellcome Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB3 7EJ, England	University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge	Krude, T (corresponding author), Univ Cambridge, CRC, Wellcome Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk1@mole.bio.cam.ac.uk		Krude, Torsten/0000-0002-1842-1933				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Jackman MR, 1997, CANCER SURV, V29, P47; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRUDE T, 1994, J BIOL CHEM, V269, P21021; KRUDE T, 1993, J BIOL CHEM, V268, P14432; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Krude T, 1999, CURR BIOL, V9, pR394, DOI 10.1016/S0960-9822(99)80251-6; LASSLE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P1, DOI 10.1016/0167-4781(92)90045-2; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Paulson JR, 1996, J CELL SCI, V109, P1437; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Reed SI, 1997, CANCER SURV, V29, P7; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Weisshart Klaus, 1999, P295	61	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35512	35521		10.1074/jbc.M003073200	http://dx.doi.org/10.1074/jbc.M003073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938080	hybrid			2022-12-25	WOS:000165422800090
J	Kronfeld, I; Kazimirsky, G; Lorenzo, PS; Garfield, SH; Blumberg, PM; Brodie, C				Kronfeld, I; Kazimirsky, G; Lorenzo, PS; Garfield, SH; Blumberg, PM; Brodie, C			Phosphorylation of protein kinase C delta on distinct tyrosine residues regulates specific cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; PHORBOL ESTER; PKC-DELTA; SIGNAL-TRANSDUCTION; GLUTAMINE-SYNTHETASE; GLIAL-CELLS; ACTIVATION; EXPRESSION; DOMAINS; SRC	Protein kinase C delta (PKC delta) inhibits proliferation and decreases expression of the differentiation marker glutamine synthetase (GS) in C6 glioma cells. Here, we report that distinct, specific tyrosine residues on PKC delta are involved in these two responses. Transfection of cells with PKC delta mutated at tyrosine 155 to phenylalanine caused enhanced proliferation in response to 12-phorbol la-myristate 13-acetate, whereas GS expression resembled that for the PKC delta wild-type transfectant. Conversely, transfection with PKC delta mutated at tyrosine 187 to phenylalanine resulted in increased expression of GS, whereas the rate of proliferation resembled that of the PKC delta wild-type transfectant. The tyrosine phosphorylation of PKC delta and the decrease in GS expression induced by platelet-derived growth factor (PDGF) were abolished by the Src kinase inhibitors PP1 and PP2. In response to PDGF, Fyn associated with PKC delta via tyrosine 187. Finally, overexpression of dominant negative Fyn abrogated the decrease in GS expression and reduced the tyrosine phosphorylation of PKC delta induced by PDGF. We conclude that the tyrosine phosphorylation of PKC delta and its association with tyrosine kinases may be an important point of divergence in PKC signaling.	Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diag Res Ctr, IL-52900 Ramat Gan, Israel; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brodie, C (corresponding author), Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diag Res Ctr, IL-52900 Ramat Gan, Israel.	chaya@mail.biu.ac.il						Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kiley SC, 1999, CANCER RES, V59, P3230; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 1998, FASEB J, V12, P35; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	43	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35491	35498		10.1074/jbc.M005991200	http://dx.doi.org/10.1074/jbc.M005991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945993	hybrid			2022-12-25	WOS:000165422800087
J	Nakatsu, Y; Asahina, H; Citterio, E; Rademakers, S; Vermeulen, W; Kamiuchi, S; Yeo, JP; Khaw, MC; Saijo, M; Kodo, N; Matsuda, T; Hoeijmakers, JHJ; Tanaka, K				Nakatsu, Y; Asahina, H; Citterio, E; Rademakers, S; Vermeulen, W; Kamiuchi, S; Yeo, JP; Khaw, MC; Saijo, M; Kodo, N; Matsuda, T; Hoeijmakers, JHJ; Tanaka, K			XAB2, a novel tetratricopeptide repeat protein involved in transcription-coupled DNA repair and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; ACTIVE GENES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; ELONGATION COMPLEXES	Nucleotide excision repair is a highly versatile DNA repair system responsible for elimination of a wide variety of lesions from the genome. It is comprised of two subpathways: transcription-coupled repair that accomplishes efficient removal of damage blocking transcription and global genome repair, Recently, the basic mechanism of global genome repair has emerged from biochemical studies. However, little is known about transcription-coupled repair in eukaryotes, Here we report the identification of a novel protein designated XAB2 (XPA-binding protein 2) that was identified by virtue of its ability to interact with XPA, a factor central to both nucleotide excision repair subpathways, The XAB2 protein of 855 amino acids consists mainly of 15 tetratricopeptide repeats. In addition to interacting with XPA, immunoprecipitation experiments demonstrated that a fraction of XAB2 is able to interact with the transcription-coupled repair-specific proteins CSA and CSB as well as RNA polymerase II. Furthermore, antibodies against XAB2 inhibited both transcription-coupled repair and transcription in vivo but not global genome repair when microinjected into living fibroblasts. These results indicate that XAB2 is a novel component involved in transcription-coupled repair and transcription.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Erasmus Univ, Ctr Biomed Genet, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands	Osaka University; Japan Science & Technology Agency (JST); Erasmus University Rotterdam	Tanaka, K (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	ktanaka@imcb.osaka-u.ac.jp	Vermeulen, Wim/W-8708-2019; Hoeijmakers, Jan/AAX-6972-2021	Vermeulen, Wim/0000-0003-3616-734X; Nakatsu, Yoshimichi/0000-0001-7408-7071; Citterio, Elisabetta/0000-0003-2347-3495				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; Araujo SJ, 2000, GENE DEV, V14, P349; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DECOCK JGR, 1992, MUTAT RES, V274, P85, DOI 10.1016/0921-8777(92)90055-8; Dix I, 1999, RNA, V5, P360, DOI 10.1017/S1355838299981396; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Hanawalt PC, 1999, NATO ADV SCI I A-LIF, V302, P169; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MAYNE LV, 1982, CANCER RES, V42, P1473; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	51	106	115	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34931	34937		10.1074/jbc.M004936200	http://dx.doi.org/10.1074/jbc.M004936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944529	Green Published, hybrid			2022-12-25	WOS:000165422800016
J	Sher, I; Lang, T; Lubinsky-Mink, S; Kuhn, J; Adir, N; Chatterjee, S; Schomburg, D; Ron, D				Sher, I; Lang, T; Lubinsky-Mink, S; Kuhn, J; Adir, N; Chatterjee, S; Schomburg, D; Ron, D			Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; HEPARAN-SULFATE; EXPRESSION; MOLECULES; DOMAINS; COMMON; REGIONS; CLONING; PROTEIN; FAMILY	Fibroblast growth factors (FGFs) mediate a multitude of physiological and pathological processes by activating a family of tyrosine kinase receptors (FGFRs), Each FGFR binds to a unique subset of FGFs and ligand binding specificity is essential in regulating FGF activity, FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR, Previously, mutations in FGF-2 identified a set of residues that are important for high affinity receptor binding, known as the primary receptor-binding site. FGF-7 contains this primary site as well as a region that restricts interaction with FGFR1. The sequences that confer on FGF-7 its specific binding to KGFR have not been identified. By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of FGF-7 contributes to high affinity receptor binding and is critical for KGFR recognition. Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1. Point mutations in residues comprising this loop of FGF-7 reduced both binding affinity and biological potency. The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR, Our results show that topologically similar regions in these two FGFs have different roles in regulating receptor binding specificity and suggest that specificity may require the concerted action of distinct regions of an FGF.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Univ Koeln, Inst Biochem, D-50674 Koeln, Germany	Technion Israel Institute of Technology; Technion Israel Institute of Technology; University of Cologne	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Adir, Noam/ABE-6990-2020	Schomburg, Dietmar/0000-0002-3354-822X				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Chang DZ, 1996, J BIOL CHEM, V271, P13349, DOI 10.1074/jbc.271.23.13349; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GRAY TE, 1995, BIOCHEMISTRY-US, V34, P10325, DOI 10.1021/bi00033a002; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JOHNSON WC, 1990, PROTEINS STRUCT FUNC, V205; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Osslund TD, 1998, PROTEIN SCI, V7, P1681, DOI 10.1002/pro.5560070803; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; Rubin J. S., 1995, V74, P191; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 1999, J BIOL CHEM, V274, P35016, DOI 10.1074/jbc.274.49.35016; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	41	12	13	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34881	34886		10.1074/jbc.M003293200	http://dx.doi.org/10.1074/jbc.M003293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950949	hybrid			2022-12-25	WOS:000165422800010
J	Steinberg, SJ; Morgenthaler, J; Heinzer, AK; Smith, KD; Watkins, PA				Steinberg, SJ; Morgenthaler, J; Heinzer, AK; Smith, KD; Watkins, PA			Very long-chain acyl-CoA synthetases - Human "bubblegum" represents a new family of proteins capable of activating very long-chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; ALPHA-OXIDATION; PHYTANIC ACID; RAT-LIVER; GENE; EXPRESSION; CLONING; CELLS; HYPERTENSION; PREDICTION	Activation by thioesterification to coenzyme A is a prerequisite for most reactions involving fatty acids. Enzymes catalyzing activation, acyl-CoA synthetases, have been classified by their chain length specificities, The most recently identified family is the very long-chain acyl-CoA synthetases (VLCS), Although several members of this group are capable of activating very long-chain fatty acids (VLCFA), one is a bile acid-CoA synthetase,and others have been characterized as fatty acid transport proteins, It was reported that the Drosophila melanogaster mutant bubblegum (BGM) had elevated VLCFA and that the product of the defective gene had sequence homology to acyl-CoA synthetases. Therefore, we cloned full-length cDNA for a human homolog of BGM, and we investigated the properties of its protein product, hsBG, to determine whether it had VLCS activity. Northern blot analysis showed that hsBG is expressed primarily in brain, Compared with vector-transfected cells, COS-l cells expressing hsBG; had increased acyl-CoA synthetase activity with either long-chain fatty acid (2.4-fold) or VLCFA (2.6-fold) substrates, Despite this increased VLCFA activation, hsBG-expressing cells did not have increased rates of VLCFA degradation, Confocal microscopy showed that hsBG had a cytoplasmic localization in some COS-1 cells expressing the protein, whereas it appeared to associate with plasma:membrane in others, Fractionation of these cells revealed that most of the hsBG-dependent acyl-CoA synthetase activity was soluble and not membrane-bound. Immunoaffinity-purified hsBG from transfected COS-1 cells was enzymatically active, hsBG and hsVLCS are only 15% identical, and comparison with sequences of two: conserved motifs from all known families of acyl-CoA synthetases revealed that hsBG along with the D, melanogaster and murine homologs comprise a new family of acyl-CoA synthetases, Thus, two protein families: are now known that contain enzymes capable of activating VLCFA. Because hsBG is expressed in brain but previously described VLCSs were not highly expressed in this organ, hsBG may play a central role in brain VLCFA metabolism and myelinogenesis.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD10981] Funding Source: Medline; NINDS NIH HHS [NS 37355, NS10533] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; IWAI N, 1994, HYPERTENSION, V23, P375, DOI 10.1161/01.HYP.23.3.375; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SAMANI NJ, 1995, J HUM HYPERTENS, V9, P501; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVENNERHOLM L, 1968, J LIPID RES, V9, P215; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210	33	101	110	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35162	35169		10.1074/jbc.M006403200	http://dx.doi.org/10.1074/jbc.M006403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954726	hybrid			2022-12-25	WOS:000165422800046
J	Tolkunova, E; Park, H; Xia, J; King, MP; Davidson, E				Tolkunova, E; Park, H; Xia, J; King, MP; Davidson, E			The human lysyl-tRNA synthetase gene encodes both the cytoplasmic and mitochondrial enzymes by means of an unusual alternative splicing of the primary transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC AMINOACYLATION; ESCHERICHIA-COLI; IN-VITRO; IDENTIFICATION; TRANSLATION; NUCLEOTIDE; EXPRESSION; TRNA(LYS); CLONING; INITIATION	Two cDNAs encoding human lysyl-tRNA synthetase have been identified. One encodes the cytoplasmic form of the enzyme identified previously. The second cDNA contains the same sequence but with a 180-bp insertion at the 5'-end of the mRNA. This results in a predicted protein whose carboxyl 576 amino acids are identical to those of the cytoplasmic enzyme but with a different amino terminus of 49 amino acids that contains a putative mitochondrial targeting sequence. Expression of the two lysyl-tRNA synthetase-green fluorescent protein gene fusions in a human cell line confirmed that the cytoplasmic form was targeted to the cytoplasm and the mitochondrial form to mitochondria, The genomic lysyl-tRNA synthetase gene consisted of 15 exons. The two isoforms were created by alternative splicing of the first three exons of the gene. The cytoplasmic form was created by splicing exon 1 to exon 3, The inclusion of exon 2 between exons 1 and 3 produced an mRNA encoding the mitochondrial isoform with an additional upstream small open reading frame, consisting mainly of a portion of the 5' coding region of the cytoplasmic isoform, This is the first example of mitochondrial targeting sequence being encoded on the second exon of a gene. Ribonuclease protection analysis showed that the mRNA encoding the cytoplasmic isoform makes up approximately 70%, and the mitochondrial isoform approximately 30%, of the mature transcripts from the lysyl-tRNA synthetase gene. The mitochondrial form of the enzyme, purified after expression in Escherichia coli, aminoacylated in vitro transcripts corresponding to both the cytoplasmic and mitochondrial tRNA(Lys), despite the difference in the discriminator base sequence in the acceptor stems of these tRNAs.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Jefferson University	King, MP (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	Michael.King@mail.tju.edu	Tolkunova, Elena/U-7174-2017	Tolkunova, Elena/0000-0003-1254-2619				Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; CHATTON B, 1988, J BIOL CHEM, V263, P52; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; DANPURE C, 1997, TRENDS CELL BIOL, V5, P230; Davidson E, 1997, TRENDS CARDIOVAS MED, V7, P16, DOI 10.1016/S1050-1738(96)00122-3; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; GATTI DL, 1991, J MOL BIOL, V218, P557, DOI 10.1016/0022-2836(91)90701-7; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; LEE CP, 1993, P NATL ACAD SCI USA, V90, P7149, DOI 10.1073/pnas.90.15.7149; Leehey MA, 1995, BIOCHEMISTRY-US, V34, P16235, DOI 10.1021/bi00050a001; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MIRANDE M, 1986, BIOCHIMIE, V68, P1001, DOI 10.1016/S0300-9084(86)80043-8; Mudge SJ, 1998, GENE, V209, P45, DOI 10.1016/S0378-1119(98)00007-9; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Nichols RC, 1996, GENOMICS, V36, P210, DOI 10.1006/geno.1996.0449; OHANLON TP, 1995, BIOCHEM BIOPH RES CO, V210, P556, DOI 10.1006/bbrc.1995.1696; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rodova M, 1999, BIOCHEM BIOPH RES CO, V255, P765, DOI 10.1006/bbrc.1999.0141; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	39	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35063	35069		10.1074/jbc.M006265200	http://dx.doi.org/10.1074/jbc.M006265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952987	hybrid			2022-12-25	WOS:000165422800033
J	Zhang, Y; Redina, O; Altshuller, YM; Yamazaki, M; Ramos, J; Chneiweiss, H; Kanaho, Y; Frohman, MA				Zhang, Y; Redina, O; Altshuller, YM; Yamazaki, M; Ramos, J; Chneiweiss, H; Kanaho, Y; Frohman, MA			Regulation of expression of phospholipase D1 and D2 by PEA-15, a novel protein that interacts with them	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH-EFFECTOR DOMAIN; ADP-RIBOSYLATION FACTOR; KINASE-C; D DEFINES; APOPTOSIS; FAMILY; ASTROCYTES; ACTIVATION; ALPHA; PHOSPHOPROTEIN	Phospholipase D (PLD), a signal-transducing membrane-associated enzyme, is implicated in diverse processes including apoptosis, ERK activation, and glucose transport, Prior studies have identified specific PLD activators and repressors that directly regulate its enzymatic activity. Using two-hybrid screens, we have identified PEA-15 as a PLD interactor that unexpectedly functions to:alter its level of expression. PEA-15 is a widely expressed death effector domain-containing phosphoprotein involved in signal transduction, apoptosis,:ERK activation, and glucose transport. The PLD1-interacting site on PEA-15 consists of part of the death effector domain domain plus additional C-terminal flanking:sequences, whereas the PEA-15-interacting site on:PLD1 overlaps the previously identified RhoA-interacting site. PEA-15 did not affect basal or stimulated;in vitro PLD1 enzymatic activation. However, coexpression of PEA-15 increased levels of PLD1 activity. This increased activation correlated with higher PLD1 protein expression levels, as marked by faster accumulation and longer persistence of PLD1 when PEA-15 was present; PEA-15 similarly increased protein expressions level of PLDS and co-immunoprecipitated with it. These results: suggest that PEA-IB may stabilize PLD or act as a PLD chaperone. The common involvement of PEA-15 and PLD in,:apoptosis, ERK activation, and glucose transport additionally suggests functional significance.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Coll France, INSERM U114, F-75231 Paris 05, France; Coll France, Chaire Neuropharmacol, F-75231 Paris 05, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Tokyo Metropolitan Institute of Medical Science; Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France	Frohman, MA (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.		herve, chneiweiss/Q-6818-2019; Ramos, Joe/G-4074-2010; Redina, Olga E/T-1650-2017	herve, chneiweiss/0000-0001-7675-5061; Ramos, Joe/0000-0002-9708-2115; Redina, Olga/0000-0003-0942-8460	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54813] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Otsuki T, 1999, BIOCHEM BIOPH RES CO, V265, P630, DOI 10.1006/bbrc.1999.1731; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Servitja JM, 1998, BRIT J PHARMACOL, V124, P1728, DOI 10.1038/sj.bjp.0701997; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Sugars JM, 1999, J BIOL CHEM, V274, P30023, DOI 10.1074/jbc.274.42.30023; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	34	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35224	35232		10.1074/jbc.M003329200	http://dx.doi.org/10.1074/jbc.M003329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10926929	hybrid			2022-12-25	WOS:000165422800054
J	Bennett, ER; Su, HL; Kanner, BI				Bennett, ER; Su, HL; Kanner, BI			Mutation of arginine 44 of GAT-1, a (Na++Cl-)-coupled gamma-aminobutyric acid transporter from rat brain, impairs net flux but not exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA TRANSPORTER; SEROTONIN TRANSPORTER; TRANSMEMBRANE TOPOLOGY; XENOPUS OOCYTES; SODIUM; EXPRESSION; IDENTIFICATION; SITE; PERMEATION; RESIDUES	The gamma -aminobutyric acid (GABA) transporter GAT-1 is a prototype of a large family of neurotransmitter transporters that includes those of dopamine and serotonin, GAT-1 maintains low synaptic concentrations of neurotransmitter by coupling GABA uptake to the fluxes of sodium and chloride. Here we identify a stretch of four amino acid residues predicted to lie in the juxtamembrane region prior to transmembrane domain 1 in the cytoplasmic amino-terminal tail of GAT-1, which is critical for its function. Two residues, arginine 44 and tryptophan 47, are fully conserved within the transporter family, and their deletion abolishes GABA transport in the HeLa cell expression system used. Tryptophan 47 can be replaced only by aromatic residues without Toss of activity. Arginine 44 is essential for activity, Only when it is replaced by lysine, low activity levels (around 15% of those of the wild type) are observed. Using a reconstitution assay, we show that mutants in which this residue is replaced by lysine or histidine exhibit sodium- and chloride-dependent GABA exchange similar to the wild type. This indicates that these mutants are selectively impaired in the reorientation of the unloaded transporter, a step in the translocation cycle by which net flux and exchange differ. The high degree of conservation in the consensus sequence RXXW suggests that this region may influence the reorientation step in related transporters as well.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il	Bennett, Estelle R/A-5067-2017		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barker EL, 1999, J NEUROSCI, V19, P4705; Beckman ML, 1998, J NEUROSCI, V18, P6103; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1981, BIOCHEMISTRY-US, V20, P3354, DOI 10.1021/bi00515a007; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V731, P54, DOI 10.1016/0005-2736(83)90397-8; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KEYES SR, 1982, J BIOL CHEM, V257, P1172; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0	36	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34106	34113		10.1074/jbc.M004229200	http://dx.doi.org/10.1074/jbc.M004229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926932	hybrid			2022-12-25	WOS:000165095300018
J	Haskell, CA; Cleary, MD; Charo, IF				Haskell, CA; Cleary, MD; Charo, IF			Unique role of the chemokine domain of fractalkine in cell capture - Kinetics of receptor dissociation correlate with cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; HUMAN CC CHEMOKINE; CX3C CHEMOKINE; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; PHYSIOLOGICAL FLOW; DISTINCT ROLES; L-SELECTIN; RESPONSES; CX(3)CR1	The chemokine fractalkine (FR) has two structural features that make it unique in the chemokine family: a CX3C motif and an extended carboxyl terminus that anchors it to the cell surface. This mucin-like stalk or an equivalent spacer is required for FK to mediate the adhesion of cells expressing its receptor, CX(3)CR1, To determine whether the ability of FK to act as a cell adhesion molecule is due to the unique presentation of a chemokine domain on a stalk or to properties of the chemokine domain itself, we created a series of chimeras in which other soluble chemokines (RANTES (regulated on activation normal T cell expressed), monocyte chemoattractant protein 1, macrophage inflammatory protein 1 beta, secondary lymphoid tissue chemokine, and interleukin 8) were fused to the mucin stalk. When tested in a static-cell adhesion assay, many of these chemokine chimeras demonstrated activity equivalent to that of FK, In flow assays, however, none of the chimeras captured cells as efficiently as FK, Interestingly, FK captured cells expressing either CX(3)CR1 or the viral receptor US28. Cells bound to FK without rolling or detaching, whereas the interleukin 8 and monocyte chemoattractant protein 1 chimeras induced primarily cell rolling and detaching, respectively. In binding studies, FK has a significantly slower off-rate from its receptors than any of the other chemokine chimeras had for their cognate receptors, We conclude that presentation of a chemokine atop a mucin-like stalk is not, in and of itself, sufficient to capture cells. The unique ability of FK to mediate adhesion under flow may be a function of its slow receptor off-rate.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063894, R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63894, HL-52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Franci C, 1996, J IMMUNOL, V157, P5606; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Goda S, 2000, J IMMUNOL, V164, P4313, DOI 10.4049/jimmunol.164.8.4313; Gosling J, 2000, J IMMUNOL, V164, P2851, DOI 10.4049/jimmunol.164.6.2851; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Kitayama J, 1997, J IMMUNOL, V159, P3929; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LEE J, 1992, J BIOL CHEM, V267, P16283; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Pachynski RK, 1998, J IMMUNOL, V161, P952; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158	39	111	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34183	34189		10.1074/jbc.M005731200	http://dx.doi.org/10.1074/jbc.M005731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940307	hybrid			2022-12-25	WOS:000165095300027
J	Izawa, I; Nishizawa, M; Ohtakara, K; Ohtsuka, K; Inada, H; Inagaki, M				Izawa, I; Nishizawa, M; Ohtakara, K; Ohtsuka, K; Inada, H; Inagaki, M			Identification of Mrj, a DnaJ/Hsp40 family protein, as a keratin 8/18 filament regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRISEOFULVIN-TREATED MICE; RHO-ASSOCIATED KINASE; ALPHA-B-CRYSTALLIN; INTERMEDIATE FILAMENTS; MOLECULAR CHAPERONES; DYNAMIC PROPERTY; MALLORY BODIES; PHOSPHORYLATION; DISEASE; HSP70	To elucidate the function of keratins 8 and 18 (K8/18), major components of the intermediate filaments of simple epithelia, we searched for K8/18-binding proteins by screening a yeast two-hybrid library. We report here that human Mrj, a DnaJ/Hsp40 family protein, directly binds to K18. Among the interactions between DnaJ/Hsp40 family proteins and various intermediate filament proteins that we tested using two-hybrid methods, Mrj specifically interacted with K18, Immunostaining with anti-Mrj antibody showed that Mrj colocalized with K8/18 filaments in HeLa cells. Mrj was immunoprecipitated not only with K18, but also with the stress-induced and constitutively expressed heat shock protein Hsp/c70. Mrj bound to K18 through its C terminus and interacted with Hsp/c70 via its N terminus, which contains the J domain. Microinjection of anti-Mrj antibody resulted in the disorganization of K8/18 filaments, without effects on the organization of actin filaments and microtubules, Taken together, these results suggest that Mrj may play an important role in the regulation of K8/18 filament organization as a K18-specific co-chaperone working together with Hsp/c70.	Aichi Canc Ctr, Inst Res, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Inst Res, Cell Stress Biol Res Grp, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 5148507, Japan	Aichi Cancer Center; Aichi Cancer Center; Mie University	Inagaki, M (corresponding author), Aichi Canc Ctr, Inst Res, Div Biochem, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016					BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DENK H, 1975, LAB INVEST, V32, P773; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRANKE WW, 1979, LAB INVEST, V40, P207; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Hutton E, 1998, J CELL BIOL, V143, P487, DOI 10.1083/jcb.143.2.487; Inada H, 1998, BIOCHEM BIOPH RES CO, V253, P21, DOI 10.1006/bbrc.1998.9732; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; INAGAKI M, 1994, BRAIN PATHOL, V4, P239, DOI 10.1111/j.1750-3639.1994.tb00839.x; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; JENSEN K, 1994, HEPATOLOGY, V20, P1330, DOI 10.1016/0270-9139(94)90776-5; JENSEN K, 1994, HEPATOLOGY, V20, P1061, DOI 10.1002/hep.1840200440; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Liang P, 1997, J CELL SCI, V110, P1431; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liao JA, 1997, FEBS LETT, V417, P316, DOI 10.1016/S0014-5793(97)01315-X; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; NAPOLITANO EW, 1985, J CELL BIOL, V101, P1323, DOI 10.1083/jcb.101.4.1323; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Oka M, 1998, J BIOL CHEM, V273, P29727, DOI 10.1074/jbc.273.45.29727; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; Perng MD, 1999, J CELL SCI, V112, P2099; Sambrook J., 2002, MOL CLONING LAB MANU; Seki N, 1999, J HUM GENET, V44, P185, DOI 10.1007/s100380050139; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Takahashi K, 1996, P NATL ACAD SCI USA, V93, P14776, DOI 10.1073/pnas.93.25.14776; Toivola DM, 1997, J CELL SCI, V110, P23; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	58	75	88	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34521	34527		10.1074/jbc.M003492200	http://dx.doi.org/10.1074/jbc.M003492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10954706	hybrid			2022-12-25	WOS:000165095300071
J	Cohen, A; Nelson, H; Nelson, N				Cohen, A; Nelson, H; Nelson, N			The family of SMF metal ion transporters in yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; COPPER TRANSPORT; PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; PROCESSING PROTEASE; MOLECULAR-BIOLOGY; IRON TRANSPORT; TASTE BEHAVIOR; BSD2 GENE	Metal ions are vital for all organisms, and metal ion transporters play a crucial role in maintaining their homeostasis. The yeast (Saccharomyces cerevisiae) Smf transporters and their homologs in other organisms have a central role in the accumulation of metal ions and their distribution in different tissues and cellular organelles. In this work we generated null mutations in each individual SMF gene in yeast as well as in all combinations of the genes. Each null mutation exhibited sensitivity to metal ion chelators at different concentrations. The combination of null mutants Delta SMF1 + Delta SMF2 and the triple null mutant Delta 3SMF failed to grow on medium buffered at pH 8 and 7.5, respectively. Addition of 5 muM copper or 25 muM manganese alleviated the growth arrest at the high pH or in the presence of the chelating agent, The transport of manganese was analyzed in the triple null mutant and in this mutant expressing each Smf protein. Although overexpression of Smf1p and Smf2p resulted in uptake that was higher than wild type cells, the expression of Smf3p gave no significant uptake above that of the triple mutant Delta 3SMF. Western analysis with antibody against Smf3p indicated that this transporter does not reach the plasma membrane and may function at the Gels or post-Gels complexes. The iron uptake resulting from expression of Smf1p and Smf2p was analyzed in a mutant in which its iron transporters FET3 and FET4 were inactivated. Overexpression of Smf1p gave rise to a significant iron uptake that was sensitive to the sodium concentrations in the medium. We conclude that the Smf proteins play a major role in copper and manganese homeostasis and, under certain circumstances, Smf1p may function in iron transport into the cells.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.							Andrews NC, 1998, BLOOD, V92, P1845, DOI 10.1182/blood.V92.6.1845.418k35_1845_1851; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1983, METHOD ENZYMOL, V97, P510; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Orgad S, 1998, J EXP BIOL, V201, P115; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tabuchi M, 1999, BIOCHEM J, V344, P211, DOI 10.1042/0264-6021:3440211; WEST AH, 1992, J BIOL CHEM, V267, P24625; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	44	106	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33388	33394		10.1074/jbc.M004611200	http://dx.doi.org/10.1074/jbc.M004611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930410	hybrid			2022-12-25	WOS:000090104600031
J	Kala, SV; Neely, MW; Kala, G; Prater, CI; Atwood, DW; Rice, JS; Lieberman, MW				Kala, SV; Neely, MW; Kala, G; Prater, CI; Atwood, DW; Rice, JS; Lieberman, MW			The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE RISK-FACTORS; ARTESIAN WELL WATER; HEPATOBILIARY TRANSPORT; MALIGNANT NEOPLASMS; BLACKFOOT DISEASE; URINARY-EXCRETION; DRINKING-WATER; PROTEIN GENE; RESISTANCE; RATS	Worldwide, millions of people are exposed to arsenic in drinking water that exceeds the World Health Organization standard of 10 mug/liter by as much as 50-300-fold, yet little is known about the molecular basis for arsenic excretion. Here me show that transport of arsenic into bile depends on the MRP2/cMOAT transporter and that glutathione is obligatory for such transport, Using reversed phase liquid chromatography/mass spectrometry, we demonstrate that two arsenic-glutathione complexes not previously identified in vivo, arsenic tri-glutathione and methylarsenic diglutathione, account for most of the arsenic in the bile. The structure of the compounds was also confirmed by nuclear magnetic resonance spectroscopy, Our findings may help explain the increased susceptibility of malnourished human populations to arsenic.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	mikel@bcm.tmc.edu			NIEHS NIH HHS [ES 10389] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010389] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; BRAY TM, 1993, CAN J PHYSIOL PHARM, V71, P746, DOI 10.1139/y93-111; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; BUCHET JP, 1987, TOXICOL APPL PHARM, V91, P65, DOI 10.1016/0041-008X(87)90194-3; CHEN CJ, 1988, ARTERIOSCLEROSIS, V8, P452, DOI 10.1161/01.ATV.8.5.452; CHEN CJ, 1985, CANCER RES, V45, P5895; CULLEN WR, 1984, J INORG BIOCHEM, V21, P179, DOI 10.1016/0162-0134(84)83002-0; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; Gregus Z, 2000, TOXICOL SCI, V56, P18, DOI 10.1093/toxsci/56.1.18; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GYURASICS A, 1991, BIOCHEM PHARMACOL, V41, P937, DOI 10.1016/0006-2952(91)90199-F; Habib GM, 2000, HEPATOLOGY, V32, P556, DOI 10.1053/jhep.2000.9715; HSUEH YM, 1995, BRIT J CANCER, V71, P109, DOI 10.1038/bjc.1995.22; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KLAASSEN CD, 1996, CASARETT DOULLS TOXI, P691; Kool M, 1997, CANCER RES, V57, P3537; Mazumder DNG, 1998, INT J EPIDEMIOL, V27, P871, DOI 10.1093/ije/27.5.871; MOREL G, 1995, TOXICOL LETT, V78, P111, DOI 10.1016/0378-4274(94)03240-8; National Research Council, 1999, ARS DRINK WAT; Paulusma CC, 1999, BIOCHEM J, V338, P393, DOI 10.1042/0264-6021:3380393; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tsai SM, 1999, ARCH ENVIRON HEALTH, V54, P186, DOI 10.1080/00039899909602258; VAHTER M, 1987, TOXICOL LETT, V37, P41, DOI 10.1016/0378-4274(87)90165-2; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; WHO, 1999, ARS EXPS, P1; Yoshida K, 1998, J TOXICOL ENV HEAL A, V54, P179; Zakharyan RA, 1999, CHEM RES TOXICOL, V12, P1278, DOI 10.1021/tx9901231; ZHANG P, 1996, CHIN J HEMATOL, V17, P58	33	257	272	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33404	33408		10.1074/jbc.M007030200	http://dx.doi.org/10.1074/jbc.M007030200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938093	hybrid			2022-12-25	WOS:000090104600033
J	Kim, S; Harris, M; Varner, JA				Kim, S; Harris, M; Varner, JA			Regulation of integrin alpha(v)beta(3)-mediated endothelial cell migration and angiogenesis by integrin alpha(5)beta(1) and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; MESODERMAL DEFECTS; BLOOD-VESSELS; HUMAN SKIN; ADHESION; RHO; ACTIVATION; EMBRYOS; GROWTH; PHOSPHORYLATION	Recent studies indicate that angiogenesis depends, in part, on ligation of integrin alpha (5)beta (1) by fibronectin. Evidence is now provided that integrin alpha (5)beta (1) regulates the function of integrin alpha (v)beta (3) on endothelial cells during their migration in vitro or angiogenesis in vivo. Secretion of fibronectin by endothelial cells leads to the ligation of integrin alpha (5)beta (1), which potentiates alpha (v)beta (3)-mediated migration on vitronectin without influencing alpha (v)beta (3)-mediated cell adhesion. Endothelial cell attachment to vitronectin suppresses protein kinase A (PKA) activity, while addition of soluble anti-alpha (5)beta (1) restores this activity. Moreover, agents that activate intracellular PKA, such as forskolin, dibutyryl cAMP or alpha (5)beta (1) antagonists, suppress endothelial cell migration on vitronectin in vitro or angiogenesis in vivo. In contrast, inhibitors of PRA reverse the anti-migratory or anti-angiogenic effects mediated by alpha (5)beta (1) antagonists. Therefore, alpha (v)beta (3)-mediated endothelial cell. migration and angiogenesis can be regulated by PRA activity, which depends on the ligation state of integrin alpha (5)beta (1).	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Varner, JA (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Varner, Judith/0000-0002-9251-0600; Kim, Semi/0000-0001-8043-1465				Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; BRODSKY FM, 1982, J IMMUNOL, V128, P129; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brooks PC, 1999, METH MOL B, V129, P257; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carron CP, 1998, CANCER RES, V58, P1930; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; CLARK RAF, 1982, J INVEST DERMATOL, V79, P269, DOI 10.1111/1523-1747.ep12500076; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DRAKE CJ, 1995, J CELL SCI, V108, P2655; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Goh KL, 1997, DEVELOPMENT, V124, P4309; Imhof BA, 1997, EUR J IMMUNOL, V27, P3242, DOI 10.1002/eji.1830271223; KACZMAREK J, 1994, INT J CANCER, V58, P11; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; NEWMAN PJ, 1985, BLOOD, V65, P227; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; PACIFICI R, 1994, J IMMUNOL, V153, P2222; Padmanabhan J, 1999, J NEUROBIOL, V39, P407, DOI 10.1002/(SICI)1097-4695(19990605)39:3<407::AID-NEU7>3.0.CO;2-S; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Varner J A, 1997, EXS, V79, P361; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; YANG JT, 1993, DEVELOPMENT, V119, P1093	42	191	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33920	33928		10.1074/jbc.M003668200	http://dx.doi.org/10.1074/jbc.M003668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944524	hybrid			2022-12-25	WOS:000090104600102
J	Pagano, A; Ruegg, D; Litschig, S; Stoehr, N; Stierlin, C; Heinrich, M; Floersheim, P; Prezeau, L; Carroll, F; Pin, JP; Cambria, A; Vranesic, I; Flor, PJ; Gasparini, F; Kuhn, R				Pagano, A; Ruegg, D; Litschig, S; Stoehr, N; Stierlin, C; Heinrich, M; Floersheim, P; Prezeau, L; Carroll, F; Pin, JP; Cambria, A; Vranesic, I; Flor, PJ; Gasparini, F; Kuhn, R			The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan [b]chromen-1 alpha-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; AGONIST SELECTIVITY; GLUTAMATE-RECEPTOR-1; EXPRESSION; SUBTYPES; VARIANTS; PROTEINS; PROFILE; CPCCOET; TYPE-5	We have investigated the mechanism of inhibition and site of action of the novel human metabotropic glutamate receptor 5 (hmGluR5) antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), which is structurally unrelated to classical metabotropic glutamate receptor (mGluR) ligands, Schild analysis indicated that MPEP acts in a non-competitive manner. MPEP also inhibited to a large extent constitutive receptor activity in cells transiently overexpressing rat mGluR5, suggesting that MPEP acts as an inverse agonist, To investigate the molecular determinants that govern selective ligand binding, a mutagenesis study was performed using chimeras and single amino acid substitutions of hmGluR1 and hmGluR5, The mutants were tested for binding of the novel mGluR5 radioligand [H-3]2-methyl-6-(3-methoxyphenyl)ethynyl pyridine (M-MPEP), a close analog of MPEP, Replacement of Ala-810 in transmembrane (TM) VII or Pro-655 and Ser-658 in TMIII with the homologous residues of hmGluR1 abolished radioligand binding, In contrast, the reciprocal hmGluR1 mutant bearing these three residues of hmGluR5 showed high affinity for [H-3]M-MPEP. Radioligand binding to these mutants was also inhibited by 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPC-COEt), a structurally unrelated non-competitive mGluR1 antagonist previously shown to interact with residues Thr-815 and Ala-818 in TMVII of hmGluR1, These results indicate that MPEP and CPCCOEt bind to overlapping binding pockets in the TBI region of group I mGluRs but interact with different non conserved residues.	Novartis Pharma AG, Nervous Syst Res, CH-4057 Basel, Switzerland; Univ Catania, Dipartimento Sci Chim, I-95125 Catania, Italy; CNRS, Ctr INSERM, UPR 9023 CNRS, F-34094 Montpellier, France	Novartis; University of Catania; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Kuhn, R (corresponding author), Novartis Pharma AG, Nervous Syst Res, Klybeckstr 141, CH-4057 Basel, Switzerland.		Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Carroll, Fiona/0000-0001-8951-1947				ALMOSLIH MI, 1973, J GEN VIROL, V73, P189; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bruno V, 2000, NEUROPHARMACOLOGY, V39, P2223, DOI 10.1016/S0028-3908(00)00079-4; Casabona G, 1997, EUR J NEUROSCI, V9, P12, DOI 10.1111/j.1460-9568.1997.tb01348.x; Chapman AG, 2000, NEUROPHARMACOLOGY, V39, P1567, DOI 10.1016/S0028-3908(99)00242-7; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DAGGETT LP, 1995, NEUROPHARMACOLOGY, V34, P871, DOI 10.1016/0028-3908(95)00085-K; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Hermans E, 1998, NEUROPHARMACOLOGY, V37, P1645, DOI 10.1016/S0028-3908(98)00132-4; JOLY C, 1995, J NEUROSCI, V15, P3970; KNOEPFEL T, 1995, J MED CHEM, V38, P1417; Litschig S, 1999, MOL PHARMACOL, V55, P453; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; Moro S, 1998, J MED CHEM, V41, P1456, DOI 10.1021/jm970684u; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; WALKER K, 2000, IN PRESS NEUROPHARMA; Wroblewska B, 1997, J NEUROCHEM, V69, P174	27	237	241	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33750	33758		10.1074/jbc.M006230200	http://dx.doi.org/10.1074/jbc.M006230200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934211	hybrid			2022-12-25	WOS:000090104600079
J	Potter, MD; Nicchitta, CV				Potter, MD; Nicchitta, CV			Regulation of ribosome detachment from the mammalian endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SECRETORY PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; PRESECRETORY PROTEINS; SEQUENCE RECOGNITION; NASCENT PROTEINS; BOUND POLYSOMES; CHAIN COMPLEXES; MESSENGER-RNA; BINDING	In current models, protein translocation in the endoplasmic reticulum (ER) occurs in the context of two cycles, the signal recognition particle (SRP) cycle and the ribosome cycle. Both SRP and ribosomes bind to the ER membrane as a consequence of the targeting process of translocation. Whereas SRP release from the ER membrane is regulated by the GTPase activities of SRP and the SRP receptor, ribosome release from the ER membrane is thought to occur in response to the termination of protein synthesis. We report that ER-bound ribosomes remain membrane-bound following the termination of protein synthesis and in the bound state can initiate the translation of secretory and cytoplasmic proteins. Two principal observations are reported. 1) Membrane-bound ribosomes engaged in the synthesis of proteins lacking a signal sequence are released from the ER membrane as ribosome-nascent polypeptide complexes. 2) Membrane-hound ribosomes translating secretory proteins can access the translocon in an SRP receptor-independent manner. We propose that ribosome release from the ER membrane occurs in the context of protein translation, with release occurring by default in the absence of productive nascent polypeptide-membrane interactions.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	C.Nicchitta@cellbio.duke.edu			NIDDK NIH HHS [DK57897] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ADESNIK M, 1981, EUR J BIOCHEM, V114, P271, DOI 10.1111/j.1432-1033.1981.tb05146.x; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORGESE D, 1973, J MOL BIOL, V74, P415, DOI 10.1016/0022-2836(73)90037-5; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Green R, 1999, NAT STRUCT BIOL, V6, P999, DOI 10.1038/14881; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KLAPPA P, 1995, EUR J BIOCHEM, V232, P755, DOI 10.1111/j.1432-1033.1995.tb20870.x; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MECHLER B, 1975, J CELL BIOL, V67, P25, DOI 10.1083/jcb.67.1.25; MECHLER B, 1981, J CELL BIOL, V88, P42, DOI 10.1083/jcb.88.1.42; MECHLER B, 1975, J CELL BIOL, V67, P16, DOI 10.1083/jcb.67.1.16; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MEYER DI, 1980, J CELL BIOL, V87, P503, DOI 10.1083/jcb.87.2.503; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Polacek N, 2000, MOL CELL, V6, P159, DOI 10.1016/S1097-2765(00)00017-4; Potter MD, 2000, J BIOL CHEM, V275, P2037, DOI 10.1074/jbc.275.3.2037; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; Zheng T, 1999, J BIOL CHEM, V274, P36623, DOI 10.1074/jbc.274.51.36623	48	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33828	33835		10.1074/jbc.M005294200	http://dx.doi.org/10.1074/jbc.M005294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924518	hybrid			2022-12-25	WOS:000090104600090
J	Reynaud, C; Fabre, S; Jalinot, P				Reynaud, C; Fabre, S; Jalinot, P			The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is involved in Rho signaling to the serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; FILAMENT-BINDING PROTEIN; ESCHERICHIA-COLI; PLASMA-MEMBRANE; TAX ONCOPROTEIN; HUMAN HOMOLOG; DOMAIN; FAMILY; RECOGNITION; COMPLEXES	The human T-cell lymphotrophic virus, type 1 Tax protein can interact via its C terminus with various proteins including a PDZ domain. In this work, one of them, TIP-1, is characterized as a cytoplasmic 14-kDa protein mainly corresponding to one PDZ domain. A two-hybrid screen performed with TIP-1 as bait showed that it interacts with the human homologue of rhotekin that was previously identified in mice as a Rho effector. Both human and mouse rhotekins exhibit at their C termini the sequence QSPV-COOH that matches the X(S/T)XV-COOH consensus known for proteins recognizing PDZ domains. Mutation of the serine and valine residues to alanine impairs interaction of rhotekin with TIP-I. Transient expression experiments with a reporter construct including the c-Fos serum response element (SRE) showed that coexpression of TIP-I with the constitutively active RhoA.V14 mutant and human rhotekin caused a strong activation of the SRE. A negative mutant of Rho, RhoA.N19, was unable to cooperate with TIP-1 and rhotekin, The positive effect of TIP-I was also lost when the C terminus of rhotekin was mutated. These data show that the complex of active Rho with its effector rhotekin bound to TIP-1 produces in the cytoplasm a signal that triggers strong activation of the SRE.	Ecole Normale Super Lyon, CNRS, UMR 5665, Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR 5665, Lab Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr	FABRE, Stéphane/AAQ-8400-2020; Fabre, Stéphane/ABC-1483-2020	FABRE, Stéphane/0000-0001-7350-9500; Reynaud, Caroline/0000-0003-0760-0263				Chan AML, 1996, ONCOGENE, V12, P1259; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hildebrand JD, 1999, CELL, V99, P485, DOI 10.1016/S0092-8674(00)81537-8; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1997, PROTEIN SCI, V6, P464; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas MK, 1999, MOL CELL BIOL, V19, P8492; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VAN AL, 1997, GENE DEV, V11, P2295; WALLIS OC, 1990, J MOL ENDOCRINOL, V4, P61, DOI 10.1677/jme.0.0040061; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	38	62	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33962	33968		10.1074/jbc.M000465200	http://dx.doi.org/10.1074/jbc.M000465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940294	Green Published, hybrid			2022-12-25	WOS:000090104600108
J	Sharma, SC; Richards, JS				Sharma, SC; Richards, JS			Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells - Relation of JunD and Fra2 to terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; GROWTH-FACTOR-BETA; C-FOS; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; INDUCIBLE ENHANCER; SIGNALING PATHWAY; HORMONAL-CONTROL; NULL MUTATION; TRANSCRIPTION; GENE	AP1 transcription factors control rapid responses of mammalian cells to stimuli that impact proliferation, differentiation, and transformation. To determine which AP1 factors are present in and regulated by hormones in ovarian cells during specific stages of proliferation and differentiation, we used both in vitro and in vivo models, Western blotting, immunohistochemistry, DNA binding assays, and transfections of AP1 promoter-reporter constructs. The expression patterns of Jun and Fos family members in response to hormones (follicle-stimulating hormone (FSH), luteinizing hormone (LH), and cAMP) were distinct. JunB, c-Jun, c-Fos, and Fra2 mere rapidly but transiently induced by FSH in immature granulosa cells. JunD and Fra2 were induced by LEI and maintained as granulosa cells terminally differentiated into luteal cells. Forskolin and phorbol myristate acetate acted synergistically to enhance transcription of an AP1(-73COL)-luciferase construct. JunD appears to be one mediator of this effect, since JunD was a major component of the AP1-DNA binding complex in granulosa cells, and menin, a selective inhibitor of JunD, blocked transcription of -73COL-luciferase, Thus, FSH and LH via cAMP induce specific AP1 factors, the AP1 expression patterns are distinct, and that of JunD and Fra2 correlates with the transition of proliferating granulosa cells to terminally differentiated, non-dividing luteal cells.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Richards, JS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	joanner@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495, R37HD016229, R56HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229, HD-07495] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Alliston TN, 2000, ENDOCRINOLOGY, V141, P385, DOI 10.1210/en.141.1.385; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Ardekani AM, 1998, ENDOCRINOLOGY, V139, P3271, DOI 10.1210/en.139.7.3271; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Cook SJ, 1999, MOL CELL BIOL, V19, P330; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; EPSEY LL, 2000, ENDOCRINOLOGY, V141, P2385; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; Hagglund AC, 1999, ENDOCRINOLOGY, V140, P4351, DOI 10.1210/en.140.9.4351; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hu PPC, 1999, MOL ENDOCRINOL, V13, P2039, DOI 10.1210/me.13.12.2039; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Neyns B, 1999, INT J CANCER, V82, P687; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; RICHARDS JS, 2000, IN PRESS STEROIDS; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Robker RL, 1998, BIOL REPROD, V59, P476, DOI 10.1095/biolreprod59.3.476; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	47	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33718	33728		10.1074/jbc.M003555200	http://dx.doi.org/10.1074/jbc.M003555200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934195	hybrid			2022-12-25	WOS:000090104600075
J	Silva, PI; Daffre, S; Bulet, P				Silva, PI; Daffre, S; Bulet, P			Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI PROMASTIGOTES; INDUCIBLE ANTIBACTERIAL PEPTIDE; INSECT IMMUNITY; COLORIMETRIC ASSAY; DISULFIDE BONDS; BROAD-SPECTRUM; PROTEGRIN-1; CONFORMATION; TRIDENTATUS	We have purified a small size antimicrobial peptide, named gomesin, from the hemocytes of the unchallenged tarantula spider Acanthoscurria gomesiana, Gomesin has a molecular mass of 2270.4 Ha, with 18 amino acids, including a pyroglutamic acid as the N terminus, a C-terminal arginine Lu-amide, and four cysteine residues forming two disulfide bridges, This peptide shows marked sequence similarities to antimicrobial peptides from other arthropods such as tachyplesin and polyphemusin from horseshoe crabs and androctonin from scorpions, Interestingly, it also shows sequence similarities to protegrins, antimicrobial peptides from porcine leukocytes, Gomesin strongly affects bacterial growth, as well as the development of filamentous fungi and yeast. In addition, we showed that gomesin affects the viability of the parasite Leishmania amazonensis.	Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Lab Artropodes, BR-05503900 Sao Paulo, Brazil; Inst Biol Mol & Cellulaire, CNRS, UPR Reponse Immunitaire & Dev Insectes 9022, F-67084 Strasbourg, France	Universidade de Sao Paulo; Instituto Butantan; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Daffre, S (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.	sidaffre@icb.usp.br	Silva Junior, Pedro Ismael/E-1437-2011; Daffre, Sirlei/M-4233-2013; BULET, Philippe/C-8557-2014	Silva Junior, Pedro Ismael/0000-0001-6619-6489; Daffre, Sirlei/0000-0002-9966-0433; BULET, Philippe/0000-0001-9016-265X				Aitken Alastair, 1996, P339, DOI 10.1007/978-1-60327-259-9_51; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BULET P, 1991, J BIOL CHEM, V266, P24520; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Fogaca AC, 1999, J BIOL CHEM, V274, P25330, DOI 10.1074/jbc.274.36.25330; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Harwig SSL, 1996, EUR J BIOCHEM, V240, P352, DOI 10.1111/j.1432-1033.1996.0352h.x; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; Iwanaga S, 1998, J BIOCHEM, V123, P1; KATSU T, 1993, BIOL PHARM BULL, V16, P178; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KIDERLEN AF, 1990, J IMMUNOL METHODS, V127, P11, DOI 10.1016/0022-1759(90)90334-R; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Mandard N, 1999, J BIOMOL STRUCT DYN, V17, P367, DOI 10.1080/07391102.1999.10508368; Mitta G, 1999, J CELL SCI, V112, P4233; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Rao AG, 1999, ARCH BIOCHEM BIOPHYS, V361, P127, DOI 10.1006/abbi.1998.0962; SODERHALL K, 1983, DEV COMP IMMUNOL, V7, P229, DOI 10.1016/0145-305X(83)90004-6; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Tam JP, 2000, BIOCHEM BIOPH RES CO, V267, P783, DOI 10.1006/bbrc.1999.2035; TAMAMURA H, 1993, CHEM PHARM BULL, V41, P978; TAMAMURA H, 1993, BIOCHIM BIOPHYS ACTA, V1163, P209, DOI 10.1016/0167-4838(93)90183-R; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	41	200	207	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33464	33470		10.1074/jbc.M001491200	http://dx.doi.org/10.1074/jbc.M001491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942757	hybrid			2022-12-25	WOS:000090104600041
J	Sun, CH; Cai, ML; Meadows, RP; Xu, N; Gunasekera, AH; Herrmann, J; Wu, JC; Fesik, SW				Sun, CH; Cai, ML; Meadows, RP; Xu, N; Gunasekera, AH; Herrmann, J; Wu, JC; Fesik, SW			NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ORIENTED MACROMOLECULES; BACULOVIRUS INHIBITOR; DISTANCE RESTRAINTS; CELL-DEATH; GENE; IAP; CASPASES; DYNAMICS; HOMOLOGY	The inhibitor of apoptosis proteins (IAPs) regulate the caspase family of cysteine proteases, which play an important role in the execution of programmed cell death. Human X-linked inhibitor of apoptosis protein (XIAP) is a potent inhibitor of caspases-3, -7, and -9, Here we show that the Bir3 domain is the minimal region of XIAP that is needed for potent caspase-9 inhibition. The three-dimensional structure of the Bir3 domain of XIAP, determined by NMR spectroscopy, resembles a classical zinc finger and consists of five cu-helices, a three-stranded beta -sheet, and a zinc atom chelated to three cysteines and one histidine, The structure of the Bir3 domain is similar to that of the Bir2 domain of XIAP but differs from the previously determined structure of the Bir3 domain of MIHB. Based on site-directed mutagenesis, tee have identified the regions of the Bir3 domain of XIAP that are important for inhibiting caspase-9. Despite the structural similarities of the Bir2 and Bir3 domain of XIAP, a different set of residues were found to be critical for inhibiting the individual caspases, These results suggest that XIAP inhibits caspase-3 and caspase-9 in a different manner.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; Idun Pharmaceut Inc, Dept Biochem, La Jolla, CA 92037 USA	Abbott Laboratories	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, 100 Abbott Pk Rd,D-47G,AP10-LL, Abbott Pk, IL 60064 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974	27	215	247	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33777	33781		10.1074/jbc.M006226200	http://dx.doi.org/10.1074/jbc.M006226200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934209	hybrid			2022-12-25	WOS:000090104600083
J	Wharton, W; Savell, J; Cress, WD; Seto, E; Pledger, WJ				Wharton, W; Savell, J; Cress, WD; Seto, E; Pledger, WJ			Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A - Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; GROWTH-FACTOR; E2F ACTIVITY; 3T3 CELLS; S-PHASE; YEAST; EXPRESSION; P27(KIP1); REGULATOR	Trichostatin A (TSA), a global repressor of histone deacetylase activity, inhibits the proliferation of a number of cell types. However, the identification of the mechanisms underlying TSA-mediated growth arrests has remained elusive. In order to resolve in more detail the cellular process modulated during the growth inhibition induced by TSA, me studied the effect of the drug on G(0)/G(1) traverse in mitogen-stimulated quiescent Balb/c-3T3 cells. Cyclin D1 and retinoblastoma proteins were induced following the mitogenic stimulation of both control and TSA-treated cells, and cyclin D1 formed complexes with CDK4 under both conditions. However, cyclin D1-associated kinase was not increased in growth-arrested cells. The lack of cyclin D-associated kinase was paralleled by an accumulation of RE in a hypophosphorylated form, as would be expected. In contrast, p130 became partially phosphorylated, accompanied by a marked increase in p130-dependent E2F DNA binding activity and a partial release of free E2F-4, Despite the presence of E2F complexes not bound to pocket proteins, late G(1) EaF-dependent gene expression was not observed, The lack of cyclin D1-associated kinase in TSA-treated cultures was potentially due to high levels of the cyclin-dependent inhibitor p27(kip1). However, the modulation of p27(kip1) levels by the deacetylase inhibitor cannot be responsible for the induction of the cell cycle arrest, since the growth of murine embryo fibroblasts deficient in both p27(kip1) and p21(cip1) was also inhibited by TSA, These data support a model in which TSA inhibits very early cell cycle traverse, which, in turn, leads to a decrease in cyclin D1-associated kinase activation and a repression of late cell cycle-dependent events. Alterations in early G(0)/G(1) gene expression accompany the TSA-mediated growth arrest.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wharton, W (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Coll Med, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA727694] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Allfrey V G, 1966, Proc Can Cancer Conf, V6, P313; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Ausubel FM, 1998, CURRENT PROTOCOLS MO; DeRubertis F, 1996, NATURE, V384, P589; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elend M, 1999, CURR BIOL, V9, pR936, DOI 10.1016/S0960-9822(00)80109-8; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAYOL X, 1995, ONCOGENE, V11, P801; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; Stiegler P, 1998, CANCER RES, V58, P5049; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wang AH, 1999, MOL CELL BIOL, V19, P7816; WHARTON W, 1979, IN VITRO CELL DEV B, V15, P861; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	39	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33981	33987		10.1074/jbc.M005600200	http://dx.doi.org/10.1074/jbc.M005600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945992	hybrid			2022-12-25	WOS:000090104600111
J	Zhang, YB; Swietnicki, W; Zagorski, MG; Surewicz, WK; Sonnichsen, FD				Zhang, YB; Swietnicki, W; Zagorski, MG; Surewicz, WK; Sonnichsen, FD			Solution structure of the E200K variant of human prion protein - Implications for the mechanism of pathogenesis in familial prion diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP 27-30; SCRAPIE; NMR; CONVERSION; RESISTANT; STABILITY; SYSTEM; DOMAIN	Prion propagation in transmissible spongiform encephalopathies involves the conversion of cellular prion protein, PrPC, into a pathogenic conformer, PrPSc. Hereditary forms of the disease are Linked to specific mutations in the gene coding for the prion protein. To gain insight into the molecular basis of these disorders, the solution structure of the familial Creutzfeldt-Jakob disease-related E200K variant of human prion protein was determined by multi-dimensional nuclear magnetic resonance spectroscopy, Remarkably, apart from minor differences in flexible regions, the backbone tertiary structure of the E200K variant is nearly identical to that reported for the wild-type human prion protein, The only major consequence of the mutation is the perturbation of surface electrostatic potential. The present structural data strongly suggest that protein surface defects leading to abnormalities in the interaction of prion protein with auxiliary proteins/chaperones or cellular membranes should be considered key determinants of a spontaneous PrPC --> PrPSc conversion in the E200K form of hereditary prion disease.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	wks3@po.cwru.edu	Swietnicki, Wieslaw/AAL-2452-2021; Swietnicki, Wieslaw/GOP-2576-2022; Sönnichsen, Frank D/D-8408-2011; Swietnicki, Wieslaw/AAU-1536-2020	Sönnichsen, Frank D/0000-0002-4539-3755; Swietnicki, Wieslaw/0000-0002-9354-8184	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055362, R01GM055362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014363] Funding Source: NIH RePORTER; NIA NIH HHS [AG14363] Funding Source: Medline; NIGMS NIH HHS [GM55362] Funding Source: Medline; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHAPMAN J, 1994, NEUROLOGY, V44, P1683, DOI 10.1212/WNL.44.9.1683; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zimmerman DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/jmbi.1997.1052	34	106	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33650	33654		10.1074/jbc.C000483200	http://dx.doi.org/10.1074/jbc.C000483200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10954699	hybrid			2022-12-25	WOS:000090104600066
J	Chekanova, JA; Shaw, RJ; Wills, MA; Belostotsky, DA				Chekanova, JA; Shaw, RJ; Wills, MA; Belostotsky, DA			Poly(A) tail-dependent exonuclease AtRrp41p from Arabidopsis thaliana rescues 5.8 S rRNA processing and mRNA decay defects of the yeast ski6 mutant and is found in an exosome-sized complex in plant and yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RNA; PROTEIN; DEADENYLATION; EXPRESSION; MUTATIONS; PH	Eukaryotic 3'-->5' exonucleolytic activities are essential for a wide variety of reactions of RNA maturation and metabolism, including processing of rRNA, small nuclear RNA, and small nucleolar RNA, and mRNA decay. Two related but distinct forms of a complex containing 10 3'-->5' exonucleases, the exosome, are found in yeast nucleus and cytoplasm, respectively, and related complexes exist in human cells. Here we report on the characterization of the AtRrp41p, an Arabidopsis thaliana homolog of the Saccharomyces cerevisiae exosome subunit Rrp41p (Ski6p). Purified recombinant AtRrp41p displays a processive phosphorolytic exonuclease activity and requires a single-stranded poly(A) tail on a substrate RNA as a "loading pad." The expression of the Arabidopsis RRP41 cDNA in yeast rescues the 5.8 S rRNA processing and 3'-->5' mRNA degradation defects of the yeast ski6-100 mutant. However, neither of these defects can explain the conditional lethal phenotype of the ski6-100 strain. Importantly, AtRrp41p shares additional function(s) with the yeast Rrp41p which are essential for cell viability because it also rescues the rrp41 (ski6) null mutant. AtRrp41p is found predominantly in a high molecular mass complex in Arabidopsis and in yeast cells, and it interacts in vitro with the yeast Rrp44p and Rrp4p exosome subunits, suggesting that it can participate in evolutionarily conserved interactions that could be essential for the integrity of the exosome complex.	SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; SUNY Albany, Ctr Genet Mol, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Belostotsky, DA (corresponding author), SUNY Albany, Dept Biol Sci, 1400 Washington Ave, Albany, NY 12222 USA.	dab@csc.albany.edu		Chekanova, Julia/0000-0002-2214-8896				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baker RE, 1998, GENETICS, V149, P73; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Guthrie C, 1991, METHODS ENZYMOL, V194; Harlow E., 1988, ANTIBODIES LAB MANUA; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; Shiomi T, 1998, J BIOCHEM-TOKYO, V123, P883; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Zhou ZH, 1997, J BACTERIOL, V179, P4391, DOI 10.1128/jb.179.13.4391-4395.1997	31	119	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33158	33166		10.1074/jbc.M005493200	http://dx.doi.org/10.1074/jbc.M005493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930416	hybrid			2022-12-25	WOS:000090003800105
J	Lu, RQ; Au, WC; Yeow, WS; Hageman, N; Pitha, PM				Lu, RQ; Au, WC; Yeow, WS; Hageman, N; Pitha, PM			Regulation of the promoter activity of interferon regulatory factor-7 gene - Activation by interferon and silencing by hypermethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR COMPLEX; CPG ISLAND METHYLATION; IFN-INDUCIBLE GENES; POSITIVE FEEDBACK; DNA METHYLATION; VIRUS-INFECTION; CELL-GROWTH; DE-NOVO; EXPRESSION; IRF-1	The molecular mechanism by which virus induces expression of the early inflammatory genes has not yet been completely elucidated. Previous studies indicated that the virus-mediated transcription of type I interferon (IFN) genes required activation of two members of IFN regulatory factor (IRF) family, IRF-3 and IRF-7, where the expression of IRF-7 was found to be indispensable for the induction of IFNA genes. To determine the factors that regulate expression of IRF-7 gene, as well as its inducibility by type I IFNs, we have isolated and characterized the promoter and first intron of the human IRF-7 gene. This region shows a presence of two potential interferon-sensitive response elements (ISRE/IRF-E). However, only the ISRE present in the first intron was functional and conferred interferon inducibility in a transient transfection assay. Using a pull-down assay with an oligodeoxynucleotide corresponding to this ISRE immobilized to magnetic beads, we have demonstrated that this ISRE binds ISGF3 complex and IRF-1 from the extract of IFN-treated cells but not from the untreated cells. We have further shown that the previously observed lack of expression of IRF-7 in 2fTGH fibrosarcoma cell line, correlated with hypermethylation of the CpG; island in the human IRF-7 promoter. The repression of the promoter activity was relieved by treatment with DNA methyltransferase inhibitor 5-azadeoxycytidine. In vitro methylation of IRF-7 promoter silenced IRF-7 directed expression of luciferase gene in HeLa cells that express endogenous IRF-7 gene. Whether silencing of IRF-7 by methylation is instrumental for the process of tumorigenesis remains to be determined.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Bunting & Blaustein Canc Res Bldg,Rm 351,1650 Orl, Baltimore, MD 21231 USA.			Yeow, Wen-Shuz/0000-0002-0436-9636	NIAID NIH HHS [R01 AI19737-17] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOULTWOOD J, 1993, BLOOD, V82, P2611; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; Esteller M, 2000, CANCER RES, V60, P2368; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KANE MF, 1977, CANCER RES, V1, P808; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; Kim TK, 2000, CANCER RES, V60, P1153; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2000, J VIROL, V74, P1061, DOI 10.1128/JVI.74.3.1061-1068.2000	44	136	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31805	31812		10.1074/jbc.M005288200	http://dx.doi.org/10.1074/jbc.M005288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924517	hybrid			2022-12-25	WOS:000089858900038
J	Woo, CH; Eom, YW; Yoo, MH; You, HJ; Han, HJ; Song, WK; Yoo, YJ; Chun, JS; Kim, JH				Woo, CH; Eom, YW; Yoo, MH; You, HJ; Han, HJ; Song, WK; Yoo, YJ; Chun, JS; Kim, JH			Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A(2)-linked cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PLATELET-ACTIVATING-FACTOR; LEUKOTRIENE B-4; PHOSPHATIDYLINOSITOL 3-KINASE; RAC GTPASE; ARACHIDONIC-ACID; RECEPTOR; FIBROBLASTS; WORTMANNIN; CYTOKINE	Reactive oxygen species (ROS) are important regulatory molecules implicated in the signaling cascade triggered by tumor necrosis factor (TNF)-alpha, although the events through which TNF-alpha induces ROS generation are not yet well characterized. We therefore investigated selected candidates likely to mediate TNF-alpha-induced ROS generation. Consistent with the role of Rac in that process, stable expression of Rac(Asn-17), a dominant negative Rad mutant, completely blocked TNF-alpha-induced ROS generation. To understand better the mediators downstream of Rac, we investigated the involvement of cytosolic phospholipase A(2) (cPLA(2)) activation and metabolism of the resultant arachidonic acid (AA) by B-lipoxygenase (5-LO). TNF-alpha-induced ROS generation was blocked by inhibition of cPLA(2) or 5-LO, but not cyclooxygenase, suggesting that TNF-alpha-induced ROS generation is dependent on synthesis of AA and its subsequent metabolism to leukotrienes. Consistent with that hypothesis, TNF-alpha Rac-dependently stimulated endogenous production of leukotriene B-4 (LTB4), while exogenous application of LTB4 increased levels of ROS. In contrast, application of leukotrienes C-4, D-4, and E-4 or prostaglandin E-2 had little effect. Our findings suggest that LTB4 production by 5-LO is situated downstream of the Rac-cPLA(2) cascade, and we conclude that Rac, cPLA(2), and LTB4 play pivotal roles in the ROS-generating cascade triggered by TNF-alpha.	Kwangju Inst Sci & Technol, K JIST, Dept Life Sci, Kwangju 500712, South Korea; Chonnam Natl Univ, Coll Vet Med, Dept Vet Physiol, Kwangju 500757, South Korea	Gwangju Institute of Science & Technology (GIST); Chonnam National University	Kim, JH (corresponding author), Kwangju Inst Sci & Technol, K JIST, Dept Life Sci, Kwangju 500712, South Korea.		Han, Ho Jae/M-1476-2016; Eom, Young/AAW-4659-2021; Kim, Jae-Hong/B-2530-2009	Han, Ho Jae/0000-0002-0657-1766; Kim, Jae-Hong/0000-0002-8019-0208; Eom, Young Woo/0000-0002-5985-6490				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1998, MOL CELLS, V8, P90; Kim BC, 1998, BIOCHEM J, V330, P1009, DOI 10.1042/bj3301009; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; Li YQ, 1996, J CLIN INVEST, V97, P1605, DOI 10.1172/JCI118585; Lindsay MA, 1998, J IMMUNOL, V160, P4526; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shindo K, 1997, THORAX, V52, P1024, DOI 10.1136/thx.52.12.1024; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Toda A, 1999, BIOCHEM BIOPH RES CO, V262, P806, DOI 10.1006/bbrc.1999.1284; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Woo CH, 2000, BIOCHEM BIOPH RES CO, V268, P231, DOI 10.1006/bbrc.2000.2102; Woo CH, 2000, BIOCHEM J, V348, P525, DOI 10.1042/0264-6021:3480525; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	31	200	211	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32357	32362		10.1074/jbc.M005638200	http://dx.doi.org/10.1074/jbc.M005638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934206	hybrid			2022-12-25	WOS:000089858900109
J	Fulci, G; Labuhn, M; Maier, D; Lachat, Y; Hausmann, O; Hegi, ME; Janzer, RC; Merlo, A; Van Meir, EG				Fulci, G; Labuhn, M; Maier, D; Lachat, Y; Hausmann, O; Hegi, ME; Janzer, RC; Merlo, A; Van Meir, EG			p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	ONCOGENE			English	Article						p14arf; p16; mdm2; egfr; brain tumor; tumor suppressor	CELL LUNG-CANCER; HIGH-GRADE GLIOMAS; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETION; BRAIN-TUMORS; CDK4 AMPLIFICATION; MALIGNANT GLIOMAS; ONCOPROTEIN MDM2; P16(INK4A) GENE; P19(ARF)	P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently: deleted in human tumors, Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci, To examine this question we performed a multigenic analysis on 29 gliomas, We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26, Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis, The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV, either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%), These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and Loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.	CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; CHU Vaudois, Univ Hosp, Dept Neuropathol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Emory University; University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Van Meir, EG (corresponding author), CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland.		Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; BIERNAT W, 1997, NEUROPATHOL EXP NEUR, V56, P180; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; Costello JF, 1997, CANCER RES, V57, P1250; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; DURO D, 1995, ONCOGENE, V11, P21; FRYE RA, 1989, ONCOGENE, V4, P1153; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; Gazzeri S, 1998, CANCER RES, V58, P3926; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; HE J, 1994, CANCER RES, V54, P5804; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; Ichimura K, 2000, CANCER RES, V60, P417; JEN J, 1994, CANCER RES, V54, P6353; Kamb A, 1994, Nat Genet, V8, P23; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kleihues P, 1994, Recent Results Cancer Res, V135, P25; LANDERS JE, 1994, ONCOGENE, V9, P2745; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; MAO L, 1995, CANCER RES, V55, P2995; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SCHMIDT EE, 1994, CANCER RES, V54, P6321; STONE S, 1995, CANCER RES, V55, P2988; Sure U, 1997, J NEUROPATH EXP NEUR, V56, P782; Teng DHF, 1997, CANCER RES, V57, P5221; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang SI, 1997, CANCER RES, V57, P4183; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	123	124	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3816	3822		10.1038/sj.onc.1203700	http://dx.doi.org/10.1038/sj.onc.1203700			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949938				2022-12-25	WOS:000088568400016
J	Lee, YI; Lee, S; Das, GC; Park, US; Park, SM; Lee, YI				Lee, YI; Lee, S; Das, GC; Park, US; Park, SM; Lee, YI			Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma	ONCOGENE			English	Article						insulin-like growth factor II; p53 mutant; transcriptional activation; hepatocellular carcinoma	X GENE-PRODUCT; FUNCTION MUTATIONS; P4 PROMOTER; TREE SHREWS; VIRUS; EXPRESSION; CELLS; HEPATOCYTES; APOPTOSIS; SITE	Aflatoxin B1 (AFB1) induced mutation of the p53 gene at codon 249 (p53mt249) is critical during the formation of hepatocellular carcinoma (HCC) following hepatitis B virus (HBV) infection. p53mt249 markedly increases insulin-like growth factor II (IGF-II) transcription largely from promoter 4, accumulating the fetal form of IGF-II, Modulation of the transcription factor binding to IGF-II P4 by wild-type p53 and p53mt249 was identified. Wild-type p53 inhibited binding of transcription factors Sp1 and TBP on the P4 promoter, while p53mt249 enhanced the formation of transcriptional complexes through enhanced DNA-protein (Spl or TBP) and protein-protein (Sp1 and TBP) interactions. p53mt249 stimulates transcription factor Spl phosphorylation which might be a cause of increased transcription factor binding on the P4 promoter while wild-type p53 does not. Transfection of hepatocytes with p53mt249 impaired induction of apoptosis by the HBV-X protein and TNF-alpha. Therefore, the blocking of apoptosis through enhanced production of IGF-II should provide a favorable opportunity for the selection of transformed hepatocytes. These results explain the molecular basis for the genesis of HCC by p53mt249 which was found to be induced by a potent mutagen, AFB1.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, Taejon 305600, South Korea; Univ Texas, Ctr Hlth, Dept Mol Biol, Tyler, TX 75710 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, POB 115, Taejon 305600, South Korea.							AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARIANI E, 1988, CANCER RES, V48, P6844; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FU XX, 1998, J VIROL, V62, P4322; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HSIAO M, 1994, AM J PATHOL, V145, P702; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULLA JE, 1993, CANCER RES, V53, P9; HYUN SW, 1993, FEBS LETT, V332, P153, DOI 10.1016/0014-5793(93)80503-M; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kim SO, 1996, CANCER RES, V56, P3831; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; LAMAS E, 1989, FALK S OCT 15 17 BAS, V55, P45; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LUIS P, 1997, SCIENCE, V278, P687; LUSE DS, 1980, CELL, V20, P691, DOI 10.1016/0092-8674(80)90315-3; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, V1; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PERREM K, 1995, ONCOGENE, V11, P1299; SANDEEP RD, 1997, CELL, V91, P231; Shivakumar CV, 1996, ONCOGENE, V13, P323; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su JJ, 1997, EXP MOL MED, V29, P177, DOI 10.1038/emm.1997.27; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Yan RQ, 1996, J CANCER RES CLIN, V122, P289, DOI 10.1007/BF01261405; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YEH FS, 1989, CANCER RES, V49, P2506; Zhang LJ, 1998, DNA CELL BIOL, V17, P125, DOI 10.1089/dna.1998.17.125	35	74	77	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3717	3726		10.1038/sj.onc.1203694	http://dx.doi.org/10.1038/sj.onc.1203694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949925				2022-12-25	WOS:000088568400003
J	Sutherland, LC; Edwards, SE; Cable, HC; Poirier, GG; Miller, BA; Cooper, CS; Williams, GT				Sutherland, LC; Edwards, SE; Cable, HC; Poirier, GG; Miller, BA; Cooper, CS; Williams, GT			LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis	ONCOGENE			English	Article						LUCA-15; CD95; apoptosis; chromosome 3; jurkat; antisense	FLICE-INHIBITORY PROTEIN; EPSTEIN-BARR VIRUS; INDUCED CELL-DEATH; C-ELEGANS; IMMUNE ESCAPE; LUNG-CANCER; FAS; EXPRESSION; TUMORS; RNA	Using an expression cloning system to discover novel genes involved in apoptosis, we identified a 326 bp bone marrow cDNA fragment (termed Je2) that suppresses, upon transfection, CD95-mediated apoptosis in Jurkat T cells, Sequence homology revealed that Je2, maps to 3p21.3, to an intronic region of the candidate TSG LUCA-15 locus. It represents, in fact, an antisense transcript to the 3'-UTR of two novel splice variants of this gene. Overexpression of sequence representing one of these splice variants (a 2.6 kit cDNA termed Clone 26), inhibited proliferation of Jurkat cells and sensitized them to CD95-mediated apoptosis, This study therefore implicates the LUCA-15 gene locus in the control of apoptosis.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA; Keele Univ, Sch Life Sci, Keele ST5 5BG, Staffs, England; Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; CHU Laval, Ctr Rech, Eastern Quebec Peptide Sequencing Facil, Ste Foy, PQ G1V 4G2, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Keele University; University of London; Institute of Cancer Research - UK; Laval University	Sutherland, LC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930; Poirier, Guy/0000-0002-4869-1424	NCRR NIH HHS [M01 RR10732] Funding Source: Medline; NIDDK NIH HHS [DK46778] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046778, R01DK046778] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Cook DM, 1996, ONCOGENE, V13, P1789; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Okura T, 1996, J IMMUNOL, V157, P4277; Peltz SW, 1999, J EXP MED, V190, P1729, DOI 10.1084/jem.190.12.1729; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; Sutherland LC, 2000, J IMMUNOL METHODS, V234, P43, DOI 10.1016/S0022-1759(99)00202-1; Sutherland LC, 1997, J IMMUNOL METHODS, V207, P179, DOI 10.1016/S0022-1759(97)00118-X; Tsuruda K, 1999, LEUKEMIA RES, V23, P159, DOI 10.1016/S0145-2126(98)00158-1; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wei MH, 1996, CANCER RES, V56, P1487; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Williams GT, 1998, TOXICOL LETT, V103, P485, DOI 10.1016/S0378-4274(98)00343-9; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	40	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3774	3781		10.1038/sj.onc.1203720	http://dx.doi.org/10.1038/sj.onc.1203720			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949932				2022-12-25	WOS:000088568400010
J	Higashimoto, Y; Saito, S; Tong, XH; Hong, A; Sakaguchi, K; Appella, E; Anderson, CW				Higashimoto, Y; Saito, S; Tong, XH; Hong, A; Sakaguchi, K; Appella, E; Anderson, CW			Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; PROTEIN; GENE; EXPRESSION; PHOSPHOSERINE; MUTATIONS; ANALOGS; SIGNALS; ISOFORM; GROWTH	To characterize the sites in human p53 that become phosphorylated in response to DNA damage, we have developed polyclonal antibodies that recognize p53 only when it is phosphorylated at specific sites. Several attempts to generate an antibody to p53 phosphorylated at Ser(6) using a phosphoserine-containing peptide as an immunogen were unsuccessful; however, phosphorylation-specific antibodies were produced by using the phosphoserine mimetic, L-2-amino-4-phosphono-4,4-di-fluorobutanoicacid (F(2)Pab), in place of phosphoserine. Fmoc-F(2)Pab was prepared by an improved synthesis and chemically incorporated using solid phase peptide synthesis, Affinity-purified antibodies elicited by immunizing rabbits with an F(2)Pab peptide coupled to keyhole limpet hemocyanin recognized a p53(1-39) peptide phosphorylated only at Ser(6) but not the unphosphorylated peptide or the same peptide phosphorylated at Ser(9), Ser(15), Ser(20), Ser(33), or Ser(37). Untreated A549 cells exhibited a background of constitutive phosphorylation at Ser(6) that increased approximately 10-fold upon exposure to either ionizing radiation or UV light. Similar results were obtained for Sers using antibodies raised against a conventional phosphopeptide. Ser(9) was phosphorylated by casein kinase 1 in vitro in a phosphoserine 6-dependent manner. Our data identify two additional DNA damage-induced phosphorylations in human p53 and show that F(2)Pab-derivatized peptides can be used to develop phosphorylation site-specific polyclonal antibodies.	NCI, NIH, Bethesda, MD 20892 USA; AnaSpec Inc, San Jose, CA 95131 USA; Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu University; United States Department of Energy (DOE); Brookhaven National Laboratory	Appella, E (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.			Higashimoto, Yuichiro/0000-0003-1382-8598; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; APPELLA E, 2000, IN PRESS PATHOL BIOL; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berkowitz DB, 1996, J ORG CHEM, V61, P4666, DOI 10.1021/jo9604752; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Christenson E, 1997, Recent Results Cancer Res, V143, P263; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DOVER R, 1994, J CELL SCI, V107, P1181; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hollstein M, 1998, MUTAT RES-FUND MOL M, V405, P145, DOI 10.1016/S0027-5107(98)00131-6; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYOSHI K, 1995, PEPTIDE CHEM, V33, P25; OTAKA A, 1995, TETRAHEDRON LETT, V36, P927, DOI 10.1016/0040-4039(94)02374-K; Prives C, 1999, J PATHOL, V187, P112; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	32	104	111	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23199	23203		10.1074/jbc.M002674200	http://dx.doi.org/10.1074/jbc.M002674200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930428	hybrid			2022-12-25	WOS:000088419400082
J	Go, C; He, W; Zhong, L; Li, P; Huang, J; Brinkley, BR; Wang, XJ				Go, C; He, W; Zhong, L; Li, P; Huang, J; Brinkley, BR; Wang, XJ			Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGF beta RII	ONCOGENE			English	Article						skin carcinogenesis; transforming growth factor beta receptor; transgenic; cell cycle progression; cdk inhibitors; centrosome	GROWTH-FACTOR-BETA; II RECEPTOR GENE; CHEMICAL CARCINOGENESIS; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; DOWN-REGULATION; CDK INHIBITOR; MUTATION; MICE; ARREST	Mutations in the transforming growth factor beta type II receptor (TGF beta RII) have been found in various malignant tumors, suggesting that loss of TGF beta signaling plays a causal role in late-stage cancer development, To test whether loss of TGF beta RII is involved in early-stage carcinogenesis, ne have generated transgenic mice expressing a dominant negative TGF beta RII (Delta beta RII) in the epidermis, These mice exhibited an increased susceptibility to chemical carcinogenesis protocols at both early and late stages. In the current study, parameters for cell cycle progression and chromosome instability were analysed in Delta beta RII tumors. Delta beta RII papillomas showed an increased S phase in flow cytometry. Bromodeoxyuridine (BrdU) labeling and mitotic indices in Delta beta RII papillomas also showed a threefold increase compared to papillomas developing in non-transgenic mice, When papillomas further progressed to squamous cell carcinomas (SCC), both control and Delta beta RII SCC showed similar BrdU labeling indices and percentages of S phase cells. However, Delta beta RII SCC cells showed a sixfold increase in the G2/M population. Mitotic indices in Delta beta RII SCC also showed a threefold increase compared to non-transgenic SCC, Consistent with a perturbed cell cycle, Delta beta RII papillomas and SCC showed reduced expression of the TGF beta target genes p15 (INK4b), p21 (WAF-1) and p27 (Kip1), inhibitors of cyclin-dependent kinases (cdks). However, most Delta beta RII papilloma cells exhibited normal centrosome numbers, and Delta beta RII SCC exhibited a similar extent of centrosome abnormalities compared to control SCC (35-40% cells). Most of Delta beta RII SCC exhibited diploid chromosome profiles. These data indicate that inactivation of TGF beta RII accelerates skin tumorigenesis at early stages by the acceleration of loss of cell cycle control, but not by increased chromosome instability.	Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Wang, XJ (corresponding author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA.				NCI NIH HHS [CA64255, CA79998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064255, R01CA079998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; BERTSCH S, 1982, CELL TISSUE KINET, V15, P81, DOI 10.1111/j.1365-2184.1982.tb01026.x; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Go C, 1999, CANCER RES, V59, P2861; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iacopetta BJ, 1998, J PATHOL, V184, P390; Iavarone A, 1997, NATURE, V387, P417; Imai Y, 1998, INT J CANCER, V76, P407, DOI 10.1002/(SICI)1097-0215(19980504)76:3<407::AID-IJC19>3.0.CO;2-7; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SATTERWHITE DJ, 1994, INVAS METAST, V14, P309; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	43	20	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3623	3631		10.1038/sj.onc.1203701	http://dx.doi.org/10.1038/sj.onc.1203701			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951568				2022-12-25	WOS:000088568300008
J	Kaul, SC; Sugihara, T; Yoshida, A; Nomura, H; Wadhwa, R				Kaul, SC; Sugihara, T; Yoshida, A; Nomura, H; Wadhwa, R			Gros1, a potential growth suppressor on chromosome 1: its identity to basement membrane-associated proteoglycan, leprecan	ONCOGENE			English	Article						Gros1/leprecan; proteoglycan; tumor suppressor; chomosome 1	IN-SITU HYBRIDIZATION; ALLELIC LOSS; MULTIFUNCTIONAL REGULATOR; MEDIATED SUPPRESSION; BREAST-CANCER; REGION; CARCINOMA; DELETION; DECORIN; HETEROZYGOSITY	By immunoscreening with an antibody raised against a plasma membrane protein, we have cloned a growth suppressor gene, Gros1 and assigned it to short arm of human chromosome 1. Two alternatively spliced forms of the gene encoding 84- and 41-kDa (carboxy-terminus truncated) proteins were cloned. The two transcripts, 4.4 and 2.7 kb, were expressed weakly in most of the human tissues, with a high expression of the smaller transcript in placenta, ovary and testis. Normal human fibroblasts in culture shelved two transcripts, with a higher level of expression of the 4.4 kb transcript. Transformed cells on the other hand showed predominant expression of the 2.7 kb transcript. Two Gros1 transcripts were also detected in most of the mouse tissues. Stable transfection of the mouse cDNA encoding the 85-kDa protein into NIH3T3 cells resulted in their slow growth and reduced colony-forming efficiency. Stable clones expressing antisense RNA on the other hand exhibited higher colony forming efficiency. Wlile our data implied that Gros1 is a novel growth suppressor gene on human chromosome 1, an independent study has recently characterized its rat-homolog as a <(le)under bar>ucine <(pr)under bar>oline-(e) under bar nriched novel basement membrane-associated proteogly<(can)under bar> leprecan. We describe here cloning, expression and biological activity analysis implying that this novel proteoglycan is a potential growth suppressor on chromosome 1p31, frequently altered in many malignancies.	Chugai Res Inst Mol Med, Ibaraki, Osaka 30041, Japan; AIST, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Wadhwa, R (corresponding author), Chugai Res Inst Mol Med, 153-2 Nagai, Ibaraki, Osaka 30041, Japan.		Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; ARIYAMA T, 1995, GENOMICS, V25, P114, DOI 10.1016/0888-7543(95)80116-4; Arlt MF, 1996, HUM MOL GENET, V5, P1017, DOI 10.1093/hmg/5.7.1017; Bomme L, 1998, GENE CHROMOSOME CANC, V21, P185, DOI 10.1002/(SICI)1098-2264(199803)21:3<185::AID-GCC2>3.0.CO;2-W; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; Caput D, 1997, B CANCER, V84, P1081; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Carrino DA, 2000, ARCH BIOCHEM BIOPHYS, V373, P91, DOI 10.1006/abbi.1999.1545; Chen HL, 1996, CANCER GENET CYTOGEN, V86, P102, DOI 10.1016/0165-4608(95)00186-7; CHENG NC, 1995, ONCOGENE, V10, P291; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Di Vinci A, 1998, CANCER-AM CANCER SOC, V83, P415; Fujimoto Y, 1998, Rinsho Byori, V46, P9; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iolascon A, 1997, LEUKEMIA, V11, P359, DOI 10.1038/sj.leu.2400596; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; Lee WC, 1996, CANCER RES, V56, P4297; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Merle B, 1999, J CELL BIOCHEM, V75, P538; MOLEY JF, 1992, CANCER RES, V52, P770; MUNN KE, 1995, ONCOGENE, V10, P1653; NAGAI H, 1995, CANCER RES, V55, P1752; Nakanishi K, 1999, INT J CANCER, V80, P527, DOI 10.1002/(SICI)1097-0215(19990209)80:4<527::AID-IJC8>3.3.CO;2-P; Nash MA, 1999, CANCER RES, V59, P6192; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Perlman EJ, 1996, GENE CHROMOSOME CANC, V16, P15, DOI 10.1002/(SICI)1098-2264(199605)16:1<15::AID-GCC2>3.0.CO;2-6; PRAML C, 1995, ONCOGENE, V11, P1357; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Stander M, 1998, GENE THER, V5, P1187, DOI 10.1038/sj.gt.3300709; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Verbeek MM, 1999, AM J PATHOL, V155, P2115, DOI 10.1016/S0002-9440(10)65529-0; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0	41	29	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3576	3583		10.1038/sj.onc.1203696	http://dx.doi.org/10.1038/sj.onc.1203696			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951563				2022-12-25	WOS:000088568300003
J	Tsuchiya, T; Tamura, G; Sato, K; Endoh, Y; Sakata, K; Jin, Z; Motoyama, T; Usuba, O; Kimura, W; Nishizuka, S; Wilson, KT; James, SP; Yin, J; Fleisher, AS; Zou, TT; Silverberg, SG; Kong, DH; Meltzer, SJ				Tsuchiya, T; Tamura, G; Sato, K; Endoh, Y; Sakata, K; Jin, Z; Motoyama, T; Usuba, O; Kimura, W; Nishizuka, S; Wilson, KT; James, SP; Yin, J; Fleisher, AS; Zou, TT; Silverberg, SG; Kong, DH; Meltzer, SJ			Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia	ONCOGENE			English	Article						hvpermethylation; APC; gastric cancer	MUTATION CLUSTER REGION; POLYPOSIS-COLI GENE; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BETA-CATENIN; CELL-LINES; HYPERMETHYLATION; IDENTIFICATION; CARCINOMA; STOMACH	The adenomatous polyposis coli (APC) tumor suppressor gene is mutationally inactivated in both familial and sporadic forms of colorectal cancers. In addition, hypermethylation of CpG islands in the upstream portion of APC, a potential alternative mechanism of tumor suppressor gene inactivation, has been described in colorectal cancer. Because a subset of both gastric and colorectal cancers display the CpG island methylator phenotype, we hypothesized that epigenetic inactivation of APC was likely to occur in at least some gastric cancers, APC exhibits two forms of transcripts from exons 1A and 1B in the stomach. Therefore, we investigated CpG island methylation in the sequences upstream off sons 1A and 1B, i.e., promoters 1A and 1B, respectively. We evaluated DNAs from 10 gastric cancer cell lines, 40 primary gastric cancers, and 40 matching non-cancerous gastric mucosae, Methylated alleles of promoter 1A were present in 10 (100%) of 10 gastric cancer cell lines, 33 (82.5%) of 40 primary gastric cancers, and 39 (97.5%) of 40 non-cancerous gastric mucosae. In contrast, promoter 1B was unmethylated in all of these same samples, APC transcripts from exon 1A were not expressed in nine of the 10 methylated gastric cancer cell lines, whereas APC transcripts were expressed from exon 1B. Thus, expression from a given promoter correlated well with its methylation status. We conclude that in contrast to the colon, methylation of promoter 1A is a normal el ent in the stomach; moreover, promoter 1B is protected from methylation in the stomach and thus probably does not participate in this form of epigenetic APC inactivation.	Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Surg, Yamagata 9909585, Japan; Univ Calif Irvine, Irvine Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	Yamagata University; Yamagata University; University of California System; University of California Irvine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Tsuchiya, T (corresponding author), Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.			Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA078843, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA77057, CA85069, CA78843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Fleisher AS, 1999, CANCER RES, V59, P1090; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NISHIMURA K, 1995, INT J ONCOL, V7, P587; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OSHIMA M, 1993, CANCER RES, V53, P5589; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; Powell SM, 1996, ONCOGENE, V12, P1953; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Sparks AB, 1998, CANCER RES, V58, P1130; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tamura G, 1996, CANCER RES, V56, P612; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681	29	160	169	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3642	3646		10.1038/sj.onc.1203704	http://dx.doi.org/10.1038/sj.onc.1203704			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951570				2022-12-25	WOS:000088568300010
J	Yang, TB; Poovaiah, BW				Yang, TB; Poovaiah, BW			An early ethylene up-regulated gene encoding a calmodulin-binding protein involved in plant senescence and death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SIGNAL-TRANSDUCTION; RESPONSE PATHWAY; CALCIUM; EXPRESSION; POLLINATION; PERCEPTION; MECHANISM; APOPTOSIS; TARGETS	S-35-Labeled calmodulin (CaM) was used to screen a tobacco anther cDNA library. A positive clone (NtER1) with high homology to an early ethylene-up-regulated gene (ER66) in tomato, and an Arabidopsis homolog was isolated and characterized. Based on the helical wheel projection, a 25-mer peptide corresponding to the predicted CaM-binding region of NtER1 (amino acids 796-820) was synthesized. The gel-mobility shift assay showed that the peptide formed a stable complex with CaM only in the presence of Ca2+. CaM binds to NtER1 with high affinity (K-d similar to 12 nM) in a calcium-dependent manner. Tobacco flowers at different stages of development were treated with ethylene or with 1-methylcyclopropene for 2 h before treating with ethylene. Northern analysis showed that the NtER1 was rapidly induced after 15 min of exposure to ethylene. However, the 2-h 1-methylcyclopropene treatment totally blocked NtER1 expression in flowers at all stages of development, suggesting that NtER1 is an early ethylene-up-regulated gene. The senescing leaves and petals had significantly increased NtER1 induction as compared with young leaves and petals, implying that NtER1 is developmentally regulated and acts as a trigger for senescence and death. This is the first documented evidence for the involvement of Ca2+/CaM-mediated signaling in ethylene action.	Washington State Univ, Lab Plant Mol Biol & Physiol, Dept Hort, Pullman, WA 99164 USA	Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Lab Plant Mol Biol & Physiol, Dept Hort, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Abeles F, 1992, ETHYLENE PLANT BIOL; [Anonymous], SENESCENCE AGEING PL; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; BOLLER T, 1983, PLANTA, V157, P22, DOI 10.1007/BF00394536; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; Chang C, 1999, CURR OPIN PLANT BIOL, V2, P352, DOI 10.1016/S1369-5266(99)00004-7; CLORE GM, 1993, CURR OPIN STRUC BIOL, V3, P838, DOI 10.1016/0959-440X(93)90146-C; Deikman J, 1997, PHYSIOL PLANTARUM, V100, P561, DOI 10.1034/j.1399-3054.1997.1000318.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Gallardo M, 1999, PHYTOCHEMISTRY, V50, P373, DOI 10.1016/S0031-9422(98)00591-3; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; Groover A, 1999, PLANT PHYSIOL, V119, P375, DOI 10.1104/pp.119.2.375; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; Kieber JJ, 1997, ANNU REV PLANT PHYS, V48, P277, DOI 10.1146/annurev.arplant.48.1.277; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; KUSHAD MM, 1984, PLANT PHYSIOL, V76, P293, DOI 10.1104/pp.76.2.293; Kwak SH, 1997, PLANT CELL PHYSIOL, V38, P1142, DOI 10.1093/oxfordjournals.pcp.a029099; LESHEM YY, 1987, PHYSIOL PLANTARUM, V69, P551, DOI 10.1111/j.1399-3054.1987.tb09239.x; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LICOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MATTOO AK, 1988, SENESCENCE AGING PLA, P242; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MEYER RC, 1991, PLANT MOL BIOL, V17, P277, DOI 10.1007/BF00039505; NICOTERA P, 1994, MOL CELL BIOCHEM, V135, P89, DOI 10.1007/BF00925964; NOODEN LD, 1988, SENESCENCE AGING PLA, P2; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; POOVAIAH BW, 1973, PLANT PHYSIOL, V52, P236, DOI 10.1104/pp.52.3.236; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; PORAT R, 1995, PHYSIOL PLANTARUM, V93, P778, DOI 10.1111/j.1399-3054.1995.tb05131.x; RAZ V, 1992, PLANT CELL, V4, P1123, DOI 10.1105/tpc.4.9.1123; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SEREK M, 1995, PLANT GROWTH REGUL, V16, P93, DOI 10.1007/BF00040512; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; TREWAVAS A, 1999, PLANT PHYSIOL, V120, P428; Trewavas AJ, 1997, PLANT CELL, V9, P1181, DOI 10.1105/tpc.9.7.1181; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; Xu Y, 2000, PLANT PHYSIOL, V122, P1323, DOI 10.1104/pp.122.4.1323; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; Yang T, 1998, PLANT MOL BIOL, V37, P109, DOI 10.1023/A:1005902905512; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137; Yang TB, 1996, MOL GEN GENET, V252, P684, DOI 10.1007/BF02173974; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	53	106	121	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38467	38473		10.1074/jbc.M003566200	http://dx.doi.org/10.1074/jbc.M003566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952977	hybrid			2022-12-25	WOS:000165739800045
J	Adam, PJ; Regan, CP; Hautmann, MB; Owens, GK				Adam, PJ; Regan, CP; Hautmann, MB; Owens, GK			Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22 alpha in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TGF-BETA; TRANSGENIC MICE; CACCC ELEMENT; CARG ELEMENTS; DNA-SEQUENCE; GENE; PROMOTER; GROWTH-FACTOR-BETA-1; IDENTIFICATION	Transforming growth factor beta (TGF-beta) is implicated in the regulation of smooth muscle cell (SMC) differentiation. We previously identified a novel TGF-beta control element (TCE) in the promoters of SMC differentiation marker genes, including alpha -smooth muscle actin and SM22 alpha. In this study, the importance of the TCE in regulation of SM22 alpha gene expression in vivo was investigated by mutating it within the context of a mouse SM22 alpha promoter-lacZ transgenic construct. Mutation of the TCE completely abolished SM22 alpha promoter activity in arterial SMCs as well as in developing heart and skeletal muscle. To identify the transcription factor(s) binding to the TCE, we performed yeast one-hybrid cloning analysis and identified gut-enriched Kruppel-like factor (GKLF), However, cotransfection studies in cultured cells showed that GKLF repressed the TGF-beta -dependent increases in SM22 alpha and alpha -smooth muscle actin promoter activities. Furthermore, GKLF was not highly expressed in differentiated SMCs in vivo, and TGF-beta down-regulated GKLF expression in dedifferentiated cultured SMCs. In contrast, overexpression of a related factor (BTEB2) transactivated SM22 alpha promoter activity. Thus, our findings suggest a reciprocal role for related Kruppel-like transcription factors in the regulation of SMC differentiation through a TCE-dependent mechanism.	Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Owens, GK (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, POB 449 Hlth Sci Ctr, Charlottesville, VA 22908 USA.			Regan, Chris/0000-0002-3201-5878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854, T32HL007284, P01HL019242] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL07284, R01HL38854, P01HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Asano H, 1999, MOL CELL BIOL, V19, P3571; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLANK RS, 1992, J BIOL CHEM, V267, P984; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Moessler H, 1996, DEVELOPMENT, V122, P2415; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VERBEEK MM, 1994, AM J PATHOL, V144, P372; VERNET M, 1993, METHOD ENZYMOL, V225, P434; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yang X, 1999, DEVELOPMENT, V126, P1571; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	48	199	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37798	37806		10.1074/jbc.M006323200	http://dx.doi.org/10.1074/jbc.M006323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954723	hybrid			2022-12-25	WOS:000165618700067
J	Guth, S; Valcarcel, J				Guth, S; Valcarcel, J			Kinetic role for mammalian SF1/BBP in spliceosome assembly and function after polypyrimidine tract recognition by U2AF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR SF1; BRANCHPOINT SEQUENCE; EXON SEQUENCES; SITE SELECTION; PROTEIN; BINDING; SNRNP; REGION; DOMAIN	Two sequences important for pre-mRNA splicing precede the 3' end of introns in higher eukaryotes, the branch point (BP) and the polypyrimidine (Py) tract. Initial recognition of these signals involves cooperative binding of the splicing factor SF1/mammalian branch point binding protein (mBBP) to the BP and of U2AF(65) to the By tract. Both factors are required for recruitment of the U2 small nuclear ribonucleoprotein particle (U2 snRNP) to the BP in reactions reconstituted from purified components. In contrast, extensive depletion of ST1/BBP in Saccharomyces cerevisiae does not compromise spliceosome assembly or splicing significantly. As BP sequences are less conserved in mammals, these discrepancies could reflect more stringent requirements for SF1/BBP in this system. We report here that extensive depletion of SF1/mBBP from nuclear extracts of HeLa cells results in only modest reduction of their activity in spliceosome assembly and splicing. Some of these effects reflect differences in the kinetics of U2 snRNP binding. Although U2AF(65) binding was reduced in the depleted extracts, the defects caused by SF1/mBBP depletion could not be fully restored by an increase in occupancy of the Py tract by exogenously added U2AF65, arguing for a role of SF1/mBBP in U2 snRNP recruitment distinct from promoting U2AF65 binding.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Valcarcel, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571; Guth-Gundel, Sabine/0000-0001-9115-1397				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Arning S, 1996, RNA, V2, P794; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; Berglund JA, 1998, RNA, V4, P998, DOI 10.1017/S1355838298980499; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Burge CB, 1999, RNA WORLD, P525; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; GAUR RK, 1995, RNA, V1, P407; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; Guth S, 1999, MOL CELL BIOL, V19, P8263; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; Kramer A, 1998, GENE, V211, P29, DOI 10.1016/S0378-1119(98)00058-4; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LEE CG, 1993, J BIOL CHEM, V268, P13472; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Rutz B, 1999, RNA, V5, P819, DOI 10.1017/S1355838299982286; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	46	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38059	38066		10.1074/jbc.M001483200	http://dx.doi.org/10.1074/jbc.M001483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954700	hybrid			2022-12-25	WOS:000165618700100
J	Feinberg, H; Torgersen, D; Drickamer, K; Weis, WI				Feinberg, H; Torgersen, D; Drickamer, K; Weis, WI			Mechanism of pH-dependent N-acetylgalactosamine binding by a functional mimic of the hepatocyte asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ANIMAL LECTINS; PROTEIN; RAT; SYSTEM	Efficient release of ligands from the Ca2+-dependent carbohydrate-recognition domain (CRD) of the hepatic asialoglycoprotein receptor at endosomal pH requires a small set of conserved amino acids that includes a critical histidine residue. When these residues are incorporated at corresponding positions in an homologous galactose-binding derivative of serum mannose-binding protein, the:pH dependence of ligand binding becomes more like that of the receptor. The modified CRD displays 40-fold preferential binding to N-acetylgalactosamine compared with galactose, making it a good functional mimic of the asialoglycoprotein receptor. In the crystal structure of the modified CRD bound to N-acetylgalactosamine, the histidine (His(202)) contacts the 2-acetamido; methyl group and also participates in a network of interactions involving Asp(212), Arg(216), and Tyr(218) that-positions a water molecule in a hydrogen bond with the sugar amide group. These interactions appear to produce the preference for N-acetylgalactosamine over galactose and are also likely to influence the pK(a) of His(202). Protonation of His(202) would disrupt its interaction with an asparagine that serves as a ligand for Ca2+ and sugar. The structure of the modified CRD without sugar displays several different conformations that may represent structures of intermediates in the release of Ca2+ and sugar ligands caused by protonation of His(202).	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Stanford University; University of Oxford	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg,299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400	25	45	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35176	35184		10.1074/jbc.M005557200	http://dx.doi.org/10.1074/jbc.M005557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931846	hybrid			2022-12-25	WOS:000165422800048
J	Hayes, DS; Peng, ZY; Setlow, P				Hayes, DS; Peng, ZY; Setlow, P			Equilibrium and kinetic binding interactions between DNA and a group of novel, nonspecific DNA-binding proteins from spores of Bacillus and Clostridium species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-TYPE SMALL; SINGLE-STRANDED-DNA; ACID-SOLUBLE PROTEINS; ESCHERICHIA-COLI; SUBTILIS SPORES; IN-VITRO; NONCOOPERATIVE BINDING; MUTANT SMALL; MEGATERIUM; VIVO	Binding of alpha/beta -type small acid-soluble spore proteins (SASP) is the major determinant of DNA resistance to damage caused by UV radiation, heat, and oxidizing agents in spores of Bacillus and Clostridium species. Analysis of several alpha/beta -type SASP showed that these proteins have essentially no secondary structure in the absence of DNA, but become significantly cu-helical upon binding to double-stranded DNAs or oligonucleotides. Folding of alpha/beta -type SASP induced by a variety of DNAs and :oligonucleotides was measured by CD spectroscopy, and this allowed determination of a DNA binding site size of 4 base pairs as well as equilibrium binding parameters of the alpha/beta -type SASP-DNA interaction, Analysis of the equilibrium binding data further allowed determination of both intrinsic binding constants (LC) and cooperativity factors (omega), as the alpha/beta -type SASP-DNA interaction was significantly cooperative, with the degree of cooperativity depending on both the bound DNA and the salt concentration, Kinetic analysis of the interaction of one alpha/beta -type SASP, SspC(Tyr), With DNA indicated that each binding event involves the dimerization of SspC(Tyr) monomers at a DNA binding site. The implications of these findings for the structure of the alpha/beta -type SASP.DNA complex and the physiology of alpha/beta -type SASP degradation during spore germination are discussed.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	Setlow, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, MC-3305,263 Farmington Ave, Farmington, CT 06030 USA.	setlow@sun.uchc.edu			NIGMS NIH HHS [GM19698, GM54533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019698, R29GM054533, R37GM019698] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; CABRERAMARTINEZ RM, 1989, FEMS MICROBIOL LETT, V61, P139, DOI 10.1111/j.1574-6968.1989.tb03567.x; Cantor CR, 1980, BIOPHYSICAL CHEM BEH; DEJONG EAM, 1987, BIOCHEMISTRY-US, V26, P2039, DOI 10.1021/bi00381a037; Driks A, 2000, PROKARYOTIC DEVELOPMENT, P191; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; GERHARDT P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P43; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; GROCH N, 1992, EUR J BIOCHEM, V207, P677, DOI 10.1111/j.1432-1033.1992.tb17095.x; Hayes CS, 1998, J BIOL CHEM, V273, P17326, DOI 10.1074/jbc.273.28.17326; Hayes CS, 1998, J BACTERIOL, V180, P2694, DOI 10.1128/JB.180.10.2694-2700.1998; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; LOSHON CA, 1986, J BACTERIOL, V167, P168, DOI 10.1128/jb.167.1.168-173.1986; MARQUIS RE, 1994, J APPL BACTERIOL, V76, pS40, DOI 10.1111/j.1365-2672.1994.tb04356.x; MASON JM, 1986, J BACTERIOL, V167, P174, DOI 10.1128/jb.167.1.174-178.1986; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P4034, DOI 10.1021/bi952555q; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MOHR SC, 1991, P NATL ACAD SCI USA, V88, P77, DOI 10.1073/pnas.88.1.77; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; SANCHEZSALAS JL, 1992, J BACTERIOL, V174, P807, DOI 10.1128/jb.174.3.807-814.1992; SANCHEZSALAS JL, 1992, BIOCHIMIE, V74, P651, DOI 10.1016/0300-9084(92)90137-4; SETLOW B, 1991, J BACTERIOL, V173, P1642, DOI 10.1128/jb.173.5.1642-1653.1991; SETLOW B, 1995, J BACTERIOL, V177, P4149, DOI 10.1128/jb.177.14.4149-4151.1995; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW B, 1993, APPL ENVIRON MICROB, V59, P3418, DOI 10.1128/AEM.59.10.3418-3423.1993; SETLOW B, 1995, APPL ENVIRON MICROB, V61, P2787, DOI 10.1128/AEM.61.7.2787-2790.1995; SETLOW P, 1975, J BIOL CHEM, V250, P8159; SETLOW P, 1975, J BIOL CHEM, V250, P8168; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; SETLOW P, 1994, J APPL BACTERIOL, V76, pS49, DOI 10.1111/j.1365-2672.1994.tb04357.x; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; Setlow P., 1981, SPORULATION GERMINAT, P13; Sober H. A., 1970, HDB BIOCH SELECTED D; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWERDLOW BM, 1981, J BACTERIOL, V148, P20, DOI 10.1128/JB.148.1.20-29.1981; TOVARROJO F, 1991, J BACTERIOL, V173, P4827, DOI 10.1128/jb.173.15.4827-4835.1991; URBANKE C, 1990, BIOCHEMISTRY-US, V29, P1744, DOI 10.1021/bi00459a012; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	53	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35040	35050		10.1074/jbc.M005669200	http://dx.doi.org/10.1074/jbc.M005669200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954716	hybrid			2022-12-25	WOS:000165422800031
J	Kawashima, H; Hirose, M; Hirose, J; Nagakubo, D; Plaas, AHK; Miyasaka, M				Kawashima, H; Hirose, M; Hirose, J; Nagakubo, D; Plaas, AHK; Miyasaka, M			Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; HYALURONAN-BINDING; MONOCLONAL-ANTIBODIES; HEPARAN-SULFATE; CELL-ADHESION; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; AMINO-TERMINUS; LIGAND; DOMAIN	Here:we show that a large chondroitin sulfate proteoglycan, versican, derived from a renal adenocarcinoma cell line ACHN, binds L-selectin, P-selectin, and CD44. The binding was mediated by the interaction of the chondroitin:sulfate (CS) chain of versican with the carbohydrate-binding domain of L- and P-selectin and CD44. The binding of versican to L- and P-selectin was inhibited by CS B, CS E, and heparan sulfate (HS) but not by: any other glycosaminoglycans tested. On the other hand, the binding to CD44 was inhibited by hyaluronic acid, chondroitin (CH), CS A, CS B, CS C, CS D, and CS E but not by HS or keratan sulfate. A cross-blocking study indicated that L- and P-selectin recognize: close or overlapping sites on versican, whereas CD44 recognizes separate sites. We also show that soluble L- and P-selectin directly bind to immobilized CS B, CS E, and HS and that soluble CD44 directly binds to immobilized hyaluronic acid, CH, and all the CS chains examined. Consistent with these results, structural analysis showed that versican is modified with at least CS B and CB C. Thus, proteoglycans sufficiently modified with the appropriate glycosaminoglycans should be able: to bind L-selectin, P-selectin, and/or CD44.	Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Bioregulat, Suita, Osaka 5650871, Japan; Shriners Hosp Children, Cell Biol Lab, Tampa, FL 33612 USA	Osaka University	Miyasaka, M (corresponding author), Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Bioregulat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		まゆみ, 廣瀬/AAK-5735-2020; Nagakubo, Daisuke/AAW-3621-2021	Nagakubo, Daisuke/0000-0003-1213-1246				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Goda K, 1999, EUR J IMMUNOL, V29, P1551, DOI 10.1002/(SICI)1521-4141(199905)29:05<1551::AID-IMMU1551>3.0.CO;2-0; Hamai A, 1997, J BIOL CHEM, V272, P9123; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; IMAI Y, 1993, NATURE, V361, P555; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Li RH, 1998, EUR J IMMUNOL, V28, P1745, DOI 10.1002/(SICI)1521-4141(199806)28:06<1745::AID-IMMU1745>3.0.CO;2-5; LIAO HX, 1995, J IMMUNOL, V155, P3938; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; Mikhailov D, 1999, J BIOL CHEM, V274, P25317, DOI 10.1074/jbc.274.36.25317; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NELSON RM, 1993, BLOOD, V82, P3253; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SCHLOSSMAN SF, 1995, LEUCOCYTE TYPING, V5, P1713; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SORRELL JM, 1988, J IMMUNOL, V140, P4263; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Watanabe N, 1999, J BIOCHEM-TOKYO, V125, P826, DOI 10.1093/oxfordjournals.jbchem.a022355; Wolff EA, 1999, J BIOL CHEM, V274, P2518, DOI 10.1074/jbc.274.4.2518; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	61	206	212	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35448	35456		10.1074/jbc.M003387200	http://dx.doi.org/10.1074/jbc.M003387200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950950	hybrid			2022-12-25	WOS:000165422800082
J	Martins, A; Shuman, S				Martins, A; Shuman, S			Mechanism of phosphoanhydride cleavage by baculovirus phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CAPPING ENZYME BINDS; MESSENGER-RNA; CRYSTAL-STRUCTURE; NUCLEOSIDE TRIPHOSPHATASE; CATALYTIC MECHANISM; TERMINAL DOMAIN; POLYMERASE; GUANYLYLTRANSFERASE; 5'-TRIPHOSPHATASE	Baculovirus phosphatase (BVP) is a member of the metazoan RNA triphosphatase enzyme family that includes the RNA triphosphatase component of the mRNA capping apparatus, BVP and other metazoan RNA triphosphatases belong to a superfamily of phosphatases that act via the formation and hydrolysis of a covalent cysteinyl-phosphate intermediate. Here we demonstrate the formation of a BVP phosphoenzyme upon reaction with [gamma-P-32]ATP and identify the linkage as a thiophosphate based on its chemical lability, We surmise:that the phosphate is linked to Cys(119) of BVP because replacement of Cys(119) by alanine or serine abrogates phosphoenzyme formation and phosphohydrolase activity. The catalytic cysteine is situated within a conserved phosphate-binding loop ((118)HCTHGINRTGY(128)). We show that all of the non-aliphatic side chains of the phosphate-binding loop are functionally important, insofar as mutants H118A, H121A, N124A, R125A, T126A, and Y128A were inactive in gamma phosphate hydrolysis and the T120A mutant was 7% as active as wild-type BVP, Structure-activity relationships at the essential positions: of the phosphate-binding loop were elucidated by conservative substitutions. A conserved aspartic acid (Asp(60)) invoked as a candidate general acid catalyst was dispensable for phosphohydrolase activity and phosphoenzyme formation by BVP, We propose that the low pK(a) of the bridging oxygen of the beta phosphate leaving group circumvents a requirement for expulsion by a proton donor during attack by cysteine on the gamma phosphorus. in contrast, a conserved aspartic acid is essential for the phosphomonoesterase reactions catalyzed by protein phosphatases, where the serine or tyrosine leaving groups have a much higher pK(a) than does ADP.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497				DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Evans B, 1996, BIOCHEMISTRY-US, V35, P13609, DOI 10.1021/bi9605651; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yokoska J, 2000, BIOCHEM BIOPH RES CO, V268, P617, DOI 10.1006/bbrc.2000.2188; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35070	35076		10.1074/jbc.M005748200	http://dx.doi.org/10.1074/jbc.M005748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954717	hybrid			2022-12-25	WOS:000165422800034
J	Baggio, L; Adatia, F; Bock, T; Brubaker, PL; Drucker, DJ				Baggio, L; Adatia, F; Bock, T; Brubaker, PL; Drucker, DJ			Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; PROGLUCAGON GENE-TRANSCRIPTION; DIABETIC-PATIENTS; BODY-WEIGHT; FASTING HYPERGLYCEMIA; BIOLOGICAL-ACTIVITY; PROMOTES SATIETY; FUSION GENE; DB/DB MICE	Activation of glucagon-like peptide (GLP)-1 receptor signaling promotes glucose lowering via multiple mechanisms, including regulation of food intake, glucose-dependent insulin secretion, and stimulation of beta -cell mass. As GLP-1 exhibits a short t(1/2) in vivo, the biological consequences of prolonged GLP-1 receptor signaling remains unclear. To address this question, we have now generated metallothionein promoter-prepro exendin (MT-Ex) transgenic mice. MT-Ex mice process preproexendin correctly, as is made evident by detection of circulating plasma exendin-4 immunoreactivity using high pressure liquid chromatography and an exendin-4-specific radioimmunoassay, Despite elevated levels of exendin-4, fasting plasma glucose and glucose clearance following oral and intraperitoneal glucose tolerance tests are normal in MT-Ex mice. Induction of transgene expression significantly reduced glycemic excursion during both oral and intraperitoneal glucose tolerance tests (p < 0.05) and increased levels of glucose-stimulated insulin following oral glucose administration (p < 0.05), Despite evidence that exendin-4 may induce beta -cell proliferation, beta -cell mass and islet histology were normal in MT-Ex mice. MT-Ex mice exhibited no differences in basal food intake or body weight; however, induction of exendin-4 expression was associated with reduced short term food ingestion (p < 0.05), In contrast, short term water intake was significantly reduced in the absence of zinc in fluid-restricted MT-Ex mice (p < 0.05), These findings illustrate that sustained elevation of circulating exendin-4 is not invariably associated with changes in glucose homeostasis, increased beta -cell mass, or reduction in food intake in mice in vivo.	Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Physiol, Toronto, ON M5G 2C4, Canada; Kobenhavns Kommunehosp, Bartholin Inst, Copenhagen, Denmark	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, 101 Coll St,CCRW3-845, Toronto, ON M5G 2C4, Canada.	d.drucker@utoronto.ca	Drucker, Daniel J/A-4092-2010					Bhavsar S, 1998, DIABETES, V47, pA192; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; Burcelin R, 1999, ANN NY ACAD SCI, V875, P277, DOI 10.1111/j.1749-6632.1999.tb08510.x; Chen YQE, 1997, J BIOL CHEM, V272, P4108, DOI 10.1074/jbc.272.7.4108; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337/diacare.19.6.580; DAlessio DA, 1996, J CLIN INVEST, V97, P133, DOI 10.1172/JCI118380; Deacon CF, 1998, DIABETOLOGIA, V41, P271, DOI 10.1007/s001250050903; DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; Donahey JCK, 1998, BRAIN RES, V779, P75, DOI 10.1016/S0006-8993(97)01057-3; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; EHRLICH P, 1994, AM J PHYSIOL-ENDOC M, V267, pE662, DOI 10.1152/ajpendo.1994.267.5.E662; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Flint A, 1998, J CLIN INVEST, V101, P515, DOI 10.1172/JCI990; Greig NH, 1999, DIABETOLOGIA, V42, P45, DOI 10.1007/s001250051111; Gromada J, 1996, BRIT J PHARMACOL, V118, P769, DOI 10.1111/j.1476-5381.1996.tb15466.x; Gutzwiller JP, 1999, AM J PHYSIOL-REG I, V276, pR1541, DOI 10.1152/ajpregu.1999.276.5.R1541; HENDRICK GK, 1993, METABOLISM, V42, P1, DOI 10.1016/0026-0495(93)90163-I; Hill ME, 1999, MOL ENDOCRINOL, V13, P1474, DOI 10.1210/me.13.9.1474; Holst JJ, 1998, DIABETES, V47, P1663, DOI 10.2337/diabetes.47.11.1663; JONES IR, 1987, DIABETOLOGIA, V30, P707, DOI 10.1007/BF00296993; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Knudsen LB, 2000, J MED CHEM, V43, P1664, DOI 10.1021/jm9909645; KOLLIGS F, 1995, DIABETES, V44, P16, DOI 10.2337/diabetes.44.1.16; LOW MJ, 1985, CELL, V41, P211, DOI 10.1016/0092-8674(85)90075-3; Meeran K, 1999, ENDOCRINOLOGY, V140, P244, DOI 10.1210/en.140.1.244; Nauck MA, 1998, DIABETES CARE, V21, P1925, DOI 10.2337/diacare.21.11.1925; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Pohl M, 1998, J BIOL CHEM, V273, P9778, DOI 10.1074/jbc.273.16.9778; Rachman J, 1996, DIABETES, V45, P1524, DOI 10.2337/diabetes.45.11.1524; Raufman JP, 1996, REGUL PEPTIDES, V61, P1, DOI 10.1016/0167-0115(96)00135-8; SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172/JCI1349; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Scrocchi LA, 1998, ENDOCRINOLOGY, V139, P3127, DOI 10.1210/en.139.7.3127; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; Seeley RJ, 2000, ENDOCRINOLOGY, V141, P473, DOI 10.1210/en.141.2.473; Siegel EG, 1999, REGUL PEPTIDES, V79, P93, DOI 10.1016/S0167-0115(98)00155-4; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Szayna M, 2000, ENDOCRINOLOGY, V141, P1936, DOI 10.1210/en.141.6.1936; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; Todd JF, 1997, EUR J CLIN INVEST, V27, P533, DOI 10.1046/j.1365-2362.1997.1490691.x; Tseng CC, 1996, AM J PHYSIOL-ENDOC M, V270, pE661, DOI 10.1152/ajpendo.1996.270.4.E661; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172/JCI119482; White SA, 1999, HORM METAB RES, V31, P519, DOI 10.1055/s-2007-978787; Widmann C, 1996, MOL ENDOCRINOL, V10, P62, DOI 10.1210/me.10.1.62; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Young AA, 1999, DIABETES, V48, P1026, DOI 10.2337/diabetes.48.5.1026; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	58	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34471	34477		10.1074/jbc.M005119200	http://dx.doi.org/10.1074/jbc.M005119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952981	hybrid			2022-12-25	WOS:000165095300064
J	Seroz, T; Perez, C; Bergmann, E; Bradsher, J; Egly, JM				Seroz, T; Perez, C; Bergmann, E; Bradsher, J; Egly, JM			p44/SSL1, the regulatory subunit of the XPD/RAD3 helicase, plays a crucial role in the transcriptional activity of TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; COCKAYNE-SYNDROME; OPEN COMPLEX; PROTEIN; MUTATIONS; GENE	In order to unravel the mechanism that regulates transcription of protein-coding genes, we investigated the function of the p44 subunit of TFIIH, a basal transcription factor that is also involved in DNA repair. We have shown previously that mutations in the C terminus of the XPD helicase, another subunit of TFIIH, prevent its regulation by p44 (Coin, F., Bergmann, E,, Tremeau-Bravard, A, and Egly, J. M. (1999) EMBO 18, 1357-1366). By using a site-directed mutagenesis approach within the p44 region from amino acids 66 to 200, we indicate how a decrease in the interaction between p44 and XPD results in a decrease of the XPD helicase activity and leads to a defect in the first steps of the transcription reaction, namely the first phosphodiester bond formation and promoter clearance. We thus provide some explanation for the transcriptional defect found in SSL1 mutated yeast (Wang, Z,, Buratowski, S., Svejstrup, J. Q,, Feaver, W. J.. Wu, X., Kornberg, R. D., Donahue, T, F., and Friedberg, E. C, (1995) Mol. Cell. Biol. 15, 2288-2293). Moreover, this study shows how the activity of the the cyclin-dependent kinase-activating kinase associated with TFIIH complex in stimulating transcription is mediated in part by p44/XPD interaction.	ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.	egly@igbmc.u-strasbg.fr			NIGMS NIH HHS [F32 GM20174-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020174] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; Burglen L, 1997, AM J HUM GENET, V60, P72; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; de Boer J, 1999, CANCER RES, V59, P3489; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Lee BS, 2000, MOL CELL BIOL, V20, P2436, DOI 10.1128/MCB.20.7.2436-2445.2000; Lehmann AR, 1998, BIOESSAYS, V20, P146, DOI 10.1002/(SICI)1521-1878(199802)20:2<146::AID-BIES7>3.3.CO;2-5; Maines S, 1998, GENETICS, V150, P963; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, J BIOL CHEM, V269, P9826; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Vermeulen W, 1997, BIOCHEM SOC T, V25, P309, DOI 10.1042/bst0250309; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	36	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33260	33266		10.1074/jbc.M004764200	http://dx.doi.org/10.1074/jbc.M004764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924514	hybrid			2022-12-25	WOS:000090104600014
J	Marini, I; Moschini, R; Del Corso, A; Mura, U				Marini, I; Moschini, R; Del Corso, A; Mura, U			Complete protection by alpha-crystallin of lens sorbitol dehydrogenase undergoing thermal stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; B-CRYSTALLIN; DENATURATION; SYSTEM	Sorbitol dehydrogenase (L-iditol:NAD(+) 2-oxidoreductase, E.C. 1.1.1.14) (SDH) was significantly protected from thermally induced inactivation and aggregation by bovine lens cu-crystallin, An alpha -crystallin/SDH ratio as low as 1:2 in weight was sufficient to preserve the transparency of the enzyme solution kept for at least 2 h at 55 degreesC, Moreover, an alpha -crystallin/SDH ratio of 5:1 (w/w) was sufficient to preserve the enzyme activity fully at 55 degreesC for at least 40 min. The protection by alpha -crystallin of SDH activity was essentially unaffected by high ionic strength (i.e. 0.5 M NaCl). On the other hand, the transparency of the protein solution was lost at a high salt concentration because of the precipitation of the alpha -crystallin/SDH adduct, Magnesium and calcium ions present at millimolar concentrations antagonized the protective action exerted by alpha -crystallin against the thermally induced inactivation and aggregation of SDH, The lack of protection of alpha -crystallin against the inactivation of SDH induced at 55 degreesC by thiol blocking agents or EDTA together with the additive effect of NADH in stabilizing the enzyme in the presence of rw-crystallin suggest that functional groups involved in catalysis are freely accessible in SDH while interacting with alpha -crystallin. Two different adducts between alpha -crystallin and SDH were isolated by gel filtration chromatography, One adduct was characterized by a high M-r of approximately 800,000 and carried exclusively inactive SDH, A second adduct, carrying active SDH, had a size consistent with an interaction of the enzyme with monomers or low M,aggregates of alpha -crystallin. Even though it had a reduced efficiency with respect to alpha -crystallin, bovine serum albumin was shown to mimic the chaperone-like activity of alpha -crystallin in protecting SDH from thermal denaturation. These findings suggest that the multimeric structural organization of alpha -crystallin may not be a necessary requirement for the stabilization of the enzyme activity.	Univ Pisa, Dipartimento Fisiol & Biochim, Biochim Lab, I-56100 Pisa, Italy	University of Pisa	Mura, U (corresponding author), Univ Pisa, Dipartimento Fisiol & Biochim, Biochim Lab, Via S Maria 55, I-56100 Pisa, Italy.		Moschini, Roberta/AAL-8338-2020	Moschini, Roberta/0000-0001-5227-2348; DEL CORSO, ANTONELLA/0000-0003-3165-6128				BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Derham BK, 1997, BBA-GEN SUBJECTS, V1336, P187, DOI 10.1016/S0304-4165(97)00029-9; Head MW, 1996, J CELL SCI, V109, P1029; HESS JF, 1998, MOL VIS, V15, P4; Hook DWA, 1998, INT J BIOL MACROMOL, V22, P295, DOI 10.1016/S0141-8130(98)00027-0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; JEFFERY J, 1988, ADV ENZYMOL RAMB, V61, P47; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Koretz JF, 1998, INT J BIOL MACROMOL, V22, P283, DOI 10.1016/S0141-8130(98)00026-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marini I, 1997, ARCH BIOCHEM BIOPHYS, V340, P383, DOI 10.1006/abbi.1997.9882; MARINI I, 1995, BIOCHEM BIOPH RES CO, V212, P413, DOI 10.1006/bbrc.1995.1985; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; vanNoort JM, 1996, J MOL MED-JMM, V74, P285, DOI 10.1007/s001090050030; WANG KY, 1994, J BIOL CHEM, V269, P13601; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	32	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32559	32565		10.1074/jbc.M006133200	http://dx.doi.org/10.1074/jbc.M006133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930418	hybrid			2022-12-25	WOS:000090003800026
J	Marcinkiewicz, C; Taooka, Y; Yokosaki, Y; Calvete, JJ; Marcinkiewicz, MM; Lobb, RR; Niewiarowski, S; Sheppard, D				Marcinkiewicz, C; Taooka, Y; Yokosaki, Y; Calvete, JJ; Marcinkiewicz, MM; Lobb, RR; Niewiarowski, S; Sheppard, D			Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9 ss 1 with VCAM-1, tenascin-C, and osteopontin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; BINDING-SITE; ALPHA(9)BETA(1) INTEGRIN; NEUTROPHIL MIGRATION; GLYCOPROTEIN IB; TERMINAL DOMAIN; VIPER VENOMS; III REPEAT; RGD; PROTEINS	The integrin alpha 9 beta 1 is expressed on epithelial cells, smooth muscle cells, skeletal muscle, and neutrophils and recognizes at least three distinct ligands: vascular cell adhesion molecule 1 (VCAM-1), tenascin-C, and osteopontin. The alpha 9 subunit is structurally similar to the integrin alpha 4 subunit, and alpha 9 beta 1 and alpha 4 beta 1 both recognize VCAM-1 as a ligand. We therefore examined whether the disintegrin EC3, which we have recently shown specifically inhibits the binding of alpha 4 integrins to ligands, would also be a functional inhibitor of alpha 9 beta 1. EC3 and a novel heterodimeric disintegrin that we identified, EC6, both were potent inhibitors of alpha 9 beta 1-mediated adhesion to VCAM-1 and of neutrophil migration across tumor necrosis factor-activated endothelial cells. A peptide containing a novel MLDG motif shared by both of these disintegrins also inhibited alpha 9 beta 1- and alpha 4 beta 1-mediated adhesion to VCAM-1. Surprisingly though, concentrations of EC3 that completely inhibited adhesion of alpha 9-transfected cells to VCAM-1 had little or no effect on adhesion to either of the other alpha 9 beta 1 ligands, osteopontin and tenascin-C. Furthermore, peptides AEIDGIEL and SV-VYGLR, which we have previously shown inhibit binding of alpha 9 beta 1-expressing cells to tenascin-C and osteopontin, respectively, had no effect on adhesion to VCAM-1. These data suggest that there are structurally distinct requirements for interactions of the alpha 9 beta 1 integrin with VCAM-1 and the extracellular matrix ligands osteopontin and tenascin-C.	Univ Calif San Francisco, Lung Biol Ctr, Ctr Environm & Occupat Hlth, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Temple Univ, Sch Med, Dept Physiol, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Natl Hiroshima Hosp, Dept Internal Med, Higashihiroshima 7390041, Japan; Natl Hiroshima Hosp, Dept Lab Med, Higashihiroshima 7390041, Japan; CSIC, Inst Biomed, E-46010 Valencia, Spain; Biogen Inc, Cambridge, MA 02142 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Biogen	Sheppard, D (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Ctr Environm & Occupat Hlth, Cardiovasc Res Inst, Box 0854, San Francisco, CA 94143 USA.	deans@itsa.ucsf.edu	Calvete, Juan J/K-9619-2014; Calvete, Juan/P-2555-2019	Calvete, Juan J/0000-0001-5026-3122; Calvete, Juan/0000-0001-5026-3122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, R37HL053949, R01HL053949, R01HL033259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/AI33259, HL47412, HL53949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; Brando C, 2000, BIOCHEM BIOPH RES CO, V267, P413, DOI 10.1006/bbrc.1999.1897; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRESHAM HD, 1986, J IMMUNOL, V137, P868; HUANG TF, 1987, J BIOL CHEM, V262, P16157; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Marcinkiewicz C, 1999, BIOCHEMISTRY-US, V38, P13302, DOI 10.1021/bi9906930; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; MCLANE MA, 1994, BIOCHEM J, V301, P289; MUSIAL J, 1990, CIRCULATION, V82, P261, DOI 10.1161/01.CIR.82.1.261; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RAHMAN S, 1995, BIOCHEM J, V312, P223, DOI 10.1042/bj3120223; Shang T, 1999, J LEUKOCYTE BIOL, V66, P809, DOI 10.1002/jlb.66.5.809; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Tan L, 1999, BLOOD, V93, P2605, DOI 10.1182/blood.V93.8.2605.408k18_2605_2616; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; TRIPANILOMBARDO V, 1985, J CLIN INVEST, V76, P1950; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328	34	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31930	31937		10.1074/jbc.M003209200	http://dx.doi.org/10.1074/jbc.M003209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10926928	hybrid			2022-12-25	WOS:000089858900054
J	Jiang, XJ; Wang, XD				Jiang, XJ; Wang, XD			Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS CED-4; APOPTOSIS; OLIGOMERIZATION; PROCASPASE-9; DATP; REQUIREMENT; PATHWAYS; HOMOLOG; COMPLEX; DEATH	We report here the biochemical analysis of the reconstituted de novo procaspase-9 activation using highly purified cytochrome c, recombinant apoptotic protease-activating factor-1 (Apaf-1), and recombinant procaspase-9. Using a nucleotide binding assay, we found that Apaf-1 alone bound dATP poorly and the nucleotide binding to Apaf-1 was significantly stimulated by cytochrome c, The binding of dATP to Apaf-1 induces the formation of a multimeric Apaf-1 cytochrome c complex, apoptosome. Procaspase-9 also synergistically promotes dATP binding to Apaf-1 in a cytochrome c-dependent manner, The dATP bound to apoptosome remained as dATP, not dADP. A nonhydrolyzable ATP analog, AD-PCP (beta,gamma-methylene adenosine 5'-triphosphate), was able to support apoptosome formation and caspase activation in place of dATP or ATP. These data indicate that the key event in Apaf-1-mediated caspase-9 activation is cytochrome c-induced dATP binding to Apaf-1.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Wang, Xiaodong/0000-0001-9885-356X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GMRO1-57158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	21	387	408	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31199	31203		10.1074/jbc.C000405200	http://dx.doi.org/10.1074/jbc.C000405200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10940292	hybrid			2022-12-25	WOS:000089762700064
J	Pandey, P; Nakazawa, A; Ito, Y; Datta, R; Kharbanda, S; Kufe, D				Pandey, P; Nakazawa, A; Ito, Y; Datta, R; Kharbanda, S; Kufe, D			Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells	ONCOGENE			English	Article						TPA; differentiation; caspases	PROTEIN-KINASE-C; ESTER-INDUCED DIFFERENTIATION; SIGNAL-TRANSDUCTION PATHWAY; CYTOCHROME-C; MACROPHAGE DIFFERENTIATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; HL-60 CELLS; RELEASE	Human myeloid leukemia cells respond to 12-tetradecanoylphorbol-13-acetate (TPA) and other activators of protein kinase C (PKC) with the induction of terminal monocytic differentiation, The present studies demonstrate that TPA treatment of U-937 leukemia cells is associated with release of mitochondrial cytochrome c, activation of caspase-3 and induction of internucleosomal DNA fragmentation. By contrast, the TUR cell variant, which is deficient in PKC beta, failed to respond to TPA with release of cytochrome c and induction of the caspase-3 cascade. Moreover, stable overexpression of PKC beta in TUR cells reconstituted sensitivity to TPA-induced cytochrome c release and activation of caspase-3, The results also demonstrate that treatment of cells with the caspase inhibitor z-VAD-fmk blocks both TPA-induced apoptosis and monocytic differentiation, Similar results were obtained in U-937 cells stably expressing the CrmA caspase inhibitor. These findings demonstrate that TPA induces cytochrome c release by a PKC beta-dependent mechanism and that activation of caspase-mediated signaling is required for induction of the differentiated monocytic phenotype.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Pandey, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA29431, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; COLLINS SJ, 1987, BLOOD, V70, P1233; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FUJIKI H, 1984, BIOCHEM BIOPH RES CO, V120, P339, DOI 10.1016/0006-291X(84)91259-2; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HASS R, 1992, CANCER RES, V52, P1445; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; Kim CN, 1997, CANCER RES, V57, P3115; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCFARLANE DE, 1994, J BIOL CHEM, V269, P4327; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STONE RM, 1988, BLOOD, V72, P739; STONE RM, 1988, BLOOD, V72, P208; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG KD, 1994, BLOOD, V83, P490	39	36	37	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3941	3947		10.1038/sj.onc.1203751	http://dx.doi.org/10.1038/sj.onc.1203751			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951587	Bronze			2022-12-25	WOS:000088614300013
J	Zohn, IE; Klinger, M; Karp, X; Kirk, H; Symons, M; Chrzanowska-Wodnicka, M; Der, CJ; Kay, RJ				Zohn, IE; Klinger, M; Karp, X; Kirk, H; Symons, M; Chrzanowska-Wodnicka, M; Der, CJ; Kay, RJ			G2A is an oncogenic G protein-coupled receptor	ONCOGENE			English	Article						G protein-coupled receptor; Rho; G alpha(12); G alpha(13)	GTP-BINDING PROTEIN; SERUM RESPONSE FACTOR; NUCLEOTIDE EXCHANGE FACTORS; STRESS FIBER FORMATION; MUTANT ALPHA-SUBUNIT; RHO-FAMILY GTPASES; THROMBIN RECEPTOR; RAS TRANSFORMATION; NEOPLASTIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID	G2A is a heptahelical cell surface protein that has recently been described as a potential tumor suppressor, based on its ability to counteract transformation of pre-B cells and fibroblasts by Bcr-Abl, an oncogenic tyrosine kinase, We have isolated cDNAs encoding G2A in the course of screening libraries for clones that cause oncogenic transformation of NIH3T3 fibroblasts, When expressed at high levels in NIH3T3 cells by retroviral transduction, G2A induced a full range of phenotypes characteristic of oncogenic transformation, including loss of contact inhibition, anchorage-independent survival and proliferation, reduced dependence on serum, and tumorigenicity in mice. When expressed by transfection, G2A greatly enhanced the ability of a weakly oncogenic form of Raf-1 to transform NIH3T3 cells. These results demonstrate that G2A is potently oncogenic both on its own and in cooperation with another oncogene, Expression of G2A in fibroblasts and endothelial cells resulted in changes in cell morphology and cytoskeleton structure that were equivalent to those induced by the G protein subunit G alpha(13), Transformation of NIH3T3 cells via G2A expression,vas completely suppressed by co-expression of LscRGS, a GTPase activating protein that suppresses signaling by G alpha(12) and G alpha(13). Hyperactivity of G alpha(12) or G alpha(13) has previously been shown to result in activation of Rho GTPases, G2A expression resulted in activation of Rho, and transformation via G2A was suppressed by a dominant negative form of RhoA, These results indicate that G2A may be directly coupled to G alpha(13), and that it is the activation of this Rho-activating Ga protein which is responsible for the ability of G2A to transform fibroblasts.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4E6, Canada; Onyx Pharmaceut, Richmond, CA 94806 USA	British Columbia Cancer Agency; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.		Karp, Xantha/AAU-9847-2021	Der, Channing/0000-0002-7751-2747; Zohn, Irene/0000-0001-7688-682X; Karp, Xantha/0000-0001-6602-5583; Chrzanowska, Magdalena/0000-0003-4182-2126	NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GLUKHOVA MA, 1990, DEV BIOL, V141, P193, DOI 10.1016/0012-1606(90)90114-X; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Joyce DE, 1997, BLOOD, V90, P1893, DOI 10.1182/blood.V90.5.1893; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARI B, 1994, J BIOL CHEM, V269, P8517; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TORDAI A, 1993, J IMMUNOL, V150, P4876; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	70	53	59	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3866	3877		10.1038/sj.onc.1203731	http://dx.doi.org/10.1038/sj.onc.1203731			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951580				2022-12-25	WOS:000088614300005
J	Bahr, C; Rohwer, A; Stempka, L; Rincke, G; Marks, F; Gschwendt, M				Bahr, C; Rohwer, A; Stempka, L; Rincke, G; Marks, F; Gschwendt, M			DIK, a novel protein kinase that interacts with protein kinase C delta - Cloning, characterization, and gene analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; PKC-DELTA; PROTEOLYTIC ACTIVATION; TUMOR PROMOTION; PHORBOL ESTER; CELLS; EXPRESSION; APOPTOSIS; KERATINOCYTES	A novel serine/threonine kinase, termed DIK, was cloned-using the yeast two-hybrid system to screen a cDNA library from the human keratinocyte cell line Ha-CaT with the catalytic domain of rat protein kinase C6 (PKC delta (cat)) CDNA as bait. The predicted 784-amino acid polypeptide with a calculated molecular mass of 86 kDa contains a-catalytic kinase domain and a putative regulatory domain with ankyrin-like repeats and a nuclear localization signal. Expression of DIK at the mRNA and protein level could be demonstrated in several cell lines. The dik gene is located on chromosome 21q22.3 and possesses 8 exons and 7 introns, DIK was synthesized in an in vitro transcription/translation system and expressed:as recombinant protein in bacteria, HEK, COS-7, and baculovirus-infected insect cells. In the in vitro system and in cells, but not in bacteria, various post-translationally modified forms of DIK were produced. DM was shown to exhibit protein kinase activity toward autophosphorylation and substrate phosphorylation. The interaction of PKC delta (cat) and PKC delta with DIK was confirmed by coimmunoprecipitation of the proteins from HEK cells transiently transfected with PRC delta (cat) or PKC gamma and DIK expression constructs.	German Canc Res Ctr, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gschwendt, M (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	m.gschwendt@dkfz.de						Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blobe GC, 1996, CANCER SURV, V27, P213; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CUTLER RE, 1994, ENDOCRINOLOGY, V135, P1669, DOI 10.1210/en.135.4.1669; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Reddig PJ, 1999, CANCER RES, V59, P5710; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	47	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36350	36357		10.1074/jbc.M004771200	http://dx.doi.org/10.1074/jbc.M004771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948194	hybrid			2022-12-25	WOS:000165382000099
J	Bang, S; Jeong, EJ; Kim, IK; Jung, YK; Kim, KS				Bang, S; Jeong, EJ; Kim, IK; Jung, YK; Kim, KS			Fas- and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction - A typical model for convergent signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-ASSOCIATED PROTEIN TRADD; DEATH DOMAIN; CELL-DEATH; TNF RECEPTOR; MUTATIONAL ANALYSIS; CD95 FAS/APO-1; COMPLEX; PATHWAYS; ANTIGEN	FADD is known to function as a common signaling conduit in Fas- and tumor necrosis factor (TNF)-mediated apoptosis, The convergent death signals from the Fas receptor and TNF receptor 1 are transferred to FADD by death domain interactions triggering the same cellular event, caspase-8 activation. In this work, we investigated whether the same binding surface of FADD is used for both signaling pathways by using FADD death domain mutants. Mutations in helices alpha2 and alpha3 of the FADD death domain, the interacting surface with the Fas death domain, affected TNF-mediated apoptosis to various extents. This indicated that TNF-mediated apoptosis uses the same binding surface of the FADD death domain as Fas-mediated apoptosis. The binding specificity is not the same, however. Some mutations affected the binding affinity of the Fas death domain for the FADD death domain, but did not influence TNF-mediated apoptosis and vice versa, Interestingly, all mutants tested that affected TNF-mediated apoptosis have structural perturbations, implying that the structural integrity, involving helices alpha2 and alpha3 in particular, is critical in TNF-mediated apoptosis. Our results suggest that different signaling molecules use a similar structural interaction to trigger the same cellular event, such as caspase-8 recruitment, which could be typical in convergent signal transduction.	Korea Inst Sci & Technol, Struct Biol Ctr, Seoul 130650, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea	Korea Institute of Science & Technology (KIST); Gwangju Institute of Science & Technology (GIST)	Kim, KS (corresponding author), Korea Inst Sci & Technol, Struct Biol Ctr, Cheongryang Box 131, Seoul 130650, South Korea.			Jung, Yong-Keun/0000-0002-9686-3120				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Martinez O M, 1999, Int Rev Immunol, V18, P527, DOI 10.3109/08830189909088497; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1996, Behring Inst Mitt, P144; WONG GHW, 1994, J IMMUNOL, V152, P1751; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Zhang J, 1996, MOL CELL BIOL, V16, P2756	26	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36217	36222		10.1074/jbc.M006620200	http://dx.doi.org/10.1074/jbc.M006620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10952991	hybrid			2022-12-25	WOS:000165382000081
J	Heikkinen, J; Risteli, M; Wang, CG; Latvala, J; Rossi, M; Valtavaara, M; Myllyla, R				Heikkinen, J; Risteli, M; Wang, CG; Latvala, J; Rossi, M; Valtavaara, M; Myllyla, R			Lysyl hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOFORM; CLONING; SPECIFICITY; ANTIBODIES; EXPRESSION; ENZYME; GENE	Lysyl hydroxylase (EC 1.14.11.4) and glucosyltransferase (EC 2.4.1.66) are enzymes involved in post-translational modifications during collagen biosynthesis, We reveal in this paper that the protein produced by the cDNA for human lysyl hydroxylase isoform 3 (LH3) has both lysyl hydroxylase and glucosyltransferase (GGT) activities. The other known lysyl hydroxylase isoforms, LH1, LH2a, and LH2b, have no GGT activity, Furthermore,: antibodies recognizing the amino acid sequence of human LH3 and those against a highly purified chicken GGT partially inhibited the GGT activity. Similarly, a partial inhibition was observed when these antibodies were tested against GGT extracted from human skin fibroblasts. In vitro mutagenesis experiments demonstrate that the amino acids involved in the GGT active site differ from those required for LH3 activity.	Oulu Univ, Dept Biochem, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu	Heikkinen, J (corresponding author), Oulu Univ, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.		Wang, Chunguang/AAE-7054-2020; Wang, Chunguang/AAE-6997-2020	Wang, Chunguang/0000-0001-5569-321X; 				AUSUBEL FM, 1988, CURRENT PROCOLS MOL; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; KADLER K, 1994, PROTEIN PROFILE, V1, P545; KADLER K, 1994, PROTEIN PROFILE, V1, P525; KELLOKUMPU S, 1994, J BIOL CHEM, V269, P30524; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKOKI, 1992, POST TRANSLATIONAL M, P1; Krol BJ, 1996, J INVEST DERMATOL, V106, P11, DOI 10.1111/1523-1747.ep12326956; MYLLYLA R, 1977, BIOCHIM BIOPHYS ACTA, V480, P113, DOI 10.1016/0005-2744(77)90326-6; MYLLYLA R, 1981, BIOCHIM BIOPHYS ACTA, V658, P299, DOI 10.1016/0005-2744(81)90300-4; MYLLYLA R, 1976, EUR J BIOCHEM, V70, P225, DOI 10.1111/j.1432-1033.1976.tb10973.x; MYLLYLA R, 1975, EUR J BIOCHEM, V52, P401, DOI 10.1111/j.1432-1033.1975.tb04008.x; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Valtavaara M., 1999, ACTA U OULUENSIS A, V334, P1; Wang CG, 2000, DNA CELL BIOL, V19, P71, DOI 10.1089/104454900314582; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X	24	100	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36158	36163		10.1074/jbc.M006203200	http://dx.doi.org/10.1074/jbc.M006203200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10934207	hybrid			2022-12-25	WOS:000165382000073
J	Kao, SY; Lemoine, FJ; Marriott, SJ				Kao, SY; Lemoine, FJ; Marriott, SJ			Suppression of DNA repair by human T cell leukemia virus type 1 Tax is rescued by a functional p53 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; WILD-TYPE P53; NUCLEAR ANTIGEN; HTLV-I; POLYMERASE-DELTA; HUMAN FIBROBLASTS; TUMOR-SUPPRESSOR; PROTEIN; EXPRESSION; GENE	The Tax protein of human T cell leukemia virus type 1 is a viral transactivator and transforming protein. Tax is known to suppress cellular nucleotide excision repair (NER), and this activity has been proposed to play an important role in Tax transformation. In this study we have investigated the mechanism by which Tax suppresses NER with specific focus on the previously characterized ability of Tax to inhibit p53 function. Suppression of NER by Tax was rescued by overexpression of wild-type p53; however, a p53 transactivation-incompetent mutant did not restore NER activity. The cyclin-dependent kinase inhibitor p21, a major transcriptional target of p53, plays an important role in regulating DNA replication and repair. Overexpression of p21 reversed Tax-induced suppression of NER; however, a p21 C-terminal mutant that lacks the proliferating cell nuclear antigen binding domain did not restore NER activity. Thus, p53 and its downstream effector p21 can inhibit Tax-mediated suppression of DNA repair. These results imply that the inactivation of p53 function by Tax contributes to Tax suppression of DNA repair.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	susanm@bcm.tmc.edu			NCI NIH HHS [CA-77371, CA-09197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BRAVO R, 1980, EXP CELL RES, V127, P249, DOI 10.1016/0014-4827(80)90430-9; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAO SY, 2000, RES ADV VIROL, V1, P1; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOEB LA, 1991, CANCER RES, V51, P3075; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Lydy SL, 1998, VIROLOGY, V250, P60, DOI 10.1006/viro.1998.9378; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; McDonald E, 1996, CANCER RES, V56, P2250; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REID RL, 1993, ONCOGENE, V8, P3029; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SMITH ML, 1995, ONCOGENE, V10, P1053; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	46	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35926	35931		10.1074/jbc.M004397200	http://dx.doi.org/10.1074/jbc.M004397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10931836	hybrid			2022-12-25	WOS:000165382000042
J	Wilkening, G; Linke, T; Uhlhorn-Dierks, G; Sandhoff, K				Wilkening, G; Linke, T; Uhlhorn-Dierks, G; Sandhoff, K			Degradation of membrane-bound ganglioside GM1 - Stimulation by bis(monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL DEGRADATION; SULFATIDE ACTIVATOR; SPHINGOLIPIDS; LOCALIZATION; SPECIFICITY; TOPOLOGY; STORAGE; ENZYME; LIVER; FORMS	According to our hypothesis (Furst, W,, and Sandhoff, K, (1992) Biochim, Biophys. Acta 1126, 1-16) glycosphingolipids of the plasma membrane are digested after endocytosis as components of intraendosomal and intralysosomal vesicles and membrane structures. The lysosomal degradation of glycosphingolipids with short oligosaccharide chains by acid exohydrolases requires small, non-enzymatic cofactors, called sphingolipid activator proteins (SAPs), A total of five activator proteins have been identified as follows: namely the saposins SAP-A, -B, -C, and -D, which are derived from the single chain SAP-precursor protein (prosaposin), and the GM2 activator protein. A deficiency of prosaposin results in the storage of ceramide and sphingolipids with short oligosaccharide head groups. The loss of the GM2 activator protein blocks the degradation of the ganglioside GM2. The enzymatic hydrolysis of the ganglioside GM1 is catalyzed by beta -galactosidase, a water-soluble acid exohydrolase, The lack of ganglioside GM1 accumulation in patients suffering from either prosaposin or GM2 activator protein deficiency has led to the hypothesis that SAPs are not needed for the hydrolysis of the ganglioside GM1 in vivo, In this study we demonstrate that an activator protein is required for the enzymatic degradation of membrane-bound ganglioside GM1 and that both SAP-B and the GM2 activator protein significantly enhance the degradation of the ganglioside GM1 by acid beta -galactosidase in a liposomal, detergent-free assay system. These findings offer a possible explanation for the observation that no storage of the ganglioside GM1 has been observed in patients with either isolated prosaposin or isolated GM2 activator deficiency. We also demonstrate that anionic phospholipids such as bis(monoacylglycero)phosphate and phosphatidylinositol, which specifically occur in inner membranes of endosomes and in lysosomes, are essential for the activator-stimulated hydrolysis of the ganglioside GM1. Assays utilizing surface:plasmon resonance spectroscopy showed that bis(monoacylglycero)phosphate increases the binding of both beta -galactosidase and activator proteins to substrate-carrying membranes.	Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Bonn	Sandhoff, K (corresponding author), Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.							BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P595; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Giehl A, 1999, EUR J BIOCHEM, V261, P650, DOI 10.1046/j.1432-1327.1999.00302.x; HUBBES M, 1992, BIOCHEM J, V285, P827, DOI 10.1042/bj2850827; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kolter T, 1999, ANGEW CHEM INT EDIT, V38, P1532, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U; LINKE T, 2000, IN PRESS BIOL CHEM; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; NAOI M, 1988, CHROMATOGRAPHIA, V426, P75; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Schutte CG, 1998, PROTEIN SCI, V7, P1039; STREMMEL W, 1976, H-S Z PHYSIOL CHEM, V357, P803, DOI 10.1515/bchm2.1976.357.1.803; SUZUKI Y, 1972, J LIPID RES, V13, P687; SWALLOW DM, 1993, ANN HUM GENET, V57, P187, DOI 10.1111/j.1469-1809.1993.tb01594.x; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; VOGEL A, 1987, ARCH BIOCHEM BIOPHYS, V259, P627, DOI 10.1016/0003-9861(87)90529-7; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; WIEGANDT H, 1965, Z NATURFORSCH PT B, VB 20, P164; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; WU YY, 1994, J BIOL CHEM, V269, P16276	25	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35814	35819		10.1074/jbc.M006568200	http://dx.doi.org/10.1074/jbc.M006568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942779	hybrid			2022-12-25	WOS:000165382000026
J	Egawa, T; Shimada, H; Ishimura, Y				Egawa, T; Shimada, H; Ishimura, Y			Formation of compound I in the reaction of native myoglobins with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SPERM WHALE MYOGLOBIN; HORSERADISH-PEROXIDASE; EPOXIDATION; CATALYSIS; MUTANTS; ROLES; INTERMEDIATE; PEROXYGENASE; REPLACEMENT	Reaction of ferric native myoglobin (Mb) with hydrogen peroxide (H2O2) was studied by the aid of stopped-flow rapid-scan spectrophotometry. In contrast to the results in previous studies where compound I was reported to be undetectable, both sperm whale and horse heart: metmyoglobins (metMbs) formed a significant quantity of compound I, an oxoferryl porphyrin pi -cation radical(Por(+)-Fe-IV(0)), during their reactions with H2O2. With both kinds of Mbs, formation of compound I was,more clearly observed in D2O than in H2O. The compound thus formed was capable of performing monooxygenation of thioanisole to methyl phenyl sulfoxide and a 2-electron oxidation of H2O2 giving O-2 and H2O as products. It was also converted into ferryl myoglobin (Por-Fe-IV(0)-globin(+)) spontaneously. Rate constants for these reactions and that for a direct conversion of metMb to ferryl Mb through the homolysis of H2O2 were determined. These results established unambiguously that native metMb can form both compound I and ferryl Mb upon reaction with H2O2 and that these high valent iron compounds serve as essential intermediates in Mb-assisted peroxidative reactions. The observed deuterium effect on the apparent stability of compound I was attributable to that effect on the hydrogen abstraction step in the 2-electron oxidation of H2O2 by compound I.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Ishimura, Y (corresponding author), Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; Golub G., 1965, SIAM J NUMER ANAL, V2, P205, DOI DOI 10.1137/0702016; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HARAMI T, 1977, J CHEM PHYS, V67, P1164, DOI 10.1063/1.434969; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HUG SJ, 1990, BIOCHEMISTRY-US, V29, P1475, DOI 10.1021/bi00458a019; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P345; MORISHIMA I, 1978, BIOCHEMISTRY-US, V17, P4384, DOI 10.1021/bi00614a005; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 1996, J AM CHEM SOC, V118, P9784, DOI 10.1021/ja961223l; PEISACH J, 1968, J BIOL CHEM, V243, P1871; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RAO SI, 1993, J BIOL CHEM, V268, P803; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SZABO ZG, 1969, COMPREHENSIVE CHEM K, V2, P31; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WILKS A, 1992, J BIOL CHEM, V267, P8827; YONETANI T, 1967, J BIOL CHEM, V242, P1974	37	108	110	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34858	34866		10.1074/jbc.M004026200	http://dx.doi.org/10.1074/jbc.M004026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945982	hybrid			2022-12-25	WOS:000165422800007
J	Recheis, B; Osanger, A; Haubenwallner, S; Schneider, WJ; Nimpf, J				Recheis, B; Osanger, A; Haubenwallner, S; Schneider, WJ; Nimpf, J			Chicken coagulation factor XIIIA is produced by the theca externa and stabilizes the ovarian follicular wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULOSA-CELLS; TISSUE TRANSGLUTAMINASE; CROSS-LINKING; OOCYTE GROWTH; DOMESTIC-FOWL; RECEPTOR; IDENTIFICATION; BINDING; CHONDROCYTES; FIBRONECTIN	Development of the follicle in egg-laying species such as the chicken is regulated by systemic factors as well as by-the highly orchestrated interplay of differentially expressed genes within this organ. Differential mRNA display analysis of defined phases of follicle development resulted in the characterization of coagulation factor XIIIA. It is expressed and produced by cells of the theca externa in a highly regulated manner during distinct growth phases of the follicle. Transcripts for factor XIIIA are already detectable at the beginning of follicle development,and peak at the end of phase 2. Protein levels, however, still increase during phase 3, peak shortly after ovulation, and persist until the postovulatory tissue is completely resorbed. Factor XIIIA is secreted asa monomer into the extracellular matrix of the theca-externa and is not associated with factor XIIIB as is the case in plasma. Our data suggest that, due to its transglutaminase activity, factor XIIIA stabilizes the follicular wall by cross-linking matrix components. Thus, coagulation factor XIIIA might play a key role in coping with-the massive mechanical stress exerted by the large amount of yolk accumulating during the rapid growth phase of the oocyte.	Inst Med Biochem, Dept Mol Genet, Bioctr, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna	Nimpf, J (corresponding author), Inst Med Biochem, Dept Mol Genet, Bioctr, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.	JNIMPF@mol.univie.ac.at		Nimpf, Johannes/0000-0002-9273-3492				AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ASEM EK, 1994, J REPROD FERTIL, V101, P375, DOI 10.1530/jrf.0.1010375; Bausek N, 2000, J BIOL CHEM, V275, P28866, DOI 10.1074/jbc.275.37.28866; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CERIO R, 1990, AM J DERMATOPATH, V12, P221, DOI 10.1097/00000372-199006000-00002; Chapeau C, 1996, POULTRY SCI, V75, P1536, DOI 10.3382/ps.0751536; DAHL E, 1970, Z ZELLFORSCH MIK ANA, V109, P195, DOI 10.1007/BF00365241; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; Hermann M, 1998, FASEB J, V12, P897, DOI 10.1096/fasebj.12.10.897; HERZ J, 1991, J BIOL CHEM, V266, P21232; JOHNSON A L, 1990, Critical Reviews in Poultry Biology, V2, P319; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOPACIUK S, 1976, THROMB RES, V8, P453, DOI 10.1016/0049-3848(76)90223-1; Monsonego A, 1998, FASEB J, V12, P1163, DOI 10.1096/fasebj.12.12.1163; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; Nimpf J, 1998, ATHEROSCLEROSIS, V141, P191, DOI 10.1016/S0021-9150(98)00172-5; NIMPF J, 1988, J LIPID RES, V29, P657; Nurminskaya M, 1998, J CELL BIOL, V142, P1135, DOI 10.1083/jcb.142.4.1135; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PERRY MM, 1978, J ANAT, V125, P481; PORTER TE, 1989, ENDOCRINOLOGY, V125, P109, DOI 10.1210/endo-125-1-109; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; Schneider WJ, 1998, BIOL CHEM, V379, P965; Ueki S, 1996, J CELL SCI, V109, P2727; VIEIRA PM, 1995, J LIPID RES, V36, P601; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; YOSHIMURA Y, 1985, Japanese Poultry Science, V22, P274	33	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35320	35327		10.1074/jbc.M005025200	http://dx.doi.org/10.1074/jbc.M005025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948196	hybrid			2022-12-25	WOS:000165422800066
J	Sawaya, BE; Khalili, K; Gordon, J; Taube, R; Amini, S				Sawaya, BE; Khalili, K; Gordon, J; Taube, R; Amini, S			Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-CYCLE ARREST; NUCLEAR-LOCALIZATION; TYPE-1 VPR; INDEPENDENT TRANSACTIVATION; MUTATIONAL ANALYSIS; IN-VITRO; P-TEFB; BINDING; RNA	The virion-associated protein of human immunodeficiency virus, type 1 (HIV-1), Vpr, is a small protein with 96 amino acid residues that has the ability to modulate transcription of HIV-1 long terminal repeat (LTR) promoter activity and affects several cellular functions. In this study we have employed molecular approaches to further investigate the mechanism by which Vpr exerts its regulatory effect upon the LTR. We show that by structural and functional interaction with Tat, a potent viral regulatory protein, Vpr synergistically enhances the transcriptional activity of the HIV-1 LTR, Because Tat utilizes cyclin T1 and its partner, CDK9 to elevate the level of transcription from the LTR, we examined the cooperativity between Vpr, Tat, and cyclin T1/CDK9 on viral gene transcription. Results from co-transfection studies indicated superactivation of LTR by Tat and cyclin T1/CDK9 in the presence of wild type Vpr. This activation was not observed with the R73S mutant of Vpr, which contains arginine to serine transition at residue 73, Interestingly, expression of R73S mutant in cells exerts a negative effect on the observed superactivation of the LTR by Tat, cyclin T1/CDK9, and wild type Vpr, Results from protein-protein interaction studies indicated that Vpr is associated with both Tat and cyclin T1 in cells expressing these proteins. Use of deletion mutant proteins in binding studies revealed that the binding sites for Tat and Vpr within cyclin T1 are distinct and that association of these two viral proteins with cyclin T1 is independent from each other. These observations suggest a working model on the cooperative interaction of Vpr with viral and cellular proteins and its involvement in control of viral gene transcription and replication. Moreover identification of R73S mutant of Vpr provides a new therapeutic avenue for controlling HIV-1 gene transcription and replication in the infected cells.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Immunol, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Amini, S (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96, Philadelphia, PA 19122 USA.		TAUBE, RAN/F-2029-2012	TAUBE, RAN/0000-0002-2062-4537				Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P601; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Cole Ruth, 1997, P117; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Endo S, 1989, Virus Genes, V3, P99; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gummuluru S, 1999, J VIROL, V73, P5422, DOI 10.1128/JVI.73.7.5422-5430.1999; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; Sawaya BE, 2000, J VIROL, V74, P4877, DOI 10.1128/JVI.74.10.4877-4881.2000; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Yong Voon Wee, 1997, P157; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; Zhao YQ, 1996, J VIROL, V70, P5821, DOI 10.1128/JVI.70.9.5821-5826.1996; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	39	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35209	35214		10.1074/jbc.M005197200	http://dx.doi.org/10.1074/jbc.M005197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931842	hybrid			2022-12-25	WOS:000165422800052
J	Thome, KC; Dhar, SK; Quintana, DG; Delmolino, L; Shahsafaei, A; Dutta, A				Thome, KC; Dhar, SK; Quintana, DG; Delmolino, L; Shahsafaei, A; Dutta, A			Subsets of human origin recognition complex (ORC) subunits are expressed in non-proliferating cells and associate with non-ORC proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; DROSOPHILA HOMOLOG; XENOPUS; GENE; CDK; IDENTIFICATION; LATHEO; PHOSPHORYLATION; LOCALIZATION; EUKARYOTES	The origin recognition complex (ORC) in yeast is a complex of six tightly associated subunits essential for the initiation of DNA replication. Human ORC subunits are nuclear in proliferating cells and in proliferative tissues like the testis, consistent with a role of human ORC in DNA replication. Orc2, Orc3, and Orc5 also are detected in non-proliferating cells like cardiac myocytes, adrenal cortical cells, and neurons, suggesting an additional role of these proteins in non-proliferating cells. Although Orc2-5 co-immunoprecipitate with each other under mild extraction conditions, a hole complex of the subunits is difficult to detect. When extracted under more stringent extraction conditions, several of the subunits eo-immunoprecipitate with stoichiometric amounts of other unidentified proteins but not with any of the known ORC subunits, The variation in abundance of individual ORC subunits (relative to each other) in several tissues, expression of some subunits in non-proliferating tissues, and the absence of a stoichiometric complex of all the subunits in cell extracts indicate that subunits of human ORC in somatic cells might have activities independent of their role as a six subunit complex involved in replication initiation. Finally, all ORC subunits remain consistently nuclear, and Orc2 is consistently phosphorylated through all stages of the cell cycle, whereas Orc1 is selectively phosphorylated in mitosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Mol Oncol,Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Mol Oncol,Dept Pathol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016; Quintana, David G/M-5628-2018	Dutta, Anindya/0000-0002-4319-0073; Quintana, David G./0000-0002-4909-6686	NCI NIH HHS [CA60499] Funding Source: Medline; NHLBI NIH HHS [T32 HL07627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOYNTON S, 1992, GENETICS, V131, P655; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Dorfman DM, 1997, MODERN PATHOL, V10, P859; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LOO S, 1995, MOL CELL BIOL, V16, P741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Rohrbough J, 1999, NEURON, V23, P55, DOI 10.1016/S0896-6273(00)80753-9; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421	37	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35233	35241		10.1074/jbc.M005765200	http://dx.doi.org/10.1074/jbc.M005765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954718	hybrid			2022-12-25	WOS:000165422800055
J	Jiang, LH; Rassendren, F; Surprenant, A; North, RA				Jiang, LH; Rassendren, F; Surprenant, A; North, RA			Identification of amino acid residues contributing to the ATP-binding site of a purinergic P2X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION SELECTIVITY; CHANNELS; PURINOCEPTORS; PROTEINS; SUBUNIT; MOTIFS; PORE	P2X receptor subunits have intracellular N and C termini, two membrane-spanning domains, and an extracellular loop of about 280 amino acids. We expressed the rat P2X(2), receptor in human embryonic kidney cells, and used alanine-scanning mutagenesis on 30 residues with polar side chains conserved among the seven rat P2X receptor subunits. This identified a region proximal to the first transmembrane domain which contained 2 lysine residues that were critical for the action of ATP (Lys(69) and Lys(71)). We substituted cysteines in this region (Asp(57) to Asp(71)) and found that for S65C and I67C ATP-evoked currents were inhibited by methanethiosulfonates. At I67C, the inhibition by negatively charged ethylsulfonate and pentylsulfonate derivatives could be overcome by increasing the ATP concentration, consistent with a reduced affinity of ATP binding. The inhibitory action of the methanethiosulfonates was prevented by pre-exposure to ATP, suggesting occlusion of the binding site. Finally, introduction of negative charges into the receptor by mutagenesis at this position (I67E and I67D) also gave receptors in which the ATP concentration-response curve was right-shifted. The results suggest that residues close to IIe(67) contribute to the ATP-binding site.	Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier, France	University of Sheffield; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	North, RA (corresponding author), Univ Sheffield, Inst Mol Physiol, Alfred Denny Bldg, Sheffield S10 2TN, S Yorkshire, England.		Jiang, Lin-Hua/D-2030-2010; Jiang, Lin-Hua/AAU-1078-2020; North, Richard/GQA-6156-2022; Rassendren, Francois/AAA-6190-2021	Jiang, Lin-Hua/0000-0001-6398-0411; Jiang, Lin-Hua/0000-0001-6398-0411; Rassendren, Francois/0000-0003-3320-2461				Anson LC, 1998, J NEUROSCI, V18, P581; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Egan TM, 1998, J NEUROSCI, V18, P2350; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Evans RJ, 1996, J PHYSIOL-LONDON, V497, P413, DOI 10.1113/jphysiol.1996.sp021777; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Hille B., 1992, IONIC CHANNELS EXCIT; IMOTO K, 1993, FEBS LETT, V325, P100, DOI 10.1016/0014-5793(93)81422-V; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Zimmermann H, 1999, PROG BRAIN RES, V120, P371	25	179	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34190	34196		10.1074/jbc.M005481200	http://dx.doi.org/10.1074/jbc.M005481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940304	hybrid			2022-12-25	WOS:000165095300028
J	Stone, SJ; Vance, JE				Stone, SJ; Vance, JE			Phosphatidylserine synthase-1 and-2 are localized to mitochondria-associated membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; RAT-LIVER; TRANSMEMBRANE PROTEINS; BIOSYNTHETIC-ENZYMES; GENETIC-EVIDENCE; CONTACT SITES; MOUSE-LIVER; CLONING	We report the subcellular localization of enzymes involved in phosphatidylserine biosynthesis in mammalian cells, Several lines of evidence suggest that phosphatidylserine synthase-l (PSS1) is highly enriched in mitochondria-associated membranes (MAM) and is largely excluded from the bulk of the endoplasmic reticulum (ER). Taking advantage of the substrate specificity of PSS1, we showed that (i) MAM contain choline exchange activity, whereas this activity is very low in the bulk of the ER, (ii) serine exchange activity is inhibited by choline to a much greater extent in MAM than in ER, and (iii) MAM use phosphatidylcholine and phosphatidylethanolamine as substrates for phosphatidylserine biosynthesis, whereas the ER utilizes only phosphatidylethanolamine. According to immunoblotting of proteins from both CHO-K1 cells and murine liver, PSS1 is localized to MAM, and in hepatoma cells stably expressing PSS1 this protein is highly enriched in MAM. Since the ER contains serine and ethanolamine exchange activities, we had predicted that PSS2 would account for the serine exchange activity in the ER. Unexpectedly, using immunoblotting experiments, we found that (i) PSS2 of CRO-K1 cells is present only in MAM and (ii) PSS2 is restricted to MAM of McArdle cells expressing recombinant PSS2. These data leave open the question of which enzyme imparts PSS activity to the ER and suggest that a third isoform of PSS might be located in the ER.	Univ Alberta, Dept Med, Heritage Med Res Ctr 332, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Dept Med, Heritage Med Res Ctr 332, Edmonton, AB T6G 2S2, Canada.							ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; CUI Z, 1993, J BIOL CHEM, V268, P16655; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 1999, BIOCHEM J, V342, P57, DOI 10.1042/0264-6021:3420057; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; VOELKER DR, 1986, J BIOL CHEM, V261, P1002	24	253	257	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34534	34540		10.1074/jbc.M002865200	http://dx.doi.org/10.1074/jbc.M002865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938271	hybrid			2022-12-25	WOS:000165095300073
J	Tait, SWG; Reid, EB; Greaves, DR; Wileman, TE; Powell, PP				Tait, SWG; Reid, EB; Greaves, DR; Wileman, TE; Powell, PP			Mechanism of inactivation of NF-kappa B by a viral homologue of I kappa B alpha - Signal-induced release of I kappa B alpha results in binding of the viral homologue to NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SWINE FEVER; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTIONAL ACTIVATION; INDUCED DEGRADATION; VIRUS; APOPTOSIS; COMPLEX; PHOSPHORYLATION; INHIBITION; PROTEINS	Activation of the nuclear factor kappaB plays a key role in viral pathogenesis, resulting in inflammation and modulation of the immune response. We have previously shown that A238L, an open reading frame from African swine fever virus (ASFV), encoding a protein with 40% homology to porcine I kappaB alpha exerts a potent anti-inflammatory effect in host, macrophages, where it down-regulates NF-kappaB-dependent gene transcription and proinflammatory cytokine production. This paper reveals the mechanism of suppression of NF-kappaB activity by A238Lp. A238Lp is synthesized throughout infection as two molecular mass forms of 28 and 32 kDa, and vaccinia-mediated expression of A238L demonstrated that both proteins are produced from a single gene. Significantly, the higher 32-kDa form of A238L, but not the 28-kDa form, interacts directly with RelA, the 65-kDa subunit of NF-kappaB, indicating that the binding is dependent on a posttranslational modification. Immunoprecipitation analysis shows the NF-kappaB p65-A238L p32 heterodimer is a separate complex from NF-kappaB-I kappaB alpha, and it resides in the cytoplasm. Moreover, we show that ASFV infection stimulates the NF kappaB signal transduction pathway, which results in the rapid degradation of endogenous I kappaB alpha, although both forms of A238Lp are resistant to stimulus-induced degradation. Using the proteasome inhibitor MG132, we show that when degradation of I kappaB alpha is inhibited, A238Lp binding to NF-kappaB p65 is reduced. The results suggest that the virus exploits its activation of the NF-kappaB pathway to enable its own I kappaB homologue to bind to NF-kappaB p65. Last, we show that synthesis of I kappaB alpha is increased during ASFV infection, indicating RelA-independent transcription of the I kappaB alpha gene.	Inst Anim Hlth, Dept Pathol & Immunol, BBSRC, Pirbright GU24 0NF, Surrey, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Oxford	Powell, PP (corresponding author), Inst Anim Hlth, Dept Immunol, Ash Rd, Pirbright GU24 0NF, Surrey, England.	penny.powell@bbsrc.ac.uk		Tait, Stephen/0000-0001-7697-132X; Greaves, David/0000-0003-2856-9410; Powell, Penny/0000-0002-5347-0490				Alcami A, 1998, SEMIN VIROL, V8, P419, DOI 10.1006/smvy.1997.0143; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Chacon MR, 1995, VIROLOGY, V214, P670, DOI 10.1006/viro.1995.0083; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krajcsi P, 1998, J GEN VIROL, V79, P1323, DOI 10.1099/0022-1317-79-6-1323; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Mebus C. A., 1987, African swine fever, P21; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Oura CAL, 1998, J GEN VIROL, V79, P1427, DOI 10.1099/0022-1317-79-6-1427; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Revilla Y, 1997, VIROLOGY, V228, P400, DOI 10.1006/viro.1996.8395; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rouiller I, 1998, J VIROL, V72, P2373, DOI 10.1128/JVI.72.3.2373-2387.1998; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wilkinson P. J., 1989, Virus infections of porcines., P17; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34656	34664		10.1074/jbc.M000320200	http://dx.doi.org/10.1074/jbc.M000320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934190	hybrid			2022-12-25	WOS:000165095300089
J	Angell, JE; Lindner, DJ; Shapiro, PS; Hofmann, ER; Kalvakolanu, DV				Angell, JE; Lindner, DJ; Shapiro, PS; Hofmann, ER; Kalvakolanu, DV			Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DNA FRAGMENTATION; GTP-BINDING; IFN-GAMMA; TNF-ALPHA; APOPTOSIS; PROTEIN; EXPRESSION; CANCER; PML	We show here that the combination of interferon-beta (TFN-beta) and all-trans-retinoic acid (RA) induces the death of tumor cells. To understand the molecular basis for synergistic growth-suppressive action and to identify the gene products that participate in this process, me have employed an antisense knock-out technique. This approach permits the isolation of cell death-associated genes based on their selective inactivation by over-expression of antisense cDNAs, Because the antisense mRNA inactivates gene expression of death-specific genes, transfected cells survive in the presence death inducers. Several Genes associated with Retinoid-IFN-induced Mortality (GRIM) were identified using this approach. Here me report, the isolation of a novel GRIM gene, GRIM-19. This 552-base pair cDNA encodes a 16-kDa protein. Antisense expression of GRIM-19 confers a strong resistance against IFN/RA-induced death by reducing the intracellular levels of GRIM-19 protein. Overexpression of GRIM-19 enhances cell death in response to IFN/RA. GRIM-IS is primarily a nuclear protein whose expression is induced by the IFN/RA combination. Together, our studies identify a novel cell death-regulatory molecule.	Univ Maryland, Sch Med, Greenbaum Canc Ctr, BRB, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenbaum Canc Ctr, BRB, 9th Floor,655 W Baltimore St, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NCI NIH HHS [CA78282, CA71401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boehm U, 1998, J IMMUNOL, V161, P6715; BORDEN EC, 1995, J NATL CANCER I, V87, P257, DOI 10.1093/jnci/87.4.257; Carlow DA, 1998, J IMMUNOL, V161, P2348; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; GILLY M, 1992, J IMMUNOL, V148, P3275; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOLDSTEIN D, 1986, CANCER RES, V46, P4315; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Hong Waun Ki, 1994, P597; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SEN GC, 1997, TRANSCRIPTIONAL REGU; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SORACE JM, 1995, J LEUKOCYTE BIOL, V58, P477, DOI 10.1002/jlb.58.4.477; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; STUDZINSKI GP, 1995, UNPUB PRACTICAL APPR; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wang ZG, 1998, SCIENCE, V279, P1547; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	50	173	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33416	33426		10.1074/jbc.M003929200	http://dx.doi.org/10.1074/jbc.M003929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924506	hybrid			2022-12-25	WOS:000090104600035
J	Asazuma, N; Wilde, JI; Berlanga, O; Leduc, M; Leo, A; Schweighoffer, E; Tybulewicz, V; Bon, C; Liu, SK; McGlade, CJ; Schraven, B; Watson, SP				Asazuma, N; Wilde, JI; Berlanga, O; Leduc, M; Leo, A; Schweighoffer, E; Tybulewicz, V; Bon, C; Liu, SK; McGlade, CJ; Schraven, B; Watson, SP			Interaction of linker for activation of T cells with multiple adapter proteins in platelets activated by the glycoprotein VI-selective ligand, convulxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; COLLAGEN-RELATED PEPTIDE; TYROSINE KINASE SYK; PHOSPHOLIPASE C-GAMMA-2; INTEGRIN ALPHA(2)BETA(1); MOLECULAR-CLONING; NUCLEAR FACTOR; SLP-76; LAT; PHOSPHORYLATION	The snake venom toxin convulxin activates platelets through the collagen receptor glycoprotein VI (GPVI)/Fc receptor gamma -chain (FcR gamma -chain) complex leading to tyrosine phosphorylation and activation of the tyrosine Syk and phospholipase C gamma2 (PLC gamma2), In the present study, we demonstrate that convulxin is a considerably more powerful agonist than collagen or the GPVI-selective collagen-related peptide (CRP), Confirmation that the response to convulxin is mediated solely via Syk was provided by studies on Syk-deficient platelets. The increase in phosphorylation of the FcR gamma -chain is associated with marked increases in tyrosine phosphorylation of downstream proteins including Syk, linker for activation of T cells (LAT), SLP-76, and PLC gamma2, The transmembrane adapter LAT coprecipitates with SLP-76 and PLC gamma2, as well as with a number of other adapter proteins, some of which have not been previously described in platelets, including Cbl, Grb2, Gads, and SKAP-HOM. Cads is constitutively associated with SLP-76 and is probably the protein bridging its association with LAT, There was no detectable association between Grb2 and SLP-76 in control or stimulated cells, suggesting that the interaction of LAT with Grb2 is present in a separate complex to that of LAT Gads SLP-76. These results show that the trimeric convulxin stimulates a much greater phosphorylation of the FcR gamma -chain and subsequent downstream responses relative to CRP and collagen, presumably because of its ability to cause a greater degree of cross-linking of GPVI, The adapter LAT appears to play a critical role in recruiting a number of other adapter proteins to the surface membrane in response to activation of GPVI, presumably at sites of glycolipid-enriched microdomains, enabling an organized signaling cascade that leads to platelet activation.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany; Inst Pasteur, Unite Venens, F-75724 Paris 15, France; Univ Toronto, Hosp Sick Children, Res Inst, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England	University of Oxford; Ruprecht Karls University Heidelberg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); MRC National Institute for Medical Research	Watson, SP (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	steve.watson@pharm.ox.ac.uk	Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Liu, Stanley/0000-0001-6851-0857				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; IVO MBF, 1997, TOXICON, V35, P1217; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lindholm CK, 1999, J BIOL CHEM, V274, P28050, DOI 10.1074/jbc.274.39.28050; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LUI J, 1998, P NATL ACAD SCI USA, V95, P8779; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Mountford JC, 1999, THROMB HAEMOSTASIS, V82, P1153; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	40	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33427	33434		10.1074/jbc.M001439200	http://dx.doi.org/10.1074/jbc.M001439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942756	hybrid			2022-12-25	WOS:000090104600036
J	Thangaraju, M; Kaufmann, SH; Couch, FJ				Thangaraju, M; Kaufmann, SH; Couch, FJ			BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACT IN-VIVO; TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; SUSCEPTIBILITY GENE; SIGNALING PATHWAYS; CARCINOMA CELLS; FAS; EXPRESSION; PROTEIN	The BRCA1 tumor suppressor gene has previously been implicated in induction of high levels of apoptosis in osteocarcinoma cell lines. Overexpression of BRCA1 was shown to induce an apoptotic signaling pathway involving the c-Jun N-terminal kinase (JNK), but the signaling steps upstream and downstream of JNK were not delineated. To better understand the role of BRCA1 in apoptosis, we examined the effect of wild-type and C-terminal-truncated dominant negative BRCA1 on breast and ovarian cancer cell lines subjected to a number of different pro-apoptotic stimuli, including growth factor withdrawal, substratum detachment, ionizing radiation, and treatment with anticancer agents. All of these treatments were found to induce substantial levels of apoptosis in the presence of wild-type BRCA1, whereas dominant negative BRCA1 truncation mutants diminished the apoptotic response. Subsequent mapping of the apoptotic pathway induced by growth factor withdrawal demonstrated that BRCA1 enhanced signaling through a pathway that sequentially involved H-Ras, MEKK4, JNK, Fas ligand/Fas interactions, and caspase-9 activation. In addition, the pathway functioned independently of the p53 tumor suppressor. These data suggest that BRCA1 is an important modulator of the response to cellular stress and that loss of this apoptotic potential due to BRCA1 mutations may contribute to tumor development.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Couch, FJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, 1001 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.			Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA78878, R01 CA069008, CA69008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008, R29CA078878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAN SJ, 1995, CANCER RES, V55, P1649; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rao VN, 1996, ONCOGENE, V12, P523; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	64	121	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33487	33496		10.1074/jbc.M005824200	http://dx.doi.org/10.1074/jbc.M005824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938285	hybrid			2022-12-25	WOS:000090104600044
J	Bruehl, RE; Bertozzi, CR; Rosen, SD				Bruehl, RE; Bertozzi, CR; Rosen, SD			Minimal sulfated carbohydrates for recognition by L-selectin and the MECA-79 antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; SIALYL-LEWIS-X; LEUKOCYTE ADHESION MOLECULE; LYMPHOCYTE HOMING RECEPTOR; MANNOSE-BINDING PROTEIN; MAJOR CAPPING GROUP; P-SELECTIN; CELL-ADHESION; LINKED OLIGOSACCHARIDES; VASCULAR ADDRESSIN	Sulfated forms of sialyl-Le(X) containing Gal-B-SQ, or GlcNAc-6-SO4 have been implicated as potential recognition determinants on high endothelial venule ligands for L-selectin, The optimal configuration of sulfate esters on the N-acetyllactosamine (Gal beta1-->4GlcNAc) core of sulfosialyl-le(X), however, remains unsettled. Using a panel of sulfated lactose (Gal beta1-->4Glc) neoglycolipids as substrates in direct binding assays, we found that 6',6-disulfolactose was the preferred structure for L-selectin, although significant binding to 6'- and 6-sulfolactose was observed as well. Binding was EDTA-sensitive and blocked by L-selectin-specific monoclonal antibodies. Surprisingly, 6',6-disulfolactose was poorly recognized by MECA-79, a carbohydrate- and sulfate-dependent monoclonal antibody that binds competitively to L-selectin ligands. Instead, MECA-79 bound preferentially to 6-sulfolactose. The difference in preferred substrates between L-selectin and MECA-79 may explain the variable activity of MECA-79 as an inhibitor of lymphocyte adhesion to high endothelial venules in lymphoid organs. Our results suggest that both Gal-6-SO4 and GlcNAc-6SO(4) may contribute to L-selectin recognition, either as components of sulfosialyl-le(X) capping groups or in internal structures. By contrast, only GlcNAc-6-SO4 appears to contribute to MECA-79 binding.	Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA.			Rosen, Steven/0000-0002-6245-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM059907] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM23547, R01GM59907-01, R01GM5741] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Berg EL, 1998, AM J PATHOL, V152, P469; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BERTOZZI CR, 1995, CHEM BIOL, V2, P703, DOI 10.1016/1074-5521(95)90096-9; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; DASGUPTA F, 1994, EXPERT OPIN INV DRUG, V3, P709; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1992, COLD SPRING HARB SYM, V57, P259, DOI 10.1101/SQB.1992.057.01.031; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Malhotra R, 1996, BIOCHEM J, V320, P589, DOI 10.1042/bj3200589; Malhotra R, 1996, BIOCHEM J, V314, P297, DOI 10.1042/bj3140297; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MANNORI G, 1995, CANCER RES, V55, P4425; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MICHIE SA, 1993, AM J PATHOL, V143, P1688; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; NELSON RM, 1993, BLOOD, V82, P3253; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; PICKFORD LB, 1989, J NEUROCYTOL, V18, P465, DOI 10.1007/BF01474543; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Shailubhai K, 1997, GLYCOBIOLOGY, V7, P305; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; Singer MS, 1996, J IMMUNOL METHODS, V196, P153, DOI 10.1016/0022-1759(96)00106-8; Spevak W, 1996, J ORG CHEM, V61, P3417, DOI 10.1021/jo9522522; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Yoshino K, 1997, J MED CHEM, V40, P455, DOI 10.1021/jm9605290; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	73	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32642	32648		10.1074/jbc.M001703200	http://dx.doi.org/10.1074/jbc.M001703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938267	hybrid			2022-12-25	WOS:000090003800038
J	Yamamoto, H; Ochiya, T; Takahama, Y; Ishii, Y; Osumi, N; Sakamoto, H; Terada, M				Yamamoto, H; Ochiya, T; Takahama, Y; Ishii, Y; Osumi, N; Sakamoto, H; Terada, M			Detection of spatial localization of Hst-1/Fgf-4 gene expression in brain and testis from adult mice	ONCOGENE			English	Article						Hst-1/Fgf-4; brain; testis; in situ; RT-PCR; adult	FACTOR-LIKE IMMUNOREACTIVITY; FIBROBLAST GROWTH-FACTORS; RAT SERTOLI CELLS; MESSENGER-RNA; SKELETAL-MUSCLE; NERVOUS-SYSTEM; FGF-4; RECEPTOR; MOUSE; HST-1	HST-1, a member of the fibroblast grow th factor (FGF) family (FGF-4), has been shown to be a signaling molecule whose expression is essential for embryonic development. However, HST-1/FGF-4 expression has not been detected or reported in adult tissues so far analysed. To investigate whether there is a possible role of HST-1/FGF-4 in adult stage, we have carried out a highly sensitive RT-PCR analysis of Hst-1/Fgf-4 gene expression in adult mice tissues. Results show Hst-1/Fgf-4 gene expression in the nervous system, intestines, and testis of normal adult mice. In situ hybridization technique was used to localize Hst-1/Fgf-4 gene expression in the cerebellum and testis from 10-week-old mice. Cell type-specific gene expression was detected: Purkinje cells in the cerebellum and Sertoli cells in testis, These findings suggest that the Hst-1/Fgf-4 gene also plays an important role in adult tissues, and may offer insights into the biological significance of HST-1/FGF-4 in cerebellar and testicular functions.	Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cell Biol, Kodaira, Tokyo 1878502, Japan	National Cancer Center - Japan; Nara Medical University; National Center for Neurology & Psychiatry - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji 5-chome, Tokyo 1040045, Japan.		Osumi, Noriko/T-2823-2019; Ochiya, Takahiro/AAH-7585-2019	Osumi, Noriko/0000-0003-0548-6452; 				BEAN AJ, 1991, P NATL ACAD SCI USA, V88, P10237, DOI 10.1073/pnas.88.22.10237; Cancilla B, 1998, BIOL REPROD, V58, P1138, DOI 10.1095/biolreprod58.5.1138; Collignon J, 1996, DEVELOPMENT, V122, P509; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; ELHUSSEINI AE, 1994, MOL CELL ENDOCRINOL, V104, P191, DOI 10.1016/0303-7207(94)90122-8; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; GOMEZPINILLA F, 1993, BRAIN RES, V606, P79, DOI 10.1016/0006-8993(93)91572-A; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; GUILLOU F, 1990, CELL TISSUE RES, V260, P395, DOI 10.1007/BF00318642; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HEIKINHEIMO O, 1995, MOL REPROD DEV, V42, P397, DOI 10.1002/mrd.1080420405; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; LEMAGUERESSEBATTISTONI B, 1994, ENDOCRINOLOGY, V135, P2404, DOI 10.1210/en.135.6.2404; MATSUDA S, 1992, NEUROSCIENCE, V50, P99, DOI 10.1016/0306-4522(92)90384-E; MATSUDA S, 1994, NEUROSCIENCE, V59, P651, DOI 10.1016/0306-4522(94)90184-8; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Nakamua S, 1999, GLIA, V28, P53, DOI 10.1002/(SICI)1098-1136(199910)28:1<53::AID-GLIA7>3.0.CO;2-V; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; ORTH JM, 1990, ANAT REC, V226, P320, DOI 10.1002/ar.1092260308; Ozawa K, 1996, MOL BRAIN RES, V41, P279, DOI 10.1016/0169-328X(96)00108-8; PARANKO J, 1986, DEV BIOL, V117, P35, DOI 10.1016/0012-1606(86)90345-3; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Shamim H, 1999, DEVELOPMENT, V126, P945; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; THEILLET C, 1989, ONCOGENE, V4, P915; Todo T, 1998, BRAIN RES, V783, P179, DOI 10.1016/S0006-8993(97)01340-1; TSUDA H, 1989, CANCER RES, V49, P3104; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	45	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3805	3810		10.1038/sj.onc.1203752	http://dx.doi.org/10.1038/sj.onc.1203752			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949936				2022-12-25	WOS:000088568400014
J	Trusolino, L; Cavassa, S; Angelini, P; Ando, M; Bertotti, A; Comoglio, PM; Boccaccio, C				Trusolino, L; Cavassa, S; Angelini, P; Ando, M; Bertotti, A; Comoglio, PM; Boccaccio, C			HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity	FASEB JOURNAL			English	Article						growth factors; tyrosine kinase receptors; MET; adhesion; integrin activation	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; SCATTER FACTOR; EPITHELIAL-CELLS; MET RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SOMATIC MUTATIONS; MET/HGF RECEPTOR; CARCINOMA-CELLS; METASTASIS	Hepatocyte growth factor/scatter factor (HGF/SF) controls a genetic program known as 'invasive growth', which involves as critical steps cell adhesion, migration, and trespassing of basement membranes. We show here that in MDA-MD-231 carcinoma cells, these steps are elicited by HGF/SF but not by epidermal growth factor (EGF). Neither factor substantially alters the production or activity of extracellular matrix proteases. HGF/SF, but not EGF, selectively promotes cell adhesion on laminins 1 and 5, fibronectin, and vitronectin through a PI3-K-dependent mechanism. Increased adhesion is followed by enhanced invasiveness through isolated matrix proteins as well as through reconstituted basement membranes. Inhibition assays using function-blocking antibodies show that this phenomenon is mediated by multiple integrins including beta 1, beta 3, beta 4, and beta 5. HGF/SF triggers clustering of all these integrins at actin-rich adhesive sites and lamellipodia but does not quantitatively modify their membrane expression. These data suggest that HGF/SF promotes cell adhesion and invasiveness by increasing the avidity of integrins for their specific ligands.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin	Boccaccio, C (corresponding author), Inst Canc Res, Div Mol Oncol, Str Prov 142, I-10060 Turin, Italy.		Boccaccio, Carla/AHE-7875-2022; Comoglio, Paolo/G-6323-2011; Trusolino, Livio/A-3896-2011	Boccaccio, Carla/0000-0003-2620-9083; Bertotti, Andrea/0000-0001-8196-7608; Trusolino, Livio/0000-0002-6379-3365; Comoglio, Paolo/0000-0002-7056-5328				ALBINI A, 1987, CANCER RES, V47, P3239; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FABBRO D, 1986, CANCER RES, V46, P2720; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; Longati P, 1996, CELL DEATH DIFFER, V3, P23; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Park WS, 1999, CANCER RES, V59, P307; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	59	106	107	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1629	1640		10.1096/fj.14.11.1629	http://dx.doi.org/10.1096/fj.14.11.1629			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928998				2022-12-25	WOS:000088627800018
J	Wang, TG; Gotoh, Y; Jennings, MH; Rhoads, CA; Aw, TY				Wang, TG; Gotoh, Y; Jennings, MH; Rhoads, CA; Aw, TY			Lipid hydroperoxide-induced apoptosis in human colonic CaCo-2 cells is associated with an early loss of cellular redox balance	FASEB JOURNAL			English	Article						GSH/GSSG ratio; intestinal cell death; redox shifts; peroxidized lipids; intestinal oxidative stress; diamide and GSH oxidation	PERFORMANCE LIQUID-CHROMATOGRAPHY; MITOCHONDRIAL-DNA; SMALL-INTESTINE; GLUTATHIONE; DEATH; RAT; PROLIFERATION; ACTIVATION; PEROXIDES; RADICALS	Apoptosis plays a critical role in maintaining homeostasis of the intestinal epithelium, Dietary oxidants like peroxidized lipids could perturb cellular redox status and disrupt mucosal turnover. The objective of this study,vas to delineate the role of lipid hydroperoxide (LOOH) -induced redox shifts in intestinal apoptosis using the human colonic CaCo-2 cell. We found that subtoxic concentrations of LOOM increased CaCo-2 cell apoptosis, This LOOM-induced apoptosis was associated with a significant decrease in the ratio of reduced glutathione-to-oxidized glutathione (GSH/GSSG), which preceded DNA fragmentation by 12 to 14 h, suggesting a temporal relationship between the two events. Oxidation of GSM with the thiol oxidant diamide caused significant decreases in cellular GSH and GSH/GSSG at 15 min that correlated with the activation of caspase 3 (60 min) and cleavage of PARP (120 min), confirming a temporal link between induction of cellular redox imbalance and initiation of apoptotic cell death. These kinetic studies further reveal that oxidant-mediated early redox change (within 1 h) was a primary inciting event of the apoptotic cascade, Once initiated, the recovery of redox balance did not prevent the progression of CaCo-2 cell apoptosis to its biological end point at 24 h. Collectively, the study shows that subtoxic levels of LOOM disrupt intestinal redox homeostasis, which contributes to apoptosis, These results provide insights into the mechanism of hydroperoxide-induced mucosal turnover that have important implications for understanding oxidant-mediated genesis of gut pathology.	Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Aw, TY (corresponding author), Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.				NIDDK NIH HHS [R01 DK044510, R01 DK044510-07, DK 44510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; ANDREWS JS, 1960, J NUTR, V70, P199, DOI 10.1093/jn/70.2.199; Aw T. Y., 1997, FASEB Journal, V11, pA219; AW TY, 1992, AM J PHYSIOL, V262, pG99, DOI 10.1152/ajpgi.1992.262.1.G99; BEACH D, 1988, CURRENT COMMUNICATIO; Bloom P D, 1996, Semin Gastrointest Dis, V7, P151; BULL AW, 1984, CANCER RES, V44, P4924; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CEPINSKAS G, 1994, GASTROENTEROLOGY, V107, P80, DOI 10.1016/0016-5085(94)90063-9; CONTGREAVE IA, 1998, BIOCHEM BIOPH RES CO, V242, P1; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; Flores S. C., 1997, Oxidative stress and the molecular biology of antioxidant defenses., P117; Garland JM, 1997, BRIT J HAEMATOL, V99, P756, DOI 10.1046/j.1365-2141.1997.4733277.x; Hara H, 1996, J NUTR, V126, P800, DOI 10.1093/jn/126.4.800; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KANEDA T, 1955, J BIOCHEM-TOKYO, V42, P561; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KIMURA T, 1984, J NUTR SCI VITAMINOL, V30, P125, DOI 10.3177/jnsv.30.125; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; MEUNIER V, 1995, CELL BIOL TOXICOL, V11, P187, DOI 10.1007/BF00756522; MILLER DL, 1977, GASTROENTEROLOGY, V73, P1326; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PARKS DA, 1983, SURGERY, V94, P415; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; Que FG, 1996, GASTROENTEROLOGY, V110, P1238, DOI 10.1053/gast.1996.v110.pm8613014; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Stefanis L, 1998, J NEUROSCI, V18, P9204; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WATSON AJM, 1995, ALIMENT PHARM THER, V9, P215; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	37	79	80	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1567	1576		10.1096/fj.14.11.1567	http://dx.doi.org/10.1096/fj.14.11.1567			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928991				2022-12-25	WOS:000088627800011
J	Brasaemle, DL; Rubin, B; Harten, IA; Gruia-Gray, J; Kimmel, AR; Londos, C				Brasaemle, DL; Rubin, B; Harten, IA; Gruia-Gray, J; Kimmel, AR; Londos, C			Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; CHOLESTERYL ESTER HYDROLASE; DEPENDENT PROTEIN-KINASE; ACYL-COA SYNTHETASE; LEYDIG TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; LIPID PARTICLES; ENDOPLASMIC-RETICULUM; MEMBRANE-FRACTION; MAMMALIAN-CELLS	The perilipins are the most abundant proteins at the surfaces of lipid droplets in adipocytes and are also found in steroidogenic cells. To investigate perilipin function, perilipin A, the predominant isoform, was ectopically expressed in fibroblastic 3T3-L1 pre-adipocytes that normally lack the perilipins. In control cells, fluorescent staining of neutral lipids with Bodipy 493/503 showed a few minute and widely dispersed lipid droplets, while in cells stably expressing perilipin A, the lipid droplets were more numerous and tightly clustered in one or two regions of the cytoplasm. Immunofluorescence microscopy revealed that the ectopic perilipin A localized to the surfaces of the tiny clustered lipid droplets; subcellular fractionation of the cells using sucrose gradients confirmed that the perilipin A localized exclusively to lipid droplets. Cells expressing perilipin A stored 6-30-fold more triacylglycerol than control cells due to reduced lipolysis of triacylglycerol stores. The lipolysis of stored triacylglycerol was 5 times slower in lipid-loaded cells expressing perilipin A than in lipid-loaded control cells, when triacylglycerol synthesis was blocked with 6 muM triacsin C. This stabilization of triacylglycerol was not due to the suppression of triacylglycerol lipase activity by the expression of perilipin A. We conclude that perilipin A increases the triacylglycerol content of cells by forming a barrier that reduces the access of soluble lipases to stored lipids, thus inhibiting triacylglycerol hydrolysis. These studies suggest that perilipin A plays a major role in the regulation of triacylglycerol storage and lipolysis in adipocytes.	Rutgers State Univ, Dept Nutrit Sci, New Brunswick, NJ 08901 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; NIDDK, Mol Mechanisms Dev Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Membrane Regulat Sect, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Drexel University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutrit Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.			Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503, ZIADK015505, Z01DK015505] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1987, FUNCTIONAL HISTOLOGY; Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BELFRAGE P, 1969, J LIPID RES, V10, P341; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; CUI Z, 1993, J BIOL CHEM, V268, P16655; DELALLERA M, 1979, BIOCHIM BIOPHYS ACTA, V574, P414, DOI 10.1016/0005-2760(79)90237-6; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; GOCZE PM, 1992, ENDOCRINOLOGY, V131, P2972, DOI 10.1210/en.131.6.2972; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gros J, 1999, J CELL SCI, V112, P3791; Hammersen F., 1985, HISTOLOGY COLOR ATLA; HARRISON EH, 1990, J LIPID RES, V31, P2187; HILAIRE N, 1995, J BIOL CHEM, V270, P27027, DOI 10.1074/jbc.270.45.27027; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLST LS, 1994, FEBS LETT, V355, P125, DOI 10.1016/0014-5793(94)01185-0; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Khoo J C, 1975, Methods Enzymol, V35, P181, DOI 10.1016/0076-6879(75)35154-9; KHOO JC, 1993, J LIPID RES, V34, P1969; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Londos C, 1996, INT J OBESITY, V20, pS97; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; MOREAU H, 1991, BIOCHEMISTRY-US, V30, P1037, DOI 10.1021/bi00218a022; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCOW RO, 1980, FED PROC, V39, P2610; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Spector A A, 1980, Prog Lipid Res, V19, P155; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Weiss L., 1983, HISTOLOGY CELL TISSU; YEAMAN SJ, 1994, ADV ENZYME REGUL, V34, P355, DOI 10.1016/0065-2571(94)90022-1	50	357	380	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38486	38493		10.1074/jbc.M007322200	http://dx.doi.org/10.1074/jbc.M007322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10948207	hybrid			2022-12-25	WOS:000165739800048
J	Bankhead, T; Segall, AM				Bankhead, T; Segall, AM			Characterization of a mutation of bacteriophage lambda integrase - Putative role in core binding and strand exchange for a conserved residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ATTACHMENT SITES; DNA; TOPOISOMERASE; PROTEIN; ATTL; FLEXIBILITY; MECHANISM; COMPLEXES; SYNAPSE	Site-specific recombination is involved in processes ranging from resolution of bacterial chromosome dimers to adeno-associated viral integration and is a versatile tool for mammalian genetics. The bacteriophage h-encoded site-specific recombinase integrase (Int) is one of the best studied site-specific recombinases and mediates recombination via four distinct pathways. We have characterized a mutant version of lambda Int, IntT236I; this mutant can perform the bent-L pathway only, whereas the corresponding IntT236A mutant can perform bent-L, excision and integration pathways. Experiments with both IntT236I and IntT236A show that the hydroxyl group of threonine is necessary for wild-type recombination. Substitution of the threonine by serine leads to nearly complete rescue of the mutant phenotypes. In addition, our data show that the IntT236I mutant is defective partially due to obstructive steric interactions. Comparisons of crystal structures reveal that the threonine at residue 236 may play an important role in stabilizing recombination intermediates through solvent-mediated protein-DNA interactions at the core-binding sites and that the hydroxyl group is important for effective cleavage and Holliday junction formation. Our data also indicate that Int contacts the core sites differently in intermediates assembled in excisive versus bent-L recombination.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Segall, AM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.		Bankhead, Troy/V-9033-2019	Bankhead, Troy/0000-0002-4336-0298; Segall, Anca/0000-0002-8454-5248	NIGMS NIH HHS [GM52487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Cassell G, 2000, J MOL BIOL, V299, P1193, DOI 10.1006/jmbi.2000.3828; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hallet B, 1999, MOL CELL, V4, P949, DOI 10.1016/S1097-2765(00)80224-5; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Jessop L, 2000, J BACTERIOL, V182, P1024, DOI 10.1128/JB.182.4.1024-1034.2000; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; NAGARAJA R, 1990, J BACTERIOL, V172, P6540, DOI 10.1128/jb.172.11.6540-6550.1990; Neidhardt F. C. E. A., 1996, ESCHERICHIA COLI SAL; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; SEGALL AM, 1993, EMBO J, V12, P4567, DOI 10.1002/j.1460-2075.1993.tb06145.x; Segall AM, 1998, J BIOL CHEM, V273, P24258, DOI 10.1074/jbc.273.37.24258; Segall AM, 1996, GENES CELLS, V1, P453, DOI 10.1046/j.1365-2443.1996.d01-254.x; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; Shuman S, 1998, MOL CELL, V1, P741, DOI 10.1016/S1097-2765(00)80073-8; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1998, J MOL BIOL, V279, P513, DOI 10.1006/jmbi.1998.1786; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	30	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36949	36956		10.1074/jbc.M004679200	http://dx.doi.org/10.1074/jbc.M004679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10938278	hybrid			2022-12-25	WOS:000165577700071
J	Chen, H; Hu, B; Allegretto, EA; Adams, JS				Chen, H; Hu, B; Allegretto, EA; Adams, JS			The vitamin D response element-binding protein - A novel dominant-negative regulator of vitamin D-directed transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WORLD PRIMATE CELLS; DNA-BINDING; SQUIRREL-MONKEY; HNRNP PROTEINS; MESSENGER-RNA; RECEPTOR; RESISTANCE; CLONING; ESTROGEN; GENE	Vitamin D resistance in certain primate genera is associated with the constitutive overexpression of a non-vitamin D receptor (VDR)-related, vitamin D response element-binding protein (VDRE-BP) and squelching of vitamin D-directed transactivation. We used DNA affinity chromatography to purify proteins associated with non-VDR-VDRE binding activity from vitamin D-resistant New World primate cells. In electrophoretic mobility shift assays, these proteins bound specifically to either single-strand or double-strand oligonucleotides harboring the VDRE, Amino acid sequencing of tryptic peptides from a 34-kDa (VDRE-BP1) and 38-kDa species (VDRE-BP-2) possessed sequence homology with human heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and hnRNPA2, respectively. cDNAs bearing the open reading frame for both VDRE-BPs were cloned and used to transfect wild-type, hormone-responsive primate cells, Transient and stable overexpression of the VDREBP2 cDNA, but not the VDRE-BP1 cDNA, in wild-type cells with a VDRE-luciferase reporter resulted in significant reduction in reporter activity. These data suggest that the hnRNPA2-related VDRE-BP2 is a dominant-negative regulator of vitamin D action.	Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Burns & Allen Res Inst, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pathol, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ligand Pharmaceuticals	Adams, JS (corresponding author), Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd,Rm B-131, Los Angeles, CA 90048 USA.		Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NIAMS NIH HHS [AR37399] Funding Source: Medline; NIDDK NIH HHS [DK07682] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037399] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JS, 1985, AM J PRIMATOL, V9, P219, DOI 10.1002/ajp.1350090307; ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; BIAMONTI G, 1989, NUCLEIC ACIDS RES, V16, P3751; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BRANDON DD, 1989, CANCER RES, V49, pS2203; BROWN GM, 1970, ENDOCRINOLOGY, V86, P519, DOI 10.1210/endo-86-3-519; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Chen H, 1997, J CLIN INVEST, V99, P669, DOI 10.1172/JCI119210; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; CHROUSOS GP, 1984, J CLIN ENDOCR METAB, V58, P516, DOI 10.1210/jcem-58-3-516; CHROUSOS GP, 1984, ENDOCRINOLOGY, V115, P25, DOI 10.1210/endo-115-1-25; CHROUSOS GP, 1982, P NATL ACAD SCI-BIOL, V79, P2036, DOI 10.1073/pnas.79.6.2036; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gacad MA, 1997, J BIOL CHEM, V272, P8433, DOI 10.1074/jbc.272.13.8433; GACAD MA, 1992, AM J PRIMATOL, V28, P263, DOI 10.1002/ajp.1350280404; GACAD MA, 1991, J CLIN INVEST, V87, P996, DOI 10.1172/JCI115108; GACAD MA, 1992, ENDOCRINOLOGY, V131, P2581, DOI 10.1210/en.131.6.2581; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; HOLICK MF, 1987, FASEB J, V46, P1876; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JIANPING YE, 1996, MOL CELL BIOL, V16, P4744; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAHIRI DK, 1986, NUCLEIC ACIDS RES, V14, P4077, DOI 10.1093/nar/14.10.4077; Lipsett M.B., 1985, Recent Progress in Hormone Research, V41, P199; Malloy PJ, 1999, AM J MED, V106, P355, DOI 10.1016/S0002-9343(98)00419-7; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; PIKE JW, 1987, J BIOL CHEM, V262, P1305; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244; SHARP ZD, 1990, BIOCHIM BIOPHYS ACTA, V1048, P306, DOI 10.1016/0167-4781(90)90073-B; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; TAKAHASHI N, 1985, BIOCHEM J, V227, P555, DOI 10.1042/bj2270555; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; ZERIVITZ K, 1989, GENE ANAL TECH, V6, P101, DOI 10.1016/0735-0651(89)90016-2; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	55	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35557	35564		10.1074/jbc.M007117200	http://dx.doi.org/10.1074/jbc.M007117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948206	hybrid			2022-12-25	WOS:000165422800095
J	Vincent, B; Paitel, E; Frobert, Y; Lehmann, S; Grassi, J; Checler, F				Vincent, B; Paitel, E; Frobert, Y; Lehmann, S; Grassi, J; Checler, F			Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-APP MATURATION; ALZHEIMERS-DISEASE; MONOCLONAL-ANTIBODIES; NORMAL BRAIN; PRP0/0 MICE; PEPTIDE; NEUROTOXICITY; SEQUENCE; RELEASE	Cellular prion protein (PrPc) undergoes a proteolytic attach at the 110/111 down arrow 112 peptide bond, whereas the PrP isoform (PrPres) that accumulates in the brain tissue in Creutzfeldt-Jakob disease reveals an alternate cleavage site at about residue 90. Interestingly, the normal processing of PrP occurs inside the 106-126 amino acid region thought to be responsible for the neurotoxicity of the pathogenic prions, whereas PrPres cleavage preserves this potentially toxic domain, Therefore, any molecular mechanisms leading to enhanced cleavage at the 110/111 down arrow 112 peptide bond Could be of potential interest, We set up TSM1 neurons and HEK293 stable transfectants overexpressing the wild-type or 3F4-tagged murine PrPc, respectively, Both mock-transfected and PrPc-expressing cell Lines produced an 11-12-kDa PrP fragment (referred to as N1), the immunological: characterization of which strongly suggests that it corresponds to the N-terminal PrPc fragment derived hom normal processing. We have established that the recovery of secreted N1 is increased by the protein kinase C agonists PDBu and PMA in a time- and dose-dependent manner in both cell lines. In contrast, secretion of N1 remains unaffected by the inactive PDBu analog alpha PDD and by the protein kinase A effecters dibutyryl cAMP and forskolin. Overall, our data indicate that the normal processing of PrPc is up-regulated by protein kinase C but not protein kinase A in human cells and murine neurons.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; CNRS, UPR 1142, Inst Genet Humaine, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; Lehmann, Sylvain/P-1301-2017	Checler, Frederic/0000-0003-2098-1750; Lehmann, Sylvain/0000-0001-6117-562X; Vincent, Bruno/0000-0003-3876-2118				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Krasemann S, 1996, J IMMUNOL METHODS, V199, P109, DOI 10.1016/S0022-1759(96)00165-2; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Kretzschmar HA, 1997, J NEURAL TRANSM-SUPP, P191; Marambaud P, 1999, BRIT J PHARMACOL, V126, P1186, DOI 10.1038/sj.bjp.0702406; Marambaud P, 1998, MOL MED, V4, P715, DOI 10.1007/BF03401766; Negro A, 2000, BIOCHEM BIOPH RES CO, V271, P337, DOI 10.1006/bbrc.2000.2628; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028	29	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35612	35616		10.1074/jbc.M004628200	http://dx.doi.org/10.1074/jbc.M004628200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952979	hybrid			2022-12-25	WOS:000165422800103
J	Cunningham, SA; Arrate, MP; Rodriguez, JM; Bjercke, RJ; Vanderslice, P; Morris, AP; Brock, TA				Cunningham, SA; Arrate, MP; Rodriguez, JM; Bjercke, RJ; Vanderslice, P; Morris, AP; Brock, TA			A novel protein with homology to the junctional adhesion molecule - Characterization of leukocyte interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; DOWN-SYNDROME; IMMUNOGLOBULIN SUPERFAMILY; PDZ DOMAINS; PECAM-1; LIGAND; ALPHA(V)BETA(3); ORGANIZATION; CD31/PECAM-1; RECOGNITION	We have cloned a novel cDNA belonging to the Ig superfamily that shows 44% similarity to the junctional adhesion molecule (JAM) and maps to chromosome 21q21.2. The open reading frame of JAM2 predicts a 34-kDa type I integral membrane protein that features two Ig-Like folds and three N-linked glycosylation sites in the extracellular domain. A single protein kinase C phosphorylation consensus site and a PDZ-binding motif are present in the short intracellular tail. Heterologous expression of JAM2 in Chinese hamster ovary cells defined a 48-kDa protein that localizes predominantly to the intercellular borders. Northern blot analysis showed that JAM2 is preferentially expressed in the heart. JAM2 homotypic interactions were demonstrated by the ability of JAM2-Fc to capture JAM2-expressing Chinese hamster ovary cells. We further showed that JAM2, but not JAM1, is capable of adhering to the HSB and HPB-ALL lymphocyte cell lines. Neutralizing mouse anti-JAM2 polyclonal antibodies provided evidence against homotypic interactions in this assay. Biotinylation of HSB cell membranes revealed a 43-kDa counter receptor that precipitates specifically with JAM2-Fc. These characteristics of JAM2 led us to hypothesize a role for this novel protein in adhesion events associated with cardiac inflammatory conditions.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System	Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, 7000 Fannin,Suite 1920, Houston, TX 77030 USA.	scunningham@tbc.com						ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Buckley CD, 1996, J CELL SCI, V109, P437; Cunningham SA, 1999, J BIOL CHEM, V274, P18421, DOI 10.1074/jbc.274.26.18421; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hartwell DW, 1999, THROMB HAEMOSTASIS, V82, P850, DOI 10.1055/s-0037-1615922; KOBAYASHI T, 1994, CLIN EXP IMMUNOL, V96, P110; KORENBERG JR, 1992, AM J HUM GENET, V50, P294; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V100, pS25; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Ruef J, 1999, THROMB HAEMOSTASIS, V82, P109, DOI 10.1055/s-0037-1614638; Sheibani N, 1999, DEV DYNAM, V214, P44, DOI 10.1002/(SICI)1097-0177(199901)214:1<44::AID-DVDY5>3.0.CO;2-L; SIMIONESCU M, 1976, J CELL BIOL, V68, P705, DOI 10.1083/jcb.68.3.705; SIMMONS DL, 1999, ADV MOL CEL, V28, P113; SINET PM, 1994, BIOMED PHARMACOTHER, V48, P247, DOI 10.1016/0753-3322(94)90140-6; Sobocka MB, 2000, BLOOD, V95, P2600; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takashima S, 1997, CURR OPIN NEUROL, V10, P148, DOI 10.1097/00019052-199704000-00013; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4	36	124	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34750	34756		10.1074/jbc.M002718200	http://dx.doi.org/10.1074/jbc.M002718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945976	hybrid			2022-12-25	WOS:000165095300100
J	Brewer, G				Brewer, G			Regulation of c-myc mRNA decay in vitro by a phorbol ester-inducible, ribosome-associated component in differentiating megakaryoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; MESSENGER-RNA TURNOVER; IN-VITRO; GENE-EXPRESSION; BINDING-PROTEIN; CODING REGION; POSTTRANSCRIPTIONAL REGULATION; STABILITY INVITRO; MAMMALIAN-CELLS; LEUKEMIA-CELLS	The R562 leukemia cell line is bipotential for erythroid and megakaryoblastic differentiation. The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) activates a genetic program of gene expression in these cells leading to their differentiation into megakaryoblasts, a platelet precursor. Thus, K562 cells offer a means to examine early changes in gene expression necessary for megakaryoblastic commitment and differentiation. An essential requirement for differentiation of many hematopoietic cell types is the down-regulation of c-myc expression, because its constitutive expression blocks differentiation. TPA-induced differentiation of K562 cells causes rapid down-regulation of c-myc expression, due in part to an mRNA decay rate that is 4-fold faster compared with dividing cells. A cell-free mRNA decay system reconstitutes TPA-induced destabilization of c-myc mRNA, but it requires at least two components for reconstitution. One component fractionates to the post-ribosomal supernatant from either untreated or treated cells. This component is sensitive to cycloheximide and micrococcal nuclease. The other component is polysome-associated and is induced or activated by TPA. Although in dividing cells c-myc mRNA decays via a sequential pathway involving removal of the poly(A) tract followed by degradation of the mRNA body, TPA activates a deadenylation-independent pathway. The cell-free mRNA decay system reconstitutes this alternate decay pathway as well.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Brewer, G (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NCI NIH HHS [CA52243] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BREWER G, 1992, PROMEGA NOTES, V40, P11; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DeMarchi S, 1997, NUMER FUNC ANAL OPT, V18, P65, DOI 10.1080/01630569708816747; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1985, P NATL ACAD SCI USA, V82, P5323, DOI 10.1073/pnas.82.16.5323; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MORELLO D, 1993, ONCOGENE, V8, P1921; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; ROSS J, 1986, MOL CELL BIOL, V6, P4362, DOI 10.1128/MCB.6.12.4362; ROSS J, 1995, MICROBIOL REV, V59, P16; RuizEchevarria MJ, 1996, TRENDS BIOCHEM SCI, V21, P433, DOI 10.1016/S0968-0004(96)10055-4; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Zelus BD, 1996, J VIROL, V70, P2411, DOI 10.1128/JVI.70.4.2411-2419.1996; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	52	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33336	33345		10.1074/jbc.M006145200	http://dx.doi.org/10.1074/jbc.M006145200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931849	hybrid			2022-12-25	WOS:000090104600025
J	Mikusova, K; Yagi, T; Stern, R; McNeil, MR; Besra, GS; Crick, DC; Brennan, PJ				Mikusova, K; Yagi, T; Stern, R; McNeil, MR; Besra, GS; Crick, DC; Brennan, PJ			Biosynthesis of the galactan component of the mycobacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOPYRANOSE MUTASE; ESCHERICHIA-COLI; TUBERCULOSIS; GALACTOFURANOSE; IDENTIFICATION; GENE; ARABINOGALACTAN; OLIGOSACCHARIDE; CHROMATOGRAPHY; TUNICAMYCIN	The structural core of the cell walls of Mycobacterium spp. consists of peptidoglycan bound by a Linker unit (-alpha -L-Rhap-(1-->3)-D-GlcNAc-P-) to a galactofuran, which in turn is attached to arabinofuran and mycolic acids. The sequence of reactions leading to the biogenesis of this complex starts with the formation of the Linker unit on a polyprenyl-P to produce polyprenyl-P-P-GlcNAc-Rha (Mikusova, K., Mikus, M., Besra, G. S., Hancock, I., and Brennan, P. J. (1996) J. Biol. Chem. 271, 7820-7828), me now establish that formation of the galactofuran takes place on this intermediate with UDP-Galf as the Galf donor presented in the form of UDP-Galp and UDP-Galp mutase (the glf gene product) and is catalyzed by galactofuranosyl transferases, one of which, the Mycobacterium tuberculosis H37Rv3808c gene product, has been identified. Evidence is also presented for the growth of the arabinofuran on this polyprenyl-P-P-linker unit-galactan intermediate catalyzed by unidentified arabinosyl transferases, with decaprenyl-P-Araf or B-P-ribosyl-PP as the Araf donor, The product of these steps, the lipid-linked-LU-galaetan-arabinan has been partially characterized in terms of its heterogeneity, size, and composition. Biosynthesis of the major components of mycobacterial cell walls is proving to be extremely complex. However, partial definition of arabinogalactan synthesis, the site of action of several major anti-tuberculosis drugs, facilitates the present day thrust for new drugs to counteract multiple drug-resistant tuberculosis.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Colorado State University	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	pbrennan@cvmbs.colostate.edu	Yagi, Tetsuya/J-3303-2012; McNeil, Michael/G-3325-2019; Mikusova, Katarina/I-3622-2014; Crick, Dean/H-8251-2017	Crick, Dean/0000-0001-9281-7058; Besra, Gurdyal/0000-0002-5605-0395; Mikusova, Katarina/0000-0002-0100-4877	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706, R37AI018357, R22AI018357, U19AI038087, R01AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38087, AI-33706, AI-18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; [Anonymous], CURRENT OPINION ANTI; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Breton C, 1998, J BIOCHEM, V123, P1000; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DAFFE M, 1990, J BIOL CHEM, V265, P6734; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; FOLCH J, 1957, J BIOL CHEM, V226, P497; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; Lee R, 1996, ANAL BIOCHEM, V242, P1, DOI 10.1006/abio.1996.0419; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; LIND T, 1993, J BIOL CHEM, V268, P20705; LUCAS JJ, 1975, J BIOL CHEM, V250, P1992; Ma YF, 1997, MICROBIOL-SGM, V143, P937, DOI 10.1099/00221287-143-3-937; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Nassau PM, 1996, J BACTERIOL, V178, P1047, DOI 10.1128/jb.178.4.1047-1052.1996; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; RUSH JS, 1993, J BIOL CHEM, V268, P13110; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V136, P217; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; Weston A, 1998, TUBERCLE LUNG DIS, V78, P123, DOI 10.1016/S0962-8479(98)80005-1; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9	34	105	110	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33890	33897		10.1074/jbc.M006875200	http://dx.doi.org/10.1074/jbc.M006875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934214	hybrid			2022-12-25	WOS:000090104600098
J	Miller, MA; McGowan, SE; Gantt, KR; Champion, M; Novick, SL; Andersen, KA; Bacchi, CJ; Yarlett, N; Britigan, BE; Wilson, ME				Miller, MA; McGowan, SE; Gantt, KR; Champion, M; Novick, SL; Andersen, KA; Bacchi, CJ; Yarlett, N; Britigan, BE; Wilson, ME			Inducible resistance to oxidant stress in the protozoan Leishmania chagasi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI-RHODESIENSE; HEAT-SHOCK PROTEIN-70; ALPHA-DIFLUOROMETHYLORNITHINE; TRYPANOTHIONE REDUCTASE; MAJOR PROMASTIGOTES; DONOVANI-CHAGASI; DEVELOPMENTAL MODIFICATION; SURFACE LIPOPHOSPHOGLYCAN; INTRACELLULAR SURVIVAL; LIPID-PEROXIDATION	Leishmania sp, protozoa are introduced into a mammalian skin by a sandfly vector, whereupon they en counter increased temperature and toxic oxidants generated during phagocytosis, We studied the effects of 37 degreesC "heat shock" or sublethal menadione, which generates superoxide and hydrogen peroxide, on Leishmania chagasi virulence. Both heat and menadione caused parasites to become more resistant to H2O2-mediated toxicity. Peroxide resistance was also induced as promastigotes developed in culture from logarithmic to their virulent stationary phase form. Peroxide resistance was not associated with an increase in reduced thiols (trypanothione and glutathione) or increased activity of ornithine decarboxylase, which is rate-limiting in trypanothione synthesis. Membrane lipophosphoglycan increased in size as parasites developed to stationary phase but not after environmental exposures. Instead, parasites underwent a heat shock response upon exposure to heat or sublethal menadione, detected by increased levels of HSP70. Transfection of promastigotes with L, chagasi HSP70 caused a heat inducible increase in resistance to peroxide, implying it is involved in antioxidant defense. We conclude that leishmania have redundant mechanisms for resisting toxic oxidants, Some are induced during developmental change and others are induced in response to environmental stress.	Univ Iowa, Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Immunol Program, Iowa City, IA 52242 USA; Pace Univ, Haskins Labs, New York, NY 10038 USA; Pace Univ, Dept Biol, New York, NY 10038 USA; Pace Univ, Dept Chem, New York, NY 10038 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa; University of Iowa; Pace University; Pace University; Pace University	Wilson, ME (corresponding author), Univ Iowa, Vet Affairs Med Ctr, Iowa City, IA 52242 USA.	mary-wilson@uiowa.edu	Yarlett, Nigel/B-3523-2009	Wilson, Mary/0000-0001-8680-7275; Champion, Matthew M./0000-0001-5927-5277; McGowan, Stephen/0000-0003-3084-1962	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034954, R21AI032135, R01AI032135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34954, AI32135] Funding Source: Medline; NIDDK NIH HHS [DK/AI52550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen KA, 1996, AM J TROP MED HYG, V54, P471, DOI 10.4269/ajtmh.1996.54.471; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BACCHI CJ, 1993, BIOCHEM PHARMACOL, V46, P471, DOI 10.1016/0006-2952(93)90524-Z; BACCHI CJ, 1981, J PROTOZOOL, V28, P20, DOI 10.1111/j.1550-7408.1981.tb02798.x; Beaucamp N, 1998, FEBS LETT, V441, P215, DOI 10.1016/S0014-5793(98)01553-1; BERENS RL, 1976, J PARASITOL, V62, P360, DOI 10.2307/3279142; BROWN T, 2000, CURRENT PROTOCOLS MO; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chong KY, 1998, J MOL CELL CARDIOL, V30, P599, DOI 10.1006/jmcc.1997.0623; COONS T, 1990, MOL BIOCHEM PARASIT, V39, P77, DOI 10.1016/0166-6851(90)90010-J; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DAVIS LS, 1991, CURRENT PROTOCOLS IM; DEANDRADE CR, 1992, J CLIN MICROBIOL, V30, P330, DOI 10.1128/JCM.30.2.330-335.1992; DESCOTEAUX A, 1991, J IMMUNOL, V146, P2747; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Freeman ML, 1999, FREE RADICAL BIO MED, V26, P737, DOI 10.1016/S0891-5849(98)00258-5; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HANSON S, 1992, J BIOL CHEM, V267, P2350; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; ISMAIL SO, 1994, INFECT IMMUN, V62, P657, DOI 10.1128/IAI.62.2.657-664.1994; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LATHIGRA RB, 1991, CURR TOP MICROBIOL, V167, P125; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Mukhopadhyay R, 1996, P NATL ACAD SCI USA, V93, P10383, DOI 10.1073/pnas.93.19.10383; MURRAY HW, 1981, J EXP MED, V153, P1690, DOI 10.1084/jem.153.6.1690; MURRAY HW, 1986, ANNU REV MED, V37, P61; MURRAY HW, 1985, J IMMUNOL, V134, P1619; PEARSON RD, 1982, J IMMUNOL, V129, P1282; PEARSON RD, 1983, J IMMUNOL, V131, P1994; PHILLIPS MA, 1987, MOL BIOCHEM PARASIT, V22, P9, DOI 10.1016/0166-6851(87)90064-8; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Pompella A, 1997, INT J VITAM NUTR RES, V67, P289; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Smith VP, 1998, EXP PARASITOL, V88, P103, DOI 10.1006/expr.1998.4209; Su CY, 1999, BIOCHEM BIOPH RES CO, V265, P279, DOI 10.1006/bbrc.1999.1649; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998; WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994; YARLETT N, 1991, EXP PARASITOL, V72, P205, DOI 10.1016/0014-4894(91)90138-M; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	65	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33883	33889		10.1074/jbc.M003671200	http://dx.doi.org/10.1074/jbc.M003671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931831	hybrid			2022-12-25	WOS:000090104600097
J	Siess, DC; Vedder, CT; Merksen, LS; Tanaka, T; Freed, AC; McCoy, SL; Heinrich, MC; Deffebach, ME; Bennett, RM; Hefeneider, SH				Siess, DC; Vedder, CT; Merksen, LS; Tanaka, T; Freed, AC; McCoy, SL; Heinrich, MC; Deffebach, ME; Bennett, RM; Hefeneider, SH			A human gene coding for a membrane-associated nucleic acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SYSTEMIC LUPUS-ERYTHEMATOSUS; CELL-SURFACE MOLECULES; ANTI-DNA ANTIBODIES; RING FINGER DOMAIN; ZINC-FINGER; PLASMID DNA; RECEPTOR; OLIGODEOXYNUCLEOTIDES; FAMILY	Studies to clone a cell-surface DNA-binding protein involved in the binding and internalization of extracellular DNA have led to the isolation of a gene for a membrane-associated nucleic acid-binding protein (MNAB). The full-length cDNA is 4.3 kilobases with an open reading frame of 3576 base pairs encoding a protein of similar to 130 kDa (GenBank accession numbers AF255303 and AF255304), The MNAB gene is on human chromosome 9 with wide expression in normal tissues and tumor cells. A C3HC4 RING finger and a CCCH zinc finger have been identified in the amino-terminal half of the protein. MNAB bound DNA (K-D similar to4 nM) and mutagenesis of a single conserved amino acid in the zinc finger reduced DNA binding by 50%. A potential transmembrane domain exists near the carboxyl terminus, Antibodies against the amino terminal half of the protein immunoprecipitated a protein of molecular mass similar to 150 kDa and reacted with cell surfaces. The MNAB protein is membrane-associated and primarily localized to the perinuclear space, probably to the endoplasmic reticulum or trans-Golgi network, Characterization of the MNAB protein as a cell-surface DNA-binding protein, critical in binding and internalization of extracellular DNA, awaits confirmation of its localization to cell surfaces.	Vet Affairs Med Ctr, Dept Immunol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Dept Pulmonol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Dept Hematol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Targeted Gene Delivery Inc, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University	Hefeneider, SH (corresponding author), Vet Affairs Med Ctr, Dept Immunol, R&D18,3710 SW US Vet Hosp Rd, Portland, OR 97201 USA.	Hefeneid@OHSU.edu	Heinrich, Michael/AAC-6745-2019	Bennett, Robert/0000-0002-7526-3425; Heinrich, Michael/0000-0003-3790-0478	NCI NIH HHS [R43 CA78140] Funding Source: Medline; NIAMS NIH HHS [R1AR3429B] Funding Source: Medline; NIDCD NIH HHS [R01 DC03573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA078140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Akhtar S, 1996, ANTISENSE NUCLEIC A, V6, P197, DOI 10.1089/oli.1.1996.6.197; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; Bennett R M, 1993, Antisense Res Dev, V3, P235; BENNETT RM, 1991, CLIN EXP IMMUNOL, V86, P374; BENNETT RM, 1992, CLIN EXP IMMUNOL, V90, P428; BENNETT RM, 1987, J EXP MED, V166, P850, DOI 10.1084/jem.166.4.850; BENNETT RM, 1986, LANCET, V1, P186; BENNETT RM, 1983, J CLIN INVEST, V71, P611, DOI 10.1172/JCI110807; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; EHRLICH M, 1976, BIOCHIM BIOPHYS ACTA, V454, P397, DOI 10.1016/0005-2787(76)90266-5; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; EMLEN W, 1988, AM J PATHOL, V133, P54; Feltquate DM, 1998, J CELL BIOCHEM, P304; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Freimark BD, 1998, J IMMUNOL, V160, P4580; GASPARRO FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P315, DOI 10.1111/j.1751-1097.1990.tb04187.x; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hawley P, 1996, ANTISENSE NUCLEIC A, V6, P185, DOI 10.1089/oli.1.1996.6.185; HEFENEIDER SH, 1992, CLIN IMMUNOL IMMUNOP, V63, P245, DOI 10.1016/0090-1229(92)90229-H; HEFENEIDER SH, 1992, LUPUS, V1, P167, DOI 10.1177/096120339200100308; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KABAKOV AE, 1991, CLIN EXP IMMUNOL, V83, P359; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Manzel L, 1999, ANTISENSE NUCLEIC A, V9, P459, DOI 10.1089/oli.1.1999.9.459; McCoy SL, 2000, J IMMUNOL METHODS, V241, P141, DOI 10.1016/S0022-1759(00)00205-2; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; RAZ E, 1993, EUR J IMMUNOL, V23, P383, DOI 10.1002/eji.1830230213; REDDY BA, 1991, NUCLEIC ACIDS RES, V19, P6330, DOI 10.1093/nar/19.22.6330; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; RIEBER M, 1989, BIOCHEM BIOPH RES CO, V159, P1441, DOI 10.1016/0006-291X(89)92271-7; Robinson HL, 1999, INT J MOL MED, V4, P549; RUSSELL JL, 1980, J IMMUNOL, V125, P2328; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHWARTZ DA, 1997, AM J RESP CRIT CARE, V144, pA501; Siemienski K, 1997, GENE, V195, P35, DOI 10.1016/S0378-1119(97)00147-9; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; Takagi T, 1998, BIOCHEM BIOPH RES CO, V245, P729, DOI 10.1006/bbrc.1998.8521; Tsan MF, 1997, P ASSOC AM PHYSICIAN, V109, P409; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; YAKUBOV L, 1991, NUCLEIC ACIDS RES S, V24, P311; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; Yew NS, 1999, HUM GENE THER, V10, P223, DOI 10.1089/10430349950019011; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	67	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33655	33662		10.1074/jbc.M004461200	http://dx.doi.org/10.1074/jbc.M004461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938276	hybrid			2022-12-25	WOS:000090104600067
J	Babenko, AP; Gonzalez, GC; Bryan, J				Babenko, AP; Gonzalez, GC; Bryan, J			Accelerated publication - Hetero-concatemeric K(IR)6.X-4/SUR1(4) channels display distinct conductivities but uniform ATP inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; SULFONYLUREA RECEPTOR; SUBUNIT STOICHIOMETRY; UNITARY CONDUCTANCE; ION CHANNELS; TERMINUS; KIR6.1; CELLS; SELECTIVITY; ACTIVATION	K(IR)6.1 and K(IR)6.2 are the pore-forming subunits of K-NDP, the nucleotide-diphosphate-activated K-ATP channels, and classical K-ATP channels, respectively. "Hybrid" channels, in which the structure is predetermined by concatemerizing K(IR)6.1 and K(IR)6.2, exhibit distinct conductivities specified by subunit number and position. Inclusion of one K(IR)6.2 is sufficient to open K(IR)6.X-X-X-X/SUR1(4) in the absence of nucleotide stimulation through sulfonylurea receptor-1 (SUR1). ATP inhibited the spontaneous bursting of hybrid channels with an IC50(ATP) similar to 10(-5) M, similar to that of K(IR)6.2(4)-containing channels. These findings and a transient increase in K-NDP channel activity following rapid wash-out of MgATP suggested that K(IR)6.1 is not ATP-insensitive as previously believed. We propose that SUR-dependent, inhibitory ATP-enhanced interactions of the cytoplasmic domains of both K(IR)6.1 and K(IR)6.2 stabilize a closed form of the M2 bundle in the gating apparatus.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.							Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; Berneche S, 2000, BIOPHYS J, V78, P2900, DOI 10.1016/S0006-3495(00)76831-7; Capener CE, 2000, BIOPHYS J, V78, P2929, DOI 10.1016/S0006-3495(00)76833-0; Crank J., 1975, MATH DIFFUSION; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FURUKAWA T, 1994, J PHYSIOL-LONDON, V479, P95, DOI 10.1113/jphysiol.1994.sp020280; Kondo C, 1998, RECEPTOR CHANNEL, V6, P129; Li L, 1999, BIOPHYS J, V76, pA77; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Repunte VP, 1999, EMBO J, V18, P3317, DOI 10.1093/emboj/18.12.3317; Seharaseyon J, 2000, J BIOL CHEM, V275, P17561, DOI 10.1074/jbc.275.23.17561; Silverman SK, 1998, BIOPHYS J, V75, P1330, DOI 10.1016/S0006-3495(98)74051-2; Takano M, 1998, J PHYSIOL-LONDON, V512, P395, DOI 10.1111/j.1469-7793.1998.395be.x; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zheng J, 1998, J GEN PHYSIOL, V112, P457, DOI 10.1085/jgp.112.4.457	31	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31563	31566		10.1074/jbc.C000553200	http://dx.doi.org/10.1074/jbc.C000553200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10956638	hybrid			2022-12-25	WOS:000089858900003
J	Argentini, M; Barboule, N; Wasylyk, B				Argentini, M; Barboule, N; Wasylyk, B			The contribution of the RING finger domain of MDM2 to cell cycle progression	ONCOGENE			English	Article						cell cycle regulation; RING finger domain; p53 degradation; ubiquitination	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; ONCOPROTEIN MDM2; TRANSCRIPTIONAL ACTIVATION; P53-ASSOCIATED PROTEIN; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; IN-VIVO	The MDM2 oncoprotein binds to p53 and abrogates p53-mediated G1 arrest and apoptosis, We show that MDM2 over-expression accelerates cell cycle progression of RPMI2650 cells by overcoming the negative effect of endogenous wild type p53 at the G1/S checkpoint. The interaction with p53 and transcription inhibition are necessary but not sufficient, The RING finger domain of MDM2 is also required for the positive effect of MDM2 on the cell cycle, Surprisingly, several point mutants in the zinc binding sites of the RING finger are fully competent for cell cycle stimulation even though they abolish MDM2-directed degradation of p53 and MDM2 E3-ligase activity. In contrast, alterations in and around the cryptic nucleolar localization sequence (KR motif) inhibit MDM2-mediated cell cycle progression as well as p53 degradation and MDM2 E3 ligase activity, We found that all the RING mutants decrease inhibition of both p53 dependent reporters and endogenous p21(CIP1/WAF1/SDI1). These results indicate that the RING finger of MDM2 has a role in the regulation of the cell cycle that is independent of p53 degradation and endogenous p21(CIP1/WAF1/SDI1) regulation.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu G, 1999, MOL CELL BIOL, V19, P724; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JUVEN T, 1993, ONCOGENE, V8, P3411; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	30	30	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3849	3857		10.1038/sj.onc.1203737	http://dx.doi.org/10.1038/sj.onc.1203737			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951578				2022-12-25	WOS:000088614300003
J	Grooteclaes, ML; Frisch, SM				Grooteclaes, ML; Frisch, SM			Evidence for a function of CtBP in epithelial gene regulation and anoikis	ONCOGENE			English	Article						E1a; CtBP; epithelial phenotype; anoikis; E-cadherin	E-CADHERIN EXPRESSION; ZINC-FINGER; CELLULAR PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; NEGATIVE MODULATION; TUMOR PROGRESSION; SUPPRESSOR GENE; BREAST-CANCER; E1A PROTEIN; REPRESSION	Previously, we reported that adenovirus E1a protein behaves as a tumor suppressor in human cells. It apparently functions by transcriptionally inducing an array of epithelial cell adhesion genes, while repressing other cell-type specific genes, thus producing an epithelial phenotype. Concomitantly, the cells become sensitive to anoikis (apoptosis of epithelial cells detached from extracellular matrix), potentially causing tumor suppression. E1a protein interacts with the nuclear acetylases p300, CBP and P/CAF, and also with the co-repressor protein CtBP. In this study, we have determined the role of these interactions in E1a's phenotypic effects on human tumor cells. The results indicate that E1a's interaction with CtBP activates at least three epithelial cell adhesion gene promoters. The E-cadherin repressor appeared to be the CtBP-interacting protein delta EF1/ZEB, which bound the ras-repressible E-boxes of the E-cadherin promoter. The E1a-CtBP interaction also contributed to anoikis-sensitization. E1a's interactions with the nuclear acetylases conferred epithelial morphologies but did not activate epithelial genes. These latter interactions did not sensitize tumor cells to anoikis but nevertheless conferred tumor suppression. These results implicate CtBP as an antagonist of the epithelial phenotype and anoikis, They also indicate a new but undefined role for nuclear acetylases in maintaining the transformed phenotype.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Frisch, SM (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; COOK JL, 1989, J VIROL, V63, P3408, DOI 10.1128/JVI.63.8.3408-3415.1989; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mymryk JS, 1996, ONCOGENE, V13, P1581; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Takagi T, 1998, DEVELOPMENT, V125, P21; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745	51	252	260	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3823	3828		10.1038/sj.onc.1203721	http://dx.doi.org/10.1038/sj.onc.1203721			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949939				2022-12-25	WOS:000088568400017
J	Mikulits, W; Pradet-Balade, B; Habermann, B; Beug, H; Garcia-Sanz, JA; Mullner, EW				Mikulits, W; Pradet-Balade, B; Habermann, B; Beug, H; Garcia-Sanz, JA; Mullner, EW			Isolation of translationally controlled mRNAs by differential screening	FASEB JOURNAL			English	Article						T cell activation; translational control; array hybridization	T-CELL ACTIVATION; TRANSCRIPTION FACTOR CHOP; P38 MAP KINASE; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; PROTEIN-SYNTHESIS; CYTOPLASMIC POLYADENYLATION; LYMPHOCYTE STIMULATION; TRANSFERRIN RECEPTOR; GENE-EXPRESSION	Translational regulation plays an important role in the control of gene expression, Changes in translation initiation rates are the most common translation-regulating mechanisms, resulting in alterations in mRNA loading of ribosomes. This differential mobilization of mRNAs onto polyribosomes tvas used in differential screening to directly identify cDNAs whose transcripts are translationally controlled during antigenic stimulation of primary human T lymphocytes. Ribosome-free and polysome-bound mRNAs were prepared from quiescent and activated T cells and used as templates to synthesize four cDNA pools, These in turn were used as probes to hybridize four identical replicas of a T cell library or, alternatively, four cDNA arrays. Translational activation was indicated by redistribution of the hybridization signals from the ribosome-free fraction in resting T cells to the polysome-associated fraction in activated T cells. Translational repression corresponded to the opposite hybridization pattern. Fifty-two cDNAs were identified as translationally controlled by screening 472 genes in a cDNA array; 12 additional ones were obtained by screening a cDNA library. Several of the transcripts corresponded to mRNAs previously reported to be translationally controlled, thus validating the method. For the majority, however, such regulation had not yet been described, Translational control was verified for representative examples by demonstrating the redistribution of the corresponding mRNAs on polysome gradients in response to T cell activation, Our strategy therefore provides an efficient tool to directly isolate or identify translationally controlled mRNAs in a variety of physiological situations, Moreover, differential screening using arrays enables simultaneous analysis of both transcriptional and translational regulation, further enhancing the power of gene expression analysis.	Univ Vienna, Bioctr, Inst Mol Biol, A-1030 Vienna, Austria; Univ Vienna, Bioctr, Inst Mol Pathol, A-1030 Vienna, Austria; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mullner, EW (corresponding author), Univ Vienna, Bioctr, Inst Mol Biol, Dr Bohr-Gasse, A-1030 Vienna, Austria.	jasanz@cnb.uam.es	Garcia-Sanz, Jose A/E-7684-2011; Mikulits, Wolfgang/AAH-4043-2021; Habermann, Bianca/N-4886-2016; Garcia-Sanz, Jose A./AAA-2956-2019	Garcia-Sanz, Jose A/0000-0002-1153-6025; Habermann, Bianca/0000-0002-2457-7504; Garcia-Sanz, Jose A./0000-0002-1153-6025; Mikulits, Wolfgang/0000-0003-4612-7106				AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BERGER SL, 1978, BIOCHIM BIOPHYS ACTA, V517, P84, DOI 10.1016/0005-2787(78)90036-9; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; DeSilva DR, 1997, CELL IMMUNOL, V180, P116, DOI 10.1006/cimm.1997.1182; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Espel E, 1996, EUR J IMMUNOL, V26, P2417, DOI 10.1002/eji.1830261023; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; EVMIN B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Friedman AD, 1996, CANCER RES, V56, P3250; Garcia-Sanz JA, 1998, FASEB J, V12, P299, DOI 10.1096/fasebj.12.3.299; GarciaSanz JA, 1996, J EXP MED, V184, P159, DOI 10.1084/jem.184.1.159; Gonalons E, 1998, J IMMUNOL, V161, P1837; GRABTREE GR, 1989, SCIENCE, V243, P355; Grant KR, 1997, IMMUNOLOGY, V90, P564, DOI 10.1046/j.1365-2567.1997.00196.x; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hershey JWB, 1996, TRANSLATIONAL CONTRO; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LAURENZI MA, 1994, EUR J BIOCHEM, V223, P733, DOI 10.1111/j.1432-1033.1994.tb19047.x; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOWENTHAL JW, 1985, J IMMUNOL, V134, P931; LUETHY JD, 1992, CANCER RES, V52, P5; MACDONALD HR, 1986, ANNU REV CELL BIOL, V2, P231; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; Meyuhas Oded, 1996, V30, P363; Mikulits W, 1999, BIOTECHNIQUES, V26, P846, DOI 10.2144/99265bm09; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; Mullner E. W., 1997, MANUAL IMMUNOLOGICAL, V1, P457; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, V1, P389; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P407; Neumann F, 1997, EXP CELL RES, V230, P252, DOI 10.1006/excr.1996.3417; NEUMANN F, 1995, NUCLEIC ACIDS RES, V23, P195, DOI 10.1093/nar/23.2.195; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; RICHTER JD, 1993, DEV GENET, V14, P407, DOI 10.1002/dvg.1020140602; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosenwald IB, 1995, CELL PROLIFERAT, V28, P631, DOI 10.1111/j.1365-2184.1995.tb00050.x; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SAFER D, 1997, BIOCHEMISTRY-US, V36, P2806; Salmon RA, 1997, J IMMUNOL, V159, P5309; SARGENT TD, 1987, METHOD ENZYMOL, V152, P423; SCHOBITZ B, 1990, J BIOL CHEM, V265, P15387; SEISER C, 1993, J BIOL CHEM, V268, P13074; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; VARESIO L, 1980, J IMMUNOL, V124, P2288; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEINBERG AD, 1990, J IMMUNOL, V144, P4712; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; Zhang J, 1999, J IMMUNOL, V162, P3819	86	90	95	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1641	1652		10.1096/fj.14.11.1641	http://dx.doi.org/10.1096/fj.14.11.1641			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928999				2022-12-25	WOS:000088627800019
J	Drum, CL; Yan, SZ; Sarac, R; Mabuchi, Y; Beckingham, K; Bohm, A; Grabarek, Z; Tang, WJ				Drum, CL; Yan, SZ; Sarac, R; Mabuchi, Y; Beckingham, K; Bohm, A; Grabarek, Z; Tang, WJ			An extended conformation of calmodulin induces interactions between the structural domains of adenylyl cyclase from Bacillus anthracis to promote catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATION-ENERGY TRANSFER; SITE-DIRECTED MUTAGENESIS; BORDETELLA-PERTUSSIS; POINT MUTATIONS; 2 SERIES; CRYSTAL-STRUCTURE; EUKARYOTIC CELLS; PEPTIDE COMPLEX; CALCIUM-BINDING; CA2+ BINDING	The edema factor exotoxin produced by Bacillus anthracis fs an adenylyl cyclase that is activated by calmodulin (CaM) at resting state calcium concentrations in infected cells. A C-terminal 60-kDa fragment corresponding to the catalytic domain of edema factor (EF3) was cloned, overexpressed in Escherichia coli, and purified. The N-terminal 43-kDa domain (EF3-N) of EF3, the sole domain of edema factor homologous to adenylyl cyclases from Bordetella pertussis and Pseudomonas aeruginosa, is highly resistant to protease digestion. The C-terminal 160-amino acid domain (EF3-C) of EF3 is sensitive to proteolysis in the absence of CaM. The addition of CaM protects EF3-C from being digested by proteases. EF3-N and EF3-C were expressed separately, and both fragments were required to reconstitute full CaM-sensitive enzyme activity. Fluorescence resonance energy transfer experiments using a double-labeled CaM molecule were performed and indicated that CaM adopts an extended conformation upon binding to EF3. This contrasts sharply with the compact conformation adopted by CaM upon binding myosin light chain kinase and CaM-dependent protein kinase type II. Mutations in each of the four calcium binding sites of CaM were examined for their effect on EF3 activation. Sites 3 and 4 were found critical for the activation, and neither the N- nor the C-terminal domain of CaM alone was capable of activating EF3. A genetic screen probing loss-of-function mutations of EF3 and site-directed mutations based on the:homology of the edema factor family revealed a conserved pair of aspartate residues and an arginine that: are important for catalysis. Similar residues are essential for di-metal-mediated catalysis in mammalian adenylyl cyclases and a family of DNA polymerases and nucleotidyltransferases. This suggests that edema factor may utilize a similar catalytic mechanism.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	University of Chicago; Boston Biomedical Research Institute; Rice University	Tang, WJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	wtang@uchicago.edu	Drum, Chester/A-6089-2015	Drum, Chester/0000-0001-6327-4584; Tang, Wei-Jen/0000-0002-8267-8995; Grabarek, Zenon/0000-0002-3636-5701	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R44DA005778, R43DA005778] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41637] Funding Source: Medline; NIDA NIH HHS [DA05778] Funding Source: Medline; NIGMS NIH HHS [GM53459] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; DOMENIGHINI M, 1995, HANDB NAT T, V8, P59; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Fairclough R H, 1978, Methods Enzymol, V48, P347; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; Hanna P, 1998, CURR TOP MICROBIOL, V225, P13; Huber PAJ, 1996, BIOCHEM J, V316, P413, DOI 10.1042/bj3160413; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LABRUYERE E, 1990, BIOCHEMISTRY-US, V29, P4922, DOI 10.1021/bi00472a024; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; MUNIER H, 1993, J BIOL CHEM, V268, P1695; MUNIER H, 1992, J BIOL CHEM, V267, P9816; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAO T, 1983, BIOCHEMISTRY-US, V22, P3059, DOI 10.1021/bi00282a006; TAO T, 1979, BIOCHEMISTRY-US, V18, P2759, DOI 10.1021/bi00580a011; TAO T, 1981, BIOCHEMISTRY-US, V20, P5051, DOI 10.1021/bi00520a035; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; XIA ZG, 1990, J BIOL CHEM, V265, P6517; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	47	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36334	36340		10.1074/jbc.M004778200	http://dx.doi.org/10.1074/jbc.M004778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10926933	hybrid			2022-12-25	WOS:000165382000097
J	Vadlamudi, RK; Adam, L; Wang, RA; Mandal, M; Nguyen, D; Sahin, A; Chernoff, J; Hung, MC; Kumar, R				Vadlamudi, RK; Adam, L; Wang, RA; Mandal, M; Nguyen, D; Sahin, A; Chernoff, J; Hung, MC; Kumar, R			Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS TRANSFORMATION; RAT-1 FIBROBLASTS; PAK KINASES; CDC42; RAC1; PAXILLIN; PHOSPHORYLATION; LOCALIZATION; INHIBITION	Stimulation of growth factor signaling has been implicated;in the development of invasive phenotypes and the activation of pal-activated kinase (Pak1) in human breast; cancer cells (Adam, L., Vadlamudi, R., Kondapaka, S. B., Chernoff, J., Mendelsohn, J,, and Kumar, Ri (1998) J. Biol. Chem. 273, 28238-28246; Adam, L., Vadlamudi, R,, Mandal, M,, Chernoff, J., and Kumar, R. (2000) J. Biol. Chem. 275, 12041-12050). To study the role of: Pak1 in the regulation of motility and growth of breast:epithelial cells, we developed human epithelial MCF-7 clones that overexpressed the kinase-active T423E Pak1 mutant under an inducible tetracycline promoter or that stably expressed the kinase-active H83L,H86L Pak1 mutant, which is deficient in small GTPase binding sites, The expression of both T423E and H83L,H86L Pak1 mutants in breast epithelial cells was accompanied:by increased cell motility without any apparent effect On the growth rate of cells, The T423E Pak1 mutant was primarily localized to filopodia, and the H83L,H86L Pak1 mutant was primarily localized to ruffles. Cells expressing T423E Pak1 exhibited a regulatable stimulation of mitogen-activated protein kinase and Jun N-terminal kinase activities. The expression of kinase-active Pak1 mutants significantly stimulated anchorage-independent growth of cells in soft agar in a preferential mitogen-activated protein kinase-sensitive manner.: In addition, regulatable expression of kinase-active Pak1-resulted in an abnormal organization of mitotic spindles characterized by appearance of multiple spindle orientations. We also provide evidence to suggest a close correlation between the status of Pak1 kinase activity and base-line invasiveness of human breast cancer cells and breast tumor grades. This study is the first demonstration of Pak1 regulation of anchorage-independent growth, potential Pak1 regulation of invasiveness, and abnormal organization of mitotic spindles of human epithelial breast cancer cells.	Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19100 USA	University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, 1515 Holcomble Blvd, Houston, TX 77030 USA.	rkumar@notes.mdacc.tmc.edu	Hung, Mien-Chie/ABD-5911-2021; Mandal, Mahitosh/GMW-6195-2022; Wang, Brian/HGA-9535-2022; Chernoff, Jonathan/I-7631-2014	Hung, Mien-Chie/0000-0003-4317-4740; Mandal, Mahitosh/0000-0003-3861-3323; Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [U01CA065746, P30CA016672, R01CA065746] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80066, CA65746, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, METHOD ENZYMOL, V238, P277; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QIU A, 1992, P NATL ACAD SCI USA, V92, P11781; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tang CK, 1996, CANCER RES, V56, P3350; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vadlamudi R, 1999, CANCER RES, V59, P2843; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	29	215	227	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36238	36244		10.1074/jbc.M002138200	http://dx.doi.org/10.1074/jbc.M002138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945974	hybrid			2022-12-25	WOS:000165382000084
J	Wang, HY; Doronin, S; Malbon, CC				Wang, HY; Doronin, S; Malbon, CC			Insulin activation of mitogen-activated protein kinases Erk1,2 is amplified via beta-adrenergic receptor expression and requires the integrity of the Tyr(350) of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; TYROSINE KINASE; LINKED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(2)-ADRENERGIC RECEPTORS; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CROSS-TALK; PHOSPHORYLATION; CELLS	Insulin activates a complex set of intracellular responses, including the activation of mitogen-activated protein kinases Erk1,2. The counterregulatory actions of insulin on:catecholamine action are well known and include phosphorylation of the beta (2)-adrenergic receptor on Tyr(350), Tyr(354), and Tyr(364) in the C-terminal cytoplasmic domain, as well as enhanced sequestration of the beta (2)-adrenergicreceptor. Both beta -adrenerse agonists and insulin provoke sequestration of beta (2)-adrenerac receptors in a synergistic manner. In the current work, crosstalk between insulin action and beta (2)-adrenergic receptors revealed that insulin activation of Erk1,2 was amplified via beta (2)-adrenerse receptors. In Chinese hamster ovary cells, expression of beta (2)-adrenerse receptors enhanced 5-10-fold the activation of Erk1,2 by insulin and prolonged the activation, the greatest enhancement occurring at 5 min post-insulin. The potentiation of insulin signaling on Erk1,2 was proportional to the level of expression of beta (2)-adrenerse receptor. The potentiation of insulin signaling requires the integrity of Tyr350 Of the beta (2)-adrenergic receptor, a residue phosphorylated in response to insulin. beta (2)-adrenergic receptors with a Y350F mutation failed to potentiate insulin activation of Erk1,2. Expression of the C-terminal domain of the beta (2)-adrenerse receptor (pro(323)-Leu(418)) in cells expressing the intact: beta (2)-adrenergic receptor acts as a dominant negative,:blocking the potentiation of insulin activation of Erk1,2 via the beta (2)-adrenergic receptor. Blockade of beta (2)-adrenergic receptor sequestration does not alter the ability of the beta (2)-adrenergic receptor to potentiate insulin action On Erk1,2, We propose a new paradigm in which a G-protein-linked receptor, such as the beta (2)-adrenergic receptor, itself acts as a receptor-based scaffold via its binding site for Src homology 2 domains, facilitating signaling of the mitogen-activated protein kinase pathway by insulin.	SUNY Stony Brook, Hlth Sci Ctr, Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA.	craig@pharm.som.sunysb.edu	malbon, craig/ABF-3604-2020					Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BOUVIER M, 1995, METHOD ENZYMOL, V250, P300; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; GEORGE ST, 1988, BIOCHEM BIOPH RES CO, V150, P665, DOI 10.1016/0006-291X(88)90443-3; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Karoor V, 1998, Adv Pharmacol, V42, P425; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Malbon CC, 1998, CELL SIGNAL, V10, P523, DOI 10.1016/S0898-6568(97)00194-0; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; ROCCA GJD, 1997, J BIOL CHEM, V272, P19125; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shih ML, 1998, CELL SIGNAL, V10, P575, DOI 10.1016/S0898-6568(97)00195-2; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36086	36093		10.1074/jbc.M004404200	http://dx.doi.org/10.1074/jbc.M004404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940302	hybrid			2022-12-25	WOS:000165382000064
J	Li, SH; Chow, LH; Pickering, JG				Li, SH; Chow, LH; Pickering, JG			Cell surface-bound collagenase-1 and focal substrate degradation stimulate the rear release of motile vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN ATHEROSCLEROTIC PLAQUE; I COLLAGEN; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; CATHEPSIN-K; MIGRATION; INTEGRIN; EXPRESSION	TO migrate in the vessel wall, smooth muscle cells (SMCs) must contend with abundant type I collagen. We investigated: the mechanisms used by human SMCs to efficiently migrate on type I collagen, following stimulation with fibroblast growth factor-2 (FGF-2). FGF-a-stimulated migration was inhibited by a hydroxamic acid inhibitor of matrix metalloproteinases and by a neutralizing anti-collagenase-1 antibody. Moreover, migration speed of SMCs plated on mutant collagenase-resistant type I collagen was not increased by FGF-S. Time-lapse video analysis of unstimulated SMCs migrating on collagen revealed discrete phases of leading edge membrane extension and rear retraction, the latter often after rupture of an elongated tail. FGF-2 stimulation yielded a more synchronous, gliding motion with a collagenase-1-mediated decrease in tail ripping. Surface labeling of SMCs with biotin followed by immunoprecipitation revealed that a proportion of active collagenase-1, expressed in response to FGF-2, was bound to the plasma membrane. Pericellular collagen substrate cleavage-was verified by immunostaining for neoepitopes generated by collagenase-1 action and was localized to discrete zones beneath the cell tail and the leading edge. These results identify a novel mechanism by which SMC migration on collagen is enhanced, whereby rear release from the substrate is orchestrated by the localized actions of membrane-bound collagenase-1.	Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Med Cardiol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Med Biophys, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Biochem, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Pickering, JG (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Med Cardiol, 339 Winderemere Rd, London, ON N6A 5A5, Canada.	gpickering@rri.on.ca	Pickering, J. Geoffrey/G-3341-2011	Pickering, J. Geoffrey/0000-0001-6474-3274				BARD JBL, 1975, J CELL BIOL, V67, P400, DOI 10.1083/jcb.67.2.400; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BILATO C, 1995, J CLIN INVEST, V96, P1905, DOI 10.1172/JCI118236; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; JACKSON CL, 1993, AM J PATHOL, V143, P1024; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Li SH, 1999, CIRC RES, V85, P338, DOI 10.1161/01.RES.85.4.338; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Messent AJ, 1998, J CELL SCI, V111, P1127; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nikkari ST, 1996, AM J PATHOL, V148, P777; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Palecek SP, 1996, J CELL SCI, V109, P941; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pickering JG, 1996, AM J CARDIOL, V78, P633, DOI 10.1016/S0002-9149(96)00384-0; Pickering JG, 1997, ARTERIOSCL THROM VAS, V17, P475, DOI 10.1161/01.ATV.17.3.475; PICKERING JG, 1993, J CLIN INVEST, V91, P724, DOI 10.1172/JCI116254; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; Strauss BH, 1996, CIRC RES, V79, P541, DOI 10.1161/01.RES.79.3.541; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	45	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35384	35392		10.1074/jbc.M005139200	http://dx.doi.org/10.1074/jbc.M005139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948197	hybrid			2022-12-25	WOS:000165422800074
J	Thorne, RF; Marshall, JF; Shafren, DR; Gibson, PG; Hart, IR; Burns, GF				Thorne, RF; Marshall, JF; Shafren, DR; Gibson, PG; Hart, IR; Burns, GF			The integrins alpha(3)beta(1) and alpha(6)beta(1) physically and functionally associate with CD36 in human melanoma cells - Requirement for the extracellular domain of CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLYCOPROTEIN-IV CD36; PROTEIN-TYROSINE KINASES; ROD OUTER SEGMENTS; SIGNAL-TRANSDUCTION; VITRONECTIN RECEPTOR; ADHESION MOLECULES; RESTING PLATELETS; MONOCLONAL-ANTIBODIES; MEMBRANE MICRODOMAINS; UROKINASE RECEPTOR	Lateral association between different transmembrane glycoproteins Can serve to modulate integrin function. Here we characterize a physical association between the integrins alpha (3)beta (1) and alpha (6)beta (1) and CD36 on the surface of melanoma cells and show that ectopic expression of CD36 by CD36-negative MV3 melanoma cells increases their haptotactic migration on extracellular matrix components. The association was demonstrated by co-immunoprecipitation, reimmunoprecipitation, and immunoblotting of surface-labeled cells lysed in Brij 96 detergent. Confocal microscopy illustrated the co-association of alpha (3) and CD36 in cell membrane projections and ruffles. A requirement for the extracellular domain of CD36 in this association was shown by co-immunoprecipitation experiments using surface-labeled MV3 melanoma or COS-7 cells:that had been transiently transfected with chimeric constructs between CD36 and intercellular adhesion molecule 1 (ICAM-1) or with a truncation mutant of CD36. CD36 is known to engage in signal transduction and to localize to membrane microdomains or rafts in several-cell types. Toward a mechanistic explanation for the functional effects of CD36 expression, we demonstrate that in fractionated Triton X-100 lysates of the MV3 cells stably transfected with CD36, CD36 was greatly enriched with the detergent-insoluble fractions that represent plasma membrane rafts. Significantly, when these fractionated lysates were reprobed for endogenous beta (1) integrin, it was found that a 4-fold increase in the proportion of the mature protein was contained within the detergent-insoluble fractions when extracted from the CD36-transfected cells compared with MV3 cells transfected with vector only. These results suggest that in melanoma cells CD36 expression may induce the sequestration:of certain integrins into membrane microdomains and promote cell migration.	Univ Newcastle, Fac Med & Hlth Sci, Canc Res Unit, Newcastle, NSW 2300, Australia; Univ Newcastle, Fac Med & Hlth Sci, Dept Microbiol, Newcastle, NSW 2308, Australia; John Hunter Hosp, Dept Resp Med, Newcastle, NSW 2305, Australia; St Thomas Hosp, Rayne Inst, Imperial Canc Res Fund, Richard Dimbleby Dept Canc Res, London SE1 7EH, England	University of Newcastle; University of Newcastle; John Hunter Hospital; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Thorne, RF (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Canc Res Unit, Level 5,David Maddison Clin Sci Bldg,Cnr King & W, Newcastle, NSW 2300, Australia.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X; Marshall, John/0000-0002-0494-2295				Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; AIKEN ML, 1990, BLOOD, V76, P2501; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Ardini E, 1997, J BIOL CHEM, V272, P2342; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGER G, 1993, BLOOD, V82, P3034; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CHAN KFJ, 1988, J BIOL CHEM, V263, P568; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; DANEN EHJ, 1993, INT J CANCER, V54, P315, DOI 10.1002/ijc.2910540225; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEDHAR S, 1995, CANCER METAST REV, V14, P165, DOI 10.1007/BF00690289; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DIAZRICART M, 1993, BLOOD, V82, P491; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dorahy DJ, 1998, BIOCHEM J, V333, P373, DOI 10.1042/bj3330373; Dorahy DJ, 1997, J BIOL CHEM, V272, P1323, DOI 10.1074/jbc.272.2.1323; Dorahy DJ, 1996, BIOCHEM BIOPH RES CO, V218, P575, DOI 10.1006/bbrc.1996.0102; Erwig LP, 1999, BLOOD, V93, P1406, DOI 10.1182/blood.V93.4.1406.404k10_1406_1412; Fadok VA, 1998, J IMMUNOL, V161, P6250; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; FRA AM, 1994, J BIOL CHEM, V269, P30745; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Ko YG, 1999, J IMMUNOL, V162, P7217; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kronenberg A, 1998, THROMB HAEMOSTASIS, V79, P1021; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LISANTI MP, 1994, J CELL BIOL, V126, P11; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Mannion BA, 1996, J IMMUNOL, V157, P2039; Mazurov A V, 1992, Platelets, V3, P181, DOI 10.3109/09537109209013181; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MonierGavelle F, 1997, J CELL BIOL, V137, P1663, DOI 10.1083/jcb.137.7.1663; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARCE SFA, 1994, BLOOD, V84, P384; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; Radford KJ, 1997, J IMMUNOL, V158, P3353; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUBENSTEIN E, 1994, EUROPEAN J IMMUNOLOG, V24, P3005; Ryeom SW, 1996, J CELL SCI, V109, P387; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SI ZY, 1994, PATHOLOGY, V26, P6, DOI 10.1080/00313029400169011; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; Stern M, 1996, AM J PATHOL, V149, P911; STOMSKI FC, 1992, EXP CELL RES, V198, P85, DOI 10.1016/0014-4827(92)90152-X; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; Thorne RF, 1997, BIOCHEM BIOPH RES CO, V240, P812, DOI 10.1006/bbrc.1997.7755; THORNE RF, 2000, THROMBOSIS VESSEL WA, P149; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Warren AP, 2000, IMMUNOLOGY, V99, P62, DOI 10.1046/j.1365-2567.2000.00953.x; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WONG JEL, 1989, BLOOD S1, V74, P638; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	107	78	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35264	35275		10.1074/jbc.M003969200	http://dx.doi.org/10.1074/jbc.M003969200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956645	hybrid			2022-12-25	WOS:000165422800059
J	Gaines, P; Geiger, JN; Knudsen, G; Seshasayee, D; Wojchowski, DM				Gaines, P; Geiger, JN; Knudsen, G; Seshasayee, D; Wojchowski, DM			GATA-1-and FOG-dependent activation of megakaryocytic alpha IIB gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; CREB-BINDING-PROTEIN; PLATELET GLYCOPROTEIN-IIB; ZINC-FINGER PROTEIN; DNA-BINDING; ERYTHROID-DIFFERENTIATION; 5'-FLANKING REGION; KRUPPEL FAMILY; MICE LACKING; GPIIB GENE	FOG is a multitype zinc finger protein that is essential for megakaryopoiesis, binds to the amino-terminal finger of GATA-1, and modulates the transcription of GATA-1 target genes. Presently investigated are effects of FOG and GATA-1 on the transcription of the megakaryocytic integrin gene, alpha IIb. In GATA-1-deficient FDCER cells (in the presence of endogenous FOG), ectopically expressed GATA-1 activated transcription 3-10-fold both from alpha IIb templates and the endogenous alpha IIb gene. The increased expression of FOG increased reporter construct transcription 30-fold overall. Unexpectedly, alpha IIb gene transcription also was stimulated efficiently upon the ectopic expression in of FOG per se. This occurred in the absence of any detectable expression of GATA-1 and was observed in multiple independent sublines for both the endogenous alpha IIb gene and transfected constructs yet proved to depend largely upon conserved GATA elements 457 and 55 base pairs upstream from the transcriptional start site, In 293 cells, FOG plus GATA-1 but not FOG alone only moderately stimulated alpha IIb transcription, and no direct interactions of FOG with the alpha IIb promoter were detectable Thus, FOG acts in concert with GATA-1 to stimulate alpha IIb expression but also can act via a GATA-1-independent route, which is proposed to involve additional hematopoietic-restricted cofactors (possibly GATA-2).	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 115 William L Henning Bldg, University Pk, PA 16802 USA.	dmw1@psu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009749, R01HL044491] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL09749, R01 HL44491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1994, BLOOD, V84, P3385; Cortes M, 1999, CURR OPIN IMMUNOL, V11, P167, DOI 10.1016/S0952-7915(99)80028-4; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DENARIER E, 1993, BIOCHEM BIOPH RES CO, V195, P1360, DOI 10.1006/bbrc.1993.2193; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Doubeikovski A, 1997, J BIOL CHEM, V272, P24300, DOI 10.1074/jbc.272.39.24300; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; Hung HL, 1999, MOL CELL BIOL, V19, P3496; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seshasayee D, 2000, J BIOL CHEM, V275, P22969, DOI 10.1074/jbc.M002931200; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZON LI, 1993, BLOOD, V81, P3234	58	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34114	34121		10.1074/jbc.M006017200	http://dx.doi.org/10.1074/jbc.M006017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926935	hybrid			2022-12-25	WOS:000165095300019
J	Hashimoto, Y; Niikura, T; Ito, Y; Nishimoto, I				Hashimoto, Y; Niikura, T; Ito, Y; Nishimoto, I			Multiple mechanisms underlie neurotoxicity by different types of Alzheimer's disease mutations of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; CEREBELLAR GRANULE NEURONS; APOPTOTIC CELL-DEATH; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; BETA-PROTEIN; MITOCHONDRIAL DYSFUNCTION; GENE-EXPRESSION; PC12 CELLS; IN-VITRO	We examined a neuronal cell system in which single-cell expression of either familial Alzheimer's disease (FAD) gene V642I-APP or K595N/M596L-APP (NL-APP) in an inducible plasmid was controlled without affecting transfection efficiency. This system revealed that (i) low expression of both mutants exerted toxicity sensitive to both Ac-DEVD-CHO (DEVD) and glutathione ethyl ester (GEE), whereas wild-type APP (wtAPP) only at higher expression levels caused GEE/DEVD-resistant death to lesser degrees; (ii) toxicity by the V642I mutation was entirely GEE/DEVD sensitive; and (iii) toxicity by higher expression of NL-APP was GEE/DEVD resistant. The GEE/DEVD-sensitive death was sensitive to pertussis toxin and was due to G(o)-interacting His(657)-Lys(676) domain. The GEE/DEVD-resistant death was due to C-terminal Met(677)-Asn(695). APP mutants lacking either domain unraveled elaborate intracellular cross-talk between these domains. EB18Q-APP, responsible for non-AD type of a human disease, only exerted GEE/DEVD-resistant death at higher expression. Therefore, (i) different FAD mutations in APP cause neuronal cell death through different cytoplasmic domains via different sets of mechanisms; (ii) expression levels of FAD genes are critical in activating specific death mechanisms; and (iii) toxicity by low expression of both mutants most likely reflects the pathogenetic mechanism of FAD.	Keio Univ, Sch Med, Dept Pharmacol, Tokyo 160, Japan; Keio Univ, Sch Med, Dept Neurosci, Tokyo 160, Japan	Keio University; Keio University	Niikura, T (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, Tokyo 160, Japan.		Hashimoto, Yuichi/N-1508-2015	Hashimoto, Yuichi/0000-0001-5863-3618				Brouillet E, 1999, J NEUROSCI, V19, P1717; Bursztajn S, 1998, J NEUROSCI, V18, P9790; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CARRACEDO J, 1995, EUR J IMMUNOL, V25, P3094, DOI 10.1002/eji.1830251116; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; FERNANDEZMADRID I, 1991, ANN NEUROL, V30, P730, DOI 10.1002/ana.410300516; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; HAAN J, 1992, CLIN NEUROL NEUROSUR, V94, P317, DOI 10.1016/0303-8467(92)90181-2; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lin SZ, 1997, BRAIN RES, V771, P184, DOI 10.1016/S0006-8993(97)00763-4; LOCKHART BP, 1994, J NEUROSCI RES, V39, P494, DOI 10.1002/jnr.490390416; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Luo JJ, 1999, J NEUROSCI RES, V55, P629, DOI 10.1002/(SICI)1097-4547(19990301)55:5<629::AID-JNR10>3.0.CO;2-Y; MAATSCHIEMAN MLC, 1994, ACTA NEUROPATHOL, V88, P371; MANELLI AM, 1995, BRAIN RES BULL, V38, P569, DOI 10.1016/0361-9230(95)02034-X; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Okamoto T, 1996, EMBO J, V15, P3769, DOI 10.1002/j.1460-2075.1996.tb00750.x; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; Pike CJ, 1997, J NEUROCHEM, V69, P1601; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; RAMIREZ R, 1994, J EXP MED, V180, P1147, DOI 10.1084/jem.180.3.1147; Sharma K, 1998, BIOCHEM BIOPH RES CO, V242, P134, DOI 10.1006/bbrc.1997.7933; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vinters HV, 1998, ACTA NEUROPATHOL, V95, P235, DOI 10.1007/s004010050793; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; YAN GM, 1995, J NEUROCHEM, V65, P2425; Yin DL, 1997, NEUROSCI RES, V29, P121, DOI 10.1016/S0168-0102(97)00080-1; Zhao B, 1997, J NEUROSCI RES, V47, P253	45	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34541	34551		10.1074/jbc.M005332200	http://dx.doi.org/10.1074/jbc.M005332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934205	hybrid			2022-12-25	WOS:000165095300074
J	Mayr, C; Richter, K; Lilie, H; Buchner, J				Mayr, C; Richter, K; Lilie, H; Buchner, J			Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROLYL CIS/TRANS ISOMERASES; STEROID-RECEPTOR COMPLEXES; CIS-TRANS-ISOMERIZATION; GLUCOCORTICOID RECEPTOR; CHAPERONE FUNCTION; CITRATE SYNTHASE; TRIGGER FACTOR; FK506-BINDING IMMUNOPHILIN; MOLECULAR CHAPERONES	Hsp90 is an abundant cytosolic molecular chaperone. It controls the folding of target proteins including steroid hormone receptors and kinases in complex with several partner proteins. Prominent members of this protein family are large peptidyl prolyl cis/trans isomerases (PPIases), which catalyze the cis/trans isomerization of prolyl peptide bonds in proteins and possess chaperone activity. In Saccharomyces cerevisiae, two closely related large Hsp90-associated PPIases, Cpr6 and Cpr7, exist. We show here that these homologous proteins bind with comparable affinity to Hsp90 but exhibit significant structural and functional differences. Cpr6 is more stable than Cpr7 against thermal denaturation and displays an up to 100-fold higher PPIase activity. In contrast, the chaperone activity of Cpr6 is much lower than that of Cpr7. Based on these results we suggest that the two immunophilins pet-form overlapping but not identical tasks in the Hsp90 chaperone cycle.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06114 Halle, Germany	Technical University of Munich; Martin Luther University Halle Wittenberg	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Buchner J, 1998, METHOD ENZYMOL, V290, P409, DOI 10.1016/S0076-6879(98)90034-9; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caamano CA, 1998, J BIOL CHEM, V273, P20473, DOI 10.1074/jbc.273.32.20473; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GALAT A, 1992, BIOCHEMISTRY-US, V31, P21607; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; HARDING MW, 1989, NATURE, V341, P761; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Janowski B, 1997, ANAL BIOCHEM, V252, P299, DOI 10.1006/abio.1997.2330; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KIM PS, 1982, AN REV BIOCH, V51, P247; KONFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Marsh JA, 1998, MOL CELL BIOL, V18, P7353, DOI 10.1128/MCB.18.12.7353; Mayr C, 2000, J CHROMATOGR B, V737, P295, DOI 10.1016/S0378-4347(99)00393-X; Mayr LM, 1996, BIOCHEMISTRY-US, V35, P5550, DOI 10.1021/bi953035y; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Schmid FX, 1996, BIOL CHEM, V377, P417; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; Scholz C, 1998, J MOL BIOL, V277, P723, DOI 10.1006/jmbi.1997.1604; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, SCI MED, V2, P38; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Warth R, 1997, BIOL CHEM, V378, P381, DOI 10.1515/bchm.1997.378.5.381; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; WIELAND O., 1964, BIOCHEM Z, V339, P501; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	59	89	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34140	34146		10.1074/jbc.M005251200	http://dx.doi.org/10.1074/jbc.M005251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942767	hybrid			2022-12-25	WOS:000165095300022
J	Valet, P; Grujic, D; Wade, J; Ito, M; Zingaretti, MC; Soloveva, V; Ross, SR; Graves, RA; Cinti, S; Lafontan, M; Lowell, BB				Valet, P; Grujic, D; Wade, J; Ito, M; Zingaretti, MC; Soloveva, V; Ross, SR; Graves, RA; Cinti, S; Lafontan, M; Lowell, BB			Expression of human alpha 2-adrenergic receptors in adipose tissue of beta 3-adrenergic receptor-deficient mice promotes diet-induced obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-CELL FUNCTION; REGIONAL VARIATION; ADIPOCYTES; LIPOLYSIS; WOMEN; WHITE; GENE; ADRENOCEPTORS; DISRUPTION; BINDING	Catecholamines play an important role in controlling white adipose tissue function and development. beta- and alpha2-adrenergic receptors (ARs) couple positively and negatively, respectively, to adenylyl cyclase and are coexpressed in human adipocytes. Previous studies have demonstrated increased adipocyte alpha2/beta -AR balance in obesity, and it has been proposed that increased alpha2-ARs in adipose tissue with or without decreased beta -ARs may contribute mechanistically to the development of increased fat mass. To critically test this hypothesis, adipocyte alpha2/beta -AR balance was genetically manipulated in mice. Human alpha 2A-ARs were transgenically expressed in the adipose tissue of mice that were either homozygous (-/-) or heterozygous (+/-) for a disrupted beta3-AR allele. Mice expressing alpha2-ARs in fat, in the absence of beta3-ARs (beta3-AR (-/-) background), developed high fat diet-induced obesity. Strikingly, this effect was due entirely to adipocyte hyperplasia and required the presence of alpha2-ARs, the absence of beta3-ARs, and a high fat diet. Of note, obese alpha2-transgenic, beta3 (-/-) mice failed to develop insulin resistance, which may reflect the fact that expanded fat mass was due to adipocyte hyperplasia and not adipocyte hypertrophy. In summary, we have demonstrated that increased alpha2/beta -AR balance in adipocytes promotes obesity by stimulating adipocyte hyperplasia. This study also demonstrates one way in which two genes (alpha2 and beta3-AR) and diet interact to influence fat mass.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Toulouse 3, CHR Rangueil, Inst Louis Bugnard, INSERM U317, F-31403 Toulouse, France; Univ Ancona, Inst Normal Human Morphol, I-60020 Ancona, Italy; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Chicago, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Marche Polytechnic University; University of Pennsylvania; University of Pennsylvania; University of Chicago	Lowell, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, RN-325,330 Brookline Ave, Boston, MA 02215 USA.		Valet, Philippe/N-7472-2017	Valet, Philippe/0000-0001-6520-7393; CINTI, Saverio/0000-0003-0362-5017				ARNER P, 1992, AM J CLIN NUTR, V55, P228; BERLAN M, 1985, EUR J CLIN INVEST, V15, P341, DOI 10.1111/j.1365-2362.1985.tb00282.x; Berman DM, 1998, METABOLISM, V47, P467, DOI 10.1016/S0026-0495(98)90061-0; BJORNTORP P, 1991, INT J OBESITY, V15, P67; CARPENE C, 1990, J LIPID RES, V31, P811; CARPENE C, 1976, J LIPID RES, P24; CASTAN I, 1994, AM J PHYSIOL, V266, pR1141, DOI 10.1152/ajpregu.1994.266.4.R1141; Cinti S, 1998, DIABETOLOGIA, V41, P171, DOI 10.1007/s001250050886; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; GALITZKY J, 1990, J PHARMACOL EXP THER, V252, P312; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HIRSCH J, 1968, J LIPID RES, V9, P110; JOHNSON PR, 1972, J LIPID RES, V13, P2; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LACASA D, 1986, J LIPID RES, V27, P368; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; MAURIEGE P, 1995, J LIPID RES, V36, P672; MAURIEGE P, 1995, AM J PHYSIOL-ENDOC M, V269, pE341, DOI 10.1152/ajpendo.1995.269.2.E341; MAURIEGE P, 1991, J LIPID RES, V32, P1625; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Revelli JP, 1997, J CLIN INVEST, V100, P1098, DOI 10.1172/JCI119620; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SALMON DMW, 1985, INT J OBESITY, V9, P443; SCHNEIDER BS, 1981, AM J PHYSIOL, V240, pE358, DOI 10.1152/ajpendo.1981.240.4.E358; SJOSTROM L, 1971, J LIPID RES, V12, P521; SOLOVEVA V, 1994, J CELL BIOCHEM, V18, P172; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Van Harmelen V, 1998, DIABETES, V47, P913, DOI 10.2337/diabetes.47.6.913	33	75	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34797	34802		10.1074/jbc.M005210200	http://dx.doi.org/10.1074/jbc.M005210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10948198	Green Published, hybrid			2022-12-25	WOS:000165095300106
J	Yamashita, T; Terakita, A; Shichida, Y				Yamashita, T; Terakita, A; Shichida, Y			Distinct roles of the second and third cytoplasmic loops of bovine rhodopsin in G protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED PHOSPHOLIPID-VESICLES; BETA-ADRENERGIC RECEPTORS; GTP-BINDING PROTEIN; CONNECTING HELIX-C; NEUROTRANSMITTER RECEPTORS; TRANSDUCIN ACTIVATION; ADENYLATE-CYCLASE; MECHANISMS; MUTANTS; SITES	In contrast to the extensive studies of light-induced conformational changes in rhodopsin, the cytoplasmic architecture of rhodopsin related to the G protein activation and the selective recognition of G protein subtype is still unclear. Here, we prepared a set of bovine rhodopsin mutants whose cytoplasmic loops were replaced by those of other ligand-binding receptors, and we compared their ability for G protein activation in order to obtain a cine to the roles of the second and third cytoplasmic loops of rhodopsin. The mutants bearing the third loop of four other G(o)-coupled receptors belonging to the rhodopsin superfamily showed significant G(o) activation, indicating that the third loop of rhodopsin possibly has a putative site(s) related to the interaction of G protein and that it is simply exchangeable with those of other G(o)-coupled receptors. The mutants bearing the second loop of other receptors, however, had little ability for G protein activation, suggesting that the second loop of rhodopsin contains a specific region essential for rhodopsin to be a G protein-activating form. Systematic chimeric and point mutational studies indicate that three amino acids (Glu(134), Val(138) and Cys(140)) in the N-terminal region of the second loop of rhodopsin are crucial for efficient G protein activation. These results suggest that the second and third cytoplasmic loops of bovine rhodopsin have distinct roles in G protein activation and subtype specificity.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Sci & Technol Corp, CREST, Kyoto 6068502, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Shichida, Y (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan.			Terakita, Akihisa/0000-0002-8379-8913				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ARCHARYA S, 1997, J BIOL CHEM, V272, P6519; ASANO T, 1984, J BIOL CHEM, V259, P9351; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRYXELL KJ, 1991, J MOL EVOL, V33, P367, DOI 10.1007/BF02102867; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; IWABE N, 1993, THESIS KYUSHU U JAPA; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1994, METHOD ENZYMOL, V237, P131; Kojima D, 1997, J BIOL CHEM, V272, P22979, DOI 10.1074/jbc.272.37.22979; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; Siebert F, 1995, ISRAEL J CHEM, V35, P309; Tachibanaki S, 1997, BIOCHEMISTRY-US, V36, P14173, DOI 10.1021/bi970932o; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Terakita A, 1998, FEBS LETT, V439, P110, DOI 10.1016/S0014-5793(98)01340-4; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WEISS ER, 1988, J BIOL CHEM, V263, P6150; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; YOSHIZAWA T, 1982, METHOD ENZYMOL, V81, P333; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	43	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34272	34279		10.1074/jbc.M002954200	http://dx.doi.org/10.1074/jbc.M002954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10930404	hybrid			2022-12-25	WOS:000165095300039
J	Enke, DK; Kaldis, P; Solomon, MJ				Enke, DK; Kaldis, P; Solomon, MJ			Kinetic analysis of the cyclin-dependent kinase-activating kinase (Cak1p) from budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; TYROSINE KINASE; CDC28 MUTATION; MAP KINASE; MECHANISM; BINDING; COMPLEMENTATION; COMPLEX	Cak1p, the Cyclin-dependent kinase-activating kinase from budding yeast, is an unusual protein kinase that lacks many of the highly conserved motifs observed among members of the protein kinase superfamily, Cak1p phosphorylates and activates Cdc28p, the major cyclin-dependent kinase (CDK) in yeast, and is thereby required for passage through the yeast cell cycle. In this paper, me explore the kinetics of CDK phosphorylation by Cak1p, and me examine the role of the catalytic step in the reaction mechanism. Cak1p proceeds by a sequential reaction mechanism, binding to both ATP and CDK2 with reasonable affinities, exhibiting Ii, values of 7.2 and 0.6 muM, respectively. Interestingly, these values are approximately the same as the K-M values, indicating that the binding of substrates is fast with respect to catalysis and that the most likely reaction mechanism is rapid equilibrium random. Cak1p is a slow enzyme, with a catalytic rate of only 4.3 min(-1). The absence of a burst phase indicates that product release is not rate-limiting. This result, and a solvent isotope effect, suggests that a catalytic step is rate-limiting.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Solomon, MJ (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.		Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NIGMS NIH HHS [GM47830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; KWIATKOWSKI AP, 1990, BIOCHEMISTRY-US, V29, P153, DOI 10.1021/bi00453a019; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Lew J, 1997, BIOCHEMISTRY-US, V36, P6717, DOI 10.1021/bi963164u; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; POSNER I, 1992, J BIOL CHEM, V267, P20638; Rudolph F B, 1979, Methods Enzymol, V63, P138; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; VIOLA RE, 1982, BIOCHEMISTRY-US, V21, P1295, DOI 10.1021/bi00535a029; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUAN CJ, 1990, J BIOL CHEM, V265, P16205	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33267	33271		10.1074/jbc.M004748200	http://dx.doi.org/10.1074/jbc.M004748200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934199	hybrid			2022-12-25	WOS:000090104600015
J	Guo, NH; Kawamoto, S				Guo, NH; Kawamoto, S			An intronic downstream enhancer promotes 3 ' splice site usage of a neural cell-specific exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRACT-BINDING-PROTEIN; VERTEBRATE NONMUSCLE MYOSIN; ALTERNATIVE EXON; SR-PROTEINS; DEVELOPMENTAL CONSEQUENCES; SEQUENCE ELEMENTS; PREMESSENGER RNA; FACTOR U2AF(35); CHAIN-B	The human nonmuscle myosin heavy chain B gene contains a 30-nucleotide alternative exon, N30, that is included in the mRNA from neural cells but is skipped in all other cells. We have previously identified an intronic distal downstream enhancer (IDDE) region that is required for neural cell-specific inclusion of N30, In this study, me investigated the mechanism by which the IDDE promotes N30 exon usage. In vitro splicing analysis using neural cell nuclear extracts and two-exon pre-mRNA substrates, which consist of the N30 exon and either the upstream (E5) or downstream (E6) exon, demonstrates that the IDDE activates upstream E5-N30 splicing by facilitating early prespliceosome complex formation. The IDDE has no effect on N30-E6 splicing where the IDDE resides. Inspection of splice site consensus sequences shows that a polypyrimidine (Py) tract preceding N30 is suboptimal for U2AF binding. Optimizing the Py tract completely relieves the requirement for the IDDE in E5-N30 splicing in vitro. In transfected cells, the wild-type minigene transcripts, which consist of three exons, E5, N30, and E6, undergo neural cell-specific and IDDE-dependent alternative splicing of N30, Optimizing the Py tract in minigenes also completely relieves the requirement for the IDDE in N30 inclusion. Furthermore, overexpression of the truncated U2AF65, which contains the arginine and serine dipeptide-rich domain and linker domain, but lacks the RNA binding domain, selectively inhibits the IDDE-mediated N30 inclusion in mRNA from the wild-type minigene in a dominant negative fashion. These results support the hypothesis that the IDDE facilitates the recognition of the 3' splice site preceding N30 by a network of protein-protein interactions implicated in the recruitment of U2AF to a suboptimal Py tract.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kawamoto, S (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004225] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashiya M, 1997, RNA, V3, P996; AUSUBEL FM, 1990, CURR PROTOCOLS MOL B, V2; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; Carlo T, 1996, RNA, V2, P342; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chou MY, 1999, MOL CELL BIOL, V19, P69; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; FU XD, 1995, RNA, V1, P663; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; MacDougall C, 1995, DEV BIOL, V172, P353, DOI 10.1006/dbio.1995.8047; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stamm S, 1999, MOL BRAIN RES, V64, P108, DOI 10.1016/S0169-328X(98)00313-1; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; Standiford DM, 1997, GENETICS, V147, P725; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wu Q, 1999, MOL CELL BIOL, V19, P3225; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	57	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33641	33649		10.1074/jbc.M005597200	http://dx.doi.org/10.1074/jbc.M005597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931847	hybrid			2022-12-25	WOS:000090104600065
J	Marshall, NF; Dahmus, ME				Marshall, NF; Dahmus, ME			C-terminal domain phosphatase sensitivity of RNA polymerase II in early elongation complexes on the HIV-1 and adenovirus 2 major late templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT RELEASE FACTOR; FACTOR P-TEFB; IN-VITRO; PROTEIN PHOSPHATASE; TAT TRANSACTIVATION; PURIFICATION; KINASE; ACTIVATION; INITIATION; DROSOPHILA	The fate of RNA polymerase II in early elongation complexes is under the control of factors that regulate and respond to the phosphorylation state of the C-terminal domain (CTD). Phosphorylation of the CTD protects early elongation complexes from negative transcription elongation factors such as NELF, DSIF, and factor 2. To understand the relationship between transcript elongation and the sensitivity of RNA polymerase IIO to dephosphorylation, elongation complexes at defined positions on the Ad2-ML and human immunodeficiency virus type 1 (HIV-1) templates were purified, and their sensitivity to CTD phosphatase was determined. Purified elongation complexes treated with 1% Sarkosyl and paused at U-14/G(16) on an HIV-1 template and at G(11) on the Ad2-ML template are equally sensitive to dephosphorylation by CTD phosphatase. Multiple elongation complexes paused at more promoter distal sites are more resistant to dephosphorylation than are U-14/G(16) and G(11) complexes. The HIV-1 long terminal repeat and adenovirus 2 major late promoter do not appear to differentially influence the CTD phosphatase sensitivity of stringently washed complexes. Subsequent elongation by 1% Sarkosyl-washed U-14/G(16) complexes is unaffected by prior CTD phosphatase treatment. This result is consistent with the hypothesis that CTD phosphatase requires the presence of specific elongation factors to propagate a negative effect on transcript elongation. The action of CTD phosphatase on elongation complexes is inhibited by HIV-1 Tat protein, This observation is consistent with the idea that Tat suppression of CTD phosphatase plays a role in transactivation.	Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Dahmus, ME (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA.	medahmus@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018952, R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18952, GM-33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Pessler F, 1998, J BIOL CHEM, V273, P5375, DOI 10.1074/jbc.273.9.5375; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	47	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32430	32437		10.1074/jbc.M005898200	http://dx.doi.org/10.1074/jbc.M005898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938286	hybrid			2022-12-25	WOS:000090003800009
J	Wu, XS; Edwards, HD; Sather, WA				Wu, XS; Edwards, HD; Sather, WA			Side chain orientation in the selectivity filter of a voltage-gated Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTEINE ACCESSIBILITY METHOD; RAT PHEOCHROMOCYTOMA CELLS; K+ CHANNEL; ION PERMEATION; POTASSIUM CHANNEL; CALCIUM CHANNELS; BINDING-SITES; SUBSTITUTED CYSTEINES; LINING RESIDUES	Four glutamate residues (EEEE locus) are essential for ion selectivity in voltage-gated Ca2+ channels, with ion-specific differences in binding to the locus providing the basis of selectivity. Whether side chain carboxylates or alternatively main chain carbonyls of these glutamates project into the pore to form the ion-binding locus has been uncertain. We have addressed this question by examining effects of sulfhydryl-modifying agents (methanethiosulfonates) on 20 cysteine-substituted mutant forms of an L-type Ca2+ channel. Sulfhydryl modifiers partially blocked whole oocyte Ba2+ currents carried by wild type channels, but this block was largely reversed with washout. In contrast, each of the four EEEE locus glutamate --> cysteine mutants (6 position) was persistently blocked by sulfhydryl modifiers, indicating covalent attachment of a modifying group to the side chain of the substituted cysteine. Cysteine substitutions at positions immediately adjacent to the EEEE locus glutamates (+/-1 positions) were also generally susceptible to sulfhydryl modification. Sulfhydryl modifiers had lesser effects on channels substituted one position further from the EEEE locus (+/-2 positions). These results indicate that the carboxylate-bearing side chains of the EEEE locus glutamates and their immediate neighbors project into the water-filled lumen of the pore to form an ion-binding locus. Thus the structure of the Ca2+ channel selectivity filter differs substantially from that of ancestral K+ channels.	Univ Colorado, Hlth Sci Ctr, Ctr Neurosci, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sather, WA (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Neurosci, Dept Pharmacol, Box B-138,4200 E 9th Ave, Denver, CO 80262 USA.			Sather, William/0000-0003-1482-8055	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035245] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35245] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; Chen XH, 1997, J BIOL CHEM, V272, P30002, DOI 10.1074/jbc.272.48.30002; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; CHIAMVIMONVAT N, 1995, CIRC RES, V76, P325, DOI 10.1161/01.RES.76.3.325; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Egan TM, 1998, J NEUROSCI, V18, P2350; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Fearon IM, 1999, J PHYSIOL-LONDON, V514, P629, DOI 10.1111/j.1469-7793.1999.629ad.x; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1992, IONIC CHANNELS EXCIT, P525; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Hu H, 1997, CIRC RES, V81, P742; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; Klockner U, 1996, J BIOL CHEM, V271, P22293; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHAUER CK, 1987, J AM CHEM SOC, V109, P3646, DOI 10.1021/ja00246a022; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; TANG SQ, 1993, J BIOL CHEM, V268, P13026; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; Williamson AV, 1999, BIOPHYS J, V77, P2575, DOI 10.1016/S0006-3495(99)77092-X; XU M, 1993, J BIOL CHEM, V268, P21505; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	56	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31778	31785		10.1074/jbc.M004829200	http://dx.doi.org/10.1074/jbc.M004829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934200	hybrid			2022-12-25	WOS:000089858900034
J	Conner, SD; Wessel, GM				Conner, SD; Wessel, GM			A rab3 homolog in sea urchin functions in cell division	FASEB JOURNAL			English	Article						GTP binding protein; vesicle dynamics; membrane fusion; cytokinesis	CORTICAL GRANULE EXOCYTOSIS; ENDOCYTIC MEMBRANE-FUSION; ENDOPLASMIC-RETICULUM; PROTEIN; GOLGI; GTPASE; EFFECTOR; RABPHILIN-3A; SUBFAMILY; TRANSPORT	Rabs are monomeric GTP binding proteins belonging to the ras superfamily that function throughout the secretory pathway. Members of the rab3 family function in the final steps of the secretory pathway, vesicle fusion with the plasma membrane, In contrast to mammalian systems with several rab3 isoforms (rab3A-D), a single family member homologue of rab3 is present in the rapidly dividing cleavage stage sea urchin embryo that localizes to numerous vesicles enriched at the cell cortex. We hypothesized that whereas the contents of these rab3-positive vesicles may contribute to the embryonic extracellular matrix, the membrane and its constituent proteins may be important for other aspects of cell division. We tested the function of rab3 in cell, division by the microinjection of either antibodies or competing effector domain peptides to interfere with its function, We found that perturbing rab3 function results in cessation of cell division, whereas cells injected with either heat-inactivated antibodies or control scrambled peptides develop as normal. Moreover, neither endocytosis nor general membrane topology are affected by rab3 perturbation, Thus, we conclude that rab3-associated vesicles and/or their contents are critical for cell division.	Brown Univ, Dept Biochem & Mol Cell Biol, Providence, RI 02912 USA	Brown University	Wessel, GM (corresponding author), Brown Univ, Dept Biochem & Mol Cell Biol, 69 Brown St, Providence, RI 02912 USA.	rhet@brown.edu						ANTONY C, 1992, J CELL SCI, V103, P785; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; Burgess RW, 1997, J CELL BIOL, V138, P861, DOI 10.1083/jcb.138.4.861; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Burton JL, 1997, J BIOL CHEM, V272, P3663, DOI 10.1074/jbc.272.6.3663; Conner S, 1998, DEV BIOL, V203, P334, DOI 10.1006/dbio.1998.9057; Conner S, 1997, MOL REPROD DEV, V48, P106; Conner SD, 1999, MOL BIOL CELL, V10, P2735, DOI 10.1091/mbc.10.8.2735; Deretic D, 1997, ELECTROPHORESIS, V18, P2537, DOI 10.1002/elps.1150181408; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FELDMANN G, 1995, BIOL CELL, V83, P121, DOI 10.1016/0248-4900(96)81299-8; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Harlow E., 1988, ANTIBODIES LAB MANUA; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Johannes L, 1996, J CELL SCI, V109, P2875; KIEHART DP, 1982, METHOD CELL BIOL, V25, P13, DOI 10.1016/S0091-679X(08)61418-1; LAIDLAW M, 1994, DEVELOPMENT, V120, P1325; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LEPAGE T, 1992, DEV BIOL, V150, P23, DOI 10.1016/0012-1606(92)90004-Z; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MCCLAY DR, 1986, EMBRYO DISSOCIATION, V27; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Rappaport R., 1996, CYTOKINESIS ANIMAL C; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Terasaki M, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P501; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Turner MD, 1997, J BIOL CHEM, V272, P13479, DOI 10.1074/jbc.272.21.13479; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHALLEY T, 1995, J CELL BIOL, V131, P1183, DOI 10.1083/jcb.131.5.1183	40	16	16	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1559	1566		10.1096/fj.14.11.1559	http://dx.doi.org/10.1096/fj.14.11.1559			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928990				2022-12-25	WOS:000088627800010
J	Hong, SH; Ondrey, FG; Avis, IM; Chen, Z; Loukinova, E; Cavanaugh, PF; Van Waes, C; Mulshine, JL				Hong, SH; Ondrey, FG; Avis, IM; Chen, Z; Loukinova, E; Cavanaugh, PF; Van Waes, C; Mulshine, JL			Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?	FASEB JOURNAL			English	Article						colon cancer; arachidonic acid; inflammatory disease; COX inhibitors	SQUAMOUS-CELL CARCINOMA; PROSTAGLANDIN E(2) PRODUCTION; HOST ENVIRONMENT PROMOTES; FACTOR-KAPPA-B; CANCER CELLS; ADULT PERIODONTITIS; TUMOR PROGRESSION; EPITHELIAL-CELLS; LUNG-CANCER; BONE LOSS	High levels of prostaglandins are produced in human oropharyngeal carcinoma (OPC), Five human OPC cell lines tested expressed both isoforms of cyclooxygenases (COX), The pan-COX inhibitor ketorolac continuously and significantly decreased PGE(2) production and IL-6 and IL-8 levels in all OPC cell lines tested, but did not affect IL-1 alpha, GM-CSF levels, or in vitro tumor cell growth. In contrast, ketorolac reduced OPC growth in vivo. The OPC cell lines used express the IL-6 receptor, and IL-6 stimulation of these cells causes transduction to occur via STAT3 pathway activation. Coincubation with OPC cell lines with conditioned medium from a TPA-exposed HL-60 cells stimulated growth proportional to the IL-6 levels measured in the conditioned medium. This growth effect was specifically inhibited by anti-IL-6 antibody. These results are consistent with cytokine products of inflammatory cells having paracrine growth effects on OPC, If chronic inflammation plays a role in promoting the development of OPC, this mechanism may also apply to other epithelial tumor systems modulated by COX activity.	NCI, Med Branch, Div Clin Sci, Cell & Canc Biol Dept,Intervent Sect, Bethesda, MD 20892 USA; NIH, Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA; Procter & Gamble Oral Hlth Care Technol Div, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Procter & Gamble	Mulshine, JL (corresponding author), NCI, Med Branch, Div Clin Sci, Cell & Canc Biol Dept,Intervent Sect, Bldg 10-12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.	mulshinej@bprb.nci.nih.gov	Cavanaugh, Paul/AAY-4856-2021	Cavanaugh, Paul/0000-0002-7874-7249	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000016, ZIADC000016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; Beck J D, 1998, Ann Periodontol, V3, P127, DOI 10.1902/annals.1998.3.1.127; Cavanaugh P. F. Jr., 1995, Inflammopharmacology, V3, P313, DOI 10.1007/BF02668026; Cavanaugh PF, 1998, J PERIODONTAL RES, V33, P75; Chan G, 1999, CANCER RES, V59, P991; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; DEMARINI DM, 1983, MUTAT RES, V114, P59, DOI 10.1016/0165-1110(83)90019-2; Dong G, 1999, CANCER RES, V59, P3495; Dongari-Bagtzoglou AI, 1998, J PERIODONTOL, V69, P899, DOI 10.1902/jop.1998.69.8.899; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Duffey DC, 1999, CANCER RES, V59, P3468; ELATTAR TMA, 1987, J ORAL PATHOL MED, V16, P483; EUGUI EM, 1993, ANN NY ACAD SCI, V685, P309, DOI 10.1111/j.1749-6632.1993.tb35881.x; Ghosh J, 1997, BIOCHEM BIOPH RES CO, V235, P418, DOI 10.1006/bbrc.1997.6799; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GU L, 1987, PHARMACEUT RES, V4, P255, DOI 10.1023/A:1016420514689; HEDGES S, 1995, ADV EXP MED BIOL, V371, P189; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hida T, 1998, CANCER RES, V58, P3761; Hong SH, 1999, CANCER RES, V59, P2223; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; JEFFCOAT MK, 1995, J PERIODONTOL, V66, P329, DOI 10.1902/jop.1995.66.5.329; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; Liu XH, 1996, CANCER RES, V56, P5125; Mitchell JA, 1998, INFLAMM RES, V47, pS88; NAKANISHI Y, 1988, EXP CELL BIOL, V56, P74; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; PANJE WR, 1981, ARCH OTOLARYNGOL, V107, P658; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Potter M, 1997, HEMATOL ONCOL CLIN N, V11, P323, DOI 10.1016/S0889-8588(05)70434-2; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Rainsford KD, 1997, J PHARM PHARMACOL, V49, P991, DOI 10.1111/j.2042-7158.1997.tb06030.x; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; ROOKS WH, 1985, DRUG EXP CLIN RES, V11, P479; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523; Slavkin HC, 1999, J AM DENT ASSOC, V130, P109, DOI 10.14219/jada.archive.1999.0038; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; Smith T., 1893, US DEP AGR BUREAU AN, V1; SNYDER DS, 1986, BLOOD, V67, P1675; SNYDERMAN CH, 1995, HEAD NECK-J SCI SPEC, V17, P108, DOI 10.1002/hed.2880170206; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Tucker ON, 1999, CANCER RES, V59, P987; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vane JR, 1998, INT J TISSUE REACT, V20, P3; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693	53	73	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1499	1507		10.1096/fj.99-0802com	http://dx.doi.org/10.1096/fj.99-0802com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928984				2022-12-25	WOS:000088627800004
J	Santucci-Darmanin, S; Walpita, D; Lespinasse, F; Desnuelle, C; Ashley, T; Paquis-Flucklinger, V				Santucci-Darmanin, S; Walpita, D; Lespinasse, F; Desnuelle, C; Ashley, T; Paquis-Flucklinger, V			MSH4 acts in conjunction with MLH1 during mammalian meiosis	FASEB JOURNAL			English	Article						MSH proteins; MLH proteins; protein interaction; synapsis; meiotic recombination; mismatch DNA repair	DNA MISMATCH REPAIR; CROSSING-OVER; MUTS HOMOLOG; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEXES; CHROMOSOME SYNAPSIS; MICE; GENE; PROTEIN; YEAST	MSH4 is a meiosis-specific MutS homolog, In yeast, it is required for reciprocal recombination and proper segregation of homologous chromosomes at meiosis I. MLH1 (MutL homolog 1) facilitates both mismatch repair and crossing over during meiosis in yeast. Germ-line mutations in the MLH1 human gene are responsible for hereditary nonpolyposis cancer, but the analysis of MLH1-deficient mice has revealed that MLH1 is also required for reciprocal recombination in mammals. Here we show that hMSH4 interacts with hMLH1. The two proteins are coimmunoprecipitated regardless of the presence of DNA or ATP, suggesting that the interaction does not require the binding of MSH4 to DNA, The domain of hMSH4 responsible for the interaction is in the amino-terminal part of the protein whereas the region that contains the ATP binding site and helix-turn-helix motif does not bind to hMLH1. Immunolocalization analysis shows that MSH4 is present at sites along the synaptonemal complex as soon as homologous chromosomes synapse. The number of MSH4 foci decreases gradually as pachynema progresses, During this transition, MLH1 foci begin to appear and colocalize with MSH4, These results suggest that MSH4 is first required for chromosome synapsis and that this MutS homologue is involved later with MLH1 in meiotic reciprocal recombination.	Fac Med, UMR CNRS UNSA 6549, Neurobiol Lab Cellulaire, F-06107 Nice 2, France; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	UDICE-French Research Universities; Universite Cote d'Azur; Yale University	Paquis-Flucklinger, V (corresponding author), Fac Med, UMR CNRS UNSA 6549, Neurobiol Lab Cellulaire, Ave Valombrose, F-06107 Nice 2, France.			LESPINASSE, francoise/0000-0001-7710-0649; Santucci-Darmanin, Sabine/0000-0001-5354-6988	NIGMS NIH HHS [GM55300, GM47797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R13GM047797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1999, GENETICS, V151, P1569; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Barlow AL, 1998, EUR J HUM GENET, V6, P350, DOI 10.1038/sj.ejhg.5200200; BROCKER TA, 1999, CANCER RES, V59, P816; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Moses MJ, 1980, ANIMAL MODELS HUMAN, P169; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Santucci-Darmanin S, 1999, MAMM GENOME, V10, P423, DOI 10.1007/s003359901016; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395	26	112	114	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1539	1547		10.1096/fj.14.11.1539	http://dx.doi.org/10.1096/fj.14.11.1539			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928988				2022-12-25	WOS:000088627800008
J	Tsygankova, OM; Kupperman, E; Wen, W; Meinkoth, JL				Tsygankova, OM; Kupperman, E; Wen, W; Meinkoth, JL			Cyclic AMP activates Ras	ONCOGENE			English	Article						cAMP; Ras; proliferation; thyroid cells	DEPENDENT PROTEIN-KINASE; NERVE GROWTH-FACTOR; THYROID EPITHELIAL-CELLS; DNA-SYNTHESIS; THYROGLOBULIN EXPRESSION; NEURITE OUTGROWTH; SIGNALING PATHWAY; CAMP; RAP1; INHIBITION	In addition to protein kinase A (PKA), cAMP regulates the activity of cAMP-gated channels and Rap1-specific guanine nucleotide exchange factors, We tested the hypothesis that the targets of cAMP might also include regulators of the Ras protooncogene. In rat thyroid cells, thyrotropin (TSH) stimulates proliferation through a cAMP-mediated pathway that requires Ras activity, interference with Res impairs DNA synthesis stimulated by TSH as well as cAMP elevating agents and analogs, demonstrating that the requirement for Ras lies down-stream of cAMP. Although cAMP stimulates proliferation, microinjection of the purified PKA catalytic subunit failed to do so, suggesting that factors in addition to PKA are required for cAMP-stimulated cell cycle progression. When added to thyroid cells expressing human Ha-Ras, TSH rapidly and markedly increased the proportion of GTP-bound Ras. Ras activity was increased within 1 min of TSH addition, maximal at 5-15 min, and declined to basal levels 30-60 min after hormone treatment. Cyclic AMP elevating agents elicited similar effects on Ras, indicating that TSH activates Ras through a cAMP-mediated pathway. Although cAMP-mediated, Ras activation by TSH and cAMP was independent of PKA activity. Moreover, cAMP-stimulated Ras activation was not impaired by tyrosine kinase inhibitors. These results indicate that cAMP activates targets in addition to PKA in thyroid cells, and that these targets may include regulators of Ras. The ability of cAMP elevating agents to activate Ras in addition to PKA may explain the inability of the PKA catalytic subunit to stimulate DNA synthesis in thyroid cells.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK02494, DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696, K02DK002494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FAGIN JA, 1994, ANNU REV MED, V45, P45; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KOLCH W, 1996, ONCOGENE, V6, P1304; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MUCA C, 1994, ONCOGENE, V9, P3647; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SUAREZ HG, 1991, ONCOGENE, V6, P677; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	45	56	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3609	3615		10.1038/sj.onc.1203680	http://dx.doi.org/10.1038/sj.onc.1203680			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951566				2022-12-25	WOS:000088568300006
J	Minambres, B; Olivera, ER; Jensen, RA; Luengo, JM				Minambres, B; Olivera, ER; Jensen, RA; Luengo, JM			A new class of glutamate dehydrogenases (GDH) - Biochemical and genetic characterization of the first member, the AMP-requiring NAD-specific GDH of Streptomyces clavuligerus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM; CEPHALOSPORIN PRODUCTION; PYROCOCCUS-FURIOSUS; SEQUENCE ALIGNMENT; CLAVULANIC ACID; PURIFICATION; ENZYME; EVOLUTION; SYNTHETASE; MECHANISM	A new class of glutamate dehydrogenase (GDH) is reported. The GDH of Streptomyces clavuligerus was purified to homogeneity and characterized. It has a native molecular mass of 1,100 kDa and exists as an alpha (6) oligomeric structure composed of 183-kDa subunits, GDH, which requires AMP as an essential activator, shows a maximal rate of catalysis in 100 mM phosphate buffer, pH 7.0, at 30 degreesC. Under these conditions, GDH displayed hyperbolic behavior toward ammonia (K-m, 33 mM) and sigmoidal responses to changes in alpha -ketoglutarate (S-0.5 1.3 mM; n(H) 1.50) and NADH (S-0.5 20 mum; n(H) 1.52) concentrations. Aspartate and asparagine were found to be allosteric activators. This enzyme is inhibited by an excess of NADH or NH4+, by some tricarboxylic acid cycle intermediates and by ATP, This GDH seems to be a catabolic enzyme as indicated by the following: (i) it is NAD-specific; (ii) it shows a high value of K-m for ammonia; and (iii) when S. clavuligerus was cultured in minimal medium containing glutamate as the sole source of carbon and nitrogen, a 5-fold increase in specific activity of GDH was detected compared with cultures provided with glycerol and ammonia. GDH has 1,651 amino acids, and it is encoded by a DNA fragment of 4,953 base pairs (gdh gene), It shows strong sequence similarity to proteins encoded by unidentified open reading frames present in the genomes of species belonging to the genera Mycobacterium, Rickettsia, Pseudomonas, Vibrio, Shewanella, and Caulobacter, suggesting that it has a broad distribution. The GDH of S, clavuligerus is the first member of a class of GDHs included in a subfamily of GDHs (large GDHs) whose catalytic requirements and evolutionary implications are described and discussed.	Univ Leon, Dept Bioquim & Biol Mol, Fac Vet, E-24007 Leon, Spain; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	Universidad de Leon; United States Department of Energy (DOE); Los Alamos National Laboratory	Luengo, JM (corresponding author), Univ Leon, Dept Bioquim & Biol Mol, Fac Vet, E-24007 Leon, Spain.	dbbjlr@unileon.es	Olivera, Elias Rodriguez/Q-1166-2019; OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Luengo, Jose M./E-1935-2016	Olivera, Elias Rodriguez/0000-0003-2315-8524; OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Luengo, Jose M./0000-0002-4984-6256; Minambres Rodriguez, Baltasar/0000-0003-4590-4911				ABEYSINGHE LSB, 1993, THESIS U SHEFFIELD W; AHARONOWITZ Y, 1977, ARCH MICROBIOL, V115, P169, DOI 10.1007/BF00406371; AHARONOWITZ Y, 1979, CAN J MICROBIOL, V25, P61, DOI 10.1139/m79-010; AHARONOWITZ Y, 1978, ANTIMICROB AGENTS CH, V14, P159, DOI 10.1128/AAC.14.2.159; AHARONOWITZ Y, 1980, ARCH MICROBIOL, V125, P137, DOI 10.1007/BF00403210; ANDERSON BM, 1993, ARCH BIOCHEM BIOPHYS, V300, P483, DOI 10.1006/abbi.1993.1065; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; BAKER PJ, 1995, STRUCTURE, V3, P693, DOI 10.1016/S0969-2126(01)00204-0; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BARKER HA, 1981, ANNU REV BIOCHEM, V50, P23, DOI 10.1146/annurev.bi.50.070181.000323; BASCARAN V, 1989, J GEN MICROBIOL, V135, P2465; Beaman Blaine L., 1995, P379; BENACHENHOULAHFA N, 1993, J MOL EVOL, V36, P335; BONETE MJ, 1990, BIOCHIM BIOPHYS ACTA, V1041, P305, DOI 10.1016/0167-4838(90)90289-R; Bonete MJ, 1996, BBA-GEN SUBJECTS, V1289, P14, DOI 10.1016/0304-4165(95)00134-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANA AF, 1986, ARCH MICROBIOL, V146, P46, DOI 10.1007/BF00690157; BRANA AF, 1986, J GEN MICROBIOL, V132, P1305; BRITTON KL, 1993, J MOL BIOL, V234, P938, DOI 10.1006/jmbi.1993.1647; Britton KL, 1998, J BIOL CHEM, V273, P9023, DOI 10.1074/jbc.273.15.9023; BRITTON KL, 1992, EUR J BIOCHEM, V209, P851, DOI 10.1111/j.1432-1033.1992.tb17357.x; Britton KL, 1999, J MOL BIOL, V293, P1121, DOI 10.1006/jmbi.1999.3205; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; CONSALVI V, 1991, EUR J BIOCHEM, V196, P459, DOI 10.1111/j.1432-1033.1991.tb15837.x; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEMAIN AL, 1982, TRENDS ANTIBIOTIC RE, P233; Di Fraia R, 2000, EUR J BIOCHEM, V267, P121, DOI 10.1046/j.1432-1327.2000.00972.x; DUNCAN PA, 1992, APPL ENVIRON MICROB, V58, P4032, DOI 10.1128/AEM.58.12.4032-4037.1992; FAHIEN LA, 1970, METHODS ENZYMOLOGY B, V17, P839; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; HALL T, 2000, BIOEDIT BIOL SEQUENC; HAMMER BA, 1988, ARCH MICROBIOL, V150, P460, DOI 10.1007/BF00422287; HIGGENS CE, 1974, J ANTIBIOT, V27, P298, DOI 10.7164/antibiotics.27.298; HUDSON RC, 1993, COMP BIOCHEM PHYS B, V106, P767, DOI 10.1016/0305-0491(93)90031-Y; JAHNS T, 1993, J GEN MICROBIOL, V139, P775, DOI 10.1099/00221287-139-4-775; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KREMECKOVA H, 1992, J GEN MICROBIOL, V138, P1587, DOI 10.1099/00221287-138-8-1587; LASCU I, 1977, BIOCHIM BIOPHYS ACTA, V482, P251, DOI 10.1016/0005-2744(77)90239-X; LEJOHN HB, 1967, BIOCHEM BIOPH RES CO, V28, P96, DOI 10.1016/0006-291X(67)90412-3; MAULIK P, 1986, EUR J BIOCHEM, V155, P595, DOI 10.1111/j.1432-1033.1986.tb09530.x; MEERS JL, 1970, J GEN MICROBIOL, V64, P187, DOI 10.1099/00221287-64-2-187; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Miller PW, 1998, PLANT MOL BIOL, V37, P243, DOI 10.1023/A:1005921018137; Minambres B, 2000, BIOCHEM BIOPH RES CO, V272, P477, DOI 10.1006/bbrc.2000.2709; MINAMBRES B, 1992, J ANTIBIOT, V45, P269, DOI 10.7164/antibiotics.45.269; Mosher RH, 1999, ANTIMICROB AGENTS CH, V43, P1215, DOI 10.1128/AAC.43.5.1215; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKATANI Y, 1988, NUCLEIC ACIDS RES, V16, P6237, DOI 10.1093/nar/16.13.6237; *NOM COMM IUB, 1992, ENZ NOM; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; PAMULA F, 1992, J GEN MICROBIOL, V138, P1935, DOI 10.1099/00221287-138-9-1935; PEREZPOMARES F, 1999, BIOCHIM BIOPHYS ACTA, V426, P513; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; REITZER LJ, 1987, CELLULAR MOL BIOL, V1, P302; RICE DW, 1985, J MOL BIOL, V181, P147, DOI 10.1016/0022-2836(85)90334-1; Saitou N, 1996, METHOD ENZYMOL, V266, P427; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERONESE FM, 1975, BIOCHIM BIOPHYS ACTA, V377, P217, DOI 10.1016/0005-2744(75)90304-6; VINING LC, 1987, APPL MICROBIOL BIOT, V27, P240; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAMOTO I, 1987, J GEN MICROBIOL, V133, P2773; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	71	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39529	39542		10.1074/jbc.M005136200	http://dx.doi.org/10.1074/jbc.M005136200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10924516	hybrid			2022-12-25	WOS:000165953100080
J	Low, BC; Seow, KT; Guy, GR				Low, BC; Seow, KT; Guy, GR			The BNIP-2 and Cdc42GAP homology domain of BNIP-2 mediates its homophilic association and heterophilic interaction with Cdc42GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RHO FAMILY; RAS; COMPLEX; GAPS; EFFECTORS; SEQUENCE; CASCADE; BINDING	We recently showed that BNIP-2 is a putative substrate of the fibroblast growth factor receptor tyrosine kinase and it possesses GTPase-activating activity toward the small GTPase, Cdc42. The carboxyl terminus of BNIP-2 shares high homology to the non-catalytic do main of Cdc42GAP, termed BCH (for BNIP-2 and Cdc42GAP homology) domain. Despite the lack of obvious homology to any known catalytic domains of GTPase-activating proteins (GAPs), the BCH domain of BNIP-2 bound Cdc42 and stimulated the GTPase activity via a novel arginine-patch motif similar to that employed by one contributing partner in a Cdc42 homodimer, In contrast, the BCH domain of Cdc42GAP, although it can bind Cdc42, is catalytically inactive, This raises the possibility that these domains might have other roles in the cell. Using glutathione S-transferase recombinant proteins, immunoprecipitation studies, and yeast two-hybrid assays, it was found that BNIP-2 and Cdc42GAP could form homo and hetero complexes via their conserved BCH domains. Molecular modeling of the BNIP-2 BCH homodimer complex and subsequent deletion mutagenesis helped to identify the region (RRKMP221)-R-217 as the major BCH interaction site within BMP-S. In comparison, deletion of either the arginine-patch (RRLRK239)-R-235 (necessary for GAP activity) or region (EYV290)-E-288 (a Cdc42 binding sequence) had no effect on BCH-BCH interaction. Extensive data base searches showed that the BCH domain is highly conserved across species. The results suggest that BCH domains of BNIP-2 and Cdc42GAP represent a novel protein-protein interaction domain that could potentially determine and/or modify the physiological roles of these molecules.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbgg@imcb.nus.edu.sg	Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bax B, 1998, NATURE, V392, P447, DOI 10.1038/33040; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Calmels TPG, 1998, FEBS LETT, V426, P205, DOI 10.1016/S0014-5793(98)00331-7; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 1999, BRIT J CANCER, V80, P25; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Rittinger K, 1998, NATURE, V392, P448, DOI 10.1038/33043; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P53; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609	46	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37742	37751		10.1074/jbc.M004897200	http://dx.doi.org/10.1074/jbc.M004897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954711	hybrid			2022-12-25	WOS:000165618700060
J	Spencer, NY; Zeng, H; Patel, RP; Hogg, N				Spencer, NY; Zeng, H; Patel, RP; Hogg, N			Reaction of S-nitrosoglutathione with the heme group of deoxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOPLEGIC ISCHEMIC ARREST; NITRIC-OXIDE; BIOCHEMICAL-CHARACTERIZATION; OXYGEN-BINDING; NITROSOHEMOGLOBIN; HEMOGLOBIN; TRANSNITROSATION; GLUTATHIONE; HEART; NO	The mechanism of interaction between S-nitrosoglutathione (GSNO) and hemoglobin is a crucial component of hypotheses concerning the role played by S-nitrosohemoglobin in vivo. We previously demonstrated (Patel, R. P,, Hogg, N, Spencer, N, Y,, Kalyanaraman, B,, Matalon, S,, and Darley-Usmar, V, Me (1999) J, Biol. Chem 274, 15487-15492) that transnitrosation between oxygenated hemoglobin and GSNO is a slow, reversible process, and that the reaction between GSNO and deoxygenated hemoglobin (deoxyHb) did not conform to second order reversible kinetics. In this study we have reinvestigated this reaction and show that GSNO reacts with deoxyHb to form glutathione, nitric oxide, and ferric hemoglobin. Nitric oxide formed hom this reaction is immediately autocaptured to form nitrosylated hemoglobin. GSNO reduction by deoxyHb is essentially irreversible, The kinetics of this reaction depended upon the conformation of the protein, with more rapid kinetics occurring in the high oxygen affinity state (i.e. modification of the Cys beta -93) than in the low oxygen affinity state (i.e. treatment with inositol hexaphosphate), A more rapid reaction occurred when deoxymyoglobin was used, further supporting the observation that the kinetics of reduction are directly proportional to oxygen affinity. This observation provides a mechanism for how deoxygenation of hemoglobin/myoglobin could facilitate nitric oxide release hom S-nitrosothiols and represents a potential physiological mechanism of S-nitrosothiol metabolism.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hogg, N (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		Spencer, Netanya/AAS-7999-2020	Spencer, Netanya/0000-0003-1010-5458; Patel, Rakesh/0000-0002-1526-4303	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01008] Funding Source: Medline; NIGMS NIH HHS [GM 55792] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Bonaventura C, 1999, J BIOL CHEM, V274, P24742, DOI 10.1074/jbc.274.35.24742; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HILLE R, 1979, J BIOL CHEM, V254, P2110; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Konorev EA, 1996, FEBS LETT, V378, P111, DOI 10.1016/0014-5793(95)01429-2; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; RIGGS A, 1961, J BIOL CHEM, V236, P1948; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Tsikas D, 1999, ANAL BIOCHEM, V273, P32, DOI 10.1006/abio.1999.4209; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983	20	57	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36562	36567		10.1074/jbc.M005347200	http://dx.doi.org/10.1074/jbc.M005347200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10945989	hybrid			2022-12-25	WOS:000165577700016
J	Gao, ZY; Reavey-Cantwell, J; Young, RA; Jegier, P; Wolf, BA				Gao, ZY; Reavey-Cantwell, J; Young, RA; Jegier, P; Wolf, BA			Synaptotagmin III/VII isoforms mediate Ca2+-induced insulin secretion in pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EATON MYASTHENIC SYNDROME; GATED CALCIUM CHANNELS; FIRST C-2 DOMAIN; ARACHIDONIC-ACID; MYOINOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA-2+; CA2+ OSCILLATIONS; SYNDROME ANTIGEN; PROTEIN-KINASE	Synaptotagmins (Syt) play important roles in Ca2+-induced neuroexocytosis, Insulin secretion of the pancreatic beta -cell is dependent on an increase in intracellular Ca2+; however, Syt involvement in insulin exocytosis is poorly understood. Reverse transcriptase-polymerase chain reaction studies showed the presence of Syt isoforms III, IV, V, and VII in rat pancreatic islets, whereas Syt isoforms I, II, III, TV,V,VII, and VIII were present in insulin-secreting beta TC3 cell. Syt III and VII proteins were identified in rat islets and beta TC3 and RINm5F beta -cells by immunoblotting, Confocal microscopy showed that Syt III and VII co-localized with insulin-containing secretory granules, Two-fold overexpression of Syt III in RINm5F beta -cell (Syt III cell) was achieved by stable transfection, which conferred greater Ca2+ sensitivity for exocytosis, and resulted in increased insulin secretion. Glyceraldehyde + carbachol-induced insulin secretion in Syt III cells was 2.5-fold higher than control empty vector cells, whereas potassium-induced secretion was 6-fold higher. In permeabilized Syt III cells, Ca2+-induced and mastoparan-induced insulin secretion was also increased. In Syt VII-overexpressing RINm5F beta -cells, there was amplification of carbachol-induced insulin secretion in intact cells and of Ca2+-induced and mastoparan-induced insulin secretion in permeabilized cells. In conclusion, Syt III/VII are located in insulin-containing secretory granules, and we suggest that Syt III/VII may be the Ca2+ sensor or one of the Ca2+ sensors for insulin exocytosis of the beta -cell.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wolf, BA (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 230 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK043354, P01DK049814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49814, DK43354, DK19525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Brown H, 2000, DIABETES, V49, P383, DOI 10.2337/diabetes.49.3.383; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Chen M, 1996, ENDOCRINOLOGY, V137, P2901, DOI 10.1210/en.137.7.2901; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DAVID P, 1993, NEUROMUSCULAR DISORD, V3, P451, DOI 10.1016/0960-8966(93)90095-2; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; Gao ZY, 1998, EUR J NEUROSCI, V10, P2416, DOI 10.1046/j.1460-9568.1998.00252.x; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; Henquin JC, 1998, DIABETES METAB, V24, P30; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Komatsu M, 1997, DIABETES, V46, P1928, DOI 10.2337/diabetes.46.12.1928; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Major CD, 1999, DIABETES, V48, P1372, DOI 10.2337/diabetes.48.7.1372; MARTINMOUTOT N, 1993, J PHYSIOLOGY-PARIS, V87, P37, DOI 10.1016/0928-4257(93)90022-L; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; PRENTKI M, 1984, EXPERIENTIA, V40, P1052, DOI 10.1007/BF01971451; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; Seagar M, 1999, PHILOS T ROY SOC B, V354, P289, DOI 10.1098/rstb.1999.0380; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 2000, BIOCHEMISTRY-US, V39, P2940, DOI 10.1021/bi9920984; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; ULLRICH B, 1995, NEUROPHARMACOLOGY, V34, P1371, DOI 10.1016/0028-3908(95)00132-P; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; Vance CL, 1999, NEUROSCIENCE, V90, P665, DOI 10.1016/S0306-4522(98)00420-5; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOLLHEIM CB, 1978, J CLIN INVEST, V62, P451, DOI 10.1172/JCI109146; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067	56	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36079	36085		10.1074/jbc.M004284200	http://dx.doi.org/10.1074/jbc.M004284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10938083	hybrid			2022-12-25	WOS:000165382000063
J	Pastorcic, M; Das, HK				Pastorcic, M; Das, HK			Regulation of transcription of the human presenilin-1 gene by Ets transcription factors and the p53 protooncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; BINDING-PROTEIN; MISSENSE MUTATIONS; CELL-GROWTH; C-FOS; ACTIVATION; EXPRESSION; APOPTOSIS; PROTEOLYSIS	The expression of the human presenilin-1 cellular gene is suppressed by the p53 protooncogene. The rapid kinetic of the down-regulation has suggested that it may result from a primary mechanism. We show here that p53 also suppresses the transcription of a presenilin-1 promoter-chloramphenicol acetyltransferase reporter synthetic gene in transient infection assays in neuroblastoma (SK-N-SH) and hepatoma (HepG2) cell lines. Only:a minimum promoter including sequences from -35 td + 6 from the transcription initiation is sufficient to confer down-regulation. We have previously defined a crucial DNA element controlling 90% of the expression of the gene:within the same short area, and the identification of the transcription factors involved should also provide insights into the regulation of PSI by p53. This region,contains an Ets transcription factor binding motif, and a a-base pair alteration within the core sequence (GGAA to TTAA) of the Ets consensus also reduced transcription by more than 90%. We now show that Ets1 and Ets2: indeed transactivate a PSI promoter-chloramphenicol acetyltransferase reporter including the (-35 to +6):fragment. Furthermore, in vitro translated Ets2 binds specifically to the -10 Ets motif in electrophoretic mobility shift assays. Therefore, Ets1/2 factors bind specifically to the -10 Ets element and activate PS1 transcription. We also show that the coactivator p300 enhances the activation by Ets1 and Ets2 as well as the repression by p53. p300 is known to interact with p53 as well as with Ets1 and Ets2. We show that p53 does not bind directly to the PSI promoter. Hence the repression of PS1:transcription by p53 is likely to be mediated through protein-protein interactions.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Pastorcic, M (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	mpastor@hsc.unt.edu						Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baumeister R, 1997, Genes Funct, V1, P149; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hong CS, 1999, J NEUROSCI, V19, P637; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KAGDAD M, 1997, CELL, V90, P809; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIM K, 1989, BIOTECHNIQUES, V7, P576; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	47	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34938	34945		10.1074/jbc.M005411200	http://dx.doi.org/10.1074/jbc.M005411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10942770	hybrid			2022-12-25	WOS:000165422800017
J	Yusta, B; Boushey, RP; Drucker, DJ				Yusta, B; Boushey, RP; Drucker, DJ			The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; ADULT-RAT HEPATOCYTES; GENE-EXPRESSION; GROWTH-FACTOR; PROLIFERATION; INDUCTION; SEVERITY; MYOCYTES; CELLS	Glucagon and the glucagon-like peptides regulate metabolic functions via signaling through a glucagon receptor subfamily of G protein-coupled receptors, Activation of glucagon-like peptide-2 receptor (GLP-2R) signaling maintains the integrity of the intestinal epithelial mucose via regulation of crypt cell proliferation. Because GLP-2 decreases mortality and reduces intestinal apoptosis in rodents after experimental injury, we examined whether GLP-2R signaling directly modifies the cellular response to external injury. We show here that activation of GLP-2R signaling inhibits cycloheximide-induced apoptosis in baby hamster kidney fibroblasts expressing a transfected GLP-2 receptor. GLP-2 reduced DNA fragmentation and improved cell survival, in association with reduced activation of caspase-3 and decreased poly(ADP-ribose) polymerase cleavage and reduced caspase-8 and caspase-9-like activities. Both GLP-2 and forskolin reduced mitochondrial cytochrome c release and decreased the cycloheximide-induced cleavage of caspase-3 in the presence or absence of the PKA inhibitor H-89, Similarly, GLP-2 increased cell survival following cycloheximide in the presence of the kinase inhibitors PD98054 and LY294002. These findings provide evidence that signaling through G; protein-coupled receptors of the glucagon superfamily is directly linked to regulation of apoptosis and suggest the existence of a cAMP-dependent protein kinase-, phosphatidylinositol 3-kinase-, and mitogen-activated protein kinase-independent pathway coupling GLP-2R signaling to caspase inhibition and cell survival.	Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, 101 Coll St,CCRW3-838, Toronto, ON M5G 1L7, Canada.		Drucker, Daniel J/A-4092-2010					Boushey RP, 1999, AM J PHYSIOL-ENDOC M, V277, pE937, DOI 10.1152/ajpendo.1999.277.5.E937; Bucher N L, 1975, Adv Enzyme Regul, V13, P281; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chance WT, 1997, AM J PHYSIOL-GASTR L, V273, pG559, DOI 10.1152/ajpgi.1997.273.2.G559; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; Drucker DJ, 1999, TRENDS ENDOCRIN MET, V10, P153, DOI 10.1016/S1043-2760(98)00136-2; Drucker DJ, 1999, AM J PHYSIOL-GASTR L, V276, pG79, DOI 10.1152/ajpgi.1999.276.1.G79; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kimura M, 1997, EUR J PHARMACOL, V324, P267, DOI 10.1016/S0014-2999(97)00078-2; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Mabrouk GM, 1998, BIOCHEM J, V330, P759; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Prasad R, 2000, J PEDIATR SURG, V35, P357, DOI 10.1016/S0022-3468(00)90040-X; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scott RB, 1998, AM J PHYSIOL-GASTR L, V275, pG911, DOI 10.1152/ajpgi.1998.275.5.G911; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thangaraju M, 1999, CANCER RES, V59, P1649; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459	43	88	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35345	35352		10.1074/jbc.M005510200	http://dx.doi.org/10.1074/jbc.M005510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10940305	Green Published, hybrid			2022-12-25	WOS:000165422800069
J	Gu, YC; Publicover, SJ				Gu, YC; Publicover, SJ			Expression of functional metabotropic glutamate receptors primary cultured rat osteoblasts - Cross-talk with N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CEREBELLAR GRANULE CELLS; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; BONE-CELLS; NMDA CURRENTS; IN-VITRO; PATHWAYS; CA2+; ACTIVATION	Osteoblasts and osteoclasts express functional N-methyl-D-aspartate (NMDA) receptors, which participate in regulation of bone matrix. In rat femoral osteoblasts held in whole cell clamp there is a robust NMDA current but little if any response to L-glutamate, We have investigated expression of metabotropic glutamate receptors (mGluRs) in these cells. By reverse transcription polymerase chain reaction, we have detected expression of mGluR1b (but not mGluR1a, 2, 3, 4, 5, or 6), Blockade of mGluRs with (+/-)-alpha -methyl-carboxyphenyl-glycine resulted in an enlarged L-glutamate-induced current that resembled the response to NMDA. Conversely, prior stimulation of mGluRs with trans-(+/-)-1-amino-1,3-cyclopentanedicarboxylic acid (1S,3R-ACPD; mGluR agonist) reduced the NMDA-induced current by 77%. Monitoring of [Ca2+](i) showed that NMDA induced a sustained elevation of [Ca2+](i). which was dependent upon [Ca2+](o). Treatment with 1S,3R-ACPD generated an initial transient that was independent of [Ca2+](o), followed by a sustained, [Ca2+](o)-dependent phase, a response consistent with phospholipase C-mediated mobilization of stored Ca2+, Investigations of the interaction between the two receptors confirmed inhibitory modulation of the NMDA receptor-induced rise in [Ca2+](i) by mGluRs. Parathyroid hormone, which also activates phospholipase C in osteoblasts, had a similar inhibitory effect on the NMDA receptor-induced [Ca2+](i) response. Elevation of [Ca2+](i) mediated by mGluR activation was reduced by subsequent stimulation of NMDA receptors, This is the first description of mGluRs in bone and shows that complex glutamatergic signaling can occur in this tissue.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Publicover, SJ (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	s.j.publicover@bham.ac.uk	Publicover, Steve J/E-7970-2018	gu, yuchun/0000-0002-7558-0447				Ahmed MAAS, 2000, J CELL PHYSIOL, V183, P163; Ajubi NE, 1999, AM J PHYSIOL-ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171; Akaike N, 1997, J PHYSIOL-LONDON, V504, P665, DOI 10.1111/j.1469-7793.1997.665bd.x; AKATSU T, 1991, J BONE MINER RES, V6, P183; Birch MA, 1997, J BONE MINER RES, V12, pO10; BLEAKMAN D, 1992, MOL PHARMACOL, V42, P192; CHALLISS RAJ, 1994, NEUROPHARMACOLOGY, V33, P15, DOI 10.1016/0028-3908(94)90092-2; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; COLLWELL CS, 1994, NEUROSCIENCE, V17, P441; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; Espinosa L, 1999, J PHYSIOL-LONDON, V518, P47, DOI 10.1111/j.1469-7793.1999.0047r.x; Genever P. G., 1999, Calcified Tissue International, V64, pS41; Genever PG, 1999, BLOOD, V93, P2876; Ghosh PK, 1997, DEV BRAIN RES, V102, P1, DOI 10.1016/S0165-3806(97)00066-7; Golshani P, 1998, J NEUROPHYSIOL, V80, P143, DOI 10.1152/jn.1998.80.1.143; Gu Y, 2000, J PHYSIOL-LONDON, V523, p155P; Guyton A.C., 2011, HALL TXB MED PHYSL; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOLY C, 1995, J NEUROSCI, V15, P3970; JONES DB, 1991, CELL MATER, V1, P329; Kane MD, 1998, NEUROSCI LETT, V252, P1, DOI 10.1016/S0304-3940(98)00484-4; Kanematsu M, 1997, J BONE MINER RES, V12, P1789, DOI 10.1359/jbmr.1997.12.11.1789; KAPLAN AD, 1995, ENDOCRINOLOGY, V136, P1674, DOI 10.1210/en.136.4.1674; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Laketic-Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756-3282(99)00224-0; MARUSIC A, 1991, J IMMUNOL, V146, P2633; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; MORRISETT RA, 1990, J NEUROCHEM, V54, P1517, DOI 10.1111/j.1471-4159.1990.tb01199.x; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Pizzi M, 1999, EUR J NEUROSCI, V11, P2489, DOI 10.1046/j.1460-9568.1999.00669.x; Pizzi M, 1996, MOL PHARMACOL, V49, P586; RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330; SANTI MR, 1994, J NEUROCHEM, V63, P1207; Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201; Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756-3282(99)00215-X; Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732; Skerry TM, 1999, J BONE MINER METAB, V17, P66, DOI 10.1007/s007740050067; Tam VK, 1998, AM J PHYSIOL-CELL PH, V274, pC1686, DOI 10.1152/ajpcell.1998.274.6.C1686; TATAKIS DN, 1992, BONE MINER, V18, P1, DOI 10.1016/0169-6009(92)90795-F; Tokuda H, 1999, PROSTAG LEUKOTR ESS, V61, P189, DOI 10.1054/plef.1999.0089; Tsai JA, 1999, BIOCHEM BIOPH RES CO, V263, P206, DOI 10.1006/bbrc.1999.1339; Valerio A, 1997, NEUROREPORT, V8, P2695, DOI 10.1097/00001756-199708180-00012; Walker LM, 2000, J CELL BIOCHEM, V79, P648, DOI 10.1002/1097-4644(20001215)79:4<648::AID-JCB130>3.0.CO;2-Q; Wiemann M, 1999, CALCIFIED TISSUE INT, V65, P479, DOI 10.1007/s002239900736; Wiemann M, 1998, CALCIFIED TISSUE INT, V63, P154, DOI 10.1007/s002239900507; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964	58	74	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34252	34259		10.1074/jbc.M004520200	http://dx.doi.org/10.1074/jbc.M004520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10950953	hybrid			2022-12-25	WOS:000165095300036
J	Mao, QC; Deeley, RG; Cole, SPC				Mao, QC; Deeley, RG; Cole, SPC			Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; ORGANIC ANION TRANSPORTER; CANCER CELL-LINE; P-GLYCOPROTEIN; ATPASE ACTIVITY; LEUKOTRIENE C-4; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; DEPENDENT TRANSPORT; CYSTIC-FIBROSIS	The 190-kDa multidrug resistance protein MRP1 (ABCC1) is a polytopic transmembrane protein belonging to the ATP-binding cassette transporter superfamily,In addition to conferring resistance to various antineoplastic agents, MRP1 is a transporter of conjugated organic anions, including the cysteinyl leukotriene C-4 (LTC4). We previously characterized the ATPase activity of reconstituted immunoaffinity-purified native MRP1 and showed it could be stimulated by its organic anion substrates (Mao, Q., Leslie, E, M., Deeley, R. G., and Cole, S. P. C. (1999) Biochim. Biophys. Acta 1461, 69-82). Here we show that purified reconstituted MRP1 is also capable of active transport of its substrates. Thus LTC4 uptake by MRP1 proteoliposomes was osmotically sensitive and could be inhibited by two MRP1-specific monoclonal antibodies. LTC4 uptake was also markedly reduced by the competitive inhibitor, S-decyl-glutathione, as well as by the MRP1 substrates 17 beta -estradiol 17-beta-(D-glucuronide), oxidized glutathione, and vincristine in the presence of reduced glutathione. The K-m for ATP and LTC4 were 357 +/- 184 muM and 366 +/- 38 nM, respectively, and 2.14 +/- 0.75 muM for 17 beta -estradiol 17-beta-(D-glucuronide). Transport of vincristine required the presence of both ATP and GSH. Conversely, GSH transport was stimulated by vincristine and verapamil. Our data represent the first reconstitution of transport competent purified native MRP1 and confirm that MRP1 is an efflux pump, which can transport conjugated organic anions and co-transport vincristine together with GSH.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Rm 328,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; BUCHLER M, 1994, EUR J BIOCHEM, V224, P345, DOI 10.1111/j.1432-1033.1994.00345.x; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Cladera J, 1997, EUR J BIOCHEM, V243, P798, DOI 10.1111/j.1432-1033.1997.00798.x; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Ding GY, 1999, ANTICANCER RES, V19, P3243; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Keppler D, 1997, BIOL CHEM, V378, P787; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Lee AG, 1998, BBA-REV BIOMEMBRANES, V1376, P381, DOI 10.1016/S0304-4157(98)00010-0; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Sharom FJ, 1997, BIOCHEM SOC T, V25, P1088, DOI 10.1042/bst0251088; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zeng H, 1999, CANCER RES, V59, P5964; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	59	95	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34166	34172		10.1074/jbc.M004584200	http://dx.doi.org/10.1074/jbc.M004584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942765	hybrid			2022-12-25	WOS:000165095300025
J	Oleszewski, M; Gutwein, P; von der Lieth, W; Rauch, U; Altevogt, P				Oleszewski, M; Gutwein, P; von der Lieth, W; Rauch, U; Altevogt, P			Characterization of the L1-neurocan-binding site - Implications for L1-L1 homophilic binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CHONDROITIN SULFATE PROTEOGLYCANS; NEURITE OUTGROWTH; NERVOUS-TISSUE; N-CAM; NEUROCAN BINDING; L1; BRAIN; EXPRESSION; MUTATIONS	The L1 adhesion molecule is a 200-220-kDa membrane glycoprotein of the Ig superfamily implicated in important neural processes including neuronal cell migration, axon outgrowth, learning, and memory formation. L1 supports hemophilic L1-L1 binding that involves several Ig domains but can also bind with high affinity to the proteoglycan neurocan, it has been reported that neurocan can block hemophilic binding; however, the mechanism of inhibition and the precise binding sites in both molecules have not been determined. By using fusion proteins, site-directed mutagenesis, and peptide blocking experiments, we have characterized the neurocan-binding site in the first Ig-like domain of human L1, Results from molecular modeling suggest that the sequences involved in neurocan binding are localized on the surface of the first Ig domain and largely overlap with the G-F-C beta -strands proposed to interact with the fourth Ig domain during hemophilic binding. This suggests that neurocan may sterically hinder a proper alignment of LI domains. We find that the C-terminal portion of neurocan is sufficient to mediate binding to the first Ig domain of L1, and we suggest that the sushi domain cooperates with a glycosaminoglycan side chain in forming the binding site for L1.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; German Canc Res Ctr, Cent Spectroscop Div, D-69120 Heidelberg, Germany; Univ Lund, Dept Expt Pathol, Univ Hosp, S-22185 Lund, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Lund University; Skane University Hospital	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							APPEL F, 1993, J NEUROSCI, V13, P4764; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; Beer S, 1999, J CELL SCI, V112, P2667; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Fukuda T, 1997, J COMP NEUROL, V382, P141; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Haspel J, 2000, J NEUROBIOL, V42, P287, DOI 10.1002/(SICI)1097-4695(20000215)42:3<287::AID-NEU1>3.3.CO;2-O; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; Kamiguchi H, 1998, ANNU REV NEUROSCI, V21, P97, DOI 10.1146/annurev.neuro.21.1.97; Kenwrick S, 1998, BIOESSAYS, V20, P668, DOI 10.1002/(SICI)1521-1878(199808)20:8<668::AID-BIES10>3.0.CO;2-X; Lilien J, 1999, J NEUROSCI RES, V58, P727, DOI 10.1002/(SICI)1097-4547(19991215)58:6<727::AID-JNR1>3.0.CO;2-7; LINDSTROMDINNETZ I, 1995, EUR J BIOCHEM, V230, P920, DOI 10.1111/j.1432-1033.1995.tb20637.x; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MIAO HQ, 1995, J CELL PHYSIOL, V164, P482, DOI 10.1002/jcp.1041640306; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Nolte C, 1999, CELL TISSUE RES, V298, P261, DOI 10.1007/s004419900063; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; OOHIRA A, 1991, J NEUROSCI, V11, P822; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; Pancook JD, 1997, J IMMUNOL, V158, P4413; PERRIS R, 1991, DEVELOPMENT, V111, P583; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Retzler C, 1996, J BIOL CHEM, V271, P27304, DOI 10.1074/jbc.271.44.27304; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Talts U, 2000, EXP CELL RES, V259, P378, DOI 10.1006/excr.2000.4987; UJITA M, 1994, J BIOL CHEM, V269, P27603; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200	47	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34478	34485		10.1074/jbc.M004147200	http://dx.doi.org/10.1074/jbc.M004147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934197	hybrid			2022-12-25	WOS:000165095300065
J	Attmane-Elakeb, A; Sibella, V; Vernimmen, C; Belenfant, X; Hebert, SC; Bichara, M				Attmane-Elakeb, A; Sibella, V; Vernimmen, C; Belenfant, X; Hebert, SC; Bichara, M			Regulation by glucocorticoids of expression and activity of rBSC1, the Na+-K+ (NH4+)-2Cl(-) cotransporter of medullary thick ascending limb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC-ACIDOSIS; CL COTRANSPORTER; MEMBRANE-VESICLES; RAT-KIDNEY; VASOPRESSIN	To assess whether glucocorticoids regulate rBSC1, the apical Na+-K+(NH4+)-2Cl(-) cotransporter of kidney medullary thick ascending limb (MTAL), studies were performed in normal rats, adrenalectomized (ADX) rats, and ADX rats infused with dexamethasone for 6 days. The effects of dexamethasone on rBSC1 were also studied in vitro using isolated rat MTAL segments. Cotransport activity was estimated by intracellular pH measurements; rBSC1 protein was quantified in MTAL crude membranes by immunoblotting analysis, and mRNA was quantified by quantitative reverse transcription-polymerase chain reaction. The abundance of rBSC1 protein and mRNA increased in ADX rats infused with dexamethasone compared with ADX rats (p < 0.04), In addition, application of dexamethasone for 1-3 h to MTALs caused rBSC1 protein and mRNA abundance and cotransport activity to significantly increase in a hyperosmotic medium (450 mosmol/kg of H2O) containing 0.7 nM arginine vasopressin, which is an in vitro experimental condition that resembles the in vivo MTAL environment. Results obtained in various media and with 8-bromo-cAMP indicated that stimulation of rBSC1 expression by glucocorticoids required interactions between glucocorticoid receptor- and cAMP-dependent factors. Up to 100 nar d-aldosterone had no effect on cotransport activity in vitro. Thus glucocorticoids directly stimulate MTAL rBSC1 expression and activity, which contributes to glucocorticoid-dependent effects on the renal regulation of acid-base balance and urinary concentrating ability.	Univ Paris 07, Fac Med Xavier Bichat, INSERM U426, Inst Federat Reg Xavier Bichat, F-75870 Paris 18, France; Hop Andre Gregoire, Serv Nephrol, F-93100 Montreuil, France; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Yale University	Bichara, M (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, INSERM U426, Inst Federat Reg Xavier Bichat, 16 Rue Henri Huchard, F-75870 Paris 18, France.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036803] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36803] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amlal H, 1998, J CLIN INVEST, V101, P1045, DOI 10.1172/JCI686; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; Attmane-Elakeb A, 1998, J BIOL CHEM, V273, P33681, DOI 10.1074/jbc.273.50.33681; Attmane-Elakeb A, 1998, KIDNEY INT, V53, P439, DOI 10.1046/j.1523-1755.1998.00760.x; AttmaneElakeb A, 1997, J BIOL CHEM, V272, P25668, DOI 10.1074/jbc.272.41.25668; BOYKIN J, 1978, J CLIN INVEST, V62, P738, DOI 10.1172/JCI109184; COOKE RC, 1973, J LAB CLIN MED, V82, P784; DOUCET A, 1986, AM J PHYSIOL, V251, pF851, DOI 10.1152/ajprenal.1986.251.5.F851; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; FARMAN N, 1983, AM J PHYSIOL, V244, pF325, DOI 10.1152/ajprenal.1983.244.3.F325; FARMAN N, 1991, AM J PHYSIOL, V260, pC226, DOI 10.1152/ajpcell.1991.260.2.C226; GAMBA G, 1994, J BIOL CHEM, V269, P17713; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Kim GH, 1999, AM J PHYSIOL-RENAL, V276, pF96, DOI 10.1152/ajprenal.1999.276.1.F96; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; KNEPPER M, 1983, AM J PHYSIOL, V244, pF579, DOI 10.1152/ajprenal.1983.244.6.F579; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; LEE SM, 1983, AM J PHYSIOL, V244, pF504, DOI 10.1152/ajprenal.1983.244.5.F504; Marumo R, 1998, KIDNEY INT, V54, P877, DOI 10.1046/j.1523-1755.1998.00051.x; MAY RC, 1986, J CLIN INVEST, V77, P614, DOI 10.1172/JCI112344; MCDONALD KM, 1976, KIDNEY INT, V10, P38, DOI 10.1038/ki.1976.77; MOREL F, 1982, KIDNEY INT, V21, P55; Mount DB, 1999, AM J PHYSIOL-RENAL, V276, pF347, DOI 10.1152/ajprenal.1999.276.3.F347; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PEREZ GO, 1979, HORM RES, V11, P12, DOI 10.1159/000179033; RAYSON BM, 1984, AM J PHYSIOL, V246, pF656, DOI 10.1152/ajprenal.1984.246.5.F656; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; TODDTURLA KM, 1993, AM J PHYSIOL, V264, pF781, DOI 10.1152/ajprenal.1993.264.5.F781; WELBOURNE TC, 1988, AM J PHYSIOL, V254, pF134, DOI 10.1152/ajprenal.1988.254.1.F134; WELBOURNE TC, 1976, ENDOCRINOLOGY, V99, P762	33	27	27	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33548	33553		10.1074/jbc.M006591200	http://dx.doi.org/10.1074/jbc.M006591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942780	hybrid			2022-12-25	WOS:000090104600053
J	Farzan, M; Vasilieva, N; Schnitzler, CE; Chung, S; Robinson, J; Gerard, NP; Gerard, C; Choe, H; Sodroski, J				Farzan, M; Vasilieva, N; Schnitzler, CE; Chung, S; Robinson, J; Gerard, NP; Gerard, C; Choe, H; Sodroski, J			A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 BINDING-SITE; GENETIC RESTRICTION; INFECTION; RECEPTOR; CORECEPTOR; ANTIBODY; 7-TRANSMEMBRANE; INDIVIDUALS; AIDS	The sequential association of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 with CD4 and a seven-transmembrane segment coreceptor such as CC RB or CXCR4 initiates entry of the virus into its target cell. The N terminus of CCR5, which contains several sulfated tyrosines, plays a critical role in the CD4-dependent association of gp120 with CCR5 and in viral entry. Here we demonstrate that a tyrosine-sulfated peptide based on the N terminus of CCR5, but not its unsulfated analogue, inhibits infection of macrophages and peripheral blood mononuclear cells by CCR5-dependent, but not CXCR4-dependent, HIV-1 isolates. The sulfated peptide also inhibited the association of CCR5-expressing cells with gp120-soluble CD4 complexes and, less efficiently, with MIP-1 alpha. Moreover, this peptide inhibited the precipitation of gp120 by 48d and 23e antibodies, which recognize CD4-inducible gp120 epitopes, but not by several other antibodies that recognize proximal epitopes, The ability of the sulfated peptide to block 48d association with gp120 was dependent in part on seven tropism-determining residues in the third variable (V3) and fourth conserved (C4) domains of gp120, These data underscore the important role of the N-terminal sulfate moieties of CCR5 in the entry of R5 HIV-1 isolates and Localize a critical contact between gp120 and CCR5.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Childrens Hosp, Dept Pediat, Perlmutter Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02115 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tulane University	Farzan, M (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 4 Binney St, Boston, MA 02115 USA.		Schnitzler, Christine/G-8733-2013	Farzan, Michael/0000-0002-2990-5319; Schnitzler, Christine/0000-0002-5001-6524	NIAID NIH HHS [AI28691, R01 AI043891, AI41851, AI43891] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891, R01AI041851, P30AI028691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SULLIVAN N, 1993, J VIROL, V67, P3674, DOI 10.1128/JVI.67.6.3674-3679.1993; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; WU L, 1996, NATURE, V184, P179; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993	38	134	147	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33516	33521		10.1074/jbc.M007228200	http://dx.doi.org/10.1074/jbc.M007228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938094	hybrid			2022-12-25	WOS:000090104600048
J	Ouellette, AJ; Satchell, DP; Hsieh, MM; Hagen, SJ; Selsted, ME				Ouellette, AJ; Satchell, DP; Hsieh, MM; Hagen, SJ; Selsted, ME			Characterization of luminal paneth cell alpha-defensins in mouse small intestine - Attenuated antimicrobial activities of peptides with truncated amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-DEFENSE; SALMONELLA VIRULENCE; PHOSPHOLIPASE A(2); MESSENGER-RNA; RABBIT NP-2; HUMAN HNP-1; SECRETION; CRYPTDIN; PROTEIN; GENE	Paneth cells at the base of small intestinal crypts secrete apical granules that contain antimicrobial peptides including alpha -defensins, termed cryptdins, Using an antibody specific for mouse cryptdin-1, -2, -3, and -6, immunogold-localization studies demonstrated that cryptdins are constituents of mouse Paneth cell secretory granules. Several cryptdin peptides have been purified from rinses of adult mouse small. intestine by gel filtration and reverse-phase high performance liquid chromatography. Their primary structures were determined by peptide sequencing, and their antimicrobial activities were compared with those of the corresponding tissue forms. The isolated luminal cryptdins included peptides identical to the tissue forms of cryptdin-2, -4, and -6 as well as variants of cryptdin-1, -4, and -6 that have N termini truncated by one or two residues. In assays of antimicrobial activity against Staphylococcus aureus, Escherichia coli, and the defensin-sensitive Salmonella typhimurium phoP(-) mutant, full-length cryptdins had the same in vitro antibacterial activities whether isolated from tissue or from the lumen. In contrast, the N-terminal-truncated (des-Leu), (des-Leu-Arg)-cryptdin-6, and (des-Gly)-cryptdin-4 peptides mere markedly less active. The microbicidal activities of recombinant cryptdin-4 and (des-Gly)-cryptdin-4 peptides against E. coli, and S. typhimurium showed that the N-terminal Gly residue or the length of the cryptdin-4 N terminus are determinants of microbicidal activity. Innate immunity in the crypt lumen may be modulated by aminopeptidase modification of alpha -defensins after peptide secretion.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Harvard University; Beth Israel Deaconess Medical Center	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.	aouellet@UCI.EDU			NIDDK NIH HHS [DK 15681, DK33506, DK44632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, R37DK015681, P01DK033506, R01DK044632, R01DK015681] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH AC, 1987, BIOCHEMISTRY-US, V26, P4389, DOI 10.1021/bi00388a030; Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BOMAN HG, 1994, CIBA F SYMP, V186, P1; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; DECKX RJ, 1967, BIOCHIM BIOPHYS ACTA, V139, P204, DOI 10.1016/0005-2744(67)90136-2; Elsbach P, 1997, PROG SURG, V24, P17, DOI 10.1159/000075479; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; GHOOS Y, 1971, Histochemical Journal, V3, P175, DOI 10.1007/BF01002560; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; HAGEN SJ, 1990, J ELECTRON MICR TECH, V16, P37, DOI 10.1002/jemt.1060160106; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; MILLER SI, 1991, MOL MICROBIOL, V5, P2073, DOI 10.1111/j.1365-2958.1991.tb02135.x; MOORE KS, 1992, J HISTOCHEM CYTOCHEM, V40, P367, DOI 10.1177/40.3.1552176; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; Porter EM, 1997, INFECT IMMUN, V65, P2389, DOI 10.1128/IAI.65.6.2389-2395.1997; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Qu XD, 1996, INFECT IMMUN, V64, P5161, DOI 10.1128/IAI.64.12.5161-5165.1996; Quayle AJ, 1998, AM J PATHOL, V152, P1247; REILLY DS, 1994, DEV BIOL, V162, P123, DOI 10.1006/dbio.1994.1072; SATOH Y, 1989, ANAT REC, V225, P124, DOI 10.1002/ar.1092250207; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SATOH Y, 1992, CELL TISSUE RES, V269, P213, DOI 10.1007/BF00319611; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHANG XL, 1992, BIOCHEMISTRY-US, V31, P11348, DOI 10.1021/bi00161a012	48	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33969	33973		10.1074/jbc.M004062200	http://dx.doi.org/10.1074/jbc.M004062200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942762	hybrid			2022-12-25	WOS:000090104600109
J	Rodriguez-Manzaneque, JC; Milchanowski, AB; Dufour, EK; Leduc, R; Iruela-Arispe, ML				Rodriguez-Manzaneque, JC; Milchanowski, AB; Dufour, EK; Leduc, R; Iruela-Arispe, ML			Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE ACTIVITY; FIBROBLAST GROWTH-FACTOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FURIN CONVERTASE; ADAMTS FAMILY; CLONING; ANGIOGENESIS; PROTEIN; MOTIFS	METH-1/ADAMTS1 is a member of a newly described family of genes that contain metalloprotease, disintegrin, and thrombospondin-like motifs. We have recently shown that METH-1 protein is a potent inhibitor of angiogenesis, Here, we demonstrate that secreted human pro-METH-1 is processed in two consecutive steps to release both p87 and p65 active forms. The p87 form lacks the N-terminal prodomain and p65 results from an additional processing event in the C-terminal end. Generation of p87 was blocked with specific inhibitors of furin, and incubation of pro-METH-1 with purified furin released the p87 fragment but not p65, Generation of p65 required preformation of p87 and was suppressed by inhibitors of matrix metalloproteases. We demonstrate that matrix metalloproteases 2, 8, and 15 were able to release p65 when p87 was used as substrate. This second processing step removes two thrombospondin repeats from the carboxyl-terminal end of p87-METH-1 and alters the affinity of the protein to heparin and endothelial cultures. Furthermore, this deletion was associated with a reduced activity upon suppression of endothelial cell proliferation, We hypothesize that METH-1 processing is relevant for the modulation of the anti-angiogenic properties displayed by the protein.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Sherbrooke	Iruela-Arispe, ML (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Rm 559,611 Charles E Young Dr, Los Angeles, CA 90095 USA.		Iruela-Arispe, M. Luisa/AAJ-1297-2020; Rodriguez-Manzaneque, Juan Carlos/F-3899-2012	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029	NCI NIH HHS [CA 63356-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Carrell RW, 1999, SCIENCE, V285, P1861, DOI 10.1126/science.285.5435.1861; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DENAULT JB, 1995, FEBS LETT, V362, P276, DOI 10.1016/0014-5793(95)00249-9; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GREENWALD RA, 1992, J RHEUMATOL, V19, P927; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HORNEBECK W, 1994, PATHOL RES PRACT, V190, P895; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; MATSUO C, 1988, J CELL PHYSIOL, V134, P253, DOI 10.1002/jcp.1041340211; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANDERSTAPPEN JWJ, 1992, INT J BIOCHEM, V24, P725, DOI 10.1016/0020-711X(92)90006-M; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342	43	127	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33471	33479		10.1074/jbc.M002599200	http://dx.doi.org/10.1074/jbc.M002599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944521	hybrid			2022-12-25	WOS:000090104600042
J	Du, J; Alsayed, YM; Xin, F; Ackerman, SJ; Platanias, LC				Du, J; Alsayed, YM; Xin, F; Ackerman, SJ; Platanias, LC			Engagement of the CrkL adapter in interleukin-5 signaling in eosinophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-5 RECEPTOR-ALPHA; COLONY-STIMULATING FACTOR; MAP KINASE ACTIVATION; EXCHANGE FACTOR C3G; MYELOID CELL-LINE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; CYTOPLASMIC DOMAIN; GROWTH-FACTOR; SUBUNIT GENE	Interleukin-5 (IL-5) drives the terminal differentiation of myeloid progenitors to the eosinophil lineage; blocks eosinophil apoptosis; and primes eosinophils for enhanced functional activities in allergic, parasitic, and other eosinophil-associated diseases. Here we describe a novel signaling pathway activated by the IL-5 receptor in eosinophils involving the CrkL adapter protein. We determined whether IL-5 induces activation of CrkL, and STAT5 in eosinophils using both the human eosinophil-differentiated AML14.3D10 cell line and purified peripheral blood eosinophils from normal donors. Stimulation of AML14.3D10 cells or blood eosinophils with IL-5 induced rapid tyrosine phosphorylation of the CrkL adapter and STAT5 and the association of CrkL and STAT5 in vivo as evidenced by the detection of STAT5 in anti-CrkL immunoprecipitates. The resulting CrkL.STAT5 complexes translocated to the nucleus and bound STAT5 consensus DNA-binding sites present in the promoters of IL-5-regulated genes, as shown in gel mobility and antibody supershift assays. IL-5 also induced marked activity of an 8X-GAS (interferon gamma -activated site)-luciferase reporter construct in transient transfections of AML14.3D10 eosinophils, demonstrating that these complexes play a functional role in IL-5 signaling. CrkT, was also found to interact, via its N-terminal SH3 domain, with C3G, a guanine exchange factor for the small G-protein Rap1, which was also rapidly activated in an IL-5-dependent manner in these cells, establishing that CrkL mediates downstream activation of at least two signaling cascades in IL-5-stimulated eosinophils. Thus, the CrkL adapter plays an important role in IL-5 signaling in the eosinophil, acting as a nuclear adapter for STAT5 and as an upstream regulator of the C3G-Rap1 signaling pathway.	Univ Illinois, Coll Med A312, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Hematol Oncol Sect, Chicago, IL 60612 USA; W Side Vet Affairs Med Ctr, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ackerman, SJ (corresponding author), Univ Illinois, Coll Med A312, Dept Biochem & Mol Biol, 1819 W Polk St,MC536, Chicago, IL 60612 USA.				NCI NIH HHS [CA77816] Funding Source: Medline; NIAID NIH HHS [AI33043, AI25230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033043, R01AI025230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623, DOI 10.1152/ajpcell.1998.275.3.C623; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; ALAM R, 1995, INT ARCH ALLERGY IMM, V107, P226, DOI 10.1159/000236985; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Baumann MA, 1997, METHODS, V11, P88, DOI 10.1006/meth.1996.0392; Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bracke M, 1998, J IMMUNOL, V161, P6768; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLI SJ, 1994, CL ALLER IM, V2, P255; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huston MM, 1996, J IMMUNOL, V156, P1392; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Koenderman L, 1996, EUR RESPIR J, V9, pS119; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Lopez A F, 1992, Immunol Ser, V57, P549; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Ogata N, 1997, INT ARCH ALLERGY IMM, V114, P24, DOI 10.1159/000237712; Ogata N, 1998, BLOOD, V91, P2264, DOI 10.1182/blood.V91.7.2264.2264_2264_2271; Ozaki K, 1998, BLOOD, V92, P4652; PAUL CC, 1994, J LEUKOCYTE BIOL, V56, P74, DOI 10.1002/jlb.56.1.74; Paul CC, 1997, AM J HEMATOL, V56, P79, DOI 10.1002/(SICI)1096-8652(199710)56:2<79::AID-AJH2>3.0.CO;2-Y; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; PAUL CC, 1993, BLOOD, V81, P1193; PAZDRAK K, 1995, J IMMUNOL, V155, P397; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Ribon V, 1996, MOL CELL BIOL, V16, P45; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; Sanderson C J, 1990, Immunol Ser, V49, P231; SANDERSON CJ, 1991, INT ARCH ALLER A IMM, V94, P122, DOI 10.1159/000235342; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Sun Z, 1996, CURR TOP MICROBIOL, V211, P173; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAKATSU K, 1994, ADV IMMUNOL, V57, P145, DOI 10.1016/S0065-2776(08)60673-2; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAKATSU K, 1992, ANN NY ACAD SCI, V651, P241; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1995, AGENT ACTION SUPPL, V46, P23; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VanderBruggen T, 1996, CLIN EXP ALLERGY, V26, P880, DOI 10.1046/j.1365-2222.1996.d01-391.x; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Ward AC, 2000, BLOOD, V95, P19; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann N, 2000, J IMMUNOL, V164, P1055, DOI 10.4049/jimmunol.164.2.1055; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	85	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33167	33175		10.1074/jbc.M003655200	http://dx.doi.org/10.1074/jbc.M003655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10926930	hybrid			2022-12-25	WOS:000090003800106
J	Lee, HY; Suh, YA; Robinson, MJ; Clifford, JL; Hong, WK; Woodgett, JR; Cobb, MH; Mangelsdorf, DJ; Kurie, JM				Lee, HY; Suh, YA; Robinson, MJ; Clifford, JL; Hong, WK; Woodgett, JR; Cobb, MH; Mangelsdorf, DJ; Kurie, JM			Stress pathway activation induces phosphorylation of retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE PATHWAY; N-TERMINAL KINASE; C-JUN; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; CARCINOMA-CELLS; UP-REGULATION; RXR-ALPHA	Cellular stresses inhibit retinoid signaling, but the molecular basis for this phenomenon has not been revealed. Here, we present evidence that retinoid X receptor (RXR) is a substrate for both mitogen-activated protein kinase kinase-4 (MKR4/SEK1) and its downstream mediator c-Jun N-terminal kinase (JNK). MKK4/SEK1 and JNK recognized distinct features on RXR in the DE and AB regions, respectively. Phosphorylation by MKK4/SEK1 had profound effects on the biochemical properties of RXR, inhibiting the expression of genes activated by RXR-retinoic acid receptor complexes. Tyr-249 in the RXR DE region was required for the inhibitory effect of MKK4/SEK1. These effects were significantly reduced in MKK4/SEK1-null cells, indicating that MKK4/SEK1 is required for the suppression of retinoid signaling by stress. Findings presented here demonstrate that MKK4/SEK1 can directly modulate transcription by phosphorylating RXR, a novel MKK4/SEK1 substrate.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jmkurie@audumla.mdacc.tmc.edu	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Cobb, Melanie/0000-0003-0833-5473; Lee, Ho-Young/0000-0001-7556-9312; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL CANCER INSTITUTE [P50CA070907, R29CA067353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R29 CA67353] Funding Source: Medline; NIGMS NIH HHS [GM56498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Geisen C, 1997, CANCER RES, V57, P1460; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM YH, 1995, CANCER RES, V55, P5603; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee HY, 1996, CELL GROWTH DIFFER, V7, P997; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MILLER LA, 1993, CANCER RES, V53, P2527; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shea CR, 1991, PHYSL BIOCH MOL BIOL, V2, P910; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woodgett JR, 1996, CANCER SURV, V27, P127; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	44	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32193	32199		10.1074/jbc.M005490200	http://dx.doi.org/10.1074/jbc.M005490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10938283	hybrid			2022-12-25	WOS:000089858900088
J	Shi, LX; Lorkovic, ZJ; Oelmuller, R; Schroder, WP				Shi, LX; Lorkovic, ZJ; Oelmuller, R; Schroder, WP			The low molecular mass PsbW protein is involved in the stabilization of the dimeric photosystem II complex in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; CORE COMPLEX; SUBUNIT; SPINACH; GENE; CRYSTALLOGRAPHY; ORGANIZATION; MEMBRANE; MUTANTS; PLANTS	Arabidopsis thaliana plants have been transformed with an antisense gene to the psbW of photosystem II (PSII). Eight transgenic lines containing low levels of psbW mRNA have been obtained. Transgenic seedlings with low contents of PsbW protein (more than 96% reduced) were selected by Western blotting and used for photosynthetic functional studies. There were no distinct differences in phenotype between the antisense and wild type plants during vegetative period under normal growth light intensities. However, a sucrose gradient separation of briefly solubilized thylakoid membranes revealed that no dimeric PSII supracomplex could be detected in the transgenic plants lacking the PsbW protein. Furthermore, analysis of isolated thylakoids demonstrated that the oxygen-evolving rate in antisense plants decreased by 50% compared with the wild type, This was found to be due to up to 40% of D1 and D2 reaction center proteins of PSII disappearing in the transgenic plants. The absence of the PsbW protein also altered the contents of other PSII proteins to differing extents. These results show that in the absence of the PsbW protein, the stability of the dimeric PSII is diminished and consequently the total number of PSII complexes is greatly reduced. Thus the nuclear encoded PsbW protein may play a crucial role in the biogenesis and regulation of the photosynthetic apparatus.	Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem, SE-10691 Stockholm, Sweden; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Jena, Lehrstuhl Pflanzenphysiol, Inst Allgemeine Bot, D-07743 Jena, Germany; Sodertorns Hogskola, Univ Coll, Bipontus, SE-14104 Huddinge, Sweden	Stockholm University; Friedrich Miescher Institute for Biomedical Research; Friedrich Schiller University of Jena; Sodertorn University	Schroder, WP (corresponding author), Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem, SE-10691 Stockholm, Sweden.		Schröder, Wolfgang/A-8799-2008	Schroder, Wolfgang/0000-0001-9831-1533; Lorkovic, Zdravko/0000-0002-3074-7258				ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Barber J, 1999, CURR OPIN STRUC BIOL, V9, P469, DOI 10.1016/S0959-440X(99)80066-9; Barber J, 1999, TRENDS BIOCHEM SCI, V24, P43, DOI 10.1016/S0968-0004(98)01348-6; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bianchetti M, 1998, J BIOL CHEM, V273, P16128, DOI 10.1074/jbc.273.26.16128; Eshaghi S, 1999, FEBS LETT, V446, P23, DOI 10.1016/S0014-5793(99)00149-0; FUNK C, 1995, PHOTOSYNTHESIS LIGHT, V3, P329; Hagman A, 1997, BIOCHEMISTRY-US, V36, P12666, DOI 10.1021/bi970685o; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1999, NAT STRUCT BIOL, V6, P560, DOI 10.1038/9341; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; KITAMURA K, 1994, FEBS LETT, V354, P113, DOI 10.1016/0014-5793(94)01089-7; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; Kruse O, 2000, J BIOL CHEM, V275, P6509, DOI 10.1074/jbc.275.9.6509; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; LORKOVIC ZJ, 1995, PHOTOSYNTHESIS LIGHT, V3, P743; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Noren H, 1999, BIOSCIENCE REP, V19, P499, DOI 10.1023/A:1020280710067; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER WP, 1986, BIOCHIM BIOPHYS ACTA, V848, P359, DOI 10.1016/0005-2728(86)90211-2; Shi LX, 1997, PHOTOSYNTH RES, V53, P45, DOI 10.1023/A:1005830405809; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122	37	44	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37945	37950		10.1074/jbc.M006300200	http://dx.doi.org/10.1074/jbc.M006300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10950961	hybrid			2022-12-25	WOS:000165618700086
J	Meyermans, H; Morreel, K; Lapierre, C; Pollet, B; De Bruyn, A; Busson, R; Herdewijn, P; Devreese, B; Van Beeumen, J; Marita, JM; Ralph, J; Chen, CY; Burggraeve, B; Van Montagu, M; Messens, E; Boerjan, W				Meyermans, H; Morreel, K; Lapierre, C; Pollet, B; De Bruyn, A; Busson, R; Herdewijn, P; Devreese, B; Van Beeumen, J; Marita, JM; Ralph, J; Chen, CY; Burggraeve, B; Van Montagu, M; Messens, E; Boerjan, W			Modifications in lignin and accumulation of phenolic glucosides in poplar xylem upon down-regulation of caffeoyl-coenzyme A O-methyltransferase, an enzyme involved in lignin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLA-PLANIFOLIA ANDR; PHENYLPROPANOID METABOLISM; SUBSTRATE SPECIFICITIES; SUSPENSION-CULTURES; TRANSGENIC POPLARS; MAIZE LIGNIN; ACID; EXPRESSION; SYRINGYL; METHYLATION	Caffeoyl-coenzyme A O-methyltransferase (CCoAOMT) methylates, in vitro, caffeoyl-CoA and 5-hydroxyferuloyl-CoA, two possible precursors in monolignol biosynthesis in vivo. To clarify the in vivo role of CCoAOMT in lignin biosynthesis, transgenic poplars with 10% residual CCoAOMT protein levels in the stem xylem were generated. Upon analysis of the xylem, the affected transgenic lines had a 12% reduced Klason lignin content, an 11% increased syringyl/guaiacyl ratio in the noncondensed lignin fraction, and an increase in lignin-attached p-hydroxybenzoate but otherwise a lignin composition similar to that of wild type. Stem xylem of the CCoAOMT-down-regulated lines had a pink-red coloration, which coincided with an enhanced fluorescence of mature vessel cell walls. The reduced production of CCoAOMT caused an accumulation of O-3-beta -D-glucopyranosyl-caffeic acid, O-4-beta -D-glucopyranosyl-vanillic acid, and O-4-beta -D-glucopyranosyl-sinapic acid (GSA), as authenticated by H-1 NMR Feeding experiments showed that O-3-beta -D-glucopyranosyl-caffeic acid and GSA are storage or detoxification products of caffeic and sinapic acid, respectively. The observation that down-regulation of CCoAOMT decreases lignin amount whereas GSA accumulates to 10% of soluble phenolics indicates that endogenously produced sinapic acid is not a major precursor in syringyl lignin biosynthesis. Our in vivo results support the recently obtained in vitro enzymatic data that suggest that the route hom caffeic acid to sinapic acid is not used for lignin biosynthesis.	State Univ Ghent VIB, Dept Plantengenet, B-9000 Ghent, Belgium; State Univ Ghent VIB, Vakgrp Mol Genet, B-9000 Ghent, Belgium; Inst Natl Agron Paris Grignon, Chim Biol Lab, F-78850 Thiverval Grignon, France; Univ Ghent, Vakgrp Organ Scheikunde, B-9000 Ghent, Belgium; Univ Ghent, Vakgrp Biochem Fysiol & Microbiol, B-9000 Ghent, Belgium; Katholieke Univ Leuven, Lab Med Scheikunde, B-3000 Louvain, Belgium; USDA ARS, US Dairy Forage Res Ctr, Madison, WI 53706 USA	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; AgroParisTech; Ghent University; Ghent University; KU Leuven; United States Department of Agriculture (USDA)	Boerjan, W (corresponding author), State Univ Ghent VIB, Dept Plantengenet, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	woboe@gengenp.rug.ac.be	Lapierre, Catherine/AAD-9209-2020; Devreese, Bart/K-2841-2019; Boerjan, Wout/Y-4158-2019; Ralph, John/C-3161-2009; Devreese, Bart/B-2011-2009	Devreese, Bart/0000-0002-9764-2581; Boerjan, Wout/0000-0003-1495-510X; Ralph, John/0000-0002-6093-4521; Devreese, Bart/0000-0002-9764-2581; Lapierre, Catherine/0000-0002-6757-1524; Herdewijn, Piet/0000-0003-3589-8503				Allina SM, 1998, PLANT PHYSIOL, V116, P743, DOI 10.1104/pp.116.2.743; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BJORKMAN A, 1956, SVENSK PAPPERSTIDN, V59, P447; Boudet AM, 1998, TRENDS PLANT SCI, V3, P67, DOI 10.1016/S1360-1385(97)01176-X; Braun S., 1998, 150 MORE BASIC NMR E; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; Chen CuiYing, 1999, Plant Physiology, V120, P635; Chen CY, 2000, PLANT PHYSIOL, V123, P853, DOI 10.1104/pp.123.3.853; Chen F, 1999, PLANTA, V207, P597, DOI 10.1007/s004250050523; Christensen JH, 2000, FOR SCI, V64, P227; DEBRUYN A, 1977, B SOC CHIM BELG, V86, P259; FUNK C, 1990, PLANT PHYSIOL, V94, P95, DOI 10.1104/pp.94.1.95; FUNK C, 1992, PLANT PHYSIOL, V99, P256, DOI 10.1104/pp.99.1.256; Grabber JH, 1996, PHYTOCHEMISTRY, V43, P1189, DOI 10.1016/S0031-9422(96)00431-1; GRAND C, 1983, PLANTA, V158, P225, DOI 10.1007/BF01075258; Higuchi T., 1985, BIOSYNTHESIS BIODEGR; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; IBRAHIM RK, 1977, Z PFLANZENPHYSIOL, V85, P253, DOI 10.1016/S0044-328X(77)80251-1; IIYAMA K, 1994, PLANT PHYSIOL, V104, P315, DOI 10.1104/pp.104.2.315; Inoue K, 1998, PLANT PHYSIOL, V117, P761, DOI 10.1104/pp.117.3.761; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; Lapierre C, 1999, PLANT PHYSIOL, V119, P153, DOI 10.1104/pp.119.1.153; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P113, DOI 10.1515/hfsg.1986.40.2.113; LEPLE JC, 1992, PLANT CELL REP, V11, P137, DOI 10.1007/BF00232166; Li LG, 2000, J BIOL CHEM, V275, P6537, DOI 10.1074/jbc.275.9.6537; LOSCHER R, 1994, PLANT PHYSIOL, V106, P271, DOI 10.1104/pp.106.1.271; Lu FC, 1999, J AGR FOOD CHEM, V47, P1988, DOI 10.1021/jf981140j; Matsui N, 2000, PLANTA, V210, P831, DOI 10.1007/s004250050686; MATSUI N, 1994, HOLZFORSCHUNG, V48, P375, DOI 10.1515/hfsg.1994.48.5.375; Maury S, 1999, PLANT PHYSIOL, V121, P215, DOI 10.1104/pp.121.1.215; MAVANDAD M, 1990, PLANT PHYSIOL, V94, P671, DOI 10.1104/pp.94.2.671; Meng H, 1998, PLANT MOL BIOL, V38, P513, DOI 10.1023/A:1006071708728; Monties B., 1989, METHODS PLANT BIOCH, VVolume 1, P113; Nakamura Y, 1978, CELL CHEM TECHNOL, V12, P199; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; PAKUSCH AE, 1991, PLANT PHYSIOL, V95, P137, DOI 10.1104/pp.95.1.137; Piquemal J, 1998, PLANT J, V13, P71, DOI 10.1046/j.1365-313X.1998.00014.x; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Saka S., 1985, BIOSYNTHESIS BIODEGR, P51; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNITZLER JP, 1992, PLANTA, V188, P594, DOI 10.1007/BF00197054; THIEME H, 1969, PHARMAZIE, V24, P292; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; Vander Mijnsbrugge K, 2000, PLANTA, V210, P589; VanDoorsselaere J, 1995, PLANT J, V8, P855, DOI 10.1046/j.1365-313X.1995.8060855.x; VICKERY ML, 1981, SECONDARY PLANT META, P32; Waterhouse PM, 1999, TRENDS PLANT SCI, V4, P452, DOI 10.1016/S1360-1385(99)01493-4; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhong RQ, 1998, PLANT CELL, V10, P2033, DOI 10.1105/tpc.10.12.2033; [No title captured]	58	193	235	4	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36899	36909		10.1074/jbc.M006915200	http://dx.doi.org/10.1074/jbc.M006915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10934215	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000165577700065
J	Petersen, S; de Graaf, AA; Eggeling, L; Mollney, M; Wiechert, W; Sahm, H				Petersen, S; de Graaf, AA; Eggeling, L; Mollney, M; Wiechert, W; Sahm, H			In vivo quantification of parallel and bidirectional fluxes in the anaplerosis of Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CITRIC-ACID CYCLE; CENTRAL METABOLIC PATHWAYS; PERFUSED RAT HEARTS; INTERMEDIARY METABOLISM; ESCHERICHIA-COLI; PHOSPHOENOLPYRUVATE CARBOXYLASE; REACTION STEPS; CARBON-FLUX; QUANTITATIVE-ANALYSIS	The C-3-C-4 metabolite interconversion at the anaplerotic node in many microorganisms involves a complex set of reactions. C-3, carboxylation to oxaloacetate can originate from phosphoenolpyruvate and pyruvate, and at the Same time multiple C-4-decarboxylating enzymes may be present. The functions of such parallel reactions are not yet fully understood. Using a C-13 NMR-based strategy, we here quantify the individual fluxes at the anaplerotic node of Corynebacterium glutamicum, which is an example of a bacterium possessing multiple carboxylation and decarboxylation reactions. C. glutamicum was grown with a C-13-labeled glucose isotopomer mixture as the main carbon source and 13C-labeled lactate as a cosubstrate. 58 isotopomers as well as 15 positional labels of biomass compounds were quantified. Applying a generally applicable mathematical model to include metabolite mass and carbon labeling balances, it is shown that pyruvate carboxylase contributed 91 +/- 7% to C-3 carboxylation. The total in vivo carboxylation rate of 1.28 +/- 0.14 mmol/g dry weight/h exceeds the demand of carboxylated metabolites for biosyntheses 3-fold. Excess oxaloacetate was recycled to phosphoenolpyruvate by phosphoenolpyruvate carboxykinase. This shows that the reactions at the anaplerotic node might serve additional purposes other than only providing C-4 metabolites for biosynthesis.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ Siegen, Inst Mech & Regelungstech, D-57068 Siegen, Germany	Helmholtz Association; Research Center Julich; Universitat Siegen	de Graaf, AA (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	a.de.graaf@fz-juelich.de		Wiechert, Wolfgang/0000-0001-8501-0694				BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; CHAO YP, 1994, J BIOL CHEM, V269, P5122; CHAO YP, 1993, APPL ENVIRON MICROB, V59, P4261, DOI 10.1128/AEM.59.12.4261-4265.1993; CocaignBousquet M, 1996, APPL ENVIRON MICROB, V62, P429, DOI 10.1128/AEM.62.2.429-436.1996; COCAIGNBOUSQUET M, 1995, ENZYME MICROB TECH, V17, P260, DOI 10.1016/0141-0229(94)00023-K; Comte B, 1997, J BIOL CHEM, V272, P26125, DOI 10.1074/jbc.272.42.26125; Comte B, 1997, J BIOL CHEM, V272, P26117, DOI 10.1074/jbc.272.42.26117; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; DIESTERHAFT MD, 1973, J BIOL CHEM, V248, P6062; Dominguez H, 1998, EUR J BIOCHEM, V254, P96, DOI 10.1046/j.1432-1327.1998.2540096.x; EIKMANNS BJ, 1989, MOL GEN GENET, V218, P330, DOI 10.1007/BF00331286; EIKMANNS BJ, 1995, J BACTERIOL, V177, P774, DOI 10.1128/jb.177.3.774-782.1995; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, V2; JEFFREY FMH, 1991, TRENDS BIOCHEM SCI, V16, P5, DOI 10.1016/0968-0004(91)90004-F; JETTEN MSM, 1993, FEMS MICROBIOL LETT, V111, P183; JETTEN MSM, 1995, ANTON LEEUW INT J G, V67, P221, DOI 10.1007/BF00871217; Jucker BM, 1998, J BIOL CHEM, V273, P12187, DOI 10.1074/jbc.273.20.12187; KATZ J, 1993, J BIOL CHEM, V268, P25509; KORNBERG HL, 1966, ESSAYS BIOCH, V2; Kramer R, 1996, J BIOTECHNOL, V45, P1, DOI 10.1016/0168-1656(95)00146-8; London RE, 1999, J BACTERIOL, V181, P3562, DOI 10.1128/JB.181.11.3562-3570.1999; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MANDELSTAM J, 1973, BIOCH BACTERIAL GROW; Marx A, 1997, BIOTECHNOL BIOENG, V56, P168, DOI 10.1002/(SICI)1097-0290(19971020)56:2<168::AID-BIT6>3.0.CO;2-N; Marx A, 1996, BIOTECHNOL BIOENG, V49, P111, DOI 10.1002/(SICI)1097-0290(19960120)49:2<111::AID-BIT1>3.0.CO;2-T; Marx A, 1999, METAB ENG, V1, P35, DOI 10.1006/mben.1998.0106; MILRADDEFORCHETTI SR, 1976, J GEN MICROBIOL, V93, P75, DOI 10.1099/00221287-93-1-75; Mollney M, 1999, BIOTECHNOL BIOENG, V66, P86, DOI 10.1002/(SICI)1097-0290(1999)66:2<86::AID-BIT2>3.0.CO;2-A; MORI M, 1985, J BIOCHEM-TOKYO, V98, P1621, DOI 10.1093/oxfordjournals.jbchem.a135432; OBRIEN RW, 1977, J BIOL CHEM, V252, P1257; Park SM, 1997, APPL MICROBIOL BIOT, V47, P430, DOI 10.1007/s002530050952; PETERSWENDISCH PG, 1993, FEMS MICROBIOL LETT, V112, P269, DOI 10.1016/0378-1097(93)90611-5; PetersWendisch PG, 1997, MICROBIOL-SGM, V143, P1095, DOI 10.1099/00221287-143-4-1095; PETERSWENDISCH PG, 1996, THESIS U DUSSELDORF; RABKIN M, 1985, BIOCHEM J, V225, P761, DOI 10.1042/bj2250761; RAUGI GJ, 1975, J BIOL CHEM, V250, P5866; Rognstad R, 1996, BIOCHEM ARCH, V12, P71; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; SCHRUMPF B, 1992, APPL MICROBIOL BIOT, V37, P566; SCHRUMPF B, 1991, J BACTERIOL, V173, P4510, DOI 10.1128/JB.173.14.4510-4516.1991; SCRUTTON MC, 1972, ENZYMES, V6; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHIIO I, 1978, J BIOCHEM-TOKYO, V84, P647, DOI 10.1093/oxfordjournals.jbchem.a132170; SONNTAG K, 1993, EUR J BIOCHEM, V213, P1325, DOI 10.1111/j.1432-1033.1993.tb17884.x; Stryer L., 1988, BIOCHEMISTRY-US; SUNDQVIST KE, 1989, BIOCHEM J, V257, P913, DOI 10.1042/bj2570913; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; VALLINO JJ, 1993, BIOTECHNOL BIOENG, V41, P633, DOI 10.1002/bit.260410606; WALKER TE, 1982, J BIOL CHEM, V257, P1189; Wendisch VF, 1997, ARCH MICROBIOL, V168, P262, DOI 10.1007/s002030050497; WeusterBotz D, 1997, BIOTECHNOL PROGR, V13, P387, DOI 10.1021/bp970034j; Wiechert W, 1999, BIOTECHNOL BIOENG, V66, P69; Wiechert W, 1997, BIOTECHNOL BIOENG, V55, P118, DOI 10.1002/(SICI)1097-0290(19970705)55:1<118::AID-BIT13>3.0.CO;2-I; Wiechert W, 1997, BIOTECHNOL BIOENG, V55, P101, DOI 10.1002/(SICI)1097-0290(19970705)55:1<101::AID-BIT12>3.0.CO;2-P; WIECHERT W, 1996, ADV BIOCH ENG BIOTEC, V54	57	152	167	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35932	35941		10.1074/jbc.M908728199	http://dx.doi.org/10.1074/jbc.M908728199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10946002	hybrid, Green Published			2022-12-25	WOS:000165382000043
J	Xu, JY; Tseng, Y; Wirtz, D				Xu, JY; Tseng, Y; Wirtz, D			Strain hardening of actin filament networks - Regulation by the dynamic cross-linking protein alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSING WAVE SPECTROSCOPY; MECHANICAL-PROPERTIES; F-ACTIN; THERMAL FLUCTUATIONS; ENDOTHELIAL-CELLS; BINDING PROTEINS; GELS; VISCOELASTICITY; CYTOSKELETON; FIBROBLASTS	Mechanical stresses applied to the plasma membrane of an adherent cell induces strain hardening of the cytoskeleton, i.e. the elasticity of the cytoskeleton increases with its deformation. Strain hardening is thought to mediate the transduction of mechanical signals across the plasma membrane through the cytoskeleton. Here, we describe the strain dependence of a model system consisting of actin filaments (F-actin), a major component of the cytoskeleton, and the F-actin cross-linking protein cu-actinin, which localizes along contractile stress fibers and at focal adhesions. We show that the amplitude and rate of shear deformations regulate the resilience of F-actin networks. At low temperatures; for which the lifetime of binding of a-actinin to F-actin is long, F-actin/alpha -actinin networks exhibit strong strain hardening at short time scales and soften at long time scales. For F-actin networks in the absence of alpha -actinin or for F-actin/alpha -actinin networks at high temperatures, strain hardening appears only at very short time scales. We propose a model of strain hardening for F-actin networks, based on both the intrinsic rigidity of F-actin and dynamic topological constraints formed by the cross-linkers located at filaments entanglements. This model offers an explanation for the origin of strain hardening observed when shear stresses are applied against the cellular membrane.	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Interdept Program Mol Biophys, Baltimore, MD 21218 USA; USDA ARS, Natl Ctr Agr Utilizat Res, Peoria, IL 61604 USA	Johns Hopkins University; Johns Hopkins University; United States Department of Agriculture (USDA)	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010					ALMO S, 1994, ANN REV CELL BIOL, V10, P207; [Anonymous], 1980, VISCOELASTIC PROPERT; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bausch AR, 1999, BIOPHYS J, V76, P573, DOI 10.1016/S0006-3495(99)77225-5; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P62; Critchley David R., 1993, P22; Doi M., 1989, THEORY POLYM DYNAMIC; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gittes F, 1998, PHYS REV E, V58, pR1241, DOI 10.1103/PhysRevE.58.R1241; GRAZI E, 1993, BIOCHEMISTRY-US, V32, P8896, DOI 10.1021/bi00085a022; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; Hinner B, 1998, PHYS REV LETT, V81, P2614, DOI 10.1103/PhysRevLett.81.2614; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; Kano Y, 1996, CIRC RES, V79, P1000, DOI 10.1161/01.RES.79.5.1000; Konstantopoulos K, 1996, J CLIN INVEST, V98, P2661, DOI 10.1172/JCI119088; KUHLMAN PA, 1994, FEBS LETT, V339, P297, DOI 10.1016/0014-5793(94)80434-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leinweber B, 1999, BIOPHYS J, V77, P3208, DOI 10.1016/S0006-3495(99)77151-1; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; LUM B, 1994, AM J PHYSIOL, V267, pL223; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Mason TG, 1998, MACROMOLECULES, V31, P3600, DOI 10.1021/ma970564w; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Miyata H, 1996, BBA-GEN SUBJECTS, V1290, P83, DOI 10.1016/0304-4165(96)00003-7; Morse DC, 1998, PHYS REV E, V58, pR1237, DOI 10.1103/PhysRevE.58.R1237; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rivero F, 1996, J CELL SCI, V109, P2679; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; Schnurr B, 1997, MACROMOLECULES, V30, P7781, DOI 10.1021/ma970555n; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; Thoumine O, 1997, J CELL SCI, V110, P2109; THOUMINE O, 1995, EXP CELL RES, V219, P427, DOI 10.1006/excr.1995.1249; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	58	187	187	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35886	35892		10.1074/jbc.M002377200	http://dx.doi.org/10.1074/jbc.M002377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954703	hybrid			2022-12-25	WOS:000165382000036
J	Kumaraswamy, E; Malykh, A; Korotkov, KV; Kozyavkin, S; Hu, Y; Kwon, SY; Moustafa, ME; Carlson, BA; Berry, MJ; Lee, BJ; Hatfield, DL; Diamond, AM; Gladyshev, VN				Kumaraswamy, E; Malykh, A; Korotkov, KV; Kozyavkin, S; Hu, Y; Kwon, SY; Moustafa, ME; Carlson, BA; Berry, MJ; Lee, BJ; Hatfield, DL; Diamond, AM; Gladyshev, VN			Structure-expression relationships of the 15-kDa selenoprotein gene - Possible role of the protein in cancer etiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC-ACID HYDROXYLASE; SELENOCYSTEINE-CONTAINING PROTEINS; CLOSTRIDIUM-BARKERI; GLUTATHIONE-PEROXIDASE; MAMMALIAN-CELLS; MESSENGER-RNA; SELENIUM; SEQUENCE; MOUSE; DEIODINASE	Selenium has been implicated in cancer prevention, but the mechanism and possible involvement of seleno-proteins in this process are not understood. To elucidate whether the 15-kDa selenoprotein may play a role in cancer etiology, the complete sequence of the human 15-kDa protein gene was determined, and various characteristics associated with expression of the protein were examined in normal and malignant cells and tissues. The 51-kilobase pair gene for the 15-kDa selenoprotein consisted of five exons and four introns and was localized on chromosome 1p31, a genetic locus commonly mutated or deleted in human cancers. Two stem-loop structures resembling selenocysteine insertion sequence elements were identified in the 3'-untranslated region of the gene, and only one of these was functional. Two alleles in the human 15-kDa protein gene were identified that differed by two single nucleotide polymorphic sites that occurred within the selenocysteine insertion sequence-like structures. These S'-untranslated region polymorphisms resulted in changes in selenocysteine incorporation into protein and responded differently to selenium supplementation. Human and mouse 15-kDa selenoprotein genes manifested the highest level of expression in prostate, liver, kidney, testis, and brain, and the level of the selenoprotein was reduced substantially in a malignant prostate cell line and in hepatocarcinoma. The expression pattern of the 15-kDa protein in normal and malignant tissues, the occurrence of polymorphisms associated with protein expression, the role of selenium in differential regulation of polymorphisms, and the chromosomal location of the gene may be relevant to a role of this protein in cancer.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA; NCI, Sect Mol Biol Selenium, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Fidel Syst Inc, Gaithersburg, MD 20879 USA; Univ Illinois, Chicago, IL 60612 USA; Seoul Natl Univ, IMBG, Genet Mol Lab, Seoul 151742, South Korea; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Seoul National University (SNU); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA.		Gladyshev, Vadim N/A-9894-2013; Moustafa, Mohamed E/E-9002-2018; Moustafa, Mohamed/AAM-2211-2021; Lee, Bong-Jin/AAQ-1609-2020; Kwon, So Yeon/M-5625-2014; Gladyshev, Vadim N/J-6187-2013	Lee, Bong-Jin/0000-0001-7896-2961; Kwon, So Yeon/0000-0002-8490-9101; Kozyavkin, Sergei/0000-0001-5605-5113; Gladyshev, Vadim/0000-0002-0372-7016; Moustafa, Mohamed/0000-0003-1308-6221; Korotkov, Konstantin/0000-0002-2182-6843	NATIONAL CANCER INSTITUTE [Z01BC005317, ZIABC005317] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Cheung TH, 1999, CANCER-AM CANCER SOC, V86, P1294, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.3.CO;2-F; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; DILWORTH GL, 1982, ARCH BIOCHEM BIOPHYS, V219, P30, DOI 10.1016/0003-9861(82)90130-8; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P232, DOI 10.1073/pnas.91.1.232; Gladyshev VN, 1996, BIOCHEMISTRY-US, V35, P212, DOI 10.1021/bi951793i; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Jorcyk CL, 1998, PROSTATE, V34, P10; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; Knekt P, 1998, AM J EPIDEMIOL, V148, P975, DOI 10.1093/oxfordjournals.aje.a009574; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Martin GW, 1996, RNA, V2, P171; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; NAGAI H, 1995, CANCER RES, V55, P1752; Sambrook J., 2002, MOL CLONING LAB MANU; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SLESAREV AI, 2000, IN PRESS METHODS ENZ; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Thompson KM, 1998, J NUTR, V128, P1289, DOI 10.1093/jn/128.8.1289; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219	33	120	131	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35540	35547		10.1074/jbc.M004014200	http://dx.doi.org/10.1074/jbc.M004014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945981	hybrid, Green Submitted			2022-12-25	WOS:000165422800093
J	Rebhun, JF; Castro, AF; Quilliam, LA				Rebhun, JF; Castro, AF; Quilliam, LA			Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase - Regulation of MR-GEF by M-Ras-GTP interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; BINDING-PROTEIN; ENCODING KRIT1; MAP KINASE; FAMILY; ACTIVATION; DOMAIN; GENE; PATHWAY; TRANSFORMATION	Although the Ras subfamily of GTPases consists of similar to 20 members, only a limited number of guanine nucleotide exchange factors (GEFs) that couple extracellular stimuli to Ras protein activation have been identified. Furthermore, no novel downstream effecters have been identified for the M-Ras/R-Ras3 GTPase. Here we report the identification and characterization of three Ras family GEFs that are most abundantly expressed in brain. Two of these GEFs, MR-GEF (M-Ras-regulated GEF, KIAA0277) and PDZ-GEF (KIAA0313) bound specifically to nucleotide-free Rap1 and Rap1/Rap2, respectively. Both proteins functioned as Rap1 GEFs in vivo. A third GEF, GRP3 (KIAA0846), activated both Ras and Rap1 and shared significant sequence homology with the calcium- and diacylglycerol-activated GEFs, GRP1 and GRP2, Similarly to previously identified Rap GEFs, C3G and Smg GDS, each of the newly identified exchange factors promoted the activation of Elk-1 in the LNCaP prostate tumor cell line where B-Raf can couple Rap1 to the extracellular receptor-activated kinase cascade. MR-GEF and PDZ-GEF both contain a region immediately N-terminal to their catalytic domains that share sequence homology with Ras-associating or Ral-GDS/AF6 homology (RA) domains. By searching for in vitro interaction with Ras-GTP proteins, PDZ-GEF specifically bound to Rap1A- and Rap2B-GTP, whereas MR-GEF bound to M-Ras-GTP. C-terminally truncated MR-GEF, lacking the GEF catalytic domain, retained its ability to bind M-Ras-GTP, suggesting that the RA domain is important for this interaction. Co-immunoprecipitation studies confirmed the interaction of M-Ras-GTP with MR-GEF in vivo, In addition, a constitutively active M-Ras(71L) mutant inhibited the ability of MR-GEF to promote Rap1A activation in a dose-dependent manner. These data suggest that M-Ras may inhibit Rap1 in order to elicit its biological effects.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS-4075, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019; Rebhun, John F/H-7235-2019	Rebhun, John F/0000-0002-0764-5210				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chen TS, 1999, CANCER RES, V59, P213; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; EHINU JO, 1998, SCIENCE, V280, P1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Iouzalen N, 1998, BIOCHEM BIOPH RES CO, V250, P359, DOI 10.1006/bbrc.1998.9336; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Laberge-le Couteulx S, 1999, NAT GENET, V23, P189, DOI 10.1038/13815; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	57	119	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34901	34908		10.1074/jbc.M005327200	http://dx.doi.org/10.1074/jbc.M005327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10934204	hybrid			2022-12-25	WOS:000165422800013
J	Sharma, M; Zarnegar, M; Li, XY; Lim, B; Sun, ZJ				Sharma, M; Zarnegar, M; Li, XY; Lim, B; Sun, ZJ			Androgen receptor interacts with a novel MYST protein, HBO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAINS; HUMAN PROSTATE CELLS; ZINC-FINGER PROTEIN; HEAT-SHOCK PROTEINS; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; DNA-BINDING; HUMAN GENES; COACTIVATOR	The androgen receptor (AR), a member of the nuclear receptor superfamily, plays a central role in male sexual differentiation and prostate cell proliferation. Results of-treating prostate cancer by androgen ablation indicate that signals mediated through AR are critical for the growth of these tumors. Like other nuclear receptors, AR exerts its transcriptional function by binding to cis-elements upstream of promoters and interacting with. other transcriptional factors (e.g. activators, repressors and modulators). To determine the mechanism of AR-regulated transcription, we used the yeast two-hybrid system to identify AR-associated proteins. One of the proteins we identified is identical to the human origin recognition complex-interacting protein termed HBO1. A ligand-enhanced interaction between AR and HBO1 was further confirmed in vivo and in vitro. Immunofluorescence experiments showed that HBO1 is a nuclear:protein,:and Northern blot analysis revealed that it is ubiquitously expressed, with the highest levels present inhuman testis. HBO1 belongs to the MYST family, which is characterized by a highly conserved C2HC zinc finger and a putative histone acetyltransferase domain. Surprisingly, two yeast members of the MYST family, SAS2: and SAS3, have been shown to function as transcription silencers, despite the presence of the histone acetyltransferase domain. Using a GAL4 DNA-binding domain assay, we mapped a transcriptional repression domain within the N-terminal region of HBO1. Transient transfection experiments revealed that HBO1 specifically repressed AR-mediated transcription in both CV-1 and PC-3 cells. These results indicate that HBO1 is a new AR-interacting protein capable of modulating AR activity. It could play a significant role in regulating AR-dependent genes in normal and prostate cancer cells.	Stanford Univ, Dept Surg & Genet, Sch Med, Liem Sioe Liong Mol Biol Lab, Stanford, CA 94305 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA	Stanford University; Harvard University; Beth Israel Deaconess Medical Center	Sun, ZJ (corresponding author), Stanford Univ, Dept Surg & Genet, Sch Med, Liem Sioe Liong Mol Biol Lab, R135,Edwards Bldg, Stanford, CA 94305 USA.	zsun@stanford.edu			NATIONAL CANCER INSTITUTE [R29CA070297, R01CA070297, R01CA087767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047636] Funding Source: NIH RePORTER; NCI NIH HHS [CA70297, R01 CA070297-09, R01 CA070297-11A2, R01 CA087767-03, R01 CA087767-02, R01 CA070297-10, R01 CA070297-12, R01 CA087767, R01 CA070297, R01 CA070297-08] Funding Source: Medline; NIDDK NIH HHS [DK47636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayer DE, 1996, MOL CELL BIOL, V16, P5772; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; ISAACS JT, 1987, UROL RES, V15, P133; James P, 1996, GENETICS, V144, P1425; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Navone NM, 1997, CLIN CANCER RES, V3, P2493; ONATE SA, 1995, SCIENCE, V270, P1354; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SIMENTAL JA, 1992, J STEROID BIOCHEM, V43, P37, DOI 10.1016/0960-0760(92)90185-L; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	59	104	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35200	35208		10.1074/jbc.M004838200	http://dx.doi.org/10.1074/jbc.M004838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10930412	hybrid			2022-12-25	WOS:000165422800051
J	Cheng, AY; Kaldis, P; Solomon, MJ				Cheng, AY; Kaldis, P; Solomon, MJ			Dephosphorylation of human cyclin-dependent kinases by protein phosphatase type 2C alpha and beta 2 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; SERINE-THREONINE PHOSPHATASE; TRANSCRIPTION FACTOR TFIIH; RABBIT SKELETAL-MUSCLE; CELL-CYCLE; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; MOLECULAR-CLONING; BUDDING YEAST; MAP KINASE	We previously reported that the activating phosphorylation on cyclin-dependent kinases in yeast (Gdc28p) and in humans (Cdk2) is removed by type 2C protein phosphatases. In this study, we characterize this PP2C-like activity in HeLa cell extract and determine that it is due to PP2C beta2, a novel PP2C beta isoform, and to PP2C alpha. PP2C alpha and PP2C beta2 co-purified with Mg2+-dependent Cdk2/Cdk6 phosphatase activity in DEAE-Sepharose, Superdex-200, and Mono Q chromatographies. Moreover, purified recombinant PP2C alpha and PP2C beta2 proteins efficiently dephosphorylated monomeric Cdk2/Cdk6 in vitro. The dephosphorylation of Cdk2 and Cdk6 by PP2C isoforms was inhibited by the binding of cyclins. We found that the PP2C-like activity in HeLa cell extract, partially purified HeLa PP2C alpha and PP2C beta2 isoforms, and the recombinant PP2Cs exhibited a comparable substrate preference for a phosphothreonine containing substrate, consistent with the conservation of threonine residues at the site of activating phosphorylation in CDKs.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Solomon, MJ (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	Mark.Solomon@yale.edu	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLARKE PR, 1991, ADV PROT PHOSPHATASE, V6, P187; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1993, CELL, V75, P805; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, J CELL SCI, V111, P3585; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KREK W, 1992, NEW BIOL, V4, P323; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; Labes M, 1998, MOL CELL NEUROSCI, V12, P29, DOI 10.1006/mcne.1998.0692; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; Marley AE, 1998, FEBS LETT, V431, P121, DOI 10.1016/S0014-5793(98)00708-X; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G	63	79	85	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34744	34749		10.1074/jbc.M006210200	http://dx.doi.org/10.1074/jbc.M006210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934208	hybrid			2022-12-25	WOS:000165095300099
J	Crowder, RJ; Freeman, RS				Crowder, RJ; Freeman, RS			Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PC12 PHEOCHROMOCYTOMA CELLS; NGF-DEPENDENT SURVIVAL; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-B; SYMPATHETIC NEURONS; BETA-CATENIN; TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; INDUCED APOPTOSIS	Numerous studies reveal that phosphatidylinositol (PI) 3-kinase and Akt protein kinase are important mediators of cell survival, However, the survival-promoting mechanisms downstream of these enzymes remain uncharacterized, Glycogen synthase kinase-3 beta (GSR-3 beta), which is inhibited upon phosphorylation by Akt, was recently shown to function during cell death induced by PI 3-kinase inhibitors. In this study, we tested whether GSK-3 beta is critical for the death of sympathetic neurons caused by the withdrawal of their physiological survival factor, the nerve growth factor (NGF). Stimulation with NGF resulted in PI 3-kinase-dependent phosphorylation of GSK-3 beta and inhibition of its protein kinase activity, indicating that GSK-3 beta is targeted by PI 3-kinase/Akt in these neurons. Expression of the GSK-3 beta inhibitor Frat1, but not a mutant Frat1 protein that does not bind GSK-3 beta, rescued neurons from death caused by inhibiting PI 3-kinase. Similarly, expression of Frat1 or kinase-deficient GSK-3 beta reduced death caused by inhibiting Akt, In NGF-maintained neurons, overexpression of GSK-3 gamma caused a small but significant decrease in survival. However, expression of neither Frat1, kinase-deficient GSH-3 beta, nor GSK-3-binding protein inhibited NGF withdrawal-induced death. Thus, although GSK-3 beta function is required for death caused by inactivation of PT 3-kinase and Akt, neuronal death caused by NGF withdrawal can proceed through GSK-3 beta -independent pathways.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Freeman, RS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034400, R56NS034400] Funding Source: NIH RePORTER; NIA NIH HHS [AG00107] Funding Source: Medline; NINDS NIH HHS [R01 NS034400, NS34400] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Bartlett SE, 1997, BRAIN RES, V761, P257, DOI 10.1016/S0006-8993(97)00329-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Easton RM, 1997, J NEUROSCI, V17, P9656; Eilers A, 1998, J NEUROSCI, V18, P1713; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Miller TM, 1997, J BIOL CHEM, V272, P9847; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Virdee K, 1997, J NEUROCHEM, V69, P550; Virdee K, 1999, BRAIN RES, V837, P127, DOI 10.1016/S0006-8993(99)01643-1; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	145	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34266	34271		10.1074/jbc.M006160200	http://dx.doi.org/10.1074/jbc.M006160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10954722	hybrid			2022-12-25	WOS:000165095300038
J	Jiang, H; Karnezis, AN; Tao, MY; Guida, PM; Zhu, L				Jiang, H; Karnezis, AN; Tao, MY; Guida, PM; Zhu, L			pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels	ONCOGENE			English	Article						tumor suppressor; retinoblastoma protein; p107; E2F; growth suppression	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA GENE-PRODUCT; RB-RELATED P107; GROWTH SUPPRESSION; TRANSCRIPTION FACTORS; FAMILY MEMBERS; MICE LACKING; MUSCLE-CELLS; IN-VIVO; PROTEIN	A key difference among the three structurally similar pRB family members is that only pRB is a tumor suppressor. Identification of distinctive functional differences between pRB and p107/p130 therefore holds promise for a better understanding of the tumor suppression mechanisms of pRB, Enigmatically, pRB and p107 have been shown to have indistinguishable growth suppression activities when studied in the pRB-deficient Saos-2 cell system. In this study, we discovered that, when expressed at physiologically relevant levels, pRB and p107 had distinctive effects in causing growth suppression, pRB induced cellular p130 levels while p107 repressed them, p107, but not pRB, blocked cells inside S phase in addition to G1 arrest. In contrast, no qualitative differences were identified in their abilities to repress the expression of a set of suspected pRB/E2F repression target genes. These results indicate that pRB and p107 possess different growth suppression effects, despite the fact that they have similar E2F repression effects.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhu, L (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-519, Bronx, NY 10461 USA.							Ausubel FA, 1990, CURRENT PROTOCOLS MO; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLBRINIK D, 1996, GENE DEV, V10, P1633; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARPER JW, 1993, CELL, V75, P805; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Tiemann F, 1998, EMBO J, V17, P1040, DOI 10.1093/emboj/17.4.1040; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3878	3887		10.1038/sj.onc.1203722	http://dx.doi.org/10.1038/sj.onc.1203722			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951581				2022-12-25	WOS:000088614300006
J	Duval, D; Reinhardt, S; Kedinger, C; Boeuf, H				Duval, D; Reinhardt, S; Kedinger, C; Boeuf, H			Role of suppressors of cytokine signaling (Socs) in leukemia inhibitory factor (LIF) -dependent embryonic stem cell survival	FASEB JOURNAL			English	Article						pluripotency; apoptosis; early response genes; transcription	STAT3 ACTIVATION; TARGETED DISRUPTION; POLY(ADP-RIBOSE) POLYMERASE; NEGATIVE REGULATORS; CIS FAMILY; BOX MOTIF; APOPTOSIS; GENE; PROTEINS; MICE	Mouse embryonic stem (ES) cells remain pluripotent in vitro when grown in the presence of leukemia inhibitory factor (LIF), LIF withdrawal results in progressive ES cell differentiation. Here we show that during this differentiation process, part of the cells undergo apoptosis concomitant with an activation of the p38 MAP kinase. To gain insight into events mediated by LIF in ES cells, the expression of potential candidate genes was analyzed in the absence or presence of this cytokine by using a semiquantitative RT-PCR assay, We focused on early response genes and on a new type of cytokine repressors (the Socs proteins), some of which exhibit anti-apoptotic properties, We found that expression of c-Fos, c-Jun, and JunB was induced upon LIF treatment whereas that of JunD, the tyrosine phosphatase ESP, and the components of the LIF receptor remained unaffected, Expression of Socs-3, but not Socs-1 or Socs-2, was stimulated in the presence of LIF. Finally, uncontrolled overexpression of Socs-1 and Socs-3 led to repression of LIF-dependent transcription and severely reduced cell viability, suggesting that the disturbance of a well balanced Socs protein content has adverse effects on cell survival.	IGBMC, Inst genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kedinger, C (corresponding author), IGBMC, Inst genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.	kedinger@igbmc.u-strasbg.fr	DUVAL, David/B-8586-2011	Duval, David/0000-0001-6933-3354				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COFFER P, 1995, ONCOGENE, V10, P985; Cohen-Tannoudji M, 1998, MOL HUM REPROD, V4, P929, DOI 10.1093/molehr/4.10.929; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Sepulveda P, 1999, EMBO J, V18, P904; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gardner RL, 1997, INT J DEV BIOL, V41, P235; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lee K, 1996, MECH DEVELOP, V59, P153, DOI 10.1016/0925-4773(96)00586-2; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PESCE M, 1993, DEVELOPMENT, V118, P1089; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; Shellard J, 1996, EUR CYTOKINE NETW, V7, P699; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taupin J L, 1998, Int Rev Immunol, V16, P397, DOI 10.3109/08830189809043003; Tone E, 1998, BIOCHEM BIOPH RES CO, V253, P147, DOI 10.1006/bbrc.1998.9767; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARE CB, 1995, DEVELOPMENT, V121, P1283; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	67	98	100	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1577	1584		10.1096/fj.14.11.1577	http://dx.doi.org/10.1096/fj.14.11.1577			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928992				2022-12-25	WOS:000088627800012
J	Hertel, L; Rolle, S; De Andrea, M; Azzimonti, B; Osello, R; Gribaudo, G; Gariglio, M; Landolfo, S				Hertel, L; Rolle, S; De Andrea, M; Azzimonti, B; Osello, R; Gribaudo, G; Gariglio, M; Landolfo, S			The retinoblastoma protein is an essential mediator that links the interferon-inducible 204 gene to cell-cycle regulation	ONCOGENE			English	Article						Ifi 204; antiproliferative activity; cell cycle; retinoblastoma proteins	ANTIPROLIFERATIVE ACTIVITY; HIN-200 FAMILY; 3T3 CELLS; INHIBITION; P202; TRANSCRIPTION; PRB; EXPRESSION; INDUCTION; CLUSTER	We have previously demonstrated that overexpression of p204, a member of the Ifi 200 gene family, inhibits growth, delays G0/G1 progression into S phase, and impairs E2F-mediated transcriptional activity. In this study, we show that p204 directly binds the retinoblastoma protein (pRb) in vivo to exert its activity. Transient p204 overexpression in Rb+/+ mouse embryo fibroblasts (MEF) inhibits cell proliferation, but does not affect cell growth in MEF derived from Rb-/- mice. Two human cell lines, Saos2 and C33A, bearing an inactive pRb, but not primary human embryo fibroblasts, are resistant to the p204 antiproliferative activity. p204 contains two 200 amino acid motifs, designated as type a or b domains, each containing a canonical Rb binding motif (LXCXE). When dominant-negative mutants at the Rb binding motif were transfected in Rb+/+ MEF, p204 lost its ability to inhibit cell growth, delay cell transition from G1 to S phase, and impair DNA synthesis. Moreover p204 overexpression in Rb+/+ MEF led to a significant decrease of both DHFR and PCNA proteins, two S phase markers. BS contrast, this effect was not observed when Rb+/+ MEF were transfected with a p204 mutated at both Rb binding sites. Finally, overexpression of the LXCXE p204 mutant rendered Rb+/+ MEF resistant to the IFN-alpha antiproliferative activity, in comparison to the untransfected Rb+/+ MEF. As expected, Rb-/- cells were unsensitive to the IFN-alpha induced growth inhibition. Taken as a whole, these results suggest that (i) p204 contributes to the IFN-alpha antiproliferative activity and (ii) the primary target of p204 leading to efficient G1 arrest as web as to blockade of DNA replication from G1 phase is the pRb regulatory system.	CNR, Immunogenet & Expt Oncol Ctr, I-10126 Turin, Italy; Med Sch Novara, Dept Med Sci, Novara, Italy; Med Sch Torino, Dept Publ Hlth & Microbiol, Turin, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Eastern Piedmont Amedeo Avogadro	Landolfo, S (corresponding author), CNR, Immunogenet & Expt Oncol Ctr, Via Santan 9, I-10126 Turin, Italy.		Azzimonti, Barbara/K-3550-2016; De Andrea, Marco/J-5253-2012; Gribaudo, Giorgio/A-8872-2011	Azzimonti, Barbara/0000-0001-6364-6595; De Andrea, Marco/0000-0002-3188-5783; Gribaudo, Giorgio/0000-0002-1583-9146; Gariglio, Marisa/0000-0002-5187-0140				Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; BREJM A, 1999, BRIT J CANCER, V80, P38; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1996, J LEUKOCYTE BIOL, V60, P1; Demaeyer E., 1988, INTERFERONS OTHER RE; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gariglio M, 1998, J LEUKOCYTE BIOL, V64, P608, DOI 10.1002/jlb.64.5.608; GARIGLIO M, 1992, VIROLOGY, V187, P115, DOI 10.1016/0042-6822(92)90300-E; GARIGLIO M, 1994, EUR J BIOCHEM, V221, P731, DOI 10.1111/j.1432-1033.1994.tb18786.x; GIENI RS, 1995, J IMMUNOL METHODS, V187, P85, DOI 10.1016/0022-1759(95)00170-F; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Hertel L, 1999, VIROLOGY, V262, P1, DOI 10.1006/viro.1999.9885; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Min W, 1996, MOL CELL BIOL, V16, P359; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stiegler P, 1998, Prog Mol Subcell Biol, V20, P25; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	48	61	68	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3598	3608		10.1038/sj.onc.1203697	http://dx.doi.org/10.1038/sj.onc.1203697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951565				2022-12-25	WOS:000088568300005
J	Young, KW; Bootman, MD; Channing, DR; Lipp, P; Maycox, PR; Meakin, J; Challiss, RAJ; Nahorski, SR				Young, KW; Bootman, MD; Channing, DR; Lipp, P; Maycox, PR; Meakin, J; Challiss, RAJ; Nahorski, SR			Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production - Potential involvement of endogenous Edg-4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; P115 RHOGEF; KINASE; ACTIVATION; CELLS; SPHINGOSINE-1-PHOSPHATE; RELEASE; GROWTH; TRISPHOSPHATE	Lysophosphatidic acid (LPA)-mediated Ca2+ mobilization in human SH-SY5Y neuroblastoma cells does not involve either inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3)- or ryanodine-receptor pathways, but is sensitive to inhibitors of sphingosine kinase. This present study identifies Edg-4 as the receptor subtype involved and investigates the presence of a Ca2+ signaling cascade based upon the lipid second messenger molecule, sphingosine I-phosphate. Both LPA and direct G-protein activation increase [H-3]sphingosine l-phosphate levels in SH-SY5Y cells. Measurements of Ca-45(2+) release in premeabilized SH-SY5Y cells indicates that sphingosine I-phosphate, sphingosine, and sphingosylphosphorylcholine, but not N-acetylsphingosine are capable of mobilizing intracellular Ca2+. Furthermore, the effect of sphingosine was attenuated by the sphingosine kinase inhibitor dimethylsphingosine, or removal of ATP. Confocal microscopy demonstrated that LPA stimulated intracellular Ca2+ "puffs," which resulted from an interaction between the sphingolipid Ca2+ release pathway and Ins(1,4,5)P-3 receptors. Down-regulation of Ins(1,4,5)P-3 receptors uncovered a Ca2+ response to LPA, which was manifest as a progressive increase in global cellular Ca2+ with no discernible foci. We suggest that activation of an LPA-sensitive Edg-4 receptor solely utilizes the production of intracellular sphingosine l-phosphate to stimulate Ca2+ mobilization in SB-SY5Y cells. Unlike traditional Ca2+ release processes, this novel pathway does not require the progressive recruitment of elementary Ca2+ events.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	University of Leicester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; GlaxoSmithKline	Young, KW (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	kwy1@le.ac.uk	Bootman, Martin/AAB-3330-2019; Challiss, R.A. John/A-9412-2008	Bootman, Martin/0000-0002-6447-3451; Challiss, John/0000-0001-5506-2848				Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1999, MOL PHARMACOL, V55, P787; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; Choi OH, 1996, NATURE, V380, P634; EHLRICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Martin AK, 1999, BRIT J PHARMACOL, V126, P1559, DOI 10.1038/sj.bjp.0702464; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Young KW, 1999, BIOCHEM J, V343, P45, DOI 10.1042/0264-6021:3430045; Young KW, 1998, CELL CALCIUM, V24, P59, DOI 10.1016/S0143-4160(98)90089-6; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	38	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38532	38539		10.1074/jbc.M006631200	http://dx.doi.org/10.1074/jbc.M006631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10954727	hybrid			2022-12-25	WOS:000165739800054
J	Chen, J; Shpall, RL; Meyerdierks, A; Hagemeier, M; Bottger, EC; Naumovski, L				Chen, J; Shpall, RL; Meyerdierks, A; Hagemeier, M; Bottger, EC; Naumovski, L			Interferon-inducible Myc/STAT-interacting protein Nmi associates with IFP 35 into a high molecular mass complex and inhibits proteasome-mediated degradation of IFP 35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; LOCALIZATION; PHOSPHATASE; PATHWAY; GROWTH; TARGET; GENES	Nmi is an interferon (IFN)-inducible protein homologous to IFN-inducible protein IFP 35. The homology consists of a novel Nmi/IFP 35 domain (NID) of 90-92 amino acids that is repeated in tandem in each protein and mediates Nmi-Nmi protein interactions and subcellular localization. In a yeast two-hybrid screen with a fragment of Nmi protein containing both NIDs, we identified an interaction:between Nmi and IFP 35. Deletion derivatives of the proteins indicate that both NIDs are required for the interaction between Nmi and IFP 35. In mammalian cells, Nmi and IFP 35 co-immunoprecipitate and co-localize in large cytoplasmic speckles. Nmi and IFP 35 proteins associate into a high molecular mass complex of 300-400 kDa as determined by native gel electrophoresis and gel filtration. The association of Nmi and IFP 5 into a complex can be demonstrated in multiple cell::lines and is not dependent on treatment with IFN. Short term and long term cultures of transfected HEK293 cells suggest that Nmi and DFP 35 proteins stabilize: each other through complex formation. IFP 35 appears to be more labile because Nmi was stable in the absence of IFP 35, whereas LFP 35 was degraded in the absence of Nmi. A deletion analysis revealed that Nmi must interact with IFP 35 to prevent its degradation and that the amino terminus of Nmi is required, but not sufficient, for this function. Inhibition of the proteasome, but-not other proteases, led to increased levels of IFP 35. Thus, we have shown that Nmi and LFP 35 associate into a protein complex, that IFP 35 is degraded in a proteasome-mediated process, and that a novel function of Nmi is to prevent IFP 35 degradation. The stabilization of IFP 35 by Nmi may serve to amplify the physiologic effects of IFNs.	Stanford Med Ctr, Div Hematol Oncol, Dept Pediat, Stanford, CA 94305 USA; Med Hsch Hannover, Inst Med Mikrobiol, D-30625 Hannover, Germany	Stanford University; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Naumovski, L (corresponding author), Stanford Med Ctr, Div Hematol Oncol, Dept Pediat, 300 Pasteur Dr,H314, Stanford, CA 94305 USA.		Böttger, Erik C./F-6175-2011					BANGE FC, 1994, J BIOL CHEM, V269, P1091; Bao JX, 1996, ONCOGENE, V12, P2171; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DIANZANI F, 1997, MECH ACTION INTERFER; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902; Meyerdierks A, 1999, J HISTOCHEM CYTOCHEM, V47, P169, DOI 10.1177/002215549904700206; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Wang XY, 1996, BIOCHEM BIOPH RES CO, V229, P316, DOI 10.1006/bbrc.1996.1799; Wong C, 1997, ANAL BIOCHEM, V252, P33, DOI 10.1006/abio.1997.2284; Zhou XJ, 2000, J BIOL CHEM, V275, P21364, DOI 10.1074/jbc.M003177200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	24	48	52	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36278	36284		10.1074/jbc.M006975200	http://dx.doi.org/10.1074/jbc.M006975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10950963	hybrid			2022-12-25	WOS:000165382000090
J	Hoskins, JR; Kim, SY; Wickner, S				Hoskins, JR; Kim, SY; Wickner, S			Substrate recognition by the ClpA chaperone component of ClpAP protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; HEAT-SHOCK PROTEINS; N-END RULE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MU-TRANSPOSASE; REGULATORY SUBUNITS; MOLECULAR CHAPERONE; DNA-REPLICATION; QUALITY-CONTROL	ClpA, a member of the Clp/Hsp100 ATPase family, is a molecular chaperone and regulatory component of Clp-AP protease, We explored the mechanism of protein recognition by ClpA using a high affinity substrate, RepA, which is activated for DNA binding by ClpA and degraded by ClpAP, By characterizing RepA derivatives with N- or C-terminal deletions, we found that the N-terminal portion of RepA is required for recognition. More precisely, RepA derivatives lacking the N-terminal 5 or 10 amino acids are degraded by ClpAP at a rate similar to full-length RepA, whereas RepA derivatives lacking 15 or 20 amino acids are degraded much more slowly. Thus, ClpA recognizes an N-terminal signal in RepA beginning in the vicinity of amino acids 10-15, Moreover, peptides corresponding to RepA amino acids 4-13 and 1-15 inhibit interactions between ClpA and RepA We constructed fusions of RepA and green fluorescent protein, a protein not recognized by ClpA, and found that the N-terminal 15 amino acids of RepA are sufficient to target the fusion protein for degradation by ClpAP. However, fusion proteins containing 46 or 70 N-terminal amino acids of RepA are degraded more efficiently in vitro and are noticeably stabilized in vivo in clpA Delta and clpP Delta strains compared with wild type.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2D19,37 Convent Dr,MSC37-4255, Bethesda, MD 20892 USA.	suewick@helix.nih.gov						Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Chamberlin M J, 1992, Harvey Lect, V88, P1; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Wang LY, 1999, J BACTERIOL, V181, P1211, DOI 10.1128/JB.181.4.1211-1219.1999; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	53	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35361	35367		10.1074/jbc.M006288200	http://dx.doi.org/10.1074/jbc.M006288200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952988	hybrid			2022-12-25	WOS:000165422800071
J	Mintz-Weber, CS; Johnson, JP				Mintz-Weber, CS; Johnson, JP			Identification of the elements regulating the expression of the cell adhesion molecule MCAM/MUC18 - Loss of AP-2 is not required for MCAM expression in melanoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; GENE-TRANSCRIPTION; TUMOR-GROWTH; GLYCOPROTEIN; PROGRESSION; METASTASIS; MUC18/MCAM; BASAL; ACTS; CAMP	The cell adhesion molecule melonoma cell adhesion molecule (MCAM)/MUC18/CD146 is specifically up-regulated on tumors of neuroectodermal origin and in animal models confers metastatic capacity to human melanoma cells, To identify critical regions regulating MCAM expression in melanomas, 1 kilobase of the MCAM 5' region was analyzed for promoter activity and transcription factor binding in 1 glioma, 1 carcinoma, and 4 melanoma cell lines. The minimal MCAM promoter (-106/+22 base pair (bp)) consists of 4 Sp-l sites, two AP-2 elements, one cAMP responsive element, and the initiator surrounding the transcriptional start site. Analysis of mutated constructs indicated that the cAMP-responsive element is a major transcriptional activator in the majority of cell Lines. Site-directed mutagenesis revealed that, in AP-2 expressing cells, the AP-2 site within the core promoter (-23 bp) has an inhibitory influence on MCAM expression while the AP-2 sites at -131 and -302 bp are activating. Functional AP-2 was observed in both MCAM positive and MCAM negative melanoma cell lines indicating that expression of MCAM does not require loss of this transcription factor. Furthermore, all MCAM: constructs were strongly expressed in MCAM negative as well as MCAM positive cells, indicating that the expression of this gene is not controlled solely by the presence of transactivating factors binding to the investigated region.	Univ Munich, Inst Immunol, D-80336 Munich, Germany	University of Munich	Johnson, JP (corresponding author), Univ Munich, Inst Immunol, Goethestr 31, D-80336 Munich, Germany.							Bani MR, 1996, CANCER RES, V56, P3075; BUCK CA, 1995, MOL BASIS CANC, P175; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; HOLZMANN B, 1987, INT J CANCER, V39, P466, DOI 10.1002/ijc.2910390410; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; Karlen S, 1999, J INVEST DERMATOL, V113, P711, DOI 10.1046/j.1523-1747.1999.00746.x; KIM KS, 1993, J BIOL CHEM, V268, P15689; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEHMANN JM, 1987, CANCER RES, V47, P841; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Rummel MM, 1996, CANCER RES, V56, P2218; Schlagbauer-Wadl H, 1999, INT J CANCER, V81, P951, DOI 10.1002/(SICI)1097-0215(19990611)81:6<951::AID-IJC18>3.0.CO;2-V; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shih C, 1997, CANCER RES, V57, P1116; Shih IM, 1997, AM J PATHOL, V151, P745; SHIH IM, 1994, CANCER RES, V54, P2514; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	25	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34672	34680		10.1074/jbc.M003812200	http://dx.doi.org/10.1074/jbc.M003812200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938273	hybrid			2022-12-25	WOS:000165095300091
J	Watada, H; Mirmira, RG; Leung, J; German, MS				Watada, H; Mirmira, RG; Leung, J; German, MS			Transcriptional and translational regulation of beta-cell differentiation factor Nkx6.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INSULIN GENE; MICE LACKING; PANCREAS; BINDING; HOMEODOMAIN; INITIATION; ENTRY; CONTAINS; AGENESIS	In the mature pancreas, the homeodomain transcription factor Nkx6.1 is uniquely restricted to beta -cells, Nkx6.1 also is expressed in developing beta -cells and plays an essential role in their differentiation. Among cell Lines, both beta- and alpha -cell lines express nkx6.1 mRNA; but no protein can be detected in the alpha -cell lines, suggesting that post-transcriptional regulation contributes to the restriction of Nkx6.1 to beta -cells. To investigate the regulator of Nkx6.1 expression, we outlined the structure of the mouse nkx6.1 gene, and we identified regions that direct cell type-specific expression. The nkx6.1 gene has a long 5'-untranslated region (5'-UTR) downstream of a cluster of transcription start sites, nkx6.1 gene sequences from -5.6 to +1.0 kilobase pairs have specific promoter activity in beta -cell Lines but not in NIH3T3 cells. This activity is dependent on sequences located at about -800 base pairs and on the 5'-UTR. Electrophoretic mobility shift assays demonstrate that homeodomain transcription factors PDX1 and Nkx2.2 can bind to the sequence element located at -800 base pairs. In addition, dicistronic assays establish that the 5'-UTR region functions as a potent internal ribosomal entry site, providing cell type-specific regulation of translation. These data demonstrate that complex regulation of both Nkx6.1 transcription and translation provides the specificity of expression required during pancreas development.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075; Watada, Hirotaka/0000-0001-5961-1816	NIDDK NIH HHS [DK30255, DK31371, R01 DK021344] Funding Source: Medline; PHS HHS [K08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Li H, 1999, NAT GENET, V23, P67; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SAMBROOK J, 1989, MOL CLONING, V1, P7; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714	35	56	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34224	34230		10.1074/jbc.M004981200	http://dx.doi.org/10.1074/jbc.M004981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938085	hybrid			2022-12-25	WOS:000165095300032
J	Bofill-Cardona, E; Kudlacek, O; Yang, Q; Ahorn, H; Freissmuth, M; Nanoff, C				Bofill-Cardona, E; Kudlacek, O; Yang, Q; Ahorn, H; Freissmuth, M; Nanoff, C			Binding of calmodulin to the D-2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F LOOP REGION; DOPAMINE-RECEPTORS; A(1)-ADENOSINE RECEPTOR; REGULATORY PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; BRAIN-REGIONS; BETA-SUBUNIT; RAT-BRAIN; EXPRESSION	Signaling by D-2-dopamine receptors in neurons likely proceeds in the presence of Ca2+ oscillations. We describe here the biochemical basis for a cross-talk between intracellular Ca2+ and the D-2 receptor. By activation of calmodulin (CaM), Ca2+ directly inhibits the D-2 receptor; this conclusion is based on the following observations: (i) The receptor contains a CaM-binding motif in the NH2-terminal end of the third loop, a domain involved in activating G(i/o). A peptide fragment encompassing this domain (D2N) bound dansylated CaM in a Ca2+-dependent manner (K-D similar to 0.1 muM). (ii) Activation of purified G alpha (il) by D2N, and D-2 receptor-promoted GTP gammaS (guanosine 5'-(3-O-thio)triphosphate) binding in membranes was suppressed by Ca2+/CaM (IC50 similar to 0.1 muM), (iii) If Ca2+ influx was elicited in D-2 receptor-expressing HEK293 cells, agonist-dependent inhibition of cAMP formation decreased. This effect was not seen with other G(i)-coupled receptors (A(1)-adenosine and Mel(1A)-melatonin receptor). (iv) The D-2 receptor was retained by immobilized CaM and radiolabeled CaM was co-immunoprecipitated with the receptor. Specifically, inhibition by CaM does not result from uncoupling the D-2 receptor from its cognate G protein(s); rather, CaM directly targets the D-2 receptor to block the receptor-operated G protein activation switch.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Boehringer Ingelheim Austria GMBH, A-1120 Vienna, Austria	University of Vienna; Boehringer Ingelheim	Nanoff, C (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	christian.nanoff@univie.ac.at		Freissmuth, Michael/0000-0001-9398-1765; Kudlacek, Oliver/0000-0002-3086-8551; nanoff, christian/0000-0002-8857-2470				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BOUNDY VA, 1993, MOL PHARMACOL, V43, P666; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Hohenegger M, 1996, MOL PHARMACOL, V49, P73; Holler C, 1999, CELL MOL LIFE SCI, V55, P257, DOI 10.1007/s000180050288; Huff RM, 1996, CELL SIGNAL, V8, P453, DOI 10.1016/S0898-6568(96)00074-5; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MORI A, 1994, BRAIN RES, V654, P177, DOI 10.1016/0006-8993(94)91587-3; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; Nishi A, 1997, J NEUROSCI, V17, P8147; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; SELZER E, 1993, P NATL ACAD SCI USA, V90, P1609, DOI 10.1073/pnas.90.4.1609; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; VOSS T, 1993, J BIOL CHEM, V268, P4637; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; YAN C, 1994, J NEUROSCI, V14, P973; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9	38	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32672	32680		10.1074/jbc.M002780200	http://dx.doi.org/10.1074/jbc.M002780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10926927	hybrid			2022-12-25	WOS:000090003800042
J	Cambillau, C; Claverie, JM				Cambillau, C; Claverie, JM			Structural and genomic correlates of hyperthermostability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PYROCOCCUS-FURIOSUS; THERMOSTABILITY; RESOLUTION; STABILITY; SEQUENCE; ENZYMES; DNA	While most organisms grow at temperatures ranging between 20 and 50 degreesC, many archaea and a few bacteria have been found capable of withstanding temperatures close to 100 degreesC, or beyond, such as Pyrococcus or Aquifer Here we report the results of two independent large scale unbiased approaches to identify global protein properties correlating with an extreme thermophile lifestyle. First, we performed a comparative proteome analyses using 30 complete genome sequences from the three kingdoms. A large difference between the proportions of charged versus polar (noncharged) amino acids was found to be a signature of all hyperthermophilic organisms. Second, we analyzed the water accessible surfaces of 189 protein structures belonging to mesophiles or hyperthermophiles. We found that the surfaces of hyperthermophilic proteins exhibited the shift already observed at the genomic level, i.e, a proportion of solvent accessible charged residues strongly increased at the expense of polar residues. The biophysical requirements for the presence of charged residues at the protein surface, allowing protein stabilization through ion bonds, is therefore clearly imprinted and detectable in all genome sequences available to date.	CNRS UPR 9039, F-13402 Marseille 20, France; CNRS UMR 1889, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Cambillau, C (corresponding author), CNRS UPR 9039, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	Claverie, Jean-Michel/AAG-4889-2019; Claverie, Jean Michel/Z-2183-2019	Claverie, Jean-Michel/0000-0003-1424-0315; 				Audic S, 1998, P NATL ACAD SCI USA, V95, P10026, DOI 10.1073/pnas.95.17.10026; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Choi IG, 1997, EXTREMOPHILES, V1, P125, DOI 10.1007/s007920050025; CONNOLLY ML, 1983, SCIENCE, V306, P287; Danson MJ, 1998, TRENDS MICROBIOL, V6, P307, DOI 10.1016/S0966-842X(98)01316-X; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Lo Leggio L, 1999, PROTEINS, V36, P295; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; Pace CN, 2000, NAT STRUCT BIOL, V7, P345, DOI 10.1038/75100; PACE N, 2000, STRUCTURE LOND; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; Scheraga HA, 1998, J BIOMOL STRUCT DYN, V16, P447, DOI 10.1080/07391102.1998.10508260; Tekaia F, 1999, GENOME RES, V9, P550; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	23	230	237	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32383	32386		10.1074/jbc.C000497200	http://dx.doi.org/10.1074/jbc.C000497200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10940293	hybrid			2022-12-25	WOS:000090003800002
J	Belandia, B; Parker, MG				Belandia, B; Parker, MG			Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; DNA-BINDING DOMAIN; M-CAT ELEMENTS; FACTOR-I; NUCLEAR-RECEPTOR; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; ACTIVATION FUNCTION; ESTROGEN-RECEPTOR; GENE-EXPRESSION	SRC1, initially identified as a nuclear receptor coactivator, was found to interact with a member of the transcriptional enhancer factor (TEF) family of transcription factors, TEF-4, The interaction, which occurs in both intact cells and in a cell-free system, is mediated by the highly conserved basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) domain present in the N-terminal region of SRC1. Moreover, all three members of the p160 family of nuclear receptor coactivators, SRC1, TIF2, and RAGS, are able to potentiate transcription from a TEF response element in transient transfection experiments, and this activation requires the presence of the bHLH-PAS domain. These results suggest that the p160 proteins could be bona fide coactivators of the TEF family of transcription factors.	Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London	Parker, MG (corresponding author), Imperial Canc Res Fund, Mol Endocrinol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Belandia, Borja/H-1509-2015	Belandia, Borja/0000-0003-2448-206X				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bray S, 1999, CURR BIOL, V9, pR245, DOI 10.1016/S0960-9822(99)80154-7; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Carson JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1624, DOI 10.1152/ajpcell.1996.270.6.C1624; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen SL, 2000, GENE DEV, V14, P1209; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Glass CK, 2000, GENE DEV, V14, P121; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; Ikeda M, 1999, MOL CELL ENDOCRINOL, V147, P103, DOI 10.1016/S0303-7207(98)00211-1; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 1999, MOL ENDOCRINOL, V13, P879, DOI 10.1210/me.13.6.879; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KARIYA K, 1993, J BIOL CHEM, V268, P26658; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649	50	97	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30801	30805		10.1074/jbc.C000484200	http://dx.doi.org/10.1074/jbc.C000484200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10934189	hybrid			2022-12-25	WOS:000089762700011
J	Musil, LS; Le, ACN; VanSlyke, JK; Roberts, LM				Musil, LS; Le, ACN; VanSlyke, JK; Roberts, LM			Regulation of connexin degradation as a mechanism to increase gap junction assembly and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRAJUNCTIONAL ACETYLCHOLINE RECEPTORS; INTERCELLULAR COMMUNICATION; HALF-LIFE; ORNITHINE DECARBOXYLASE; PROTEASOME PATHWAY; ESTROGEN-RECEPTOR; CELL-LINES; PROTEIN; UBIQUITIN; TURNOVER	Connexins, the integral membrane protein constituents of gap junctions, are degraded at a rate (t(1/2) = 1.5-5 h) much faster than most other cell surface proteins. Although the turnover of connexins has been shown to be sensitive to inhibitors of either the lysosome or of the proteasome, how connexins are targeted for degradation and whether this process can be regulated to affect intercellular communication is unknown. We show here that reducing connexin degradation with inhibitors of the proteasome (but not with lysosomal blockers) is associated with a striking increase in gap junction assembly and intercellular dye transfer in cells inefficient in both processes under basal conditions. The effect of proteasome inhibitors on wild-type connexin stability, assembly, and function was mimicked by treatment of assembly-inefficient cells with inhibitors of protein synthesis such as cycloheximide. Sensitivity of connexin degradation to cycloheximide, but not to proteasome inhibitors, was abolished when connexins were rendered structurally abnormal by perturbation of essential disulfide bonds or by mutation. Our findings provide the first evidence that intercellular communication can be up-regulated at the level of connexin turnover and that a short-lived protein may be required for conformationally mature connexins to become substrates of proteasomal degradation.	Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res L474, Portland, OR 97201 USA	Oregon Health & Science University	Musil, LS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res L474, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Le, Anh-Chi/0000-0003-1619-2281				Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Borras M, 1996, J STEROID BIOCHEM, V57, P203, DOI 10.1016/0960-0760(95)00272-3; Boundy VA, 1998, J PHARMACOL EXP THER, V286, P1058; Castro C, 1999, J NEUROSCI, V19, P3752; CHANG CC, 1975, NATURE, V253, P643, DOI 10.1038/253643a0; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Deschenes SM, 1997, J NEUROSCI, V17, P9077; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; EPSTEIN ML, 1977, EXP CELL RES, V104, P25, DOI 10.1016/0014-4827(77)90064-7; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FLAGGNEWTON JL, 1981, J MEMBRANE BIOL, V63, P105, DOI 10.1007/BF01969452; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; FRITSCH JE, 1988, EXP CELL RES, V175, P277, DOI 10.1016/0014-4827(88)90192-9; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HARE JF, 1991, P NATL ACAD SCI USA, V88, P5902, DOI 10.1073/pnas.88.13.5902; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; LARSEN WJ, 1978, TISSUE CELL, V10, P585, DOI 10.1016/S0040-8166(16)30351-2; Le ACN, 1998, DEV BIOL, V204, P80, DOI 10.1006/dbio.1998.9030; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; Murakami Y, 1996, BIOCHEM J, V317, P77, DOI 10.1042/bj3170077; Musil Linda S., 1994, P173; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PENN EJ, 1987, J CELL BIOL, V105, P2327, DOI 10.1083/jcb.105.5.2327; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROOK MB, 1990, J MEMBRANE BIOL, V118, P179, DOI 10.1007/BF01868475; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; STEINBACH JH, 1979, P NATL ACAD SCI USA, V76, P3547, DOI 10.1073/pnas.76.7.3547; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; VanSlyke JK, 2000, METHODS, V20, P156, DOI 10.1006/meth.1999.0933; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; ZIEMIECKI A, 1982, MOL CELL BIOL, V2, P355, DOI 10.1128/MCB.2.4.355	57	196	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25207	25215		10.1074/jbc.275.33.25207	http://dx.doi.org/10.1074/jbc.275.33.25207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10940315	hybrid			2022-12-25	WOS:000088849400024
J	Sasaki, S; Ito, E; Toki, T; Maekawa, T; Kanezaki, R; Umenai, T; Muto, A; Nagai, H; Kinoshita, T; Yamamoto, M; Inazawa, J; Taketo, MM; Nakahata, T; Igarashi, K; Yokoyama, M				Sasaki, S; Ito, E; Toki, T; Maekawa, T; Kanezaki, R; Umenai, T; Muto, A; Nagai, H; Kinoshita, T; Yamamoto, M; Inazawa, J; Taketo, MM; Nakahata, T; Igarashi, K; Yokoyama, M			Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15	ONCOGENE			English	Article						Bach2; Maf; non-Hodgkin's lymphoma; CNC family; NF-E2	SMALL MAF PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; LEUCINE ZIPPER PROTEIN; FACTOR NF-E2; FUNCTIONAL-CHARACTERIZATION; BINDING PROTEINS; GENE-EXPRESSION; DNA-BINDING; LONG ARM; FAMILY	The transcription factor Bach2, a member of the BTB-basic region leucine zipper (bZip) factor family, binds to a 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element and the related Maf-recognition element (MARE) by forming homodimers or heterodimers with Maf-related transcription factors. Bach2 regulates transcription by binding to these elements. To understand the function in hematopoiesis, lye isolated a cDNA clone for human Bach2 (BACH2) encoding a protein of 841 amino acid residues with a deduced amino acid sequence having 89.5% identity to mouse homolog, Among human hematopoietic cell lines, BACH2 is expressed abundantly only in some B-lymphocytic cell lines. RT-PCR analysis of hematopoietic cells revealed that BACH2 mRNA is expressed in primary B-cells, Enforced expression of BACH2 in a human Burkitt cell line, RAJI that does not express endogenous BACH2, resulted in marked reduction of clonogenic activity, indicating that BACH2 possesses an inhibitory effect on cell proliferation. By fluorescent in situ hybridization, the BACH2 gene was localized to chromosome 6q15. Because deletion of the long arm of chromosome 6 (6q) is one of the commonest chromosomal alterations in human B-cell lymphoma, we examined for the loss of heterozygosity (LOH) of the BACH2 gene in human B-cell non-Hodgkin's lymphomas (NHL). Among 25 informative cases, five (20%) shelved LOH. These results indicate that BACH2 plays important roles in regulation of B cell development.	Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan; Hirosaki Univ, Fac Sci, Dept Biol, Hirosaki, Aomori 0368563, Japan; Univ Tokyo, Inst Med Sci, Dept Transfus Med & Cell Therapy, Minato Ku, Tokyo 1130033, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Tohoku Univ, Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Oncol, Minato Ku, Tokyo 1130033, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668560, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Hirosaki University; Hirosaki University; University of Tokyo; University of Tsukuba; University of Tsukuba; Tohoku University; University of Tokyo; Nagoya University; Tokyo Medical & Dental University (TMDU); University of Tokyo	Ito, E (corresponding author), Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan.		Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Ito, Etsuro/0000-0002-0168-2475; Igarashi, Kazuhiko/0000-0002-2470-2475				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; CALIGARISCAPPIO F, 1985, J CLIN INVEST, V76, P1243, DOI 10.1172/JCI112080; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; HAYASHI Y, 1990, BLOOD, V76, P1626; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IMAI T, 1991, BLOOD, V78, P1969; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P26, DOI 10.1002/gcc.2870100105; Merup M, 1998, BLOOD, V91, P3397, DOI 10.1182/blood.V91.9.3397.3397_3397_3400; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOHLER J, 1995, DEVELOPMENT, V121, P237; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; NAKAO J, 1995, J NEUROCHEM, V64, P2396; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Nishihara M, 1998, EUR J IMMUNOL, V28, P855, DOI 10.1002/(SICI)1521-4141(199803)28:03<855::AID-IMMU855>3.0.CO;2-X; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V91, P9926; OFFIT K, 1993, BLOOD, V82, P2157; OFFIT K, 1994, BLOOD, V83, P2611, DOI 10.1182/blood.V83.9.2611.bloodjournal8392611; Oyake T, 1996, MOL CELL BIOL, V16, P6083; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; Yoshimatsu T, 1998, HUM GENE THER, V9, P161, DOI 10.1089/hum.1998.9.2-161	48	56	67	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3739	3749		10.1038/sj.onc.1203716	http://dx.doi.org/10.1038/sj.onc.1203716			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949928				2022-12-25	WOS:000088568400006
J	Dufner, P; Marra, G; Raschle, M; Jiricny, J				Dufner, P; Marra, G; Raschle, M; Jiricny, J			Mismatch recognition and DNA-dependent stimulation of the ATPase activity of hMutS alpha is abolished by a single mutation in the hMSH6 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE MSH2-MSH6 COMPLEX; SACCHAROMYCES-CEREVISIAE; SLIDING CLAMP; PROTEIN BINDS; MUTS-BETA; REPAIR; MSH6; HETERODIMER; SPECIFICITY; HYDROLYSIS	The most abundant mismatch binding factor in human cells, hMutS alpha, is a heterodimer of hMSH2 and hMSH6, two homologues of the bacterial MutS protein. The C-terminal portions of all MutS homologues contain an ATP binding motif and are highly conserved throughout evolution. Although the N termini are generally divergent, they too contain short conserved sequence elements. A phenylalanine --> alanine substitution within one such motif, GXFY(X)(5)DA, has been shown to abolish the mismatch binding activity of the MutS protein of Thermus aquaticus (Malkov, V. A, Biswas, I., Camerini-Otero, R, D., and Hsieh, P, (1997) J. Biol. Chem. 272, 23811-23817); We introduced an identical mutation into one or both subunits of hMutS alpha The Phe --> Ala substitution in hMSH2 had no effect on the biological activity of the heterodimer. In contrast, the in vitro mismatch binding and mismatch repair functions of hMutS alpha were severely attenuated when the hMSH6 subunit was mutated. Moreover, this variant heterodimer also displayed a general DNA binding defect. Correspondingly, its ATPase activity could not be stimulated by either heteroduplex or homoduplex DNA Thus the N-terminal portion of hMSH6 appears to impart on hMutS alpha: not only the specificity for recognition and binding of mismatched substrates but also the ability to bind to homoduplex DNA.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Jiricny, J (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.	jiricny@imr.unizh.ch						Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; Biswas I, 2000, BIOCHEM J, V347, P881, DOI 10.1042/0264-6021:3470881; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 1999, NUCLEIC ACIDS RES, V27, P736, DOI 10.1093/nar/27.3.736; CROUSE G, 1997, DNA DAMAGE REPAIR, V1, P411; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; OHMOLOVA G, 2000, NATURE, V407, P703; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829	37	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36550	36555		10.1074/jbc.M005987200	http://dx.doi.org/10.1074/jbc.M005987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10938287	Green Accepted, hybrid			2022-12-25	WOS:000165577700014
J	Fujimura, T; Esteban, R				Fujimura, T; Esteban, R			Recognition of RNA encapsidation signal by the yeast L-A doublelstranded RNA virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; POL FUSION PROTEIN; RIBOSOMAL FRAMESHIFTING EFFICIENCY; SACCHAROMYCES-CEREVISIAE; BINDING; REPLICATION; PARTICLES; SITES; COMPLEX; CAPSIDS	The encapsidation signal of the yeast L-A virus contains a 24-nucleotide stem-loop structure with a B-nucleotide loop and an A bulged at the 5' side of the stem. The Pol part of the Gag-Pol fusion protein is responsible for encapsidation of viral RNA. Opened empty viral particles containing Gag-Pol specifically bind to this encapsidation signal in vitro. We found that binding to empty particles protected the bulged A and the flanking-two nucleotides from cleavage by Fe(II)-EDTA-generated hydroxyl radicals. The five nucleotides of the loop sequence ((4190)GAUCC(4194)) were not protected. However, T1 RNase protection and in vitro mutagenesis experiments indicated that G(4190) is essential for binding. Although the sequence of the other four nucleotides of the loop is not essential, data from RNase protection and chemical modification experiments suggested that C-4194 was also directly involved in binding to empty particles rather than indirectly through its potential base pairing with G(4190). These results suggest that the Pol domain of Gag-Pol contacts the encapsidation signal at two sites: one, the bulged A, and the other, G and C bases at the opening of the loop. These two sites are conserved in the encapsidation signal of M1, a satellite RNA of the L-A virus.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Avda Campo Charro S-N, Salamanca 37007, Spain.		Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769				ARNI R, 1988, J BIOL CHEM, V263, P15358; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; BASHKIN JS, 1993, FOOTPRINTING NUCLEIC, P75; BORER PN, 1995, BIOCHEMISTRY-US, V34, P6488, DOI 10.1021/bi00019a030; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; DINMAN JD, 1992, J VIROL, V66, P3669, DOI 10.1128/JVI.66.6.3669-3676.1992; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; DINMAN JD, 1994, GENETICS, V136, P75; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; ESTEBAN R, 1988, P NATL ACAD SCI USA, V85, P4411, DOI 10.1073/pnas.85.12.4411; FUJIMURA T, 1992, J BIOL CHEM, V267, P2708; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1988, J BIOL CHEM, V263, P454; FUJIMURA T, 1989, J BIOL CHEM, V264, P10872; ICHO T, 1989, J BIOL CHEM, V264, P6716; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; Moine H, 1997, RNA STRUCTURE FUNCTI, P77; POWERS T, 1995, RNA, V1, P194; Ribas JC, 1998, J BIOL CHEM, V273, P9306, DOI 10.1074/jbc.273.15.9306; RIBAS JC, 1994, J BIOL CHEM, V269, P28420; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; SHEN YQ, 1993, VIROLOGY, V195, P481, DOI 10.1006/viro.1993.1399; Steitz TA, 1999, RNA WORLD, P427; TZENG TH, 1992, J VIROL, V66, P999, DOI 10.1128/JVI.66.2.999-1006.1992; Valegard K, 1997, J MOL BIOL, V270, P724, DOI 10.1006/jmbi.1997.1144; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Yao WS, 1997, J VIROL, V71, P2157, DOI 10.1128/JVI.71.3.2157-2162.1997; YAO WS, 1995, J VIROL, V69, P1917, DOI 10.1128/JVI.69.3.1917-1919.1995	36	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37118	37126		10.1074/jbc.M005245200	http://dx.doi.org/10.1074/jbc.M005245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10954712	hybrid			2022-12-25	WOS:000165577700092
J	Warshaw, DM; Guilford, WH; Freyzon, Y; Krementsova, E; Palmiter, KA; Tyska, MJ; Baker, JE; Trybus, KM				Warshaw, DM; Guilford, WH; Freyzon, Y; Krementsova, E; Palmiter, KA; Tyska, MJ; Baker, JE; Trybus, KM			The light chain binding domain of expressed smooth muscle heavy meromyosin acts as a mechanical lever	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; CONFORMATIONAL STATES; LASER TRAP; CONTRACTION; KINETICS; FORCE; COMPLEX; FILAMENTS; MOVEMENT; SYSTEMS	Structural data led to the proposal that the molecular motor myosin moves actin by a swinging of the light chain binding domain, or "neck" To test the hypothesis that the neck functions as a mechanical lever, smooth muscle heavy meromyosin (HMM) mutants were expressed with shorter or longer necks by either deleting or adding light chain binding sites. The mutant HMMs were characterized kinetically and mechanically, with emphasis on measurements of unitary displacements and forces in the laser trap assay, Two shorter necked constructs had smaller unitary step sizes and moved actin more slowly than WT HMM in the motility assay. A longer necked construct that contained an additional essential light chain binding site exhibited a 1.4-fold increase in the unitary step size compared with its control. Kinetic changes were also observed with several of the constructs, The mutant lacking a neck produced force at a somewhat reduced level, while the force exerted by the giraffe construct was higher than control. The single molecule displacement and force data support the hypothesis that the neck functions as a rigid lever, with the fulcrum for movement and force located at a point within the motor domain.	Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA.			Guilford, William/0000-0002-6543-5713	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; Chaudoir BM, 1999, J CELL SCI, V112, P1611; CRAIG R, 1980, J MOL BIOL, V140, P35, DOI 10.1016/0022-2836(80)90355-1; Diffee GM, 1996, BIOPHYS J, V71, P341, DOI 10.1016/S0006-3495(96)79231-7; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOPHYS J, V68, pS19; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; PATLAK JB, 1993, BIOPHYS J, V65, P29, DOI 10.1016/S0006-3495(93)81041-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Tanaka H, 2000, BIOPHYS J, V78, p3A; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	33	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37167	37172		10.1074/jbc.M006438200	http://dx.doi.org/10.1074/jbc.M006438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10945998	hybrid			2022-12-25	WOS:000165577700097
J	Cabrele, C; Langer, M; Bader, R; Wieland, HA; Doods, HN; Zerbe, O; Beck-Sickinger, AG				Cabrele, C; Langer, M; Bader, R; Wieland, HA; Doods, HN; Zerbe, O; Beck-Sickinger, AG			The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEPTIN RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDES; PANCREATIC-POLYPEPTIDE; CIRCULAR-DICHROISM; FEEDING-BEHAVIOR; Y1 RECEPTOR; PEPTIDE-YY; OBESITY; NPY; MICE	The first Y-5 receptor-selective analog of neuropeptide Y (NPY), [Ala(31),Aib(32)]NPY, has been developed and biologically characterized. Using competition binding assays on cell lines that express different Y receptors, we determined the affinity of this analog to be 6 nM at the human Y-5 receptor, >500 nM at the Y-1 and Y-2 receptors, and >1000 nM at the Y-4 receptor. Activity studies performed in vitro using a cAMP enzyme immunoassay, and in vivo using food intake studies in rats, showed that the peptide acted as an agonist. Further peptides obtained by the combination of the Ala(31)-Aib(32) motif with chimeric peptides containing segments of NPY and pancreatic polypeptide displayed the same selectivity and even higher affinity (up to 0.2 nM) for the Y-5 receptor. In vivo administration of the new Y-5 receptor-selective agonists significantly stimulated feeding in rats. The NMR solution structures of NPY and [Ala(31),Aib(32)]NPY showed a different conformation in the C-terminal region, where the or-helix of NPY was substituted by a more flexible, 3(10)-helical turn structure.	Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland; Boehringer Ingelheim Pharma KG, Div Preclin Res, D-88397 Biberach, Germany; Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Boehringer Ingelheim; Leipzig University	Beck-Sickinger, AG (corresponding author), Swiss Fed Inst Technol, Dept Appl Biosci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Cabrele, Chiara/B-8790-2015	Cabrele, Chiara/0000-0002-7550-6896				BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; Beck Werner, 1994, Letters in Peptide Science, V1, P31, DOI 10.1007/BF00132760; Bischoff A, 1999, TRENDS PHARMACOL SCI, V20, P104, DOI 10.1016/S0165-6147(99)01319-X; CABRELE C, 2000, IN PRESS PEPTIDES; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COWLEY DJ, 1992, EUR J BIOCHEM, V205, P1099, DOI 10.1111/j.1432-1033.1992.tb16878.x; Criscione L, 1998, J CLIN INVEST, V102, P2136, DOI 10.1172/JCI4188; Dallongeville J, 1998, J MED CHEM, V41, P5337, DOI 10.1021/jm9802867; ECKERD CP, 2000, IN PRESS MOLECULES; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GERALD C, Patent No. 16542; GERALD C, Patent No. 15646; GRUNDEMAR L, 1997, NEUROPEPTIDE Y DRUG, P1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hipskind PA, 1997, J MED CHEM, V40, P3712, DOI 10.1021/jm970512x; Ingenhoven N, 1997, J RECEPT SIGNAL TR R, V17, P407, DOI 10.3109/10799899709036617; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kordik CP, 1999, J MED CHEM, V42, P181, DOI 10.1021/jm980521l; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LopezValpuesta FJ, 1996, P ROY SOC B-BIOL SCI, V263, P881, DOI 10.1098/rspb.1996.0130; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Michel MC, 1998, PHARMACOL REV, V50, P143; Mohle K, 1997, J COMPUT CHEM, V18, P1415, DOI 10.1002/(SICI)1096-987X(199708)18:11<1415::AID-JCC8>3.0.CO;2-O; Monks SA, 1996, J BIOMOL NMR, V8, P379; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; Rist B, 1998, J MED CHEM, V41, P117, DOI 10.1021/jm970533r; Schaffhauser AO, 1997, DIABETES, V46, P1792, DOI 10.2337/diabetes.46.11.1792; Small CJ, 1997, P NATL ACAD SCI USA, V94, P11686, DOI 10.1073/pnas.94.21.11686; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; Strader CD, 1998, DRUG DISCOV TODAY, V3, P250, DOI 10.1016/S1359-6446(98)01189-1; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Toniolo C, 1996, J AM CHEM SOC, V118, P2744, DOI 10.1021/ja9537383; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WIELAND HA, 1995, PEPTIDES, V16, P1389, DOI 10.1016/0196-9781(95)02028-4; Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	50	156	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36043	36048		10.1074/jbc.M000626200	http://dx.doi.org/10.1074/jbc.M000626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10944518	hybrid			2022-12-25	WOS:000165382000057
J	Xiang, H; Tschirret-Guth, RA; de Montellano, PRO				Xiang, H; Tschirret-Guth, RA; de Montellano, PRO			An A245T mutation conveys on cytochrome P450(eryF) the ability to oxidize alternative substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT COMPONENTS; SITE-DIRECTED MUTAGENESIS; SACCHAROPOLYSPORA-ERYTHRAEA; 6-DEOXYERYTHRONOLIDE-B HYDROXYLASE; OXYGEN ACTIVATION; AMINO-ACID; ERYTHROMYCIN BIOSYNTHESIS; CATALYTIC FUNCTION; ESCHERICHIA-COLI; CYP3A ISOFORMS	Cytochrome P450(eryF) (CYP107A1), which hydroxylates deoxyerythronolide B in erythromycin biosynthesis, lacks the otherwise highly conserved threonine that is thought to promote O-O bond scission. The role of this threonine is satisfied in P450(eryF) by a substrate hydroxyl group, making deoxyerythronolide B the only acceptable substrate. As shown here, replacement of Ala(245) by,threonine enables the oxidation of alternative substrates using either H2O2 or O-2/spinach ferredoxin/ferredoxin reductase as the source of oxidizing equivalents. Testosterone is oxidized to 1-, 11 alpha-, 12-, and 16 alpha -hydroxytestosterone. A kinetic solvent isotope effect of 2.2 indicates that the A245T mutation facilitates dioxygen bond cleavage. This gain-of-function evidence confirms the role of the conserved threonine in P450 catalysis, Furthermore, a Hill coefficient of 1.3 and dependence of the product distribution on the testosterone concentration suggest that two testosterone molecules bind in the active site, in accord with a published structure of the P450(eryF)-androstenedione complex. P450(eryF) is thus a structurally defined model for the P450 catalytic turnover of multiply bound substrates proposed to occur with CYP3A4, In view of its large active site and defined structure, catalytically active P450(eryF) mutants are also attractive templates for the engineering of novel P450 activities.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, S-926, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKENS J, 1994, J AM CHEM SOC, V116, P1143, DOI 10.1021/ja00082a051; ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; ANDERSEN JF, 1993, BIOCHEMISTRY-US, V32, P1905, DOI 10.1021/bi00059a004; ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; ANDERSSON T, 1994, BRIT J CLIN PHARMACO, V38, P131, DOI 10.1111/j.1365-2125.1994.tb04336.x; APLEY EC, 1985, ANAL BIOCHEM, V150, P145, DOI 10.1016/0003-2697(85)90453-1; Betlach MC, 1998, BIOCHEMISTRY-US, V37, P14937, DOI 10.1021/bi981699c; Cupp-Vickery J, 2000, P NATL ACAD SCI USA, V97, P3050, DOI 10.1073/pnas.050406897; CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585; Edholm O, 2000, BIOCHEM BIOPH RES CO, V268, P683, DOI 10.1006/bbrc.2000.2201; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HANIOKA N, 1992, J STEROID BIOCHEM, V43, P1037, DOI 10.1016/0960-0760(92)90331-C; HIROYA K, 1992, FASEB J, V6, P749, DOI 10.1096/fasebj.6.2.1347023; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Lee H, 1999, BIOCHEMISTRY-US, V38, P10808, DOI 10.1021/bi990463l; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Mueller Ernest J., 1995, P83; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SCHMIDER J, 1995, J PHARMACOL EXP THER, V275, P592; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; SHAFIEE A, 1987, BIOCHEMISTRY-US, V26, P6204, DOI 10.1021/bi00393a037; SHAFIEE A, 1988, J BACTERIOL, V170, P1548, DOI 10.1128/jb.170.4.1548-1553.1988; SMITH SJ, 1992, DRUG METAB DISPOS, V20, P566; Szklarz GD, 1997, J COMPUT AID MOL DES, V11, P265, DOI 10.1023/A:1007956612081; *TRIN SOFTW, 1993, ENZ KIN VERS 1 4; Truan G, 1998, ARCH BIOCHEM BIOPHYS, V349, P53, DOI 10.1006/abbi.1997.0400; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014; ZOTCHEV SB, 1995, GENE, V156, P101, DOI 10.1016/0378-1119(95)00012-U	43	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35999	36006		10.1074/jbc.M005811200	http://dx.doi.org/10.1074/jbc.M005811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956654	hybrid			2022-12-25	WOS:000165382000051
J	Chen, B; Zhou, GF; Kim, MY; Chishti, Y; Hussey, RE; Ely, B; Skehel, JJ; Reinherz, EL; Harrison, SC; Wiley, DC				Chen, B; Zhou, GF; Kim, MY; Chishti, Y; Hussey, RE; Ely, B; Skehel, JJ; Reinherz, EL; Harrison, SC; Wiley, DC			Expression, purification, and characterization of gp160e, the soluble trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; INFLUENZA-VIRUS; MEMBRANE-FUSION; HIV-1 GP41; OLIGOMERIC STRUCTURE; CD4 BINDING; SIV GP41; RECEPTOR; TYPE-1; GP120	The envelope glycoprotein, gp160, of simian immunodeficiency virus (SIV) shares similar to 25% sequence identity with gp160 from the human immunodeficiency virus, type I,, indicating a close structural similarity. As a result of binding to cell surface CD4 and co-receptor (e.g. CCR5 and CXCR4), both SIV and human immunodeficiency virus gp160 mediate viral entry by membrane fusion. We report here the characterization of gp160e, the soluble ectodomain of SIV gp160. The ectodomain has been expressed in both insect cells and Chinese hamster ovary (CHO)-Lec3.2.8.1 cells, deficient in enzymes necessary for synthesizing complex oligosaccharides. Both the primary and a secondary proteolytic cleavage sites between the gp120 and gp41 subunits of gp160 were mutated to prevent cleavage and shedding of gp120. The purified, soluble glycoprotein is shown to be trimeric by chemical cross-linking, gel filtration chromatography, and analytical ultracentrifugation. It forms soluble, tight complexes with soluble CD4 and a number of Fab fragments from neutralizing monoclonal antibodies. Soluble complexes were also produced of enzymatically deglycosylated gp160e and of gp160e variants with deletions in the variable segments.	Childrens Hosp, Howard Hughes Med Inst, Mol Med Lab, Boston, MA 02215 USA; Dana Farber Canc Inst, Boston, MA 02215 USA; Natl Inst Med Res, London NW7 1AA, England	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; MRC National Institute for Medical Research	Wiley, DC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Mol Med Lab, 320 Longwood Ave,Enders 673, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043649, R01AI143649] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BACHELDER RE, 1995, J VIROL, V69, P5734, DOI 10.1128/JVI.69.9.5734-5742.1995; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1991, ADV EXP MED BIOL, V300, P203; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GABUZDA D, 1991, J ACQ IMMUN DEF SYND, V4, P34; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Joshi SB, 1998, VIROLOGY, V248, P20, DOI 10.1006/viro.1998.9242; KENT KA, 1992, AIDS RES HUM RETROV, V8, P1147, DOI 10.1089/aid.1992.8.1147; KENT KA, 1991, AIDS, V5, P829, DOI 10.1097/00002030-199107000-00006; KINGSTON RE, 1992, SHORT PROTOCOLS MOL, P55; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; RUD EW, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P229; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065; WILEY DC, 1977, VIROLOGY, V79, P446, DOI 10.1016/0042-6822(77)90371-3; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	56	32	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34946	34953		10.1074/jbc.M004905200	http://dx.doi.org/10.1074/jbc.M004905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944528	hybrid			2022-12-25	WOS:000165422800018
J	Gabriel, SE; Makhlina, M; Martsen, E; Thomas, EJ; Lethem, MI; Boucher, RC				Gabriel, SE; Makhlina, M; Martsen, E; Thomas, EJ; Lethem, MI; Boucher, RC			Permeabilization via the P2X(7) purinoreceptor reveals the presence of a Ca2+-activated Cl- conductance in the apical membrane of murine tracheal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING ANION CHANNEL; HUMAN AIRWAY EPITHELIA; HUMAN NASAL EPITHELIUM; CYSTIC-FIBROSIS; INTRACELLULAR CALCIUM; CHLORIDE CHANNEL; ION-TRANSPORT; EXTRACELLULAR NUCLEOTIDES; NEUROTRANSMITTER RELEASE; ACTIVATION	Calcium-activated Cl- secretion is an important modulator of regulated ion transport in murine airway epithelium and is mediated by an unidentified Ca2+-stimulated Cl- channel. We have transfected immortalized murine tracheal epithelial cells with the cDNA encoding the permeabilizing P2X(7) purinoreceptor (P2X(7)-R) to selectively permeabilize the basolateral membrane and thereby isolate the apical membrane Ca2+-activated Cl- current. In P2X(7)-R-permeabilized cells, we have demonstrated that UTP stimulates a Cl- current across the apical membrane of CF and normal murine tracheal epithelial cells. The magnitude of the UTP-stimulated current was significantly greater in CF than in normal cells. Ion substitution studies demonstrated that the current exhibited a permselectivity sequence of Cl- > I- > Br- > gluconate(-). We have also determined a rank order of potency for putative Cl- channel blockers: niflumic acid greater than or equal to 5-nitro-2-(3-phenylpropylamino)benzoic acid > 4,4'-diisothiocyanostilbene-2,2'-disulfonate > glybenclamide much greater than diphenlyamine-2-carboxylate, tamoxifen, and p-tetra-sulfonato-tetra-methoxy-calix[4]arene. Complete characterization of this current and the corresponding single channel properties could lead to the development of a new therapy to correct the defective airway surface liquid in cystic fibrosis patients.	Univ N Carolina, CFPRT Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res & Clin Treatment Ctr, Chapel Hill, NC 27599 USA; Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4GJ, E Sussex, England	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Brighton	Gabriel, SE (corresponding author), Univ N Carolina, CFPRT Ctr, Chapel Hill, NC 27599 USA.	sgabriel@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062564] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62564] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CLARKE LL, 1992, AM J PHYSIOL, V262, pC644, DOI 10.1152/ajpcell.1992.262.3.C644; CLARKE LL, 1992, AM J PHYSIOL, V263, pC1190, DOI 10.1152/ajpcell.1992.263.6.C1190; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DEVOR DC, AM J PHYSL, V276, pC827; DUSZYK M, 1992, BIOPHYS J, V61, P583, DOI 10.1016/S0006-3495(92)81861-1; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GABRIEL SE, 1993, PEDIATR PULM, V9, P223; GABRIEL SE, 1999, IN PRESS AM J PHYSL; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; HANRAHAN JW, 1989, ANN NY ACAD SCI, V574, P30; HANRAHAN JW, 1990, J MEMBRANE BIOL, V116, P65, DOI 10.1007/BF01871673; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; Illek B, 1999, PFLUG ARCH EUR J PHY, V437, P812, DOI 10.1007/s004240050850; ISHIKAWA T, 1993, J MEMBRANE BIOL, V135, P261; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; Nichols RA, 1996, NEUROSCI LETT, V211, P135, DOI 10.1016/0304-3940(96)12728-2; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Romio L, 1999, GENE, V228, P181, DOI 10.1016/S0378-1119(98)00620-9; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SINGH AK, 1995, KIDNEY INT, V48, P985, DOI 10.1038/ki.1995.380; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; TABCHARANI JA, 1989, J MEMBRANE BIOL, V112, P109, DOI 10.1007/BF01871272; TABCHARANI JA, 1991, AM J PHYSIOL, V261, pG992, DOI 10.1152/ajpgi.1991.261.6.G992; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; ZegarraMoran O, 1997, J MEMBRANE BIOL, V156, P297, DOI 10.1007/s002329900209	45	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35028	35033		10.1074/jbc.M004953200	http://dx.doi.org/10.1074/jbc.M004953200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944530	hybrid, Green Published			2022-12-25	WOS:000165422800029
J	Kawasaki, H; Nose, T; Muta, T; Iwanaga, S; Shimohigashi, Y; Kawabata, S				Kawasaki, H; Nose, T; Muta, T; Iwanaga, S; Shimohigashi, Y; Kawabata, S			Head-to-tail polymerization of coagulin, a clottable protein of the horseshoe crab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR COAGULATION INHIBITOR; LIMULUS HEMOCYTE TRANSGLUTAMINASE; AMINO-ACID-SEQUENCE; CDNA CLONING; TISSUE LOCALIZATION; INNATE IMMUNITY; PROCLOTTING ENZYME; PURIFICATION; FIBRINOGEN; ACTIVATION	A clottable protein coagulogen of the horseshoe crab Tachypleus tridentatus is proteolytically converted into an insoluble coagulin gel through non-covalent self-polymerization, Here we identified binding sites for the polymerization, A tryptic fragment, derived from the coagulin polymer chemically cross-linked by a bifunctional cross-linker, was isolated. Amino acid sequence analysis indicated that the fragment consists of two peptides cross-linked between Lys(85) and Lys(156) The two lysine residues are oppositely located at the head and tail regions of the elongated molecule separated by a much greater distance than the length of the crosslinker, which suggests that the cross-linking occurs intermolecularly. Based on the x-ray structural analysis, exposure of a hydrophobic cove on the head in response to the release of peptide C has been postulated (Bergner, A., Oganessyan, V,, Muta, T,, Iwanaga, S., Typke, D., Huber, R,, and Bode, W, (1996) EMBO J. 15, 6789-6797), An octapeptide containing Tyr(136), which occupies the tail end of coagulin, was found to inhibit the polymerization, Replacement of Tyr(136) Of the peptide with Ala resulted in loss of the inhibitory activity. These results indicated that the polymerization of coagulin proceeds through the interaction between the newly exposed hydrophobic cove on the head and the wedge-shaped hydrophobic tail.	Kyushu Univ, Grad Sch Sci, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Biol, Fukuoka 8128581, Japan.			Nose, Takeru/0000-0001-9771-7267				Agarwala KL, 1996, J BIOL CHEM, V271, P23768, DOI 10.1074/jbc.271.39.23768; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergner A, 1997, BIOL CHEM, V378, P283, DOI 10.1515/bchm.1997.378.3-4.283; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; BUKU A, 1992, J PROTEIN CHEM, V11, P275, DOI 10.1007/BF01024866; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1962, AM J PHYSIOL, V202, P675, DOI 10.1152/ajplegacy.1962.202.4.675; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LORAND L, 1981, METHOD ENZYMOL, V80, P333; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1994, J BIOL CHEM, V269, P542; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NAKAMURA S, 1976, J BIOCHEM, V80, P1011, DOI 10.1093/oxfordjournals.jbchem.a131357; NAKAMURA S, 1976, BIOCHEM BIOPH RES CO, V72, P902, DOI 10.1016/S0006-291X(76)80217-3; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; ROBERTSON JD, 1970, BIOL BULL-US, V138, P157, DOI 10.2307/1540199; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; SMITH CL, 1992, PROTEIN SCI, V1, P1225, DOI 10.1002/pro.5560010915; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TAE HJ, 1983, METHOD ENZYMOL, V91, P580; TAKAGI T, 1984, J BIOCHEM-TOKYO, V95, P1445, DOI 10.1093/oxfordjournals.jbchem.a134752; TOKUNAGA F, 1993, J BIOL CHEM, V268, P252; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; YEE VC, 1997, STRUCTURE LOND, V15, P125	37	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35297	35301		10.1074/jbc.M006856200	http://dx.doi.org/10.1074/jbc.M006856200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948203	hybrid			2022-12-25	WOS:000165422800063
J	Talts, JF; Sasaki, T; Miosge, N; Gohring, W; Mann, K; Mayne, R; Timpl, R				Talts, JF; Sasaki, T; Miosge, N; Gohring, W; Mann, K; Mayne, R; Timpl, R			Structural and functional analysis of the recombinant G domain of the laminin alpha 4 chain and its proteolytic processing in tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; SITE-DIRECTED MUTAGENESIS; GLYCOSAMINOGLYCAN MODIFICATION; DYSTROGLYCAN BINDING; MYCOBACTERIUM-LEPRAE; SULFATIDE-BINDING; ENDOTHELIAL-CELLS; DEPENDENT BINDING; GROWTH-FACTOR; A CHAIN	The C-terminal G domains of laminin a chains have been implicated in various cellular and other interactions. The G domain of the alpha4 chain was now produced in transfected mammalian cells as two tandem arrays of LG modules, alpha 4LG1-3 and alpha 4LG4-5. The recombinant fragments Were shown to fold into globular structures and could be distinguished by specific antibodies. Both fragments were able to bind to heparin, sulfatides, and the microfibrillar fibulin-1 and fibulin-2. They were, however, poor substrates for cell adhesion and had only a low affinity;for the alpha -dystroglycan receptor when compared with: the G domains of the laminin alpha1 and alpha2 chains. Yet antibodies to alpha 4LG1-3 but not to alpha 4LG4-5 clearly inhibited alpha (6)beta (1) integrin-mediated cell adhesion to laminin-8, indicating the participation of alpha 4LG1-3 in a cell-adhesive structure of higher complexity. Proteolytic: processing within a link region between the alpha 4LG3 and alpha 4LG4 modules was shown to occur during recombinant production and in endothelial and Schwann cell culture. Cleavage could be attributed to three different peptide bonds and is accompanied by the release of the alpha 4LG4-5 segment. Immunohistology demonstrated abundant staining of alpha 4LG1-3 in vessel walls, adipose, and perineural tissue. No significant staining was found for alpha 4LG4-5 indicating their loss from tissues. Immunogold staining demonstrated an association of the alpha4 chain primarily with microfibrillar regions rather than with basement membranes, while laminin alpha2 chains appear primarily associated with various basement membranes.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Gottingen, Ctr Anat, D-37075 Gottingen, Germany; Univ Gottingen, Dept Histol, D-37075 Gottingen, Germany; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Max Planck Society; University of Gottingen; University of Gottingen; University of Alabama System; University of Alabama Birmingham	Timpl, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Miosge, Nicolai/E-3244-2010; Mann, Karlheinz/C-4254-2008	Talts, Jan/0000-0001-5777-5411				Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; ARATANI Y, 1988, J BIOL CHEM, V263, P16163; AUMAILLEY M, 1991, EXP CELL RES, V196, P177, DOI 10.1016/0014-4827(91)90248-S; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; AUMAILLEY M, 1996, LAMININS, P127; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; BURGESON RE, 1996, LAMININS, P65; DENTZMANNR, 1990, EUR J BIOCH, V191, P513; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; EKBLOM P, 1996, LAMININS; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Geberhiwot T, 1999, EXP CELL RES, V253, P723, DOI 10.1006/excr.1999.4653; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Liu JG, 1996, MATRIX BIOL, V15, P433, DOI 10.1016/S0945-053X(96)90162-6; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miosge N, 2000, J HISTOCHEM CYTOCHEM, V48, P229, DOI 10.1177/002215540004800208; Miosge N, 1999, LAB INVEST, V79, P1591; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Richards A, 1996, EUR J BIOCHEM, V238, P813, DOI 10.1111/j.1432-1033.1996.0813w.x; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1999, GUIDEBOOK EXTRACELLU, P434; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123	52	126	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35192	35199		10.1074/jbc.M003261200	http://dx.doi.org/10.1074/jbc.M003261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10934193	hybrid			2022-12-25	WOS:000165422800050
J	Jin, SH; Zhai, B; Qiu, ZL; Wu, JR; Lane, MD; Liao, K				Jin, SH; Zhai, B; Qiu, ZL; Wu, JR; Lane, MD; Liao, K			c-Crk, a substrate of the insulin-like growth factor-1 receptor tyrosine kinase, functions as an early signal mediator in the adipocyte differentiation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAIN; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; FACTOR-I; ADIPOSE CONVERSION; SH3 DOMAIN; CELL LINE; PROTEIN; ENHANCER; TRANSCRIPTION	Differentiation of 3T3-L1 preadipocytes into adipocytes is induced by a combination of inducers, including a glucocorticoid, an agent that elevates cellular cAMP, and a ligand of the insulin-like growth factor-1 receptor. Previous studies have implicated protein-tyrosine phosphatase (PTPase) HA2, a homologue of PTPase 1B, in the signaling cascade initiated by the differentiation inducers. Vanadate, a potent PTPase inhibitor, blocks adipocyte differentiation at an early stage in the program, but has no effect on the mitotic clonal expansion required for differentiation. Exposure of preadipocytes to vanadate along with the inducing agents led to the accumulation of pp35, a phosphotyrosyl protein that is a substrate for PTPase HA2. pp35 was purified to homogeneity and shown by amino acid sequence and mass analyses of tryptic peptides to be c-Crk, a known cytoplasmic target of the insulin-like growth factor-1 receptor tyrosine kinase. Transfection of 3T3-L1 preadipocytes with a c-Crk antisense RNA expression vector markedly reduced c-Crk levels and prevented differentiation into adipocytes. Studies with C3G, a protein that binds to the SH3 domain in c-Crk, showed that phosphorylation of c-Crk rendered the SH3 domain inaccessible to C3G. Taken together, these findings indicate that locking c-Crk in the phosphorylated state with vanadate prevents its participation in the signaling system that initiates adipocyte differentiation.	Chinese Acad Sci, Shanghai Inst Biochem, Shanghai Life Sci Res Ctr, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem, State Lab Mol Biol, Shanghai 200031, Peoples R China; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Johns Hopkins University	Liao, K (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, Shanghai Life Sci Res Ctr, 320 Yueyang Rd, Shanghai 200031, Peoples R China.							AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES RA, 1992, J CELL BIOCHEM, V49, P219, DOI 10.1002/jcb.240490303; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Koval AP, 1998, BIOCHEM J, V330, P923; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO K, 1995, J BIOL CHEM, V270, P12123, DOI 10.1074/jbc.270.20.12123; LIAO K, 1991, J BIOL CHEM, V266, P6544; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Loftus TM, 1997, CURR OPIN GENET DEV, V7, P603, DOI 10.1016/S0959-437X(97)80006-8; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Modan-Moses D, 1998, BIOCHEM J, V333, P825, DOI 10.1042/bj3330825; OGAWA S, 1994, ONCOGENE, V9, P1669; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; PETAL YM, 1999, P NATL ACAD SCI USA, V96, P1279; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; REED BC, 1981, J BIOL CHEM, V256, P3917; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O	52	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34344	34352		10.1074/jbc.M004927200	http://dx.doi.org/10.1074/jbc.M004927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926934	hybrid			2022-12-25	WOS:000165095300048
J	Liu, Y; Lightning, LK; Huang, HW; Moenne-Loccoz, P; Schuller, DJ; Poulos, TL; Loehr, TM; de Montellano, PRO				Liu, Y; Lightning, LK; Huang, HW; Moenne-Loccoz, P; Schuller, DJ; Poulos, TL; Loehr, TM; de Montellano, PRO			Replacement of the distal glycine 139 transforms human heme oxygenase-1 into a peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE IRON LIGAND; RESONANCE RAMAN; CARBON-MONOXIDE; CATALYTIC SITE; HYPERBILIRUBINEMIA; EXPRESSION; OXIDATION; MESSENGER; REVERSAL; COMPLEX	The human heme oxygenase-l crystal structure suggests that Gly-139 and Gly-143 interact directly with iron-bound ligands, We have mutated Gly-139 to an alanine, leucine, phenylalanine, tryptophan, histidine, or aspartate, and Gly-143 to a leucine, lysine, histidine, or aspartate, All of these mutants bind heme, but absorption and resonance Raman spectroscopy indicate that the water coordinated to the iron atom is lost in several of the Gly-139 mutants, giving rise to mixtures of hexacoordinate and pentacoordinate ligation states. The active site perturbation is greatest when large amino acid side chains are introduced. Of the Gly-139 mutants investigated, only G139A catalyzes the NADPH-cytochrome P450 reductase-dependent oxidation of heme to biliverdin, but most of them exhibit a new H2O2-dependent guaiacol peroxidation activity. The Gly-143 mutants, all of which have lost the water ligand, have no heme oxygenase or peroxidase activity, The results establish the importance of Gly-139 and Gly-143 in maintaining the appropriate environment for the heme oxygenase reaction and show that Gly-139 mutations disrupt this environment, probably by displacing the distal helix, converting heme oxygenase into a peroxidase. The principal role of the heme oxygenase active site may be to suppress the ferryl species formation responsible for peroxidase activity.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California San Francisco; University of California System; University of California Irvine; University of California System; University of California Irvine	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.			MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM34468, GM32688] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; Dolphin, 1979, PORPHYRINS, VVI, P257; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KAPPAS A, 1988, PEDIATRICS, V81, P485; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; MAINES MD, 1992, BIOCHIM BIOPHYS ACTA, V1131, P166, DOI 10.1016/0167-4781(92)90072-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P109; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; RAMETTES RW, 1965, J AM CHEM SOC, V82, P5001; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	37	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34501	34507		10.1074/jbc.M004245200	http://dx.doi.org/10.1074/jbc.M004245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942763	hybrid			2022-12-25	WOS:000165095300068
J	Nakai, A; Ishikawa, T				Nakai, A; Ishikawa, T			A nuclear localization signal is essential for stress-induced dimer-to-trimer transition of heat shock transcription factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; COILED-COIL; FACTOR TRIMERIZATION; IN-VIVO; ACTIVATION; HSF3; OLIGOMERIZATION; SEQUENCE; DOMAIN; THERMOTOLERANCE	Expression of heat shock genes is regulated mainly at the level of transcription by heat shock transcription factors (HSFs). In avian, HSF1 and HSF3 are maintained in a cryptic monomer and dimer form, respectively, in the cytoplasm in the absence of stress. Upon heat stress, they undergo conformational change associated with the formation of a trimer and nuclear translocation. In this study, we identified regions that are necessary for the dimer-to-trimer transition of chicken HSF3 (cHSF3) upon stress conditions. One of these regions coincides with a functional nuclear localization signal (NLS) of cHSF3 that was recognized by a nuclear transport receptor importin alpha. Point mutations of basic amino acids in the NLS inhibit both nuclear translocation and trimer formation of cHSF3. These results demonstrate that the NLS acts positively on the trimer formation of cHSF3 upon stress conditions.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cell Biol, Sakyo Ku, Kyoto 6068397, Japan	Kyoto University	Nakai, A (corresponding author), Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Minami Kogushi 1-1-1, Ube, Yamaguchi 7558505, Japan.							Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Chan CK, 1999, FEBS LETT, V462, P221, DOI 10.1016/S0014-5793(99)01515-X; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kawazoe Y, 1999, EUR J BIOCHEM, V265, P688, DOI 10.1046/j.1432-1327.1999.00762.x; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1379/1466-1268(1999)004<0086:NAITVH>2.3.CO;2; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Orosz A, 1996, MOL CELL BIOL, V16, P7018; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SATLSMAN K, 1998, YEAST, V15, P733; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; Tanabe M, 1998, EMBO J, V17, P1750, DOI 10.1093/emboj/17.6.1750; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	39	22	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34665	34671		10.1074/jbc.M005302200	http://dx.doi.org/10.1074/jbc.M005302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942768	hybrid			2022-12-25	WOS:000165095300090
J	Taylor, KR; Holzer, AK; Bazan, JF; Walsh, CA; Gleeson, JG				Taylor, KR; Holzer, AK; Bazan, JF; Walsh, CA; Gleeson, JG			Patient mutations in doublecortin define a repeated tubulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; DOMINANT RETINITIS-PIGMENTOSA; SUBCORTICAL LAMINAR HETEROTOPIA; DOUBLE CORTEX SYNDROME; NEURONAL MIGRATION; RAS-BINDING; HEAVY-CHAIN; GENE; TAU; IDENTIFICATION	Doublecortin (DCX) missense mutations are found in two clusters in patients with defective cortical neuronal migration. Although DCX can function as a microtubule-associated protein (MAP), the potential relationship between its MAP activity and neuronal migration is not understood. Here we show that the two clusters of patient mutations precisely define an internal tandem repeat. Each repeat alone binds tubulin, whereas neither repeat is sufficient for co-assembly with microtubules, The two tandem repeats are sufficient to mediate microtubule polymerization, and representative patient missense mutations lead to impaired polymerization both in vitro and in vivo as well as impaired microtubule stabilization. Furthermore, each repeat is predicted to have the secondary structure of a beta -grasp superfold motif, a motif not found in other MAPs. The patient mutations are predicted to disrupt the structure of the motif, suggesting that the motif may be critical for the DCX-tubulin interaction. These data provide both genetic and biochemical evidence that the interaction of DCX with microtubules is dependent upon this novel repeated tubulin-binding motif.	Univ Calif San Diego, Dept Neurosci, Biomed Sci Grad Program, Div Pediat Neurol, La Jolla, CA 92093 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Mol Biol, Prot Machine Grp, Palo Alto, CA 94304 USA; Harvard Univ, Sch Med, Div Neurogenet, Dept Neurol,Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University of California System; University of California San Diego; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gleeson, JG (corresponding author), MTF 324,9500 Gilman Dr, La Jolla, CA 92093 USA.	jogleeson@ucsd.edu	Bazan, J. Fernando/B-4562-2010		NINDS NIH HHS [P01 NS39404, 5K12NS01701-05, R01 NS 38097] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001701, R01NS038097, P01NS039404] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; Bowne SJ, 1999, HUM MOL GENET, V8, P2121, DOI 10.1093/hmg/8.11.2121; BRODTKORB E, 1992, ACTA NEUROL SCAND, V86, P24, DOI 10.1111/j.1600-0404.1992.tb08049.x; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; CRAVCHIK A, 1994, J CELL SCI, V107, P661; des Portes V, 1998, HUM MOL GENET, V7, P1063, DOI 10.1093/hmg/7.7.1063; des Portes V, 1998, CELL, V92, P51; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DOLL T, 1993, J CELL SCI, V106, P633; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRANKEL FR, 1976, P NATL ACAD SCI USA, V73, P2798, DOI 10.1073/pnas.73.8.2798; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Gleeson JG, 1999, ANN NEUROL, V45, P146, DOI 10.1002/1531-8249(199902)45:2<146::AID-ANA3>3.0.CO;2-N; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GOTTLIEB RA, 1985, J CELL BIOL, V101, P1782, DOI 10.1083/jcb.101.5.1782; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Pierce EA, 1999, NAT GENET, V22, P248, DOI 10.1038/10305; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; Sullivan LS, 1999, NAT GENET, V22, P255, DOI 10.1038/10314; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	38	126	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34442	34450		10.1074/jbc.M007078200	http://dx.doi.org/10.1074/jbc.M007078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10946000	hybrid			2022-12-25	WOS:000165095300060
J	Firulli, BA; Hadzic, DB; McDaid, JR; Firulli, AB				Firulli, BA; Hadzic, DB; McDaid, JR; Firulli, AB			The basic helix-loop-helix transcription factors dHAND and eHAND exhibit dimerization characteristics that suggest complex regulation of function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; CARDIAC MORPHOGENESIS; 2-HYBRID SYSTEM; EXPRESSION; E2A; PROTEINS; IDENTIFICATION; SELECTION; ENHANCER; SUBCLASS	dHAND and eHAND are basic helix-loop-helix (bHLH) transcription factors expressed during embryogenesis and are required for the proper development of cardiac and extraembryonic tissues. RAND genes, like the myogenic bHLH genes, are classified as class B bHLH genes, which are expressed in a tissue-restricted pattern and function by forming heterodimers with class A bHLH proteins. Myogenic bHLH genes are shown not to form homodimers efficiently, suggesting that their activity is dependent on their E-protein partners. To identify Hips (HAND-interacting proteins) that regulate the activity of the RAND genes, we screened an 9.5-10.5-day-old mouse embryonic yeast two-hybrid library with eHAND. Several HIPs held high sequence identity to eHAND, indicating that eHAND could form and function as a homodimer. Based on the high degree of amino acid identity between eHAND and dHAND, it is possible that dHAND could also form homodimers and heterodimers with eHAND, We show using yeast and mammalian two-hybrid assays as well as biochemical pull-down assays that eHAND and dHAND are capable of forming both HAND homo- and heterodimers in vivo. To investigate whether HAND genes form heterodimers with other biologically relevant bHLH proteins, we tested and show HAND heterodimerization with the recently identified Hairy-related transcription factors, HRT1-3, This finding is exciting, because both HRT and HAND genes are coexpressed in the developing heart and limb and both have been implicated in establishing tissue boundaries and pattern formation. Moreover, competition gel shift analysis demonstrates that dHAND and eHAND can negatively regulate the DNA binding of MyoD/E12 heterodimers in a manner similar to MISTI and Id proteins, suggesting a possible transcriptional inhibitory role for HAND genes. Taken together, these results show that dHAND and eHAND can form homo- and heterodimer combinations with multiple bHLH partners and that this broad dimerization profile reflects the mechanisms by which HAND genes regulate transcription.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Firulli, AB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr,7703, San Antonio, TX 78229 USA.			/0000-0001-6687-8949	NHLBI NIH HHS [R01 HL061677, R01 HL061677-03, R01 HLA61677-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061677] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; Charite J, 2000, DEVELOPMENT, V127, P2461; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; James P, 1996, GENETICS, V144, P1425; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEMCERCIER C, 1998, EMBO J, V17, P1412; Lewis AL, 1999, J BIOL CHEM, V274, P14188, DOI 10.1074/jbc.274.20.14188; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; Steidl C, 2000, GENOMICS, V66, P195, DOI 10.1006/geno.2000.6200; WRITGHT WE, 1991, MOL CELL BIOL, V11, P4101; XIN XQ, 1993, J IMMUNOL, V151, P5398; Yelon D, 2000, DEVELOPMENT, V127, P2573	35	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33567	33573		10.1074/jbc.M005888200	http://dx.doi.org/10.1074/jbc.M005888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924525	Green Accepted, hybrid			2022-12-25	WOS:000090104600056
J	Rettinger, J; Aschrafi, A; Schmalzing, G				Rettinger, J; Aschrafi, A; Schmalzing, G			Roles of individual N-glycans for ATP potency and expression of the rat P2X(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; NICOTINIC ACETYLCHOLINE-RECEPTOR; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; ENDOPLASMIC-RETICULUM; LINKED GLYCOSYLATION; EXTRACELLULAR ATP; P-2X RECEPTOR; STRUCTURAL MOTIF; SUBUNITS	P2X(1) receptor subunits assemble in the ER of Xenopus oocytes to homotrimers that appear as ATP-gated cation channels at the cell surface. Here we address the extent to which N-glycosylation contributes to assembly, surface appearance, and ligand recognition of P2X(1) receptors, SDS-polyacrylamide gel electrophoresis (PAGE) analysis of glycan minus mutants carrying Gln instead of Asn at five individual NXT/S sequons reveals that Asn(284) remains unused because of a proline in the +4 position. The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates, Like parent P2X(1), glycan minus mutants migrate as homotrimers when resolved by blue native PAGE. Recording of ATP-gated currents reveals that elimination of Asn(153) or Asn(210) diminishes or increases functional expression levels, respectively. In addition, elimination of Asn(210) causes a 3-fold reduction of the potency for ATP, If three or all four N-glycosylation sites are simultaneously eliminated, formation of P2X(1) receptors is severely impaired or abolished, respectively. We conclude that at least one N-glycan per subunit of either position is absolutely required for the formation of P2X(1) receptors and that individual N-glycans possess marked positional effects on expression levels (Asn(154), Asn(210)) and ATP potency (Asn(210)).	Univ Frankfurt, Dept Pharmacol, Bioctr N 260, D-60439 Frankfurt, Germany; Univ Freiburg, Dept Pharmacol & Toxicol, D-79104 Freiburg, Germany	Goethe University Frankfurt; University of Freiburg	Schmalzing, G (corresponding author), Inst Expt & Klin Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Aschrafi, Armaz/E-2202-2012	Aschrafi, Armaz/0000-0003-4089-0960				ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 1999, PROG BRAIN RES, V120, P3; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Collo G, 1996, J NEUROSCI, V16, P2495; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Ding SH, 2000, J PHYSIOL-LONDON, V522, P199, DOI 10.1111/j.1469-7793.2000.t01-1-00199.x; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LECONTE I, 1992, J BIOL CHEM, V267, P17415; MacKenzie AB, 1999, ANN NY ACAD SCI, V868, P716, DOI 10.1111/j.1749-6632.1999.tb11351.x; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1999, PROG BRAIN RES, V120, P61; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; NILSSON I, 1993, J BIOL CHEM, V268, P5798; North RA, 1996, SEMIN NEUROSCI, V8, P187; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATE CG, 1994, J BIOL CHEM, V269, P26303; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; WU JSR, 1994, BBA-BIOMEMBRANES, V1192, P289, DOI 10.1016/0005-2736(94)90131-7; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493	52	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33542	33547		10.1074/jbc.M002918200	http://dx.doi.org/10.1074/jbc.M002918200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942758	hybrid, Green Published			2022-12-25	WOS:000090104600052
J	Zhang, WY; Ishii, I; Kruth, HS				Zhang, WY; Ishii, I; Kruth, HS			Plasmin-mediated macrophage reversal of low density lipoprotein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; SURFACE-CONNECTED COMPARTMENTS; SMOOTH-MUSCLE CELLS; LIPID-RICH CORE; MONOCYTE-DERIVED MACROPHAGES; ACTIVATOR EXPRESSION; ELECTRON-MICROSCOPY; CORONARY-ARTERIES; GENE-EXPRESSION; DEFICIENT MICE	Evidence suggests that aggregated low density lipoprotein (AgLDL) accumulates in atherosclerotic lesions. Previously, we showed that AgLDL induces and enters surface-connected compartments (SCC) in human monocyte-derived macrophages by a process we have named patocytosis, Most AgLDL taken up by these macrophages in the absence of serum is stored in SCC and remains undegraded, We now show that macrophages released AgLDL (prepared by vortexing or treatment with phospholipase C or sphingomyelinase) from their SCC when exposed to 10% human lipoprotein-deficient serum (LPDS), Macrophages also took up AgLDL in the presence of LPDS, but subsequently released it. In both cases, the released AgLDL was disaggregated, Although the AgLDL that macrophages took up could not pass through a 0.45-mum filter, >60% of AgLDL could pass this filter after release from the macrophages. Disaggregation of AgLDL was verified by gel-filtration chromatography and electron microscopy that also showed particles larger than LDL, reflecting fusion of LDL that aggregates. The factor in serum that mediated AgLDL release and disaggregation was plasmin generated from plasminogen by macrophage urokinase plasminogen activator. AgLDL release was decreased >90% by inhibitors of plasmin (E-amino caproic acid and antiplasminogen mAb), and also by inhibitors of urokinase plasminogen activator (plasminogen activator inhibitor-1 and anti-urokinase plasminogen activator mAb), Moreover, plasminogen could substitute for LPDS and produce similar macrophage release and disaggregation of AgLDL. Because only plasmin bound to the macrophage surface is protected from serum plasmin inhibitors, interaction of AgLDL with macrophages was necessary for reversal of its aggregation by LPDS. The released disaggregated LDL particles were competent to stimulate LDL receptor-mediated endocytosis in cultured fibroblasts, Macrophage-mediated disaggregation of aggregated and fused LDL is a mechanism for transforming LDL into lipoprotein structures size-consistent with lipid particles found in atherosclerotic lesions.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002832, Z01HL002832] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCAN TMA, 1986, AM J PATHOL, V123, P413; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; COETZEE GA, 1980, ARTERY, V7, P1; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; Falkenberg M, 1996, THROMB HAEMOSTASIS, V75, P933; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; FRANK JS, 1989, J LIPID RES, V30, P967; Ganne F, 1999, THROMB HAEMOSTASIS, V81, P594; GERRITY RG, 1981, AM J PATHOL, V103, P191; GUYTON JR, 1991, J LIPID RES, V32, P953; GUYTON JR, 1989, AM J PATHOL, V134, P705; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; Hakala JK, 1999, ARTERIOSCL THROM VAS, V19, P1276, DOI 10.1161/01.ATV.19.5.1276; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kienast J, 1998, THROMB HAEMOSTASIS, V79, P579; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1984, ATHEROSCLEROSIS, V51, P281, DOI 10.1016/0021-9150(84)90175-8; Kruth HS, 1999, J BIOL CHEM, V274, P7495, DOI 10.1074/jbc.274.11.7495; Kruth HS, 1999, EUR J CELL BIOL, V78, P91, DOI 10.1016/S0171-9335(99)80010-7; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; Loscalzo Joseph, 1996, Seminars in Thrombosis and Hemostasis, V22, P503, DOI 10.1055/s-2007-999051; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; Maor I, 1997, ARTERIOSCL THROM VAS, V17, P2995, DOI 10.1161/01.ATV.17.11.2995; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; Padro T, 1997, CARDIOVASC RES, V36, P28, DOI 10.1016/S0008-6363(97)00144-2; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; RAGHUNATH PN, 1995, ARTERIOSCL THROM VAS, V15, P1432, DOI 10.1161/01.ATV.15.9.1432; Rhainds D, 1999, INT J BIOCHEM CELL B, V31, P915, DOI 10.1016/S1357-2725(99)00046-1; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; Schneider DJ, 1997, ARTERIOSCL THROM VAS, V17, P3294, DOI 10.1161/01.ATV.17.11.3294; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SMITH EB, 1976, ATHEROSCLEROSIS, V25, P71, DOI 10.1016/0021-9150(76)90049-6; STEELE JCH, 1979, THROMB RES, V15, P573, DOI 10.1016/0049-3848(79)90165-8; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847; TERTOV VV, 1992, EUR J CLIN CHEM CLIN, V30, P171; TIPPING PG, 1993, AM J PATHOL, V143, P875; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	56	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33176	33183		10.1074/jbc.M908714199	http://dx.doi.org/10.1074/jbc.M908714199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10942782	hybrid			2022-12-25	WOS:000090003800107
J	Chen, Y; Li, XF; Eswarakumar, VP; Seger, R; Lonai, P				Chen, Y; Li, XF; Eswarakumar, VP; Seger, R; Lonai, P			Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation	ONCOGENE			English	Article						embryoid bodies; FGF signaling; epithelial differentiation; Akt/PKB; PLC gamma-1	PHOSPHOLIPASE C-GAMMA; PHOSPHOINOSITIDE 3-KINASE; STEM-CELLS; PROTEIN-KINASE; MOUSE EMBRYOS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; TARGETED DISRUPTION; MESODERM INDUCTION; VISCERAL ENDODERM; CELLULAR-SURVIVAL	The role of FGF signaling in early epithelial differentiation was investigated in ES (embryonic) stem) cell derived embryoid bodies. A dominant negative fibroblast growth factor receptor (FGFR) mutation was created by stably introducing into ES cells an Fgfr2 cDNA, truncated in its enzymatic domains. These cells failed to differentiate into cystic embryoid bodies. No epithelial differentiation and cavitation morphogenesis could be observed, in the mutant, although its rate of cell proliferation remained unchanged. This phenotype was associated with a significant decrease in the activation of Akt/PKB and PLC gamma-1, as compared to the wild type, while the activation of MAPK/Erk was less affected, Requirement for PL 3-kinase signaling in embryoid body differentiation was demonstrated by specific inhibitors, Akt/PKB activation was abrogated by wortmannin in short-term experiments. In long-term cultures Ly294002 inhibited the differentiation of ES cells into embryoid bodies. Our data demonstrate that for early epithelial differentiation FGF signaling is required through the PI 3-kinase-Akt/ PKB pathway.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lonai, P (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Eswarakumar, Jacob/0000-0003-0784-0507; Eswarakumar, V.P./0000-0001-7941-8714				Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; Barbacci E, 1999, DEVELOPMENT, V126, P4795; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chai N, 1998, DEV BIOL, V198, P105, DOI 10.1016/S0012-1606(98)80031-6; CONLON RA, 1992, METHOD ENZYMOL, V225, P361; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Cross MJ, 2000, J CELL SCI, V113, P643; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Duncan SA, 1997, DEVELOPMENT, V124, P279; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRIEDMAN HM, 1982, CANCER RES, V42, P4683; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Hogan B, 1994, MANIPULATING MOUSE E; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rappolee DA, 1998, MOL REPROD DEV, V51, P254, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;254::AID-MRD4&gt;3.0.CO;2-O; RAZ V, 1991, ONCOGENE, V6, P753; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	49	104	113	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3750	3756		10.1038/sj.onc.1203726	http://dx.doi.org/10.1038/sj.onc.1203726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949929				2022-12-25	WOS:000088568400007
J	Ishii, K; Muelhauser, F; Liebl, U; Picard, M; Kuhl, S; Penke, B; Bayer, T; Wiessler, M; Hennerici, M; Beyreuther, K; Hartmann, T; Fassbender, K				Ishii, K; Muelhauser, F; Liebl, U; Picard, M; Kuhl, S; Penke, B; Bayer, T; Wiessler, M; Hennerici, M; Beyreuther, K; Hartmann, T; Fassbender, K			Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase	FASEB JOURNAL			English	Article						amyloid peptide; nitric oxide; iNOS; brain; in vivo microdialysis	NITRIC-OXIDE SYNTHASE; INTERFERON-GAMMA; MOUSE-BRAIN; IN-VIVO; DISEASE; MICROGLIA; PROTEIN; NEUROTOXICITY; EXPRESSION; DAMAGE	Glial activation contiguous to deposits of amyloid peptide (A beta) is a characteristic feature in Alzheimer's disease. We performed complementary in vitro and in vivo experiments to study the extent, kinetics, and mechanisms of microglial generation of nitric oxide (NO) induced by challenge with A beta. We showed that A beta fibrils dose-dependently induced a marked release of stable metabolites of NO in vivo that was strikingly similar regarding extent and temporal profile to the one in the parallel designed microglial cell culture experiments. However, costimulation with interferon gamma, which was a prerequisite for A beta-induced NO generation in vitro, was not required in vivo, demonstrating that factors are present in the living brain that activate glial cells synergistically with A beta. Therefore, in Alzheimer's disease, deposits of A beta fibrils alone may be sufficient to induce a chronic release of neurotoxic microglial products, explaining the progressive neurodegeneration associated with this disease. Our observation that systemic administration of selective iNOS inhibitors abolishes A beta-induced NO generation in vivo may have implications for therapy of Alzheimer's disease.	Univ Heidelberg, Dept Neurol, D-68135 Mannheim, Germany; Univ Heidelberg, ZMBH, Ctr Mol Biol, D-68135 Mannheim, Germany; Albert Szent Gyorgyi Med Univ, Dept Med Chem, Szeged, Hungary; Univ Bonn, Dept Psychiat, D-5300 Bonn, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Szeged University; University of Bonn; Helmholtz Association; German Cancer Research Center (DKFZ)	Fassbender, K (corresponding author), Univ Heidelberg, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.		Hartmann, Tobias/AAB-8297-2022	Hartmann, Tobias/0000-0001-7481-6430; Fassbender, Klaus/0000-0003-3596-868X				Beyreuther K, 1996, ANN NY ACAD SCI, V777, P74, DOI 10.1111/j.1749-6632.1996.tb34403.x; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; DING AH, 1988, J IMMUNOL, V141, P2407; Ding MZ, 1997, J BIOL CHEM, V272, P11327; ElKhoury J, 1996, NATURE, V382, P716; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GOODWIN JL, 1995, BRAIN RES, V692, P207, DOI 10.1016/0006-8993(95)00646-8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hensley K, 1998, J NEUROSCI, V18, P8126; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Knauber J, 1999, J NEURAL TRANSM, V106, P35, DOI 10.1007/s007020050139; Lee SC, 1999, J NEUROPATH EXP NEUR, V58, P1163, DOI 10.1097/00005072-199911000-00006; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; MACMICKING JD, 1995, NATURE, V375, P408; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Netland EE, 1998, NEUROBIOL AGING, V19, P201, DOI 10.1016/S0197-4580(98)00047-5; O'Mahony D, 1999, J NEUROL NEUROSUR PS, V67, P1, DOI 10.1136/jnnp.67.1.1; PAXINOS G, 1982, RAT BRAIN STEREOTACT; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; Smith MA, 1997, J NEUROSCI, V17, P2653; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUZUMURA A, 1987, J NEUROIMMUNOL, V15, P263, DOI 10.1016/0165-5728(87)90121-4; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; Weldon DT, 1998, J NEUROSCI, V18, P2161; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yun HY, 1996, CRIT REV NEUROBIOL, V10, P291, DOI 10.1615/CritRevNeurobiol.v10.i3-4.20	34	59	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1485	1489		10.1096/fj.14.11.1485	http://dx.doi.org/10.1096/fj.14.11.1485			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928982				2022-12-25	WOS:000088627800002
J	Maasch, C; Wagner, S; Lindschau, C; Alexander, G; Buchner, K; Gollasch, M; Luft, FC; Haller, H				Maasch, C; Wagner, S; Lindschau, C; Alexander, G; Buchner, K; Gollasch, M; Luft, FC; Haller, H			Protein kinase C alpha targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca2+](i)	FASEB JOURNAL			English	Article						isoforms; green fluorescent protein; vascular smooth muscle cells; receptor coupling; translocation; mutation	SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; RBL-2H3 CELLS; TRANSLOCATION; ISOZYMES; DIACYLGLYCEROL; LOCALIZATION; PERSPECTIVES; ACTIVATION; EXOCYTOSIS	Protein kinase C (PKC) isoforms exert specific intracellular functions, but the different isoforms display little substrate specificity in vitro. Selective PKC isoform targeting may be a mechanism to achieve specificity. We used a green fluorescent fusion protein (GFP) to test the hypothesis that local changes in [Ca2+](i); regulate translocation of PKC alpha and that different modes of Ca2+ and Ca2+ release play a role in PKCa targeting. We constructed deletion mutants of PKC alpha. to analyze the Ca2+-sensitive domains and their role in targeting. Confocal microscopy was used and [Ca2+](i) was measured by fluo-3. The fusion protein PKC alpha-GFP was expressed in vascular smooth muscle cells and showed a cytosolic distribution similar to the wildtype PKC alpha protein. The Ca2+ ionophore ionomycin induced a speckled cytosolic PKC alpha-GFP distribution, followed by membrane translocation, while depolarization by KCI induced primarily membrane translocation. Selective voltage-operated Ca2+ channel opening led to a localized accumulation of PKC alpha-GFP near the plasma membrane. Opening Ca2+ stores with InsP(3), thapsigargin, or ryanodine induced a specific PKC alpha-GFP targeting to distinct intracellular areas. The G-protein-coupled receptor agonist thrombin induced a rapid translocation of the fusion protein to focal domains. The tyrosine kinase receptor agonist PDGF induced Ca2+ influx and led to a linear PKC alpha-GFP membrane association. PKC alpha-GFP deletion mutants demonstrated that the C2 domain, but not the catalytic subunit, is necessary for Ca2+-induced PKC alpha targeting. Targeting was also abolished when the ATP binding site was deleted. We conclude that PKC alpha can rapidly be translocated to distinct intracellular or membrane domains by local increases in [Ca2+](i). The targeting mechanism is dependent on the C2 and ATP binding site of the enzyme. Localized [Ca2+](i) changes determine the spatial and temporal targeting of PKC alpha.	Med Hsch Hannover, D-30625 Hannover, Germany; Free Univ Berlin, Inst Biochem, D-1000 Berlin, Germany; Humboldt Univ, Charite, Fak Med, Franz Volhard Clin, Berlin, Germany; Humboldt Univ, Charite, Fak Med, Max Delbruck Ctr Mol Med, Berlin, Germany	Hannover Medical School; Free University of Berlin; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Haller, H (corresponding author), Med Hsch Hannover, OE 6840,Carl-Neuberg-Str 1, D-30625 Hannover, Germany.		Lindschau, Carsten/AAE-6721-2020; Lindschau, Carsten/G-1798-2011	Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; HA KS, 1993, J BIOL CHEM, V268, P10534; Haller H, 1998, CIRC RES, V82, P157; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HALLER H, 1994, KIDNEY INT, V46, P1653, DOI 10.1038/ki.1994.465; HALLER H, 1989, J BIOCH, V270, P375; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KHALIL RA, 1994, AM J PHYSIOL, V266, pC1544, DOI 10.1152/ajpcell.1994.266.6.C1544; KHALIL RA, 1992, J PHYSIOL-LONDON, V455, P585, DOI 10.1113/jphysiol.1992.sp019317; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LUO JH, 1993, J BIOL CHEM, V268, P23580; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, JNCI-J NATL CANCER I, V76, P363; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; ROSALES OR, 1992, BIOCHEM BIOPH RES CO, V189, P40, DOI 10.1016/0006-291X(92)91522-R; ROSEN DM, 1998, FASEB J, V12, P35; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704	38	69	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1653	1663		10.1096/fj.14.11.1653	http://dx.doi.org/10.1096/fj.14.11.1653			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10929000				2022-12-25	WOS:000088627800020
J	Pircher, TJ; Zhao, SQ; Geiger, JN; Joneja, B; Wojchowski, DM				Pircher, TJ; Zhao, SQ; Geiger, JN; Joneja, B; Wojchowski, DM			Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death	ONCOGENE			English	Article						Pim-1kinase; genotoxin-induced apoptosis	INHIBITS APOPTOSIS; C-MYC; IONIZING-RADIATION; GENE-EXPRESSION; TRANSGENIC MICE; MYELOID CELLS; BONE-MARROW; ACTIVATION; DIFFERENTIATION; ERYTHROPOIETIN	The hematopoietic cell S/T kinase Pim-1 was originally discovered as a target of murine leukemia provirus integration, and when expressed at increased levels is predisposing to lymphomagenesis. Recently, Pim-1 has been shown to enhance the activities of p100, c-Myb and cdc25a, and in part this might explain reported effects on mitogenesis. In the context of cytokine withdrawal, Pim-1 also can attenuate programmed cell death (PCD). Cytokine withdrawal, however, alters signaling pathways and can complicate the dissection of mitogenic vs apoptotic responses. To better study possible effects of Pim-1 on PCD, a hematopoietic cell model was developed in which proliferation was supported efficiently by SCF plus EPO in the absence of endogenous Pim-1 gene expression. This was provided by factor-dependent FDCW2 cells that express endogenous and functional c-Kit, and were transfected stably with truncated Epo receptor form mutated at a Y343 STAT5 binding site. In proliferating cells, exogenously expressed Pim-1 was observed to efficiently inhibit PCD as induced by either Co-60 or adriamycin, and the dose-dependent nature of this effect was established in several independent clones, By comparison, effects of exogenous Pim-1 on mitogenesis were nominal. In addition, in cell fractionation studies an estimated 25% of M-r 34 000 Pim-1 (but not M-r 44 000 Pim-1) was present in nuclear extracts. Thus, Pim-1 efficiently buffers hematopoietic progenitor cells against death as induced by several clinically important apoptotic agents, and may directly target nuclear effecters.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Program Immunobiol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 115 Henning Bldg, University Pk, PA 16802 USA.				NHLBI NIH HHS [HLR0144491] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG RY, 1979, BIOCHEMISTRY-US, V18, P2069, DOI 10.1021/bi00577a035; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; IHLE JN, 1982, J IMMUNOL, V129, P1377; ITOH N, 1993, J IMMUNOL, V151, P621; Joneja B, 1997, BLOOD, V90, P3533, DOI 10.1182/blood.V90.9.3533; KLEIN AK, 1985, RADIAT RES, V101, P332, DOI 10.2307/3576399; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; STEWART BE, 1995, J INVEST DERMATOL, V105, P699, DOI 10.1111/1523-1747.ep12324482; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Xu J, 1999, MOL CELL BIOL, V19, P12; Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561	43	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3684	3692		10.1038/sj.onc.1203684	http://dx.doi.org/10.1038/sj.onc.1203684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951575				2022-12-25	WOS:000088568300015
J	Gong, QM; Brown, LJ; MacDonald, MJ				Gong, QM; Brown, LJ; MacDonald, MJ			Functional analysis of two promoters for the human mitochondrial glycerol phosphate dehydrogenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-IV GENE; LINKED GLYCEROPHOSPHATE DEHYDROGENASE; BINDING-PROTEIN-ALPHA; PANCREATIC-ISLETS; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; PYRUVATE-CARBOXYLASE; TRANSCRIPTION FACTOR; BETA-CELLS; MULTIPLE TRANSCRIPTS; 5'-END HETEROGENEITY	Mitochondrial glycerol phosphate dehydrogenase (mGPD) is abundant in the normal pancreatic insulin cell, but its level is lowered 50% by diabetes. To evaluate mGPD expression, we cloned and characterized the 5'-flanking region of the human mGPD gene. The gene has two alternative first exons and two promoters. The downstream promoter (B) is 10 times more active than the upstream promoter (A) in insulin secreting cells (INS-1) and HeLa cells. Promoter B has higher activity in INS-1 than in non-beta cells. Deletion and mutation analysis suggested that a NRF-2 binding site at -94 to -101 and an E2F binding site at -208 to -215 are important regulatory cis elements in promoter B, Gel mobility shift assays indicated that the -94 to -101 region binds the NRF-2 protein. When INS-1 cells were maintained in the presence of high glucose (25 mM) for 7 days, mGPD was the only 1 of 6 enzyme activities lowered (53%), mGPD promoter B activity was reduced by 60% in INS-1 cells by the high glucose, but in HepG2 cells and HeLa cells, promoter B activity was unchanged or slightly increased. Deletion analysis indicated the glucose responsiveness was distributed across the region from -340 to -260 in promoter B. The results indicate that mGPD gene transcription in the beta cell is regulated differently from other cells and that decreased mGPD promoter B transcription is at least in part the cause of the decreased beta cell mGPD levels in diabetes.	Univ Wisconsin, Childrens Diabet Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	MacDonald, MJ (corresponding author), Univ Wisconsin, Sch Med, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.				NIDDK NIH HHS [DK28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AZHAR S, 1983, METABOLISM, V32, P1019, DOI 10.1016/0026-0495(83)90070-7; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BASU A, 1993, J BIOL CHEM, V268, P4188; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Brown LJ, 1996, GENE, V172, P309, DOI 10.1016/0378-1119(96)00019-4; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; FERNANDEZALVAREZ J, 1994, DIABETOLOGIA, V37, P177, DOI 10.1007/s001250050090; Ferrer J, 1996, DIABETES, V45, P262, DOI 10.2337/diabetes.45.2.262; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; GIROIX MH, 1993, BIOCHEM MED METAB B, V50, P301, DOI 10.1006/bmmb.1993.1072; Gong DW, 1998, DNA CELL BIOL, V17, P301, DOI 10.1089/dna.1998.17.301; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Jitrapakdee S, 1997, J BIOL CHEM, V272, P20522, DOI 10.1074/jbc.272.33.20522; Jitrapakdee S, 1998, J BIOL CHEM, V273, P34422, DOI 10.1074/jbc.273.51.34422; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; LEE YP, 1965, J BIOL CHEM, V240, P1427; LEHN DA, 1994, GENE, V150, P417, DOI 10.1016/0378-1119(94)90469-3; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P305, DOI 10.1006/abbi.1995.1297; MACDONALD MJ, 1990, CANCER RES, V50, P7203; MACDONALD MJ, 1983, J CLIN ENDOCR METAB, V57, P662, DOI 10.1210/jcem-57-3-662; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; OHNEDA M, 1994, AM J PHYSIOL-ENDOC M, V267, pE968, DOI 10.1152/ajpendo.1994.267.6.E968; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; OSTENSON CG, 1993, DIABETOLOGIA, V36, P722, DOI 10.1007/BF00401142; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; RASSCHAERT J, 1994, MOL CELL BIOCHEM, V135, P137, DOI 10.1007/BF00926516; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SCHENKMAN JB, 1965, ENDOCRINOLOGY, V76, P1055, DOI 10.1210/endo-76-6-1055; SENER A, 1993, FEBS LETT, V316, P224, DOI 10.1016/0014-5793(93)81297-D; SENER A, 1993, BIOCHEM MOL BIOL INT, V30, P397; SMALE ST, 1989, CELL, V57, P13; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	57	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38012	38021		10.1074/jbc.M004078200	http://dx.doi.org/10.1074/jbc.M004078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954707	hybrid			2022-12-25	WOS:000165618700095
J	Thrower, EC; Mobasheri, H; Dargan, S; Marius, P; Lea, EJA; Dawson, AP				Thrower, EC; Mobasheri, H; Dargan, S; Marius, P; Lea, EJA; Dawson, AP			Interaction of luminal calcium and cytosolic ATP in the control of type 1 inositol (1,4,5)-trisphosphate receptor channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; TRISPHOSPHATE-SENSITIVE STORES; ENDOPLASMIC-RETICULUM; CEREBELLAR MICROSOMES; CELLS; ACTIVATION; BINDING; ENTRY; HETEROGENEITY; MOBILIZATION	Ca2+ within intracellular stores (luminal Ca2+) is believed to play a role in regulating Ca2+ release into the cytosol via the inositol (1,4,5)-trisphosphate (Ins(1,4,5)P-3)-gated Ca2+ channel (or Ins(1,4,5)P-3 receptor). To investigate this, we incorporated purified Type 1 Ins(1,4,5)-P-3 receptor from rat cerebellum into planar lipid bilayers and monitored effects at altered luminal [Ca2+] using K+ as the current carrier. At a high luminal [Ca2+] and in the presence of optimal [Ins(1,4,5)P-3] and cytosolic [Ca2+], a short burst of Ins(1,4,5)P-3 receptor channel activity was followed by complete inactivation. Lowering the luminal [Ca2+] caused the channel to reactivate indefinitely. At luminal [Ca2+], reflecting a partially empty store, channel activity did not inactivate. The addition of cytosolic ATP to a channel inactivated by high luminal [Ca2+] caused reactivation. We provide evidence that luminal Ca2+ is exerting its effects via a direct interaction with the luminal face of the receptor. Activation of the receptor by ATP may act as a device by which cytosolic Ca2+ overload is prevented when the energy state of the cell is compromised.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Dawson, AP (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	a.dawson@uea.ac.uk	Mobasheri, Hamid/AAX-7520-2020; Mobasheri, Hamid/GYD-7401-2022	Amici-Dargan, Sheila/0000-0001-7563-5041				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRCHMACHIN MA, 1986, BIOCHIM BIOPHYS ACTA, V855, P277, DOI 10.1016/0005-2736(86)90175-6; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bygrave FL, 1996, CELL CALCIUM, V19, P547, DOI 10.1016/S0143-4160(96)90064-0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; Dawson AP, 1997, CURR BIOL, V7, pR544, DOI 10.1016/S0960-9822(06)00277-6; DEMPSTER J, 1995, STRATHCLYDE ELECTROP; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; HIROSE K, 1994, NATURE, V372, P791; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Missiaen L, 1996, CELL CALCIUM, V19, P91, DOI 10.1016/S0143-4160(96)90016-0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; ONDIAS K, 1998, ANN NY ACAD SCI, V853, P149; PARYS JB, 1993, J BIOL CHEM, V268, P25206; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; SCHINDLER H, 1980, FEBS LETT, V122, P77, DOI 10.1016/0014-5793(80)80405-4; SHUTTLEWORTH TJ, 1995, CELL CALCIUM, V17, P393, DOI 10.1016/0143-4160(95)90085-3; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SUAREZISLA BA, 1991, J PHYSIOL-LONDON, V441, P575, DOI 10.1113/jphysiol.1991.sp018768; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thrower E., 1997, Biophysical Journal, V72, pA294; Thrower EC, 1998, BIOCHEM J, V330, P559; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	54	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36049	36055		10.1074/jbc.M000970200	http://dx.doi.org/10.1074/jbc.M000970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956640	hybrid			2022-12-25	WOS:000165382000058
J	Casanovas, O; Miro, B; Estanyol, JM; Itarte, E; Agell, N; Bachs, O				Casanovas, O; Miro, B; Estanyol, JM; Itarte, E; Agell, N; Bachs, O			Osmotic stress regulates the stability of cyclin D1 in a p38(SAPK2)-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; RETINOBLASTOMA PROTEIN; GROWTH-FACTOR; ANTIPROLIFERATIVE AGENTS; KINETIC MECHANISM; CELLULAR-RESPONSE; DEPENDENT KINASES; KIDNEY-CELLS; HEAT-SHOCK	We report here that different cell stresses regulate the stability of cyclin D1 protein. Exposition of Granta 519 cells to osmotic shock, oxidative stress, and arsenite induced the post-transcriptional down-regulation of cyclin D1. In the case of osmotic shock, this effect was completely reversed by the addition of p38(SAPK2)-specific inhibitors (SB203580 or SB220025), indicating that this effect is dependent on p38(SAPK2) activity. Moreover, the use of proteasome inhibitors prevented this down-regulation. Thus, osmotic shock induces proteasomal degradation of cyclin D1 protein by a p38(SAPK2)-dependent pathway. The effect of p38(SAPK2) On cyclin D1 stability might be mediated by direct phosphorylation at specific sites. We found that p38(SAPK2) phosphorylates cyclin D1 in vitro at Thr(286) and that this phosphorylation triggers the ubiquitination of cyclin D1. These results link for the first time a stress-induced MAP kinase pathway to cyclin D1 protein stability, and they will help to understand the molecular mechanisms by which stress transduction pathways regulate the cell cycle machinery and take control over cell proliferation.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi Sunyer, Barcelona 08036, Spain; Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, Bellaterra, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Autonomous University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, Casanova 143, Barcelona 08036, Spain.	bachs@medicina.ub.es	Agell, Neus/E-9640-2016; Itarte, Emilio/K-5275-2014; Miro-Mur, Francesc A./AAT-3013-2020; Itarte, Emilio/Q-6246-2019; Estanyol, Josep M/I-1039-2015; Casanovas, Oriol/L-5210-2014	Agell, Neus/0000-0002-1205-6074; Itarte, Emilio/0000-0002-9366-5807; Miro-Mur, Francesc A./0000-0003-3936-2693; Estanyol, Josep M/0000-0001-8621-0057; Casanovas, Oriol/0000-0002-4298-3995				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BATES S, 1994, ONCOGENE, V9, P1633; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Fox T, 1999, FEBS LETT, V461, P323, DOI 10.1016/S0014-5793(99)01488-X; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEET K, 1995, MOL CELL BIOL, V15, P4908; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; SHERR CJ, 1994, STEM CELLS, V12, P47; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Vadiveloo PK, 1998, J BIOL CHEM, V273, P23104, DOI 10.1074/jbc.273.36.23104; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VAIRO G, 1991, J IMMUNOL, V146, P3469; Villalonga P, 2000, ONCOGENE, V19, P690, DOI 10.1038/sj.onc.1203341; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	124	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35091	35097		10.1074/jbc.M006324200	http://dx.doi.org/10.1074/jbc.M006324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952989	hybrid			2022-12-25	WOS:000165422800037
J	Pollock, VV; Barber, MJ				Pollock, VV; Barber, MJ			Serine 121 is an essential amino acid for biotin sulfoxide reductase functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; FORMATE DEHYDROGENASE; MOLYBDENUM-COFACTOR; DIMETHYLSULFOXIDE REDUCTASE; METHIONINE SULFOXIDE; NITRATE REDUCTASE; STRUCTURAL GENE; OPERON	Rhodobacter sphaeroides f. sp. denitrificans biotin sulfoxide reductase (BSOR) catalyzes the reduction of d-biotin d-sulfoxide (BSO) to biotin, an important step in oxidized vitamin salvaging, In addition to BSO, the enzyme also catalyzes the reduction of a variety of other substrates, including methionine sulfoxide, with decreased efficiencies, suggesting a potential role as a general cell protector against oxidative damage. Recombinant BSOR, expressed as a glutathione S-transferase fusion protein, contains the molybdopterin guanine dinucleotide cofactor (MGD) as its sole prosthetic group, which is required for the reduction of BSO by either NADPH or reduced methyl viologen, Comparison of the amino acid sequences of BSOR and the closely related MGD-containing enzyme, dimethyl sulfoxide reductase, has indicated a number of conserved residues, including an active site serine residue, serine 121, which has been potentially identified as the fifth coordinating ligand of Mo in BSOR. Site-directed mutagenesis has been used to replace serine 121 with cysteine, threonine, or alanine residues in the BSOR sequence to asses the role of this residue in catalysis and/or Mo coordination. All three BSOR mutant proteins were expressed, purified to homogeneity, and demonstrated to contain both MGD by fluorescence spectroscopy and Mo by inductively coupled plasma mass spectrometry, similar to wild-type enzyme. However, all three mutant proteins were devoid of BSOR activity using either NADPH or reduced methyl viologen as the electron donor. These results strongly suggest that serine 121 in BSOR is essential for catalysis but is not essential for either Mo coordination or MGD binding.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Barber, MJ (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA.	mbarber@com1.med.usf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BERG BL, 1991, J BIOL CHEM, V266, P22380; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; Campbell ADC, 1996, J MOL EVOL, V42, P85, DOI 10.1007/BF02198832; CLEARY PP, 1974, BIOCH CELL BIOL, V56, P69; del Campillo-Campbell A, 1979, Methods Enzymol, V62, P379; EJIRI SI, 1980, ANAL BIOCHEM, V102, P393, DOI 10.1016/0003-2697(80)90173-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; Garton SD, 2000, J BIOL CHEM, V275, P6798, DOI 10.1074/jbc.275.10.6798; George GN, 1999, J AM CHEM SOC, V121, P1256, DOI 10.1021/ja982843k; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; HILTON JC, 1294, BIOCHIM BIOPHYS ACTA, P111; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; Pollock VV, 1997, J BIOL CHEM, V272, P3355, DOI 10.1074/jbc.272.6.3355; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Shaw AL, 1996, BBA-BIOENERGETICS, V1276, P176, DOI 10.1016/0005-2728(96)00092-8; Temple CA, 2000, BIOCHEMISTRY-US, V39, P4046, DOI 10.1021/bi9921541; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trieber CA, 1996, J BIOL CHEM, V271, P27339, DOI 10.1074/jbc.271.44.27339; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	31	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35086	35090		10.1074/jbc.M006872200	http://dx.doi.org/10.1074/jbc.M006872200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948204	hybrid			2022-12-25	WOS:000165422800036
J	Bhakat, KK; Mitra, S				Bhakat, KK; Mitra, S			Regulation of the human O-6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; DNA-REPAIR PROTEIN; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHROMATIN STRUCTURE; TRICHOSTATIN-A; CELL-LINES; EXPRESSION; E1A; CBP; ACETYLATION	O-6-Methylguanine-DNA methyltransferase (MGMT)(1), a ubiquitous DNA repair protein, removes O-6-alkylguanine from DNA, including cytotoxic O-6-chloroethylguanine induced by chemotherapeutic N-alkyl N-nitrosourea-type drugs, e.g. 1,3-bis(2-chloroethyl)-1-nitrosourea. Treating the pancreatic carcinoma cell line MIA PaCa-2 with trichostatin A (TSA), a specific inhibitor of histone deacetylase, increased MGMT mRNA and protein levels by 2-3-fold. Surprisingly, TSA treatment increased MGMT promoter-dependent luciferase activity by some 40-fold in a transient reporter expression assay. Deletion and point mutation analysis showed that two AP-1 binding sites in the MGMT promoter are involved in activation by TSA Ectopic expression of the transcriptional coactivators cAMP response element-binding protein-binding protein (CBP) and p300, which have intrinsic histone acetyltransferase activity, enhanced luciferase expression. Overexpression of adenovirus E1A, which binds CBP/p300, strongly inhibited both basal and TSA-inducible MGMT promoter activity, while a mutant E1A, defective in binding CBP/p300, did not. Chromatin immunoprecipitation assays revealed that TSA treatment increased histone acetylation in the endogenous MGMT promoter region, which also showed association with CBP/p300. Taken together, our results indicate that targeted histone acetylation results in the remodeling of chromatin by recruitment of the coactivator CBP/p300, and constitutes an important step in regulating MGMT expression.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Rt 1079, Galveston, TX 77555 USA.		Bhakat, Kishor/C-8072-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007572] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 07572] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Biswas T, 1999, ONCOGENE, V18, P525, DOI 10.1038/sj.onc.1202320; Boldogh I, 1998, CANCER RES, V58, P3950; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CITRON M, 1991, CANCER RES, V51, P4131; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DADEY MV, 1996, EMBO J, V15, P2508; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOTE RS, 1980, BIOCHEM BIOPH RES CO, V97, P654, DOI 10.1016/0006-291X(80)90314-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1992, CANCER RES, V52, P6404; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kokkinakis DM, 1997, CANCER RES, V57, P5360; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MYES CA, 1998, MOL CELL BIOL, V18, P2184; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Qian XLC, 1997, CANCER RES, V57, P3672; Sambrook J., 2002, MOL CLONING LAB MANU; Silber JR, 1996, P NATL ACAD SCI USA, V93, P6941, DOI 10.1073/pnas.93.14.6941; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; VanLint C, 1996, GENE EXPRESSION, V5, P245; VONWRONSKI MA, 1992, ONCOL RES, V4, P167; WASHINGTON WJ, 1989, MECH AGEING DEV, V48, P43, DOI 10.1016/0047-6374(89)90024-9; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	45	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34197	34204		10.1074/jbc.M005447200	http://dx.doi.org/10.1074/jbc.M005447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942771	hybrid			2022-12-25	WOS:000165095300029
J	von Lindern, M; Parren-van Amelsvoort, M; van Dijk, T; Deiner, E; van den Akker, E; van Emst-de Vries, S; Willems, P; Beug, H; Lowenberg, B				von Lindern, M; Parren-van Amelsvoort, M; van Dijk, T; Deiner, E; van den Akker, E; van Emst-de Vries, S; Willems, P; Beug, H; Lowenberg, B			Protein kinase C alpha controls erythropoietin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; TERMINAL DIFFERENTIATION; DNA-SYNTHESIS; MAST-CELLS; IN-VITRO; ACTIVATION; ASSOCIATION	Protein kinase C (PKC) is implied in the activation of multiple targets of erythropoietin (Epo) signaling, but its exact role in Epo receptor (EpoR) signal transduction and in the regulation of erythroid proliferation and differentiation remained elusive. We analyzed the effect of PKC inhibitors with distinct modes of action on EpoR signaling in primary human erythroblasts and in a recently established murine erythroid cell line. Active PKC appeared essential for Epo-induced phosphorylation of the Epo receptor itself, STAT5, Gab1, Erk1/2, AKT, and other downstream targets. Under the same conditions, stem cell factor-induced signal transduction was not impaired. LY294002, a specific inhibitor of phosphoinositol 3-kinase, also suppressed Epo-induced signal transduction, which could be partially relieved by activators of PKC. PKC inhibitors or LY294002 did not affect membrane expression of the EpoR, the association of JAK2 with the EpoR, or the in vitro kinase activity of JAK2. The data suggest that PKC controls EpoR signaling instead of being a downstream effector. PKC and phosphoinositol 3-kinase may act in concert to regulate association of the EpoR complex such that it is responsive to ligand stimulation. Reduced PKC-activity inhibited Epo-dependent differentiation, although it did not effect Epo-dependent "renewal divisions" induced in the presence of Epo, stem cell factor, and dexamethasone.	Erasmus Univ, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Inst Mol Pathol, A-1030 Vienna, Austria; Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Erasmus University Rotterdam; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Radboud University Nijmegen	von Lindern, M (corresponding author), Erasmus Univ, Inst Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	vonlindern@hema.fgg.eur.nl	Willems, P.H.G.M./L-4759-2015; von Lindern, Marieke/AAH-2350-2020	Willems, P.H.G.M./0000-0002-0915-1599; 				Berridge MJ, 1997, CRIT REV IMMUNOL, V17, P155, DOI 10.1615/CritRevImmunol.v17.i2.30; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Blobe GC, 1996, CANCER SURV, V27, P213; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Chin H, 1998, BLOOD, V91, P3734; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dubyak GR, 1997, ARCH BIOCHEM BIOPHYS, V341, P129, DOI 10.1006/abbi.1997.9946; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Haslauer M, 1999, BLOOD, V94, P114, DOI 10.1182/blood.V94.1.114.413k21_114_126; HE TC, 1993, BLOOD, V82, P3530; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HESS AD, 1988, J IMMUNOL, V141, P3263; Hoefsloot LH, 1997, BLOOD, V89, P1690, DOI 10.1182/blood.V89.5.1690.1690_1690_1700; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; JENIS DM, 1989, INT J CELL CLONING, V7, P190, DOI 10.1002/stem.5530070306; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Li YK, 1996, J BIOL CHEM, V271, P27025, DOI 10.1074/jbc.271.43.27025; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; PATEL HR, 1995, EXP HEMATOL, V23, P619; Porzig H, 1995, N-S ARCH PHARMACOL, V353, P11; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rey-Ladino JA, 1999, J IMMUNOL, V162, P5792; Sheng M, 2000, J CELL SCI, V113, P1851; SPIVAK JL, 1992, EXP HEMATOL, V20, P500; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Teng JMC, 1996, J IMMUNOL, V156, P3222; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Tsushima H, 1997, CELL GROWTH DIFFER, V8, P1317; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOGNUM AW, 1990, BLOOD, V76, P697; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5	68	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34719	34727		10.1074/jbc.M007042200	http://dx.doi.org/10.1074/jbc.M007042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940312	hybrid			2022-12-25	WOS:000165095300096
J	Adak, S; Wang, Q; Stuehr, DJ				Adak, S; Wang, Q; Stuehr, DJ			Arginine conversion to nitroxide by tetrahydrobiopterin-free neuronal nitric-oxide synthase - Implications for mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; NO SYNTHASE; ELECTRON-TRANSFER; PTERIN; SUBSTRATE; DOMAIN; CATALYSIS; COMPLEX; CALMODULIN; OXIDATION	We studied catalysis by tetrahydrobiopterin (H4B)-free neuronal nitric oxide synthase (nNOS) to understand how heme and H4B participate in nitric oxide (NO) synthesis. H4B-free nNOS catalyzed Arg oxidation to N-omega-hydroxy-L-Arg (NOHA) and citrulline in both NADPH- and H2O2-driven reactions. Citrulline formation was time- and enzyme concentration-dependent but was uncoupled relative to NADPH oxidation, and generated nitrite and nitrate without forming NO. Similar results mere observed when NOHA served as substrate. Steady-state and stopped-Bow spectroscopy with the H4B-free enzyme revealed that a ferrous heme-NO complex built up after initiating catalysis in both NADPH- and H2O2-driven reactions, consistent with formation of nitroxyl as an immediate product. This differed from the H4B-replete enzyme, which formed a ferric heme-NO complex as an immediate product that could then release NO. We make the following conclusions. 1) H4B is not essential for Arg oxidation by nNOS, although it helps couple NADPH oxidation to product formation in both steps of NO synthesis. Thus, the NADPH- or H2O2-driven reactions form common heme-oxy species that can react with substrate in the presence or absence of H4B. 2) The sole essential role of H4B is to enable nNOS to generate NO instead of nitroxyl, On this basis we propose a new unified model for heme-dependent oxygen activation and H4B function in both steps of NO synthesis.	Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,Immunol NB-3, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Adhikari S, 2000, FEBS LETT, V475, P35, DOI 10.1016/S0014-5793(00)01616-1; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7982, DOI 10.1021/ja00312a031; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FUKUTO JM, 1993, J MED CHEM, V36, P2666, DOI 10.1021/jm00070a010; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KAPPOCK TJ, 1996, CHEM REV, V96, P1659; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mansuy Daniel, 1995, P537; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MICHEL T, 1997, J CLIN INVEST, V100, P2417; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WINK DA, 1996, METHODS NITRIC OXIDE, P403	44	210	211	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33554	33561		10.1074/jbc.M004337200	http://dx.doi.org/10.1074/jbc.M004337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945985	hybrid			2022-12-25	WOS:000090104600054
J	Hardeland, U; Bentele, M; Jiricny, J; Schar, P				Hardeland, U; Bentele, M; Jiricny, J; Schar, P			Separating substrate recognition from base hydrolysis in human thymine DNA glycosylase by mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CELLS; CRYSTAL-STRUCTURE; NUCLEAR EXTRACTS; G/T MISMATCH; G.T MISPAIRS; HELA-CELLS; URACIL; 3,N-4-ETHENOCYTOSINE; KINETICS	Human thymine DNA glycosylase (TDG) was discovered as an enzyme that can initiate base excision repair at sites of 5-methylcytosine- or cytosine deamination in DNA by its ability to release thymine or uracil from G.T and G.U mismatches. Crystal structure analysis of an Escherichia coli homologue identified conserved amino acid residues that are critical for its substrate recognition/interaction and base hydrolysis functions. Guided by this revelation, we performed a mutational study of structure function relationships with the human TDG. Substitution of the postulated catalytic site asparagine with alanine (N140A) resulted in an enzyme that bound mismatched substrates but was unable to catalyze base removal. Mutation of Met-269 in a motif with a postulated role in protein-substrate interaction selectively inactivated stable binding of the enzyme to mismatched substrates but not so its glycosylase activity. These results establish that the structure function model postulated for the E. coli enzyme is largely applicable to the human TDG. We further provide evidence for G.U being the preferred substrate of TDG, not only at the mismatch recognition step of the reaction but also in base hydrolysis, and for the importance of stable complementary strand interactions by TDG to compensate for its comparably poor hydrolytic potential.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Schar, P (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.		Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147				Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164; MAJOR PP, 1982, CANCER RES, V42, P3005; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Zhu B, 2000, P NATL ACAD SCI USA, V97, P5135, DOI 10.1073/pnas.100107597	20	109	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33449	33456		10.1074/jbc.M005095200	http://dx.doi.org/10.1074/jbc.M005095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938281	hybrid, Green Accepted			2022-12-25	WOS:000090104600039
J	Shao, JY; Sheng, HM; Inoue, H; Morrow, JD; DuBois, RN				Shao, JY; Sheng, HM; Inoue, H; Morrow, JD; DuBois, RN			Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE-2 GENE; INTESTINAL EPITHELIAL-CELLS; PROTEIN-KINASE PATHWAY; GROWTH-FACTOR-ALPHA; N-TERMINAL KINASE; COLORECTAL-CANCER; ASPIRIN USE; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL REGULATION; INHIBITOR SUPPRESSES	Cyclooxygenase-2 (COX-2) is not normally expressed in the human large intestine, but its levels are increased in the majority of human colorectal carcinomas, Here we investigate the regulation of constitutive COX-2 expression and prostaglandin production in human colorectal carcinoma cells. Both COX-2 mRNA and protein were expressed in well differentiated HCA-7, Moser, LS-174, and HT-29 cells, albeit at different levels. COX-2 expression was not detected in several poorly differentiated colon cancer cell lines including DLD-1, Transcriptional regulation played a key role for the expression of COX-2 in human colon carcinoma cells, and both the nuclear factor for interleukin-6 regulatory element and the cAMP-response element were responsible for regulation of COX-2 transcription. COX-2 mRNA was more stable in HCA-7 cells than in the other cell lines tested. Both transcriptional and post-transcriptional regulation of COX-2 involved the MAP kinase pathway. Modulation of the Akt/protein kinase B or Rho B signaling pathways altered the levels of COX-2 expression. Furthermore, COX-2 protein is degraded through ubiquitin proteolysis, and its half-life was similar to3.5-8 h, HCA-7 cells produced significant quantities of prostaglandin E-2 and other prostaglandins. Moser and LS-174 cells also generated prostaglandins, but levels were significantly lower than that observed in HCA-7 cells.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Vet Affairs Med Ctr,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Vet Affairs Med Ctr,Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Vet Affairs Med Ctr,Dept Cell Biol, Nashville, TN 37232 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 5658565, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; National Cerebral & Cardiovascular Center - Japan	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [CA-77839] Funding Source: Medline; NIDDK NIH HHS [DK-48831, DK-47297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297, R01DK048831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; delPeso L, 1997, SCIENCE, V278, P687; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; Goldman AP, 1998, CARCINOGENESIS, V19, P2195, DOI 10.1093/carcin/19.12.2195; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Haas AL, 1997, FASEB J, V11, P1053, DOI 10.1096/fasebj.11.13.9367340; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Mestre JR, 1997, CANCER RES, V57, P2890; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Nishimura G, 1999, JPN J CANCER RES, V90, P1152, DOI 10.1111/j.1349-7006.1999.tb00690.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Rioux N, 1998, CANCER RES, V58, P5354; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; SANO H, 1995, CANCER RES, V55, P3785; Shao JY, 1999, CARCINOGENESIS, V20, P185, DOI 10.1093/carcin/20.2.185; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Watanabe K, 1999, CANCER RES, V59, P5093; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	57	238	246	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33951	33956		10.1074/jbc.M002324200	http://dx.doi.org/10.1074/jbc.M002324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930401	hybrid			2022-12-25	WOS:000090104600106
J	Chung, SW; Kang, BY; Kim, SH; Pak, YK; Cho, D; Trinchieri, G; Kim, TS				Chung, SW; Kang, BY; Kim, SH; Pak, YK; Cho, D; Trinchieri, G; Kim, TS			Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MONOCYTE-DERIVED MACROPHAGES; BLOOD MONONUCLEAR-CELLS; IL-12 PRODUCTION; GENE-EXPRESSION; PPAR-GAMMA; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; INTERFERON-GAMMA; DENDRITIC CELLS	Lipopolysaccharide (LPS) increases the production of interleukin-12 (IL-12) from mouse macrophages via a kappaB site within the IL-12 p40 promoter. In this study, we found that oxidized low density lipoprotein (oxLDL) inhibited this LPS-stimulated production of IL-12 in a dose-dependent manner while native LDL did not. OxLDL inhibited p40 promoter activation in monocytic RAW264.7 cells transiently transfected with p40 promoter/reporter constructs, and the repressive effect mapped to a region in the p40 promoter containing a binding site for nuclear factor-kappaB (NF-kappaB) (p40-kappaB), Activation of macrophages by LPS in the presence of oxLDL resulted in markedly reduced binding to the kappaB site, as demonstrated by the electrophoretic mobility shift assays. In contrast, native LDL did not inhibit the IL-12 p40 promoter activation and NF-kappaB binding to the kappaB sites, suggesting that oxidative modification of LDL was crucial for the inhibition of NF-kappaB-mediated IL-12 production. 9-Hydroxyoctadecadienoic acid, a major oxidized lipid component of oxLDL, significantly inhibited IL-12 production in LPS-stimulated mouse macrophages and also suppressed NF-kappaB-mediated activation in IL-12 p40 promoter. The NF-kappaB components p50 and p65 directly bound peroxisome proliferator-activated receptor-gamma (PPAP-gamma) in vitro, In cotransfections of CV-1 and HeLa cells, PPAR-gamma inhibited the NF-kappaB transactivation in an oxLDL-dependent manner. From these results, we propose that oxLDL-mediated suppression of the IL-12 production from LPS-activated mouse macrophages may, at least in part, involve both inhibition of the NF-kappaB-DNA interactions and physical interactions between NF-kappaB and PPAR-gamma.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Natl Inst Hlth, Div Metab Dis, Seoul 122701, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110799, South Korea; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Chonnam National University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Seoul National University (SNU); The Wistar Institute	Kim, TS (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	taekim@chonnam.chonnam.ac.kr	Pak, Youngmi Kim/AAI-1091-2020; Trinchieri, Giorgio/F-9369-2015	Pak, Youngmi Kim/0000-0001-7424-3484; Trinchieri, Giorgio/0000-0001-5892-7464				Benjamin D, 1996, J IMMUNOL, V156, P1626; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Caspi NR, 1998, CLIN IMMUNOL IMMUNOP, V88, P4, DOI 10.1006/clin.1998.4540; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Constantinescu CS, 1998, IMMUNOL LETT, V62, P25, DOI 10.1016/S0165-2478(98)00025-X; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; DeKruyff R, 1998, J IMMUNOL, V160, P2231; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONG LG, 1991, J LIPID RES, V32, P1899; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HOFF HF, 1992, J BIOL CHEM, V267, P602; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JOUGASAKI M, 1992, CIRC RES, V71, P614, DOI 10.1161/01.RES.71.3.614; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kang KF, 1996, J IMMUNOL, V156, P1402; Kim CH, 1995, J INFLAMM, V45, P312; Kim TS, 1997, J IMMUNOL, V158, P4137; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KU G, 1992, J BIOL CHEM, V267, P14183; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEHR HA, 1993, LAB INVEST, V68, P388; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LIPTON BA, 1995, J LIPID RES, V36, P2232; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; McDyer JF, 1998, J ALLERGY CLIN IMMUN, V102, P11; Moller DR, 1997, IMMUNOLOGY, V91, P197, DOI 10.1046/j.1365-2567.1997.00246.x; Moller DR, 1997, J IMMUNOL, V159, P5157; Moore DD, 1995, GLOB MOB SURV; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P649; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; THOMAS CE, 1994, J LIPID RES, V35, P417; Tone Y, 1996, EUR J IMMUNOL, V26, P1222, DOI 10.1002/eji.1830260606; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Yoshimoto T, 1996, J IMMUNOL, V156, P1082	64	305	317	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32681	32687		10.1074/jbc.M002577200	http://dx.doi.org/10.1074/jbc.M002577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934192	hybrid			2022-12-25	WOS:000090003800043
J	Uliel, L; Weisman-Shomer, P; Oren-Jazans, H; Newcomb, T; Loeb, LA; Fry, M				Uliel, L; Weisman-Shomer, P; Oren-Jazans, H; Newcomb, T; Loeb, LA; Fry, M			Human Ku antigen tightly binds and stabilizes a tetrahelical form of the fragile X syndrome d(CGG)(n) expanded sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; HUMAN FMR1 GENE; QUADRUPLEX TELOMERIC DNA; SYNTHESIS IN-VITRO; TRIPLET REPEATS; AUTOANTIGEN-KU; HELA-CELLS; TRINUCLEOTIDE REPEATS; DELAYED REPLICATION; HAIRPIN STRUCTURES	Hairpin and tetrahelical structures of a d(CGG)(n) sequence in the FMR1 gene have been implicated in its expansion in fragile X syndrome. The identification of tetraplex d(CGG)(n) destabilizing proteins (Fry, M., and Loeb, L. A.(1999) J. Biol. Chem. 274, 12797-12803; Weisman-Shomer, P., Naot, Y., and Fry, M. (2000) J. Biol. Chem. 275, 2231-2238) suggested that proteins might modulate d(CGG), folding and aggregation. We assayed human TK-6 lymphoblastoid cell extracts for d(CGG)(n) oligomer binding proteins. The principal binding protein was identified as Ku antigen by its partial amino acid sequence and antigenicity. The purified 88/75-kDa heterodimeric Ku bound with similar affinities (K-d similar to1.8-10.2 x 10(-9) mol/liter) to double-stranded d(CGG)(8).d(CCG)(8), hairpin d(CGG)(8), single-stranded d(CII)(8), or tetraplex structures of telomeric or IgG switch region sequences. However,Ku associated more tightly with bimolecular G'2 tetraplex d(CGG)(8) (K-d similar to0.35 x 10(-9) mol/liter). Binding to Ku protected G'2 d(CGG)(8) against nuclease digestion and impeded its unwinding by the tetraplex destabilizing protein qTBP42, Stabilization of d(CGG)(n) tetraplex domains in FMR1 by Ku or other proteins might promote d(CGG) expansion and FMR1 silencing.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Univ Washington, Dept Pathol, Gottstein Med Canc Res Lab, Seattle, WA 98195 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Washington; University of Washington Seattle	Fry, M (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.				NCI NIH HHS [P01-CA-47852] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey DB, 1995, MENTAL RETARDATION D, V1, P238; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; Cooper MP, 2000, GENE DEV, V14, P907; Deissler H, 1997, J BIOL CHEM, V272, P16761, DOI 10.1074/jbc.272.27.16761; Deissler H, 1996, J BIOL CHEM, V271, P4327; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GRIFFITH AJ, 1992, MOL BIOL REP, V16, P91, DOI 10.1007/BF00419754; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Malter HE, 1997, NAT GENET, V15, P165, DOI 10.1038/ng0297-165; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Muller-Hartmann H, 2000, J BIOL CHEM, V275, P6447, DOI 10.1074/jbc.275.9.6447; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; Torrance H, 1998, J BIOL CHEM, V273, P20810, DOI 10.1074/jbc.273.33.20810; TOTH EC, 1993, NUCLEIC ACIDS RES, V21, P3257, DOI 10.1093/nar/21.14.3257; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VISHWANATHA JK, 1990, BIOCHEMISTRY-US, V29, P8753, DOI 10.1021/bi00489a036; Weisman-Shomer P, 2000, J BIOL CHEM, V275, P2231, DOI 10.1074/jbc.275.3.2231; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZHANG WW, 1993, BIOCHEM J, V293, P769, DOI 10.1042/bj2930769; Zhao YF, 1996, J BIOMOL STRUCT DYN, V14, P235, DOI 10.1080/07391102.1996.10508113	59	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33134	33141		10.1074/jbc.M005542200	http://dx.doi.org/10.1074/jbc.M005542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924524	hybrid			2022-12-25	WOS:000090003800102
J	Haque, SJ; Harbor, PC; Williams, BRG				Haque, SJ; Harbor, PC; Williams, BRG			Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; INDUCED STAT INHIBITOR; SOCS-BOX MOTIF; ERYTHROPOIETIN RECEPTOR; JAK/STAT PATHWAY; GENE-EXPRESSION; SH2 DOMAIN; TRANSDUCTION; CLONING	Suppressor of cytokine signaling (SOCS) family proteins were originally identified as cytokine-induced negative regulators of cytokine signaling. We show that SOCS-1 and SOCS-3 inhibit interleukin (IL)-4-dependent signal transducer and activator of transcription 6 (Stat6) activation of and subsequent gene induction. By contrast, SOCS-2 and cytokine-inducible Src homology domain 2 (SH2)-containing protein up-regulate these processes. IL-4 initiates transmembrane signaling through two types of receptor complexes comprising the IL-4R alpha subunit and the associated Janus kinase 1 (Jak1) as common essential components. We demonstrate that both SOCS-1- and SOCS-3-mediated down-regulation of IL-4 signaling is due to an inhibition of the receptor associated Jak1 activity. The SOCS proteins contain an amino-terminal region of variable length and primary structure, a central SH2 domain, and a carboxyl-terminal conserved motif termed SOCS-box. We show that the SH2 domains of SOCS-2, SOCS-3, and cytokine-inducible SH2-containing protein are functionally redundant in regulating the IL-4-dependent Jak-Stat signaling. The Pre-SH2 domains of SOCS-2 and SOCS-3 confer the specificity of their regulatory function. Importantly, the Pre-SH2 domain of SOCS-3 alone can inhibit IL-4 signaling. The SH2-proximal 25 amino acids of SOCS-3 are sufficient for this inhibition, and the Thr residue at position 24 and the Phe residue at position 25 are individually indispensable for its inhibitory function. Thus, the Thr-Phe motif in the Pre-SH2 domain plays a critical role in SOCS 3-mediated inhibition of the IL-4-dependent Jak-Stat signaling, likely by regulating the mode of SOCS-Jak interaction.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB4-0,9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NCI NIH HHS [P01-CA62220] Funding Source: Medline; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AMAN MJ, 1997, CURR BIOL, V7, P784; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Losman JA, 1999, J IMMUNOL, V162, P3770; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; OShea JJ, 1997, J CLIN IMMUNOL, V17, P431, DOI 10.1023/A:1027388508570; PAUL WE, 1991, BLOOD, V77, P1859; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YIN TG, 1994, J BIOL CHEM, V269, P26614; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	53	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26500	26506		10.1074/jbc.275.34.26500	http://dx.doi.org/10.1074/jbc.275.34.26500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10950967	hybrid			2022-12-25	WOS:000088999700085
J	Kvaratskhelia, M; Wardleworth, BN; Norman, DG; White, MF				Kvaratskhelia, M; Wardleworth, BN; Norman, DG; White, MF			A conserved nuclease domain in the archaeal Holliday junction resolving enzyme Hjc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; 4-WAY DNA JUNCTION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; EVOLUTIONARY RELATIONSHIPS; SACCHAROMYCES-CEREVISIAE; CATALYTIC CENTER; RUVC RESOLVASE; MG2+ BINDING; ACTIVE-SITE	Holliday junction resolving enzymes are ubiquitous proteins that function in the pathway of homologous recombination, catalyzing the rearrangement and repair of DNA. They are metal ion-dependent endonucleases with strong structural specificity for branched DNA species. Whereas the eukaryotic nuclear enzyme remains unknown, an archaeal Holliday junction resolving enzyme, Hjc, has recently been identified. We demonstrate that Hjc manipulates the global structure of the Holliday junction into a 2-fold symmetric X shape, with local disruption of base pairing around the point of cleavage that occurs in a region of duplex DNA 3' to the point of strand exchange. Primary and secondary structural analysis reveals the presence of a conserved catalytic metal ion binding domain in Hjc that has been identified previously in several restriction enzymes. The roles of catalytic residues conserved within this domain have been confirmed by site-directed mutagenesis, This is the first example of this domain in an archaeal enzyme of known function as well as the first in a Holliday junction resolving enzyme.	Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee	White, MF (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.		White, Malcolm F/A-6055-2010	White, Malcolm F/0000-0003-1543-9342				ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; Davies GP, 1999, J MOL BIOL, V290, P565, DOI 10.1006/jmbi.1999.2908; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; Groll DH, 1997, BIOCHEMISTRY-US, V36, P11389, DOI 10.1021/bi9705826; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; KEELING PJ, 1995, P NATL ACAD SCI USA, V92, P5761, DOI 10.1073/pnas.92.13.5761; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; Kvaratskhelia M, 2000, J MOL BIOL, V295, P193, DOI 10.1006/jmbi.1999.3363; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; Lilley DMJ, 1999, NAT STRUCT BIOL, V6, P897, DOI 10.1038/13255; Lilley DMJ, 1997, P NATL ACAD SCI USA, V94, P9513, DOI 10.1073/pnas.94.18.9513; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MURCHIE AIH, 1991, EMBO J, V10, P713, DOI 10.1002/j.1460-2075.1991.tb08001.x; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; Ortiz-Lombardia M, 1999, NAT STRUCT BIOL, V6, P913; Pohler JRG, 1996, J MOL BIOL, V260, P678; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Stanford NP, 1999, J MOL BIOL, V288, P105, DOI 10.1006/jmbi.1999.2673; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WEST SC, 1987, J BIOL CHEM, V262, P12752; White MF, 1997, J MOL BIOL, V269, P647, DOI 10.1006/jmbi.1997.1097; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, MOL CELL BIOL, V17, P6465, DOI 10.1128/MCB.17.11.6465; White MF, 1997, J MOL BIOL, V266, P122, DOI 10.1006/jmbi.1996.0795; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	49	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25540	25546		10.1074/jbc.M003420200	http://dx.doi.org/10.1074/jbc.M003420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10940317	hybrid			2022-12-25	WOS:000088849400066
J	Brassac, T; Castro, A; Lorca, T; Le Peuch, C; Doree, M; Labbe, JC; Galas, S				Brassac, T; Castro, A; Lorca, T; Le Peuch, C; Doree, M; Labbe, JC; Galas, S			The polo-like kinase Plx1 prevents premature inactivation of the APC(Fizzy)-dependent pathway in the early Xenopus cell cycle	ONCOGENE			English	Article						Plx1; cyclin; APC/cyclosome; microcystin; phosphatase	ANAPHASE-PROMOTING COMPLEX; AMPHIBIAN EGGS; CHROMOSOME SEGREGATION; INTERPHASE EXTRACTS; MEIOTIC METAPHASE; MITOTIC CYCLINS; OKADAIC ACID; M-PHASE; MITOSIS; PROTEOLYSIS	Members of the polo-like family of protein kinases have been involved in the control of APC (anaphase-promoting complex) during the cell cycle, Set how they activate APC is not understood in any detail. In Xenopus oocytes, Cati-dependent degradation of cyclin B associated with release from arrest at second meiotic metaphase was demonstrated to require the polo-like kinase Plx1. The aim of the present study mas to examine, beyond Ca2+-dependent resumption of meiosis, the possible role of Plx1 in the control of cyclin degradation during the early mitotic cell cycle, Plx1 was found to be dispensable for MPF to turn on the cyclin degradation machinery, However, it is required to prevent premature inactivation of the APC-dependent proteolytic pathway. Microcystin suppresses the requirement for Plx1 in both Ca2+-dependent exit from meiosis, associated with degradation of both cyclin B and A downstream of CaMK2 activation, and prevention of premature APC(Fizzy) inactivation in the early mitotic cell cycle, These results are consistent with the view that Plx1 antagonizes an unidentified microcystin-sensitive phosphatase that inactivates APC(Fizzy).	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Galas, S (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		Galas, Simon/X-1312-2019; labbe, jean-claude/B-2277-2009; CASTRO, ANNA/F-4350-2010	Galas, Simon/0000-0002-1717-1266; CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				Abrieu A, 1998, J CELL SCI, V111, P1751; Abrieu A, 1997, MOL BIOL CELL, V8, P249, DOI 10.1091/mbc.8.2.249; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brown KD, 1996, J CELL SCI, V109, P961; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	44	19	22	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3782	3790		10.1038/sj.onc.1203724	http://dx.doi.org/10.1038/sj.onc.1203724			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949933				2022-12-25	WOS:000088568400011
J	Loukas, A; Hintz, M; Linder, D; Mullin, NP; Parkinson, J; Tetteh, KKA; Maizels, RM				Loukas, A; Hintz, M; Linder, D; Mullin, NP; Parkinson, J; Tetteh, KKA; Maizels, RM			A family of secreted mucins from the parasitic nematode Toxocara canis bears diverse mucin domains but shares similar flanking six-cysteine repeat motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; INFECTIVE LARVAE; TRYPANOSOMA-CRUZI; CAENORHABDITIS-ELEGANS; CARBOHYDRATE EPITOPES; BRUGIA-MALAYI; ANTIGENS; SURFACE; PROTEIN; GENES	Infective larvae of the parasitic nematode Toxocara canis secrete a family of mucin-Like glycoproteins, which are implicated in parasite immune evasion. Analysis of T. canis expressed sequence tags identified a family of four mRNAs encoding distinct apomucins (Tc-muc-1-4), one of which had been previously identified in the TES-120 family of glycoproteins secreted by this parasite. The protein products of all four cDNAs contain signal peptides, a repetitive serine/threonine-rich tract, and varying numbers of 36-amino acid six-cysteine (SXC) domains. SXC domains are found in many nematode proteins and show similarity to cnidarian (sea anemone) toxins. Antibodies to the SXC domains of TcMUG-1 and Tc-MUC-3 recognize differently migrating members of TES-120. TES-120 proteins separated by chromatographic methods showed distinct amino acid composition, mass, and sequence information by both Edman degradation and matrix-assisted laser desorption ionization/time of flight mass spectrometry on peptide fragments. Tc-MUC-1, -2, and -3 were shown to be secreted mucins with real masses of 39.7, 47.8, and 45.0 kDa in contrast to their predicted peptide masses of 15.7, 16.2, and 26.0 kDa, respectively. The presence of SXC domains in all mucin products supports the suggestion that the SXC motif is required for mucin assembly or export. Homology modeling indicates that the six-cysteine domains of the T. canis mucins adopt a similar fold to the sea anemone potassium channel-blocking toxin BgK, forming three disulfide bonds within each subunit.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Giessen Klinikum, Inst Biochem, D-35392 Giessen, Germany	University of Edinburgh; University of Edinburgh; University Hospital of Giessen & Marburg	Maizels, RM (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Parkinson, John/A-4424-2008; Loukas, Alex/B-7355-2014	Parkinson, John/0000-0001-9815-1189; Loukas, Alex/0000-0002-0896-8441; Mullin, Nicholas/0000-0003-4802-440X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BADLEY JE, 1987, J PARASITOL, V73, P593, DOI 10.2307/3282142; BADLEY JE, 1987, PARASITE IMMUNOL, V9, P133, DOI 10.1111/j.1365-3024.1987.tb00494.x; BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; Blaxter M, 1996, INT J PARASITOL, V26, P1025, DOI 10.1016/S0020-7519(96)00060-4; Blaxter M, 1998, SCIENCE, V282, P2041, DOI 10.1126/science.282.5396.2041; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; Daub J, 2000, PARASITOLOGY, V120, P171, DOI 10.1017/S0031182099005375; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; de Diego J, 1997, J IMMUNOL, V159, P4983; Dell A, 1999, BBA-MOL BASIS DIS, V1455, P353, DOI 10.1016/S0925-4439(99)00064-2; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; FATTAH DI, 1986, EXP PARASITOL, V61, P421, DOI 10.1016/0014-4894(86)90198-0; Freitas-Junior LHG, 1998, MOL BIOCHEM PARASIT, V93, P101, DOI 10.1016/S0166-6851(98)00025-5; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; Gems D, 1996, P NATL ACAD SCI USA, V93, P1665, DOI 10.1073/pnas.93.4.1665; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; GLICKMAN LT, 1993, TOXOCARA AND TOXOCARIASIS, P3; Gomez-Escobar N, 1998, EXP PARASITOL, V88, P200, DOI 10.1006/expr.1998.4248; Gum JR, 1997, J BIOL CHEM, V272, P26678, DOI 10.1074/jbc.272.42.26678; HAYES DF, 1990, J IMMUNOL, V145, P962; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; KHOO K-H, 1991, Glycobiology, V1, P163, DOI 10.1093/glycob/1.2.163; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; Komatsu M, 1999, CANCER RES, V59, P2229; Loukas A, 1999, CURR BIOL, V9, P825, DOI 10.1016/S0960-9822(99)80366-2; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MAIZELS RM, 1987, J IMMUNOL, V139, P207; MAIZELS RM, 1984, PARASITE IMMUNOL, V6, P23, DOI 10.1111/j.1365-3024.1984.tb00779.x; Maizels RM, 2000, INT J PARASITOL, V30, P495, DOI 10.1016/S0020-7519(00)00022-9; MARIN MS, 1992, MOL BIOCHEM PARASIT, V55, P155, DOI 10.1016/0166-6851(92)90136-8; MEGHJI M, 1986, MOL BIOCHEM PARASIT, V18, P155, DOI 10.1016/0166-6851(86)90035-6; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; PAGE AP, 1992, PARASITOLOGY, V105, P297, DOI 10.1017/S0031182000074229; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1991, PARASITOLOGY, V103, P451, DOI 10.1017/S0031182000059977; Pan TL, 1998, DEV GENES EVOL, V208, P259, DOI 10.1007/s004270050180; Pastrana DV, 1998, INFECT IMMUN, V66, P5955, DOI 10.1128/IAI.66.12.5955-5963.1998; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEED B, 1992, Current Biology, V2, P457, DOI 10.1016/0960-9822(92)90647-S; SMITH HV, 1981, MOL BIOCHEM PARASIT, V4, P183, DOI 10.1016/0166-6851(81)90017-7; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Tetteh KKA, 1999, INFECT IMMUN, V67, P4771, DOI 10.1128/IAI.67.9.4771-4779.1999; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zang XX, 1999, BLOOD, V94, P1418, DOI 10.1182/blood.V94.4.1418.416k03_1418_1428	53	73	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39600	39607		10.1074/jbc.M005632200	http://dx.doi.org/10.1074/jbc.M005632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10950959	hybrid			2022-12-25	WOS:000165953100086
J	Atshaves, BP; Starodub, O; McIntosh, A; Petrescu, A; Roths, JB; Kier, AB; Schroeder, F				Atshaves, BP; Starodub, O; McIntosh, A; Petrescu, A; Roths, JB; Kier, AB; Schroeder, F			Sterol carrier protein-2 alters high density lipoprotein-mediated cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-CELL FIBROBLASTS; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; LIPID DROPLETS; IN-VIVO; BINDING; EXPRESSION; LIVER; OVEREXPRESSION; ESTERIFICATION	Although sterol carrier protein-2 (SCP-2) participates in the uptake and intracellular trafficking of cholesterol, its effect on "reverse cholesterol transport" has not been explored. As shown herein, SCP-2 expression inhibited high density lipoprotein (HDL)-mediated efflux of [H-3]cholesterol and fluorescent 22-(N-(7-nitro-benz-oxa-1,3-diazol-4-yl)amino) -23,24-bisnor-5-cholen-3b-ol (NBD-cholesterol) up to 61 and 157%, respectively. Confocal microscopy of living cells allowed kinetic analysis of two intracellular pools of HDL-mediated NBD-cholesterol efflux: the highly fluorescent lipid droplet pool and the less fluorescent pool outside the lipid droplets, designated the cytoplasmic compartment, Both the whole cell and the cytoplasmic compartment exhibited two similar kinetic pools, the half-times of which were consistent with protein (t(1/2)(b) near 1 min) and vesicular (t(1/2)(d) = 10-20 min) mediated sterol transfer. Although SCP-2 expression did not alter cytoplasmic sterol pool sizes, the rapid t(1/2)(b) decreased 36%, while the slower t(1/2)(d) increased 113%. Lipid droplets also exhibited two kinetic pools of NBD-cholesterol efflux but with half-times over 200% shorter than those of the cytoplasmic compartment. The lipid droplet slower effluxing pool size and t(1/2)(d), were increased 48% and 115%, respectively, in SCP-a-expressing cells. Concomitantly, the level of the lipid droplet-specific adipose differentiation-related protein decreased 70%. Overall, HDL-mediated sterol efflux from L-cell fibroblasts reflected that of the cytoplasmic rather than lipid droplet compartment, SCP-2 differentially modulated sterol efflux from the two cytoplasmic pools. However, net efflux was determined primarily by inhibition of the slowly effluxing pool rather than by acceleration of the rapid protein-mediated pool. Finally, SCP-2 expression also inhibited sterol efflux from lipid droplets, an effect related to decreased adipose differentiation-related protein, a lipid droplet surface protein that binds cholesterol with high affinity.	Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Schroeder, F (corresponding author), Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 1998, AM J PHYSIOL-CELL PH, V274, pC633, DOI 10.1152/ajpcell.1998.274.3.C633; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; AVIRAM M, 1989, J LIPID RES, V30, P65; BAN T, 1991, ARTERY, V18, P54; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BISGAIER CL, 1985, J STEROID BIOCHEM, V23, P967, DOI 10.1016/0022-4731(85)90054-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRASAEMLE DL, 1988, J LIPID RES, V29, P481; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; DICK JPR, 1993, J ROY SOC MED, V86, P171; DIETSCHY JM, 1970, NEW ENGL J MED, V282, P1128, DOI 10.1056/NEJM197005142822005; Fielding CJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P273; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, J LIPID RES, V38, P1503; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Fuchs M, 1997, FASEB J, V11, pA1060; Fuchs M, 1998, BIOCHEM J, V336, P33, DOI 10.1042/bj3360033; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Ito T, 1996, GASTROENTEROLOGY, V110, P1619, DOI 10.1053/gast.1996.v110.pm8613070; KAWATA S, 1991, CLIN CHIM ACTA, V197, P201, DOI 10.1016/0009-8981(91)90140-8; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; McArthur MJ, 1999, J LIPID RES, V40, P1371; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Moncecchi DM, 1991, PHYSL BIOCH STEROLS, P1; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; MyersPayne SC, 1996, J NEUROCHEM, V66, P313; Neufeld EB, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P93; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; POORTHUIS BJHM, 1982, BIOCHIM BIOPHYS ACTA, V710, P99, DOI 10.1016/0005-2760(82)90195-3; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1981, FEBS LETT, V135, P127, DOI 10.1016/0014-5793(81)80959-3; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; Smart EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P253; Sparrow CP, 1999, J LIPID RES, V40, P1747; STECK TL, 1988, J BIOL CHEM, V263, P13023; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; Weisiger RA, 1996, COMP BIOCHEM PHYS B, V115, P319, DOI 10.1016/S0305-0491(96)00179-4; Weisiger RA, 1996, HEPATOLOGY, V24, P1288	62	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36852	36861		10.1074/jbc.M003434200	http://dx.doi.org/10.1074/jbc.M003434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10954705	hybrid			2022-12-25	WOS:000165577700059
J	Kim, SH; Li, ZG; Sacks, DB				Kim, SH; Li, ZG; Sacks, DB			E-cadherin-mediated cell-cell attachment activates Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; ADHESION COMPLEX; BINDING PROTEIN; EXCHANGE FACTOR; MDCK CELLS; KINASE-B; DOMAIN; IQGAP1	E-cadherin is a transmembrane protein that mediates Ca2+-dependent cell-cell adhesion. Cdc42, a member of the Rho family of small GTPases, participates in cytoskeletal rearrangement and cell cycle progression. Recent evidence reveals that members of the Rho family modulate E-cadherin function. To further examine the role of Cdc42 in E-cadherin-mediated cell-cell adhesion, we developed an assay for active Cdc42 using the GTPase-binding domain of the Wiskott-Aldrich syndrome protein. Initiation of E cadherin-mediated cell-cell attachment significantly increased in a time-dependent manner the amount of active Cdc42 in MCF-7 epithelial cell lysates. By contrast, Cdc42 activity was not increased under identical conditions in MCF-7 cells incubated with anti-E-cadherin antibodies nor in MDA-MB-231 (E-cadherin negative) epithelial cells. By fusing the Wiskott-Aldrich syndrome protein/GTPase-binding domain to a green fluorescent protein, activation of endogenous Cdc42 by E-cadherin was demonstrated in live cells. These data indicate that E-cadherin activates Cdc42, demonstrating bi-directional interactions between the Rho- and E-cadherin signaling pathways.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735	NATIONAL CANCER INSTITUTE [R55CA075205, R01CA075205] Funding Source: NIH RePORTER; NCI NIH HHS [CA75205] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Braga VMM, 1999, J CLIN PATHOL-MOL PA, V52, P197, DOI 10.1136/mp.52.4.197; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	48	181	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36999	37005		10.1074/jbc.M003430200	http://dx.doi.org/10.1074/jbc.M003430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10950951	hybrid			2022-12-25	WOS:000165577700077
J	Medley, QG; Serra-Pages, C; Iannotti, E; Seipel, K; Tang, M; O'Brien, SP; Streuli, M				Medley, QG; Serra-Pages, C; Iannotti, E; Seipel, K; Tang, M; O'Brien, SP; Streuli, M			The Trio guanine nucleotide exchange factor is a RhoA target - Binding of RhoA to the Trio immunoglobulin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LIGHT-CHAIN KINASE; CELL-SHAPE CHANGES; FAMILY G-PROTEINS; ACTIN CYTOSKELETON; SIGNALING PATHWAYS; C-ELEGANS; GTPASES; VAV; ACTIVATION	Trio isa complex protein containing two guanine nucleotide exchange factor domains each with associated pleckstrin homology domains, a serine/threonine kinase domain, two SH3 domains, an immunoglobulin-like domain, and spectrin-like repeats. Trio was originally identified as a LAR tyrosine phosphatase-binding protein and is involved in actin remodeling, cell migration, and cell growth. Herein we provide evidence that Trio not only activates RhoA but is also a RhoA target. The RhoA-binding site was mapped to the Trio immunoglobulin-like domain. RhoA isoprenylation is necessary for the RhoA-Trio interaction, because mutation of the RhoA carboxyl-terminal cysteine residue blocked binding, The:existence of an intramolecular functional link between RhoA activation and RhoA binding is suggested by the finding that Trio exchange activity enhanced RhoA binding to Trio. Furthermore, immunofluorescence studies of HeLa cells showed that although ectopically:expressed Trio was evenly distributed within the cell, co-expression of Trio with RhoA resulted in relocalization of Trio into punctate structures. Relocalization was not observed with Trio constructs lacking the immunoglobulin-like domain, indicating that RhoA acts to regulate,Trio localization via binding to the immunoglobulin-like domain. We propose that Trio-mediated RhoA: activation and subsequent RhoA-mediated relocalization of Trio functions to modulate and coordinate Trio signaling.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Streuli, M (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.			Seipel, Katja/0000-0003-3128-1573	NCI NIH HHS [CA75091, CA55547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075091, R01CA055547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; Blangy A, 2000, J CELL SCI, V113, P729; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Johnson RC, 2000, J BIOL CHEM, V275, P19324, DOI 10.1074/jbc.M000676200; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PASTERIS NG, 1994, CELL, V79, P669; Penzes P, 2000, J BIOL CHEM, V275, P6395, DOI 10.1074/jbc.275.9.6395; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Seipel K, 1999, J CELL SCI, V112, P1825; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; VAN AL, 1997, GENE DEV, V11, P2295; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZMUIDZINAS A, 1995, EMBO J, V14, P1; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	53	28	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36116	36123		10.1074/jbc.M003775200	http://dx.doi.org/10.1074/jbc.M003775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948190	hybrid			2022-12-25	WOS:000165382000068
J	Levkowitz, G; Oved, S; Klapper, LN; Harari, D; Lavi, S; Sela, M; Yarden, Y				Levkowitz, G; Oved, S; Klapper, LN; Harari, D; Lavi, S; Sela, M; Yarden, Y			c-Cbl is a suppressor of the Neu oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; DROSOPHILA EGF RECEPTOR; HUMAN BREAST-CANCER; ERBB RECEPTORS; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; MAMMARY-TUMORS; MONOCLONAL-ANTIBODIES; DOWN-REGULATION	A rodent oncogenic mutant of the Neu receptor tyrosine kinase is a useful experimental model because overexpression of:the respective receptor, namely HER2/ErbB-2 in human malignancies is associated with relatively aggressive diseases. Here we show that the oncogenic form of Neu is constitutively associated with the product of the c-cbl proto-oncogene and is part of a large complex that includes the phosphoinositide 3-kinase and Shc. Ectopic expression of c-Cbl, a ubiquitin-protein isopeptide ligase specific to activated tyrosine kinases, causes rapid removal of Neu from the cell surface-and severely reduces signaling downstream of oncogenic Neu. c-Cbl-induced down-regulation of Neu involves covalent attachment of ubiquitin molecules and requires the carboxyl-terminal domain of Neu. The negative effect of c-Cbl is antagonized by v-Cbl, a virus-encoded oncogenic truncated form of c-Cbl. In an in vivo model, infection of a Neu-transformed neuroblastoma with: a c-Cbl-encoding retrovirus caused enhanced down-regulation of Neu and correlated with tumor retardation. Our results implicate c-Cbl in negative regulation of Neu and offer a potential target for treatment of HER2/ErbB-2-positive human malignancies.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; 	NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Baselga J, 1997, Oncology (Williston Park), V11, P43; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baulida J, 1996, J BIOL CHEM, V271, P5251; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 2000, CANCER RES, V60, P3384; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LONARDO F, 1990, New Biologist, V2, P992; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Magnifico A, 1998, FEBS LETT, V422, P129, DOI 10.1016/S0014-5793(97)01612-8; MAIER LA, 1991, CANCER RES, V51, P5361; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Muller WJ, 1998, BIOCHEM SOC SYMP, P149; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON D, 1998, P AN M AM SOC CLIN, V17, P98; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORKIN A, 1993, ONCOGENE, V8, P3021; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Trebak M, 1998, CELL IMMUNOL, V188, P151, DOI 10.1006/cimm.1998.1348; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	79	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35532	35539		10.1074/jbc.M002661200	http://dx.doi.org/10.1074/jbc.M002661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10940298	hybrid			2022-12-25	WOS:000165422800092
J	Davaille, J; Gallois, C; Habib, A; Li, LY; Mallat, A; Tao, JC; Levade, T; Lotersztajn, S				Davaille, J; Gallois, C; Habib, A; Li, LY; Mallat, A; Tao, JC; Levade, T; Lotersztajn, S			Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts - A cyclooxygenase-2 mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; STELLATE CELLS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; RECEPTOR EDG-1; SPHINGOSINE-1-PHOSPHATE; PROLIFERATION	Proliferation of hepatic myofibroblasts (hMF) is central for the development of fibrosis during liver injury, and factors that may limit their growth are potential antifibrotic agents. Sphingosine I-phosphate (S1P) is a bioactive sphingolipid with growth-regulating properties, either via Edg receptors or through intracellular actions. In this study, we examined the effects of S1P on the proliferation of human hMF. Human hMF expressed mRNAs for the S1P receptors Edg1, Edg3, and Edg5. These receptors were functional at nanomolar concentrations and coupled to pertussis toxin-sensitive and -insensitive G proteins, as demonstrated in guanosine 5'-3-O-(thio)triphosphate binding assays. S1P potently inhibited hMF growth (IC50 = 1 muM), in a pertussis toxin-insensitive manner. Analysis of the mechanisms involved in growth inhibition revealed that SIP rapidly increased prostaglandin E-2 production and in turn cAMP, two growth inhibitory messengers for hMF; C-2-ceramide and sphingosine, which inhibited hMF proliferation, did not affect cAMP levels. Production of cAMP by S1P was abolished by NS-398, a selective inhibitor of COX-2. Also, S1P potently induced COX-2 protein expression. Blocking COX-2 by NS-398 blunted the antiproliferative effect of SIP. We conclude that SIP inhibits proliferation of hMF, probably via an intracellular mechanism, through early COX-2-dependent release of prostaglandin E-2 and cAMP, and delayed COX-2 induction. Our results shed light on a novel role for S1P as a growth inhibitory mediator and point out its potential involvement in the negative regulation of liver fibrogenesis.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Hop Lariboisiere, INSERM, U348, F-75010 Paris, France; CHU Rangueil, INSERM, U466, F-31403 Toulouse, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Habib, Aida/H-8647-2019; Lotersztajn, Sophie/K-9160-2017; Levade, Thierry/O-8948-2014	Habib, Aida/0000-0001-6027-0043; lotersztajn, Sophie/0000-0002-0053-7807				Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Gallois C, 2000, ANN NY ACAD SCI, V905, P311; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Knittel T, 1999, HISTOCHEM CELL BIOL, V112, P387, DOI 10.1007/s004180050421; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Olaso E, 1998, J HEPATOL, V29, P836, DOI 10.1016/S0168-8278(98)80269-9; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	36	111	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34628	34633		10.1074/jbc.M006393200	http://dx.doi.org/10.1074/jbc.M006393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942778	hybrid			2022-12-25	WOS:000165095300085
J	Langmade, SJ; Ravindra, R; Daniels, PJ; Andrews, GK				Langmade, SJ; Ravindra, R; Daniels, PJ; Andrews, GK			The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN-I GENE; DIETARY ZINC-DEFICIENCY; MESSENGER-RNA; RESPONSE ELEMENT; TRANSGENIC MICE; CONFERS RESISTANCE; SYNAPTIC VESICLES; BINDING-ACTIVITY; DNA-BINDING; EXPRESSION	Metal regulation of the mouse zinc transporter (ZnT)-1 gene was examined in cultured cells and in the developing conceptus. Zinc or cadmium treatment of cell lines rapidly (3 h) and dramatically (about la-fold) induced ZnT1 mRNA levels. In cells incubated in medium supplemented with Chelex-treated fetal bovine serum, to remove metal ions, levels of ZnT1 mRNA were reduced, and induction of this message in response to zinc or cadmium was accentuated (up to 31-fold induction). Changes in ZnT1 gene expression in these experiments paralleled those of metallothionein I (MT-I), Inhibition of RNA synthesis blocked metal induction of ZnT1 and MT-1 mRNAs, whereas inhibition of protein synthesis did not. Metal response element-binding transcription factor (MTF)-1 mediates metal regulation of the metallothionein I gene. In vitro DNA-binding assays demonstrated that mouse MTF-1 can bind avidly to the two metal-response element sequences found in the ZnT1 promoter. Using mouse embryo fibroblasts with homozygous deletions of the MTF-1 gene, it was shown that this transcription factor is essential for basal as well as metal (zinc and cadmium) regulation of the ZnT1 gene in these cells. In vivo, ZnT1 mRNA was abundant in the midgestation visceral yolk sac and placenta. Dietary zinc deficiency during pregnancy down-regulated ZnT1 and MT-I mRNA levels (4-5-fold and >20-fold, respectively) in the visceral yolk sac, but had little effect on these mRNAs in the placenta. Homozygous knockout of the MTF-1 gene in transgenic mice also led to a 4-6-fold reduction in ZnT1 mRNA levels and a loss of MT-I mRNA in the visceral yolk sac, These results suggest that MTF-1 mediates the response to metal ions of both the ZnT1 and the MT-I genes the visceral yolk sac, Overall, these studies suggest that MTF-1 directly coordinates the regulation of genes involved in zinc homeostasis and protection against metal toxicity.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	gandrews@kumc.edu			NCI NIH HHS [CA 61262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS GK, 1987, DEVELOPMENT, V100, P463; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; ANDREWS GK, 1991, DEV BIOL, V145, P13, DOI 10.1016/0012-1606(91)90209-L; Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; ANDREWS GK, 1987, EUR J BIOCHEM, V166, P527, DOI 10.1111/j.1432-1033.1987.tb13545.x; ANDREWS GK, 1993, METALLOTHIONEIN, V3, P351; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Davis SR, 1998, J NUTR, V128, P825, DOI 10.1093/jn/128.5.825; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARASAWA M, 1991, J INVEST DERMATOL, V97, P97, DOI 10.1111/1523-1747.ep12478393; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; Lichtlen P, 1999, BIOL CHEM, V380, P711, DOI 10.1515/BC.1999.089; Liu YP, 1995, TOXICOL APPL PHARM, V135, P222, DOI 10.1006/taap.1995.1227; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MCCLAIN CJ, 1990, J LAB CLIN MED, V116, P275; MCCORMICK CC, 1991, BIOCHEM J, V273, P185, DOI 10.1042/bj2730185; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; NOLL M, 2000, BIOCHEM MOL BIOL INT, V49, P297; OESTREICHER P, 1989, J NUTR, V119, P639, DOI 10.1093/jn/119.4.639; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Swerdlow H, 1997, ANAL CHEM, V69, P848, DOI 10.1021/ac961104o; Tsuda M, 1997, J NEUROSCI, V17, P6678; WALSH CT, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3431820; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676	43	309	320	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34803	34809		10.1074/jbc.M007339200	http://dx.doi.org/10.1074/jbc.M007339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952993	hybrid			2022-12-25	WOS:000165095300107
J	Choudhury, A; Singh, RK; Moniaux, N; El-Metwally, TH; Aubert, JP; Batra, SK				Choudhury, A; Singh, RK; Moniaux, N; El-Metwally, TH; Aubert, JP; Batra, SK			Retinoic acid-dependent transforming growth factor-beta 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; GENE-EXPRESSION; FACTOR-BETA; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; GENOMIC ORGANIZATION; SIALOMUCIN COMPLEX; COMPLEMENTARY-DNA	The MUC4 mucin is considered as the homologue of rat sialomucin complex (SMC, rat Muc4) due to its similar structural organization. Like SMC, MUC4 may also exist as two subunits: a mucin type unit known as MUC4 alpha and a growth factor-like transmembrane subunit, MUC4 beta. The expression of MUC4 in normal human pancreas is not detectable, but it is highly expressed in pancreatic tumor cells. In the present study, we investigated the regulation of MUC4 expression in human pancreatic tumor cells CD18/HPAF, exhibiting a high level of MUC4 transcripts and protein, When these cells were adapted to grow in the serum-free medium (CD18/HPAF-SF), the MUC4 expression was undetectable. Among several serum constituents, all-trans-retinoic acid (RA) induced the expression of MUC4 transcripts in a concentration- and time-dependent manner, The RA-mediated increase in the level of the MUC4 transcript coincided with an increased expression of transforming growth factor-beta2 (TGF-beta2) transcript. The antagonist of the retinoic acid receptor (RAR)-alpha (Ro41-5253) abrogated the expression of MUC4 and TGF-beta2 induced by RA. The exogenous addition of TGF-beta2 also increased the MUC4 expression. The TGF-P-neutralizing antibody blocked the RA-induced as well as TGF-beta2-mediated MUC4 expression. In conclusion, induction of MUC4 expression in pancreatic carcinoma by RA is mediated through the RAR-alpha signaling pathway, and TGF-beta2 may serve as an interim mediator of this regulated expression.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; INSERM, U377, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, Omaha, NE 68198 USA.		Moniaux, Nicolas/Y-3243-2018; El-Metwally, Tarek H./AAH-2054-2020	Moniaux, Nicolas/0000-0001-9718-1386; El-Metwally, Tarek H./0000-0001-9040-6642	NATIONAL CANCER INSTITUTE [R01CA078590, R29CA072781, R01CA072781] Funding Source: NIH RePORTER; NCI NIH HHS [CA72781, CA 78590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1988, CANCER RES, V48, P3898; Ashley DM, 1998, CANCER RES, V58, P302; AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bobek LA, 1996, GENOMICS, V31, P277, DOI 10.1006/geno.1996.0049; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; Buisine MP, 1998, BIOCHEM J, V332, P729, DOI 10.1042/bj3320729; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209, DOI 10.1165/ajrcmb.20.2.3259; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; CHOUDHURY A, 2001, IN PRESS TERATOGENES, V21; Copin MC, 2000, INT J CANCER, V86, P162, DOI 10.1002/(SICI)1097-0215(20000415)86:2<162::AID-IJC3>3.3.CO;2-I; DAHIYA R, 1993, CANCER RES, V53, P1437; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; FRIESS H, 1993, CANCER RES, V53, P2704; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gipson IK, 1999, BIOL REPROD, V60, P58, DOI 10.1095/biolreprod60.1.58; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1994, J BIOL CHEM, V269, P2440; Guzman K, 1996, AM J PHYSIOL-LUNG C, V270, pL846, DOI 10.1152/ajplung.1996.270.5.L846; Guzman K, 1995, BIOCHEM BIOPH RES CO, V217, P412, DOI 10.1006/bbrc.1995.2792; HO JJL, 1994, PANCREAS, V9, P674; HO SB, 1993, CANCER RES, V53, P641; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Issing WJ, 1996, ANTICANCER RES, V16, P2373; KELLY D, 1990, CYTOTECHNOLOGY, V4, P227, DOI 10.1007/BF00563783; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim YS, 1999, ANN ONCOL, V10, P51, DOI 10.1023/A:1008332602541; KIM YW, 1989, PANCREAS, V4, P353, DOI 10.1097/00006676-198906000-00013; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Koo JS, 1999, BIOCHEM J, V338, P351, DOI 10.1042/0264-6021:3380351; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAN MS, 1990, J BIOL CHEM, V265, P15294; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li DC, 1997, J PATHOL, V181, P305; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Moniaux N, 2000, EUR J BIOCHEM, V267, P4536, DOI 10.1046/j.1432-1327.2000.01504.x; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; RANCHALIS JE, 1987, BIOCHEM BIOPH RES CO, V148, P783, DOI 10.1016/0006-291X(87)90944-2; Reid CJ, 1997, MOL MED, V3, P403; Reid CJ, 1998, GUT, V42, P220, DOI 10.1136/gut.42.2.220; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; SIDDIKI J, 1987, P NATL ACAD SCI USA, V84, P6060; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; TASHIRO Y, 1994, HUM PATHOL, V25, P364, DOI 10.1016/0046-8177(94)90144-9; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Vandenhaute B, 1997, J HEPATOL, V27, P1057, DOI 10.1016/S0168-8278(97)80150-X; Williams SJ, 1999, CANCER RES, V59, P4083; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; Yoon JH, 1997, AM J RESP CELL MOL, V16, P724, DOI 10.1165/ajrcmb.16.6.9191474	74	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33929	33936		10.1074/jbc.M005115200	http://dx.doi.org/10.1074/jbc.M005115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938282	hybrid			2022-12-25	WOS:000090104600103
J	Grange, M; Sette, C; Cuomo, M; Conti, M; Lagarde, M; Prigent, AF; Nemoz, G				Grange, M; Sette, C; Cuomo, M; Conti, M; Lagarde, M; Prigent, AF; Nemoz, G			The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding - Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; BLOOD MONONUCLEAR-CELLS; EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-D; RAT THYMOCYTES; POTENTIAL ROLE; TUMOR-CELLS; ACTIVATION; PHOSPHORYLATION	Hormones and growth factors induce in many cell types the production of phosphatidic acid (PA), which has been proposed to play a role as a second messenger. We have previously shown in an acellular system that PA selectively stimulates certain isoforms of type 4 cAMP-phosphodiesterases (PDE4), Here we studied the effect of endogenous PA on PDE activity of transiently transfected MA10 cells overexpressing the PA-sensitive isoform PDE4D3, Cell treatment with inhibitors of PA degradation, including propranolol, induced an accumulation of endogenous PA accompanied by a stimulation of PDE activity and a significant decrease in both cAMP levels and protein kinase A activity. Furthermore, in FRTL5 cells, which natively express PDE4D3, pretreatment with compounds inducing PA accumulation prevented both cAMP increase and cAMP-responsive element-binding protein phosphorylation triggered by thyroid-stimulating hormone. To determine the mechanism of PDE stimulation by PA, endogenous phospholipids were labeled by preincubating MA10 cells overexpressing PDE4D3 with [P-32]orthophosphate. Immunoprecipitation experiments showed that PA was specifically bound to PDE4D3, supporting the hypothesis that PDE4D3 activation occurs through direct binding of PA to the protein. PA binding site on PDE4D3 was characterized by engineering deletions of selected regions in the N-terminal regulatory domain of the enzyme, Deletion of amino acid residues 31-59 suppressed both PA-activating effect and PA binding, suggesting that this region rich in basic and hydrophobic residues contains the PA binding site. These observations strongly suggest that endogenous PA can modulate cAMP levels in intact cells, through a direct activation of PDE4D3.	Inst Natl Sci Appl, Lab Biochim & Pharmacol, INSERM U352, F-69621 Villeurbanne, France; Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00173 Rome, Italy; Univ Rome La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Stanford Univ, Med Ctr, Div Human Reprod, Stanford, CA 94305 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Rome Tor Vergata; Sapienza University Rome; Stanford University	Nemoz, G (corresponding author), Inst Natl Sci Appl, Lab Biochim & Pharmacol, INSERM U352, Bat 406, F-69621 Villeurbanne, France.		Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266				Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; CAMPAGNE MMV, 1990, J BIOL CHEM, V265, P5840; Cockcroft S, 1996, CHEM PHYS LIPIDS, V80, P59, DOI 10.1016/0009-3084(96)02546-7; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grange Muriel, 1998, Cell Biochemistry and Biophysics, V29, P1, DOI 10.1007/BF02737825; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; HOWE R, 1966, NATURE, V210, P1336, DOI 10.1038/2101336a0; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JIN SLC, 1992, J BIOL CHEM, V267, P18929; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KASZKIN M, 1992, CANCER RES, V52, P5627; LAURITZEN L, 1994, MOL CELL ENDOCRINOL, V104, P229, DOI 10.1016/0303-7207(94)90125-2; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; MARCOZ P, 1993, BIOCHIM BIOPHYS ACTA, V1176, P129, DOI 10.1016/0167-4889(93)90187-T; MARCOZ P, 1993, MOL PHARMACOL, V44, P1027; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V158, P105, DOI 10.1016/S0006-291X(89)80183-4; MESKINI N, 1995, EUR J BIOCHEM, V233, P907, DOI 10.1111/j.1432-1033.1995.907_3.x; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Naro F, 1999, MOL BIOL CELL, V10, P4355, DOI 10.1091/mbc.10.12.4355; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; PERRY DK, 1992, J IMMUNOL, V149, P2749; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Sambrook J., 1989, MOL CLONING, pA1; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; YAMAKI M, 1993, KIDNEY INT, V43, P1286, DOI 10.1038/ki.1993.181; Zakaroff-Girard A, 1999, J LEUKOCYTE BIOL, V65, P381, DOI 10.1002/jlb.65.3.381	57	95	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33379	33387		10.1074/jbc.M006329200	http://dx.doi.org/10.1074/jbc.M006329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938092	hybrid			2022-12-25	WOS:000090104600030
J	Grewal, T; Heeren, J; Mewawala, D; Schnitgerhans, T; Wendt, D; Salomon, G; Enrich, C; Beisiegel, U; Jackle, S				Grewal, T; Heeren, J; Mewawala, D; Schnitgerhans, T; Wendt, D; Salomon, G; Enrich, C; Beisiegel, U; Jackle, S			Annexin VI stimulates endocytosis and is involved in the trafficking of low density lipoprotein to the prelysosomal compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SUBCELLULAR-DISTRIBUTION; BINDING PROTEINS; TYROSINE KINASE; MEMBRANE; CELLS; ENDOSOMES; RECEPTOR; FUSION; TRANSFERRIN	Annexins are calcium-binding proteins with a wide distribution in most polarized and nonpolarized cells that participate in a variety of membrane-membrane interactions. At the cell surface, annexin VI is thought to remodel the spectrin cytoskeleton to facilitate budding of coated pits. However, annexin VI is also found in late endocytic compartments in a number of cell types, indicating an additional important role at later stages of the endocytic pathway. Therefore overexpression of annexin VI in Chinese hamster ovary cells was used to investigate its possible role in endocytosis and intracellular trafficking of low density Lipoprotein (LDL) and transferrin, While overexpression of annexin VI alone did not alter endocytosis and degradation of LDL, coexpression of annexin VI and LDL receptor resulted in an increase in LDL uptake with a concomitant increase of its degradation. Whereas annexin VI showed a wide intracellular distribution in resting Chinese hamster ovary cells, it was mainly found in the endocytic compartment and remained associated with LDE-containing vesicles even at later stages of the endocytic pathway. Thus, data presented in this study suggest that after stimulating endocytosis at the cell surface, annexin VI remains hound to endocytic vesicles to regulate entry of ligands into the prelysosomal compartment.	Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, D-20246 Hamburg, Germany; Univ Barcelona, Fac Med, Inst Invest Biomed August Pi I Sunyer, Dept Biol Celular, Barcelona 08036, Spain	University of Hamburg; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Grewal, T (corresponding author), Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, Martinistr 52, D-20246 Hamburg, Germany.	grewal@uke.uni-hamburg.de		Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; DONELLY SR, 1997, CELL MOL LIFE SCI, V53, P533; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAN H, 1995, EUR J BIOCHEM, V230, P741, DOI 10.1111/j.1432-1033.1995.0741h.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FISCHER HD, 1980, J BIOL CHEM, V255, P9608; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GERKE V, 1985, J BIOL CHEM, V260, P1688; GERKE V, 1997, BIOCHIM BIOPHYS ACTA, V1357, P1229; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KIM MJ, 1994, ATHEROSCLEROSIS, V108, P5; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Massey-Harroche D, 1998, J CELL SCI, V111, P3007; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Ortega D, 1998, J CELL SCI, V111, P261; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J., 1989, MOL CLONING, pA1; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; TAGOE CE, 1994, BBA-BIOMEMBRANES, V1192, P272, DOI 10.1016/0005-2736(94)90128-7; THIEL C, 1992, J CELL SCI, V103, P733; Turpin E, 1998, BBA-MOL CELL RES, V1402, P115, DOI 10.1016/S0167-4889(97)00151-1; WATANABE T, 1994, J BIOL CHEM, V269, P17656	47	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33806	33813		10.1074/jbc.M002662200	http://dx.doi.org/10.1074/jbc.M002662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940299	hybrid			2022-12-25	WOS:000090104600087
J	Pitson, SM; Moretti, PAB; Zebol, JR; Xia, P; Gamble, JR; Vadas, MA; D'Andrea, RJ; Wattenberg, BW				Pitson, SM; Moretti, PAB; Zebol, JR; Xia, P; Gamble, JR; Vadas, MA; D'Andrea, RJ; Wattenberg, BW			Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation - A dominant-negative sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; PROTEIN-COUPLED RECEPTORS; DIACYLGLYCEROL KINASE; MOLECULAR-CLONING; CALCIUM MOBILIZATION; PHOSPHOLIPASE-C; 3T3 FIBROBLASTS; 2ND MESSENGER; CELL-GROWTH; SPHINGOSINE-1-PHOSPHATE	Sphingosine kinase (SK) catalyzes the formation of sphingosine 1-phosphate (S1P), a lipid messenger that plays an important role in a variety of mammalian cell processes, including inhibition of apoptosis and stimulation of cell proliferation. Basal levels of SIP in cells are generally low but can increase rapidly when cells are exposed to various agonists through rapid and transient activation of SK activity. To date, elucidation of the exact signaling pathways affected by these elevated S1P levels has relied on the use of SK inhibitors that are known to have direct effects on other enzymes in the cell. Furthermore, these inhibitors block basal SK activity, which is thought to have a housekeeping function in the cell. To produce a specific inhibitor of SK activation we sought to generate a catalytically inactive, dominant-negative SK. This was accomplished by site-directed mutagenesis of Gly(82) to Asp of the human SK, a residue identified through sequence similarity to the putative catalytic domain of diacylglycerol kinase. This mutant had no detectable SK activity when expressed at high levels in HEK293T cells. Activation of endogenous SK activity by tumor necrosis factor-alpha (TNF alpha), interleukin-lp, and phorbol esters in HEK293T cells was blocked by expression of this inactive sphingosine kinase (hSK(G82D)), Basal SK activity was unaffected by expression of hSR(G82D). Expression of hSK(G82D) had no effect on TNF alpha -induced activation of protein kinase C and sphingomyelinase activities. Thus, hSK(G82D) acts as a specific dominant-negative SK to block SK activation. This discovery provides a powerful tool for the elucidation of the exact signaling pathways affected by elevated S1P levels following SK activation. To this end we have employed the dominant-negative SK to demonstrate that TNF alpha activation of extracellular signal-regulated kinases 1 and 2 (ERK1,2) is dependent on SK activation.	Univ Adelaide, Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; University of Adelaide; University of Adelaide	Wattenberg, BW (corresponding author), Univ Adelaide, Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Frome Rd, Adelaide, SA 5000, Australia.	brian.wattenberg@imvs.sa.gov.au	Pitson, Stuart/B-9342-2009; Vadas, Mathew/R-1378-2019; Xia, Pu/G-3090-2010	Pitson, Stuart/0000-0002-9527-2740; Xia, Pu/0000-0003-4705-8878; Gamble, Jennifer/0000-0002-0179-9964				An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BEUHRER BM, 1996, BIOCHIM BIOPHYS ACTA, V1303, P233; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Edsall LC, 1997, J NEUROSCI, V17, P6952; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Guan ZH, 1999, J BIOL CHEM, V274, P36200, DOI 10.1074/jbc.274.51.36200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kozawa O, 1997, J BIOL CHEM, V272, P25099, DOI 10.1074/jbc.272.40.25099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKOSHI H, 1991, CANCER RES, V51, P6019; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; SU Y, 1994, J BIOL CHEM, V269, P16512; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Xu J, 2000, ANN NY ACAD SCI, V905, P81	60	170	180	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33945	33950		10.1074/jbc.M006176200	http://dx.doi.org/10.1074/jbc.M006176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944534	hybrid			2022-12-25	WOS:000090104600105
J	Wang, D; Westerheide, SD; Hanson, JL; Baldwin, AS				Wang, D; Westerheide, SD; Hanson, JL; Baldwin, AS			Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser(529) is controlled by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE PHOSPHORYLATION; TRANSACTIVATION DOMAIN; FAMILY MEMBERS; GROWTH-FACTOR; P65 SUBUNIT; PEST DOMAIN; IN-VIVO	Nuclear factor kappaB (NF-kappaB)/Rel transcription factors are key regulators of a variety of genes involved in immune and inflammatory responses, growth, differentiation, apoptosis, and development. In unstimulated cells, NF-kappaB/Rel proteins are sequestered in the cytoplasm by I kappaB inhibitor proteins. Many extracellular stimuli, such as tumor necrosis factor alpha (TNF alpha), cause rapid phosphorylation of I kappaB at N-terminal serine residues leading to ubiquitination and degradation of the inhibitor. Subsequently, NF-kappaB proteins translocate to the nucleus and activate gene expression through KB response elements. TNF alpha, as well as certain other stimuli, also induces the phosphorylation of the NP-kappaB proteins. Previously, we have shown that TNF alpha induces RelA/p65 phosphorylation at serine 529 and that this inducible phosphorylation increases NF-kappaB transcriptional activity on an exogenously supplied reporter (1). In this report, we demonstrate that casein kinase II (CKII) interacts with p65 in vivo and can phosphorylate p65 at serine 529 in vitro. A CKII inhibitor (PD144795) inhibited TNF alpha -induced p65 phosphorylation in vivo. Furthermore, our results indicate that the association between I kappaB alpha and p65 inhibits p65 phosphorylation by CKII and that degradation of I kappaB alpha allows CKII to phosphorylate p65 to increase NF-kappaB transactivation potential. These data may explain the ability of CKII to modulate cell growth and demonstrate a mechanism whereby CKII can function in an inducible manner.	Univ N Carolina, Dept Biol, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Dept Biol, Curriculum Genet & Mol Biol, CB 3280, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA072771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA72771] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; Critchfield JW, 1996, AIDS RES HUM RETROV, V12, P39, DOI 10.1089/aid.1996.12.39; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharma HW, 1996, ANTICANCER RES, V16, P589; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	62	364	374	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32592	32597		10.1074/jbc.M001358200	http://dx.doi.org/10.1074/jbc.M001358200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938077	Green Published, hybrid			2022-12-25	WOS:000090003800031
J	Datta, R; Oki, E; Endo, K; Biedermann, V; Ren, J; Kufe, D				Datta, R; Oki, E; Endo, K; Biedermann, V; Ren, J; Kufe, D			XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PROTEIN-KINASE; LEUKEMIA-CELLS; ACTIVATION; MITOCHONDRIA; INHIBITORS; INDUCTION; PATHWAY; DEATH; IAP	The IAP (inhibitor of apoptosis) family of anti-apoptotic proteins regulates programmed cell death. Of the six known human IAP-related proteins, XIAP is the most potent inhibitor. To study the mechanistic effects of XIAP on DNA damage-induced apoptosis, we prepared U-937 cells that stably overexpress XIAP. The results demonstrate that XIAP inhibits apoptosis induced by 1-[beta-D-arabinofuranosyl]cytosine (ara-C) and other genotoxic agents. XIAP had no detectable effect on ara-C-induced release of mitochondrial cytochrome c and attenuated cleavage of procaspase-9. In addition, we show that ara-C induces the association of XIAP with the cleaved fragments of caspase-9 and thereby inhibition of caspase-9 activity. The results also demonstrate that ara-C induces cleavage of procaspase-3 by a caspase-8-dependent mechanism and that XIAP inhibits caspase-3 activity. These results demonstrate that XIAP functions downstream of procaspase-9 cleavage as an inhibitor of both proteolytically processed caspase-9 and -3 in the cellular response to genotoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA29431] Funding Source: Medline; NIGMS NIH HHS [GM58200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FRAM RJ, 1982, CANCER RES, V42, P4050; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; GUNJI H, 1991, CANCER RES, V51, P741; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; ROBERTSON MJ, 1995, LEUKEMIA LYMPHOMA, V17, P51, DOI 10.3109/10428199509051703; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	40	81	87	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31733	31738		10.1074/jbc.M910231199	http://dx.doi.org/10.1074/jbc.M910231199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930419	hybrid			2022-12-25	WOS:000089858900028
J	Barrett, P; Choi, WS; Morris, M; Morgan, P				Barrett, P; Choi, WS; Morris, M; Morgan, P			A role for tyrosine phosphorylation in the regulation and sensitization of adenylate cyclase by melatonin	FASEB JOURNAL			English	Article						pars tuberalis; tyrosine kinase; G-protein; receptors	OVINE PARS-TUBERALIS; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; HERBIMYCIN-A; INHIBITORY RECEPTORS; CAMP ACCUMULATION; PINEAL MELATONIN; CELLS; ACTIVATION; PITUITARY	Mimicking short photoperiod melatonin signals (16 h exposure) on primary cell cultures of melatonin target cells of the ovine pars tuberalis (PT) results in an enhanced cAMP response to forskolin stimulation relative to untreated cells, a phenomenon termed sensitization. The sensitized response of PT cells may be an important aspect of the interpretation of the melatonin signal to initiate appropriate seasonal physiological responses. The aim of this study is to add to our understanding of the molecular mechanisms involved in the sensitization of PT cells by melatonin, We demonstrate that sensitization of PT cells by melatonin is mediated via a G(i)-coupled melatonin receptor. The sensitized cAMP response is not only obtained with the pharmacological tool forskolin, but also with cholera toxin, an activator of G(s alpha). Changes in the level of G(s alpha) or G(i alpha) G-protein subunits are ruled out as part of the sensitization mechanism. However, changes in tyrosine phosphorylation may be involved as tyrosine kinase inhibitors sensitize ovine PT cells and tyrosine phosphatase inhibitors significantly blunt adenylate cyclase activity, including the sensitized response to melatonin. The adenylate cyclase isoforms mediating the sensitized response may be broad as 7 of the 9 isoforms of adenylate cyclase are expressed in the PT.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland	University of Aberdeen	Barrett, P (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.			Morgan, Peter/0000-0002-5071-6512; Barrett, Perry/0000-0003-3604-2950				Ammer H, 1996, BRAIN RES, V707, P235, DOI 10.1016/0006-8993(95)01265-6; Ammer H, 1997, MOL PHARMACOL, V52, P993, DOI 10.1124/mol.52.6.993; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Barrett P, 1996, MOL ENDOCRINOL, V10, P892, DOI 10.1210/me.10.7.892; BARRETT P, 1994, J NEUROENDOCRINOL, V6, P509, DOI 10.1111/j.1365-2826.1994.tb00613.x; Barrett P, 1998, ENDOCRINOLOGY, V139, P163, DOI 10.1210/en.139.1.163; BARTNESS TJ, 1989, EXPERIENTIA, V45, P939, DOI 10.1007/BF01953051; BATES MD, 1991, MOL PHARMACOL, V39, P55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buc HA, 1996, INT J IMMUNOPHARMACO, V18, P135, DOI 10.1016/0192-0561(95)00116-6; CARLSON LL, 1989, ENDOCRINOLOGY, V125, P2670, DOI 10.1210/endo-125-5-2670; Drake PG, 1996, ENDOCRINOLOGY, V137, P4960, DOI 10.1210/en.137.11.4960; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOLDMAN B, 1981, BIOL REPROD, V24, P778, DOI 10.1095/biolreprod24.4.778; HAZLERIGG DG, 1993, ENDOCRINOLOGY, V132, P285, DOI 10.1210/en.132.1.285; HAZLERIGG DG, 1994, J ENDOCRINOL, V142, P127, DOI 10.1677/joe.0.1420127; Hazlerigg DG, 1996, ENDOCRINOLOGY, V137, P210, DOI 10.1210/en.137.1.210; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MCNULTY S, 1995, J ENDOCRINOL, V145, P471, DOI 10.1677/joe.0.1450471; MCNULTY S, 1994, J NEUROENDOCRINOL, V6, P523, DOI 10.1111/j.1365-2826.1994.tb00615.x; MCNULTY S, 1994, MOL CELL ENDOCRINOL, V99, P73, DOI 10.1016/0303-7207(94)90148-1; MORGAN PJ, 1990, J NEUROENDOCRINOL, V2, P773, DOI 10.1111/j.1365-2826.1990.tb00639.x; MORGAN PJ, 1989, J MOL ENDOCRINOL, V3, pR5, DOI 10.1677/jme.0.003R005; Morgan PJ, 1998, J NEUROENDOCRINOL, V10, P319, DOI 10.1046/j.1365-2826.1998.00232.x; MORGAN PJ, 1995, J NEUROENDOCRINOL, V7, P361, DOI 10.1111/j.1365-2826.1995.tb00770.x; MURAKAMI Y, 1988, CANCER RES, V48, P1587; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nevo I, 1998, MOL PHARMACOL, V54, P419, DOI 10.1124/mol.54.2.419; Ogiwara T, 1997, J ENDOCRINOL, V152, P193, DOI 10.1677/joe.0.1520193; Ross AW, 1998, ENDOCRINOLOGY, V139, P1723, DOI 10.1210/en.139.4.1723; SCHWABE U, 1979, NATURE, V277, P143, DOI 10.1038/277143a0; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Thomas JM, 1996, MOL PHARMACOL, V49, P907; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; Watts VJ, 1996, MOL PHARMACOL, V50, P966; Witt-Enderby PA, 1998, ENDOCRINOLOGY, V139, P3064, DOI 10.1210/en.139.7.3064; YUNG LY, 1995, FEBS LETT, V372, P99, DOI 10.1016/0014-5793(95)00963-A	42	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1619	1628		10.1096/fj.14.11.1619	http://dx.doi.org/10.1096/fj.14.11.1619			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928997				2022-12-25	WOS:000088627800017
J	Arcondeguy, T; Lawson, D; Merrick, M				Arcondeguy, T; Lawson, D; Merrick, M			Two residues in the T-loop of GlnK determine NifL-dependent nitrogen control of nif gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; P-II; AZOTOBACTER-VINELANDII; GLUTAMINE-SYNTHETASE; ENTERIC BACTERIA; WILD-TYPE; URIDYLYLTRANSFERASE; INHIBITION	X-ray crystallographic analysis of the Escherichia coli P-II protein paralogues GInB and GlnK has shown that they share a superimposable structural core but can differ in conformation of the T-loop, a region of the protein (residues 37-54) that has been shown to be important for interaction with other proteins. In Klebsiella pneumoniae GlnK has been shown to have a clearly defined function in regulating NifL-mediated inhibition of NifA activity in response to the nitrogen status, and GlnB, when expressed from the chromosome, does not substitute for GlnB Because the T-loops of K. pneumoniae and E. coli GlnB and GlnK differ at just three residues, 43, 52, and 54, we have used a previously constructed heterologous system, in which a pneumoniae nifLA. is expressed in E. coli, to investigate the importance of GlnK residues 43, 52, and 54 for regulation of the NifLA interaction. By site-directed mutagenesis of glnB we have shown that residue 54 is the single most important amino acid in the T-loop in the context of the regulation of NifA activity. Furthermore, a combination of just two changes, in residues 54 and 43, allows GlnB to function as GlnK and completely relieve NifL inhibition of NifA activity.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Merrick, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Coloney Lane, Norwich NR4 7UH, Norfolk, England.	mike.merrick@bbsrc.ac.uk	Lawson, David M/D-1810-2009					Arcondeguy T, 1999, FEMS MICROBIOL LETT, V180, P263, DOI 10.1016/S0378-1097(99)00497-8; Atkinson MR, 1998, MOL MICROBIOL, V29, P431, DOI 10.1046/j.1365-2958.1998.00932.x; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; CHEN YM, 1982, J BACTERIOL, V150, P214, DOI 10.1128/JB.150.1.214-220.1982; CONTRERAS A, 1991, GENE, V103, P83, DOI 10.1016/0378-1119(91)90395-R; CONTRERAS A, 1991, J BACTERIOL, V173, P7741, DOI 10.1128/jb.173.24.7741-7749.1991; EDWARDS R, 1995, MOL GEN GENET, V247, P189, DOI 10.1007/BF00705649; Forchhammer K, 1999, MOL MICROBIOL, V33, P338, DOI 10.1046/j.1365-2958.1999.01477.x; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; HOLTEL A, 1988, MOL GEN GENET, V215, P134, DOI 10.1007/BF00331314; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Jaggi R, 1996, FEBS LETT, V391, P223, DOI 10.1016/0014-5793(96)00737-5; Jiang P, 1997, J BACTERIOL, V179, P4342, DOI 10.1128/jb.179.13.4342-4353.1997; Jiang P, 1997, J BACTERIOL, V179, P4354, DOI 10.1128/jb.179.13.4354-4360.1997; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Meletzus D, 1998, J BACTERIOL, V180, P3260, DOI 10.1128/JB.180.12.3260-3264.1998; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Miller JH., 1972, EXPT MOL GENETICS; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; REYESRAMIREZ F, 2000, NITROGEN FIXATION MO, P97; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; van Heeswijk WC, 2000, P NATL ACAD SCI USA, V97, P3942, DOI 10.1073/pnas.97.8.3942; VANHEESWIJK WC, 1995, FEMS MICROBIOL LETT, V132, P153, DOI 10.1016/0378-1097(95)00302-L; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979	27	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38452	38456		10.1074/jbc.M001935200	http://dx.doi.org/10.1074/jbc.M001935200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952972	hybrid			2022-12-25	WOS:000165739800043
J	Lee, VT; Tam, C; Schneewind, O				Lee, VT; Tam, C; Schneewind, O			LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-CALCIUM RESPONSE; PROTEIN-TYROSINE-PHOSPHATASE; V-ANTIGEN; YOP SECRETION; MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATOR; NEGATIVE REGULATION; VIRULENCE PLASMID; LOW-CA2+ RESPONSE; EUKARYOTIC CELLS	Pathogenic Yersinia species employ type III machines to transport virulence factors across the bacterial envelope. Some substrates for the type III machinery are secreted into the extracellular medium, whereas others are targeted into the cytosol of host cells. We found that during infection of tissue culture cells, yersiniae secrete small amounts of LcrV into the extracellular medium. Knockout mutations of lcrV abolish Yersinia targeting and reduce expression of the lcrGVHyopBD operon. In contrast, a block in LcrV secretion does not affect targeting, but results in premature expression and secretion of Yop proteins into the extracellular medium. LcrV-mediated activation of the type III pathway is thought to occur by sequestration of the regulatory factor LcrG, presumably via the formation of LcrV LcrG complexes. These results suggest that intrabacterial LcrV regulates the expression and targeting of Yop proteins during Yersinia infection, whereas secreted LcrV is required to ensure specificity of Yop injection into eukaryotic cells.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Lee, Vincent T./0000-0002-3593-0318	NIAID NIH HHS [AI 42797] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAOUI A, 1994, J BACTERIOL, V176, P4534, DOI 10.1128/JB.176.15.4534-4542.1994; ALLAOUI A, 1995, MOL MICROBIOL, V18, P343, DOI 10.1111/j.1365-2958.1995.mmi_18020343.x; Anderson DM, 1999, MOL MICROBIOL, V31, P1139, DOI 10.1046/j.1365-2958.1999.01254.x; BERGMAN T, 1994, J BACTERIOL, V176, P2619, DOI 10.1128/JB.176.9.2619-2626.1994; BERGMAN T, 1991, J BACTERIOL, V173, P1607, DOI 10.1128/jb.173.5.1607-1616.1991; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; BURROWS TW, 1956, BRIT J EXP PATHOL, V37, P481; BURROWS TW, 1958, BRIT J EXP PATHOL, V39, P278; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; CORNELIS G, 1975, J GEN MICROBIOL, V87, P285, DOI 10.1099/00221287-87-2-285; CORNELIS G, 1989, J BACTERIOL, V171, P254, DOI 10.1128/jb.171.1.254-262.1989; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Fields KA, 1999, INFECT IMMUN, V67, P5395, DOI 10.1128/IAI.67.10.5395-5408.1999; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GOGUEN JD, 1984, J BACTERIOL, V160, P842, DOI 10.1128/JB.160.3.842-848.1984; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; Hill J, 1997, INFECT IMMUN, V65, P4476, DOI 10.1128/IAI.65.11.4476-4482.1997; HOE NP, 1993, J BACTERIOL, V175, P7901, DOI 10.1128/JB.175.24.7901-7909.1993; HOE NP, 1992, J BACTERIOL, V174, P4275, DOI 10.1128/JB.174.13.4275-4286.1992; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; Lee VT, 1999, MOL MICROBIOL, V31, P1619, DOI 10.1046/j.1365-2958.1999.01270.x; Lee VT, 1999, IMMUNOL REV, V168, P241, DOI 10.1111/j.1600-065X.1999.tb01296.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; NAKAJIMA R, 1995, INFECT IMMUN, V63, P3021, DOI 10.1128/IAI.63.8.3021-3029.1995; Nilles ML, 1997, J BACTERIOL, V179, P1307, DOI 10.1128/jb.179.4.1307-1316.1997; Nilles ML, 1998, J BACTERIOL, V180, P3410, DOI 10.1128/JB.180.13.3410-3420.1998; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Pettersson J, 1999, MOL MICROBIOL, V32, P961, DOI 10.1046/j.1365-2958.1999.01408.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PRICE SB, 1989, J BACTERIOL, V171, P5646, DOI 10.1128/jb.171.10.5646-5653.1989; REISS B, 1984, EMBO J, V3, P3317, DOI 10.1002/j.1460-2075.1984.tb02297.x; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; Sarker MR, 1998, J BACTERIOL, V180, P1207, DOI 10.1128/JB.180.5.1207-1214.1998; Sarker MR, 1998, INFECT IMMUN, V66, P2976, DOI 10.1128/IAI.66.6.2976-2979.1998; SKRZYPEK E, 1993, J BACTERIOL, V175, P3520, DOI 10.1128/jb.175.11.3520-3528.1993; Stainier I, 1997, MOL MICROBIOL, V26, P833, DOI 10.1046/j.1365-2958.1997.6281995.x; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; UNE T, 1984, J IMMUNOL, V133, P2226; WATTIAU P, 1994, J BACTERIOL, V176, P3878, DOI 10.1128/JB.176.13.3878-3884.1994; Welkos S, 1998, MICROB PATHOGENESIS, V24, P185, DOI 10.1006/mpat.1997.0188; Williams AW, 1998, J BACTERIOL, V180, P350, DOI 10.1128/JB.180.2.350-358.1998; YOTHER J, 1986, J BACTERIOL, V165, P443, DOI 10.1128/jb.165.2.443-447.1986	54	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36869	36875		10.1074/jbc.M002467200	http://dx.doi.org/10.1074/jbc.M002467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10930402	hybrid			2022-12-25	WOS:000165577700061
J	Poso, D; Sessions, RB; Lorch, M; Clarke, AR				Poso, D; Sessions, RB; Lorch, M; Clarke, AR			Progressive stabilization of intermediate and transition states in protein folding reactions by introducing surface hydrophobic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERING PROCEDURE; AMINO-ACIDS; BARNASE; ENZYME; PROPENSITIES; BACKBONE; DYNAMICS; TOPOLOGY; SOLVENT; CD2	It can be argued from the principle of solvent exclusion that the introduction of hydrophobic residues onto the surface of a protein wildrophobic surface mutations. This effect is slightly moderated in the folded state presumably by the perturbation of van der Waals' contacl not destabilize the folded state because the nonpolar side chain will be at least as exposed in ocal electrostatic interactions that have a greater influence in this fully compact structure. The fact that in all but one case we find that stabilization of the rapidly collapsthe unfolded state as it is when the protein chain is folded. A comparison of the folding pathway of wild type and 11 site-directed mutants of CD2.d1 shows this to be true. In fact, owing to partial burial of nonpolar groups as folding proceeds, we find that the rapidly formed intermediate state and, to a greater extent, the transition state are generally stabilized by hyts and/or led intermediate is accompanied by a faster acquisition of the folded state refutes the argument that I states are generally "off pathway" conformations or ensembles that lead to the inhibition of otherwise more rapid folding trajectories.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Clarke, AR (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			Sessions, Richard/0000-0003-0320-0895				Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; Clarke AR, 1997, CURR OPIN BIOTECH, V8, P400, DOI 10.1016/S0958-1669(97)80060-2; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CREIGHTON TE, 1994, NAT STRUCT BIOL, V1, P135, DOI 10.1038/nsb0394-135; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Gu H, 1999, PROTEIN SCI, V8, P2734; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; LESSER GJ, 1990, PROTEINS, V8, P6, DOI 10.1002/prot.340080104; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; Lorch M, 1999, BIOCHEMISTRY-US, V38, P1377, DOI 10.1021/bi9817820; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; NAKAI K, 1988, PROTEIN ENG, V2, P93, DOI 10.1093/protein/2.2.93; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; Oliveberg M, 1998, ACCOUNTS CHEM RES, V31, P765, DOI 10.1021/ar970089m; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P13396, DOI 10.1021/bi971294c; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P5786, DOI 10.1021/bi9629283; Parker MJ, 1998, NAT STRUCT BIOL, V5, P194, DOI 10.1038/nsb0398-194; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Schindler T, 1998, PROTEINS, V30, P401, DOI 10.1002/(SICI)1097-0134(19980301)30:4<401::AID-PROT7>3.3.CO;2-G; SERRANO L, 1992, J MOL BIOL, V224, P805, DOI 10.1016/0022-2836(92)90563-Y; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SIMTH CK, 1994, BIOCHEMISTRY-US, V33, P5510	31	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35723	35726		10.1074/jbc.M001747200	http://dx.doi.org/10.1074/jbc.M001747200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10938078	hybrid			2022-12-25	WOS:000165382000013
J	Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC				Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC			The location of the mobile electron carrier ferredoxin in vascular plant photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; FLASH ABSORPTION-SPECTROSCOPY; SYNECHOCYSTIS SP PCC-6803; 3-DIMENSIONAL STRUCTURE; THYLAKOID MEMBRANES; ANGSTROM RESOLUTION; SOLUBLE FERREDOXIN; LINKED COMPLEX; BINDING-SITES; REDUCTION	In this study, we present the location of the ferredoxin-binding site in photosystem I from spinach. Image analysis of negatively stained two-dimensional crystals indicates that the addition of ferredoxin and chemical cross-linkers do not significantly alter the unit cell, parameters (for untreated photosystem I, a = 26.4 nm, b = 27.6 nm, and gamma = 90 degrees, space group p22(1)2(1) and for ferredoxin cross-linked photosystem I, a = 26.2 nm, b = 27.2 nm, and gamma = 90 degrees, space group p22(1)2(1)), Fourier difference analysis reveals that ferredoxin is bound on top of the stromal ridge principally interacting with the extrinsic subunits PsaC and PsaE, This location would be accessible to the stroma, thereby promoting efficient electron transfer away from photosystem I. This observation is significantly different from that of the ferredoxin binding site proposed for cyanobacteria, A model for the binding of ferredoxin in vascular plants is proposed and is discussed-relative to observations in cyanobacteria.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Manchester; University of Leeds	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.			Ford, Robert/0000-0002-0958-1505				AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; Fischer N, 1999, J BIOL CHEM, V274, P23333, DOI 10.1074/jbc.274.33.23333; FORD RC, 1995, MICRON, V26, P133, DOI 10.1016/0968-4328(95)00005-O; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V36, P275; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Kitmitto A, 1998, J BIOL CHEM, V273, P29592, DOI 10.1074/jbc.273.45.29592; Kitmitto A, 1997, J BIOL CHEM, V272, P19497, DOI 10.1074/jbc.272.31.19497; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; Mullineaux CW, 1999, AUST J PLANT PHYSIOL, V26, P671, DOI 10.1071/PP99027; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SETIF PQY, 1994, BIOCHEMISTRY-US, V33, P8495, DOI 10.1021/bi00194a014; SETIF PQY, 1995, BIOCHEMISTRY-US, V34, P9059, DOI 10.1021/bi00028a015; Shin M, 1971, METHOD ENZYMOL, V23, P440; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x	34	15	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36250	36255		10.1074/jbc.M006549200	http://dx.doi.org/10.1074/jbc.M006549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948201	hybrid			2022-12-25	WOS:000165382000086
J	Brabetz, W; Muller-Loennies, S; Brade, H				Brabetz, W; Muller-Loennies, S; Brade, H			3-Deoxy-D-manno-oct-2-ulosonic acid (Kdo) transferase (WaaA) and Kdo kinase (KdkA) of Haemophilus influenzae are both required to complement a waaA knockout mutation of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE; GENE; STRAIN; BIOSYNTHESIS; CHLAMYDIA; EPITOPE; KDTA; PHOSPHORYLATION; IDENTIFICATION; ANTIBODIES	The lipopolysaccharide (LPS) of the deep rough mutant Haemophilus influenzae I69 consists of lipid A and a single 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) residue substituted with one phosphate at position 4 or 5 (Helander, I. M,, Lindner, B,, Brade, H., Altmann, K,, Lindberg, A. A., Rietschel, E, T,, and Zahringer, U, (1988) fur. J, Biochem, 177, 483-492), The waaA gene encoding the essential LPS-specific Kdo transferase was cloned from this strain, and its nucleotide sequence was identical to H, influenzae DSM11121, The gene was expressed in the Gram-positive host Corynebacterium glutamicum: and characterized in vitro to encode a monofunctional Kdo transferase. waaA of H, influenzae could not complement a knockout mutation in the corresponding gene of an Re-type Escherichia coli strain. However, complementation was possible by coexpressing the recombinant waaA together with the LPS-specific Kdo kinase gene (kdkA) of H, influenzae DSM11121 or I69, respectively. The sequences of both kdkA genes were determined and differed in 25 nucleotides, giving rise to six amino acid exchanges between the deduced proteins. Both E, coli strains which expressed waaA and kdkA from H, influenzae synthesized an LPS containing a single Kdo residue that was exclusively phosphorylated: at position 4, The structure was determined by nuclear magnetic resonance spectroscopy of deacylated LPS, Therefore, the reaction products of both cloned Kdo kinases represent only one of the two chemical structures synthesized by H, influenzae I69.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany	Forschungszentrum Borstel	Brabetz, W (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Parkallee 22, D-23845 Borstel, Germany.	wbrabetz@fz-borstel.de						AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bode CE, 1998, EUR J BIOCHEM, V254, P404, DOI 10.1046/j.1432-1327.1998.2540404.x; Brabetz W, 2000, EUR J BIOCHEM, V267, P5458, DOI 10.1046/j.1432-1327.2000.01619.x; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; HOISETH SK, 1992, PROKARYOTES, P3312; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; Hood DW, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P39; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; IMOTO M, 1985, TETRAHEDRON LETT, V26, P1545, DOI 10.1016/S0040-4039(00)98548-4; Isobe T, 1999, J BACTERIOL, V181, P2648, DOI 10.1128/JB.181.8.2648-2651.1999; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KUSHNER SR, 1972, P NATL ACAD SCI USA, V69, P1366, DOI 10.1073/pnas.69.6.1366; LIEBL W, 1990, DECHEMA BIOTECHNOLOG, V4, P323; LOBAU S, 1995, MOL MICROBIOL, V18, P391, DOI 10.1111/j.1365-2958.1995.mmi_18030391.x; MAMAT U, 1993, MOL MICROBIOL, V10, P935, DOI 10.1111/j.1365-2958.1993.tb00965.x; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MOXON ER, 1992, J INFECT DIS, V165, pS77, DOI 10.1093/infdis/165-Supplement_1-S77; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Preston A, 1996, J BACTERIOL, V178, P396, DOI 10.1128/jb.178.2.396-402.1996; Rick PD, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P283; ROZALSKI A, 1989, INFECT IMMUN, V57, P2645, DOI 10.1128/IAI.57.9.2645-2652.1989; Rozalski A, 1997, MOL MICROBIOL, V23, P569, DOI 10.1046/j.1365-2958.1997.d01-1877.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; White KA, 1999, J BIOL CHEM, V274, P31391, DOI 10.1074/jbc.274.44.31391; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Zahradka D, 1999, J BACTERIOL, V181, P6179, DOI 10.1128/JB.181.19.6179-6183.1999; ZAMZE SE, 1987, BIOCHEM J, V245, P583, DOI 10.1042/bj2450583; ZWAHLEN A, 1985, J INFECT DIS, V152, P485, DOI 10.1093/infdis/152.3.485	43	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34954	34962		10.1074/jbc.M005204200	http://dx.doi.org/10.1074/jbc.M005204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952982	hybrid			2022-12-25	WOS:000165422800019
J	Zhang, DJ; Tang, W; Yao, PM; Yang, CW; Xie, BX; Jackowski, S; Tabas, I				Zhang, DJ; Tang, W; Yao, PM; Yang, CW; Xie, BX; Jackowski, S; Tabas, I			Macrophages deficient in CTP : phosphocholine cytidylyltransferase-alpha are viable under normal culture conditions but are highly susceptible to free cholesterol-induced death - Molecular genetic evidence that the induction of phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; FOAM CELL NECROSIS; ACYL-COENZYME-A; LOADED MACROPHAGES; MEMBRANE-FUNCTION; APOPTOTIC CELLS; UP-REGULATION; FED RABBITS; BIOSYNTHESIS; PROLIFERATION	Macrophages in atherosclerotic lesions accumulate excess free cholesterol (FC) and phospholipid. Because excess FC is toxic to macrophages, these observations may have relevance to macrophage death and necrosis in atheromata. Previous work by us showed that at early stages of FC loading, when macrophages are still healthy,there is activation of the phosphatidylcholine (PC) biosynthetic enzyme, CTP:phosphocholine cytidylyltransferase (CT), and accumulation of PC mass, We hypothesized that this is an adaptive response, albeit transient, that prevents the FC:PC ratio from reaching a toxic level; To test this hypothesis directly, we created mice With macrophage-targeted disruption of the major CT gene, CT alpha, using the Cre-lox system. Surprisingly, the number of peritoneal macrophages harvested from CT alpha ;deficient mice and their overall health under normal culture conditions appeared normal, Moreover, CT activity-and PC biosynthesis and in vitro CT activity were decreased by 70-90% but were not absent. As a likely explanation of this residual activity, we showed that CT beta2, a form of CT that arises from another gene, is induced in CT alpha -deficient macrophages. To test our hypothesis that increased PC biosynthesis is an adaptive response to FC loading, the viability of wild-type versus CT alpha -deficient macrophages under control and FC-loading conditions was compared. After 5 h of FC loading, death increased from 0.7% to only 2.0% in wild-type macrophages but from 0.9% to 29.5% in CT alpha -deficient macrophages, These data offer the first molecular genetic evidence that activation of CT alpha and induction of PC biosynthesis in FC-loaded macrophages is an adaptive response. Furthermore, the data reveal that CT beta2 in macrophages is induced in the absence of CT alpha and that a low: level of residual CT activity, presumably due to CT beta2, is enough to keep the cells viable in the peritoneum in vivo and under normal culture conditions.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Rockefeller Univ, Gene Targeting Lab, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	Columbia University; Columbia University; Rockefeller University; St Jude Children's Research Hospital	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [HL-54591] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BAURIEDEL G, 1999, CIRCULATION, V96, P190; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COHN ZA, 1975, FED PROC, V34, P1725; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; Fazio S, 1999, CIRCULATION, V100, P613; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HAMILTON DL, 1984, J MOL BIOL, V178, P481, DOI 10.1016/0022-2836(84)90154-2; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Newby AC, 1999, CARDIOVASC RES, V41, P321; PAPAHADJOPOULOS D, 1974, J THEOR BIOL, V43, P329, DOI 10.1016/S0022-5193(74)80064-0; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; RAPP JH, 1983, J LIPID RES, V24, P1329; REKHTER MD, 1995, AM J PATHOL, V147, P668; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Schwartz BR, 1999, J IMMUNOL, V162, P4842; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 1997, CURR OPIN LIPIDOL, V8, P263, DOI 10.1097/00041433-199710000-00004; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabas I, 1997, TRENDS CARDIOVAS MED, V7, P256, DOI 10.1016/S1050-1738(97)00086-8; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	44	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35368	35376		10.1074/jbc.M007099200	http://dx.doi.org/10.1074/jbc.M007099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944538	hybrid			2022-12-25	WOS:000165422800072
J	Fukasawa, M; Nishijima, M; Itabe, H; Takano, T; Hanada, K				Fukasawa, M; Nishijima, M; Itabe, H; Takano, T; Hanada, K			Reduction of sphingomyelin level without accumulation of ceramide iu Chinese hamster ovary cells affects detergent-resistant membrane domains and enhances cellular cholesterol efflux to methyl-beta-cyclodextrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ANCHORED PROTEIN; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; TRANSPORT; DEGRADATION; VESICLES; BIOSYNTHESIS; INSOLUBILITY; TRAFFICKING	We examined the effects of reduction of sphingomyelin level on cholesterol behavior in cells using 2 types of Chinese hamster ovary cell mutants deficient in sphingomyelin synthesis: LY-A strain defective in intracellular trafficking of ceramide for sphingomyelin synthesis, and LP-B strain defective in the enzyme catalyzing the initial step of sphingolipid biosynthesis. Although the sphingomyelin content in LY-A and LY-B cells was similar to 40 and similar to 15% respectively, of the wild-type level without accumulation of ceramide, these mutant cells were almost identical in cholesterol content and also in plasma membrane cholesterol level to the wild-type cells. However, density gradient fractionation analysis of Triton X-100-treated lysates of cells prelabeled with [H-3]cholesterol showed that the [H-3]cholesterol level in the low-density floating fraction was lower in sphingomyelin-deficient cells than in wild-type cells. When cells mere exposed to methyl-beta -cyclodextrin, cholesterol was more efficiently fluxed from sphingomyelin-deficient cells than wild-type cells. These results suggest that the steady state level of cholesterol at the plasma membrane is little affected by the sphingomyelin levels in Chinese hamster ovary cells, but that sphingomyelin levels play an important role in the retention of cholesterol in the plasma membrane against efflux to extracellular cholesterol-acceptors, due to interaction between sphingomyelin and cholesterol in detergent-resistant membrane domains.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990195, Japan	National Institute of Infectious Diseases (NIID); Teikyo University	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.		板部板部, 洋之/ABC-7746-2020	Hanada, Kentaro/0000-0003-1383-2781				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; Fielding CJ, 1997, J LIPID RES, V38, P1503; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; GUPTA AK, 1991, J LIPID RES, V32, P125; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HARMALA AS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P97, DOI 10.1016/0005-2760(93)90054-D; HEIDER JG, 1978, J LIPID RES, V19, P514; Ito J, 2000, J LIPID RES, V41, P894; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIEGER M, 1983, ANAL BIOCHEM, V135, P383, DOI 10.1016/0003-2697(83)90700-5; KUDEHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PORN MI, 1995, BIOCHEM J, V308, P269; PORN MI, 1993, J LIPID RES, V34, P1385; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; Rothblat GH, 1999, J LIPID RES, V40, P781; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175	48	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34028	34034		10.1074/jbc.M005151200	http://dx.doi.org/10.1074/jbc.M005151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10930414	hybrid			2022-12-25	WOS:000165095300006
J	Leu, FP; Hingorani, MM; Turner, J; O'Donnell, M				Leu, FP; Hingorani, MM; Turner, J; O'Donnell, M			The delta subunit of DNA polymerase III holoenzyme serves as a sliding clamp unloader in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; LAGGING-STRAND REPLICATION; CELL NUCLEAR ANTIGEN; ACCESSORY PROTEINS; ATP HYDROLYSIS; ALPHA-SUBUNIT; BETA-SUBUNIT; PCNA; PURIFICATION; COMPLEX	In Escherichia coli, the circular beta sliding clamp facilitates processive DNA replication by tethering the polymerase to primer-template DNA. When synthesis is complete, polymerase dissociates from beta and DNA and cycles to a new start site, a primed template loaded with beta. DNA polymerase cycles frequently during lagging strand replication while synthesizing l-a-kilobase Okazaki fragments. The clamps left behind remain stable on DNA (t(1/2) similar to 115 min) and must be removed rapidly for reuse at numerous primed sites on the lagging strand. Here we show that delta, a single subunit of DNA polymerase III holoenzyme, opens beta and slips it off DNA (k(unloading) = 0.011 s(-1)) at a rate similar to that of the multisubunit gamma complex clamp loader by itself (0.015 s(-1)) or within polymerase (pol) III* (0.0065 s(-1)). Moreover, unlike gamma complex and pol III*, delta does not require ATP to catalyze clamp unloading. Quantitation of gamma complex subunits (gamma, delta, delta', chi, psi) in E. coli cells reveals an excess of delta, free from gamma complex and pol III*. Since pol III* and gamma complex occur in much lower quantities and perform several DNA metabolic functions in replication and repair, the delta subunit probably aids beta clamp recycling during DNA replication.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, Lab DNA Reprod, New York, NY 10021 USA; Cornell Univ, Dept Pharmacol, Joan & Sanford I Weill Grad Sch Med Sci, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Cornell University	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, P1627; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HUANG CC, 1981, J BIOL CHEM, V256, P4087; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KELMAN Z, 1995, THESIS CORNELL U; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG T, 1972, J BIOL CHEM, V247, P5369; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER LF, 1994, DIABETES SPECTRUM, V7, P225; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WU YH, 1984, J BIOL CHEM, V259, P2117; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	65	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34609	34618		10.1074/jbc.M005495200	http://dx.doi.org/10.1074/jbc.M005495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924523	hybrid			2022-12-25	WOS:000165095300083
J	Takahashi, M; Mukai, H; Oishi, K; Isagawa, T; Ono, Y				Takahashi, M; Mukai, H; Oishi, K; Isagawa, T; Ono, Y			Association of immature hypophosphorylated protein kinase C epsilon with an anchoring protein CG-NAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHORYLATION; PDK1; DOMAIN; ACTIVATION; FAMILY; GOLGI; ZETA; PKN	Protein kinase C (PKC) family requires phosphorylation of itself to become competent for responding to second messengers. Much attention has been focused on elucidating the role of phosphorylation in PKC activity; however, it remains unknown where this modification takes place in the cells. This study examines whether anchoring protein is involved in the regulation of PKC phosphorylation. A certain population of PKC epsilon in rat brain extracts as well as that expressed in COS7 cells was associated with an endogenous anchoring protein CG-NAP (centrosome and Golgi localized PKN-associated protein). Pulse chase experiments revealed that the associated PKC epsilon was an immature species at the hypophosphorylated state. In vitro binding studies confirmed that non- or hypophosphorylated PKC epsilon directly bound to CG-NAP via its catalytic domain, whereas sufficiently phosphorylated PKC epsilon did not. PKC epsilon mutant at a potential phosphorylation site of Thr-566 or Ser-729 to Ala, possessing almost no catalytic activity, was associated and co-localized with CG-NAP at Golgi/centrosome area. On the other hand, wild type and a phosphorylation-mimicking mutant at Thr-566 were mainly distributed in cytosol and represented second messenger-dependent catalytic activation. These results suggest that CG-NAP anchors hypophosphorylated PKC epsilon at the Golgi/centrosome area during maturation and serves as a scaffold for the phosphorylation reaction.	Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan	Kobe University; Kobe University	Ono, Y (corresponding author), Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan.			Mukai, Hideyuki/0000-0002-0167-8695				Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Mochly-Rosen D, 1998, FASEB J, V12, P35; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, J BIOL CHEM, V263, P6927; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476	27	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34592	34596		10.1074/jbc.M005285200	http://dx.doi.org/10.1074/jbc.M005285200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945988	hybrid			2022-12-25	WOS:000165095300081
J	Tamura, K; Chen, YQE; Lopez-Ilasaca, M; Daviet, L; Tamura, N; Ishigami, T; Akishita, M; Takasaki, I; Tokita, Y; Pratt, RE; Horiuchi, M; Dzau, VJ; Umemura, S				Tamura, K; Chen, YQE; Lopez-Ilasaca, M; Daviet, L; Tamura, N; Ishigami, T; Akishita, M; Takasaki, I; Tokita, Y; Pratt, RE; Horiuchi, M; Dzau, VJ; Umemura, S			Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; GROWTH-FACTOR-BETA; ANGIOTENSIN-II; COLLAGEN-SYNTHESIS; PRESSURE-OVERLOAD; RECEPTOR SUBTYPES; IN-VITRO; EXPRESSION; STRAIN; TRANSCRIPTION	Fibronectin plays an important role in vascular remodeling. A functional interaction between mechanical stimuli and locally produced vasoactive agents is suggested to be crucial for vascular remodeling. We examined the effect of mechanical stretch on fibronectin gene expression in vascular smooth muscle cells and the role of vascular angiotensin II in the regulation of the fibronectin gene in response to stretch. Cyclic stretch induced an increase in vascular fibronectin mRNA levels that was inhibited by actinomycin D and CV11974, an angiotensin II type 1 receptor antagonist; cycloheximide and PD123319, an angiotensin II type 2 receptor antagonist, did not affect the induction. In transfection experiments, fibronectin promoter activity was stimulated by stretch and inhibited by CV11974 but not by PD123319, DNA-protein binding experiments revealed that cyclic stretch enhanced nuclear binding to the AP-1 site, which was partially supershifted by antibody to c-Jun. Site-directed mutation of the AP-1 site significantly decreased the cyclic stretch-mediated activation of fibronectin promoter. Furthermore, antisense c-jun oligo nucleotides decreased the stretch-induced stimulation of the fibronectin promoter activity and the mRNA expression. These results suggest that cyclic stretch stimulates vascular fibronectin gene expression mainly via the activation of AP-1 through the angiotensin II type 1 receptor.	Yokohama City Univ, Sch Med, Dept Internal Med 2, Yokohama, Kanagawa 236, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa 236, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Fujisawa Municipal Hosp, Dept Med, Div Renal, Fujisawa, Kanagawa 251, Japan	Yokohama City University; Yokohama City University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tamura, K (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	tamukou@med.yokohama-cu.ac.jp						BENES AJ, 1985, J CELL SCI, V75, P35; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Haller H, 1996, CIRC RES, V79, P765, DOI 10.1161/01.RES.79.4.765; Hamaguchi A, 1999, HYPERTENSION, V34, P126, DOI 10.1161/01.HYP.34.1.126; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IKEDA U, 1995, CIRCULATION, V92, P2683, DOI 10.1161/01.CIR.92.9.2683; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KATO H, 1991, J HYPERTENS, V9, P17; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; KINUGAWA K, 1993, EUR J PHARMACOL, V235, P313, DOI 10.1016/0014-2999(93)90153-9; Li Q, 1998, J VASC RES, V35, P93, DOI 10.1159/000025570; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; NODA M, 1993, BIOCHEM PHARMACOL, V46, P311; Nyui N, 1997, BIOCHEM BIOPH RES CO, V235, P36, DOI 10.1006/bbrc.1997.6706; RuizOrtega M, 1997, KIDNEY INT, V52, P1497, DOI 10.1038/ki.1997.480; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SHIOTA N, 1992, HYPERTENSION, V20, P168, DOI 10.1161/01.HYP.20.2.168; SUDHIR K, 1993, J CLIN INVEST, V92, P3003, DOI 10.1172/JCI116923; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKASAKI I, 1990, J BIOL CHEM, V265, P21935; Tamura K, 1998, KIDNEY INT, V54, P382, DOI 10.1046/j.1523-1755.1998.00025.x; Tamura K, 1999, J HYPERTENS, V17, P81, DOI 10.1097/00004872-199917010-00013; Tamura K, 1998, J BIOL CHEM, V273, P26487, DOI 10.1074/jbc.273.41.26487; Tamura K, 1996, HYPERTENSION, V27, P1216, DOI 10.1161/01.HYP.27.6.1216; vonHarsdorf R, 1997, J CLIN INVEST, V100, P1294, DOI 10.1172/JCI119643; Wilson E, 1998, HYPERTENSION, V31, P170, DOI 10.1161/01.HYP.31.1.170; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258	37	42	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34619	34627		10.1074/jbc.M004421200	http://dx.doi.org/10.1074/jbc.M004421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10930408	hybrid			2022-12-25	WOS:000165095300084
J	Tepper, AD; Diks, SH; van Blitterswijk, WJ; Borst, J				Tepper, AD; Diks, SH; van Blitterswijk, WJ; Borst, J			Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; GLYCOSPHINGOLIPID SYNTHESIS; ACID SPHINGOMYELINASE; CELLS; RESISTANCE; GLYCOSYLATION; CYTOTOXICITY; PROPAGATION; EXPRESSION; GENERATION	Ceramide (Cer) accumulating during the execution phase of apoptosis is generated from plasma membrane sphingomyelin (SM), which gains access to a sphingomyelinase due to phospholipid scrambling (Tepper, A. D., Ruurs, P., Wiedmer T., Sims, P., Borst, J., and van Blitterswijk W. J. (2000) J. Cell. Biol; 150, 155-164), To evaluate the functional significance of this Cer pool, we aimed to convert it to glucosylceramide (GlcCer), by constitutive overexpression of glucosylceramide synthase (GCS). Jurkat cells, retrovirally transduced with GCS cDNA, showed a 10-12-fold increase in GCS activity in vitro and a 7-fold elevated basal GlcCer level in vivo. However, Cer accumulating during apoptosis induced by ligation of the death receptor CD95, treatment with the anti-cancer drug etoposide, or exposure to gamma -radiation was not glycosylated by GCS. Likewise, Cer liberated at the plasma membrane by bacterial SMase was not concerted by the enzyme. Thus, GCS, located at the Golgi, is topologically segregated from Cer produced in the plasma membrane. In contrast, de novo synthesized Cer as well as an exogenously supplied cell-permeable Cer analog were efficiently glycosylated, apparently due to different. Cer topology and distinct physicochemical behavior of the synthetic Cer species, respectively. Exogenous cell-permeable Cer species, despite their conversion by GCS, effectively induced apoptosis. We also observed that GCS activity is down-regulated in cells undergoing apoptosis. In conclusion, GCS can convert de novo synthesized Cer but not SM-derived Cer, and, therefore, the ability of GCS overexpression to protect cells ii om possible detrimental effects of Cer accumulation is limited.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jborst@nki.nl		Borst, Jannie/0000-0002-8043-5009				Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DHAIBO GS, 1997, J EXP MED, V185, P481; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; MANDON EC, 1992, J BIOL CHEM, V267, P11144; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO RE, 1998, BIOCHEMISTRY-US, V27, P4439; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	37	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34810	34817		10.1074/jbc.M005142200	http://dx.doi.org/10.1074/jbc.M005142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945987	hybrid			2022-12-25	WOS:000165095300108
J	Zhao, X; Creuzenet, C; Belanger, M; Egbosimba, E; Li, JJ; Lam, JS				Zhao, X; Creuzenet, C; Belanger, M; Egbosimba, E; Li, JJ; Lam, JS			WbpO, a UDP-N-acetyl-D-galactosamine dehydrogenase from Pseudomonas aeruginosa serotype O6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; CAPSULAR POLYSACCHARIDE; GLUCOSE-DEHYDROGENASE; MOLECULAR CHARACTERIZATION; ALCOHOL-DEHYDROGENASE; CIRCULAR-DICHROISM; BACILLUS-SUBTILIS; SOMATIC ANTIGENS; VI ANTIGEN	WbpO is associated with E-band lipopolysaccharide biosynthesis in Pseudomonas aeruginosa serotype O6, This protein is thought to catalyze the enzymatic conversion of UDP-N-acetyl-D-galactosamine (UDP-GalNAc) to UDP-N-acetyl-D-galactosaminuronic acid (UDP-Gal-NAcA). WbpO was overexpressed with a C-terminal hexahistidine tag. The soluble form Of expressed WbpO (WbpO(Sol)) exhibited a secondary structure with 29.2% cy-helix and 20.1% beta -strand. However, no enzymatic activity could be detected using either high performance anion exchange chromatography or capillary electrophoresis-mass spectrometry analysis, An insoluble form of expressed WbpO was purified in the presence of guanidine hydrochloride by immobilized metal ion affinity chromatography, After refolding, this preparation of WbpO (designated as WbpO(Rf))exhibited stable secondary structure at pH 7.5 to 8.2, and it was enzymatically active. Capillary electrophoresis-mass spectrometry and tandem mass spectrometry analysis showed that WbpO(Rf) catalyzed the conversion of UDP-GalNAc to UDP-GalNAcA. 26 and 22% of the substrate could be converted to UDP-GalNAcA in the presence of NAD(+) and NADP(+) as the cofactors, respectively. The K-m values of WbpO(Rf) for UDP-GalNAc, NAD(+), and NADP(+) were 7.79, 0.65, and 0.44 mM, respectively, WbpO, can also catalyze the conversion of UDP-GlcNAc to UDP-GlcNAcA. In conclusion, this is the first report of the overexpression, purification, and biochemical characterization of an NAD(+)/NADP(+)-dependent UDP-GalNAc dehydrogenase, Our results also complete the biosynthetic pathway for GalNAcA that is part of the O-antigen of P. aeruginosa serotype O6 lipopolysaccharide.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; Bert F, 1996, J ANTIMICROB CHEMOTH, V37, P809, DOI 10.1093/jac/37.4.809; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Burrows LL, 1999, J BACTERIOL, V181, P973, DOI 10.1128/JB.181.3.973-980.1999; Burrows LL, 1997, J BACTERIOL, V179, P1482, DOI 10.1128/jb.179.5.1482-1489.1997; CASEY JP, 1972, J AM CHEM SOC, V94, P6141, DOI 10.1021/ja00772a036; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Dahan D, 1996, FEBS LETT, V392, P304, DOI 10.1016/0014-5793(96)00841-1; DEKIEVIT TR, 1995, MOL MICROBIOL, V16, P565; GUISEZ Y, 1993, PROTEIN EXPRES PURIF, V4, P240, DOI 10.1006/prep.1993.1031; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haseley SR, 1997, EUR J BIOCHEM, V244, P761, DOI 10.1111/j.1432-1033.1997.00761.x; HASHIMOTO Y, 1993, J BACTERIOL, V175, P4456, DOI 10.1128/JB.175.14.4456-4465.1993; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HILT W, 1991, BIOCHIM BIOPHYS ACTA, V1076, P298, DOI 10.1016/0167-4838(91)90281-4; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; HUANG JZ, 1995, MOL MICROBIOL, V16, P977, DOI 10.1111/j.1365-2958.1995.tb02323.x; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; *INT UN BIOCH NOM, 1979, ENZ NOM, P19; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAHN PC, 1968, J AM CHEM SOC, V90, P4168, DOI 10.1021/ja01017a051; KAWAMURA T, 1982, METHOD ENZYMOL, V83, P519; KAWAMURA T, 1985, J BIOCHEM-TOKYO, V98, P105, DOI 10.1093/oxfordjournals.jbchem.a135248; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; KAYA S, 1989, J BIOCHEM, V105, P35, DOI 10.1093/oxfordjournals.jbchem.a122613; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; KNIREL YA, 1987, EUR J BIOCHEM, V166, P189, DOI 10.1111/j.1432-1033.1987.tb13501.x; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT JB, 1996, ORGANIC STRUCTURAL S, P295; LILJEBJELKE K, 1995, ANAL BIOCHEM, V225, P296, DOI 10.1006/abio.1995.1158; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; Matheron C, 1999, APPL ENVIRON MICROB, V65, P1941; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; OGASAHARA K, 1976, J BIOCHEM-TOKYO, V79, P819, DOI 10.1093/oxfordjournals.jbchem.a131135; ORGAMBIDE G, 1991, J BIOL CHEM, V266, P8312; Parolis H, 1997, CARBOHYD RES, V303, P319, DOI 10.1016/S0008-6215(97)00178-X; PAULY HE, 1975, H-S Z PHYSIOL CHEM, V356, P1613, DOI 10.1515/bchm2.1975.356.2.1613; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; PITT TL, 1988, EUR J CLIN MICROBIOL, V7, P238, DOI 10.1007/BF01963095; REDDY GP, 1993, ANAL BIOCHEM, V214, P106, DOI 10.1006/abio.1993.1463; Reddy GP, 1998, EUR J BIOCHEM, V255, P279, DOI 10.1046/j.1432-1327.1998.2550279.x; REEN RK, 1993, BIOCHEM PHARMACOL, V46, P229, DOI 10.1016/0006-2952(93)90408-O; Robertson D, 1996, BIOCHEM J, V313, P311, DOI 10.1042/bj3130311; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 1989, MOL CLONING LAB MANU, pA2; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Shashkov AS, 1998, CARBOHYD RES, V306, P297, DOI 10.1016/S0008-6215(97)10048-9; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stanislavsky ES, 1997, FEMS MICROBIOL REV, V21, P243, DOI 10.1016/S0168-6445(97)00059-4; Todaka T, 2000, ARCH BIOCHEM BIOPHYS, V374, P189, DOI 10.1006/abbi.1999.1450; Trivic S, 1998, J ENZYM INHIB, V13, P57, DOI 10.3109/14756369809035827; Vachee A, 1997, PATHOL BIOL, V45, P357; WAXIN H, 1993, RES MICROBIOL, V144, P363, DOI 10.1016/0923-2508(93)90193-6; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	64	22	27	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33252	33259		10.1074/jbc.M004191200	http://dx.doi.org/10.1074/jbc.M004191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931835	hybrid			2022-12-25	WOS:000090104600013
J	Boland, MP; Fitzgerald, KA; O'Neill, LAJ				Boland, MP; Fitzgerald, KA; O'Neill, LAJ			Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; CATALYTIC ACTIVITY; MAMMALIAN-CELLS; KINASE COMPLEX; FAS-LIGAND; SACCHAROMYCES-CEREVISIAE; ANTINEOPLASTIC AGENTS; LIPID-PEROXIDATION; IONIZING-RADIATION; INDUCED APOPTOSIS	Topoisomerase II is a target for a number of chemotherapeutic agents used in the treatment of cancer. Its essential physiological role in modifying the topology of DNA involves the generation of transient double-strand breaks. Anti-cancer drugs, such as mitoxantrone, that target this enzyme interrupt its catalytic cycle and give rise to persistent double strand breaks, which may be lethal to a cell. We investigated the role of such lesions in signaling the activation of the transcription factor nuclear factor kappa B (NF kappa B) by this drug. Mitoxantrone activated NF kappa B and stimulated I kappa B alpha degradation in the promyelocytic leukemia cell line HL60 but not in the variant cells, HL60/MX2 cells, which lack the beta isoform of topoisomerase II and express a truncated alpha isoform that results in an altered subcellular distribution. Treatment of sensitive HL60 cells with mitoxantrone led to a depletion of both isoforms, suggesting the stabilization of transient DNA-topoisomerase II complexes. This depletion was absent in the variant cells, HL60/MX2. Activation of caspase 3 by mitoxantrone was also impaired in the HL60/MX2 cells. NF kappa B activation in response to tumor necrosis factor and bleomycin, the latter causing topoisomerase II-independent DNA damage, was intact in both cell lines. An inhibitor rather than a poison of topoisomerase II, Imperial Cancer Research Fund 187 (ICRF 187) the mechanism of which does not involve the generation of double strand breaks, did not activate NF kappa B, nor did it induce apoptosis in parental HL60 cells. However, ICRF 187 protected against I kappa B degradation in parental HL60 cells in response to mitoxantrone. This protection was also shown with another topoisomerase II inhibitor, merbarone, which is structurally and functionally distinct from ICRF 187. Their effects were specific, as neither protected against tumor necrosis factor-stimulated I kappa B degradation. The poisoning of topoisomerase II with resultant DNA damage is therefore a critical signal for NF kappa B activation.	Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland; Trinity Coll Dublin, Inst Biotechnol, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	O'Neill, LAJ (corresponding author), Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland.	laoneill@tcd.ie	Fitzgerald, Katherine/ABE-6317-2020	Fitzgerald, Kate/0000-0003-3175-609X; O'Neill, Luke/0000-0002-4333-2748				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN GA, 1995, CANCER RES, V55, P78; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Consoli U, 1997, LEUKEMIA, V11, P2066, DOI 10.1038/sj.leu.2400511; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; Errington F, 1999, MOL PHARMACOL, V56, P1309, DOI 10.1124/mol.56.6.1309; FISHER GR, 1992, CANCER CHEMOTH PHARM, V30, P451, DOI 10.1007/BF00685596; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; FRY AM, 1991, CANCER RES, V51, P6592; Furuke K, 1999, J IMMUNOL, V162, P1988; GERWITZ DA, 1999, BIOCHEM PHARMACOL, V57, P724; Gieseler F, 1996, LEUKEMIA, V10, pS46; Gilmore TD, 1996, ONCOGENE, V13, P1367; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HARKER WG, 1989, CANCER RES, V49, P4542; HARKER WG, 1991, BIOCHEMISTRY-US, V30, P9953, DOI 10.1021/bi00105a020; HARKER WG, 1995, CANCER RES, V55, P4962; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jensen PB, 1997, BIOCHEM PHARMACOL, V54, P755; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Liu BQ, 1996, J IMMUNOL, V157, P160; McPherson JP, 1997, ANTICANCER RES, V17, P4243; Meczes EL, 1997, CANCER CHEMOTH PHARM, V39, P367, DOI 10.1007/s002800050585; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 1999, MOL PHARMACOL, V55, P216, DOI 10.1124/mol.55.2.216; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; ROBSON CN, 1987, CANCER RES, V47, P1560; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SEHESTED M, 1993, BIOCHEM PHARMACOL, V46, P389, DOI 10.1016/0006-2952(93)90514-W; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SIKIC BI, 1986, CANCER SURV, V5, P81; Son YS, 1998, CANCER CHEMOTH PHARM, V41, P353, DOI 10.1007/s002800050751; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VILE GF, 1989, CANCER CHEMOTH PHARM, V24, P105; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weiss G, 1999, GEN PHARMACOL, V32, P155, DOI 10.1016/S0306-3623(98)00100-1; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; WILSON RE, 1993, ONCOGENE, V8, P3229; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	63	64	66	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25231	25238		10.1074/jbc.275.33.25231	http://dx.doi.org/10.1074/jbc.275.33.25231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10940316	hybrid			2022-12-25	WOS:000088849400027
J	Fukada, M; Watakabe, I; Yuasa-Kawada, J; Kawachi, H; Kuroiwa, A; Matsuda, Y; Noda, M				Fukada, M; Watakabe, I; Yuasa-Kawada, J; Kawachi, H; Kuroiwa, A; Matsuda, Y; Noda, M			Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-NERVE PROJECTION; NEURAL-SPECIFIC PROTEIN; GROWTH CONE COLLAPSE; SEMAPHORIN-III; HUMAN DIHYDROPYRIMIDINASE; AXON GUIDANCE; SPINAL-CORD; GENE; NEUROPILIN; UNC-33	The CRMP (collapsin response mediator protein) family is thought to play key roles in growth cone guidance during neural development. The four members (CRMP1-4) identified to date have been demonstrated to form hetero-multimeric structures through mutual associations. In this study, we cloned a novel member of this family, which we call CRMP5, by the yeast two-hybrid method. This protein shares relatively low amino acid identity with the other CRMP members (49-50%) and also with dihydropyrimidinase (51%), whereas CRMP1-4 exhibit higher identity with each other (68-75%), suggesting that CRMP5 might be categorized into a third subfamily. The mouse CRMP5 gene was located at chromosome 5 B1, Northern blot and in situ hybridization analyses indicated that CRMP5 is expressed throughout the nervous system similarly to the other members (especially CRMP1 and CRMP4) with the expression peak in the first postnatal week. Association experiments using the yeast two-hybrid method and coimmunoprecipitation showed that CRMP5 interacts with dihydropyrimidinase and all the CRMPs including itself, except for CRMP1, although the expression profile almost overlaps with that of CRMP1 during development. These results suggest that CRMP complexes in the developing nervous system are classifiable into two populations that contain either CRMP1 or CRMP5. This indicates that different complexes may have distinct functions in shaping the neural networks.	Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Lab Cytogenet,Kita Ku, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Fac Sci, Chromosome Res Unit, Sapporo, Hokkaido 0600810, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Hokkaido University; Hokkaido University	Noda, M (corresponding author), Natl Inst Basic Biol, Div Mol Neurobiol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X; KAWACHI, HIROYUKI/0000-0002-7508-5569; Kuroiwa, Asato/0000-0002-3942-3372; Yuasa-Kawada, Junichi/0000-0002-1382-3159				Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Byk T, 1996, J NEUROSCI, V16, P688; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; EVANS EP, 1996, GENETIC VARIANTS STR, P1446; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Goshima Y, 1997, J NEUROBIOL, V33, P316, DOI 10.1002/(SICI)1097-4695(199709)33:3<316::AID-NEU9>3.0.CO;2-4; Hamajima N, 1998, AM J HUM GENET, V63, P717, DOI 10.1086/302022; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Kamata T, 1998, MOL BRAIN RES, V57, P201, DOI 10.1016/S0169-328X(98)00082-5; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kato Y, 1998, MOL REPROD DEV, V51, P105, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;105::AID-MRD13&gt;3.0.CO;2-6; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; KIKUGAWA M, 1994, EUR J BIOCHEM, V219, P393, DOI 10.1111/j.1432-1033.1994.tb19951.x; Kitamura K, 1999, DNA Res, V6, P291, DOI 10.1093/dnares/6.5.291; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; Matsuo T, 2000, J BIOL CHEM, V275, P16560, DOI 10.1074/jbc.M001312200; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Quach TT, 2000, GENE, V242, P175, DOI 10.1016/S0378-1119(99)00528-4; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; SOMSSICH IE, 1996, GENETIC VARIANTS STR, P1450; Suzuki H, 1996, NUCLEIC ACIDS RES, V24, P289, DOI 10.1093/nar/24.2.289; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Torres R, 1998, DNA Res, V5, P393, DOI 10.1093/dnares/5.6.393; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	45	109	121	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37957	37965		10.1074/jbc.M003277200	http://dx.doi.org/10.1074/jbc.M003277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956643	Green Submitted, hybrid			2022-12-25	WOS:000165618700088
J	Houvras, Y; Benezra, M; Zhang, HB; Manfredi, JJ; Weber, BL; Licht, JD				Houvras, Y; Benezra, M; Zhang, HB; Manfredi, JJ; Weber, BL; Licht, JD			BRCA1 physically and functionally interacts with ATF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; FACTOR-ALPHA PROMOTER; TRANSCRIPTIONAL ACTIVATION; MALIGNANT-MELANOMA; NUCLEAR PROTEINS; RING FINGER; CDNA-CLONES; SOFT PARTS; CELL-CYCLE; IN-VIVO	BRCA1, a breast and ovarian cancer susceptibility gene, encodes a 220-kDa protein whose precise biochemical function::remains unclear. BRCA1 contains an N-terminal- RING finger that mediates protein-protein interaction. The C-terminal domain of BRCA1 (BRCT) can activate transcription and interacts with RNA polymerase holoenzyme. Using the yeast two-hybrid system, we identified an interaction between the BRCA1 RING finger and ATF1, a member of the cAMP response element-binding protein/activating transcription factor (CREB/ATF) family. We demonstrate that BRCA1 and ATF1 can physically associate in vitro, in yeast, and in human cells. BRCA1 stimulated transcription from a cAMP response-element reporter gene in transient transfections. BRCA1 also stimulated transcription from a natural promoter, that of tumor necrosis factor-alpha, in a manner dependent on the integrity of the cAMP response element. These results implicate BRCA1 in transcriptional activation of ATF1 target genes, some of which are involved in the transcriptional response to DNA damage.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Pennsylvania; University of Pennsylvania	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,POB 1130, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; Houvras, Yariv/0000-0003-0751-3215	NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA80058, CA75417] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07280-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cui JQ, 1998, ONCOL REP, V5, P591; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Fujimura Y, 1996, ONCOGENE, V12, P159; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Hayes F, 2000, CANCER RES, V60, P2411; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Kibitel J, 1998, PHOTOCHEM PHOTOBIOL, V67, P541, DOI 10.1111/j.1751-1097.1998.tb09452.x; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LIU F, 1993, J BIOL CHEM, V268, P6714; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Speleman F, 1997, MODERN PATHOL, V10, P496; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Vispe S, 1997, BIOCHIMIE, V79, P587, DOI 10.1016/S0300-9084(97)82007-X; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	62	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36230	36237		10.1074/jbc.M002539200	http://dx.doi.org/10.1074/jbc.M002539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945975	hybrid			2022-12-25	WOS:000165382000083
J	Hemming, SA; Jansma, DB; Macgregor, PF; Goryachev, A; Friesen, JD; Edwards, AM				Hemming, SA; Jansma, DB; Macgregor, PF; Goryachev, A; Friesen, JD; Edwards, AM			RNA polymerase II subunit Rpb9 regulates transcription elongation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; TFIIS; VIABILITY; MOTIF	RNA polymerase II lacking the Rpb9 subunit uses alternate transcription initiation sites in vitro and in vivo and is unable to respond to the transcription elongation factor TFIIS in vitro. Here, we show that RPB9 has a synthetic phenotype with the TFIIS gene. Disruption of RPB9 in yeast also resulted in sensitivity to 6-azauracil, which is a phenotype linked to defects in transcription elongation. Expression of the TFIIS gene on a high-copy plasmid partially suppressed the 6-azauracil sensitivity of Delta rpb9 cells. We set out to determine the relevant cellular role of yeast RpbS by assessing the ability of 20 different site-directed and deletion mutants of RPB9 to complement the initiation and elongation defects of Delta rpb9 cells in vivo. RpbS is composed of two zinc ribbons.' The N-terminal zinc ribbon restored the wild-type pattern of initiation start sites, but was unable to complement the growth defects associated with defects in elongation. Most of the site-directed mutants complemented the elongation-specific growth phenotypes and reconstituted the normal pattern of transcription initiation: sites. The anti-correlation between the growth defects of cells disrupted for RPB9 and the selection of transcription:start sites suggests that this is not the primary cellular role for RpbS. Genome-wide transcription profiling of Delta rpb9 cells revealed only a few changes, predominantly in genes related to metabolism.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Goryachev, Andrew B/A-6553-2013	Goryachev, Andrew B/0000-0002-1332-4819; Edwards, Aled/0000-0002-4782-6016				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; CARLES C, 1991, J BIOL CHEM, V266, P24092; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; HARRISON DA, 1992, MOL CELL BIOL, V12, P928, DOI 10.1128/MCB.12.3.928; Hemming SA, 2000, J BIOL CHEM, V275, P2288, DOI 10.1074/jbc.275.4.2288; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	22	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35506	35511		10.1074/jbc.M004721200	http://dx.doi.org/10.1074/jbc.M004721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938084	hybrid			2022-12-25	WOS:000165422800089
J	Hummel, HS; Gillespie, RD; Swindle, J				Hummel, HS; Gillespie, RD; Swindle, J			Mutational analysis of 3 ' splice site selection during trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BRUCEI PROVIDES EVIDENCE; TRYPANOSOMA-CRUZI; MAMMALIAN INTRONS; SECONDARY STRUCTURE; BRANCH POINT; T-BRUCEI; VSG GENE; U5 SNRNP; SEQUENCE	trans-Splicing is essential for mRNA maturation in trypanosomatids. A conserved AG dinucleotide serves as the 3' splice acceptor site, and analysis of native processing sites suggests that selection of this site is determined according to a 5'-3' scanning model. A series of stable gene replacement lines were generated that carried point mutations at or near the 3' splice site within the intergenic region separating CUB2.65, the calmodulin-ubiquitin associated gene, and FUS1, the ubiquitin fusion gene of Trypanosoma cruzi. In one stable line, the elimination of the native 3' splice acceptor site led to the accumulation of Y-branched splicing intermediates, which served as templates for mapping the first trans-splicing branch points in T. cruzi, In other lines, point mutations shifted the position of the first consensus AG dinucleotide either upstream or downstream of the wild-type 3' splice acceptor site in this intergenic region, Consistent with the scanning model, the first AG dinucleotide downstream of the branch points was used as the predominant 3' splice acceptor site. In: all of the stable lines, the point mutations affected splicing efficiency in this region.	Univ Tennessee, Dept Immunol & Microbiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Swindle, J (corresponding author), Univ Tennessee, Dept Immunol & Microbiol, 858 Madison Ave, Memphis, TN 38163 USA.	jswindle@IDRI.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026578] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26578] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achsel T, 1998, MOL CELL BIOL, V18, P6756, DOI 10.1128/MCB.18.11.6756; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AJIOKA J, 1993, MOL BIOCHEM PARASIT, V57, P127, DOI 10.1016/0166-6851(93)90250-2; Brys A, 1996, RNA, V2, P707; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Chen SY, 2000, P NATL ACAD SCI USA, V97, P593, DOI 10.1073/pnas.97.2.593; Chua K, 1999, NATURE, V402, P207, DOI 10.1038/46086; DELANGE T, 1984, NUCLEIC ACIDS RES, V12, P4431, DOI 10.1093/nar/12.11.4431; DESHLER JO, 1991, GENE DEV, V5, P1252, DOI 10.1101/gad.5.7.1252; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GILLESPIE RD, 1993, MOL BIOCHEM PARASIT, V60, P281, DOI 10.1016/0166-6851(93)90139-O; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V13, P5789, DOI 10.1093/nar/13.16.5789; HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HODGES PE, 1995, YEAST, V11, P337; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1994, MOL CELL BIOL, V14, P7428, DOI 10.1128/MCB.14.11.7428; JAISHANKAR S, 1996, MICROBIOLOGY IMMUNOL; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LANG KM, 1983, SCIENCE, V220, P1351, DOI 10.1126/science.6304877; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lucke S, 1997, EMBO J, V16, P4433, DOI 10.1093/emboj/16.14.4433; Luukkonen BGM, 1997, EMBO J, V16, P779, DOI 10.1093/emboj/16.4.779; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; PERRY K, 1991, EXPERIENTIA, V47, P118, DOI 10.1007/BF01945412; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEA C, 1987, CELL, V50, P603, DOI 10.1016/0092-8674(87)90033-X; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; Spritz R A, 1983, Prog Clin Biol Res, V134, P77; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; SWINDLE J, 1988, EMBO J, V7, P1121, DOI 10.1002/j.1460-2075.1988.tb02921.x; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; ULFENDAHL PJ, 1989, NUCLEIC ACIDS RES, V17, P925, DOI 10.1093/nar/17.3.925; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	56	19	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35522	35531		10.1074/jbc.M002424200	http://dx.doi.org/10.1074/jbc.M002424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938269	hybrid			2022-12-25	WOS:000165422800091
J	Santra, M; Eichstetter, I; Iozzo, RV				Santra, M; Eichstetter, I; Iozzo, RV			An anti-oncogenic role for decorin - Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; DROSOPHILA EGF RECEPTOR; HUMAN-BREAST-CANCER; GENE-EXPRESSION; SULFATE PROTEOGLYCAN; NEU PROTOONCOGENE; SIGNALING NETWORK; FAMILY; ACTIVATION; LIGAND	The leucine-rich proteoglycan decorin interacts with the epidermal growth factor receptor and triggers a signaling pathway that leads to growth suppression. We find that decorin causes a functional inactivation of the oncogenic ErbB2 protein in breast carcinoma cells. Upon de novo expression of decorin, the ErbB2 protein is reduced by similar to 40%, whereas its degree of tyrosyl phosphorylation is almost completely abrogated. Both co-culture experiments or experiments with recombinant decorin demonstrate an initial induction of ErbB2 tyrosine kinase, followed by a profound and long-lasting downregulation of its activity. This leads to growth inhibition and cytodifferentiation of mammary tumor cells and a concurrent suppression of their tumorigenic potential in vivo. These decorin-mediated effects appear to involve the activation of ErbB4, which in turn would block the phosphorylation of heterodimers containing either ErbB2 or ErbB3. These results provide an explanation for the heightened decorin levels around invasive carcinomas and suggest that decorin may function as a natural antagonist of neoplastic cells enriched in ErbB2.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Cellular Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Kimmel Canc Ctr, Rm 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA39481, CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KAHARI VM, 1995, J INVEST DERMATOL, V104, P503, DOI 10.1111/1523-1747.ep12605969; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Leevers SJ, 1999, NAT CELL BIOL, V1, pE10, DOI 10.1038/8969; MANN DM, 1990, J BIOL CHEM, V265, P5317; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; Neame P. J., 2000, PROTEOGLYCANS STRUCT, P201; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; Zhang K, 1996, J BIOL CHEM, V271, P3884	67	167	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35153	35161		10.1074/jbc.M006821200	http://dx.doi.org/10.1074/jbc.M006821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10942781	hybrid			2022-12-25	WOS:000165422800045
J	Wu, YM; Bressette, D; Carrell, JA; Kaufman, T; Feng, P; Taylor, K; Gan, YX; Cho, YH; Garcia, AD; Gollatz, E; Dimke, D; LaFleur, D; Migone, TS; Nardelli, B; Wei, P; Ruben, SM; Ullrich, SJ; Olsen, HS; Kanakaraj, P; Moore, PA; Baker, KP				Wu, YM; Bressette, D; Carrell, JA; Kaufman, T; Feng, P; Taylor, K; Gan, YX; Cho, YH; Garcia, AD; Gollatz, E; Dimke, D; LaFleur, D; Migone, TS; Nardelli, B; Wei, P; Ruben, SM; Ullrich, SJ; Olsen, HS; Kanakaraj, P; Moore, PA; Baker, KP			Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS ENTRY MEDIATOR; CELL-GROWTH; KAPPA-B; LIGAND; IDENTIFICATION; ACTIVATION; DOMAIN; BAFF	An expression cloning approach was employed to identify the receptor for B-lymphocyte stimulator (BLyS) and identified the tumor necrosis factor receptor superfamily member TACI as a BLyS-binding protein. Expression of TACI in HEK293T cells confers on the cells the ability to bind BLyS with subnanomolar affinity. Furthermore, a TACI-Fc fusion protein recognizes both the cleaved, soluble form of BLyS as well as the membrane BLyS present on the cell surface of a recombinant cell line. TACI mRNA is found predominantly in B-cells and correlates with BLyS binding in a panel of B-cell lines. We: also demonstrate that TACI interacts with nanomolar affinity with the BLyS-related tumor necrosis factor homologue APRIL for which no clear in vivo role has been described. BLyS and APRIL are capable of signaling through TACI to mediate NF-KB responses in HEK293 cells. We conclude that TACI is a receptor for BLS S and APRIL and discuss the implications for B-cell biology.	Human Genome Sci Inc, Dept Mol Biol, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Cell Biol, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Gene Discovery, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Prot Dev, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc	Baker, KP (corresponding author), Human Genome Sci Inc, Dept Mol Biol, Rockville, MD 20850 USA.	kevin_baker@hgsi.com						Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; KANAKARAJ P, 2000, IN PRESS CYTOKINE; Kelly K, 2000, CANCER RES, V60, P1021; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; PACHOLCZYK T, 1990, BIOTECHNIQUES, V9, P556; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Tribouley C, 1999, BIOL CHEM, V380, P1443, DOI 10.1515/BC.1999.186; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; WALLACH D, 1999, CYTOKINE NETWORK IMM, P51; Ware Carl F., 1998, P549; Ware CF, 2000, NATURE, V404, P949, DOI 10.1038/35010263; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889	31	196	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35478	35485		10.1074/jbc.M005224200	http://dx.doi.org/10.1074/jbc.M005224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956646	hybrid			2022-12-25	WOS:000165422800085
J	Dean, YD; McGreal, EP; Akatsu, H; Gasque, P				Dean, YD; McGreal, EP; Akatsu, H; Gasque, P			Molecular and cellular properties of the rat AA4 antigen, a C-type lectin-like receptor with structural homology to thrombomodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL-CELLS; APOPTOTIC BODIES; PHAGOCYTIC-CELLS; CDNA CLONING; YOLK-SAC; IN-VITRO; SURFACE; C1Q; EXPRESSION	The murine fetal stem cell marker AA4 has recently been cloned and is known to be the homolog of the human phagocytic Clq receptor involved in host defense. We herein report the molecular cloning and the cellular expression pattern of the rat AA4 antigen. Modular architecture analysis indicated that the rat AA4 is a member of C-type lectin-like family and, interestingly, displays similar domain composition and organization to thrombomodulin. Northern blot and reverse transcriptase-polymerase chain reaction analyses indicated that rat AA4 was encoded by a single transcript of 7 kilobases expressed constitutively in all tissues. In situ hybridization showed that AA4 was expressed predominantly by pneumocytes and vascular endothelial cells. Using an affinity purified polyclonal antibody raised against a rat AA4-Fc fusion protein, AA4 was identified as a glycosylated protein of 100 kDa expressed by endothelial cells > platelets > NK cells and monocytes (ED1+ cells). The staining was associated to the cell surface and intracytoplasmic vesicles. Conversely, erythrocytes, T and B lymphocytes, neutrophils, and macrophages (ED2+ cells) were consistently negative for AA4. As expected, the macrophage cell line NR8383 expressed weak levels of AA4. Taken together, our results support the idea that AA4/C1qRp is involved in some cell-cell interactions.	Univ Wales Coll Med, Brain Inflammat & Immun Grp, Dept Med Biochem, Heath Hosp, Cardiff CF14 4XN, S Glam, Wales; Choju Med Inst, Toyohashi, Aichi 4418124, Japan	Cardiff University	Gasque, P (corresponding author), Univ Wales Coll Med, Brain Inflammat & Immun Grp, Dept Med Biochem, Heath Hosp, Tenovus Bldg, Cardiff CF14 4XN, S Glam, Wales.							Akatsu H, 1997, MICROBIOL IMMUNOL, V41, P575, DOI 10.1111/j.1348-0421.1997.tb01894.x; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Conway EM, 1997, BLOOD, V89, P652, DOI 10.1182/blood.V89.2.652; Conway EM, 1999, BLOOD, V93, P3442, DOI 10.1182/blood.V93.10.3442.410k17_3442_3450; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; DITTMAN WA, 1990, BLOOD, V75, P329; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Eggleton P, 2000, CLIN EXP IMMUNOL, V120, P406, DOI 10.1046/j.1365-2249.2000.01218.x; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GUAN E, 1994, J IMMUNOL, V152, P4005; Hess KL, 1997, EXP CELL RES, V236, P404, DOI 10.1006/excr.1997.3745; Holmgren L, 1999, BLOOD, V93, P3956, DOI 10.1182/blood.V93.11.3956.411k05_3956_3963; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; JORDAN CT, 1995, EXP HEMATOL, V23, P1011; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Korb LC, 1997, J IMMUNOL, V158, P4525; Lafay M, 1998, THROMB HAEMOSTASIS, V79, P848, DOI 10.1055/s-0037-1615076; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Marcos MAR, 1997, J IMMUNOL, V158, P2627; Matsushita Y, 1998, CANCER LETT, V127, P195, DOI 10.1016/S0304-3835(98)00038-X; MCKEARN JP, 1984, J IMMUNOL, V132, P332; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Nepomuceno RR, 1998, J IMMUNOL, V160, P1929; Nepomuceno RR, 1999, J IMMUNOL, V162, P3583; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Norsworthy PJ, 1999, MAMM GENOME, V10, P789, DOI 10.1007/s003359901093; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Potocnik AJ, 1997, P NATL ACAD SCI USA, V94, P10295, DOI 10.1073/pnas.94.19.10295; Ray RJ, 1996, EUR J IMMUNOL, V26, P1504, DOI 10.1002/eji.1830260715; Singhrao SK, 1999, LAB INVEST, V79, P1247; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Tenner AJ, 1998, IMMUNOBIOLOGY, V199, P250, DOI 10.1016/S0171-2985(98)80031-4; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Zhang YM, 1998, J CLIN INVEST, V101, P1301, DOI 10.1172/JCI925	45	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34382	34392		10.1074/jbc.M006229200	http://dx.doi.org/10.1074/jbc.M006229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10934210	hybrid			2022-12-25	WOS:000165095300053
J	Foster, W; Helm, A; Turnbull, I; Gulati, H; Yang, BX; Verkman, AS; Skach, WR				Foster, W; Helm, A; Turnbull, I; Gulati, H; Yang, BX; Verkman, AS; Skach, WR			Identification of sequence determinants that direct different intracellular folding pathways for aquaporin-1 and aquaporin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSMEMBRANE CONDUCTANCE REGULATOR; STOP-TRANSFER SEQUENCE; CHIP28 WATER CHANNELS; HUMAN P-GLYCOPROTEIN; PROTEIN TRANSLOCATION; SIGNAL SEQUENCE; ER MEMBRANE; STRUCTURAL REQUIREMENTS; SECRETORY PROTEINS	Homologous aquaporin water channels utilize different folding pathways to acquire their transmembrane (TM) topology in the endoplasmic reticulum (ER), AQP4 acquires each of its six TM segments via cotranslational translocation events, whereas AQP1 is initially synthesized with four TM segments and subsequently converted into a six membrane-spanning topology, To identify sequence determinants responsible for these pathways, peptide segments from AQP1 and AQP4 were systematically exchanged, Chimeric proteins were then truncated, fused to a C-terminal translocation reporter, and topology was analyzed by protease accessibility. In each chimeric context, TM1 initiated ER targeting and translocation, However, AQP4-TM2 cotranslationally terminated translocation, while AQP1-TM2 failed to terminate translocation and passed into the ER lumen, This difference in stop transfer activity was due to two residues that altered both the length and hydrophobicity of TM2 (Asn(49) and Lys(51) in AQP1 versus Met(48) and Leu(50) in AQP4), A second peptide region was identified within the TM3-4 peptide loop that enabled AQP4-TM3 but not AQP1-TM3 to reinitiate translocation and cotranslationally span the membrane. Based on these findings, it was possible to convert AQP1 into a cotranslational biogenesis mode similar to that of AQP4 by substituting just two peptide regions at the N terminus of TM2 and the C terminus of TM3, Interestingly, each of these substitutions disrupted water channel activity. These data thus establish the structural basis for different AQP folding pathways and provide evidence that variations in cotranslational folding enable polytopic proteins to acquire and/or maintain primary sequence determinants necessary for function.	Oregon Hlth Sci Univ, Div Mol Med, Portland, OR 97201 USA; Univ Calif San Francisco, Cardiovasc Res Unit, San Francisco, CA 94143 USA	Oregon Health & Science University; University of California System; University of California San Francisco	Skach, WR (corresponding author), Oregon Hlth Sci Univ, Div Mol Med, 3181 SW San Jackson Pk Rd, Portland, OR 97201 USA.			Foster, William/0000-0002-5594-0791	NIDDK NIH HHS [DK51818] Funding Source: Medline; NIGMS NIH HHS [GM53457] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BROWN D, 1995, HISTOCHEM CELL BIOL, V104, P1, DOI 10.1007/BF01464780; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Frokiaer J, 1998, AM J MED SCI, V316, P291; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; HO NS, 1989, GENE, V77, P51; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Moss K, 1998, MOL BIOL CELL, V9, P2681, DOI 10.1091/mbc.9.9.2681; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SHI LB, 1994, J BIOL CHEM, V269, P10417; Skach WR, 1998, METHOD ENZYMOL, V292, P265; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Verbavatz JM, 1997, J CELL SCI, V110, P2855; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Verkman AS, 1998, AM J MED SCI, V316, P310, DOI 10.1097/00000441-199811000-00004; WALTER P, 1983, METHOD ENZYMOL, V96, P4; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; Zhang JT, 1998, MOL BIOL CELL, V9, P853, DOI 10.1091/mbc.9.4.853; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471; ZHANG R, 1991, AM J PHYSIOL, V260, P26	70	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34157	34165		10.1074/jbc.M000165200	http://dx.doi.org/10.1074/jbc.M000165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944517	hybrid			2022-12-25	WOS:000165095300024
J	Reunanen, N; Foschi, M; Han, JH; Kahari, VM				Reunanen, N; Foschi, M; Han, JH; Kahari, VM			Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA LEVELS; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH-FACTOR; GRANULATION-TISSUE; OKADAIC ACID; MAP-KINASES; CELLS; TRANSFORMATION	Treatment with the lipid second messenger, ceramide, activates extracellular signal-regulated kinase-1/2 (ERK1/2), c-Jun N-terminal kinase, and p38 in human skin fibroblasts and induces their collagenase-1 expression (Reunanen, N., Westermarck, J., Hakkinen, L., Holmstrom, T. H, Elo, T., Eriksson, J. E., and Kahari, V.-M. (1998) J. Biol. Chem. 213, 5137-5145). Here we show that C-2-ceramide inhibits expression of type I and III collagen mRNAs in dermal fibroblasts, suppresses pro alpha2(I) collagen promoter activity, and reduces stability of type I collagen mRNAs. The down-regulatory effect of C-2-ceramide on type I collagen mRNA levels was abrogated by protein kinase C inhibitors H7, staurosporine, and Re-31-8220 and potently inhibited by a combination of MEK1,2 inhibitor PD98059 and p38 inhibitor 8B203580. Activation of ERK1/2 by adenovirus-mediated expression of constitutively active MEK1 resulted in marked down-regulation of type I collagen mRNA levels and production in fibroblasts, whereas activation of p38 by constitutively active MAPK kinase-3b and MAPK kinase-6b slightly up-regulated type I collagen expression. These results identify the ERK1/2 signaling cascade as a potent negative regulatory pathway with respect to type I collagen expression in fibroblasts, suggesting that it mediates inhibition of collagen production in response to mitogenic stimulation and transformation.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Florence, Dept Med, I-50134 Florence, Italy; Scripps Res Inst, Dept Immunol, San Diego, CA 92121 USA	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Florence; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Han, J/G-4671-2010; Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; BOAST S, 1990, J BIOL CHEM, V265, P13351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gebken J, 1999, J BIOCHEM, V126, P676, DOI 10.1093/oxfordjournals.jbchem.a022502; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; HAMALAINEN L, 1985, J BIOL CHEM, V260, P720; Johansson N, 2000, J CELL SCI, V113, P227; KAHARI VM, 1984, BIOCHIM BIOPHYS ACTA, V781, P183, DOI 10.1016/0167-4781(84)90136-2; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LAATO M, 1987, BIOCHEM J, V247, P385, DOI 10.1042/bj2470385; Laine P, 2000, BIOCHEM J, V349, P19, DOI 10.1042/0264-6021:3490019; MAKELA JK, 1990, BIOCHIM BIOPHYS ACTA, V1049, P171, DOI 10.1016/0167-4781(90)90037-3; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OKA H, 1995, CANCER RES, V55, P4182; Palcy S, 1999, BIOCHEM J, V343, P21, DOI 10.1042/0264-6021:3430021; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; SANDBERG M, 1989, MATRIX, V9, P82, DOI 10.1016/S0934-8832(89)80025-3; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Simon C, 1998, CANCER RES, V58, P1135; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; WESTERMARCK J, 1995, BIOCHEM J, V308, P995, DOI 10.1042/bj3080995; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	40	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34634	34639		10.1074/jbc.C000175200	http://dx.doi.org/10.1074/jbc.C000175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926924	hybrid			2022-12-25	WOS:000165095300086
J	Bhatt, RR; Ferrell, JE				Bhatt, RR; Ferrell, JE			Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; MAP KINASE; MEIOTIC MATURATION; SIGNAL-TRANSDUCTION; PHORBOL ESTER; INHIBITORY KINASE; METAPHASE ARREST; ONCOGENE PRODUCT; DOCKING SITE	The 90-kDa ribosomal S6 kinases, the p90 Rsks, are a family of intracellular serine/threonine protein kinases distinguished by two distinct kinase domains. Rsks are activated downstream of the ERK1 (p44) and ERK2 (p42) mitogen-activated protein (MAP) kinases in diverse biological contexts, including progression through meiotic and mitotic M phases in Xenopus oocytes and cycling Xenopus egg extracts, and are critical for the M phase functions of Xenopus p42 MAPK, Here we report the cloning and biochemical characterization of Xenopus Rsk2. Xenopus Rsk1 and Rsk2 are specifically recognized by commercially available RSK1 and RSK2 antisera on immunoblots, but both Rsk1 and Rsk2 are immunoprecipitated by RSK1, RSK2, and RSK3 sera. Rsk2 is about 20-fold more abundant than the previously described Xenopus Rsk1 protein; their concentrations are approximately 120 and 5 nM, respectively. Rsk2, like Rsk1, forms a heteromeric complex with p42 MAP kinase. This interaction depends on sequences at the extreme C terminus of Rsk2 and can be disrupted by a synthetic peptide derived from the C-terminal 20 amino acids of Rsk2. Finally, we demonstrate that p42 MAP kinase can activate recombinant Rsk2 in vitro to a specific activity comparable to that found in Rsk2 that has been activated maximally in vivo, These findings underscore the importance of the Rsk2 isozyme in the M phase functions of p42 MAP kinase and provide tools for further examining Rsk2 function.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	ferrell@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16415, GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1991, METHOD ENZYMOL, V200, P252; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gotoh Y, 1995, Prog Cell Cycle Res, V1, P287; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOLLER DE, 1994, AM J PHYSL 1, V299, pC351; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murakami MS, 1998, DEVELOPMENT, V125, P237; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	73	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32983	32990		10.1074/jbc.M006386200	http://dx.doi.org/10.1074/jbc.M006386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934212	hybrid			2022-12-25	WOS:000090003800083
J	Hiller, O; Lichte, A; Oberpichler, A; Kocourek, A; Tschesche, H				Hiller, O; Lichte, A; Oberpichler, A; Kocourek, A; Tschesche, H			Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT CATALYTIC DOMAIN; AMINO-ACID-SEQUENCE; BETA-FACTOR-XIIA; BLOOD-COAGULATION; BREAST CARCINOMAS; MATRILYSIN MMP-7; ACTIVATION; GELATINASE; NEOVASCULARIZATION; STROMELYSIN-1	The effects of plasma proteins on controlling the activity of matrix metalloproteinases (MMPs, matrixins) have been the focus of numerous studies, although only a few have examined the influence of matrixins on plasma proteins. Recently, it has been shown that MMPs may play a role in the degradation of fibrin, We have now investigated the role of collagenase-a (MMP-8), macrophage elastase (MMP-12), collagenase-3 (MMP-13), and membrane type 1-matrix metalloproteinase (MT1-MMP, MMMP-14) in the degradation of fibrinogen and Factor XII of the plasma clotting system. Our data demonstrate that the catalytic domains of MMP-8, MMP-12, MMP-13, and MMP-14 can proteolytically process fibrinogen and, with the exception of MMP-8, also inactivate Factor XII (Hageman factor). We have identified the amino termini of the major protein fragments. Cleavage of fibrinogen occurred in all chains and resulted in significantly impaired clotting. Moreover, rapid proteolytic inactivation of Factor XII (Hageman factor) by MMP-18, MMP-13, and MMP-14 was noted. These results support the hypothesis of an impaired thrombolytic potential of MMP-degraded Factor MI in vivo. MMP-induced degradation of fibrinogen supports a plasmin-independent fibrinolysis mechanism. Consequently, degradation of these proteins may be important in inflammation, atherosclerosis, and angiogenesis, all of which are known to be influenced by MMP activity.	Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany	University of Bielefeld	Tschesche, H (corresponding author), Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany.	harald.tschesche@uni-bielefeld.de						BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Bini A, 1999, BIOCHEMISTRY-US, V38, P13928, DOI 10.1021/bi991096g; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COOL DE, 1985, J BIOL CHEM, V260, P3666; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DIEKMANN O, 1994, BRAZ J MED BIOL RES, V27, P1865; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; Henschen-Edman AH, 1999, HAEMOSTASIS, V29, P179; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; HERTFELDER HJ, 1994, EUR J CLIN CHEM CLIN, V32, P441; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Imai S, 1998, J BONE JOINT SURG BR, V80B, P701, DOI 10.1302/0301-620X.80B4.7952; JOCHUM M, 1984, ADV EXP MED BIOL, V167, P391; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; KLEINE T, 1993, BIOCHEMISTRY-US, V32, P14125, DOI 10.1021/bi00214a008; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MACHEIN U, 1997, CELLULAR PEPTIDASE I, P97; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MOORE WM, 1986, BIOCHEMISTRY-US, V25, P5189, DOI 10.1021/bi00366a031; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAGASE H, INHIBITORS METALLOPR; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; REINKE H, 1991, ADV LIF SCI, P55; SCHETTLER A, 1991, EUR J BIOCHEM, V197, P197, DOI 10.1111/j.1432-1033.1991.tb15899.x; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Willmroth F, 1998, IMMUNOBIOLOGY, V198, P375, DOI 10.1016/S0171-2985(98)80046-6; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	53	102	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33008	33013		10.1074/jbc.M001836200	http://dx.doi.org/10.1074/jbc.M001836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930399	hybrid			2022-12-25	WOS:000090003800086
J	Miller, MA; Malik, IA; Shenk, MA; Steele, RE				Miller, MA; Malik, IA; Shenk, MA; Steele, RE			The Src/Csk regulatory circuit arose early in metazoan evolution	ONCOGENE			English	Article						evolution; metazoan; Src; Csk; protein-tyrosine kinase; Cnidaria	PROTEIN-TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; YEAST; GENE; HYDRA; EXPRESSION; IDENTIFICATION; HOMOLOG; CSK; DNA	We have identified a gene encoding a member of the Csk family of non-receptor protein-tyrosine kinases (PTKs) in the early-diverging metazoan Hydra. In situ hybridization analysis of the distribution of RNA from the Hydra Csk gene indicates that it is expressed in most of the epithelial cells of the adult polyp and in gametogenic cells. Comparison of the expression pattern of Hydra Csk with that of STK, the Hydra Src gene orthologue, reveals that the two genes are largely co-expressed. Such co-expression is consistent with a role for Hydra Csk in regulation of STK activity. This possibility was tested directly by co-expressing Hydra Csk with STK in yeast. Co-expression suppressed the growth inhibition seen when STK alone is expressed in yeast. Suppression was dependent on the presence of the putative regulatory tyrosine in the carboxyl-terminal tail of STK. Phosphotyrosine immunoblot analysis confirmed that expression of Csk resulted in suppression of STK kinase activity. Taken together these data indicate that the regulatory circuit involving Src and Csk PTKs was established prior to the divergence of the phylum Cnidaria from the rest of the metazoans.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dev Biol Ctr, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Steele, RE (corresponding author), Univ Calif Irvine, Dept Biol Chem, 240D Med Sci I, Irvine, CA 92697 USA.			Miller, Michael/0000-0003-4872-7121				BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CHAN TA, 1994, ONCOGENE, V9, P1253; COOPER JA, 1987, ONCOGENE RES, V1, P297; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Grens A, 1995, DEVELOPMENT, V121, P4027; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LIU HP, 1992, GENETICS, V132, P665; Martinez DE, 1997, DEV BIOL, V192, P523, DOI 10.1006/dbio.1997.8715; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; OTTILIE S, 1992, ONCOGENE, V7, P1625; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; SIKORSKI RS, 1989, GENETICS, V122, P19; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; Steele RE, 1999, GENE, V239, P91, DOI 10.1016/S0378-1119(99)00373-X; Suga H, 1999, J MOL EVOL, V48, P646, DOI 10.1007/PL00006508; Swofford D., 1998, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	31	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3925	3930		10.1038/sj.onc.1203714	http://dx.doi.org/10.1038/sj.onc.1203714			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951585				2022-12-25	WOS:000088614300011
J	Berjanskii, MV; Riley, MI; Xie, AY; Semenchenko, V; Folk, WR; Van Doren, SR				Berjanskii, MV; Riley, MI; Xie, AY; Semenchenko, V; Folk, WR; Van Doren, SR			NMR structure of the N-terminal J domain of murine polyomavirus T antigens - Implications for DnaJ-like domains and for mutations of T antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE NMR; PROTEIN PHOSPHATASE 2A; ESCHERICHIA-COLI DNAJ; SIMIAN-VIRUS-40 LARGE-T; SV40 LARGE T; MIDDLE-T; SIDE-CHAIN; MOLECULAR CHAPERONES; COUPLING-CONSTANTS; CHEMICAL-SHIFTS	The NMR structure of the N-terminal, DnaJ-like domain of murine polyomavirus tumor antigens (PyJ) has been determined to high precision, with root mean square -deviations to the mean structure of 0.38 Angstrom for backbone atoms and 0.94 Angstrom for all heavy atoms of ordered residues 5-41 and 50-69, PyJ possesses a three-helix fold, in which anti-parallel helices II and III are bridged by helix I, similar to the four-helix fold of the J domains of DnaJ and human DnaJ-1. PyJ differs significantly in the lengths of N terminus, helix I, and helix III. The universally conserved HPD motif appears to form a His-Pro C-cap of helix II. Helix I features a stabilizing Schellman C-cap that is probably conserved universally among J domains. On the helix II surface where positive charges of other J domains have been implicated in binding of hsp70s, PyJ contains glutamine residues. Nonetheless, chimeras that replace the J domain of DnaJ with PyJ function like wild-type DnaJ in promoting growth of Escherichia coli. This activity can be modulated by mutations of at least one of these glutamines. T antigen mutations reported to impair cellular transformation by the virus, presumably via interactions with PP2A, cluster in the hydrophobic folding core and at the extreme N terminus, remote from the HPD loop.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Van Doren, SR (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.		Berjanskii, Mark/AAA-1352-2022	Van Doren, Steven/0000-0003-2838-4598; Folk, William/0000-0003-2216-3233	NATIONAL CANCER INSTITUTE [R01CA038538] Funding Source: NIH RePORTER; NCI NIH HHS [CA38538] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; Apeler H, 1997, EUR J BIOCHEM, V247, P890, DOI 10.1111/j.1432-1033.1997.t01-1-00890.x; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Auger I, 1997, J CLIN INVEST, V99, P1818, DOI 10.1172/JCI119348; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOUCHER W, 1992, J AM CHEM SOC, V114, P2262, DOI 10.1021/ja00032a053; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CLOWES RT, 1993, J BIOMOL NMR, V3, P349, DOI 10.1007/BF00212520; CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DOTSCH V, 1995, J MAGN RESON SER B, V108, P285, DOI 10.1006/jmrb.1995.1135; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Fletcher CM, 1996, J BIOMOL NMR, V8, P292, DOI 10.1007/BF00410328; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; GRONENBORN AM, 1994, J BIOMOL NMR, V4, P455; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Huang K, 1999, PROTEIN SCI, V8, P203; Ivanov IG, 1997, INT J BIOCHEM CELL B, V29, P659, DOI 10.1016/S1357-2725(96)00161-6; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lemieux B, 2000, VIROLOGY, V269, P370, DOI 10.1006/viro.2000.0231; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; MADSEN JC, 1993, J BIOMOL NMR, V3, P239; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MONTELIONE GT, 1989, J AM CHEM SOC, V111, P5474, DOI 10.1021/ja00196a068; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLEJNICZAK ET, 1992, J MAGN RESON, V100, P444, DOI 10.1016/0022-2364(92)90280-K; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEDEN KWC, 1992, VIRUS GENES, V6, P107, DOI 10.1007/BF01703060; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Porras A, 1996, J VIROL, V70, P6902; Prieto J, 1997, J MOL BIOL, V274, P276, DOI 10.1006/jmbi.1997.1322; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; Schuchner S, 1999, J VIROL, V73, P9266; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P79; Sheng Q, 2000, J VIROL, V74, P5280, DOI 10.1128/JVI.74.11.5280-5290.2000; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; VANDOREN SR, 1994, J MAGN RESON SER B, V104, P193, DOI 10.1006/jmrb.1994.1076; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xia XH, 1998, GENETICS, V149, P37; ZAVILDE J, 1998, MOL CELL BIOL, V18, P1408	73	31	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36094	36103		10.1074/jbc.M006572200	http://dx.doi.org/10.1074/jbc.M006572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10950962	hybrid			2022-12-25	WOS:000165382000065
J	Lee, KB; Ptasienski, JA; Bunemann, M; Hosey, MM				Lee, KB; Ptasienski, JA; Bunemann, M; Hosey, MM			Acidic amino acids flanking phosphorylation sites in the M-2 muscarinic receptor regulate receptor phosphorylation, internalization, and interaction with arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADRENERGIC-RECEPTOR; VISUAL ARRESTIN; BETA-ARRESTIN; ACETYLCHOLINE-RECEPTOR; CHOLINERGIC RECEPTORS; KINASE ACTIVATION; RHODOPSIN KINASE; CHICK HEART; DESENSITIZATION	The studies reported here address the molecular events underlying the interactions of arrestins with the M-2 muscarinic acetylcholine receptor (mAChR), In particular, we focused on the role of receptor phosphorylation in this process. Agonist-dependent phosphorylation of the M-2 mAChR can occur at clusters of serines and threonines at positions 286-290 (site pi) or 307-311 (site P2) in the third intracellular loop (Pals-Rylaarsdam, R,, and Hosey, M, M. (1997) J, Biol, Chem, 272, 14152-14158). Phosphorylation at either P1 or P2 can support agonist-dependent internalization. However, phosphorylation at P2 is required for receptor interaction with arrestins (Pals-Rylaarsdam, R,, Gurevich, V, V,, Lee, K. B,, Ptasienski, J, A., Benovic, J, L,, and Hosey, M, M, (1997) J, Biol, Chem. 272, 23682-26389), The present study investigated the role of acidic amino acids between P1 and P2 in regulating receptor phosphorylation, internalization, and receptor/arrestin interactions. Mutation of the acidic amino acids at positions 298-300 (site Al) and/or 304-305 (site A2) to alanines had significant effects on agonist-dependent phosphorylation, P2 was identified as the preferred site of agonist-dependent phosphorylation, and full phosphorylation at P2 required the acidic amino acids at Al or their neutral counterparts. In contrast, phosphorylation at site P1 was dependent on site A2, In addition, sites Al and A2 significantly affected the ability of the wild type and P1 and P2 mutant receptors to internalization and to interact with arrestina. Substitution of asparagine and glutamine for the aspartates and glutamates at sites Al or A2 did not influence receptor phosphorylation but did influence arrestin interaction with the receptor. We propose that the amino acids at sites Al and A2 play important roles in agonist-dependent phosphorylation at sites P2 and Fl, respectively, and also play an important role in arrestin interactions with the M-2 mAChR.	Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Inst Neurosci, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Lee, KB (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Hogan Hall 2-100,2153 N Sheridan Rd, Evanston, IL 60208 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; CRAFT CM, 1995, FEBS LETT, V362, P247, DOI 10.1016/0014-5793(95)00213-S; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUHN H, 1982, METHOD ENZYMOL, V81, P489; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang LR, 1997, J BIOL CHEM, V272, P14762, DOI 10.1074/jbc.272.23.14762	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35767	35777		10.1074/jbc.M002225200	http://dx.doi.org/10.1074/jbc.M002225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10952973	hybrid			2022-12-25	WOS:000165382000020
J	Qiu, L; Joazeiro, C; Fang, N; Wang, HY; Elly, C; Altman, Y; Fang, DY; Hunter, T; Liu, YC				Qiu, L; Joazeiro, C; Fang, N; Wang, HY; Elly, C; Altman, Y; Fang, DY; Hunter, T; Liu, YC			Recognition and ubiquitination of notch by Itch, a hect-type E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; PROTEIN LIGASE; DOMAIN; DEGRADATION; EXPRESSION; REGULATOR; LOCUS; CELLS; MICE; CBL	Genetic studies identified Itch, which is a homologous to the EG-associated protein carboxyl terminus (Hect) domain-containing E3 ubiquitin-protein ligase that is disrupted in non-agouti lethal mice or Itchy mice. Itch-deficiency results in abnormal immune responses and constant itching in the skin. Here, Itch was shown to associate with Notch, a protein involved in cell fate decision in many mammalian cell types, including cells in the immune System. Itch binds to the N-terminal portion of the Notch intracellular domain via its WW domains and promotes ubiquitination of Notch through its Hect ubiquitin ligase domain. Thus, Itch may participate in the-regulation of immune responses by modifying Notch-mediated signaling.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Salk Inst, La Jolla, CA 92037 USA	La Jolla Institute for Immunology; Salk Institute	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA.		Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NIDDK NIH HHS [DK56558] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cornell M, 1999, GENETICS, V152, P567; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; Haas AL, 1997, FASEB J, V11, P1257; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUSTAD CM, 1995, GENETICS, V140, P255; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9	25	253	259	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35734	35737		10.1074/jbc.M007300200	http://dx.doi.org/10.1074/jbc.M007300200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940313	hybrid			2022-12-25	WOS:000165382000015
J	Guschin, D; Geiman, TM; Kikyo, N; Tremethick, DJ; Wolffe, AP; Wade, PA				Guschin, D; Geiman, TM; Kikyo, N; Tremethick, DJ; Wolffe, AP; Wade, PA			Multiple ISWI ATPase complexes from Xenopus laevis - Functional conservation of an ACF/CHRAC homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING FACTORS; MAJOR DEVELOPMENTAL TRANSITION; GENE-EXPRESSION; DNA-REPAIR; IN-VITRO; SWI-SNF; TRANSCRIPTION; NUCLEOSOME; FAMILY; TOPOISOMERASE	The nucleosomal ATPase ISWI is the catalytic subunit of several protein complexes that either organize or perturb chromatin structure in vitro. This work reports the cloning and biochemical characterization of a Xenopus ISWI homolog. Surprisingly, whereas we find four complex forms of ISWI in egg extracts, we find no functional homolog of NURF. One of these complexes, xACF, consists of ISWI, Acf1, and a previously uncharacterized protein of 175 kDa. Like both ACF and CHRAC, this complex organizes randomly deposited histones into a regularly spaced array. The remaining three forms include two novel ISWI complexes distinct from known ISWI complexes plus a histone-dependent ATPase complex. This comprehensive biochemical characterization of ISWI underscores the evolutionary conservation of the ACF/CHRAC family.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Australian National University; John Curtin School of Medical Research	Wade, PA (corresponding author), Emory Univ, Dept Pathol, Woodruff Mem Res Bldg,Rm 7105-B,1639 Pierce Dr, Atlanta, GA 30322 USA.	pwade@emory.edu	Guschin, Dmitry/O-7594-2018; Wade, Paul A/D-2374-2019; Guschin, Dmitry/U-3731-2019	Guschin, Dmitry/0000-0002-4184-0001; Wade, Paul A/0000-0002-6042-357X; Guschin, Dmitry/0000-0002-4184-0001; Tremethick, David/0000-0001-5274-8078				Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BURNS LG, 1997, BIOCHIM BIOPHYS ACTA, V1330, P159; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Gelius B, 1999, EUR J BIOCHEM, V262, P426, DOI 10.1046/j.1432-1327.1999.00379.x; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; Guschin D, 1999, CURR BIOL, V9, pR742, DOI 10.1016/S0960-9822(99)80473-4; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Henikoff S, 1997, CURR OPIN CELL BIOL, V9, P388, DOI 10.1016/S0955-0674(97)80012-9; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; LUKE M, 1989, DEV BIOL, V136, P459, DOI 10.1016/0012-1606(89)90271-6; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Moggs JG, 1999, BIOCHIMIE, V81, P45, DOI 10.1016/S0300-9084(99)80037-6; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Schlissel MS, 2000, SCIENCE, V287, P438, DOI 10.1126/science.287.5452.438; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Trachtulcova P, 2000, YEAST, V16, P35, DOI 10.1002/(SICI)1097-0061(20000115)16:1<35::AID-YEA504>3.0.CO;2-0; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	61	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35248	35255		10.1074/jbc.M006041200	http://dx.doi.org/10.1074/jbc.M006041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10942776	hybrid			2022-12-25	WOS:000165422800057
J	Jansen, MS; Cook, GA; Song, S; Park, EA				Jansen, MS; Cook, GA; Song, S; Park, EA			Thyroid hormone regulates carnitine palmitoyltransferase I alpha gene expression through elements in the promoter and first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA ABUNDANCE; BROWN ADIPOSE-TISSUE; RESPONSE ELEMENT; CPT-I; CHROMOSOMAL LOCALIZATION; BINDING PROTEIN; RECEPTOR GENE; FATTY-ACIDS; MALONYL-COA; RAT	Carnitine palmitoyltransferase I (CPT-I) catalyzes the transfer of long chain fatty acyl groups from CoA to carnitine for translocation across the mitochondrial inner membrane. CPT-I alpha is a key regulatory enzyme in the oxidation of fatty acids in the liver, CPT-I alpha is expressed in all tissues except skeletal muscle and adipose tissue, which express CPT-I beta. Expression of CPT-I alpha mRNA and enzyme activity are elevated in the liver in hyperthyroidism, fasting, and diabetes. CPT-I alpha mRNA abundance is increased 40-fold in the liver of hyperthyroid compared with hypothyroid rats, Here, we examine the mechanisms by which thyroid hormone (T3) stimulates CPT-I alpha gene expression. Four potential T3 response elements (TRE), which contain direct repeats separated by four nucleotides, are located 3000-4000 base pairs 5' to the start site of transcription in the CPT-I alpha gene. However, only one of these elements functions as a TRE. This TRE binds the T3 receptor as well as other nuclear proteins. Surprisingly, the first intron of the CPT-I alpha gene is required for the T3 induction of CPT-I alpha expression, but this region of the gene does not contain a TRE. In addition, we show that CPT-I alpha is induced by T3 in cell lines of hepatic origin but not in nonhepatic cell lines.	Univ Tennessee, Sch Med, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Park, EA (corresponding author), Univ Tennessee, Sch Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu						Bahouth SW, 1997, J MOL CELL CARDIOL, V29, P3223, DOI 10.1006/jmcc.1997.0549; BAHOUTH SW, 1991, J BIOL CHEM, V266, P15863; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; de Arrieta CM, 1999, ENDOCRINOLOGY, V140, P335, DOI 10.1210/en.140.1.335; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; Gaunitz F, 1997, BIOL CHEM, V378, P11, DOI 10.1515/bchm.1997.378.1.11; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEIMBERG M, 1985, ENDOCR REV, V6, P590, DOI 10.1210/edrv-6-4-590; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KATZ RW, 1993, J BIOL CHEM, V268, P19392; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; Madden TJ, 1997, NUCLEIC ACIDS RES, V25, P3930, DOI 10.1093/nar/25.19.3930; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MYNATT RL, 1994, BIOCHEM BIOPH RES CO, V201, P932, DOI 10.1006/bbrc.1994.1791; Olson DP, 1997, J BIOL CHEM, V272, P9907; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; Park EA, 1998, BIOCHEM J, V330, P217; PARK EA, 1993, J BIOL CHEM, V268, P613; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; Shuler FD, 1998, DNA CELL BIOL, V17, P689, DOI 10.1089/dna.1998.17.689; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	44	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34989	34997		10.1074/jbc.M001752200	http://dx.doi.org/10.1074/jbc.M001752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956641	hybrid			2022-12-25	WOS:000165422800024
J	Lee, KJ; Huang, JR; Takeda, Y; Dynan, WS				Lee, KJ; Huang, JR; Takeda, Y; Dynan, WS			DNA ligase IV and XRCC4 form a stable mixed tetramer that functions synergistically with other repair factors in a cell-free end-joining system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; KU; COMPLEX; MICE; REQUIREMENT; EXTRACTS	Repair of DNA double-strand breaks in mammalian cells occurs via a direct nonhomologous end-joining pathway. Although this pathway can be studied in vivo and in crude cell-free systems, a deeper understanding of the mechanism requires reconstitution with purified enzymes. We have expressed and purified a complex of two proteins that are critical for double-strand break repair, DNA ligase IV (DNL IV) and XRCC4. The complex is homogeneous, with a molecular mass of about 300,000 Da, suggestive of a mixed tetramer containing two copies of each polypeptide. The presence of multiple copies of DNL TV was confirmed in an experiment where different epitope-tagged forms of DNL TV were recovered simultaneously in the same complex. Cross-linking suggests that an XRCC4 XRCC4 dimer interface forms the core of the tetramer, and that the DNL TV polypeptides are in contact with XRCC4 but not with one another. Purified DNL IV.XRCC4 complex functioned synergistically with Ku protein, the DNA-dependent protein kinase catalytic subunit, and other repair factors in a cell-free end-joining assay. We suggest that a dyad-symmetric DNL IV.XRCC4 tetramer bridges the two ends of the broken DNA and catalyzes the coordinate ligation of the two DNA strands.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Rm CB-2803,1120 15th St, Augusta, GA 30912 USA.	wdynan@mail.mcg.edu		Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35886] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailin T, 1999, MOL CELL BIOL, V19, P4664; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; CHRAMBACH A, 1971, SCIENCE, V172, P440, DOI 10.1126/science.172.3982.440; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; GANGULY T, 1995, INT J RADIAT BIOL, V68, P447, DOI 10.1080/09553009514551411; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Koh SS, 1997, BIOTECHNIQUES, V23, P622, DOI 10.2144/97234bm14; Labhart P, 1999, MOL CELL BIOL, V19, P2585; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PANG D, 1997, CANCER RES, V57, P112; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Takeda Y, 1999, J IMMUNOL, V163, P6269; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034	63	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34787	34796		10.1074/jbc.M004011200	http://dx.doi.org/10.1074/jbc.M004011200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945980	hybrid			2022-12-25	WOS:000165095300105
J	Eberhardy, SR; D'Cunha, CA; Farnham, PJ				Eberhardy, SR; D'Cunha, CA; Farnham, PJ			Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; C-MYC; TRANSGENIC MICE; CELL-CYCLE; ORNITHINE DECARBOXYLASE; DEACETYLASE INHIBITOR; GROWTH-REGULATION; BINDING PROTEIN; TRANSCRIPTION; EXPRESSION	Overexpression of c-Myc can lead to altered transcriptional regulation of cellular genes and to neoplastic transformation. Although DNA binding is clearly required, the mechanism by which recruitment of c-Myc to target promoters results in transcriptional activation is highly debated. Much of this controversy comes from the difficulty in clearly defining a true Myc target gene. We have previously determined that cad is a bona fide Myc target gene and thus now use the cad promoter as a model to study Myc function. Others have shown that Myc can interact indirectly with histone acetylases and have suggested that Myc mediates transcriptional activation by causing an increase in the levels of acetylated histones on target promoters. To directly test this model, we employed a chromatin immunoprecipitation assay to examine the levels of acetylated histones on the cad promoter. Although Myc was bound to the cad promoter in S phase but not in G(0) phase, we found high levels of acetylated histones on the promoter in both stages. We also examined acetylated histones on the cad promoter before and after differentiation of U937 cells. Although the levels of c-Myc bound to the cad promoter were greatly reduced after differentiation, we saw high levels of acetylated histones on the cad promoter both before and after differentiation. Finally, we found that a 30-fold change in binding of N-Myc to the telomerase promoter did not result in a concomitant change in histone acetylation. Thus, recruitment of a Myc family member to a target promoter does not necessarily influence the amount of acetylated histones at that promoter. Further investigations are in progress to define the role of Myc in transcriptional activation.	Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA45240, CA09135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045240, R01CA045240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KACZMAREK L, 1987, J CELL PHYSIOL, V132, P545, DOI 10.1002/jcp.1041320318; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; SANDGREN EP, 1989, ONCOGENE, V4, P715; Shetty S, 1999, BIOCHEM J, V339, P751, DOI 10.1042/0264-6021:3390751; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takahashi Y, 2000, GENE DEV, V14, P804; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5	47	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33798	33805		10.1074/jbc.M005154200	http://dx.doi.org/10.1074/jbc.M005154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931841	hybrid			2022-12-25	WOS:000090104600086
J	Commins, SP; Watson, PM; Levin, N; Beiler, RJ; Gettys, TW				Commins, SP; Watson, PM; Levin, N; Beiler, RJ; Gettys, TW			Central leptin regulates the UCP1 and ob genes in brown and white adipose tissue via different beta-adrenoceptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(3)-ADRENERGIC RECEPTOR GENE; SYMPATHETIC NERVOUS-SYSTEM; MESSENGER-RNA LEVELS; ADRENERGIC-RECEPTOR; UNCOUPLING PROTEIN; BETA-3-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; C57BL/6 MICE; OB/OB MICE; OBESE GENE	The three known subtypes of beta -adrenoreceptors (beta (1)-AR, beta (2)-AR, and beta (3)-AR) are differentially expressed in brown and white adipose tissue and mediate peripheral responses to central modulation of sympathetic outflow by leptin, To assess the relative roles of the P-AR subtypes in mediating leptin's effects on adipocyte gene expression, mice with a targeted disruption of the beta (3)-adrenoreceptor gene (beta (3)-AR KO) were treated with vehicle or the beta (1)/beta (2)-AR selective antagonist, propranolol (20 mug/g body weight/day) prior to intracerebroventricular (ICV) injections of leptin (0.1 mug/g body weight/day). Leptin produced a 3-fold increase in UCP1 mRNA in brown adipose tissue of wild type (FVB/NJ) and beta (3)-AR KO mice. The response was unaltered by propranolol in wild type mice, but was completely blocked by this antagonist in beta (3)-AR KO mice. In contrast, ICV leptin had no effect on leptin mRNA in either epididymal or retroperitoneal white adipose tissue (WAT) from beta (3)-AR KOs, Moreover, propranolol did not block the ability of exogenous leptin to reduce leptin mRNA in either WAT depot site of wild type mice. These results demonstrate that the beta (3)-AR is required for leptin-mediated regulation of ob mRNA expression in WAT, but is interchangeable with the beta (1)/beta (2)-ARs in mediating leptin's effect on UCP1 mRNA expression in brown adipose tissue.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Medical University of South Carolina; Medical University of South Carolina; Amgen	Gettys, TW (corresponding author), Med Univ S Carolina, Dept Med, 916-G Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA.		Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995	NIDDK NIH HHS [DK 53981] Funding Source: Medline; NIGMS NIH HHS [GM08716] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053981] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atgie C, 1997, AM J PHYSIOL-CELL PH, V273, pC1136, DOI 10.1152/ajpcell.1997.273.4.C1136; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chaudhry A, 1999, AM J PHYSIOL-REG I, V277, pR147, DOI 10.1152/ajpregu.1999.277.1.R147; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; Commins SP, 1999, ENDOCRINOLOGY, V140, P4772, DOI 10.1210/en.140.10.4772; Deng CJ, 1997, ENDOCRINOLOGY, V138, P548, DOI 10.1210/en.138.2.548; DOOLEY DJ, 1986, EUR J PHARMACOL, V130, P137, DOI 10.1016/0014-2999(86)90193-7; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Evans BA, 1999, FEBS LETT, V444, P149, DOI 10.1016/S0014-5793(99)00049-6; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; Galitzky J, 1997, BRIT J PHARMACOL, V122, P1244, DOI 10.1038/sj.bjp.0701523; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; Gettys TW, 1997, ENDOCRINOLOGY, V138, P2697, DOI 10.1210/en.138.7.2697; Gettys TW, 1996, ENDOCRINOLOGY, V137, P4054, DOI 10.1210/en.137.9.4054; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; GRANNEMAN JG, 1995, CELL SIGNAL, V7, P9, DOI 10.1016/0898-6568(94)00066-K; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hwa JJ, 1997, AM J PHYSIOL-REG I, V272, pR1204, DOI 10.1152/ajpregu.1997.272.4.R1204; Hwa JJ, 1996, HORM METAB RES, V28, P659, DOI 10.1055/s-2007-979873; Konkar AA, 2000, MOL PHARMACOL, V57, P252; Kutoh E, 1997, LIFE SCI, V62, P445, DOI 10.1016/S0024-3205(97)01138-7; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Lollmann B, 1997, BIOCHEM BIOPH RES CO, V238, P648, DOI 10.1006/bbrc.1997.7205; Mizuno A, 1998, ENDOCRINOLOGY, V139, P3863, DOI 10.1210/en.139.9.3863; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; Niijima A, 1999, NEUROSCI LETT, V262, P125, DOI 10.1016/S0304-3940(99)00054-3; Nisoli E, 1996, MOL PHARMACOL, V49, P7; Pelleymounter MA, 2000, J PHARMACOL EXP THER, V293, P799; Preitner F, 1998, BRIT J PHARMACOL, V124, P1684, DOI 10.1038/sj.bjp.0702007; Revelli JP, 1997, J CLIN INVEST, V100, P1098, DOI 10.1172/JCI119620; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Sarmiento U, 1997, LAB INVEST, V77, P243; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; ZHAO J, 1994, AM J PHYSIOL-CELL PH, V267, pC969, DOI 10.1152/ajpcell.1994.267.4.C969; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002; Zhao J, 1997, J BIOL CHEM, V272, P32847, DOI 10.1074/jbc.272.52.32847	55	89	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33059	33067		10.1074/jbc.M006328200	http://dx.doi.org/10.1074/jbc.M006328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938091	hybrid			2022-12-25	WOS:000090003800093
J	Tang, HL; Wong-Staal, F				Tang, HL; Wong-Staal, F			Specific interaction between RNA helicase A and Tap, two cellular proteins that bind to the constitutive transport element of type D retrovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; MESSENGER-RNA; CYTOPLASMIC FIBRILS; CRM1; CTE; IDENTIFICATION; RAT8P/DBP5P; SPLICEOSOME; INHIBITION; SEQUENCES	Constitutive transport element (CTE) facilitates retroviral RNA export by interacting with the cellular RNA export machinery. Two cellular proteins, RNA helicase A (RHA) and Tip-associated protein (Tap) were identified as binding to CTE and were proposed to function as CTE co-factors (1, a), Here, we report that these two CTE-binding proteins interact with each other in vitro and in vivo. The in vitro binding of RHA to Tap is direct and independent of either CTE or the nuclear transport domain of RHA. The removal of the first 60 amino acids of Tap significantly diminishes the binding to RHA. The activity of this Tap mutant to enhance CTE-mediated gene expression is also markedly reduced. A transdominant mutant of Tap inhibited RHA-mediated up-regulation of CTE function in mammalian cells. The nuclear transport domain of RHA also interfered with Tap-mediated transactivation of the CTE function in quail cells, in which the function of CTE is dependent on the expression of a functional human Tap cDNA.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	fwongstaal@ucsd.edu	Tang, Hengli/F-2085-2014		NIGMS NIH HHS [GM56089] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bear J, 1999, MOL CELL BIOL, V19, P6306; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CULLEN BR, 1983, P NATL ACAD SCI-BIOL, V80, P2946, DOI 10.1073/pnas.80.10.2946; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, P NATL ACAD SCI USA, V94, P14394, DOI 10.1073/pnas.94.26.14394; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhang SS, 1999, J CELL SCI, V112, P1055; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	39	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32694	32700		10.1074/jbc.M003933200	http://dx.doi.org/10.1074/jbc.M003933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924507	hybrid			2022-12-25	WOS:000090003800045
J	Edwards, JC; Kapadia, S				Edwards, JC; Kapadia, S			Regulation of the bovine kidney microsomal chloride channel p64 by p59(fyn), a Src family tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SH3 DOMAINS; SUBCELLULAR-DISTRIBUTION; PROTEIN; EXPRESSION; ACTIVATION; BINDING; CELLS; PURIFICATION; ASSOCIATION	p64 is a chloride channel of intracellular membranes which is present in regulated secretory vesicles. Mechanisms by which the p64 channel could be regulated are largely unknown. p59(fyn) is a non-receptor tyrosine kinase of the Src family that has been implicated in a variety of intracellular signaling events. The N-terminal portion of p64 has several potential binding sites for Src family SH2 domains. In this paper, we demonstrate that p64 becomes tyrosine phosphorylated when co-expressed with p59(fyn) in HeLa cells. We show that co-expression of p64 with p59(fyn) renders p64 a ligand for the SH2 domain of p59(fyn) and this SH2 binding is eliminated by treating p64 with alkaline phosphatase. Using site-directed mutagenesis, we find that tyrosine 33 in the p64 sequence is necessary for SH2 binding. We also characterized p64-p59(fyn) interactions using native material from bovine kidney. We found that a small fraction of native kidney p64 can bind Fyn SH2 in vitro. Immunoprecipitation of p64 from solubilized kidney membranes yields a kinase activity with the same mobility by SDS-polyacrylamide gel electrophoresis as authentic bovine p59(fyn), Finally, we demonstrate that co-expression of p64 and p59(fyn) in HeLa cells results in enhanced p64-associated chloride channel activity.	St Louis Vet Affairs Med Ctr, Renal Div 657 111JC, St Louis, MO 63106 USA; St Louis Univ, Dept Med, Div Renal, St Louis, MO 63106 USA	Saint Louis University	Edwards, JC (corresponding author), St Louis Vet Affairs Med Ctr, Renal Div 657 111JC, 915 N Grand Ave, St Louis, MO 63106 USA.	John.Edwards3@med.va.gov			NIAMS NIH HHS [AR44838] Funding Source: Medline; NIDDK NIH HHS [DK46212] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046212] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARMITAGE P, 1971, STATISTICAL METHODS, P189; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Staub O, 1997, CURR OPIN NEPHROL HY, V6, P447, DOI 10.1097/00041552-199709000-00007; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31826	31832		10.1074/jbc.M005275200	http://dx.doi.org/10.1074/jbc.M005275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930415	hybrid			2022-12-25	WOS:000089858900041
J	Erdmann, KS; Kuhlmann, J; Lessmann, V; Herrmann, L; Eulenburg, V; Muller, O; Heumann, R				Erdmann, KS; Kuhlmann, J; Lessmann, V; Herrmann, L; Eulenburg, V; Muller, O; Heumann, R			The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain	ONCOGENE			English	Article						tumor suppressor; PDZ; protein tyrosine phosphatase	TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; BETA-CATENIN; GENE-PRODUCT; FUNCTIONAL INTERACTION; GUANYLATE KINASES; MOLECULAR-CLONING; CELL-MIGRATION; IN-VITRO; PHOSPHORYLATION	Mutations of the tumor suppressor protein APC (Adenomatous Polyposis Coli) are linked to familiar and sporadic human colon cancer. Here we describe a novel interaction between the APC protein and the protein tyrosine phosphatase PTP-BL carrying five PDZ protein-protein interaction domains. Exclusively, the second PDZ domain (PDZ2) of PTP-BL is binding to the extreme C-terminus of the APC protein, as determined by yeast two-hybrid studies. Using surface plasmon resonance analysis we established a dissociation constant (K-D) of 8.1 x 10(-9) M. We find that a naturally occurring splice insertion of five amino acids (PDZ2b) abolishes its binding affinity to the APC protein. The in vivo interaction between PTP-BL and the APC protein was shown by coprecipitation experiments in transfected COS cells. Furthermore, in cultured epithelial Madine Carnine Kidney cells the subcellular colocalization was demonstrated for the nucleus and also for the tips of cellular extensions, The interaction of the APC protein with a protein tyrosine phosphatase may indirectly modulate the steady state levels of tyrosine phosphorylations of associated proteins, such as beta-catenin playing a major role in the regulation of cell division, migration and cell adhesion.	Ruhr Univ Bochum, Dept Mol Neurobiochem, D-44780 Bochum, Germany; Max Planck Inst Mol Physiol, Arbeitsgrp Biophys Analyt, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Arbeitsgrp Tumorgenet, D-44227 Dortmund, Germany	Ruhr University Bochum; Max Planck Society; Max Planck Society	Erdmann, KS (corresponding author), Ruhr Univ Bochum, Dept Mol Neurobiochem, D-44780 Bochum, Germany.		Leßmann, Volkmar/E-8125-2013; Heumann, Rolf/ABB-9675-2021; Eulenburg, Volker/B-7263-2013; Heumann, Rolf/AAK-4390-2020; Eulenburg, Volker/B-7263-2013	Leßmann, Volkmar/0000-0002-6863-323X; Heumann, Rolf/0000-0003-4364-2655; Eulenburg, Volker/0000-0002-4878-5746; Eulenburg, Volker/0000-0001-6314-566X				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cuppen E, 1999, FEBS LETT, V459, P291, DOI 10.1016/S0014-5793(99)01191-6; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Goold RG, 1999, J CELL SCI, V112, P3373; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Midgley CA, 1997, J PATHOL, V181, P426; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Niethammer M, 1996, J NEUROSCI, V16, P2157; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Tseng HC, 1999, P NATL ACAD SCI USA, V96, P9503, DOI 10.1073/pnas.96.17.9503	57	74	74	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3894	3901		10.1038/sj.onc.1203725	http://dx.doi.org/10.1038/sj.onc.1203725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951583	Green Submitted			2022-12-25	WOS:000088614300008
J	Saavedra, HI; Knauf, JA; Shirokawa, JM; Wang, JW; Bin, OY; Elisei, R; Stambrook, PJ; Fagin, JA				Saavedra, HI; Knauf, JA; Shirokawa, JM; Wang, JW; Bin, OY; Elisei, R; Stambrook, PJ; Fagin, JA			The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway	ONCOGENE			English	Article						genomic instability; Ras; thyroid cancer; MAP kinase	SPINDLE ASSEMBLY CHECKPOINT; THYROTROPIN RECEPTOR GENE; TOPOISOMERASE II-ALPHA; XENOPUS EGG EXTRACTS; NIH 3T3 CELLS; PROTEIN-KINASE; PAPILLARY CARCINOMAS; CANCER-CELLS; METASTATIC ABILITY; MAMMALIAN-CELLS	Activating mutations of RAS are thought to be early events in the evolution of thyroid follicular neoplasms, We used a doxycycline-inducible expression system to explore the acute effects of H-RAS(V12) on genomic stability in thyroid PCCL3 cells, At 2-3 days (first or second cell cycle) there was a significant increase in the frequency of micronucleation, Treatment of cells with YVAD-CHO inhibited RAS-induced apoptosis, but had no effect on micronucleation, The effects of H-RAS(V12) were mediated by activation of MAPK, as treatment with PD98059 at concentrations verified to selectively inhibit MEK1 reduced the frequency of prevalence of cells with micronuclei. In addition, doxycycline-inducible expression of a constitutively active MEK1, but not of a mutant RAC1, mimicked the effects of H-RAS(V12). The effects of H-RAS(V12) on genome destabilization were apparent even though the sequence of p53 in PCCL3 cells was confirmed to be wild-type. Acute activation of H-RAS(V12) evoked a proportional increase in both CREST negative and CREST positive micronuclei, indicating that both clastogenic and aneugenic effects were involved. H-RAS(V12) and activated MEK1 also induced centrosome amplification, and chromosome misalignment, Evidence that acute expression of constitutively activated RAS destabilizes the genome of PCCL3 cells is consistent with a mode of tumor initiation in which this oncogene promotes phenotypic progression by predisposing to large scale genomic abnormalities.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.			Shirokawa, Jill/0000-0001-5669-1478; ELISEI, ROSSELLA/0000-0002-5333-9257; Knauf, Jeffrey/0000-0003-4456-8792	NATIONAL CANCER INSTITUTE [R01CA050706, F32CA069711, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA69711, CA50706, CA72597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ICHIKAWA T, 1990, CANCER RES, V50, P6349; ICHIKAWA T, 1991, PROSTATE, V18, P163, DOI 10.1002/pros.2990180209; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MILLER BM, 1993, MUTAGENESIS, V8, P35, DOI 10.1093/mutage/8.1.35; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nikiforov YE, 1997, CANCER RES, V57, P1690; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; OLLER AR, 1989, MUTAT RES, V216, P149, DOI 10.1016/0165-1161(89)90001-0; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Porcellini A, 1997, J MOL MED-JMM, V75, P567, DOI 10.1007/s001090050141; Powell DJ, 1998, CANCER RES, V58, P5523; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; SHIROKAWA J, 1999, 81 ANN M END SOC JUN; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; THACKER J, 1985, MUTAT RES, V150, P431, DOI 10.1016/0027-5107(85)90140-X; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WANI MA, 1994, CANCER RES, V54, P2504; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; WOESSNER RD, 1990, CANCER RES, V50, P2901; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	54	143	149	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3948	3954		10.1038/sj.onc.1203723	http://dx.doi.org/10.1038/sj.onc.1203723			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951588				2022-12-25	WOS:000088614300014
J	Van Leeuwen, FW; Hol, EM; Hermanussen, BWH; Sonnemans, MAF; Moraal, E; Fischer, DF; Evans, DAP; Chooi, KF; Burbach, JPH; Murphy, D				Van Leeuwen, FW; Hol, EM; Hermanussen, BWH; Sonnemans, MAF; Moraal, E; Fischer, DF; Evans, DAP; Chooi, KF; Burbach, JPH; Murphy, D			Molecular misreading in non-neuronal cells	FASEB JOURNAL			English	Article						RNA errors; dinucleotide deletions; frame-shifted proteins	HOMOZYGOUS BRATTLEBORO RAT; RNA SURVEILLANCE; VASOPRESSIN; MUTATIONS; PROTEIN; TRANSCRIPTS; ALZHEIMERS; DISEASE; DECAY	+1 Frame-shifted proteins such as amyloid precursor protein(+1) and ubiquitin-B+1 have been identified in the neuropathological hallmarks of Alzheimer's disease. These frameshifts are caused by dinucleotide deletions in GAGAG motifs of messenger RNA encoded by genes that have maintained the unchanged wild-type DNA sequence. This process is termed 'molecular misreading'. A key question is whether this process is confined to neurons or whether it could also occur in non-neuronal cells. A transgenic mouse line (MV-B) carrying multiple copies of a rat vasopressin minigene as a reporter driven by the MMTV-LTR promotor was used to screen non-neuronal tissues for molecular misreading by means of detection of the rat vasopressin(+1) protein and mutated mRNA. Molecular misreading was demonstrated to occur in several organs (e.g., epididymis and the parotid gland) where transgenic vasopressin expression is abundant, but its penetrance is variable both between and within tissues. This implies that non-neural tissues too, could be affected by cellular derangements caused by molecular misreading.	Netherlands Inst Brain Res, Res Grp Mol Misreading, NL-1105 AZ Amsterdam, Netherlands; Natl Univ Singapore, Inst Mol & Cell Biol, Neuropeptide Lab, Singapore 117548, Singapore; Univ Bristol, Bristol Royal Infirm, Dept Med, Mol Neuroendocrinol Res Grp, Bristol BS2 8HW, Avon, England; Univ Utrecht, Mol Neurosci Sect, Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Bristol Royal Infirmary; University of Bristol; Utrecht University; Utrecht University Medical Center	Van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Res Grp Mol Misreading, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	f.van.leeuwen@nih.knaw.nl	Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019; Murphy, David/C-3967-2012	Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; Murphy, David/0000-0003-2946-0353; Fischer, David/0000-0002-6690-0197				ABE K, 1983, ARCH HISTOL JAPON, V46, P51, DOI 10.1679/aohc.46.51; Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Benne R, 1996, CURR OPIN GENET DEV, V6, P221, DOI 10.1016/S0959-437X(96)80054-2; Bridges BA, 1999, SCIENCE, V284, P62, DOI 10.1126/science.284.5411.62; Cali BM, 1998, MOL GEN GENET, V260, P176, DOI 10.1007/s004380050883; CHOOI KF, 1994, CANCER RES, V54, P6434; Clermont Y, 1970, Biology Reprod., V3, P283; Denny PC, 1997, CRIT REV ORAL BIOL M, V8, P51, DOI 10.1177/10454411970080010301; DEVRIES GJ, 1985, J COMP NEUROL, V233, P236, DOI 10.1002/cne.902330206; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Finch CE, 1997, TRENDS NEUROSCI, V20, P501; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Hamilton D.W., 1975, HDB PHYSIOLOGY     7, P259; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; Korpelainen EI, 1998, J CELL BIOL, V143, P1705, DOI 10.1083/jcb.143.6.1705; Metzgar D, 2000, GENOME RES, V10, P72; NEWMAN AJ, 1994, CURR OPIN GENET DEV, V4, P298, DOI 10.1016/S0959-437X(05)80057-7; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Schwartz AL, 1999, ANNU REV MED, V50, P57; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Sonnemans MAF, 1996, NEUROSCIENCE, V72, P225, DOI 10.1016/0306-4522(95)00550-1; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417; VANLEEUWEN FW, 1994, BRAIN RES, V635, P328, DOI 10.1016/0006-8993(94)91456-7; VERBALIS JG, 1991, J NEUROENDOCRINOL, V3, P267, DOI 10.1111/j.1365-2826.1991.tb00274.x	28	23	24	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1595	1602		10.1096/fj.14.11.1595	http://dx.doi.org/10.1096/fj.14.11.1595			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928994				2022-12-25	WOS:000088627800014
J	Ducros, V; Charnock, SJ; Derewenda, U; Derewenda, ZS; Dauter, Z; Dupont, C; Shareck, F; Morosoli, R; Kluepfel, D; Davies, GJ				Ducros, V; Charnock, SJ; Derewenda, U; Derewenda, ZS; Dauter, Z; Dupont, C; Shareck, F; Morosoli, R; Kluepfel, D; Davies, GJ			Substrate specificity in glycoside hydrolase family 10 - Structural and kinetic analysis of the streptomyces lividans xylanase 10A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; ACTIVE-SITE; ENZYME INTERMEDIATE; ANGSTROM RESOLUTION; MACROMOLECULAR STRUCTURES; THERMOASCUS-AURANTIACUS; BETA-1,4-GLYCANASE CEX; CATALYTIC INTERMEDIATE; MOLECULAR REPLACEMENT	Endoxylanases are a group of enzymes that hydrolyze the beta-1,4-linked xylose backbone of xylans. They are predominantly found in two discrete sequence families known as glycoside hydrolase families 10 and 11. The Streptomyces lividans xylanase Xyl10A is a family 10 enzyme, the native structure of which has previously been determined by x-ray crystallography at a 2.6 Angstrom resolution (Derewenda, U., Swenson, L., Green, R., Wei, Y., Morosoli, R., Shareck, F., Kluepfel, D., and Derewenda, Z. S. (1994) J. Biol. Chem. 269, 20811-20814). Here, we report the native structure of Xyl10A refined at a resolution of 1.2 Angstrom which reveals many features such as the rare occurrence of a discretely disordered disulfide bond between residues Cys-168 and Cys-201. In order to investigate substrate binding and specificity in glycoside hydrolase family 10, the covalent xylobiosyl enzyme and the covalent cellobiosyl enzyme intermediates of Xyl10A were trapped through the use of appropriate 2-fluoroglycosides. The Lu-linked intermediate with the nucleophile, Glu-236, is in a C-4(1) chair conformation as previously observed in the family 10 enzyme Cex from Cellulomonas fimi (Notenboom, V., Birsan, C., Warren, R. A. J., Withers, S. G., and Rose, D. R. (1998) Biochemistry 37, 4751-4758). The different interactions of Xyl10A with the xylobiosyl and cellobiosyl moieties, notably conformational changes in the -2 and -1 subsites, together with the observed kinetics on a range of aryl glycosides, shed new light on substrate specificity in glycoside hydrolase family 10.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Univ Virginia, Ctr Hlth Sci, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Quebec, Inst Armand Frappier, INRS, Inst Microbiol & Biotechnol, Laval, PQ H7V 1B7, Canada	University of York - UK; University of Virginia; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Quebec; Institut national de la recherche scientifique (INRS)	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 1998, FEBS LETT, V425, P352, DOI 10.1016/S0014-5793(98)00265-8; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES KL, 1949, J BACTERIOL, V57, P141, DOI 10.1128/JB.57.2.141-145.1949; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Lo Leggio L, 1999, PROTEINS, V36, P295; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MONDOU F, 1986, GENE, V49, P323, DOI 10.1016/0378-1119(86)90368-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Namchuk MN, 1995, BIOCHEMISTRY-US, V34, P16194, DOI 10.1021/bi00049a035; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Roberge M, 1997, BIOCHEMISTRY-US, V36, P7769, DOI 10.1021/bi9703296; Roberge M, 1997, PROTEIN ENG, V10, P399, DOI 10.1093/protein/10.4.399; Sabini E, 2000, ACTA CRYSTALLOGR D, V56, P3, DOI 10.1107/S0907444999013943; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; Schmidt A, 1998, PROTEIN SCI, V7, P2081, DOI 10.1002/pro.5560071004; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047	55	74	74	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23020	23026		10.1074/jbc.275.30.23020	http://dx.doi.org/10.1074/jbc.275.30.23020			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930426	hybrid			2022-12-25	WOS:000088419400057
J	Andersson, ML; Vennstrom, B				Andersson, ML; Vennstrom, B			A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site	ONCOGENE			English	Article						thyroid hormone; receptor; P75(gag-v-erbA); corepressor; response element	RETINOIC ACID RECEPTORS; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-SEQUENCE SPECIFICITY; C-ERBA; ERYTHROID-DIFFERENTIATION; BINDING DOMAIN; COREPRESSOR SMRT; A GENE; P-BOX; PROTEIN	The v-erbA oncoprotein (P75(gag-v-erbA)) can repress thyroid hormone receptor induced transcriptional activation of target genes. A central question is hom hormone responsive elements in a target gene determine the transcriptional regulation mediated by P75(gag-v-erbA). We addressed this with receptors chimeric between P75(gag-v-erbA) and thyroid hormone receptor (TR) by testing their regulatory activities on thyroid hormone response elements (TREs) differing in the sequence of the consensus core recognition motif AGGTCA. We report here that enhances, TR dependent transcriptional activation is conferred by P75(gag-v-erbA) when the thymidine in the half site recognition motif is exchanged for an adenosine. The enhancement mas independent of the DNA binding region of P75(gag-v-erbA), whereas increased expression of corepressor abolished the enhancing effect, The data indicate that the enhancement results from an impaired DNA binding by the oncoprotein combined with an effective scavenging of corepressors. Our data thus suggest the P75(gag-v-erbA) indirectly can contribute to enhancement of thyroid hormone induced gene expression.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Vennstrom, B (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.		Andersson Lendahl, Monika/ABE-5981-2021	Andersson Lendahl, Monika/0000-0002-5690-8515				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Baniahmad A, 1998, MOL ENDOCRINOL, V12, P504, DOI 10.1210/me.12.4.504; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; DAMM K, 1993, FASEB J, V7, P904, DOI 10.1096/fasebj.7.10.8102105; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE Y, 1993, J BIOL CHEM, V268, P2021; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAWAZ Z, 1995, P NATL ACAD SCI USA, V92, P11691, DOI 10.1073/pnas.92.25.11691; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RASCLE A, 1994, ONCOGENE, V9, P2853; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schmidt S, 1998, NUCLEIC ACIDS RES, V26, P1191, DOI 10.1093/nar/26.5.1191; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1991, CELL, V65, P1; Wahlstrom GM, 1996, ONCOGENE, V13, P843; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; YEN PM, 1992, J BIOL CHEM, V267, P3565; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	53	4	4	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3563	3569		10.1038/sj.onc.1203692	http://dx.doi.org/10.1038/sj.onc.1203692			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951561	Bronze			2022-12-25	WOS:000088568300001
J	Primo, L; Roca, C; Ferrandi, C; Lanfrancone, L; Bussolino, F				Primo, L; Roca, C; Ferrandi, C; Lanfrancone, L; Bussolino, F			Human endothelial cells expressing polyoma middle T induce tumors	ONCOGENE			English	Article						hemangioma; middle T; endothelial cells; polyomavirus; human	OPPORTUNISTIC VASCULAR TUMORS; KAPOSIS-SARCOMA; GROWTH-FACTOR; KINASE-ACTIVITY; SRC FAMILY; NUDE-MICE; IN-VITRO; ANTIGEN; ONCOGENE; TRANSFORMATION	The middle T oncogene of murine polyomavirus (PymT) rapidly transforms and immortalizes murine embryonic endothelial cells (EC), leading to the formation of vascular tumors in newborn mice, by recruitment of host, non-transformed EC. These tumors are reminiscent of human vascular tumors like cavernous hemangioma, Kaposi's sarcoma or those characterizing Kasabach-Merrit syndrome. Here we investigate the in vitro and in vivo behavior of human primary umbilical cord vein EC expressing PymT. While PymT has been unable to transform human fibroblasts in earlier experiments or controls done here, mT expressing EC (PymT-EC) derived by infection with pLX-PymT retrovirus induce hemangiomas in nu/nu mice. These tumors contain not only human cells but also recruited mouse EC as shown by the presence of human and murine CD31 positive EC. In vitro analysis shows that PymT-EC retain endothelial specific markers like CD31, Von Willebrand factor, and VE-cadherin, and reach the confluence without signs of overgrowth. They are also responsive to vascular endothelial growth factor-A. However, their proliferation rate is increased. The balance between urokinase-type plasminogen activator and plasminogen activator inhibitor-1 is modified; RNA and catalytic activity for the former are elevated while PAI-1 RN4 is reduced. In contrast with murine model, where the PymT EC cells become immortal, the effects induced by PymT in human EC are transient. After 12-15 passages, human PymT EC stop proliferating, assume a senescent phenotype, and lose the ability to induce hemangiomas, At the same time both the amount of middle T protein and the level of activation of pp60(c-src) lower.	IRCC, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Genet Biol & Biochem, I-10100 Turin, Italy; European Inst Oncol, Dept Expt Oncol, I-20100 Milan, Italy	University of Turin; IRCCS European Institute of Oncology (IEO)	Bussolino, F (corresponding author), IRCC, Strada Prov 142,Km 3-95, I-10060 Turin, Italy.		Lanfrancone, Luisa/AAC-8671-2019; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Lanfrancone, Luisa/0000-0002-4523-3815; PRIMO, Luca/0000-0002-1294-0441; Bussolino, Federico/0000-0002-5348-1341				AGUZZI A, 1991, ONCOGENE, V6, P113; Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BEATTIE GM, 1982, P NATL ACAD SCI-BIOL, V79, P3033, DOI 10.1073/pnas.79.9.3033; Biancone L, 1999, J IMMUNOL, V162, P5263; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong QG, 1996, INT J CANCER, V65, P700, DOI 10.1002/(SICI)1097-0215(19960301)65:5<700::AID-IJC23>3.0.CO;2-9; Drolet BA, 1999, NEW ENGL J MED, V341, P173, DOI 10.1056/NEJM199907153410307; Ensoli B, 1998, CYTOKINE GROWTH F R, V9, P63, DOI 10.1016/S1359-6101(97)00037-3; FIORELLI V, 1995, J CLIN INVEST, V95, P1723, DOI 10.1172/JCI117849; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GHIGO D, 1995, J EXP MED, V181, P9, DOI 10.1084/jem.181.1.9; Giraudo E, 1996, J IMMUNOL, V157, P2618; GOLDENBERG DM, 1981, SCIENCE, V212, P65, DOI 10.1126/science.7209521; GOLDENBERG DM, 1982, P NATL ACAD SCI-BIOL, V79, P2389, DOI 10.1073/pnas.79.7.2389; GROSS L, 1983, ONCOGENIC VIRUSES, V2, P737; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HOLMAN PS, 1994, J VIROL, V68, P668, DOI 10.1128/JVI.68.2.668-673.1994; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LEVY JA, 1983, LANCET, V2, P78; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTESANO R, 1993, J CELL SCI, V105, P1013; Muhlner U, 1999, ONCOGENE, V18, P4200, DOI 10.1038/sj.onc.1203014; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SARTOR O, 1993, J BIOL CHEM, V268, P21014; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN BS, 1987, J VIROL, V61, P1221, DOI 10.1128/JVI.61.4.1221-1225.1987; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TARABOLETTI G, 1993, CANCER RES, V53, P3812; TRATTNER A, 1993, CANCER-AM CANCER SOC, V72, P1779, DOI 10.1002/1097-0142(19930901)72:5<1779::AID-CNCR2820720543>3.0.CO;2-M; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	56	24	25	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3632	3641		10.1038/sj.onc.1203708	http://dx.doi.org/10.1038/sj.onc.1203708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951569				2022-12-25	WOS:000088568300009
J	Srinivasula, SM; Datta, P; Fan, XJ; Fernandes-Alnemri, T; Huang, ZW; Alnemri, ES				Srinivasula, SM; Datta, P; Fan, XJ; Fernandes-Alnemri, T; Huang, ZW; Alnemri, ES			Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-SURVIVAL; APOPTOSIS; ACTIVATION; INHIBITOR; PROTEIN; OLIGOMERIZATION; MITOCHONDRIA; PROCASPASE-9; CLEAVAGE	Smac/DLABLO is a mitochondrial protein that is released along with cytochrome c during apoptosis and promotes cytochrome c-dependent caspase activation by neutralizing inhibitor of apoptosis proteins (IAPs). We provide evidence that Smac/DIABLO functions at the levels: of both :the Apaf-1-caspase-9 apoptosome and effector caspases. The N terminus of Smac/DIABLO is absolutely required for its ability to interact with the baculovirus IAP repeat (BIR3) of XIAP and to promote cytochrome c dependent caspase activation. However, it is less critical for its ability to interact with BIR1/BIR2 of XIAP and to promote the activity of the effector caspases. Consistent with the ability of Smac/DIABLO to function at the level of the effector caspases, expression of a cytosolic Smac/DIABLO in Type II cells allowed TRAIL to bypass Bcl-xL inhibition of death receptor-induced apoptosis. Combined, these data suggest that Smac/DIABLO plays a critical role in neutralizing IAP inhibition of the effector caspases in the death receptor pathway of Type II cells.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010		NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG14357, AG13487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487, R01AG014357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	33	288	323	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36152	36157		10.1074/jbc.C000533200	http://dx.doi.org/10.1074/jbc.C000533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10950947	hybrid			2022-12-25	WOS:000165382000072
J	Lewis, RJ; Nielsen, KJ; Craik, DJ; Loughnan, ML; Adams, DA; Sharpe, IA; Luchian, T; Adams, DJ; Bond, T; Thomas, L; Jones, A; Matheson, JL; Drinkwater, R; Andrews, PR; Alewood, PF				Lewis, RJ; Nielsen, KJ; Craik, DJ; Loughnan, ML; Adams, DA; Sharpe, IA; Luchian, T; Adams, DJ; Bond, T; Thomas, L; Jones, A; Matheson, JL; Drinkwater, R; Andrews, PR; Alewood, PF			Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; CA2+ CHANNELS; BETA-SUBUNIT; SYNAPTIC TRANSMISSION; PERIPHERAL NEURONS; FUNCTIONAL ASSAY; ALPHA-CONOTOXIN; GVIA; RAT; ANTAGONISTS	omega -Conotoxins selective for N-type calcium channels are useful in the management of severe pain. In an attempt to expand the therapeutic potential of this class, four new omega -conotoxins (CVIA-D) have been discovered in the venom of the piscivorous cone snail, Conus catus, using assay-guided fractionation and gene cloning. Compared with other omega -conotoxins, CVID has a novel loop 4 sequence and the highest selectivity for N-type over P/Q-type calcium channels in radioligand binding assays. CVIA-D also inhibited contractions of electrically stimulated rat vas deferens. In electrophysiological studies, omega -conotoxins CVID and MVIIA had similar potencies to inhibit current through central (alpha (1B-d)) and peripheral (alpha (1B-b)) splice variants of the rat N-type calcium channels when coexpressed with rat beta (3) in Xenopus oocytes, However, the potency of CVID and MVIIA increased when alpha (1B-d) and alpha (1B-b) were expressed in the absence of rat beta (3), an effect most pronounced for CVID at alpha (1B-d) (up to 540-fold) and least pronounced for MVIIA at alpha (1B-d) (3-fold). The novel selectivity of CVID may have therapeutic implications. H-1 NMR studies reveal that CMD possesses a combination of unique structural features, including two hydrogen bonds that stabilize loop 2 and place loop 2 proximal to loop 4, creating a globular surface that is rigid and well defined.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, 3D Ctr, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia; Univ Queensland, CSIRO Trop Agr, Brisbane, Qld 4072, Australia; Univ Queensland, Queensland Agr Biotechnol Ctr, QDPI, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Queensland; University of Queensland	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, 3D Ctr, Brisbane, Qld 4072, Australia.		Milne, Trudy J/G-2630-2011; Lewis, Richard/T-8763-2019; Adams, David John/K-3578-2019; Lewis, Richard J/E-8674-2013; Adams, David/J-9125-2014; Craik, David/B-1695-2010; Loughnan, Marion/B-4508-2009	Lewis, Richard/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Lewis, Richard J/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Alewood, Paul/0000-0001-7454-6522; Luchian, Tudor/0000-0002-9388-7266				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P3908, DOI 10.1021/bi992651h; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BOOT JR, 1994, EUR J PHARMACOL, V258, P155, DOI 10.1016/0014-2999(94)90069-8; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; Currie KPM, 1997, J NEUROSCI, V17, P4570; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Flinn JP, 1999, EUR J BIOCHEM, V262, P447, DOI 10.1046/j.1432-1327.1999.00383.x; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; Lin ZX, 1999, J NEUROSCI, V19, P5322; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; LUDRIGSEN S, 1992, J BIOMOL NMR, V2, P227; Ludwig A, 1997, J NEUROSCI, V17, P1339; MAGGI CA, 1988, N-S ARCH PHARMACOL, V338, P107, DOI 10.1007/BF00174856; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; McDonough SI, 1996, J NEUROSCI, V16, P2612; McIntosh J M, 1999, Methods Enzymol, V294, P605; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; Moreno H, 1997, P NATL ACAD SCI USA, V94, P14042, DOI 10.1073/pnas.94.25.14042; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Nielsen KJ, 1999, J MED CHEM, V42, P415, DOI 10.1021/jm981052q; Nielsen KJ, 1999, J MOL BIOL, V289, P1405, DOI 10.1006/jmbi.1999.2817; Nielsen KJ, 1999, BIOCHEMISTRY-US, V38, P6741, DOI 10.1021/bi982980u; Nielsen KJ, 1996, J MOL BIOL, V263, P297, DOI 10.1006/jmbi.1996.0576; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; PriceCarter M, 1996, BIOCHEMISTRY-US, V35, P15547, DOI 10.1021/bi9615755; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SEABROOK GR, 1989, BRIT J PHARMACOL, V97, P1125, DOI 10.1111/j.1476-5381.1989.tb12570.x; Smith AB, 1996, NEUROSCIENCE, V70, P817, DOI 10.1016/S0306-4522(96)83018-1; SMITH MT, 2000, AUST SOC CLIN EXP PH, V7, P50; STEIN EG, 1996, J MAGN RESON, V124, P1554; Stocker JW, 1997, J NEUROSCI, V17, P3002; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Wang YX, 1998, N-S ARCH PHARMACOL, V357, P159, DOI 10.1007/PL00005150; WETENBROEK RE, 1998, J NEUROSCI, V18, P6319; Wheeler DB, 1996, J NEUROSCI, V16, P2226; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x; Wright CE, 1996, BRIT J PHARMACOL, V119, P49, DOI 10.1111/j.1476-5381.1996.tb15676.x; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P1; YAMADA K, 1994, NEUROPHARMACOLOGY, V33, P251, DOI 10.1016/0028-3908(94)90016-7; Zamponi GW, 1996, J NEUROSCI, V16, P2430	59	188	205	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35335	35344		10.1074/jbc.M002252200	http://dx.doi.org/10.1074/jbc.M002252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938268	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000165422800068
J	Ozaki, M; Deshpande, SS; Angkeow, P; Suzuki, S; Irani, K				Ozaki, M; Deshpande, SS; Angkeow, P; Suzuki, S; Irani, K			Rac1 regulates stress-induced, redox-dependent heat shock factor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; JUN NH2-TERMINAL KINASE; NECROSIS-FACTOR-ALPHA; DNA-BINDING ACTIVITY; C-JUN; TRANSCRIPTION FACTOR; HEME OXYGENASE-1; GENE-EXPRESSION; PROTEIN-KINASES; FACTOR-I	The signaling pathway by which environmental stresses activate heat shock factors (HSFs) is not completely understood. We show that the small GTPase rad, and Rad-regulated reactive oxygen species (ROS) play an important role in stress-stimulated heat shock response. A dominant-negative allele of Rad (Rac1N17) inhibits the hypoxia/reoxygenation and sodium arsenite-induced transcriptional activity of HSF-1 and the transcription of heat shock protein 70. Rac1N17 also suppresses the production of intracellular ROS induced by hypoxia/reoxygenation or sodium arsenite. Moreover, direct suppression of intracellular ROS levels by antioxidants decreases stress-stimulated HSF activity. However, expression of a constitutively active mutant of Rad (Rac1V12) in the absence of extracellular stresses does not increase intracellular ROS levels or induce the heat shock response. These results show that Rad is a necessary but insufficient component of the stress-induced signaling pathway that leads to ROS production, activation of HSFs, and transcription of heat shock proteins.	Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Baltimore, MD 21205 USA; Natl Childrens Med Res Ctr, Div Expt Surg, Tokyo 1548509, Japan	Johns Hopkins University; National Center for Child Health & Development - Japan	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.		Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387				AUCOIN MM, 1995, AM J PHYSIOL-HEART C, V268, pH1651, DOI 10.1152/ajpheart.1995.268.4.H1651; BAUMAN JW, 1993, FUND APPL TOXICOL, V21, P15, DOI 10.1006/faat.1993.1066; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cool RH, 1998, BIOCHEM J, V332, P5, DOI 10.1042/bj3320005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAS DK, 1993, CARDIOVASC RES, V27, P578, DOI 10.1093/cvr/27.4.578; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kim SH, 1999, BIOCHEM BIOPH RES CO, V262, P516, DOI 10.1006/bbrc.1999.1229; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KUKREJA RC, 1994, AM J PHYSIOL-HEART C, V267, pH2213, DOI 10.1152/ajpheart.1994.267.6.H2213; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lee YJ, 1998, J BIOL CHEM, V273, P29857, DOI 10.1074/jbc.273.45.29857; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; MIVECHI NF, 1994, INT J HYPERTHER, V10, P371, DOI 10.3109/02656739409010281; MIVECHI NF, 1995, CANCER RES, V55, P5512; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; REDDY MV, 1992, INFECT IMMUN, V60, P2386, DOI 10.1128/IAI.60.6.2386-2390.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SAUNDERS EL, 1991, ARCH BIOCHEM BIOPHYS, V288, P368, DOI 10.1016/0003-9861(91)90208-Z; SCHOENIGER LO, 1994, GASTROENTEROLOGY, V106, P177, DOI 10.1016/S0016-5085(94)95209-4; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441	45	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35377	35383		10.1074/jbc.M005287200	http://dx.doi.org/10.1074/jbc.M005287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952983	hybrid			2022-12-25	WOS:000165422800073
J	Anwar, A; Ali, N; Tanveer, R; Siddiqui, A				Anwar, A; Ali, N; Tanveer, R; Siddiqui, A			Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; HEPATOCELLULAR-CARCINOMA; 3'-UNTRANSLATED REGION; 5'-UNTRANSLATED REGION; 5'-NONCODING REGION; PICORNAVIRUS RNA; GENOME; POLIOVIRUS; ELEMENT; REPLICATION	Polypyrimidine tract-binding protein (PTB) has been previously shown to physically interact with the hepatitis C virus (HCV) RNA genome at its 5'- and 3'-noncoding regions, Using high affinity SELEX RNA molecules, we present evidence for the functional requirement of PTB during HCV internal ribosome entry site (IRES)-controlled translation initiation. This study was carried out in rabbit reticulocyte translation lysates in which the HCV IRES-driven reporter RNA was introduced along with the PTB-specific SELEX RNA molecules. The SELEX RNAs specifically inhibited the HCV IRES function in the context of mono- and dicistronic mRNAs. The cap-dependent translation of a reporter (chloramphenicol acetyltransferase) RNA or naturally capped brome mosaic virus RNA, however, was not affected by the presence of SELEX during in vitro translation assays. The SELEX-mediated inhibition of the HCV IRES is shown to be relieved by the addition of recombinant human PTB in an add-back experiment. The in vivo requirement of PTB was further confirmed by cotransfection of Huh7 cells with reporter RNA and PTB-specific SELEX RNA. The HCV IRES activity was inhibited by the SELEX RNA in these cells, but not by an unrelated control RNA. Together, these results demonstrate the functional requirement of cellular PTB in HCV translation and further support the feasible use of SELEX RNA strategy in demonstrating the functional relevance of cellular protein(s) in complex biological processes.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, B172,4200 E 9th Ave, Denver, CO 80262 USA.	Aleem.Siddiqui@UCHSC.edu		Ali, Naushad/0000-0002-0058-7396				Ali N, 2000, J BIOL CHEM, V275, P27531; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Barton DJ, 1996, METHOD ENZYMOL, V275, P35; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Chen H, 1996, METHOD ENZYMOL, V275, P503; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gontarek RR, 1999, NUCLEIC ACIDS RES, V27, P1457, DOI 10.1093/nar/27.6.1457; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Hahn B, 1998, J VIROL, V72, P8782, DOI 10.1128/JVI.72.11.8782-8788.1998; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Ito T, 1999, VIROLOGY, V254, P288, DOI 10.1006/viro.1998.9541; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ito T, 1997, J VIROL, V71, P8698, DOI 10.1128/JVI.71.11.8698-8706.1997; Kaminski A, 1995, RNA, V1, P924; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sickinger S, 1999, BIOL CHEM, V380, P1217, DOI 10.1515/BC.1999.154; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Spangberg K, 1999, J GEN VIROL, V80, P1371, DOI 10.1099/0022-1317-80-6-1371; Tsuchihara K, 1997, J VIROL, V71, P6720, DOI 10.1128/JVI.71.9.6720-6726.1997; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993	45	71	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34231	34235		10.1074/jbc.M006343200	http://dx.doi.org/10.1074/jbc.M006343200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10938288	hybrid			2022-12-25	WOS:000165095300033
J	Escargueil, AE; Plisov, SY; Filhol, O; Cochet, C; Larsen, AK				Escargueil, AE; Plisov, SY; Filhol, O; Cochet, C; Larsen, AK			Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-PHASE PHOSPHOPROTEINS; CELL-CYCLE; CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; SPECIFICITY DETERMINANTS; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; IN-VITRO	DNA. topoisomerase II alpha is required for chromatin condensation during prophase, This process is temporally linked with the appearance of mitosis-specific phosphorylation sites on topoisomerase II alpha including one recognized by the MPM-2 monoclonal antibody. We now report that the ability of mitotic extracts to create the MPM-2 epitope on human topoisomerase II alpha is abolished by immunodepletion of protein kinase CK2. Furthermore, the MPM-2 phosphoepitope on topoisomerase II alpha can be generated by purified CR2. Phosphorylation of C-truncated topoisomerase II alpha mutant proteins conclusively shows, that the MPM-2 epitope is present in the last 163 amino acids. Use of peptides containing all conserved CK2 consensus sites in this region indicates that only the peptide containing Arg-1466 to Ala-1485 is able to compete with topoisomerase II alpha for binding of the MPM-2 antibody. Replacement of Ser-1469 with Ala abolishes the ability of the phosphorylated peptide to bind to the MPM-2 antibody while a peptide containing phosphorylated Ser-1469 binds tightly. Surprisingly, the MPM-2 phosphoepitope influences neither the catalytic activity of topoisomerase II alpha nor its, ability to form molecular complexes with CR2 in vitro. In conclusion, we have identified protein kinase CR2 as a new MPM-2 kinase able to phosphorylate an important mitotic protein, topoisomerase II alpha; on Ser-1469.	Inst Gustave Roussy PR2, CNRS UMR 8532, Lab Biol & Pharmacol Tumeurs, F-94805 Villejuif, France; CEA, INSERM, U244, Lab Biochim Regulat Cellulaires Endocrine, F-38054 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Larsen, AK (corresponding author), Inst Gustave Roussy PR2, CNRS UMR 8532, Lab Biol & Pharmacol Tumeurs, F-94805 Villejuif, France.	aklarsen@igr.fr	Escargueil, Alexandre/K-5192-2019; Filhol-Cochet, Odile/I-3962-2016	Escargueil, Alexandre/0000-0002-7419-7518; Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270				ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Che SL, 1997, FEBS LETT, V413, P417, DOI 10.1016/S0014-5793(97)00948-4; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAVIS FM, 1989, CELL STRUCT FUNCT, V14, P271, DOI 10.1247/csf.14.271; Ding M, 1997, EXP CELL RES, V231, P3, DOI 10.1006/excr.1996.3439; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; FILHOLCOCHET O, 1994, CELL MOL BIOL RES, V40, P529; Gulli MP, 1997, CHROMOSOMA, V105, P532, DOI 10.1007/s004120050215; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Larsen A K, 1996, Prog Cell Cycle Res, V2, P229; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Logarinho E, 1998, J CELL SCI, V111, P2897; Lu KP, 1996, NATURE, V380, P544; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MEGGIO F, 1988, BIOCHIM BIOPHYS ACTA, V971, P227, DOI 10.1016/S0005-2728(88)80111-7; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; Renzi L, 1997, J CELL SCI, V110, P2013; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Suganuma M, 1999, CANCER RES, V59, P5887; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; TOMBES RM, 1991, CELL REGUL, V2, P861, DOI 10.1091/mbc.2.11.861; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VANDRE DD, 1991, J CELL SCI, V98, P577; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	74	70	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34710	34718		10.1074/jbc.M005179200	http://dx.doi.org/10.1074/jbc.M005179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942766	hybrid			2022-12-25	WOS:000165095300095
J	Tyzack, JK; Wang, XM; Belsham, GJ; Proud, CG				Tyzack, JK; Wang, XM; Belsham, GJ; Proud, CG			ABC50 interacts with eukaryotic initiation factor 2 and associates with the ribosome in an ATP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; T-CELL ACTIVATION; POLYPEPTIDE-CHAIN INITIATION; PROTEIN-SYNTHESIS INITIATION; BINDING CASSETTE PROTEIN; TRANSFER-RNA-SYNTHETASES; ELONGATION FACTOR-III; EIF-2-ALPHA KINASE; BETA-SUBUNIT; TRANSLATIONAL CONTROL	Eukaryotic initiation factor 2 (eIF2) plays a key role in the process of translation initiation and in its control. Here we demonstrate that highly purified mammalian eIF2 contains an additional polypeptide of apparent molecular mass of 110 kDa, This polypeptide co-purified with eIF2 through five different chromatography procedures. A cDNA clone encoding the polypeptide was isolated, and its sequence closely matched that of a protein previously termed ABC50, a member of the ATP-binding cassette (ABC) family of proteins. Antibodies to ABC50 co-immunoprecipitated eIF2 and vice versa, indicating that the two proteins interact. The presence of ABC50 had no effect upon the ability of eIF2 to bind GDP but markedly enhanced the association of methionyl-tRNA with the factor. Unlike the majority of ABC proteins, which are membrane-associated transporters, ABC50 associates with the ribosome and co-sediments in sucrose gradients with the 40 and 60 S ribosomal subunits, The association of ABC50 with ribosomal subunits was increased by ATP and decreased by ADP, ABC50 is related to GCN20 and eEF3, two yeast ABC proteins that are not membrane-associated transporters and are instead implicated in mRNA translation and/or its control. Thus, these data identify ABC50 as a third ABC protein with a likely function in mRNA translation, which associates with eIF2 and with ribosomes.	Univ Dundee, Dundee DD1 5EH, Scotland; AFRC, Inst Anim Hlth, Woking GU24 0NF, Surrey, England	University of Dundee; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute	Proud, CG (corresponding author), Univ Dundee, MSI WTB Complex, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk	Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873; Proud, Christopher/0000-0003-0704-6442				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AUSABEL F, 1995, CURRENT PROTOCOLS MO; BELFIELD GP, 1995, J MOL EVOL, V41, P376, DOI 10.1007/BF01215185; BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; BENNE R, 1976, J BIOL CHEM, V251, P7675; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harlow E., 1989, ANTIBODIES LAB MANUA; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; MAO XH, 1992, J BIOL CHEM, V267, P20444; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; POLLARD JW, 1989, EUR J BIOCHEM, V182, P1, DOI 10.1111/j.1432-1033.1989.tb14793.x; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PRICE NT, 1994, BBA-GENE STRUCT EXPR, V1217, P207, DOI 10.1016/0167-4781(94)90037-X; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; PROUD CG, 1982, FEBS LETT, V143, P55, DOI 10.1016/0014-5793(82)80273-1; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Richard M, 1998, GENOMICS, V53, P137, DOI 10.1006/geno.1998.5480; SAFER B, 1975, J BIOL CHEM, V250, P9067; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Sood R, 2000, GENETICS, V154, P787; Sood R, 1997, FASEB J, V11, pA1232; THOMAS NSB, 1985, J BIOL CHEM, V260, P9860; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WETTENHALL RE, 1974, BIOCHIM BIOPHYS ACTA, V349, P214, DOI 10.1016/0005-2787(74)90082-3; WONG ST, 1982, J BIOL CHEM, V257, P5231	50	94	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34131	34139		10.1074/jbc.M002868200	http://dx.doi.org/10.1074/jbc.M002868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931828	hybrid			2022-12-25	WOS:000165095300021
J	Cid, E; Gomis, RR; Geremia, RA; Guinovart, JJ; Ferrer, JC				Cid, E; Gomis, RR; Geremia, RA; Guinovart, JJ; Ferrer, JC			Identification of two essential glutamic acid residues in glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; ALPHA-MANNOSYLTRANSFERASE; PHOSPHORYLATION SITES; SEQUENCE SIMILARITIES; CDNA CLONING; PROTEIN; LIVER; GLYCOSYLTRANSFERASES; GENE; CLASSIFICATION	The detailed catalytic mechanism by which glycosyltransferases catalyze the transfer of a glycosyl residue from a donor sugar to an acceptor is not known, Through the multiple alignment of all known eukaryotic glycogen synthases we have found an invariant 17-amino acid stretch enclosed within the most conserved region of the members of this family. This peptide includes an E-X-7-E motif, which is highly conserved in four families of retaining glycosyltransferases. Site-directed mutagenesis was performed in human muscle glycogen synthase to analyze the roles of the two conserved Glu residues (Glu-510 and Glu-518) of the motif. Proteins were transiently expressed in COS-l cells as fusions to green fluorescence protein. The E510A and E518A mutant proteins retained the ability to translocate from the nucleus to the cytosol in response to glucose and to bind to intracellular glycogen. Although the E518A variant had approximately 6% of the catalytic activity shown by the green fluorescence protein-human muscle glycogen synthase fusion protein, the E510A mutation inactivated the enzyme. These results led us to conclude that the E-X-7-E motif is part of the active site of eukaryotic glycogen synthases and that both conserved Glu residues are involved in catalysis. We propose that Glu-510 may function as the nucleophile and Glu-518 as the general acid/base catalyst.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France	University of Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Ferrer, JC (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti I Franques 1, E-08028 Barcelona, Spain.	ferrer@sun.bq.ub.es	Geremia, Roberto A/A-7972-2010; Cid, Emili/F-7207-2016; Ferrer, Joan C./AAP-2145-2021; Gomis, Roger R/E-9788-2016	Cid, Emili/0000-0002-5025-352X; Gomis, Roger R/0000-0001-6473-2858; Ferrer, Joan C./0000-0003-1212-5161				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baba O, 1993, Kokubyo Gakkai Zasshi, V60, P264; BAI G, 1990, J BIOL CHEM, V265, P7843; BAK JF, 1992, DIABETOLOGIA, V35, P777; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Campbell JA, 1998, BIOCHEM J, V329, P719, DOI 10.1042/bj3290719; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DAVIES G, 1998, GLYCOSYL TRANSFER, P119; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Geremia RA, 1999, MOL GEN GENET, V261, P933, DOI 10.1007/s004380051040; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KASLOW HR, 1985, J BIOL CHEM, V260, P9953; KASLOW HR, 1984, FEBS LETT, V172, P294, DOI 10.1016/0014-5793(84)81144-8; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; MAHRENHOLZ AM, 1988, J BIOL CHEM, V263, P10561; Nichols DJ, 2000, BIOCHEMISTRY-US, V39, P7820, DOI 10.1021/bi000407g; NUTTALL FQ, 1994, ARCH BIOCHEM BIOPHYS, V311, P443, DOI 10.1006/abbi.1994.1260; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; Pellegri G, 1996, MOL BRAIN RES, V38, P191, DOI 10.1016/0169-328X(95)00305-C; Petroni EA, 1996, J BACTERIOL, V178, P4814, DOI 10.1128/jb.178.16.4814-4821.1996; ROACH PJ, 1991, ADV ENZYME REGUL, V31, P101, DOI 10.1016/0065-2571(91)90011-A; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	46	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33614	33621		10.1074/jbc.M005358200	http://dx.doi.org/10.1074/jbc.M005358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10924520	hybrid			2022-12-25	WOS:000090104600062
J	Pei, DQ; Kang, TB; Qi, HX				Pei, DQ; Kang, TB; Qi, HX			Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STROMELYSIN-3; BREAST-CARCINOMA; MEMBRANE-PROTEIN; DOMAIN; FAMILY; SURFACE; CLONING; CELLS; ALPHA; IDENTIFICATION	Matrix metalloproteinases characterized so far are either secreted or membrane anchored via a type I transmembrane domain or a glycosylphosphatidylinositol linkage. Lacking either membrane-anchoring mechanism, the newly discovered CA-MMP/MMP-23 was reported to be expressed as a cell-associated protein. In this report, we present evidence that CA-MMP is expressed as an integral membrane zymogen with an N-terminal signal anchor, and secreted as a fully processed mature enzyme. We further demonstrate that L(20)GAALSGLCLLSALALL(36) is required for this unique membrane localization as a signal anchor and its secretion is regulated by a proprotein convertase motif RRRR79 sandwiched between its pro- and catalytic domains. Thus, CA-MMP is a type II transmembrane MMP that can be regulated by a single proteolytic cleavage for both activation and secretion, establishing a novel paradigm for protein trafficking and processing within the secretory pathway.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	peixx003@tc.umn.edu			NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kirschner M, 1999, TRENDS CELL BIOL, V9, pM42, DOI 10.1016/S0962-8924(99)01666-9; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McLaughlin RE, 1999, BBA-MOL CELL RES, V1451, P82, DOI 10.1016/S0167-4889(99)00074-9; Mody N, 1999, NEUROPHARMACOLOGY, V38, P1485, DOI 10.1016/S0028-3908(99)00099-4; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, FEBS LETT, V457, P262, DOI 10.1016/S0014-5793(99)01046-7; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Puente XS, 1996, CANCER RES, V56, P944; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	51	98	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33988	33997		10.1074/jbc.M006493200	http://dx.doi.org/10.1074/jbc.M006493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945999	hybrid			2022-12-25	WOS:000090104600112
J	Urban, S; Zieseniss, S; Werder, M; Hauser, H; Budzinski, R; Engelmann, B				Urban, S; Zieseniss, S; Werder, M; Hauser, H; Budzinski, R; Engelmann, B			Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SR-BI; SELECTIVE UPTAKE; PLASMA-MEMBRANE; HUMAN PLATELETS; ADRENAL-GLAND; CHOLESTEROL; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; CAVEOLAE	The phospholipids of lipoproteins can be transferred to cells by an endocytosis-independent uptake pathway. We analyzed the role of scavenger receptor BI (SR-BI) for the selective cellular phospholipid import. Human monocytes rapidly acquired the pyrene (py)-labeled phospholipids sphingomyelin (SM), phosphatidylcholine, and phosphatidylethanolamine from different donors (low and high density lipoproteins (LDL, HDL), lipid vesicles). The anti-SR-BI antibody directed against the extracellular loop of the membrane protein lowered the cellular import of the phospholipids by 40-80%. The phospholipid transfer from the lipid vesicles into the monocytes was suppressed by LDL, I-IDL, and apoprotein AI, Transfection of BHK cells with the cDNA for human SR-BI enhanced the cellular import of the vesicle-derived py-phospholipids by 5-6-fold. In the case of the LDL donors, transfer of py-SM to the transfected cells was stimulated to a greater extent than the uptake of the other py-phospholipids. Similar differences were not observed when the vesicles and HDL were used as phospholipid donors, The concentration of LDL required for the half-maximal phospholipid import was close to the previously reported apparent dissociation constant for LDL binding to SR-BI, The low activation energy of the SR-BI-mediated py-phospholipid import indicated that the transfer occurs entirely in a hydrophobic environment, Disruption of cell membrane caveolae by cyclodextrin treatment reduced the SR-BI-catalyzed incorporation of py-SM, suggesting that intact caveolae are necessary for the phospholipid uptake. In conclusion, SR-BI mediates the selective import of the major lipoprotein-associated phospholipids into the cells, the transfer efficiency being dependent on the structure of the donor lipoprotein.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; ETH Zurich, Inst Biochem, CH-8092 Zurich, Switzerland; Boehringer Ingelheim Pharma KG, D-88397 Biberach, Germany	University of Munich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Boehringer Ingelheim	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Acton S, 1999, ARTERIOSCL THROM VAS, V19, P1734, DOI 10.1161/01.ATV.19.7.1734; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN RE, 1991, SUBCELLULAR BIOCH, P333; Dobner P, 1998, AM J PHYSIOL-ENDOC M, V275, pE777, DOI 10.1152/ajpendo.1998.275.5.E777; Downes CP, 1998, CURR BIOL, V8, pR865, DOI 10.1016/S0960-9822(07)00546-5; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; MOLOTKOVSKY JG, 1982, EUR J BIOCHEM, V122, P573; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Murphy HC, 1997, BIOCHEM BIOPH RES CO, V234, P733, DOI 10.1006/bbrc.1997.6634; Rhainds D, 1999, EUR J BIOCHEM, V261, P227, DOI 10.1046/j.1432-1327.1999.00264.x; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SOMMER A, 1992, J BIOL CHEM, V267, P24217; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	28	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33409	33415		10.1074/jbc.M004031200	http://dx.doi.org/10.1074/jbc.M004031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938082	hybrid			2022-12-25	WOS:000090104600034
J	Ikeda, Y; Sugawara, A; Taniyama, Y; Uruno, A; Igarashi, K; Arima, S; Ito, S; Takeuchi, K				Ikeda, Y; Sugawara, A; Taniyama, Y; Uruno, A; Igarashi, K; Arima, S; Ito, S; Takeuchi, K			Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PPAR-GAMMA; SMALL MAF; DIFFERENTIAL EXPRESSION; DIABETIC NEPHROPATHY; ENDOTHELIAL-CELLS; HEME OXYGENASE-1; OXIDATIVE STRESS; PROTEINS; FAMILY	We have studied the transcription regulation of the rat thromboxane synthase (TXS) gene by peroxisome proliferator-activated receptor gamma (PPAR gamma) in macrophages, The transcription activity of a cloned 8'-flanking region (1.6 kilobases) of the rat TXS gene (5'FL-TXS) was examined by luciferase reporter gene assay. TXS mRNA expression and the transcription activity of 5'FL-TXS were inhibited by PPAR gamma ligands, 15-deoxy-(12,14)-prostaglandin J(2) (PGJ(2)), and the thiazolidinedione troglitazone (TRO) in a dose-dependent manner. Overexpression of PPAR gamma also significantly suppressed transcription, and further addition of PGJ(2) or TRO augmented the suppression. Deletion analysis showed that the element responsible for the PPAR gamma effect is located in a region containing the nuclear factor E2 (NF-EB)/AP-1 site (-98/-88), which was indicated to be the major promoter of the TXS gene. By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-EB-related factor 2). Moreover, the complex was decreased with PGJ(2), TRO, or in vitro translated PPAR gamma. The transcription suppression by PPAR gamma was confirmed using this truncated NRF2-binding element (-98/-88) by the reporter gene assay. Finally, a direct interaction between PPAR gamma and NRF2 was confirmed by glutathione S-transferase pull-down assay. In conclusion, the NRF2-binding site (-98/-88) is the major promoter of 5'FL-TXS which can be suppressed by activated PPAR gamma via a protein-protein interaction with NRF2 in macrophages.	Tohoku Univ, Grad Sch Med, Dept Med,Mol Biol Unit, Div Nephol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan; Hiroshima Univ, Dept Biochem, Sch Med, Hiroshima 7348551, Japan	Tohoku University; Hiroshima University	Takeuchi, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Med,Mol Biol Unit, Div Nephol Endocrinol & Vasc Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kazut2i@mail.cc.tohoku.ac.jp	Uruno, Akira/U-1812-2019; Uruno, Akira/ABF-3988-2020; Ito, Sadayoshi/A-3933-2015	Igarashi, Kazuhiko/0000-0002-2470-2475; Sugawara, Akira/0000-0003-4511-8101; Ito, Sadayoshi/0000-0002-5092-3626				Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BERKES EA, 1995, KIDNEY INT, V48, P1344, DOI 10.1038/ki.1995.420; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Giustina A, 1998, DIABETES, V47, P423, DOI 10.2337/diabetes.47.3.423; HORA K, 1990, NEPHRON, V56, P297, DOI 10.1159/000186157; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Ikeda Y, 1999, BIOCHEM BIOPH RES CO, V262, P494, DOI 10.1006/bbrc.1999.1226; Imano E, 1998, DIABETES CARE, V21, P2135, DOI 10.2337/diacare.21.12.2135; Ishii T, 1999, FREE RADICAL RES, V31, P351, DOI 10.1080/10715769900300921; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; Lee KD, 1996, BIOCHEM J, V319, P783, DOI 10.1042/bj3190783; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; MEHTA JL, 1988, P NATL ACAD SCI USA, V85, P4511, DOI 10.1073/pnas.85.12.4511; NEEDLEMAN P, 1977, SCIENCE, V195, P409, DOI 10.1126/science.831285; NUSING R, 1990, EICOSANOIDS, V3, P175; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; OHASHI K, 1992, J BIOL CHEM, V267, P789; Oyake T, 1996, MOL CELL BIOL, V16, P6083; REMUZZI G, 1985, J CLIN INVEST, V75, P94, DOI 10.1172/JCI111703; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Shinohara E, 1998, ATHEROSCLEROSIS, V136, P275, DOI 10.1016/S0021-9150(97)00220-7; STAHL RAK, 1990, KIDNEY INT, V38, P273, DOI 10.1038/ki.1990.196; Sugawara A, 1999, HYPERTENSION, V34, P363; SUGAWARA A, 1995, ENDOCRINOLOGY, V136, P1766, DOI 10.1210/en.136.4.1766; Takahashi N, 1998, BIOCHEM BIOPH RES CO, V244, P489, DOI 10.1006/bbrc.1998.8283; Takeuchi K, 1997, CYTOGENET CELL GENET, V76, P47, DOI 10.1159/000134513; Takeuchi K, 1996, J CLIN ENDOCR METAB, V81, P4496, DOI 10.1210/jc.81.12.4496; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsutsumi E, 1997, PROSTAG OTH LIPID M, V53, P423, DOI 10.1016/S0090-6980(97)00059-2; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Zhang LQ, 1997, GENOMICS, V45, P519, DOI 10.1006/geno.1997.4982; ZHANG LQ, 1993, BIOCHEM BIOPH RES CO, V194, P741, DOI 10.1006/bbrc.1993.1884; Zucker TP, 1998, CIRCULATION, V97, P589	47	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33142	33150		10.1074/jbc.M002319200	http://dx.doi.org/10.1074/jbc.M002319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930400	hybrid			2022-12-25	WOS:000090003800103
J	Facchinetti, V; Lopa, R; Spreafico, F; Bolognese, F; Mantovani, R; Tavner, F; Watson, R; Introna, M; Golay, J				Facchinetti, V; Lopa, R; Spreafico, F; Bolognese, F; Mantovani, R; Tavner, F; Watson, R; Introna, M; Golay, J			Isolation and characterization of the human A-myb promoter: regulation by NF-Y and Sp1	ONCOGENE			English	Article						myb; promoter; Sp1; NF-Y	CELL-CYCLE REGULATION; TRANSCRIPTION FACTOR; B-MYB; GENE-EXPRESSION; IN-VIVO; C-MYB; BURKITTS-LYMPHOMA; MUSCLE CELLS; CLASS-II; BINDING	The A-myb transcription factor shows a restricted tissue distribution and is cell cycle regulated. Furthermore its deregulation has profound effects on the growth and/or differentiation of the cells in which it is normally expressed. We have therefore characterized its promoter. A 12 kb genomic clone was isolated that comprises the first exon, part of the first intron as well as upstream regulatory sequences. Multiple transcription start sites have been identified which operate in both B lymphocytes and epithelial cells and the upsteam region was shown to have promoter, activity. The boundaries of the minimal promoter region (-183-14), of a positive upstream (-538-183) and a negative downstream regulatory region (NRE) (+83+374) have been defined. The NRE is promoter- and orientation-independent but position specific. The A-myb minimal promoter is GC-rich, does not contain any TATA box but has a functional CCAAT box. The! CCAAT box and minimal promoter is highly conserved in the corresponding murine sequence, The CCAAT box efficiently binds the NF-Y complex and its mutation decreases basal promoter activity by 50%, Two Sp1 binding sites are present upstream from the CCAAT box which can bind Sp1 and contribute to A-myb promoter activity by 70 and 30%, respectively. The two Sp1 sites and CCAAT box together contribute to over 80% of A-myb basal promoter activity and are therefore the major regulatory elements. Finally, we show that the promoter is cell cycle regulated and that the SP1 and CCAAT elements are required for S phase induction.	Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Lab Mol Immunohaematol, I-20157 Milan, Italy; Univ Milan, Dept Genet & Biol Microorganisms, I-20133 Milan, Italy; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Imperial College London; Ludwig Institute for Cancer Research	Introna, M (corresponding author), Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Lab Mol Immunohaematol, Via Eritrea 62, I-20157 Milan, Italy.		Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892				Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DeRocco SE, 1997, P NATL ACAD SCI USA, V94, P3240, DOI 10.1073/pnas.94.7.3240; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; FOOS G, 1994, ONCOGENE, V9, P2481; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1997, LEUKEMIA LYMPHOMA, V26, P271, DOI 10.3109/10428199709051776; GOLAY J, 1994, ONCOGENE, V9, P2469; GOLAY J, 1994, J IMMUNOL, V153, P543; Golay J, 1998, J IMMUNOL, V160, P2786; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Huet X, 1996, MOL CELL BIOL, V16, P3789; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Latham KE, 1996, ONCOGENE, V13, P1161; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; METTUS RV, 1994, ONCOGENE, V9, P3077; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Saville MK, 1998, ADV CANCER RES, V72, P109; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wells J, 1996, MOL CELL BIOL, V16, P634; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	53	12	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3931	3940		10.1038/sj.onc.1203730	http://dx.doi.org/10.1038/sj.onc.1203730			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951586				2022-12-25	WOS:000088614300012
J	Oei, SL; Ziegler, M				Oei, SL; Ziegler, M			ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-DEPENDENT TRANSCRIPTION; POLYMERASE-BETA; LIGASE-III; MAMMALIAN-CELLS; STRAND BREAKS; DAMAGED CELLS; XRCC1; IDENTIFICATION; PROTEIN; GENE	In mammalian cells, the base excision repair (BER) pathway is the main route to counteract the mutagenic effects of DNA lesions. DNA nicks induce, among others, DNA polymerase activities and the synthesis of poly(ADP-ribose). It is shown here that poly(ADP-ribose) serves as an energy source for the final and rate-limiting step of BER, DNA ligation. This conclusion was drawn from experiments in which the fate of [P-32]poly(ADP-ribose) or [P-32]NAD added to HeLa nuclear extracts was systematically followed. ATP was synthesized from poly(ADP-ribose) in a pathway that strictly depended on nick-induced DNA synthesis. NAD was used for the synthesis of poly(ADP-ribose), which, in turn, was converted to ATP by pyrophosphorylytic cleavage utilizing the pyrophosphate generated from dNTPs during DNA synthesis. The adenylyl moiety was then preferentially used to adenylate DNA ligase III, from which it was transferred to the 5'-phosphoryl end of the nicked DNA. Finally, ligation to the 3'-OH end resulted in the release of AMP. When using NAD, but not poly(ADP-ribose), in the presence of 3-aminobenzamide, the entire process was blocked, confirming poly(ADP-ribosyl)ation to be the essential initial step. Thus, poly(ADP-ribose) polymerase-1, DNA polymerase beta, and ligase III interact with x-ray repair cross-complementing protein-1 within the BER complex, which ensures that ATP is generated and specifically used for DNA ligation.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Free University of Berlin	Oei, SL (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.			Ziegler, Mathias/0000-0001-6961-2396				ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; [Anonymous], 1985, DNA REPAIR; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DAS SK, 1986, BIOCHEM BIOPH RES CO, V137, P1153, DOI 10.1016/0006-291X(86)90346-3; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Griesenbeck J, 1997, BIOCHEMISTRY-US, V36, P7297, DOI 10.1021/bi962710g; Hagen T, 1997, BBA-PROTEIN STRUCT M, V1340, P7, DOI 10.1016/S0167-4838(97)00021-6; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Maruta H, 1997, BIOCHEM BIOPH RES CO, V236, P265, DOI 10.1006/bbrc.1997.6910; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; OGATA N, 1981, J BIOL CHEM, V256, P4135; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	35	124	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23234	23239		10.1074/jbc.M002429200	http://dx.doi.org/10.1074/jbc.M002429200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930429	hybrid			2022-12-25	WOS:000088419400087
J	Small, KM; Forbes, SL; Brown, KM; Liggett, SB				Small, KM; Forbes, SL; Brown, KM; Liggett, SB			An Asn to Lys polymorphism in the third intracellular loop of the human alpha(2A)-adrenergic receptor imparts enhanced agonist-promoted G(i) coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ESSENTIAL-HYPERTENSION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; SUBTYPE; DESENSITIZATION; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	alpha (2A)-Adrenergic receptors (alpha (2A)AR) are presynaptic autoinhibitory receptors of noradrenergic neurons in the central and peripheral sympathetic nervous systems, which act to dynamically regulate neurotransmitter release. Signaling through the G(i)/G(o) family of G-proteins, the receptor subserves numerous homeostatic and central nervous system functions. A single nucleotide polymorphism of this receptor, which results in an Asn to Lys substitution at amino acid 251 of the third intracellular loop, was identified in the human population. The frequency of Lys-251 was 10-fold greater in African-Americans than in Caucasians, but was not associated with essential hypertension. To determine the consequences of this substitution, wild-type and Lys-251 receptors were expressed in CHO and COS-7 cells. Expression, ligand binding, and basal receptor function were unaffected by the substitution. However, agonist-promoted [S-35]GTP gammaS binding was similar to 40% greater with the Lys-251 receptor. This enhanced agonist function was observed with catecholamines, azepines, and imidazolines albeit to different degrees. In studies of agonist-promoted functional coupling to G(i), the polymorphic receptor displayed enhanced inhibition of adenylyl cyclase (60 +/- 4.4 versus 46 +/- 4.1% inhibition) and markedly enhanced stimulation of MAP kinase (57 +/- versus 15- +/- a-fold increase over basal) compared with wild-type alpha (2A)AR. The potency of epinephrine in stimulating inositol phosphate accumulation was increased similar to4 fold with the Lys-251 receptor. Unlike previously described variants of G-protein-coupled receptors, where the minor species causes either a loss of function or increased non-agonist function, Lys-251 alpha (2A)AR represents a new class of polymorphism whose phenotype is a gain of agonist-promoted function.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), 231 Bethesda Ave,Rm 7511, Cincinnati, OH 45267 USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; Dao TT, 1998, J HYPERTENS, V16, P779, DOI 10.1097/00004872-199816060-00009; DECHASSEVAL R, 1992, NUCLEIC ACIDS RES, V20, P245, DOI 10.1093/nar/20.2.245; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EASON MG, 1992, J BIOL CHEM, V267, P25473; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; GOLDSTEIN DS, 1991, HYPERTENSION S3, V18, P40; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; HOLMES B, 1983, DRUGS, V26, P212, DOI 10.2165/00003495-198326030-00003; Jewell-Motz EA, 1998, BIOCHEMISTRY-US, V37, P15720, DOI 10.1021/bi980999r; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Kotanko P, 1997, HYPERTENSION, V30, P773, DOI 10.1161/01.HYP.30.4.773; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; Liggett SB, 1998, CLIN EXP ALLERGY, V28, P77; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LOCKETTE W, 1995, AM J HYPERTENS, V8, P390, DOI 10.1016/0895-7061(95)00024-J; LUTTRELL LM, 1998, CATECHOLAMINES BRIDG, P466; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MacMillan LB, 1998, RECENT PROG HORM RES, V53, P25; Makaritsis KP, 1999, HYPERTENSION, V34, P403, DOI 10.1161/01.HYP.34.3.403; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Onions KL, 1998, HYPERTENSION, V31, P1230, DOI 10.1161/01.HYP.31.6.1230; RUFFOLO RR, 1993, ANN REV PHARM TOXICO, V32, P243; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Svetkey LP, 1996, HYPERTENSION, V27, P1210, DOI 10.1161/01.HYP.27.6.1210; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X	34	60	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38518	38523		10.1074/jbc.M004550200	http://dx.doi.org/10.1074/jbc.M004550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10948191	hybrid			2022-12-25	WOS:000165739800052
J	Frit, P; Li, RY; Arzel, D; Salles, B; Calsou, P				Frit, P; Li, RY; Arzel, D; Salles, B; Calsou, P			Ku entry into DNA inhibits inward DNA transactions in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; NUCLEOTIDE EXCISION-REPAIR; CELL-FREE-EXTRACTS; RNA-POLYMERASE-II; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; IN-VITRO; TRANSCRIPTION; BINDING	Association of the DNA end-binding Ku70/Ku80 heterodimer with the 460-kDa serine/threonine kinase catalytic subunit forms the DNA-dependent protein kinase (DNA-PK) that is required for double-strand break repair by non-homologous recombination in mammalian cells. Recently, we have proposed a model in which the kinase activity is required for translocation of the DNA end-binding subunit Ku along the DNA helix when DNA-PK assembles on DNA ends. Here, we have questioned the consequences of Ku entry into DNA on local DNA processes by using human nuclear cell extracts incubated in the presence of linearized plasmid DNA, As two model processes, we have chosen nucleotide excision repair (NER) of UVC DNA lesions and transcription from viral promoters. We show that although NER efficiency is strongly reduced on linear DNA, it can be fully restored in the presence of DNA-PK inhibitors. Simultaneously, the amount of NER proteins bound to the UVC-damaged linear DNA is increased and the amount of Ku bound to the same DNA molecules is decreased. Similarly, the poor transcription efficiency exhibited by viral promoters on linear DNA is enhanced in the presence of DNA-PK inhibitor concentrations that prevent Ku entry into the DNA substrate molecule, The present results show that DNA-PK catalytic activity can regulate DNA transactions including transcription in the vicinity of double-strand breaks by controlling Ku entry into DNA.	Inst Pharmacol & Biol Struct, CNRS UMR 5089, F-31077 Toulouse 4, France; Soc Francaise Rech & Investissements, F-33127 Berganton, St Jean Illac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, CNRS UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.		salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806				Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; Frit P, 1998, J MOL BIOL, V284, P963, DOI 10.1006/jmbi.1998.2257; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Izzard RA, 1999, CANCER RES, V59, P2581; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Johnson AP, 1996, MUTAT RES-DNA REPAIR, V364, P103, DOI 10.1016/0921-8777(96)00028-6; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li RY, 1998, J MOL BIOL, V281, P211, DOI 10.1006/jmbi.1998.1949; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Mason RM, 1996, NUCLEIC ACIDS RES, V24, P4946, DOI 10.1093/nar/24.24.4946; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Pastink A, 1999, MUTAT RES-FUND MOL M, V428, P141, DOI 10.1016/S1383-5742(99)00042-3; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; SALLES B, 1995, ANAL BIOCHEM, V232, P37, DOI 10.1006/abio.1995.9964; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhu C, 1996, CANCER SURV, V28, P295	61	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35684	35691		10.1074/jbc.M004315200	http://dx.doi.org/10.1074/jbc.M004315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945984	hybrid			2022-12-25	WOS:000165382000008
J	Creuzenet, C; Schur, MJ; Lin, JJ; Wakarchuk, WW; Lam, JS				Creuzenet, C; Schur, MJ; Lin, JJ; Wakarchuk, WW; Lam, JS			FlaA1, a new bifunctional UDP-GlcNAc C-6 dehydratase C-4 reductase from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE 4,6-DEHYDRATASE; GDP-L-FUCOSE; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE BIOSYNTHESIS; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; MOLECULAR-CLONING; GENE-CLUSTER; ACTIVE-SITE; KEY ENZYME	FlaA1 is a small soluble protein of unknown function in Helicobacter pylori, It has homologues that are essential for the virulence of numerous medically relevant bacteria. FlaA1 was overexpressed as a histidine-tagged protein and purified to homogeneity by nickel chelation and cation exchange chromatography, Spectrophotometric assays, capillary electrophoresis, and mass spectrometry analyses showed that FlaA1 is a novel bifunctional C-6 dehydratase/C-4 reductase specific for UDP-GlcNAc. It converts UDP-GlcNAc into a UDP-4-keto-6-methyl-GlcNAc intermediate, which is stereospecifically reduced into UDP-QuiNAc. Substrate conversions as high as 80% were obtained at equilibrium. The K-m and V-max for UDP-GlcNAc were 159 muM and 65 pmol/min, respectively. No exogenous cofactor was required to obtain full activity of FlaA1, Additional NADH was only used with poor efficiency for the reduction step. The biochemical characterization of FlaA1 is important for the elucidation of biosynthetic pathways that lead to the formation of 2,6-deoxysugars in medically relevant bacteria. It establishes unambiguously the first step of the pathway and provides the means of preparing the substrate UDP-QuiNAc, which is necessary for the study of downstream enzymes.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.		Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Schur, Melissa/0000-0002-6047-1416				Allard STM, 2000, ACTA CRYSTALLOGR D, V56, P222, DOI 10.1107/S0907444999016200; Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; Burrows LL, 2000, INFECT IMMUN, V68, P931, DOI 10.1128/IAI.68.2.931-936.2000; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; He XM, 1996, BIOCHEMISTRY-US, V35, P4721, DOI 10.1021/bi952706p; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; JOSENHANS C, 1995, J BACTERIOL, V177, P3010, DOI 10.1128/jb.177.11.3010-3020.1995; Knirel' Iu A, 1994, Biokhimiia, V59, P1784; Labigne A, 1996, INFECT AGENT DIS, V5, P191; Leclerc G, 1998, J BACTERIOL, V180, P5010, DOI 10.1128/JB.180.19.5010-5019.1998; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; MORENO F, 1981, CELL MOL BIOL, V27, P589; MUOTIALA A, 1992, INFECT IMMUN, V60, P1714, DOI 10.1128/IAI.60.4.1714-1716.1992; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; Sau S, 1996, J BACTERIOL, V178, P2118, DOI 10.1128/jb.178.7.2118-2126.1996; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SMOOT DT, 1990, INFECT IMMUN, V58, P1992, DOI 10.1128/IAI.58.6.1992-1994.1990; SNIPES CE, 1977, J BIOL CHEM, V252, P8113; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; THOMPSON MW, 1992, J GEN MICROBIOL, V138, P779, DOI 10.1099/00221287-138-4-779; THORSON JS, 1993, J AM CHEM SOC, V115, P5827, DOI 10.1021/ja00066a062; THORSON JS, 1993, J AM CHEM SOC, V115, P6993, DOI 10.1021/ja00068a075; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tonetti M, 1998, BIOCHIMIE, V80, P923, DOI 10.1016/S0300-9084(00)88889-6; VARA JA, 1988, J BIOL CHEM, V263, P14992; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933; YU Y, 1992, J BIOL CHEM, V267, P5868	51	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34873	34880		10.1074/jbc.M006369200	http://dx.doi.org/10.1074/jbc.M006369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954725	hybrid			2022-12-25	WOS:000165422800009
J	Nehring, RB; Horikawa, HPM; El Far, O; Kneussel, M; Brandstatter, JH; Stamm, S; Wischmeyer, E; Betz, H; Karschin, A				Nehring, RB; Horikawa, HPM; El Far, O; Kneussel, M; Brandstatter, JH; Stamm, S; Wischmeyer, E; Betz, H; Karschin, A			The metabotropic GABA(B) receptor directly interacts with the activating transcription factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; GAMMA-AMINOBUTYRIC-ACID; DNA-BINDING PROTEINS; NEGATIVELY REGULATE TRANSCRIPTION; RECTIFYING K+ CHANNELS; GLUTAMATE RECEPTORS; NUCLEOCYTOPLASMIC TRANSPORT; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; LEUCINE ZIPPER	G protein-coupled receptors regulate gene expression by cellular signaling cascades that target transcription factors and their recognition by specific DNA sequences, In the central nervous system, heteromeric metabotropic gamma -aminobutyric acid type B (GABA(B)) receptors through adenylyl cyclase regulate cAMP levels, which may control transcription factor binding to the cAMP response element. Using yeast-two hybrid screens of rat brain libraries, we now demonstrate that GABA(B) receptors are engaged in a direct and specific interaction with the activating transcription factor 4 (ATF-4), a member of the cAMP response element-binding protein/ATF family. As confirmed by pull-down assays, ATF-4 associates via its conserved basic leucine zipper domain with the C termini of both GABA(B) receptor (GABA(B)R) 1 and GABA(B)R2 at a site which serves to assemble these receptor subunits in heterodimeric complexes. Confocal fluorescence microscopy shows that GABA(B)R and ATF-4 are strongly coclustered in the soma and at the dendritic membrane surface of both cultured hippocampal neurons as well as retinal amacrine cells in vivo. In oocyte coexpression assays short term signaling of GABA(B)Rs via G proteins was only marginally affected by the presence of the transcription factor, but ATF-4 was moderately stimulated in response to receptor activation in in vivo reporter assays. Thus, inhibitory metabotropic GABA(B)Rs may regulate activity-dependent gene expression via a direct interaction with ATF-4.	Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, D-37070 Gottingen, Germany; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany; Max Planck Inst Neurobiol, Res Grp Neuron Spec Splicing, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Karschin, A (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, D-37070 Gottingen, Germany.	akarsch@gwdg.de	Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345; Kneussel, Matthias/0000-0003-4900-366X				Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Angenstein F, 1998, P NATL ACAD SCI USA, V95, P15078, DOI 10.1073/pnas.95.25.15078; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Barthel F, 1996, NEUROSCIENCE, V70, P417, DOI 10.1016/0306-4522(95)00380-0; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HEIDELBERGER R, 1991, P NATL ACAD SCI USA, V88, P7135, DOI 10.1073/pnas.88.16.7135; Heuss C, 1999, NAT NEUROSCI, V2, P1070, DOI 10.1038/15996; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K, 1998, P NATL ACAD SCI USA, V95, P14991, DOI 10.1073/pnas.95.25.14991; KERR DIB, 1995, PHARMACOL THERAPEUT, V67, P187, DOI 10.1016/0163-7258(95)00016-A; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Koulen P, 1998, EUR J NEUROSCI, V10, P1446, DOI 10.1046/j.1460-9568.1998.00156.x; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Persico AM, 1996, REV NEUROSCIENCE, V7, P233; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V444, P669, DOI 10.1113/jphysiol.1991.sp018900; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Sodickson DL, 1996, J NEUROSCI, V16, P6374; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; WOJCIK WJ, 1984, MOL PHARMACOL, V25, P24; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	64	102	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35185	35191		10.1074/jbc.M002727200	http://dx.doi.org/10.1074/jbc.M002727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10924501	hybrid, Green Published			2022-12-25	WOS:000165422800049
J	Zhong, XT; Malhotra, R; Guidotti, G				Zhong, XT; Malhotra, R; Guidotti, G			Regulation of yeast ectoapyrase Ynd1p activity by activator subunit Vma13p of vacuolar H+ -ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PREPRO-ALPHA-FACTOR; BRAIN ECTO-APYRASE; SACCHAROMYCES-CEREVISIAE; GOLGI-APPARATUS; NUCLEOSIDE-DIPHOSPHATASE; GUANOSINE DIPHOSPHATASE; NUCLEOTIDE SULFATE; GENE ENCODES; MEMBRANE	CD39-like ectoapyrases are involved in protein and lipid glycosylation in the Golgi lumen of Saccharomyces cerevisiae, By using a two-hybrid screen, we found that air activator subunit (Vma13p) of yeast vacuolar HC ATPase:CV-ATPase) binds to the cytoplasmic domain of Ynd1p, a yeast ectoapyrase. Interaction of Ynd1p with Vma13p was demonstrated by direct binding and coimmunoprecipitation, Surprisingly, the membrane-bound ADPase activity of Ynd1p in a vma13 Delta mutant was drastically increased compared with that of Ynd1p in VMA13 cells. A similar increase in the apyrase activity of Ynd1p was found in a vma1 Delta mutant, in which the catalytic subunit A of V-ATPase is missing, and the membrane peripheral subunits including Vma13p are dissociated from the membranes. However, the E286Q mutant of VMA1, which assembles inactive V-ATPase complex including Vma13p in the membrane, retained wild type levels' of Ynd1p activity, demonstrating that the presence of Vmal13p rather than the function of V-ATPase in the membrane represses Ynd1p activity. These results suggest that association of Vma13p with the cytoplasmic domain of Ynd1p regulates its apyrase activity in the Golgi lumen.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.			Malhotra, Rajeev/0000-0003-0120-4630	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Biederbick A, 1999, J CELL SCI, V112, P2473; BRANDAN E, 1982, BIOCHEMISTRY-US, V21, P4640, DOI 10.1021/bi00262a019; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Forgac M, 2000, J EXP BIOL, V203, P71; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; Graham LA, 2000, J EXP BIOL, V203, P61; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HO MN, 1993, J BIOL CHEM, V268, P18286; HURT EC, 1988, EUR J CELL BIOL, V46, P554; James P, 1996, GENETICS, V144, P1425; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KUHN NJ, 1977, BIOCHEM J, V168, P423, DOI 10.1042/bj1680423; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Makita K, 1998, INT J HEMATOL, V68, P297; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MELLMAN I, 1992, J EXP BIOL, V172, P39; MILLER JH, 1992, SHORT COURSE BACTERI, P439; Nagy AK, 1998, J BIOL CHEM, V273, P16043, DOI 10.1074/jbc.273.26.16043; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1986, METHODS YEAST GENETI, P160; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	65	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35592	35599		10.1074/jbc.M006932200	http://dx.doi.org/10.1074/jbc.M006932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954728	hybrid, Green Published			2022-12-25	WOS:000165422800100
J	Cornillon, S; Pech, E; Benghezal, M; Ravanel, K; Gaynor, E; Letourneur, F; Bruckert, F; Cosson, P				Cornillon, S; Pech, E; Benghezal, M; Ravanel, K; Gaynor, E; Letourneur, F; Bruckert, F; Cosson, P			Phg1p is a nine-transmembrane protein superfamily member involved in Dictyostelium adhesion and phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-MEDIATED INTEGRATION; CELL-DEATH; DISCOIDEUM; MUTANTS; CYTOKINESIS	To identify the molecular mechanisms involved in phagocytosis, we generated random insertion mutants of Dictyostelium discoideum and selected two mutants defective for phagocytosis. Both represented insertions in the same gene, named PHG1. This gene encodes a polytopic membrane protein with an N-terminal lumenal domain and nine potential transmembrane segments. Homologous genes can be identified in many species; however, their function is yet to be elucidated. Disruption of PHG1 caused a selective defect in phagocytosis of latex beads and Escherichia coli, but not Klebsiella aerogenes bacteria. This defect in phagocytosis was caused by a decrease in the adhesion of mutant cells to phagocytosed particles. These results indicate that the Phg1 protein is involved in the adhesion of Dictyostelium to various substrates, a crucial event of phagocytosis and demonstrate the usefulness of a genetic approach to dissect the molecular events involved in the phagocytic process.	Univ Geneva, Ctr Med, Dept Morphol, CH-1211 Geneva 4, Switzerland; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; CNRS, UPR 412, Inst Biol & Chim Prot, F-69367 Lyon, France; CEA, CNRS, UMR 314, Lab Biochim & Biophys Syst Integres, F-38054 Grenoble, France	University of Geneva; Stanford University; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Cosson, P (corresponding author), Univ Geneva, Ctr Med, Dept Morphol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	pierre.cosson@medecine.unige.ch		Letourneur, Francois/0000-0003-2232-6127				ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Chang WT, 1995, PLASMID, V34, P175, DOI 10.1006/plas.1995.0003; Chluba-de Tapia J, 1997, GENE, V197, P195, DOI 10.1016/S0378-1119(97)00263-1; COHEN CJ, 1994, J CELL BIOL, V126, P955, DOI 10.1083/jcb.126.4.955; CORNILLON S, 1994, J CELL SCI, V107, P2691; Cornillon S, 1998, CELL DEATH DIFFER, V5, P416, DOI 10.1038/sj.cdd.4400361; COZENSROBERTS C, 1990, BIOPHYS J, V58, P107, DOI 10.1016/S0006-3495(90)82357-2; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Favre-Bonte S, 1999, INFECT IMMUN, V67, P554, DOI 10.1128/IAI.67.2.554-561.1999; Hacker U, 1997, J CELL SCI, V110, P105; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; LYDAN MA, 1991, BIOCHEM BIOPH RES CO, V174, P990, DOI 10.1016/0006-291X(91)91516-F; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Monnat J, 1997, FEBS LETT, V418, P357, DOI 10.1016/S0014-5793(97)01415-4; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; Rivero F, 1999, MOL BIOL CELL, V10, P1205, DOI 10.1091/mbc.10.4.1205; Schimmoller F, 1998, GENE, V216, P311, DOI 10.1016/S0378-1119(98)00349-7; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; VOGEL G, 1980, J CELL BIOL, V86, P456	25	158	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34287	34292		10.1074/jbc.M006725200	http://dx.doi.org/10.1074/jbc.M006725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944536	hybrid			2022-12-25	WOS:000165095300041
J	Koza, RA; Hohmann, SM; Guerra, C; Rossmeisl, M; Kozak, LP				Koza, RA; Hohmann, SM; Guerra, C; Rossmeisl, M; Kozak, LP			Synergistic gene interactions control the induction of the mitochondrial uncoupling protein (Ucp1) gene in white fat tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; DIET-INDUCED OBESITY; MESSENGER-RNA; ADULT HUMANS; MICE; ADIPOCYTES; EXPRESSION; PHEOCHROMOCYTOMA; SUSCEPTIBILITY; AGONIST	Among a selected group of mouse strains susceptible to dietary obesity, those with an enhanced capacity for Ucp1 and brown adipocyte induction in white fat preferentially lost body weight following adrenergic stimulation. Eased on the generality of this mechanism for reducing obesity, a genetic analysis was initiated to identify genes that control brown adipocyte induction in white fat depots in mice, Quantitative trait locus (QTL) analysis was performed using the variations of retroperitoneal fat Ucp1 mRNA expression in progeny of genetic crosses between the A/J and C57BL/6J parental strains and selected AXE recombinant inbred strains. Three A/J-derived loci on chromosomes 2, 3, and 8 and one C57BL/6J locus on chromosome 19 were linked to Ucp1 induction in retroperitoneal fat. Although A/J-derived alleles seemed to contribute to elevated Ucp1 expression, the C57BL/6J allele on chromosome 19 increased Ucp1 mRNA to levels higher than parental values. Thus, novel patterns of C57BL/6J and A/J recombinant genotypes among the four mapped loci resulted in a transgressive variation of Ucp1 phenotypes, Although the extent, of the interchromosomal interactions have not been fully explored, strong synergistic interactions occur between a C57BL/6J allele on chromosome 19 and an A/J allele on chromosome a In addition to selective synergistic interactions between loci, variations in recessive and dominant effects also contribute to the final levels of Ucp1 expression.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	Kozaklp@pbrc.edu	Rossmeisl, Martin/C-1892-2012; Guerra, Carmen/K-5852-2014; Rossmeisl, Martin/CAF-0060-2022	Rossmeisl, Martin/0000-0001-8534-4002; Rossmeisl, Martin/0000-0001-8534-4002; Guerra, Carmen/0000-0002-3891-046X				Champigny O, 1996, J LIPID RES, V37, P1907; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHEVERUD JM, 1995, GENETICS, V139, P1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; COUSIN B, 1992, J CELL SCI, V103, P931; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Doerge RW, 1996, GENETICS, V142, P285; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FRANKEL WN, 1995, MAMM GENOME, V6, P830, DOI 10.1007/BF00292431; GARRUTI G, 1992, INT J OBESITY, V16, P383; Ghorbani M, 1997, BIOCHEM PHARMACOL, V54, P121, DOI 10.1016/S0006-2952(97)00162-7; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; LANDER ES, 1989, GENETICS, V121, P185; Lean M. E. J., 1986, BROWN ADIPOSE TISSUE, P339; LEAN MEJ, 1986, INT J OBESITY, V10, P219; LEAN MEJ, 1986, CLIN SCI, V71, P291, DOI 10.1042/cs0710291; LONCAR D, 1988, J ULTRA MOL STRUCT R, V101, P199, DOI 10.1016/0889-1605(88)90010-9; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; MARTINEZ O, 1992, THEOR APPL GENET, V88, P349; MCMILLAN I, 1974, HEREDITY, V32, P349, DOI 10.1038/hdy.1974.43; NEDERGAARD J, 1986, BROWN ADIPOSE TISSUE, P153; RICQUIER D, 1982, J CLIN ENDOCR METAB, V54, P803; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; YOUNG P, 1984, FEBS LETT, V167, P10, DOI 10.1016/0014-5793(84)80822-4	33	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34486	34492		10.1074/jbc.M002136200	http://dx.doi.org/10.1074/jbc.M002136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931824	hybrid			2022-12-25	WOS:000165095300066
J	Lee, WY; Loflin, P; Clancey, CJ; Peng, H; Lever, JE				Lee, WY; Loflin, P; Clancey, CJ; Peng, H; Lever, JE			Cyclic nucleotide regulation of Na+/glucose cotransporter (SGLT1) mRNA stability - Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3 '-untranslated region critical for stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENT; 3' UNTRANSLATED REGION; LLC-PK1 CELLS; BINDING-PROTEIN; C-FOS; GLUCOSE TRANSPORTERS; GENE-EXPRESSION; AMP ELEVATION; HIGH-AFFINITY	Expression of the Nac-coupled glucose cotransporter SGLT1 is regulated post-transcriptionally at the level of mRNA stability. We have previously demonstrated that cAMP-dependent stabilization of the SGLT1 message was correlated with the protein phosphorylation-dependent binding of cytoplasmic proteins to a uridine-rich sequence (URE) in the 3'-untranslated region (UTR). In the present study, the regulatory role of the URE was demonstrated by inserting it into the 3'-UTR of a beta -globin reporter minigene under the control of the tetracycline-regulated promoter. The resultant chimeric globin/SGLT1 mRNA expressed after transfection into LLC-PK1 cells exhibited a decreased half-life compared with the beta -globin control, indicating that the URE serves a destabilizing function, Activation of protein kinase A stabilized the chimeric message but not the beta -globin control, indicating the presence of a regulatory stabilizing sequence within the URE. A 38-kDa nucleocytoplasmic protein was identified that recognized a 12-nucleotide binding site within the URE, A mutation in this binding site that prevented protein binding assayed in vitro by UV cross-linking also prevented protein kinase A-dependent stabilization of the chimeric message assayed in vivo, These findings identify the interaction between a 38-kDa nucleocytoplasmic protein and a regulatory uridine-rich sequence in the 3'-UTR as critical for cAMP-mediated SGLT1 message stabilization.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	University of Texas System	Lever, JE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	Julia.E.Lever@uth.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027400, R37DK027400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN M, 1993, J BIOL CHEM, V268, P24138; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; DAYHUFF TJ, 1992, BIOTECHNIQUES, V13, P499; DOMINGUEZ JH, 1994, J AM SOC NEPHROL, V5, pS29; Duret L, 1997, CURR OPIN STRUC BIOL, V7, P399, DOI 10.1016/S0959-440X(97)80058-9; FAN XC, 1999, P NATL ACAD SCI USA, V96, P5; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LEE WS, 1994, J BIOL CHEM, V269, P12032; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PENG H, 1993, J CELL PHYSIOL, V154, P238, DOI 10.1002/jcp.1041540205; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; Short S, 2000, J BIOL CHEM, V275, P12963, DOI 10.1074/jbc.275.17.12963; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33998	34008		10.1074/jbc.M005040200	http://dx.doi.org/10.1074/jbc.M005040200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10950955	hybrid			2022-12-25	WOS:000090104600113
J	Mothe-Satney, I; Brunn, GJ; McMahon, LP; Capaldo, CT; Abrahams, RT; Lawrence, JC				Mothe-Satney, I; Brunn, GJ; McMahon, LP; Capaldo, CT; Abrahams, RT; Lawrence, JC			Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P70 S6 KINASE; TRANSLATIONAL REGULATOR; CELL-PROLIFERATION; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; GROWTH-FACTORS; INSULIN; INITIATION; PATHWAY	The role and control of the four rapamycin-sensitive phosphorylation sites that govern the association of PHAS-I with the mRNA cap-binding protein, eukaryotic initiation factor 4E (eIF4E), were investigated by using newly developed phospho-specific antibodies. Thr(P)-36/45 antibodies reacted with all three forms of PHAS-I that were resolved when cell extracts were subjected to SDS-polyacrylamide gel electrophoresis. Thr(P)-69 antibodies bound the forms of intermediate and lowest mobility, and Ser(P)-64 antibodies reacted only with the lowest mobility form. A portion of PHAS-I that copurified with eIF4E reacted with Thr(P)-36/45 and Thr(P)-69 antibodies but not with Ser(P)-64 antibodies. Insulin and/or amino acids increased, and rapamycin decreased, the reactivity of all three antibodies with PHAS-I in both HEK293 cells and 3T3-L1 adipocytes, Immunoprecipitated epitope-tagged mammalian target of rapamycin (mTOR) phosphorylated Thr-36/45. mTOR also phosphorylated Thr-69 and Ser-64 but only when purified immune complexes were incubated with the activating antibody, mTAb1, interestingly, the phosphorylation of Thr-69 and Ser-64 was much more sensitive to inhibition by rapamycin-FKBP12 than the phosphorylation of Thr-36/45, and the phosphorylation of Ser-64 by mTOR was facilitated by phosphorylation of Thr-SG, Thr-45, and Thr-69. In these respects the phosphorylation of PHAS-I by mTOR in vitro resembles the ordered phosphorylation of PHAS-I in cells.	Univ Virginia, Hlth Syst, Dept Pharmacol, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	University of Virginia; University of Virginia; Duke University	Lawrence, JC (corresponding author), Univ Virginia, Hlth Syst, Dept Pharmacol, Sch Med, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.		MOTHE-SATNEY, ISABELLE/Q-6377-2016; Capaldo, Chris/B-4143-2010	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385; 	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	33	111	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33836	33843		10.1074/jbc.M006005200	http://dx.doi.org/10.1074/jbc.M006005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942774	hybrid			2022-12-25	WOS:000090104600091
J	Ritz-Laser, B; Estreicher, A; Gauthier, B; Philippe, J				Ritz-Laser, B; Estreicher, A; Gauthier, B; Philippe, J			The paired homeodomain transcription factor Pax-2 is expressed in the endocrine pancreas and transactivates the glucagon gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; DNA-BINDING; ADHESION MOLECULE; WILMS-TUMOR; ELEMENT; DOMAIN; IDENTIFICATION; PROTEINS; KIDNEY; REGION	Glucagon gene expression is controlled by at least four DNA elements within the promoter; G2, G3, and G4 confer islet-specific expression, while G1 restricts glucagon transcription to Lu cells. Two islet-specific complexes are formed on G3, the insulin-responsive element of the glucagon gene; one of these corresponds to the paired homeodomain protein Pax-6, a major glucagon gene transactivator that plays a crucial role in alpha cell development. We describe here the identification of the second complex as Pax-2, another member of the paired box family. Pax-2 is known to be crucial for the development of the urogenital tract and of the central nervous system, but its presence in the endocrine pancreas has not been reported. We detected Pax-2 gene expression by RT-PCR; in islets, Pax-2 is present as two alternative splicing isoforms, Pax-2A and Pax-BE, whereas in the glucagon- and insulin-producing cell lines alpha TC1 and Min6, a distinct isoform, Pax-2D2, is found in addition to Pax-BE. Both islet-specific isoforms bind to the enhancer element G3 and to the alpha -specific promoter element G1 that also interacts with Pax-6. Pax-2A and Pax-BE dose-dependently activate transcription from the 63 and the G1 elements both in heterologous and in glucagon-producing cells. Our data indicate that Pax-a is the third paired domain protein present in the endocrine pancreas and that one of its roles may be the regulation of glucagon gene expression.	Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland	University of Geneva	Ritz-Laser, B (corresponding author), Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland.	Beate.Laser@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; Estreicher, Anne/0000-0001-6828-2508				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; Eberhard D, 1999, CANCER RES, V59, p1716S; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Havik B, 1999, BIOCHEM BIOPH RES CO, V266, P532, DOI 10.1006/bbrc.1999.1854; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; Larsson LI, 1998, MECH DEVELOP, V79, P153, DOI 10.1016/S0925-4773(98)00182-8; Lechner MS, 1996, J BIOL CHEM, V271, P21088, DOI 10.1074/jbc.271.35.21088; MANSOURI A, 1994, J CELL SCI, P35; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; NORNES HO, 1990, DEVELOPMENT, V109, P797; Pfeffer PL, 2000, DEVELOPMENT, V127, P1017; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Song DL, 1996, DEVELOPMENT, V122, P627; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sun HM, 1997, P NATL ACAD SCI USA, V94, P5156, DOI 10.1073/pnas.94.10.5156; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; Tavassoli K, 1997, HUM GENET, V101, P371, DOI 10.1007/s004390050644; Terzic J, 1998, INT J DEV BIOL, V42, P701; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; Zhou YH, 2000, GENE, V245, P319, DOI 10.1016/S0378-1119(00)00019-6	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32708	32715		10.1074/jbc.M005704200	http://dx.doi.org/10.1074/jbc.M005704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10938089	hybrid			2022-12-25	WOS:000090003800047
J	Kanda, K; Hu, HM; Zhang, L; Grandchamps, J; Boxer, LM				Kanda, K; Hu, HM; Zhang, L; Grandchamps, J; Boxer, LM			NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; VIRTUALLY IDENTICAL ENHANCERS; BURKITTS-LYMPHOMA CELLS; ALPHA PROTEOLYSIS; 3'-IGH ENHANCER; TRANSCRIPTION; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; DOWNSTREAM	The c-myc gene is translocated to one of the immunoglobulin genes in Burkitt's lymphoma resulting in deregulated expression of c-myc. Several enhancers have been shown to be important for expression of the immunoglobulin heavy chain gene. Four enhancer regions (murine-hypersensitive sites (MHS) 1, 2, 3, and 4) located 3' of the murine immunoglobulin heavy chain gene play a role in activating expression of the translocated c-myc gene. The enhancer regions also result in a shift in transcriptional initiation from the P2 promoter to P1 that is characteristic of the translocated c-myc allele. We found that the most 3' enhancer region (MHS4) activated the c-myc promoter by 46-fold in the Raji Burkitt's lymphoma cell line, and it was the most active enhancer in these cells. The addition of enhancer regions MHS1,2 and 3 to MHS4 increased c-myc transcription by an additional 3-fold and resulted in the full promoter shift from Pa to P1. By deletion analysis of enhancer region MHS4, we located a region that was critical for the transcriptional activity of MHS4. Electrophoretic mobility shift assay analysis revealed that NF-kappa B/Rel family members bound to this region. Mutation of the NF-kappa B binding site abolished both the enhancer activity and the promoter shift activity of MHS4. An active NF-kappa B site was also identified in the human HS4 enhancer. Inhibition of c-myc promoter activity driven by the immunoglobulin enhancers was observed with expression of a super-repressor I kappa B alpha construct. These results indicate that the NF-kappa B/Rel transcription factors play an important role in the deregulation of the translocated c-myc gene in Burkitt's lymphoma and suggest that interference with NF-kappa B function may represent a new approach to the treatment of Burkitt's lymphoma.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, S-161, Stanford, CA 94305 USA.				NCI NIH HHS [CA69322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chauveau C, 1998, EUR J IMMUNOL, V28, P3048, DOI 10.1002/(SICI)1521-4141(199810)28:10<3048::AID-IMMU3048>3.0.CO;2-V; Chen CQ, 1997, J IMMUNOL, V159, P1310; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HUANG Y, 1995, MOL MED, V1, P647, DOI 10.1007/BF03401605; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KESSLER DJ, 1992, ONCOGENE, V7, P2447; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; Mills FC, 1997, J EXP MED, V186, P845, DOI 10.1084/jem.186.6.845; Ong J, 1998, J IMMUNOL, V160, P4896; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; Pinaud E, 1997, EUR J IMMUNOL, V27, P2981, DOI 10.1002/eji.1830271134; Saleque S, 1997, J IMMUNOL, V158, P4780; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Snapper CM, 1996, J IMMUNOL, V156, P183; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Tang H, 1999, IMMUNITY, V11, P517, DOI 10.1016/S1074-7613(00)80127-2; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Williams SA, 1997, ANN ONCOL, V8, P25, DOI 10.1023/A:1008289430541	36	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32338	32346		10.1074/jbc.M004148200	http://dx.doi.org/10.1074/jbc.M004148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10931834	hybrid			2022-12-25	WOS:000089858900107
J	Blaydes, JP; Craig, AL; Wallace, M; Ball, HML; Traynor, NJ; Gibbs, NK; Hupp, TR				Blaydes, JP; Craig, AL; Wallace, M; Ball, HML; Traynor, NJ; Gibbs, NK; Hupp, TR			Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways	ONCOGENE			English	Article						p53; cdk; ionizing; radiation; DRB; Roscovitine	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITORS; NORMAL HUMAN FIBROBLASTS; DNA-BINDING FUNCTION; RNA-POLYMERASE-II; WILD-TYPE P53; PROTEIN-KINASE; IONIZING-RADIATION; MOUSE FIBROBLASTS	High level activation of p53-dependent transcription occurs following cellular exposure to genotoxic damaging agents such as UV-C, while ionizing radiation damage does not induce a similarly potent induction of p53-dependent gene expression. Reasoning that one of the major differences between UV-C and ionizing radiation damage is that the latter does not inhibit general transcription, we attempted to reconstitute p53-dependent gene expression in ionizing irradiated cells by co-treatment with selected transcription inhibitors that alone do not activate p53. p53-dependent transcription can be dramatically enhanced by the treatment of ionizing irradiated cells with low doses of DRB, which on its own does not induce p53 activity, The mechanism of ionizing radiation-dependent activation of p53-dependent transcription using DRB is more likely due to inhibition of gene transcription rather than prolonged DNA damage, as the non-genotoxic and general transcription inhibitor Roscovitine also synergistically activates p53 function in ionizing irradiated cells, These results identify two distinct signal transduction pathways that cooperate to fully activate p53-dependent gene expression: one responding to lesions induced by ionizing radiation and the second being a kinase pathway that regulates general RNA Polymerase it activity.	Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Photobiol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Ninewells Med Sch, Dundee Canc Res Ctr, Canc Res Campaign Labs,Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209; Gibbs, Neil K./0000-0003-2311-2489				ABARZUA P, 1995, CANCER RES, V55, P3490; Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLAYDES J, 2000, STRESS RESPONSES MET; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond J, 1996, ONCOGENE, V13, P2097; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chehab NH, 2000, GENE DEV, V14, P278; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hardmeier R, 1997, P NATL ACAD SCI USA, V94, P7572, DOI 10.1073/pnas.94.14.7572; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Hughes PE, 1997, NEUROREPORT, V8, pR5; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin Martin F., 1999, Cancer Research, V59, P3845; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Poele RHT, 1999, ONCOGENE, V18, P5765, DOI 10.1038/sj.onc.1202961; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Reavy HJ, 1997, PHOTOCHEM PHOTOBIOL, V66, P368, DOI 10.1111/j.1751-1097.1997.tb03160.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STONEWOLFF DS, 1981, MUTAT RES, V82, P147, DOI 10.1016/0027-5107(81)90146-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; YAMADA T, 1994, SEMICOND SCI TECH, V9, P775, DOI 10.1088/0268-1242/9/5S/102; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883	75	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3829	3839		10.1038/sj.onc.1203773	http://dx.doi.org/10.1038/sj.onc.1203773			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951576				2022-12-25	WOS:000088614300001
J	Dazard, JE; Piette, J; Basset-Seguin, N; Blanchard, JM; Gandarillas, A				Dazard, JE; Piette, J; Basset-Seguin, N; Blanchard, JM; Gandarillas, A			Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size	ONCOGENE			English	Article						cell cycle; mitosis; G2/M; c-myc; endoreplication; checkpoints	P53-MEDIATED TRANSCRIPTIONAL ACTIVITY; GROWTH-FACTOR-BETA; NORMAL HUMAN SKIN; TERMINAL DIFFERENTIATION; WILD-TYPE; IN-VITRO; EPIDERMAL-KERATINOCYTES; MALIGNANT PROGRESSION; MURINE KERATINOCYTES; INVOLUCRIN SYNTHESIS	p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies, One of its transcriptional targets is MDM2, which in turn down-regulates p53, The role of the p53/MDM2 regulatory loop upon genotoxic stress is well documented, but less is known about its role in normal tissue homeostasis. We have explored this pathway during the different transitions of the human epidermal differentiation programme and after isolating stem cells, transit amplifying cells or differentiating cells from epidermis, Maximum expression of p53 was found in proliferating keratinocytes. A striking and transient induction of MDM2 and a down-modulation of p53 characterized the transition from proliferation to differentiation in primary human keratinocytes. These changes were delayed in late differentiating carcinoma cells, and were clearly different in suspended primary fibroblasts. Interestingly, these changes correlated with an increase in cell size, at the time of irreversible commitment to differentiation. Induction of MDM2 was also associated with suppression of proliferation in normal, or hyperproliferative, psoriatic epidermis, Moreover, both proteins were induced as keratinocytes mere driven to leave the stem cell compartment by c-Myc activation, Overall, our results show a critical regulation of the p53/MDM2 pathway at the epidermal transition from proliferation to differentiation.	Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Hop St Louis, Inst Rech Peau, INSERM, U532, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gandarillas, A (corresponding author), Inst Genet Mol, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.							ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; BURNHAM JC, 1993, B HIST MED, V67, P1; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Di Leonardo A, 1997, CANCER RES, V57, P1013; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GANDARILLAS A, IN PRESS ONCOGENE; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HALL PA, 1989, DEVELOPMENT, V106, P619; HALL PA, 1993, ONCOGENE, V8, P203; Hannuksela-Svahn A, 1999, ACTA DERM-VENEREOL, V79, P195; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOFFMAN R, 1989, BLOOD, V74, P1196; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACK EM, 1990, HEPATOLOGY, V11, P286, DOI 10.1002/hep.1840110220; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; JONES MA, 1973, PERSPECT AM HIST, V7, P3; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laktionov PP, 1999, NUCLEIC ACIDS RES, V27, P2315, DOI 10.1093/nar/27.11.2315; LAVKER RM, 1983, J INVEST DERMATOL S, V81, P121; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCKAY IA, 1995, CLIN DERMATOL, V13, P105, DOI 10.1016/0738-081X(95)93817-8; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MILS V, 1994, DIFFERENTIATION, V58, P77, DOI 10.1046/j.1432-0436.1994.5810077.x; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOLES JP, 1993, ONCOGENE, V8, P583; MOSNER J, 1994, ONCOGENE, V9, P3321; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigro JM, 1997, CANCER RES, V57, P3635; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; OLSON DC, 1993, ONCOGENE, V8, P2353; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKINSON FK, 1983, CARCINOGENESIS, V4, P857, DOI 10.1093/carcin/4.7.857; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Peled A, 1996, ONCOGENE, V13, P1677; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Prives C, 1999, J PATHOL, V187, P112; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Sidransky D, 1996, ANNU REV MED, V47, P285; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOINI Y, 1994, BRIT J DERMATOL, V131, P514; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1993, DEVELOPMENT, P185; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; [No title captured]	93	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3693	3705		10.1038/sj.onc.1203695	http://dx.doi.org/10.1038/sj.onc.1203695			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949923				2022-12-25	WOS:000088568400001
J	Odaka, R; Mally, A; Elliot, LT; Meyers, S				Odaka, R; Mally, A; Elliot, LT; Meyers, S			Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8)	ONCOGENE			English	Article						ETO; nuclear localization signal; nuclear import; subnuclear structure	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; GRANULOCYTIC DIFFERENTIATION; FUSION PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; GENE; AML1; T(8-21)	ETO (MTG8) was first described due to its involvement in the (8;21) translocation frequently observed in acute myeloid leukemias. In the t(8;21) the AML1 gene on chromosome 21 is fused to ETO on chromosome 8. The resultant hybrid protein is comprised of the DNA, binding domain of AML-1 and the majority of ETO. This study examines the subnuclear distributions of ETO, AML-1B and AML-1/ETO proteins fused to green fluorescence protein in living cells using fluorescence microscopy. Further, we identified a 40 amino acid portion of ETO (amino acids 241-280) that was sufficient to cause nuclear import of green fluorescent protein. Mutational analysis demonstrated that lysine 265 and/or arginine 266 were required for nuclear impart of ETO, but that the surrounding basic residues were not critical, ETO interacted with the nuclear import proteins importin-alpha and beta in vitro, and mutations in ETO that abolish nuclear localization also abolished the in vitro interaction with importin-alpha and beta. These data suggest that ETO enters the nucleus via an importin-mediated pathway. additionally, ETO and AMIL-1/ETO co-localized to punctate nuclear bodies distinct from those containing promyelocytic leukemia protein. Nuclear body formation was dependent upon a region of ETO N-terminal to the nuclear localization signal. Thus, ETO and AML-1/ ETO reside in potentially novel subnuclear compartments.	Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Feist Weiler Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Meyers, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, F7-36,1501 Kings Highway, Shreveport, LA 71130 USA.		Odaka, Yoshinobu/AAY-6918-2021	Odaka, Yoshinobu/0000-0003-3966-5475	NATIONAL CANCER INSTITUTE [R29CA076186] Funding Source: NIH RePORTER; NCI NIH HHS [CA76186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1995, TRENDS CELL BIOL, V5, P189, DOI 10.1016/S0962-8924(00)88991-6; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; DETHE H, 1991, CELL, V66; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; Frank R, 1995, ONCOGENE, V11, P2667; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KOHLER MS, 1997, FEBS LETT, V417, P107; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOZU T, 1993, BLOOD, V82, P1270; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LENNY N, 1995, ONCOGENE, V11, P1761; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERS S, 1995, MOL CELL BIOL, V15, P1947; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NIWAKAWAKITA M, 1995, GENOMICS, V29, P755, DOI 10.1006/geno.1995.9941; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROWLEY JD, 1984, CANCER RES, V44, P3159; Sacchi N, 1996, ONCOGENE, V12, P437; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Speck NA, 1999, CANCER RES, V59, p1789S; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Takeda S, 1997, CYTOGENET CELL GENET, V76, P87, DOI 10.1159/000134521; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uchida N, 1997, BLOOD, V89, P2706, DOI 10.1182/blood.V89.8.2706; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Welch K, 1999, MOL CELL BIOL, V19, P8400; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	63	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3584	3597		10.1038/sj.onc.1203689	http://dx.doi.org/10.1038/sj.onc.1203689			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951564				2022-12-25	WOS:000088568300004
J	Arora, PD; Manolson, MF; Downey, GP; Sodek, J; McCulloch, CAG				Arora, PD; Manolson, MF; Downey, GP; Sodek, J; McCulloch, CAG			A novel model system for characterization of phagosomal maturation, acidification, and intracellular collagen degradation in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR MEDIATED PHAGOCYTOSIS; NATIVE COLLAGEN; LATE ENDOSOMES; MACROPHAGES; TRANSPORT; DIGESTION; MEMBRANE; SUSCEPTIBILITY; CATHEPSIN-B1; LOCALIZATION	Intracellular collagen degradation by fibroblasts is an important but poorly understood pathway for the physiological remodeling of mature connective tissues. The objective of this study was to determine whether gingival-fibroblasts that express endogenous alpha (2)beta (1) integrin, the collagen:receptor, would exhibit the cellular machinery required for phagosomal maturation and collagen degradation. There was a time-dependent increase of collagen bead internalization and a time-dependent decrease of bead-associated alpha (2)beta (1) integrin after initial bead; binding. beta -Actin and gelsolin associated transiently with beads (0-30 min) followed by LAMP-1 (60-240 min) and cathepsin B (30-240 min). Cytochalasin D prevented phagosome formation and also prevented the sequential fusion of early endosomes with lysosomes, Collagen bead-associated pH was progressively reduced from: 7.25 to 5.4, which was contemporaneous with progressive increases in degradation of bead-associated collagen (30-120 min). Concanamycin blocked acidification of phagolysosomes and collagen degradation but not phagosome maturation, Phagosomal acidification was partly dependent on elevated intracellular calcium. These studies demonstrate that the cellular machinery required for intracellular collagen degradation in fibroblasts closely resembles the vacuolar system in macrophages.	Univ Toronto, MRC, Grp Periodontal Physiol, Toronto, ON M5S 3E8, Canada; Univ Toronto, Fac Dent, Toronto, ON M5S 3E8, Canada; Univ Toronto, Fac Med, Div Respirol, Toronto, ON M5S 3E8, Canada; Univ Hlth Network, Inst Res, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	McCulloch, CAG (corresponding author), Univ Toronto, MRC, Grp Periodontal Physiol, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E8, Canada.			Manolson, Morris/0000-0001-8755-5460; Downey, Gregory P/0000-0003-3253-5862				ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; Chou DHI, 1996, J IMMUNOL, V156, P4354; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; ETHERINGTON DJ, 1976, BIOCHEM J, V153, P199, DOI 10.1042/bj1530199; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; EVERTS V, 1985, COLLAGEN REL RES, V5, P315; EVERTS V, 1994, MATRIX BIOL, V14, P665; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASSELL TM, 1983, AM J PATHOL, V112, P218; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; KIELTY CM, 1993, BIOCHEM BIOPH RES CO, V191, P1230, DOI 10.1006/bbrc.1993.1349; KNOWLES GC, 1991, J CELL SCI, V98, P551; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LANG T, 1988, EUR J CELL BIOL, V46, P39; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; LUTZ DA, 1993, ANAL BIOCHEM, V214, P205, DOI 10.1006/abio.1993.1478; MUROI M, 1993, BIOCHEM BIOPH RES CO, V193, P999, DOI 10.1006/bbrc.1993.1724; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PITT A, 1992, J BIOL CHEM, V267, P126; RABINOVITCH M, 1995, TRENDS CELL BIOL, V5, P85, DOI 10.1016/S0962-8924(00)88955-2; Ripley CR, 1997, EXP CELL RES, V236, P147, DOI 10.1006/excr.1997.3707; SODEK J, 1988, BIOL MECHANISMS TOOT, P303; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TENCATE AR, 1972, J ANAT, V112, P401; VANDERZEE E, 1995, J CELL SCI, V108, P3307; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	42	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35432	35441		10.1074/jbc.M003221200	http://dx.doi.org/10.1074/jbc.M003221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945978	hybrid			2022-12-25	WOS:000165422800080
J	Chambers, RC; Leoni, P; Blanc-Brude, OP; Wembridge, DE; Laurent, GJ				Chambers, RC; Leoni, P; Blanc-Brude, OP; Wembridge, DE; Laurent, GJ			Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG FIBROBLAST PROLIFERATION; FACTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; FACTOR-BETA; ENDOTHELIAL-CELLS; PROCOLLAGEN SYNTHESIS; PULMONARY-FIBROSIS; INDUCIBLE GENE; MESSENGER-RNA; SMOOTH-MUSCLE	The coagulation protease thrombin plays a critical role in hemostasis and exerts pro-inflammatory and profibrotic: effects via proteolytic activation of the major thrombin receptor, protease-activated receptor-1 (PAR-1), Connective tissue growth factor (CTGF) is a novel fibroblast mitogen and also promotes extracellular matrix protein production. It is selectively induced by transforming growth factor beta (TGF-beta) and is thought to be the autocrine agent responsible for mediating its pro-fibrotic effects. CTGF is up-regulated during tissue repair and in fibrotic conditions associated with activation of the coagulation cascade. We therefore hypothesized that coagulation proteases promote the production of CTGF by cells at sites of tissue injury, To begin to address this hypothesis, we assessed the effect of coagulation proteases on fibroblast CTGF expression in vitro, and we show that thrombin, at physiological concentrations, up-regulated CTGF mRNA levels 5-fold relative to base line (p < 0.01) in fetal fibroblasts and 7-fold in primary adult fibroblasts (p < 0.01), These effects were cycloheximide-insensitive and were not blocked with a pan-specific TGF-beta -neutralizing antibody. They were further paralleled by a concomitant increase in CTGF protein production and could be mimicked with selective PAR-1 agonists, In addition, fibroblasts derived from PAR-1 knockout mice were unresponsive to thrombin but responded normally to TGF-beta (1) Finally, factor Xa, which is responsible for activating prothrombin during blood coagulation, exerted similar stimulatory effects. We propose that coagulation proteases and PAR-1 may play a role in promoting connective tissue formation during normal tissue repair and the development of fibrosis by up-regulating fibroblast CTGF expression.	UCL, Royal Free & Univ Coll Med Sch, Rayne Inst, Ctr Cardiopulm Biochem & Resp Med, London WC1E 6JJ, England	University of London; King's College London; University College London	Chambers, RC (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Rayne Inst, Ctr Cardiopulm Biochem & Resp Med, 5 Univ St, London WC1E 6JJ, England.	R.Chambers@ucl.ac.uk	BLANC-BRUDE, Olivier/O-8629-2017	BLANC-BRUDE, Olivier/0000-0002-4015-0615; Chambers, Rachel/0000-0003-1370-9417				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; Allen JT, 1999, AM J RESP CELL MOL, V21, P693, DOI 10.1165/ajrcmb.21.6.3719; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; CARNEY DH, 1992, J CLIN INVEST, V89, P1469, DOI 10.1172/JCI115737; Chambers RC, 1998, BIOCHEM J, V333, P121, DOI 10.1042/bj3330121; Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GOLDSACK NR, 1999, AM J CRIT CARE MED, V159, P73; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Hong HH, 1999, LAB INVEST, V79, P1655; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KANG YH, 1991, J HISTOCHEM CYTOCHEM, V39, P413, DOI 10.1177/39.4.2005371; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCANULTY RJ, 1991, BIOCHIM BIOPHYS ACTA, V1091, P231, DOI 10.1016/0167-4889(91)90066-7; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Oemar BS, 1997, CIRCULATION, V95, P831; OHBA T, 1994, AM J RESP CELL MOL, V10, P405, DOI 10.1165/ajrcmb.10.4.7510986; Papadimitriou E, 1997, AM J PHYSIOL-CELL PH, V272, pC1112, DOI 10.1152/ajpcell.1997.272.4.C1112; Rade JJ, 1996, NAT MED, V2, P293, DOI 10.1038/nm0396-293; Ragosta M, 1996, CIRCULATION, V93, P1194, DOI 10.1161/01.CIR.93.6.1194; Ricupero DA, 1999, AM J PHYSIOL-LUNG C, V277, pL1165, DOI 10.1152/ajplung.1999.277.6.L1165; RODRIGUEZ NAH, 1995, LANCET, V346, P1071; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOUFFER GA, 1994, J CLIN INVEST, V93, P2048, DOI 10.1172/JCI117199; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TANI K, 1991, AM J RESP CELL MOL, V5, P34, DOI 10.1165/ajrcmb/5.1.34; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518; Yamabe H, 1997, NEPHROL DIAL TRANSPL, V12, P438, DOI 10.1093/ndt/12.3.438	51	208	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35584	35591		10.1074/jbc.M003188200	http://dx.doi.org/10.1074/jbc.M003188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952976	hybrid			2022-12-25	WOS:000165422800099
J	Moll, JR; Olive, M; Vinson, C				Moll, JR; Olive, M; Vinson, C			Attractive interhelical electrostatic interactions in the proline- and acidic-rich region (PAR) leucine zipper subfamily preclude heterodimerization with other basic leucine zipper subfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; TRANSCRIPTION FACTOR; DNA-BINDING; CRYSTAL-STRUCTURE; C-FOS; EXPRESSION; SPECIFICITY; LEUKEMIA; GENE; PROTEIN	Basic region-leucine zipper (B-ZIP) proteins homo- or heterodimerize to bind sequence-specific double-stranded DNA. We present circular dichroism (CD) thermal denaturation data on vitellogenin promoter-binding protein (VBP), a member of the PAR subfamily of E-ZIP proteins that also includes thyroid embryonic factor, hepatocyte leukemia factor, and albumin site D-binding protein. VBP does not heterodimerize with B-ZIP domains from C/EBP alpha, JUND, or FOS, We describe a dominant negative protein, A-VEP, that contains the VBP leucine zipper and an acidic amphipathic protein sequence that replaces the basic region critical for DNA binding. The acidic extension forms a coiled coil structure with the VEP basic region in the VBP A-VBP heterodimer, This new alpha -helical structure extends the leucine zipper N-terminally, stabilizing the complex by 2.0 kcal/mol, A-VBP abolishes DNA binding of VBP in an equimolar competition assay, but does not affect DNA binding even at 100-fold excess of CREB, C/EBP alpha, or FOS/JUND, Likewise, proteins containing the acidic extension appended to seven other leucine zippers do not inhibit VBP DNA binding. We show that conserved g <-> e' or i, i' + 5 salt bridges are sufficient to confer specificity to VBP by mutating the C/EBP alpha leucine zipper to contain the g <-> e' salt bridges that characterize VBP, A-VBP heterodimerizes with this mutant C/EBP, preventing it from binding to DNA These conserved g <-> e' electrostatic interactions define the specificity of the PAR subfamily of B-ZIP proteins and preclude interaction with other B-ZIP subfamilies.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; INSERM, U441, F-33600 Pessac, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm)	Vinson, C (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 4D06, Bethesda, MD 20892 USA.	vinsonc@dc37a.nci.nih.gov						Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hitzler JK, 1999, BRAIN RES, V820, P1, DOI 10.1016/S0006-8993(98)00999-8; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inukai T, 1997, MOL CELL BIOL, V17, P1417, DOI 10.1128/MCB.17.3.1417; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WUARIN J, 1992, J CELL SCI, P123; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	29	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34826	34832		10.1074/jbc.M004545200	http://dx.doi.org/10.1074/jbc.M004545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942764	hybrid			2022-12-25	WOS:000165095300110
J	Delehedde, M; Seve, M; Sergeant, N; Wartelle, I; Lyon, M; Rudland, PS; Fernig, DG				Delehedde, M; Seve, M; Sergeant, N; Wartelle, I; Lyon, M; Rudland, PS; Fernig, DG			Fibroblast growth factor-2 stimulation of p42/44(MAPK) phosphorylation and I kappa B degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; BASIC FGF; SULFATE PROTEOGLYCAN; CELL-PROLIFERATION; XENOPUS EGGS; RECEPTOR; BINDING; ALPHA; INHIBITOR	Fibroblast growth factor-2 (FGF-2) interacts with a dual receptor system consisting of tyrosine kinase receptors and heparan sulfate proteoglycans (HSPGs). In rat mammary fibroblasts, FGF-2 stimulated DNA synthesis and induced a sustained phosphorylation of p42/44(MAPK) and of its downstream target, p90(RSK). Moreover, FGF-S also stimulated the transient degradation of I kappaB alpha and I kappaB beta. PD098059, a specific inhibitor of p42/44(MAPK) phosphorylation, inhibited FGF-2-stimulated DNA synthesis, phosphorylation of p42/44(MAPK) and p90(RSK) and degradation of I kappaB beta. In contrast, in chlorate-treated and hence sulfated glycosaminoglycan-deficient cells, FGF-2 was unable to stimulate DNA synthesis. However, FGF-2 was able to trigger a transient phosphorylation of both p42/44(MAPK) and p90(RSK), which peaked at 15 min and returned to control levels at 30 min. In these sulfated glycosaminoglycan-deficient cells, no degradation of I kappaB alpha and I kappaB beta was observed after FGF-2 addition. However, in chlorate-treated cells, the addition of heparin or purified HSPGs simultaneously with FGF-2 restored DNA synthesis, the sustained phosphorylation of p42/44(MAPK) and p90(RSK), and the degradation of I kappaB alpha and I kappaB beta. These results suggest that the HSPG receptor for FGF-2 not only influences the outcome of FGF-2 signaling, e.g. cell proliferation, but importantly regulates the immediate-early signals generated by this growth factor.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England	University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Fernig, DG (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.		Fernig, David G/A-3590-2008; Seve, Michel/M-2786-2013; Sergeant, Nicolas/O-5467-2017	Fernig, David G/0000-0003-4875-4293; Sergeant, Nicolas/0000-0003-1448-124X; Lyon, Malcolm/0000-0001-9575-6879; DELEHEDDE, Maryse/0000-0003-2724-143X; SEVE, Michel/0000-0001-5503-9488				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Deakin JA, 1999, J CELL SCI, V112, P1999; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREVE H, 1988, J BIOL CHEM, V263, P12886; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUDLAND PS, 1984, J CELL PHYSIOL, V120, P364, DOI 10.1002/jcp.1041200315; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Sellers LA, 1999, J BIOL CHEM, V274, P16423, DOI 10.1074/jbc.274.23.16423; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sperinde GV, 2000, BIOCHEMISTRY-US, V39, P3788, DOI 10.1021/bi992243d; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WALKER A, 1994, J BIOL CHEM, V269, P931; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	59	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33905	33910		10.1074/jbc.M005949200	http://dx.doi.org/10.1074/jbc.M005949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944532	hybrid			2022-12-25	WOS:000090104600100
J	Johnson, TM; Williamson, NA; Scholz, G; Jaworowski, A; Wettenhall, REH; Dunn, AR; Cheng, HC				Johnson, TM; Williamson, NA; Scholz, G; Jaworowski, A; Wettenhall, REH; Dunn, AR; Cheng, HC			Modulation of the catalytic activity of the Src family tyrosine kinase Hck by autophosphorylation at a novel site in the unique domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN-KINASE; SH2 DOMAIN; C-SRC; PHOSPHORYLATION; PEPTIDES; BINDING; SPECIFICITY; SUBSTRATE; P34CDC2	Autophosphorylation is a key event in the activation of protein kinases, In this study, we demonstrate that autophosphorylation of the recombinant Src family kinase Hck leads to a 20-fold increase in its specific enzymatic activity. Hck was found to autophosphorylate readily to a stoichiometry of 1.3 mol of phosphate per mol of enzyme, indicating that the kinase autophosphorylated at more than one site. Solid phase sequencing and two-dimensional mapping of the phosphopeptide fragments derived from the autophosphorylated enzyme revealed that the kinase can undergo autophosphorylation at the following two sites: (i) Tyr-388, which is located to the consensus autophosphorylation site commonly found in the activation loop of many protein kinases, and (ii) Tyr-29, which is located in the unique domain of Hck, lick purified from mouse bone marrow-derived macrophages could also autophosphorylate in vitro at both Tyr-388 and Tyr-29, indicating that naturally occurring Hck can also autophosphorylate at Tyr-29, Furthermore, Hck transiently expressed in human embryonic kidney 293T cells was found to be phosphorylated at Tyr-29 and Tyr-388, proving that lick can also undergo autophosphorylation at both sites in vivo. The recombinant enzyme carrying the mutation of TST-388 to Phe was also able to autophosphorylate at Tyr-29, albeit at a significantly slower rate. A a-fold increase in the specific enzymatic activity was seen with this mutant despite the stoichiometry of autophosphorylation only approaching 0.2 mol of phosphate per mol of enzyme. This indicates that autophosphorylation of Tyr-29 contributes significantly to the activation of Hck. Regulation of the catalytic activity by phosphorylation of Tyr-29 in the unique domain may represent a new mechanism of regulation of Src family tyrosine kinases.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia	University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research	Cheng, HC (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.	h.cheng@biochemistry.unimelb.edu.au	Williamson, Nicholas A/O-9812-2016	Williamson, Nicholas A/0000-0002-2173-3452; Scholz, Glen/0000-0003-2722-6344; jaworowski, anthony/0000-0002-3844-805X; Cheng, Heung-Chin/0000-0002-4965-7148				AEHERSOLD R, 1993, PRACTICAL GUIDE PEPT, P71; ALLEN G, 1981, SEQUENCING PROTEINS, P53; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPBELL KS, 1995, EUR J IMMUNOL, V25, P2408, DOI 10.1002/eji.1830250842; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COURTNEIDGE SA, 1994, PROTEIN KINASES, P212; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson TM, 1997, J PEPT RES, V50, P365; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOAREFI I, 1997, NATURE, V385, P629; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; ROTH CW, 1983, J BIOL CHEM, V258, P768; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33353	33364		10.1074/jbc.M002022200	http://dx.doi.org/10.1074/jbc.M002022200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934191	hybrid			2022-12-25	WOS:000090104600027
J	Yamauchi, T; Yamauchi, N; Ueki, K; Sugiyama, T; Waki, H; Miki, H; Tobe, K; Matsuda, S; Tsushima, T; Yamamoto, T; Fujita, T; Taketani, Y; Fukayama, M; Kimura, S; Yazaki, Y; Nagai, R; Kadowaki, T				Yamauchi, T; Yamauchi, N; Ueki, K; Sugiyama, T; Waki, H; Miki, H; Tobe, K; Matsuda, S; Tsushima, T; Yamamoto, T; Fujita, T; Taketani, Y; Fukayama, M; Kimura, S; Yazaki, Y; Nagai, R; Kadowaki, T			Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HER2/NEU-OVEREXPRESSING METASTATIC BREAST; RAS SIGNALING PATHWAY; GROWTH-HORMONE; NEU ONCOGENE; CARCINOMA-CELLS; FACTOR-RECEPTOR; EGF RECEPTOR; PROTEIN OVEREXPRESSION; MONOCLONAL-ANTIBODY; RECURRENT DISEASE	Overexpression of the oncogene for ErbB-2 is an unfavorable prognostic marker in human breast cancer. Its oncogenic potential appears to depend on the state of tyrosine phosphorylation, However, the mechanisms by which ErbB-2 is constitutively tyrosine-phospholylated in human breast cancer are poorly understood. We now show that human breast carcinoma samples with ErbB-2 overexpression have higher proliferative and metastatic activity in the presence of autocrine secretion of prolactin (PRL). By using a neutralizing antibody or dominant negative (DN) strategies or specific inhibitors, we also show that activation of Janus kinase Jak2 by autocrine secretion of PRL is one of the significant components of constitutive tyrosine phosphorylation of ErbB-2, its association with Grb2 and activation of mitogen-activated protein (MAP) kinase in human breast cancer cell lines that overexpress ErbB-2. Furthermore, the neutralizing anti-PRL antibody or erbB-2 antisense oligonucleotide or DN Jak2 or Jak2 inhibitor or DNRas or MAP kinase kinase inhibitor inhibits the proliferation of both untreated and PRL treated cells. Our results indicate that autocrine secretion of PRL stimulates tyrosine phosphorylation of ErbB-2 by Jak2, provides docking sites for Grb2 and stimulates Ras-MAP kinase cascade, thereby causing unrestricted cellular proliferation. The identification of this novel cross-talk between ErbB-2 and the autocrine growth stimulatory loop for PRL may provide new targets for therapeutic and preventive intervention of human breast cancer.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo 113, Japan; Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Nagoya, Aichi 466, Japan; Tokyo Womens Med Coll, Dept Internal Med 2, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 108, Japan; Univ Tokyo, Grad Sch Med, Dept Obstet & Gynecol, Tokyo 113, Japan; Int Med Ctr Japan, Tokyo 162, Japan	University of Tokyo; University of Tokyo; Nagoya University; Tokyo Women's Medical University; University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Waki, Hironori/AAE-3942-2020	Waki, Hironori/0000-0002-5302-9793				Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Clark JW, 1996, INT J CANCER, V65, P186; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GINSBURG E, 1995, CANCER RES, V55, P2591; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; HUGHES JP, 1982, ENDOCRINOLOGY, V111, P827, DOI 10.1210/endo-111-3-827; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JANES PW, 1994, ONCOGENE, V9, P3601; KADOWAKI T, 1987, BIOCHEM BIOPH RES CO, V144, P699, DOI 10.1016/S0006-291X(87)80021-9; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; LEMOINE NR, 1990, ONCOGENE, V5, P227; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PATERSON MC, 1991, CANCER RES, V51, P556; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PRESS MF, 1993, CANCER RES, V53, P4960; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; WIECHEN K, 1995, INT J CANCER, V63, P604, DOI 10.1002/ijc.2910630423; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1985, NATURE, V319, P220; Yamauchi N, 1996, INT J GYNECOL PATHOL, V15, P202, DOI 10.1097/00004347-199607000-00003; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; ZOLL B, 1992, J CANCER RES CLIN, V118, P468, DOI 10.1007/BF01629432	57	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33937	33944		10.1074/jbc.M000743200	http://dx.doi.org/10.1074/jbc.M000743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938266	hybrid			2022-12-25	WOS:000090104600104
J	Nguyen, BP; Gil, SG; Carter, WG				Nguyen, BP; Gil, SG; Carter, WG			Deposition of laminin 5 by keratinocytes regulates integrin adhesion and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE ADHESION; CELL-CELL ADHESION; DIFFICILE TOXIN-B; EXTRACELLULAR-MATRIX; PYLORIC ATRESIA; ALPHA-6-BETA-4 INTEGRIN; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DISTINCT FUNCTIONS	Deposition of laminin 5 over exposed dermal collagen in epidermal wounds is an early event in repair of the basement membrane. We report that deposition of laminin 5 onto collagen switches adhesion and signaling from collagen-dependent to laminin 5-dependent, Ligation of laminin 5 by integrin alpha(6)beta(4) activates phosphoinositide S-OH-kinase (PI3K) signaling. This activation allows for adhesion and spreading via integrin alpha(3)beta(1) on laminin 5 independent of RhoGTPase, a regulator of actin stress fibers. In contrast, adhesion and spreading on collagen via alpha(2)beta(1) is Rho-dependent and is inhibited by toxin B, a Rho inhibitor. Deposition of laminin 5 and ligation of alpha(6)beta(4) increases PI3K-dependent production of phosphoinositide di- and triphosphates, PI3K activity, and phosphorylation of downstream target protein c-Jun NH3-terminal kinase, Conversely, blocking laminin 5-deposition with brefeldin A, an inhibitor of vesicle transport, or with anti-laminin 5 monoclonal antibodies abolishes the PI3K-dependent spreading mediated by alpha(3)beta(1) and phosphorylation of c-Jun NH2-terminal kinase. Studies with keratinocytes lacking alpha(6)beta(4) or laminin 5 confirm that deposition of laminin 5 and ligation by alpha(6)beta(4) are required for PI3K-dependent spreading via alpha(3)beta(1). We suggest that deposition of laminin 5 onto the collagen substratum, as in wound repair, enables human foreskin keratinocytes to interact via alpha(6)beta(4) and to switch from a RhoGTPase-dependent adhesion on collagen to a PI3K-dependent adhesion and spreading mediated by integrin alpha(3)beta(1) on laminin 5.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Carter, WG (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	wcarter@fhcrc.org			NCI NIH HHS [CA49259] Funding Source: Medline; NIAMS NIH HHS [AR21557] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Braga VMM, 1999, J CLIN PATHOL-MOL PA, V52, P197, DOI 10.1136/mp.52.4.197; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brown TA, 1996, J INVEST DERMATOL, V107, P384, DOI 10.1111/1523-1747.ep12363370; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fuchs E, 1997, CURR OPIN GENET DEV, V7, P672, DOI 10.1016/S0959-437X(97)80016-0; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lim KK, 1996, MAYO CLIN PROC, V71, P863, DOI 10.4065/71.9.863; Lo Surdo P, 1999, J BIOL CHEM, V274, P15678, DOI 10.1074/jbc.274.22.15678; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Niessen CM, 1996, J CELL SCI, V109, P1695; Pilcher BK, 1998, ARCH DERMATOL RES, V290, pS37, DOI 10.1007/PL00007452; Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Pulkkinen L, 1998, AM J HUM GENET, V63, P1376, DOI 10.1086/302116; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1996, MATRIX BIOL, V15, P369, DOI 10.1016/S0945-053X(96)90157-2; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Takizawa Y, 1997, J INVEST DERMATOL, V108, P943, DOI 10.1111/1523-1747.ep12296240; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	60	136	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31896	31907		10.1074/jbc.M006379200	http://dx.doi.org/10.1074/jbc.M006379200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10926936	hybrid			2022-12-25	WOS:000089858900050
J	Qiu, WS; Zhuang, SH; von Lintig, FC; Boss, GR; Pilz, RB				Qiu, WS; Zhuang, SH; von Lintig, FC; Boss, GR; Pilz, RB			Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NIH 3T3 CELLS; NUCLEOTIDE-EXCHANGE FACTOR; MAP KINASE; CYCLIC-AMP; DEPENDENT ACTIVATION; PC12 CELLS; SIGNAL-TRANSDUCTION; DIFFERENTIAL REGULATION; BINDING PROTEINS	Cyclic AMP can either activate or inhibit the mitogen-activated protein kinase (MAPK) pathway in different cell types; MAPK activation has been observed in B-Raf-expressing cells and has been attributed to Rap1 activation with subsequent B-Raf activation, whereas MAPK inhibition has been observed in cells lacking B-Raf and has been attributed to cAMP-dependent protein kinase (protein kinase A)-mediated phosphorylation and inhibition of Raf-l kinase. We found that cAMP stimulated MAPK activity in CHO-K1 and PC12 cells but inhibited MAPK activity in C6 and NB2A cells. In all four cell types, cAMP activated Rap1, and the 95- and 68-kDa isoforms of B-Raf were expressed, cAMP activation or inhibition of MAPK correlated with activation or inhibition of endogenous and transfected B-Raf kinase. Although all cell types expressed similar amounts of 14-3-3 proteins, approximately B-fold less 14-3-3 was associated with B-Raf in cells in which cAMP was inhibitory than in cells in which cAMP was stimulatory. We found that the cell type-specific inhibition of B-Raf could be completely prevented by overexpression of 14-3-3 isoforms, whereas expression of a dominant negative 14-3-3 mutant resulted in partial loss of B-Raf activity. Our data suggest that 14-3-3 bound to B-Raf protects the enzyme from protein kinase A-mediated inhibition; the amount of 14-3-3 associated with B-Raf may explain the tissue-specific effects of cAMP on B-Raf kinase activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R21CA081115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA81115] Funding Source: Medline; NIGMS NIH HHS [R01 GM55586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Bustin SA, 1999, DNA CELL BIOL, V18, P653, DOI 10.1089/104454999315060; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen JH, 1998, P NATL ACAD SCI USA, V95, P2648, DOI 10.1073/pnas.95.5.2648; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; EYCHENE A, 1995, ONCOGENE, V10, P1159; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6606; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HATA Y, 1991, J BIOL CHEM, V266, P6571; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MATOUSOVIC K, 1995, J CLIN INVEST, V96, P401, DOI 10.1172/JCI118049; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PAPIN C, 1995, ONCOGENE, V10, P1647; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; Sugawara F, 1996, MOL PHARMACOL, V49, P447; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	89	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31921	31929		10.1074/jbc.M003327200	http://dx.doi.org/10.1074/jbc.M003327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10931830	hybrid			2022-12-25	WOS:000089858900053
J	Bender, AT; Nakatsuka, M; Osawa, Y				Bender, AT; Nakatsuka, M; Osawa, Y			Heme insertion, assembly, and activation of apo-neuronal nitric-oxide synthase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; TETRAHYDROBIOPTERIN INTERACTION; SUBUNIT DIMERIZATION; ESCHERICHIA-COLI; DIMERIC ENZYME; L-ARGININE; BINDING; DOMAIN; INACTIVATION; BRAIN	It has been established that in the case of inducible NO synthase (NOS), a functionally active homodimer is assembled from the heme deficient monomeric apo-NOS in vitro by the addition of heme, whereas the heme-deficient neuronal isoform (apo-nNOS) is at best only partially activated. In the current study we have discovered that reactive oxygen species, which can be removed by the addition of superoxide dismutase and catalase, destroy the heme and limit the activation of apon-NOS in vitro. With the use of these improved conditions, we show for the first time that heme insertion is a rapid process that results in formation of a heme-bound monomeric nNOS that is able to form the ferrous-CO P450 complex but is unable to synthesize NO. A slow process requiring more than 90 min is required for dimerization and activation of this P450 intermediate to give an enzyme with a specific activity of approximately 1100 nmol of NO formed/min/mg of protein, similar to that of the native enzyme. Interestingly, the dimer is not SDS-resistant and is not the same dimer that forms in vivo. These studies indicate at least two intermediates in the assembly of nNOS and advance our understanding of the regulation of nNOS.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; [Anonymous], [No title captured]; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Brunner K, 1998, BIOCHEMISTRY-US, V37, P17545, DOI 10.1021/bi981138l; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Cubberley RR, 1997, BIOCHEM J, V323, P141, DOI 10.1042/bj3230141; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; Iwasaki T, 1999, J BIOL CHEM, V274, P7705, DOI 10.1074/jbc.274.12.7705; Jianmongkol S, 2000, J BIOL CHEM, V275, P13370, DOI 10.1074/jbc.275.18.13370; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; Nakatsuka M, 1998, DRUG METAB DISPOS, V26, P497; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; POU S, 1992, J BIOL CHEM, V267, P24173; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Watanabe Y, 1998, BBA-PROTEIN STRUCT M, V1388, P199, DOI 10.1016/S0167-4838(98)00191-5; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wolff DJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P73, DOI 10.1006/abbi.1996.9811	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26018	26023		10.1074/jbc.275.34.26018	http://dx.doi.org/10.1074/jbc.275.34.26018			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10950965	hybrid			2022-12-25	WOS:000088999700020
J	Malashicheva, AB; Kislyakova, TV; Aksenov, ND; Osipov, KA; Pospelov, VA				Malashicheva, AB; Kislyakova, TV; Aksenov, ND; Osipov, KA; Pospelov, VA			F9 embryonal carcinoma cells fail to stop at G1/S boundary of the cell cycle after gamma-irradiation due to p21(WAF1/CIP1) degradation	ONCOGENE			English	Article						p21(WAF1/CIP1); p53; G1 and G2 arrests; teratocarcinoma F9; gamma-irradiation	RADIATION-INDUCED APOPTOSIS; WILD-TYPE P53; DNA-DAMAGE; TERATOCARCINOMA CELLS; SPINDLE DISRUPTION; TRANSFORMED-CELLS; RETINOIC ACID; STEM-CELLS; DIFFERENTIATION; CHECKPOINT	We studied the ability of F9 teratocarcinoma cells to arrest in G1/S and G2/M checkpoints after gamma-irradiation, Wild-type p53 protein was rapidly accumulated in F9 cells after gamma-irradiation, however, this was followed not by a G1/S arrest but by a short and reversible delay of the cell cycle in G2/M. In order to elucidate the reasons of the lack of G1/S arrest in F9 cells, we investigated the expression of p53 downstream target Cdk inhibitor p21(WAF1/CIP1). In spite of p53-dependent activation of p21(WAF1/CIP1) gene promoter and p21(WAF1/CIP1) mRNA accumulation upon irradiation, the p21(WAF1/CIP1) protein was not detected by either immunoblot or immunofluorescence techniques. However, the cells treated with a specific proteasome inhibitor lactacystin revealed the p21(WAF1/CIP1) protein both in non-irradiated and irradiated cells. Therefore we suggest that p21(WAF1/CIP1) protein is degraded by a proteasome-dependent mechanism in F9 cells and the lack of G1/S arrest after gamma-irradiation is due to this degradation. We also examined the expression and activity of cell cycle regulatory proteins: G1- and G2-cyclins and cyclin-dependent kinases, In the absence of functional p21(WAF1/CIP1) inhibitor, the activity of G1 cyclin/Cdk complexes was insufficiently inhibited to cause a G1 arrest, whereas a decrease of cdc2 and cyclin B1-associated kinase activities was enough to contribute to a reversible G2 arrest following gamma-irradiation. After gamma-irradiation, the majority of F9 cells undergo apoptosis implying that wt-p53 likely triggers pro-apoptotic gene expression in DNA damaged cells. Elimination of defected cells might ensure maintenance of genome integrity in the remaining cell population.	Russian Acad Sci, Inst Cytol, Lab Mol Basis Cell Differentiat, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, Lab Mol Basis Cell Differentiat, Tikhoretsky 4, St Petersburg 194064, Russia.		Aksenov, Nikolay D/F-1679-2017; Malashicheva, Anna/K-2649-2014	Malashicheva, Anna/0000-0002-0820-2913				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARDER P, 1993, ONCOGENE, V8, P1397; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Khan SH, 1998, CANCER RES, V58, P396; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANGLEY RE, 1995, RADIAT RES, V144, P90, DOI 10.2307/3579240; LANGLEY RE, 1993, RADIAT RES, V136, P320, DOI 10.2307/3578543; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Malashicheva A B, 1998, Tsitologiia, V40, P14; Mayo LD, 1996, ONCOGENE, V13, P2315; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Orlovskaya E. I., 1997, Molekulyarnaya Biologiya (Moscow), V31, P224; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERREAULT J, 1993, J CELL PHYSL, V156, P189; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P2261; SLEIGH MJ, 1992, BIOESSAYS, V14, P769, DOI 10.1002/bies.950141109; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	43	27	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3858	3865		10.1038/sj.onc.1203736	http://dx.doi.org/10.1038/sj.onc.1203736			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951579				2022-12-25	WOS:000088614300004
J	Pritchard, DM; Print, C; O'Reilly, L; Adams, JM; Potten, CS; Hickman, JA				Pritchard, DM; Print, C; O'Reilly, L; Adams, JM; Potten, CS; Hickman, JA			Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine	ONCOGENE			English	Article						apoptosis; bcl-w; 5-fluorouracil; gamma-radiation; intestinal epithelia	RADIATION-INDUCED APOPTOSIS; GASTROINTESTINAL-TRACT; CELL-SURVIVAL; MICE; EXPRESSION; P53; PROLIFERATION; INHIBITION; FAMILY; CRYPTS	The potential role of the bcl-2 relative bcl-w as a physiological regulator of apoptosis in intestinal epithelia has been investigated, Immunoblots for bcl-w with new monoclonal antibodies revealed that it was expressed in the small intestine and colon, among other murine tissues, as well as in six: human tumour cell lines of epithelial origin, including two colon carcinoma lines, To assess whether bcl-w regulates either spontaneous or damage-induced apoptosis in the small intestine or colon, apoptosis in intestinal crypts of bcl-w -/- and wild-type mice,vas quantified microscopically on a cell positional basis. Spontaneous apoptosis within crypt epithelia was not significantly increased by loss of bcl-w, in either the small intestine or midcolon. However, after treatment with the cytotoxic drug 5-fluorouracil or with gamma-radiation, the bcl-w-null animals exhibited substantially more apoptosis than their wild-type counterparts in both tissues. The greatest enhancement of apoptosis attributable to the absence of bcl-w (up to sixfold) occurred in the small intestine, Hence, bcl-w is an important determinant of damage-induced apoptosis in intestinal epithelia, and unlike bcl-2, which regulates only colonic apoptosis, plays a major role In small intestinal epithelium.	Christie Hosp NHS Trust, Paterson Inst, CRC, Dept Epithelial Biol, Manchester M20 9BX, Lancs, England; Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Walter & Eliza Hall Institute	Pritchard, DM (corresponding author), Univ Liverpool, Dept Med, 5th Floor UCD Bldg,Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.		Adams, Jerry M/E-1199-2013	Print, Cristin/0000-0001-8345-7812; Pritchard, David Mark/0000-0001-7971-3561; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA 43540, CA80188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; Gibson L, 1996, ONCOGENE, V13, P665; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; Potten CS, 1998, BRIT J CANCER, V78, P993, DOI 10.1038/bjc.1998.618; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pritchard DM, 1998, CANCER RES, V58, P5453; Reed JC, 1999, CANC DRUG DISC DEV, V5, P99; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178	19	65	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3955	3959		10.1038/sj.onc.1203729	http://dx.doi.org/10.1038/sj.onc.1203729			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951589				2022-12-25	WOS:000088614300015
J	Komarova, EA; Christov, K; Faerman, AI; Gudkov, AV				Komarova, EA; Christov, K; Faerman, AI; Gudkov, AV			Different impact of p53 and p21 on the radiation response of mouse tissues	ONCOGENE			English	Article						p53; p21; apoptosis; radiation; proliferation; mouse tissues	CELL-CYCLE ARREST; INDUCED APOPTOSIS; P53-DEFICIENT MICE; DISTINCT PATTERNS; P53-INDEPENDENT APOPTOSIS; INTESTINAL EPITHELIUM; IONIZING-RADIATION; GAMMA-IRRADIATION; HUMAN SKIN; IN-VIVO	Mammalian tissues differ dramatically in their sensitivity to genotoxic stress, although the mechanisms determining these differences remain largely unknown. To analyse the role of p53 and p21 in determination of tissue specificity to DNA damage in vivo, we compared the effects of gamma radiation on DNA synthesis on whole-body sections of wild type, p53-deficient and p21-deficient mice, ii dramatic reduction in C-14-thymidine incorporation after gamma irradiation was observed in the majority of rapidly proliferating tissues of wild type and p21(-/-) but not in p53(-/-) mice, confirming the key role of p53 in determination of tissue response to genotoxic stress vivo and suggesting that p53-mediated inhibition of DNA synthesis does not depend on p21, Rapid radiation induced p53-dependent apoptosis was mapped to the areas of high levels of p53 mRNA in radiation sensitive tissues analysed (white pulp in the spleen and bases of crypts in small intestine), indicating that p53 regulation at the mRNA level is a determinant of cellular sensitivity to genotoxic stress. High p53 mRNA expression is inherited as a recessive trait in cell-cell hybrids suggesting the involvement of a negative control mechanism in the regulation of p53 gene expression.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Quark Biotech Inc, Ness Ziona, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL C, 1993, CANCER RES, V53, P2697; Christov KT, 1996, CARCINOGENESIS, V17, P1741, DOI 10.1093/carcin/17.8.1741; CLARKE AR, 1994, ONCOGENE, V9, P1767; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MacCallum DE, 1996, ONCOGENE, V13, P2575; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Uberti D, 1999, EXP CELL RES, V252, P123, DOI 10.1006/excr.1999.4606; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3	41	97	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3791	3798		10.1038/sj.onc.1203717	http://dx.doi.org/10.1038/sj.onc.1203717			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949934				2022-12-25	WOS:000088568400012
J	Shtrichman, R; Sharf, R; Kleinberger, T				Shtrichman, R; Sharf, R; Kleinberger, T			Adenovirus E4orf4 protein interacts with both B alpha and B ' subunits of protein phosphatase 2A, but E4orf4-induced apoptosis is mediated only by the interaction with B alpha	ONCOGENE			English	Article						protein phosphatase 2A (PP2A); adenovirus E4orf4 protein; apoptosis	CATALYTIC SUBUNIT; REGULATORY SUBUNITS; TRANSFORMED-CELLS; EARLY REGION-4; CORE ENZYME; PP2A; PHOSPHORYLATION; BINDING; KINASE; IDENTIFICATION	Adenovirus E4orf4 protein is a multifunctional viral regulator, which is involved in down regulation of virally-modulated signal transduction, in control of alternative splicing of viral mRNAs? and in induction of apoptosis in transformed cells. It has been previously shown that E4orf4 interacts with protein phosphatase 2A through the phosphatase B alpha subunit. It was further shown that PP2A is required for performing the various E4orf4 functions. We report here that E4orf4 interacts with multiple isoforms of the PP2A-B' subunit, as well as with B alpha. We map the interaction sites of the B subunits on E4orf4 and show that they overlap but are not identical. We identify a dominant negative E4orf4 mutant, which disrupts the PP2A holoenzyme. We show that induction of apoptosis by E4orf4, which we previously reported to require the interaction with B alpha, is not affected by the interaction with B'. Our results suggest that the interaction of E4orf4 with various PP2A subpopulations may mediate the different E4orf4 functions.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinberger, T (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Gonda Ctr Mol Microbiol, POB 9649, IL-31096 Haifa, Israel.							AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Harlow E., 1988, ANTIBODIES LAB MANUA; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256	48	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3757	3765		10.1038/sj.onc.1203705	http://dx.doi.org/10.1038/sj.onc.1203705			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949930				2022-12-25	WOS:000088568400008
J	Magdinier, F; Billard, LM; Wittmann, G; Frappart, L; Benchaib, M; Lenoir, GM; Guerin, JF; Dante, R				Magdinier, F; Billard, LM; Wittmann, G; Frappart, L; Benchaib, M; Lenoir, GM; Guerin, JF; Dante, R			Regional methylation of the 5 ' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells	FASEB JOURNAL			English	Article						DNA methylation; oocytes; spermatozoa; breast cancer	SPORADIC BREAST-CANCER; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSOR; PROMOTER REGION; MECP2; LOCALIZATION; CHROMATIN; LINES	In mammalians, demethylation of specific promoter regions often correlates with gene activation; inversely, dense methylation of CpG islands leads to gene silencing, probably mediated by methyl-CpG binding proteins. In cell Lines and cancers, inhibition of tissue-specific genes and tumor suppressor genes expression seems to be related to such hypermethylation. The 5' end of the breast cancer predisposition gene BRCA1 is embedded in a large CpG island of similar to 2.7 kb in length. In human sporadic breast cancers, the down-regulation of BRCA1 does not seem to be related to BRCA1 gene alterations. Southern blot analysis and the bisulfite sequencing method indicate that the BRCA1 CpG island is regionally methylated in all human tissues analyzed and unmethylated in the gametes, suggesting a role for DNA methylation in the control of gene expression. We have therefore investigated the potential role of methyl-CpG binding proteins in the regulation of BRCA1 gene expression. In vitro, partial methylation of constructs containing this region strongly inhibits gene expression in the presence of MeCP2 protein. Moreover, iu the five human cell lines analyzed, chemically induced hypomethylation is associated with BRCA1 gene activation. These data suggest that methyl-CpG binding proteins might be associated with the control of BRCA1 gene expression and that methyl-DNA binding proteins may participate in the regulation of gene expression in mammalian cells.	UCBL1, UMR 5641, Genet Lab, F-69373 Lyon 08, France; UCBL1, Lab Biol Reprod & Dev, F-69373 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), UCBL1, UMR 5641, Genet Lab, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016; , Benchaib/AAE-7278-2020; Benchaib, Mehdi/AAO-2976-2021	Magdinier, Frederique/0000-0002-0159-9559; 				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin Stephen B., 1997, V72, P141; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; Dobrovic A, 1997, CANCER RES, V57, P3347; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; NAN X, 1997, CELL, V88, P1; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH AP, 1992, HDB HUMAN PERFORMANC, V2, P1; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TOH Y, 1994, J BIOL CHEM, V269, P22958; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; XU C, 1997, J BIOL CHEM, V34, P20994; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	43	60	70	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1585	1594		10.1096/fj.14.11.1585	http://dx.doi.org/10.1096/fj.14.11.1585			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928993	Green Submitted			2022-12-25	WOS:000088627800013
J	Bhattacharya, AA; Curry, S; Franks, NP				Bhattacharya, AA; Curry, S; Franks, NP			Binding of the general anesthetics propofol and halothane to human serum albumin - High resolution crystal structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLATILE ANESTHETICS; LIGAND-BINDING; SITES; ACID; ENFLURANE; PROTEINS; ISOFLURANE; STABILITY; DYNAMICS; F-19-NMR	Human serum albumin (HSA) is one of the most abundant proteins in the circulatory system and plays a key role in the transport of fatty acids, metabolites, and drugs. For many drugs, binding to serum albumin is a critical determinant of their distribution and pharmacokinetics; however, there have as yet been no high resolution crystal structures published of drug-albumin complexes. Here we describe high resolution crystal structures of HSA with two of the most widely used general anesthetics, propofol and halothane. In addition, we describe a crystal structure of HSA complexed with both halothane and the fatty acid, myristate. We show that the intravenous anesthetic propofol binds at two discrete sites on HSA in preformed pockets that have been shown to accommodate fatty acids. Similarly we show that the inhalational agent halothane binds (at concentrations in the pharmacologically relevant range) at three sites that are also fatty acid binding loci. At much higher halothane concentrations, we have identified additional sites that are occupied, All of the higher affinity anesthetic binding sites are amphiphilic in nature, with both polar and apolar parts, and anesthetic binding causes only minor changes in local structure.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BW, England	Imperial College London	Curry, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Prince Consort Rd, London SW7 2BW, England.			Franks, Nicholas/0000-0003-4874-4212; Curry, Stephen/0000-0002-0552-8870				ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; ALTMAYER P, 1995, ARZNEIMITTEL-FORSCH, V45-2, P1053; ALTMAYER P, 1987, ACTA ANAESTH SCAND, V31, P756, DOI 10.1111/j.1399-6576.1987.tb02659.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carter D. C., 1994, ADV PROTEIN CHEM, V45, P152; Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DALE O, 1986, BIOCHEM PHARMACOL, V35, P557, DOI 10.1016/0006-2952(86)90347-3; DALE O, 1986, BRIT J ANAESTH, V58, P1022, DOI 10.1093/bja/58.9.1022; DALE O, 1984, BRIT J ANAESTH, V56, P535, DOI 10.1093/bja/56.5.535; DIPAOLO T, 1974, NATURE, V252, P471, DOI 10.1038/252471a0; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; FRANKS NP, 1985, CHEM BRIT, V21, P919; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; GURSKY O, 1994, P NATL ACAD SCI USA, V91, P12388, DOI 10.1073/pnas.91.26.12388; HANSCH C, 1975, J MED CHEM, V18, P546, DOI 10.1021/jm00240a002; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Johansson JS, 1999, ANESTHESIOLOGY, V90, P235, DOI 10.1097/00000542-199901000-00030; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; KATZ Y, 1977, BIOCHIM BIOPHYS ACTA, V471, P1, DOI 10.1016/0005-2736(77)90387-X; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Peters T., 1996, ALL ALBUMIN BIOCH GE; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; SAIFER A, 1961, J LIPID RES, V2, P268; SOGAMI M, 1968, BIOCHEMISTRY-US, V7, P2172, DOI 10.1021/bi00846a020; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Tanner JW, 1999, BBA-PROTEIN STRUCT M, V1430, P46, DOI 10.1016/S0167-4838(98)00258-1	41	468	489	2	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38731	38738		10.1074/jbc.M005460200	http://dx.doi.org/10.1074/jbc.M005460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10940303	hybrid			2022-12-25	WOS:000165739800082
J	Angenieux, C; Salamero, J; Fricker, D; Cazenave, JP; Goud, B; Hanau, D; de la Salle, H				Angenieux, C; Salamero, J; Fricker, D; Cazenave, JP; Goud, B; Hanau, D; de la Salle, H			Characterization of CD1e, a third type of CD1 molecule expressed in dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; T-CELLS; HELA-CELLS; ANTIGENS; GLYCOLIPIDS; DISTINCT; BINDING; MOUSE; BETA(2)-MICROGLOBULIN; PROTEINS	Dendritic cells express several alternatively spliced CD1e mRNAs. These molecules encode proteins characterized by the presence of either one, two, or three cu domains and either a 51- or 63-amino acid cytoplasmic domain. Moreover, mRNAs encoding isoforms lacking the transmembrane domain are observed. Several of these CD1e isoforms were expressed in transfected cells, and two of them, with three a domains, displayed a particular processing pathway. These latter isoforms slowly leave the endoplasmic reticulum due to the presence of atypical dilysine motifs in the cytoplasmic tail. These molecules are associated with the beta (2)-microglobulin and accumulate in late Golgi and late endosomal compartments. In the latter compartments, they are cleaved into soluble forms that appear to be stable, In dendritic cells, these isoforms are mainly located in the Golgi apparatus, and upon maturation they are redistributed to late endosomal compartments. This work demonstrates the existence of CD1e molecules. As compared with other CD1 molecules, CD1e displays fundamentally different properties and therefore may represent a third type of CD1 molecules.	Etab Francais Sang Alsace, Equipe Propre INSERM 99 08, F-67065 Strasbourg, France; Etab Francais Sang Alsace, Unite INSERM 311, F-67065 Strasbourg, France; Inst Curie, UMR CNRS 144, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	de la Salle, H (corresponding author), Etab Francais Sang Alsace, Equipe Propre INSERM 99 08, F-67065 Strasbourg, France.		Goud, Bruno/GWC-4807-2022; De La Salle, Henri/H-9353-2016; Cazenave, Jean-Pierre/AAE-2935-2019	De La Salle, Henri/0000-0001-5136-0776; salamero, jean/0000-0002-2610-5826				BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chiu YH, 1999, J EXP MED, V189, P103, DOI 10.1084/jem.189.1.103; Dascher CC, 1999, J IMMUNOL, V163, P5478; HANAU D, 1987, P NATL ACAD SCI USA, V84, P2901, DOI 10.1073/pnas.84.9.2901; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Mandal M, 1998, MOL IMMUNOL, V35, P525, DOI 10.1016/S0161-5890(98)00055-8; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Murakami M, 1998, J IMMUNOL, V160, P2649; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Saudrais C, 1998, J IMMUNOL, V160, P2597; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Somnay-Wadgaonkar K, 1999, INT IMMUNOL, V11, P383, DOI 10.1093/intimm/11.3.383; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Sugita M, 1999, IMMUNITY, V11, P743, DOI 10.1016/S1074-7613(00)80148-X; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; WOOLFSON A, 1994, P NATL ACAD SCI USA, V91, P6683, DOI 10.1073/pnas.91.14.6683	26	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37757	37764		10.1074/jbc.M007082200	http://dx.doi.org/10.1074/jbc.M007082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10948205	hybrid			2022-12-25	WOS:000165618700062
J	Wagner, PD; Vu, ND				Wagner, PD; Vu, ND			Phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins/nucleoside diphosphate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; ENZYMATIC-ACTIVITY; TUMOR-METASTASIS; MELANOMA-CELLS; PC12 CELLS; MUTATION; GENE; TRANSFECTION; MOTILITY; OVEREXPRESSION	The biochemical mechanism(s) by which Nm23 proteins/nucleoside diphosphate kinases suppress tumor metastasis, inhibit cell motility, and affect cellular differentiation are not known. Here we report that Nm23 proteins can phosphorylate geranyl and farnesyl pyrophosphates to give triphosphates. Wild type Nm23-H1 had higher geranyl and farnesyl pyrophosphate kinase activities than did mutants of Nm23-H1 that do not inhibit-cell motility. The phosphorylation of farnesyl pyrophosphate appears to occur in vivo as cells with an elevated level of Nm23-H1 contained more farnesyl triphosphate than did control cells. To our knowledge, this is the first report that farnesyl triphosphate exists in cells, The phosphorylation of farnesyl pyrophosphate by Nm23 proteins could alter isoprenoid metabolism, and cells with an elevated level of Nm23 proteins were found to contain more farnesylated 46- and 24-kDa proteins than did control cells. The phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins provides a novel mechanism by which these proteins might-exert their biological effects.	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wagner, PD (corresponding author), NCI, Biochem Lab, NIH, Bldg 37,Rm 4C24, Bethesda, MD 20892 USA.							BABA H, 1995, CANCER RES, V55, P1977; BEYER P, 1985, METHOD ENZYMOL, V111, P248; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; DANESI R, 1995, BIOCHEM BIOPH RES CO, V206, P637, DOI 10.1006/bbrc.1995.1090; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FARNSWORTH CC, 1990, METHODS COMPANION ME, P231; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; KANTOR JD, 1993, CANCER RES, V53, P1971; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; PARHAR RS, 1995, INT J CANCER, V60, P204; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; SHECHTER I, 1973, BIOCHIM BIOPHYS ACTA, V316, P222, DOI 10.1016/0005-2760(73)90012-X; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1997, ADV ONCOL, V13, P3; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; VU ND, 1993, BIOCHEM J, V296, P169, DOI 10.1042/bj2960169; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 2000, BIOCHEM J, V346, P623, DOI 10.1042/0264-6021:3460623; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WATSON JA, 1985, J BIOL CHEM, V260, P4083; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; ZHANG DL, 1993, ANAL BIOCHEM, V213, P356, DOI 10.1006/abio.1993.1432; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	38	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35570	35576		10.1074/jbc.M006106200	http://dx.doi.org/10.1074/jbc.M006106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952986	hybrid			2022-12-25	WOS:000165422800097
J	Zhu, WD; Shiojima, I; Hiroi, Y; Zou, YZ; Akazawa, H; Mizukami, M; Toko, H; Yazaki, Y; Nagai, R; Komuro, I				Zhu, WD; Shiojima, I; Hiroi, Y; Zou, YZ; Akazawa, H; Mizukami, M; Toko, H; Yazaki, Y; Nagai, R; Komuro, I			Functional analyses of three Csx/Nkx-2.5 mutations that cause human congenital heart disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN-DNA COMPLEX; TRANSCRIPTION FACTOR; BINDING TARGETS; GATA-4; TINMAN; APOPTOSIS; GENES	A homeodomain-containing transcription factor Csx/Nkx-2.5 is an important regulator of cardiogenesis in mammals. Three different mutants, Gln170ter (designated A) and Thr178Met (designated B) in the helix 2 of the homeodomain and Gln198ter mutation (designated C) just after homeodomain, have been reported to cause atrial septal defect with atrial ventricular block. We here examined the functions of these three mutants of Csx/Nkx-2.5. The atrial natriuretic peptide (ANP) promoter was activated by wild type Csx/Nkx-2.5 (WT, similar to8-fold), B (similar to2-fold), and C (similar to6-fold) but not by A. When A, B, or C was cotransfected into COS-7 cells with the same amount of WT, WT-induced activation of the ANP promoter was attenuated by A and B (A > B), whereas C further enhanced the activation. Immunocytochemical analysis using anti-Myc tag antibody indicated that transfected Myc-tagged WT, B, and C were localized in the nucleus of both COS-7 cells and cardiomyocytes of neonatal rats, whereas A was distributed diffusely in the cytoplasm and nucleus in COS-7 cells. Electrophoretic mobility shift assay showed that Csx/Nkx-2.5-binding sequences were bound strongly by WT and C, weakly by B, but not by A Immunoprecipitation and GST pull-down assay revealed that WT and all mutants interacted with GATA-4, The synergistic activation of the ANP promoter by WT and GATA-4 was further enhanced by C but was inhibited by A and B, In the cultured cardiomyocytes, overexpression of C but not WT, A, or B, induced apoptosis, These results suggest that although the three mutants induce the same cardiac phenotype, transactivation ability and DNA binding ability are different among the three mutants and that apoptosis may be a cause for C-induced cardiac defect.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Komuro, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	komuro-tky@umin.ac.jp		Akazawa, Hiroshi/0000-0002-3574-9607				BODMER R, 1993, DEVELOPMENT, V118, P719; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Takimoto E, 2000, BIOCHEM BIOPH RES CO, V270, P1074, DOI 10.1006/bbrc.2000.2561; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Wu CF, 1997, J BIOL CHEM, V272, P14860, DOI 10.1074/jbc.272.23.14860; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	25	53	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35291	35296		10.1074/jbc.M000525200	http://dx.doi.org/10.1074/jbc.M000525200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948187	hybrid			2022-12-25	WOS:000165422800062
J	Hudder, A; Werner, R				Hudder, A; Werner, R			Analysis of a Charcot-Marie-Tooth disease mutation reveals an essential internal ribosome entry site element in the connexin-32 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; 5'-UNTRANSLATED REGION; TRANSLATION INITIATION; 5'-NONCODING SEQUENCES; C-MYC; EXPRESSION; BINDING; LEADER; SYSTEM; EIF4G	A mutation located in the 5'-untranslated region (5'-UTR) of the nerve-specific connexin-32 mRNA, previously found in a family with Charcot-Marie-Tooth disease (CMTX), was analyzed for its effect on the expression of a reporter gene (luciferase) in transgenic mice and in transfected cells. Whereas both mutant and wild-type genes appeared to be transcribed and spliced efficiently, no luciferase was detected from the mutant in either system, suggesting that the mutation affects translation of the mRNA When the 5'-UTR of nerve-specific connexin-32 mRNA was inserted between the two genes of a bicistronic vector and transfected into various cell Lines, expression of the second gene was significantly increased. Because the mutant did not facilitate translation of the second gene in the bicistronic mRNA system, this result suggested that the CMTX mutation abolished function of an internal ribosome entry site (IRES) in the 5'-UTR of the wild-type connexin-32 mRNA The CMTX phenotype of the mutant 5'-UTR further suggested that the wild-type IRES was essential for the translation of the connexin-32 mRNA in nerve cells, In addition, other sequence elements of the connexin-32 IRES were characterized by mutation analysis; A mutation in either of the first two elements investigated showed loss of IRES function, whereas mutation of a third element showed gain of function.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Werner, R (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.		Hudder, Alice/A-9342-2009		NICHD NIH HHS [HD34152] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034152] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; FLAGIELLO L, 1999, HUM MUTAT, V195, P361; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; HILL JR, 1992, J BIOL CHEM, V267, P21886; HOFFMAN MA, 1995, J VIROL, V65, P4867; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; Ionasescu VV, 1996, NEUROLOGY, V47, P541, DOI 10.1212/WNL.47.2.541; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kim JG, 1998, MOL CELL NEUROSCI, V12, P119, DOI 10.1006/mcne.1998.0701; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; NEUHAUS IM, 1995, GENE, V158, P257, DOI 10.1016/0378-1119(94)00899-4; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PERICAKVANCE MA, 1995, HUM HERED, V45, P121, DOI 10.1159/000154272; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Robertson MEM, 1999, RNA, V5, P1167, DOI 10.1017/S1355838299990301; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Schiavi A, 1999, FEBS LETT, V464, P118, DOI 10.1016/S0014-5793(99)01699-3; Witherell GW, 1995, VIROLOGY, V214, P660, DOI 10.1006/viro.1995.0081; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018; Zhang J, 1999, VIROLOGY, V261, P263, DOI 10.1006/viro.1999.9879; ZUKER M, 1999, ALGORITHMS THERMODYN	32	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34586	34591		10.1074/jbc.M005199200	http://dx.doi.org/10.1074/jbc.M005199200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931843	hybrid			2022-12-25	WOS:000165095300080
J	Koh, H; Lee, KH; Kim, D; Kim, S; Kim, JW; Chung, J				Koh, H; Lee, KH; Kim, D; Kim, S; Kim, JW; Chung, J			Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase C-related kinase 2 (PRK2) cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; POTENTIAL EFFECTOR; IN-VITRO; ACTIVATION; PHOSPHORYLATION; INSULIN	Akt is stimulated by several growth factors and has a major anti-apoptotic role in the cell. Therefore, we hypothesized that a pathway leading to the inhibition of Akt might be utilized in the process of apoptosis. Accordingly, we used a yeast two-hybrid screening assay to identify the proteins that interact with and possibly inhibit Akt, We found that the C-terminal region of protein kinase C-related kinase 2 (PRK2), containing amino acids 862 to 908, specifically binds to Akt in yeast and mammalian cells. During early stages of apoptosis, the C-terminal region of PRK2 is cleaved from the inhibitory N-terminal region and can bind Akt, The protein-protein interaction between Akt and the PRK2 C-terminal region specifically down-modulates the protein kinase activities of Akt by inhibiting phosphorylation at threonine 308 and serine 473 of Akt, This inhibition of Abt leads to the inhibition of the downstream signaling of Akt in vivo. The PRK2 C-terminal fragment strongly inhibits the Akt-mediated phosphorylation of BAD, a pro-apoptotic Bcl-2 family protein, and blocks the anti-apoptotic activities of Akt in vivo. These results provide direct evidence that the products of protein cleavage during apoptosis inhibit pro-survival signalings, leading to the amplification of pro-apoptotic signalings in the cell.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Pai Chai Univ, Dept Biochem, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Pai Chai University	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong, Taejon 305701, South Korea.	jchung@mail.kaist.ac.kr	Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Francois F, 1999, J NEUROCHEM, V73, P1773, DOI 10.1046/j.1471-4159.1999.731773.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Ozes ON, 1999, NATURE, V401, P82; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	55	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34451	34458		10.1074/jbc.M001753200	http://dx.doi.org/10.1074/jbc.M001753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10926925	hybrid			2022-12-25	WOS:000165095300061
J	Mao, AJ; Bechberger, J; Lidington, D; Galipeau, J; Laird, DW; Naus, CCG				Mao, AJ; Bechberger, J; Lidington, D; Galipeau, J; Laird, DW; Naus, CCG			Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; C6 GLIOMA-CELLS; GREEN FLUORESCENT PROTEIN; EMBRYONAL CARCINOMA-CELLS; MICE LACKING CONNEXIN43; HIGH-TITER; NERVOUS-SYSTEM; HELA-CELLS; IN-VITRO; EXPRESSION	Given the roles proposed for gap junctional intercellular communication in neuronal differentiation and growth control, we examined the effects of connexin43 (Cx43) expression in a neuroblastoma cell line. A vesicular stomatitis virus G protein (VSVG)-pseudotyped retrovector was engineered to co-express the green fluorescent protein (GFP) and Cx43 in the communication-deficient neuro-2a (N2a) cell line. The 293 GPG packaging cell line was used to produce VSVG-pseudotyped retrovectors coding for GFP, Cx43, or chimeric Cx43 GFP fusion protein. The titer of viral supernatant, as measured by flow cytometry for GFP fluorescence, was approximately 2.0 x 10(7) colony form units (CFU)/ml and was free of replication-competent retroviruses. After a 7-day treatment with retinoic acid (20 muM), N2a transformants (N2a-Cx43 and N2a-Cx43 GFP) maintained the expression of Cx43 and Cx43 GFP. Expression of both constructs resulted in functional coupling, as evidenced by electrophysiological and dye-injection analysis. Suppression of cell growth correlated with expression of both Cx43 or Cx43 GFP and retinoic acid treatment. Based on morphology and immunocytochemistry for neurofilament, no difference was observed in the differentiation of N2a cells compared with cells expressing Cx43 constructs. In conclusion, constitutive expression of Cx43 in N2a cells does not alter retinoic acid-induced neuronal differentiation but does enhance growth inhibition.	Univ Western Ontario, Dept Anat & Cell Biol, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Med Biophys, Child Hlth Res Inst, London, ON N6A 5C1, Canada; McGill Univ, Lady Davis Inst, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Lady Davis Institute; McGill University	Naus, CCG (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Child Hlth Res Inst, Med Sci Bldg, London, ON N6A 5C1, Canada.		Laird, Dale w/E-4176-2015; Laird, Dale W/AAL-2407-2020; Galipeau, Jacques/R-9909-2019	Laird, Dale W/0000-0002-4568-3285; Galipeau, Jacques/0000-0002-9374-1996; Lidington, Darcy/0000-0001-7582-7924				AboodyGuterman KS, 1997, NEUROREPORT, V8, P3801, DOI 10.1097/00001756-199712010-00029; Bagley J, 1998, TRANSPLANTATION, V65, P1233, DOI 10.1097/00007890-199805150-00015; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Bani-Yaghoub M, 1999, EXP NEUROL, V156, P16, DOI 10.1006/exnr.1998.6950; BaniYaghoub M, 1997, J NEUROSCI RES, V49, P19, DOI 10.1002/(SICI)1097-4547(19970701)49:1<19::AID-JNR3>3.0.CO;2-G; Belliveau DJ, 1997, DEV GENET, V21, P187, DOI 10.1002/(SICI)1520-6408(1997)21:3<187::AID-DVG2>3.0.CO;2-3; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone R, 1997, EUR J NEUROSCI, V9, P1, DOI 10.1111/j.1460-9568.1997.tb01346.x; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CEPEDA C, 1993, CEREB CORTEX, V3, P95, DOI 10.1093/cercor/3.2.95; COOK JE, 1995, MICROSC RES TECHNIQ, V31, P408, DOI 10.1002/jemt.1070310510; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; Dudek F.E., 1983, BASIC MECHANISMS NEU, P31; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FREDERICK M, 1993, CURRENT PROTOCOLS MO; Galipeau J, 1999, CANCER RES, V59, P2384; HOLDER JW, 1993, CANCER RES, V53, P3475; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Juneja SC, 1999, BIOL REPROD, V60, P1263, DOI 10.1095/biolreprod60.5.1263; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; LAIRD DW, 1990, J CELL SCI, V97, P109; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; MESNIL M, 1995, CANCER RES, V55, P629; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Nadarajah B, 1996, J COMP NEUROL, V376, P326, DOI 10.1002/(SICI)1096-9861(19961209)376:2<326::AID-CNE13>3.0.CO;2-J; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; NAUS CCG, 1992, CANCER RES, V52, P4208; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; ROZENTAL R, 1995, DEV BIOL, V167, P350, DOI 10.1006/dbio.1995.1029; RUCH RJ, 1994, ANN CLIN LAB SCI, V24, P216; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; VEENSTRA RD, 1992, CIRC RES, V71, P1277, DOI 10.1161/01.RES.71.5.1277; Wang LJ, 1996, EXP NEUROL, V139, P1, DOI 10.1006/exnr.1996.0074; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	44	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34407	34414		10.1074/jbc.M003917200	http://dx.doi.org/10.1074/jbc.M003917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924505	hybrid			2022-12-25	WOS:000165095300056
J	Rhee, SH; Hwang, D				Rhee, SH; Hwang, D			Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL WALL COMPONENTS; HUMAN COLON-CANCER; GENETIC-CONTROL; BACTERIAL LIPOPOLYSACCHARIDE; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; DROSOPHILA TOLL; CUTTING EDGE; MICE; RECOGNITION	Genetic evidence indicating that TOLL-like receptor 4 (Tlr4) is the lipopolysaccharide (LPS) receptor in mice was reported. However, biochemical evidence that murine Tlr4 confers LPS responsiveness has not been convincingly demonstrated. Inducible cyclooxygenase (COX-2) is selectively expressed in LPS-stimulated macrophages in part mediated through the activation of NF kappaB. Thus, we determined whether murine Tlr4 confers LPS responsiveness as evaluated by the activation of NF kappaB and COX-2 expression. Transfection of a murine macrophage-like cell line (RAW264.7) with the constitutively active form (Delta Tlr4) of Tlr4 is sufficient to activate NF kappaB and COX-2 expression. However, the truncated form (Delta Tlr4(P712H)) of the missense mutant Tlr4(P712H) found in LPS-hyporesponsive mouse strain (C3H/HeJ) inhibits LPS-induced NF kappaB activation and COX-2 expression. The inability of Delta Tlr4(P712H) to activate NF kappaB and induce COX-2 expression is rescued by a constitutively active adapter protein myeloid differentiation factor 88 (MyD88), which interacts directly with the cytoplasmic domain of Tlr proteins. Furthermore, MyD88 is co-immunoprecipitated with the wild-type Delta Tlr4 but not with the Delta Tlr4(P712H) mutant. Together, these results indicate that Tlr4 confers LPS responsiveness in RAW264.7 cells and suggest that hyporesponsiveness of C3H/HeJ mice to LPS is attributed to the disruption of Tlr4-mediated signaling pathways that results from the inability of the mutant Tlr4(P712H) to interact with MyD88.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Hwang, D (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.				NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER; NCI NIH HHS [CA-75613] Funding Source: Medline; NIDDK NIH HHS [DK-41868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MORRISON DC, 1978, AM J PATHOL, V93, P526; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Paik JH, 2000, J BIOL CHEM, V275, P28173; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENSTREICH DL, 1982, CRC CR REV IMMUNOL, V3, P263; SANO H, 1995, CANCER RES, V55, P3785; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tracey K J, 1990, Adv Surg, V23, P21; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vogel SN, 1999, J IMMUNOL, V162, P5666; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	41	227	241	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34035	34040		10.1074/jbc.M007386200	http://dx.doi.org/10.1074/jbc.M007386200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952994	hybrid			2022-12-25	WOS:000165095300007
J	Saito, S; Hiroi, Y; Zou, YZ; Aikawa, R; Toko, H; Shibasaki, F; Yazaki, Y; Nagai, R; Komuro, I				Saito, S; Hiroi, Y; Zou, YZ; Aikawa, R; Toko, H; Shibasaki, F; Yazaki, Y; Nagai, R; Komuro, I			beta-adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGESTIVE-HEART-FAILURE; CYTOCHROME-C; CELL-DEATH; BAD PHOSPHORYLATION; RECEPTOR BLOCKADE; HYPERTROPHY; RELEASE; DISSOCIATION; MITOCHONDRIA; INVOLVEMENT	Apoptosis of cardiac myocytes is one of the causes of heart failure. Here we examine the mechanism by which the activation of beta -adrenergic receptor induces cardiomyocyte apoptosis. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling and DNA ladder analyses revealed that isoproterenol (Iso) induced the apoptosis of cardiac myocytes of neonatal rats through an increase in intracellular Ca2+ levels. The Iso-induced cardiomyocyte apoptosis was strongly inhibited by the L-type Ca2+ channel antagonist nifedipine and by the calcineurin inhibitors cyclosporin A and FK506. Iso reduced the phosphorylation levels of the proapoptotic Bcl-2 family protein Bad and induced cytochrome c release from mitochondria to the cytosol through calcineurin activation. Infusion of Iso increased calcineurin activity by similar to3-fold in the hearts of wild-type mice but not in the hearts of transgenic mice that overexpress dominant negative mutants of calcineurin. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling analysis revealed that infusion of Iso induced apoptosis of cardiac myocytes and that the number of apoptotic cardiomyocytes was significantly less in the hearts of the transgenic mice compared with the wild-type mice. These results suggest that calcineurin plays a critical role in Iso-induced apoptosis of cardiac myocytes, possibly through dephosphorylating Bad.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Komuro, I (corresponding author), Chiba Univ, Sch Med, Dept Med 3, Chuo Ku, 1-8-1 Inohana, Chiba 2608677, Japan.							Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; DEL PL, 1997, SCIENCE, V278, P687; DOUGHTY RN, 1994, J AM COLL CARDIOL, V23, P814, DOI 10.1016/0735-1097(94)90773-0; Geng YJ, 1999, CIRC RES, V84, P34; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Newton GE, 1996, CIRCULATION, V94, P353, DOI 10.1161/01.CIR.94.3.353; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; Saraste A, 1997, CIRCULATION, V95, P320; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SHEU SS, 1987, AM J PHYSIOL, V252, pH697, DOI 10.1152/ajpheart.1987.252.4.H697; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shizukuda Y, 1998, AM J PHYSIOL-HEART C, V275, pH961, DOI 10.1152/ajpheart.1998.275.3.H961; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; SWEDBERG K, 1984, AM J CARDIOL, V54, P783, DOI 10.1016/S0002-9149(84)80208-8; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshikawa T, 1996, AM HEART J, V131, P329, DOI 10.1016/S0002-8703(96)90362-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	34	138	151	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34528	34533		10.1074/jbc.M002844200	http://dx.doi.org/10.1074/jbc.M002844200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931827	hybrid			2022-12-25	WOS:000165095300072
J	Abel, A; Wittau, N; Wieland, T; Schultz, G; Kalkbrenner, F				Abel, A; Wittau, N; Wieland, T; Schultz, G; Kalkbrenner, F			Cell cycle-dependent coupling of the vasopressin V-1a receptor to different G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; GONADOTROPIN-RELEASING-HORMONE; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C ISOZYMES; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNITS; RGS PROTEINS; MOLECULAR PHARMACOLOGY; FUNCTIONAL EXPRESSION; ARGININE-VASOPRESSIN	Arginine vasopressin (AVP) regulates biological processes by binding to G protein-coupled receptors. In Swiss 3T3 fibroblasts, expressing the V-1a subtype of vasopressin receptors, AVP mobilizes calcium from intracellular stores. In proliferating cells, the AVP-induced increase in intracellular calcium concentration ([Ca2+](i)) was mediated by G proteins of the G(q) family, which are insensitive to pertussis toxin (PTX) pretreatment of the cells. In quiescent cells, the AVP-induced increase in [Ca2+](i) was partially PTX-sensitive, suggesting an involvement of G. proteins. We confirmed this by photoaffinity labeling of G proteins in Swiss 3T3 cell membranes activated by AVP. In Swiss 3T3 cells arrested in the G(0)/G(1) phase of the cell cycle, the AVP-induced increase in [Ca2+](i) was also partially PTX-sensitive but was PTX-insensitive in cells arrested in other phases of the cell cycles. The blocking effect of PTX pretreatment in G(0)/G(1) cells was mimicked by microinjection of antisense oligonucleotides suppressing the expression of the G alpha (i3) subunits. These results were confirmed by microinjection of antibodies directed against the C terminus of G protein alpha -subunits. The data presented indicate that in Swiss 3T3 fibroblasts synchronized in the G(0)/G(1) phase of the cell cycle the V-1a receptor couples to G(q/11) and G(i3) to activate the phospholipase C-beta, leading to release of intracellular calcium.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Hamburg, Krankenhaus Eppendorf, Abt Allgemeine Pharmakol, D-20246 Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg	Kalkbrenner, F (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	Frank.Kalkbrenner@bc.boehringeringelheim.com	Wieland, Thomas/G-1772-2012; Wieland, Thomas/Q-1506-2019	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				BAERTSCHI AJ, 1985, ENDOCRINOLOGY, V116, P499, DOI 10.1210/endo-116-2-499; Barberis C, 1999, DRUG NEWS PERSPECT, V12, P279, DOI 10.1358/dnp.1999.12.5.863621; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIZZARRI C, 1994, ENDOCRINOLOGY, V134, P133, DOI 10.1210/en.134.1.133; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Dulin NO, 1999, MOL CELL BIOL, V19, P714; DUZIC E, 1992, J BIOL CHEM, V267, P9844; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; JARD S, 1986, MOL PHARMACOL, V30, P171; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Kalkbrenner F, 1996, BBA-MOL CELL RES, V1314, P125, DOI 10.1016/S0167-4889(96)00072-9; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIEHNE K, 1995, J CELL PHYSIOL, V162, P367, DOI 10.1002/jcp.1041620309; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LEVY A, 1990, CLIN ENDOCRINOL, V33, P73, DOI 10.1111/j.1365-2265.1990.tb00467.x; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; LOLAIT SJ, 1995, P NATL ACAD SCI USA, V92, P6783, DOI 10.1073/pnas.92.15.6783; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; SERRADEILLEGAL C, 1994, BIOCHEM PHARMACOL, V47, P633; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; Strakova Z, 1997, MOL PHARMACOL, V51, P217, DOI 10.1124/mol.51.2.217; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; TAYLOR CW, 1988, BIOCHEM J, V249, P917, DOI 10.1042/bj2490917; THIBONNIER M, 1993, REGUL PEPTIDES, V45, P79, DOI 10.1016/0167-0115(93)90186-C; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; Thibonnier M, 1997, ENDOCRINOLOGY, V138, P4109, DOI 10.1210/en.138.10.4109; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; WANGE RL, 1991, J BIOL CHEM, V266, P11409; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026; ZHU X, 1994, MOL PHARMACOL, V46, P460	53	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32543	32551		10.1074/jbc.M002171200	http://dx.doi.org/10.1074/jbc.M002171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931825	hybrid			2022-12-25	WOS:000090003800024
J	Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; Li, J; Whittaker, P; Stavrides, G; Hunt, AR; Huntly, BJP; Campbell, LJ; Bentley, DR; Deloukas, P; Green, AR				Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; Li, J; Whittaker, P; Stavrides, G; Hunt, AR; Huntly, BJP; Campbell, LJ; Bentley, DR; Deloukas, P; Green, AR		UK Canc Cytogenetics Grp	Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes	ONCOGENE			English	Article						chromosome 20; tumour suppressor genes; myeloproliferative disorders; myelodysplastic syndromes	MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; MOLECULAR ANALYSIS; HUMAN GENOME; LEUKEMIA; MAP; REFINEMENT; LIBRARIES; SEGMENT; YEAST	Deletion of the long arm of chromosome 20 represents the most common chromosomal abnormality associated with the myeloproliferative disorders (MPDs) and is also found in other myeloid malignancies including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Previous studies have identified a common deleted region (CDR) spanning approximately 8 Mb. We have now used G-banding, FISH or microsatellite PCR to analyse 113 patients with a 20q deletion associated with a myeloid malignancy. Our results define a new MPD CDR of 2.7 Mb, an MDS/AML CDR of 2.6 Mb and a combined 'myeloid' CDR of 1.7 Mb, We have also constructed the most detailed physical map of this region to date - a bacterial clone map spanning 5 Mb of the chromosome which contains 456 bacterial clones and 202 DNA markers. Fifty-one expressed sequences were localized within this contig of which 37 lie within the MPD CDR and 20 within the MDS/AML CDR, Of the 16 expressed sequences (sis genes and 10 unique ESTs) within the 'myeloid' CDR, five were expressed in both normal bone marrow and purified CD34 positive cells. These data identify a set of genes which are both positional and expression candidates for the target gene(s) on 20q.	Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Sangor Ctr, Hinxton CB10 1SA, Cambs, England; St Vincents Hosp, Victorian Canc Cytogenet Serv, Fitzroy, Vic 3065, Australia	University of Cambridge; Wellcome Trust Sanger Institute; St Vincent's Hospital Melbourne	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.		Deloukas, Panos/B-2922-2013; huntly, brian JP/E-6725-2014	Deloukas, Panos/0000-0001-9251-070X; huntly, brian JP/0000-0003-0312-161X; Hunt, Adrienne/0000-0002-1227-0310; Green, Anthony/0000-0002-9795-0218				Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V87, P1561, DOI 10.1182/blood.V87.4.1561.bloodjournal8741561; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; Bench AJ, 1998, GENOMICS, V49, P351, DOI 10.1006/geno.1998.5231; BENCH AJ, 1998, MYELOPROLIFERATIVE D, P819; BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BERNARDI G, 1993, GENE, V135, P57, DOI 10.1016/0378-1119(93)90049-9; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEWALD GW, 1993, CANCER GENET CYTOGEN, V68, P60, DOI 10.1016/0165-4608(93)90075-W; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; HEIM S, 1992, CANCER, V70, P1701, DOI 10.1002/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S; HOLLINGS PE, 1994, GENE CHROMOSOME CANC, V11, P21, DOI 10.1002/gcc.2870110105; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KRALOVICS R, 1998, MYELOPROLIFERATIVE D, P803; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; LEBEAU MM, 1985, P NATL ACAD SCI USA, V82, P6692; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MITELMAN F, 1995, CATALOG CHROMOSOME A; MORRIS CM, 1989, BLOOD, V74, P1768; NACHEVA E, 1995, CANCER GENET CYTOGEN, V80, P87, DOI 10.1016/0165-4608(94)00150-A; NACHEVA E, 1995, CANCER GENET CYTOGEN, V82, P9, DOI 10.1016/0165-4608(94)00286-K; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; ROSS MT, 1997, GENOME MAPPING, P165; ROULSTON D, 1993, BLOOD, V82, P3424; Saville MK, 1998, ADV CANCER RES, V72, P109; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Stoffel M, 1996, P NATL ACAD SCI USA, V93, P3937, DOI 10.1073/pnas.93.9.3937; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809	39	127	132	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3902	3913		10.1038/sj.onc.1203728	http://dx.doi.org/10.1038/sj.onc.1203728			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10952764				2022-12-25	WOS:000088614300009
J	Rodriguez, MI; Finbow, ME; Alonso, A				Rodriguez, MI; Finbow, ME; Alonso, A			Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation	ONCOGENE			English	Article						papillomavirus; receptors; membrane proteins; vacuolar H+-ATPase; endosomes; recycling	PORE-FORMING PROTEIN; EPITHELIAL-CELL LINE; BOVINE PAPILLOMAVIRUS; TRANSFORMING PROTEIN; TYPE-16 DNA; GENE-EXPRESSION; ONCOPROTEIN; KERATINOCYTES; SITE; COMMUNICATION	Human papillomavirus type 16 E5 protein (HPV16 E5) upregulates ligand-mediated activation of the epidermal growth factor receptor (EGFR) in transfected human keratinocytes. HPV16 E5 binds to the 16 kDa proteolipid (subunit c) of the vacuolar H+-ATPase (16K), responsible for endosomal acidification, and this binding has been suggested to be responsible for increased recycling of the EGFRs, Using mutant deletions we show here that amino acids 53-78, but not 79-83 are necessary for binding to the 16K proteolipid, EGF treatment of cells expressing wild type or mutants of the E5 protein show that deletion of the last carboxy terminal 5 amino acids results in loss of ES-mediated EGFR overactivation, Thus, our results show that the binding capacity of HPV16 E5 to 16K can be dissociated from the effect of the viral protein on EGFR activation.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Helmholtz Association; German Cancer Research Center (DKFZ); Beatson Institute	Alonso, A (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld-242, D-69120 Heidelberg, Germany.		García, Isabel Rodríguez/AAG-2211-2019; Rodríguez, Isabel/L-9327-2013	García, Isabel Rodríguez/0000-0001-7213-1411; Rodríguez, Isabel/0000-0001-7213-1411				ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; BauerHofmann R, 1996, VIROLOGY, V217, P33, DOI 10.1006/viro.1996.0090; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; DURST M, 1987, ONCOGENE, V1, P251; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; FINBOW ME, 1991, MOL CARCINOGEN, V4, P441, DOI 10.1002/mc.2940040605; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; NEAL MA, 1995, J INVEST DERMATOL, V105, P668; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PIM D, 1992, ONCOGENE, V7, P27; PIRISI L, 1987, J VIROL, V57, P572; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	38	51	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3727	3732		10.1038/sj.onc.1203718	http://dx.doi.org/10.1038/sj.onc.1203718			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949926				2022-12-25	WOS:000088568400004
J	Jacobs, MG; Robinson, PJ; Bletchly, C; Mackenzie, JM; Young, PR				Jacobs, MG; Robinson, PJ; Bletchly, C; Mackenzie, JM; Young, PR			Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction	FASEB JOURNAL			English	Article						flavivirus; dengue; viral nonstructural proteins; GPI; antibody	YELLOW-FEVER VIRUS; T-CELL ACTIVATION; ANCHORED MEMBRANE-PROTEINS; DECAY-ACCELERATING FACTOR; BORNE ENCEPHALITIS-VIRUS; HEMORRHAGIC-FEVER; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; STRUCTURAL PROTEINS; ENDOTHELIAL-CELLS	Dengue virus nonstructural protein I (NS1) is expressed on the surface of infected cells and is a target of human antibody responses to dengue virus infection. We show here that dengue virus uses the cellular glycosyl-phosphatidylinositol (GPI) linkage pathway to express a GPI-anchored form of NS1 and that GPI anchoring imparts a capacity for signal transduction in response to binding of NS1-specific antibody. This study is the first to identify GPI linkage of a virus-encoded protein. The GPI anchor addition signal for NS1 was identified, by transfection of HeLa cells with dengue cDNA constructs, as a downstream hydrophobic domain in NS2A, GPI linkage of NS1 in both transfected and infected cells was demonstrated by cleavage of NS1 from the surface by PI-specific phospholipase C and by metabolic incorporation of the GPI-specific components ethanolamine and inositol. In common with other GPI-anchored proteins, addition of specific antibody resulted in signal transduction, as evidenced by tyrosine phosphorylation of cellular proteins. Antibody-induced signal transduction by GPI-linked NS1 suggests a mechanism of cellular activation that may contribute to the pathogenesis of human dengue disease. Signal transduction by a GPI-anchored viral antigen interacting with a specific antibody that it induces is a new concept in the pathogenesis of viral disease.	Univ Queensland, SASVRC, Dept Microbiol & Parasitol, St Lucia, Qld 4072, Australia; Imperial Coll, Sch Med, Dept Paediat, London W2 1PG, England; Imperial Coll, Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England; Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Brisbane, Qld 4029, Australia	University of Queensland; Imperial College London; Imperial College London; Royal Children's Hospital Brisbane	Young, PR (corresponding author), Univ Queensland, SASVRC, Dept Microbiol & Parasitol, St Lucia, Qld 4072, Australia.		Mackenzie, Jason/H-5632-2019; Young, Paul R/A-6176-2010	Mackenzie, Jason/0000-0001-6613-8350; Young, Paul R/0000-0002-2040-5190				Anderson R, 1997, J VIROL, V71, P4226, DOI 10.1128/JVI.71.6.4226-4232.1997; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHURDBOONCHART V, 1991, AM J TROP MED HYG, V44, P481, DOI 10.4269/ajtmh.1991.44.481; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; FALCONAR AKI, 1991, J GEN VIROL, V72, P961, DOI 10.1099/0022-1317-72-4-961; FALGOUT B, 1989, J VIROL, V63, P1852, DOI 10.1128/JVI.63.5.1852-1860.1989; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; FALKLER WA, 1973, J IMMUNOL, V111, P1804; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0; HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1989, REV INFECT DIS, V11, pS830; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; Huang JH, 1999, J MED VIROL, V57, P1, DOI 10.1002/(SICI)1096-9071(199901)57:1&lt;1::AID-JMV1&gt;3.0.CO;2-T; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; KUNO G, 1990, J MED VIROL, V32, P102, DOI 10.1002/jmv.1890320207; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLOIS H, 1995, J GEN VIROL, V76, P979, DOI 10.1099/0022-1317-76-4-979; LEBLOIS H, 1993, NUCLEIC ACIDS RES, V21, P1668, DOI 10.1093/nar/21.7.1668; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Low M.G., 1992, LIPID MODIFICATION P, P117; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; Mason JC, 1996, J IMMUNOL, V157, P874; MASON PW, 1989, VIROLOGY, V169, P354, DOI 10.1016/0042-6822(89)90161-X; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Morozova OV, 1997, VIRUS RES, V49, P9, DOI 10.1016/S0168-1702(96)01433-5; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; OSULLIVAN MA, 1994, J GEN VIROL, V75, P2387, DOI 10.1099/0022-1317-75-9-2387; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; Robinson PJ, 1997, ADV EXP MED BIOL, V419, P365; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; *WHO, 1996, 117 WHO; WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4; WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8	55	117	121	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1603	1610		10.1096/fj.14.11.1603	http://dx.doi.org/10.1096/fj.14.11.1603			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928995				2022-12-25	WOS:000088627800015
J	Kim, HS; Park, CH; Cha, SH; Lee, JH; Lee, S; Kim, Y; Rah, JC; Jeong, SJ; Suh, YH				Kim, HS; Park, CH; Cha, SH; Lee, JH; Lee, S; Kim, Y; Rah, JC; Jeong, SJ; Suh, YH			Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity	FASEB JOURNAL			English	Article						amyloid precursor protein; intracellular free calcium concentration; Alzheimer's disease; glutamate; beta-sheet conformation	AMYLOID PRECURSOR PROTEIN; BETA-PROTEIN; SELECTIVE NEUROTOXICITY; RAT-BRAIN; DISEASE; PEPTIDE; MICE; EXPRESSION; CHANNELS; TOXICITY	Numerous lines of evidence indicate that some of the neurotoxicity associated with Alzheimer's disease (AD) is due to proteolytic fragments of the amyloid precursor protein (APP). Most research has focused on the amyloid beta peptide (A beta). However, the possible role of other cleaved products of APP is less clear. We have previously shown that a recombinant carboxy-terminal 105 amino acid fragment (CT 105) of APP induced strong nonselective inward currents in Xenopus oocyte; it also revealed neurotoxicity in PC12 cells and primary cortical neurons, blocked later phase of long-term potentiation in rat hippocampus in vivo, and induced memory deficits and neuropathological changes in mice. We report here that the pretreatment with CT 105 for 24 h at a 10 mu M concentration increases intracellular calcium concentration by about twofold in SK-N-SH and PC 12 cells, but not in U251 cells, originated from human glioblastoma. In addition, the calcium increase and toxicity induced by CT 105 were reduced by cholesterol and MK 801 in SK-N-SH and PC 12 cells, whereas the toxicity of A beta(1-42) was attenuated by nifedipine and verapamil. CT 105 rendered SK-N-SH cells and rat primary cortical neurons more vulnerable to glutamate-induced excitotoxicity, Also, conformational studies using circular dichroism experiments showed that CT 105 has similar to 15% of beta-sheet content in phosphate buffer and aqueous 2,2,2-trifluoroethanol solutions. However, the content of beta-sheet conformation in dodecyl phosphocholine micelle or in the negatively charged vesicles, is increased to 22%-23%. The results of this study showed that CT 105 disrupts calcium homeostasis and renders neuronal cells more vulnerable to glutamate-induced excitotoxicity, and that some portion of CT 105 has partial beta-sheet conformation in various environments, which may be related to the self-aggregation and toxicity. This may be significantly possibly involved in inducing the neurotoxicity characteristic of AD.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, Dept Mol Pharmacol, Neurosci Res Inst, MRC, Seoul 110799, South Korea; Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 181, Japan; Konkuk Univ, Coll Nat Sci, Dept Chem, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Kyorin University; Konkuk University	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 28 Chongno Ku, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012	Rah, Jong-Cheol/0000-0003-3780-0522				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arters J., 1995, Society for Neuroscience Abstracts, V21, P1483; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Buchet R, 1996, BBA-MOL BASIS DIS, V1315, P40, DOI 10.1016/0925-4439(95)00102-6; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHONG YH, 1994, LIFE SCI, V54, P1259; CLAUDIO S, 1996, BIOCHEM J, V314, P701; COLVIN RA, 1991, BRAIN RES, V543, P139, DOI 10.1016/0006-8993(91)91056-7; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EINSTEIN G, 1994, J NEUROSCI, V14, P5077; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fraser SP, 1996, J NEUROCHEM, V66, P2034; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; FUKUCHI K, 1992, MOL BRAIN RES, V16, P37, DOI 10.1016/0169-328X(92)90191-D; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; Hartell NA, 2000, J NEUROCHEM, V74, P1112; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim HJ, 1999, NEUROREPORT, V10, P1427, DOI 10.1097/00001756-199905140-00008; Kim HS, 1998, NEUROREPORT, V9, P3875, DOI 10.1097/00001756-199812010-00020; Kim HS, 1999, NEUROREPORT, V10, P113, DOI 10.1097/00001756-199901180-00022; Kim SH, 1996, J NEUROCHEM, V67, P1172; KOO EH, 1994, J BIOL CHEM, V269, P17386; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; PFREUNDSCHUH M, 1978, P NATL ACAD SCI USA, V75, P5122, DOI 10.1073/pnas.75.10.5122; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLISNY MB, 1993, AM J PATHOL, V142, P17; RUSH RB, 1992, QUAL PROG, V25, P13; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Song DK, 1998, J NEUROCHEM, V71, P875; Suh YH, 1997, J NEUROCHEM, V68, P1781; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Ueda K, 1997, J NEUROCHEM, V68, P265; WAITE J, 1992, NEUROBIOL AGING, V13, P595, DOI 10.1016/0197-4580(92)90062-3; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	57	77	78	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1508	1517		10.1096/fj.14.11.1508	http://dx.doi.org/10.1096/fj.14.11.1508			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928985				2022-12-25	WOS:000088627800005
J	Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Stevens, MJ; Greene, DA				Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Stevens, MJ; Greene, DA			Evaluation of alpha 1-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense	FASEB JOURNAL			English	Review						motor nerve conduction; peripheral diabetic neuropathy; nerve blood flow; prazosin	ALDOSE REDUCTASE INHIBITOR; ENDONEURIAL BLOOD-FLOW; ESSENTIAL FATTY-ACIDS; ALPHA-LIPOIC ACID; RAT SCIATIC-NERVE; SORBITOL DEHYDROGENASE; CONDUCTION-VELOCITY; OXIDATIVE STRESS; ENERGY-METABOLISM; NITRIC-OXIDE	The role for nerve blood flow (NBF) vs. other factors in motor nerve conduction (MNC) slowing in short-term diabetes was assessed by evaluating alpha(1)-adrenoceptor antagonist prazosin on NBF, MNC, as well as metabolic imbalances and oxidative stress in the neural tissue. Control and diabetic rats were treated with or without prazosin (5 mg.kg(-1).d(-1) for 3 wk), NBF was measured by hydrogen clearance. Both endoneurial vascular conductance and MNC velocity were decreased in diabetic rats vs. controls, and this decrease was prevented by prazosin, Free NAD(+):NADH ratios in mitochondrial cristae, matrix, and cytosol assessed by metabolite indicator method, as well as phosphocreatine levels and phosphocreatine/creatine ratios, were decreased in diabetic rats, and this reduction was ameliorated by prazosin, Neither diabetes-induced accumulation of two major glycation agents, glucose and fructose, as well as sorbitol and total malondialdehyde plus 4-hydroxyalkenals nor depletion of myo-inositol, GSH, and taurine or decrease in (Na/K)-ATP-ase activity were affected by prazosin, In conclusion, decreased NBF, but not metabolic imbalances or oxidative stress in the neural tissue, is a key mechanism of MNC slowing in short-term diabetes. Further experiments are needed to estimate whether preservation of NBF is sufficient for prevention of nerve dysfunction and morphological abnormalities in long-standing diabetes or whether the aforementioned metabolic imbalances closely associated with impaired neurotropism are of greater importance in advanced than in early diabetic neuropathy.	Univ Michigan, Ctr Med, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Obrosova, IG (corresponding author), Univ Michigan, Ctr Med, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,MSRB II,Rm 5570, Ann Arbor, MI 48109 USA.	iobrosso@umich.edu						Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; Calcutt NA, 1998, METABOLISM, V47, P650, DOI 10.1016/S0026-0495(98)90025-7; CAMERON NE, 1992, DIABETOLOGIA, V35, P12, DOI 10.1007/BF00400846; Cameron NE, 1996, J DIABETES COMPLICAT, V10, P43, DOI 10.1016/1056-8727(94)00076-X; Cameron NE, 1999, DIABETOLOGIA, V42, P1120, DOI 10.1007/s001250051280; CAMERON NE, 1994, DIABETOLOGIA, V37, P651, DOI 10.1007/s001250050160; CAMERON NE, 1991, DIABETES, V40, P1652, DOI 10.2337/diabetes.40.12.1652; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; Cameron NE, 1997, DIABETOLOGIA, V40, P271, DOI 10.1007/s001250050674; CAMERON NE, 1995, J CLIN INVEST, V96, P1159, DOI 10.1172/JCI118104; Cameron NE, 1998, DIABETOLOGIA, V41, P390, DOI 10.1007/s001250050921; Cameron NE, 1996, METABOLISM, V45, P1147, DOI 10.1016/S0026-0495(96)90015-3; Cameron NE, 1997, EUR J PHARMACOL, V319, P239, DOI 10.1016/S0014-2999(96)00844-8; Cameron NE, 1998, DIABETES, V47, pA137; CAMERON NE, 1995, N-S ARCH PHARMACOL, V352, P685; CARRINGTON AL, 1993, EUR J PHARMACOL, V237, P257, DOI 10.1016/0014-2999(93)90277-O; Chang K, 1997, AM J PHYSIOL-ENDOC M, V273, pE164, DOI 10.1152/ajpendo.1997.273.1.E164; CHANH PH, 1987, PROSTAG LEUKOTR ESS, V28, P243; Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; COTTER MA, 1995, DIABETOLOGIA, V38, P1285; Cotter MA, 1998, EUR J PHARMACOL, V343, P217, DOI 10.1016/S0014-2999(97)01533-1; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dewhurst M, 1997, BRIT J PHARMACOL, V120, P593, DOI 10.1038/sj.bjp.0700946; Dines KC, 1999, J NEUROL SCI, V163, P17, DOI 10.1016/S0022-510X(99)00013-1; DOSS DJ, 1997, J PERIPHER NERV SYST, V2, P1; DYCK PJ, 1988, NEW ENGL J MED, V319, P542, DOI 10.1056/NEJM198809013190904; Erdelmeier I, 1998, CHEM RES TOXICOL, V11, P1184, DOI 10.1021/tx970180z; Eriksson UJ, 1998, DIABETES, V47, P1960, DOI 10.2337/diabetes.47.12.1960; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Greene DA, 1999, EUR J PHARMACOL, V375, P217, DOI 10.1016/S0014-2999(99)00356-8; GREENE DA, 1982, DIABETES, V31, P573, DOI 10.2337/diabetes.31.7.573; GREENE DA, 1983, J CLIN INVEST, V72, P1058, DOI 10.1172/JCI111030; GREENE DA, 1984, AM J PHYSIOL, V246, pE311, DOI 10.1152/ajpendo.1984.246.4.E311; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; HALE PJ, 1987, DIABETOLOGIA, V30, P464, DOI 10.1007/BF00279613; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hotta N, 1996, DIABETES, V45, P361, DOI 10.2337/diabetes.45.3.361; Hotta N, 1996, J PHARMACOL EXP THER, V276, P49; Hounsom L, 1998, DIABETOLOGIA, V41, P839, DOI 10.1007/s001250050996; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; Kalichman MW, 1998, BRAIN RES, V810, P130, DOI 10.1016/S0006-8993(98)00898-1; Kalichman MW, 1998, ACTA NEUROPATHOL, V95, P47, DOI 10.1007/s004010050764; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; KIHARA M, 1994, AM J PHYSIOL, V266, pE980, DOI 10.1152/ajpendo.1994.266.6.E980; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; LAL S, 1995, ARCH BIOCHEM BIOPHYS, V318, P191, DOI 10.1006/abbi.1995.1220; Lal S, 1997, ARCH BIOCHEM BIOPHYS, V342, P254, DOI 10.1006/abbi.1997.0117; LANGEVELD CH, 1995, FREE RADICAL BIO MED, V19, P209, DOI 10.1016/0891-5849(95)00014-O; LI YP, 1991, J NEUROCHEM, V56, P1747, DOI 10.1111/j.1471-4159.1991.tb02076.x; Love A, 1996, EUR J PHARMACOL, V31, P433; LOW PA, 1988, EXP NEUROL, V99, P201, DOI 10.1016/0014-4886(88)90139-2; LOW PA, 1985, AM J PHYSIOL, V248, pE457, DOI 10.1152/ajpendo.1985.248.4.E457; Low PA, 1997, DIABETES, V46, pS38, DOI 10.2337/diab.46.2.S38; LOW PA, 1986, AM J PHYSIOL, V250, pE94, DOI 10.1152/ajpendo.1986.250.1.E94; MASUDA T, 1990, J BIOL CHEM, V265, P20321; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; Mizisin AP, 1998, ACTA NEUROPATHOL, V95, P171, DOI 10.1007/s004010050783; Mizisin AP, 1997, J NEUROPATH EXP NEUR, V56, P1290, DOI 10.1097/00005072-199712000-00004; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; NAGAMATSU M, 1995, DIABETES CARE, V18, P1160, DOI 10.2337/diacare.18.8.1160; Ng DTF, 1998, DIABETES, V47, P961, DOI 10.2337/diabetes.47.6.961; Niwa T, 1999, J CHROMATOGR B, V731, P23, DOI 10.1016/S0378-4347(99)00113-9; Obrosova I, 1998, DIABETOLOGIA, V41, P1442, DOI 10.1007/s001250051090; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; Obrosova IG, 1999, DIABETOLOGIA, V42, P1187, DOI 10.1007/s001250051290; OGAWA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P43, DOI 10.1016/0003-9861(86)90399-1; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; Pop-Busui R, 1998, DIABETES, V47, pA137; Pop-Busui R, 1999, DIABETES, V48, pA148; ROBERTSON S, 1992, DIABETOLOGIA, V35, P1113, DOI 10.1007/BF00401363; Ryle C, 1997, MUSCLE NERVE, V20, P577, DOI 10.1002/(SICI)1097-4598(199705)20:5<577::AID-MUS6>3.0.CO;2-6; Sasaki H, 1997, ACTA NEUROPATHOL, V93, P118, DOI 10.1007/s004010050592; Schmidt RE, 1998, J NEUROPATH EXP NEUR, V57, P1175, DOI 10.1097/00005072-199812000-00010; Sima AAF, 1999, DIABETOLOGIA, V42, P773, DOI 10.1007/s001250051227; Song ZT, 1999, DIABETES, V48, pA66; Stansberry KB, 1996, DIABETES CARE, V19, P715, DOI 10.2337/diacare.19.7.715; STEVENS EJ, 1994, J PHYSIOL-LONDON, V475P, pP68; STEVENS MJ, 1993, DIABETOLOGIA, V36, P608, DOI 10.1007/BF00404069; STEVENS MJ, 1994, J CLIN INVEST, V94, P853, DOI 10.1172/JCI117406; STEVENS MJ, IN PRESS DIABETES; SUNDKVST G, 1999, J PERIPHER NERV SYST, V4, P195; SUZUKI E, 1994, J LAB CLIN MED, V124, P627; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; TOMLINSON DR, 1985, EXP NEUROL, V89, P420, DOI 10.1016/0014-4886(85)90101-3; TUCK RR, 1984, BRAIN, V107, P935, DOI 10.1093/brain/107.3.935; Van Dam PS, 1999, METABOLISM, V48, P442; vanDam PS, 1998, FREE RADICAL BIO MED, V24, P18, DOI 10.1016/S0891-5849(97)00122-6; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; ZHU X, 1993, BIOCHIM BIOPHYS ACTA, V1168, P1, DOI 10.1016/0005-2760(93)90259-C; Zhuang HX, 1997, J PHARMACOL EXP THER, V283, P366	101	49	54	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1548	1558		10.1096/fj.14.11.1548	http://dx.doi.org/10.1096/fj.14.11.1548			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928989				2022-12-25	WOS:000088627800009
J	Martemyanov, KA; Gudkov, AT				Martemyanov, KA; Gudkov, AT			Domain III of elongation factor G from Thermus thermophilus is essential for induction of GTP hydrolysis on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-TU; CRYSTAL-STRUCTURE; GUANOSINE TRIPHOSPHATE; CONFORMATIONAL-CHANGES; PROTEIN-SYNTHESIS; TERNARY COMPLEX; TRANSFER-RNA; TRANSLOCATION; TRANSLATION; ACID	Two elongation factors (EF) EF-Tu and EF-G participate in the elongation phase during protein biosynthesis on the ribosome, Their functional cycles depend on GTP binding and its hydrolysis. The EF-Tu complexed with GTP and aminoacyl-tRNA delivers tRNA to the ribosome, whereas EF-G stimulates translocation, a process in which tRNA and mRNA movements occur in the ribosome. In the present paper we report that: (a) intrinsic GTPase activity of EF-G is influenced by excision of its-domain III; (b) the EF-G lacking domain III has a 10(3)-fold decreased GTPase activity on the ribosome, whereas its affinity for GTP is slightly decreased; and (c) the truncated EF-G does not stimulate translocation despite the physical presence of domain TV, which is also very important for translocation, By contrast, the interactions of the truncated factor with GDP and fusidic acid-dependent binding of EF-G GDP complex to the ribosome are nest influenced. These findings indicate an essential contribution of domain III to activation of GTP hydrolysis. These results also suggest conformational changes of the EF-G molecule in the course of its interaction with the ribosome that might be induced by GTP binding and hydrolysis.	Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia	Russian Academy of Sciences	Gudkov, AT (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.	gudkov@vega.protres.ru						AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; BACA OG, 1976, BIOCHEMISTRY-US, V15, P4570, DOI 10.1021/bi00666a004; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BODLEY JW, 1970, J BIOL CHEM, V245, P5662; Bubunenko M G, 1990, Biomed Sci, V1, P127; Clark BFC, 1999, FEBS LETT, V452, P41, DOI 10.1016/S0014-5793(99)00562-1; Czworkowski J, 1997, BIOCHEMISTRY-US, V36, P10327, DOI 10.1021/bi970610k; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GAVRILOVA LP, 1981, J MOL BIOL, V149, P69, DOI 10.1016/0022-2836(81)90260-6; GUDKOV AT, 1984, FEBS LETT, V176, P32, DOI 10.1016/0014-5793(84)80906-0; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; KAWAKITA M, 1974, J BIOCHEM-TOKYO, V76, P801; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; Liljas A, 1996, CURR BIOL, V6, P247, DOI 10.1016/S0960-9822(02)00469-4; Martemyanov KA, 2000, PROTEIN EXPRES PURIF, V18, P257, DOI 10.1006/prep.1999.1178; Martemyanov KA, 1998, FEBS LETT, V434, P205, DOI 10.1016/S0014-5793(98)00982-X; Martemyanov KA, 1999, FEBS LETT, V452, P155, DOI 10.1016/S0014-5793(99)00635-3; Martemyanov KA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1216; MESTERS JR, 1994, J MOL BIOL, V242, P644, DOI 10.1006/jmbi.1994.1614; NEUHARD G, 1987, ESCHERICHIA COLI SAL, P445; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Spirin A, 1986, RIBOSOME STRUCTURE P; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILLIE GR, 1975, BIOCHEMISTRY-US, V14, P1713, DOI 10.1021/bi00679a025; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	39	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35820	35824		10.1074/jbc.M002656200	http://dx.doi.org/10.1074/jbc.M002656200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940297	hybrid			2022-12-25	WOS:000165382000027
J	Obata, T; Yaffe, MB; Leparc, GG; Piro, ET; Maegawa, H; Kashiwagi, A; Kikkawa, R; Cantley, LC				Obata, T; Yaffe, MB; Leparc, GG; Piro, ET; Maegawa, H; Kashiwagi, A; Kikkawa, R; Cantley, LC			Peptide and protein library screening defines optimal substrate motifs for AKT/PKB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; NF-KAPPA-B; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; STRUCTURAL BASIS; GROWTH-FACTOR; SWISS-MODEL; AKT; ACTIVATION; PHOSPHORYLATION	AKT was originally identified as a proto-oncogene with a pleckstrin homology and Ser/Thr protein kinase domains. Recent studies revealed that AKT regulates a variety of cellular functions including cell survival, cell growth, cell differentiation, cell cycle progression, transcription, translation, and cellular metabolism. To clarify:the substrate specificity of AKT, we have used an oriented peptide library approach to determine optimal amino acids at positions N-terminal and C-terminal to the site of phosphorylation. The predicted optimal peptide substrate (Arg-Lys-Arg-Xaa-Arg-Thr-Tyr-Ser*-Phe-Gly where Ser* is the phosphorylation site) has similarities to but is distinct from optimal substrates that we previously defined for related basophilic protein kinases such: as protein kinase A, Ser/Arg-rich kinases, and protein kinase C family members. The positions most important for high V-max/K-m ratio were Arg-3>Arg-5>Arg-7. The substrate specificity of AKT was further investigated by screening a lambda GEX phage HeLa cell cDNA expression library. All of the substrates identified by this procedure contained Arg-Xaa-Arg-Xaa-Xaa-(Ser/Thr) motifs and were in close agreement with the motif identified by peptide library screening. The results of this study should help in prediction of likely AKT substrates from Primary sequences.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Shiga University of Medical Science	Cantley, LC (corresponding author), Harvard Inst Med, Div Signal Transduct, 10th Floor,330 Brookline Ave, Boston, MA 02215 USA.	cantley@helix.mgh.harvard.edu	Kashiwagi, Atsunori/H-8712-2019; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Maegawa, Hiroshi/0000-0002-4611-8149	NIGMS NIH HHS [R01 GM041890, GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kobayashi T, 1999, BIOCHEM J, P319; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Ozes ON, 1999, NATURE, V401, P82; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yaffe MB, 1999, NATURE, V402, P30; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zhou SY, 1998, METH MOL B, V87, P87; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	62	320	333	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36108	36115		10.1074/jbc.M005497200	http://dx.doi.org/10.1074/jbc.M005497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945990	hybrid			2022-12-25	WOS:000165382000067
J	Daumer, KM; Khan, AU; Steinbeck, MJ				Daumer, KM; Khan, AU; Steinbeck, MJ			Chlorination of pyridinium compounds - Possible role of hypochlorite, N-chloramines, and chlorine in the oxidation of pyridinoline cross-links of articular cartilage collagen type II during acute inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; HUMAN-NEUTROPHILS; HYDROGEN-PEROXIDE; OXYGEN RADICALS; POLYMORPHONUCLEAR LEUKOCYTES; SELECTIVE DEGRADATION; CYTOCHEMICAL METHOD; MODIFIED HEMOGLOBIN; PHAGOCYTIC-CELLS; NADPH-OXIDASE	Reactive oxygen species produced by activated neutrophils and monocytes are thought to be involved in mediating the loss of collagen and other matrix proteins at sites of inflammation. To evaluate their potential to oxidize the pyridinoline (Pyd) cross links found in collagen types I and II, we reacted hydrogen peroxide (H2O2), hypochlorous acid/hypochlorite (HOCl/OCl-), and singlet oxygen (O-2((1)Deltag)) with the Pyd substitutes, pyridoxamine dihydrochloride and vitamin B-6, which share the same chemical structure and spectral properties of Pyd cross-links. Neither H2O2 (125-500 muM) nor O-2((1)Deltag) (10-25 muM) significantly changed the spectral properties of pyridoxamine or vitamin B-6. Reaction of HOCl/OCl- (12.5-50 muM) with pyridoxamine at pH 7.2 resulted in a concentration-dependent appearance of two new absorbance peaks and a decrease in fluorescence at 400 nm (excitation 325 nm). The new absorbance peaks correlated with the formation of an N-chloramine and the product of its subsequent reaction with pyridoxamine, In contrast, the extent to which HOCl reacted with vitamin B-6, which lacks a primary amine group, was variable at this pH. At lysosomal pH 5.5, Cl-2/HOCl/OCl- reacted with both pyridoxamine and vitamin B-6, Four of the chlorinated products of this reaction were identified by gas chromatography-mass spectrometry and included 3-chloropyridinium, an aldehyde, and several chlorinated products with disrupted rings, To evaluate the effects of Cl-2/HOCl/OCl- on Pyd cross-links in collagen, we exposed bone collagen type I and articular cartilage type II to HOCl. Treatment of either collagen type with HOCl at pH 5.0 or 7.2 resulted in the oxidation of amine groups and, for collagen type II, the specific decrease in Pyd cross-link fluorescence, suggesting that during inflammation both oxidations may be used by neutrophils and monocytes to promote the loss of matrix integrity.	Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; NYU, Dept Chem, New York, NY 10003 USA	Jefferson University; New York University	Steinbeck, MJ (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 1015 Walnut St,Curtis Bldg,Rm 324, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008507, R29DE011082] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08507, DE-11082, R29 DE011082-06] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; [Anonymous], 1985, SINGLET O2; BABIOR BM, 1984, BLOOD, V64, P959; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAINTON DF, 1968, J CELL BIOL, V39, P299, DOI 10.1083/jcb.39.2.299; BERGER RR, 1966, FED PROC, V25, P840; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BREALEY GJ, 1955, J AM CHEM SOC, V77, P4462, DOI 10.1021/ja01622a006; BRIGGS RT, 1975, J CELL BIOL, V67, P566, DOI 10.1083/jcb.67.3.566; BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; CECH P, 1984, BLOOD, V63, P88; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; DAVIES JMS, 1993, FREE RADICAL BIO MED, V15, P637, DOI 10.1016/0891-5849(93)90167-S; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; Deby-Dupont G, 1998, BBA-GEN SUBJECTS, V1379, P61, DOI 10.1016/S0304-4165(97)00083-4; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; DOWNS AJ, 1973, COMPREHENSIVE INORGA, P1400; Eyre D.R., 1981, CHEM BIOL MINERALISE, P51; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; Fredriksson M, 1998, J CLIN PERIODONTOL, V25, P394, DOI 10.1111/j.1600-051X.1998.tb02461.x; Fredriksson MI, 1999, J PERIODONTOL, V70, P1355, DOI 10.1902/jop.1999.70.11.1355; FUJIMOTO D, 1978, BIOCHEM BIOPH RES CO, V84, P52, DOI 10.1016/0006-291X(78)90261-9; GARTNER A, 1986, TOP CURR CHEM, V132, P1; GINIS I, 1990, BLOOD, V76, P1233; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GREENWALD RA, 1986, INFLAMMATION, V10, P15, DOI 10.1007/BF00916037; GREENWALD RA, 1991, SEMIN ARTHRITIS RHEU, V20, P219, DOI 10.1016/0049-0172(91)90018-U; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; HARLAN JM, 1985, BLOOD, V65, P513; HARRIS ED, 1988, INFLAMMATION BASIC P, P751; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HELD AM, 1978, J AM CHEM SOC, V100, P5732, DOI 10.1021/ja00486a025; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HORMEL SE, 1991, BIOCHIM BIOPHYS ACTA, V1078, P243, DOI 10.1016/0167-4838(91)90565-H; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12362, DOI 10.1073/pnas.91.26.12362; KHAN AU, 1963, J CHEM PHYS, V39, P2105, DOI 10.1063/1.1734588; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; LATIMER WM, 1938, OXIDATION STATES ELE, P48; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SALO DC, 1990, J BIOL CHEM, V265, P11919; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SEGAL AW, 1978, LANCET, V2, P446; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; SELVARAJ RJ, 1978, J INFECT DIS, V137, P481, DOI 10.1093/infdis/137.4.481; SNEED MC, 1954, COMPREHENSIVE INORGA, P152; STEINBECK MJ, 1991, J BIOL CHEM, V266, P16336; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; STEINBECK MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1659, DOI 10.1177/41.11.8292156; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639; VISSERS MCM, 1986, BIOCHIM BIOPHYS ACTA, V889, P277, DOI 10.1016/0167-4889(86)90190-4; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P357, DOI 10.1016/0003-9861(91)90372-P; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; VISSERS MCM, 1985, BLOOD, V66, P161; WASSERMA.HH, 1972, J CHEM SOC CHEM COMM, P253, DOI 10.1039/c39720000253; WEISS SJ, 1982, LAB INVEST, V47, P5; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WITKO V, 1992, J CLIN LAB ANAL, V6, P47, DOI 10.1002/jcla.1860060110; Woolley DE, 1997, ANN RHEUM DIS, V56, P151, DOI 10.1136/ard.56.3.151	71	52	53	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34681	34692		10.1074/jbc.M002003200	http://dx.doi.org/10.1074/jbc.M002003200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940296	Green Accepted, hybrid			2022-12-25	WOS:000165095300092
J	Koch, SE; Bodi, I; Schwartz, A; Varadi, G				Koch, SE; Bodi, I; Schwartz, A; Varadi, G			Architecture of Ca2+ channel pore-lining segments revealed by covalent modification of substituted cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENT; BINDING-SITE CREVICE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT CALCIUM-CHANNEL; DOPAMINE D2 RECEPTOR; RAT PHEOCHROMOCYTOMA CELLS; NORMAL HUMAN HEART; ION PERMEATION; SODIUM-CHANNEL; BETA-SUBUNIT	The cysteine accessibility method was used to explore calcium channel pore topology. Cysteine mutations were introduced into the SS1-SS2 segments of Motifs I-TV of the human cardiac L-type calcium channel, expressed in Xenopus oocytes and the current block by methanethiosulfonate compounds was measured. Our studies revealed that several consecutive mutants of motifs ZI and III are accessible to methanethiosulfonates, suggesting that these segments exist as random coils. Motif I cysteine mutants exhibited an intermittent sensitivity to these compounds, providing evidence for a beta -sheet secondary structure. Motif IV showed a periodic sensitivity, suggesting the presence of an cr-helix. These studies reveal that the SS1-SS2 segment repeat in each motif have non-uniform secondary structures. Thus, the channel architecture evolves as a highly distorted 4-fold pore symmetry.	Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA	University of Cincinnati	Varadi, G (corresponding author), Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382, HL22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRONG CM, 1992, ANN NY ACAD SCI, V635, P18; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dang TX, 1998, J GEN PHYSIOL, V111, P185, DOI 10.1085/jgp.111.2.185; Doughty SW, 1995, J MOL GRAPHICS, V13, P342, DOI 10.1016/0263-7855(95)00074-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GUY HR, 1995, SOC GEN PHY, V50, P1; HEINEMANN SH, 1994, BRAZ J MED BIOL RES, V27, P2781; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; ILES DE, 1994, HUM MOL GENET, V3, P969, DOI 10.1093/hmg/3.6.969; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Javitch JA, 1996, MOL PHARMACOL, V49, P692; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; Klockner U, 1996, J BIOL CHEM, V271, P22293; KUO CC, 1992, NEURON, V9, P515, DOI 10.1016/0896-6273(92)90189-K; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Lee JH, 1999, J NEUROSCI, V19, P1912; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; Quinn KE, 1997, J GEN PHYSIOL, V109, P255, DOI 10.1085/jgp.109.2.255; ROSENBERG RL, 1991, J GEN PHYSIOL, V97, P1207, DOI 10.1085/jgp.97.6.1207; SCHETZ JA, 1993, BIOL BULL, V185, P462, DOI 10.2307/1542486; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Stuhmer W., 1995, SINGLE CHANNEL RECOR, P341, DOI DOI 10.1007/978-1-4419-1229-9_15; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; TANG SQ, 1993, J BIOL CHEM, V268, P13026; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YATANI A, 1994, CIRC RES, V75, P315, DOI 10.1161/01.RES.75.2.315	59	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34493	34500		10.1074/jbc.M005569200	http://dx.doi.org/10.1074/jbc.M005569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10950957	hybrid			2022-12-25	WOS:000165095300067
J	Lai, MM; Luo, HR; Burnett, PE; Hong, JJ; Snyder, SH				Lai, MM; Luo, HR; Burnett, PE; Hong, JJ; Snyder, SH			The calcineurin-binding protein cain is a negative regulator of synaptic vesicle endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; MAMMALIAN PROTEIN; NERVE-TERMINALS; T-CELLS; DYNAMIN; AMPHIPHYSIN; PHOSPHORYLATION; COMPLEXES; RELEASE; KINASE	During neurotransmitter release, exocytosed neurotransmitter vesicles are recycled by endocytosis, which involves the assembly of a complex of endocytic proteins. Assembly of endocytic proteins into a functional complex depends on their dephosphorylation by calcineurin, a calcium-sensitive protein phosphatase and the inhibitory target of immunosuppressive drugs cyclosporin A and FK506. Cain is a recently identified protein inhibitor of calcineurin. We now provide evidence that cain is a component of the endocytic protein complex. The proline-rich region of cain forms a stable association with the SH3 domain of amphiphysin 1. Using a transferrin uptake assay, we found that overexpression of cain in HEK293 cells blocks endocytosis as potently as expression of a dominant negative dynamin 1 construct. The use of other calcineurin inhibitors such as cyclosporin A and FK506 also blocks endocytosis. Since binding of cain to amphiphysin 1 does not affect amphiphysin's interaction with other endocytic proteins, our results suggest that cain negatively regulates synaptic vesicle endocytosis by inhibiting calcineurin activity, rather than sterically interfering with the assembly of the endocytic protein complex.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Lai MM, 1999, J BIOL CHEM, V274, P25963, DOI 10.1074/jbc.274.37.25963; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wijdicks EFM, 1996, NEUROLOGY, V47, P1523, DOI 10.1212/WNL.47.6.1523; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	28	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34017	34020		10.1074/jbc.C000429200	http://dx.doi.org/10.1074/jbc.C000429200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931822	hybrid			2022-12-25	WOS:000165095300003
J	Cuervo, AM; Gomes, AV; Barnes, JA; Dice, JF				Cuervo, AM; Gomes, AV; Barnes, JA; Dice, JF			Selective degradation of annexins by chaperone-mediated autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER LYSOSOMES; CYTOSOLIC PROTEINS; BINDING-PROTEINS; PEPTIDE SEQUENCES; PROTEOLYSIS; PATHWAY; PURIFICATION; LOCALIZATION; MACROPHAGES; SUBSTRATE	Annexins are a family of proteins that bind phospholipids in a calcium-dependent manner. Analysis of the sequences of the different members of the annexin family revealed the presence of a pentapeptide biochemically related to KFERQ in some annexins but not in others. Such sequences have been proposed to be a targeting sequence for chaperone mediated autophagy, a lysosomal pathway of protein degradation that is activated in confluent cells in response to removal of serum growth factors. We demonstrate that annexins II and VI, which contain KFERQ-like sequences, are degraded more rapidly in response to serum withdrawal, while annexins V and XI, without such sequences, are degraded at the same rate in the presence and absence of serum. Using isolated lysosomes, only the annexins containing KFERQ-like sequences are degraded by chaperone mediated-autophagy. Annexins V and XI could associate with lysosomes but did not enter the lysosomes and were not proteolytic substrates. Furthermore, four annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes with high chaperone-mediated autophagy activity as expected for substrate proteins. These results provide striking evidence for the importance of KFERQ motifs in substrates of chaperone-mediated autophagy.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Univ W Indies, Dept Preclin Sci, Champs Fleurs, Trinidad Tobago	Tufts University; University West Indies Mona Jamaica; University West Indies Saint Augustine	Dice, JF (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	james.dice@tufts.edu		Cuervo, Ana Maria/0000-0002-0771-700X	NATIONAL INSTITUTE ON AGING [R01AG006116, R37AG006116] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Bandorowicz-Pikula J, 1998, ACTA BIOCHIM POL, V45, P721; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; Benz J, 1997, BIOL CHEM, V378, P177; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Cuervo AM, 1999, KIDNEY INT, V55, P529, DOI 10.1046/j.1523-1755.1999.00268.x; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; CULARD JF, 1992, J INVEST DERMATOL, V98, P436, DOI 10.1111/1523-1747.ep12499850; DAVIES N, 1994, BBA-GENE STRUCT EXPR, V1218, P187, DOI 10.1016/0167-4781(94)90009-4; Diakonova M, 1997, J CELL SCI, V110, P1199; DICE J, 2000, IN PRESS LYSOSOMAL P; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gomes AV, 1995, BIOCHEM MOL BIOL INT, V37, P853; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; Horst M, 1999, MOL BIOL CELL, V10, P2879, DOI 10.1091/mbc.10.9.2879; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu L, 1995, BIOCHEM MOL BIOL INT, V36, P373; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moss S. E., 1992, ANNEXINS, P1; Movitz C, 1999, BBA-BIOMEMBRANES, V1416, P101, DOI 10.1016/S0005-2736(98)00212-0; OHSUMI Y, 1983, J BIOCHEM, V93, P547; Pittis MG, 1999, J LEUKOCYTE BIOL, V66, P845, DOI 10.1002/jlb.66.5.845; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Sable CL, 1999, BIOCHEM BIOPH RES CO, V258, P162, DOI 10.1006/bbrc.1999.0544; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Speijer H, 1997, FEBS LETT, V402, P193, DOI 10.1016/S0014-5793(96)01527-X; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vishwanatha JK, 1998, CLIN CANCER RES, V4, P2559; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165; Wu FJ, 1999, BIOCHEMISTRY-US, V38, P792, DOI 10.1021/bi9819677; Zanotti G, 1998, BIOCHEM J, V329, P101, DOI 10.1042/bj3290101; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	52	62	63	2	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33329	33335		10.1074/jbc.M005655200	http://dx.doi.org/10.1074/jbc.M005655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938088	hybrid			2022-12-25	WOS:000090104600024
J	Jaitovitch-Groisman, I; Fotouhi-Ardakani, N; Schecter, RL; Woo, A; Alaoui-Jamali, MA; Batist, G				Jaitovitch-Groisman, I; Fotouhi-Ardakani, N; Schecter, RL; Woo, A; Alaoui-Jamali, MA; Batist, G			Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-GENE-PRODUCT; PRIMARY HEPATOCELLULAR-CARCINOMA; NF-KAPPA-B; AFLATOXIN B-1; LIVER-CANCER; HUMAN HEPATOCYTES; HBX PROTEIN; EXPRESSION; DNA; RAT	Persistent infection by hepatitis B virus (HBV) and exposure to chemical carcinogens correlates with the prevalence of hepatocellular carcinoma in endemic areas. The precise nature of the interaction between these factors is not known, Glutathione S-transferases (GST) are responsible for the cellular metabolism and detoxification of a variety of cytotoxic and carcinogenic compounds by catalysis of their conjugation with glutathione. Diminished GST activity could enhance cellular sensitivity to chemical carcinogens. We have investigated GST isozyme expression in hepatocellular HepG2 cells and in an HBV-transfected subline. Total GST activity and selenium-independent glutathione peroxidase activity are significantly decreased in HBV transfected cells. On immunoblotting, HBV transfected cells demonstrate a significant decrease in the level of GST Alpha class. Cytotoxicity assays reveal that the HBV transfected cells are more sensitive to a wide range of compounds known to be detoxified by GST Alpha conjugation, Although no significant difference in protein half-life between the two cell lines was found, semiquantitative reverse transcription-polymerase chain reaction shows a reduced amount of GST Alpha mRNA in the transfected cells, Because the HBV x protein (HBx) seems to play a role in HBV transfection, we also demonstrated that expression of the HBx gene into HepG2 cells decreased the amount of GST Alpha protein, Transient transfection experiments using both rat and human GST Alpha (rGSTA5 and hGSTA1) promoters in HepG2 cells show a decreased CAT activity upon HBx expression, supporting a transcriptional regulation of both genes by HBx. This effect is independent of HBx interaction with Sp1. Treatment with oltipraz, an inducer of GST Alpha, partially overcomes the effect of HBx on both promoters. Promoter deletion studies indicate that oltipraz works through responsive elements distinct from AP1 or NF-kappaB transcription factors. Thus, REV infection alters phase II metabolizing enzymes via different mechanisms than those modulated by treatment with oltipraz.	McGill Univ, McGill Ctr Translat Res Canc, Lady Davis Inst, Dept Med,Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Batist, G (corresponding author), McGill Univ, McGill Ctr Translat Res Canc, Lady Davis Inst, Dept Med,Sir Mortimer B Davis Jewish Hosp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						Alpert LC, 1997, CLIN CANCER RES, V3, P661; ANSHER SS, 1983, HEPATOLOGY, V3, P932; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BANNASCH P, 1995, CANCER RES, V55, P3318; Barsalou A, 1998, J BIOL CHEM, V273, P17138, DOI 10.1074/jbc.273.27.17138; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BOLTON MG, 1991, CANCER RES, V51, P2410; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; BOWYER SM, 1987, P NATL ACAD SCI USA, V84, P847, DOI 10.1073/pnas.84.3.847; BOYER TD, 1987, HEPATOLOGY, V7, P843, DOI 10.1002/hep.1840070509; BRAVARD A, 1993, CARCINOGENESIS, V14, P21, DOI 10.1093/carcin/14.1.21; Chi WJ, 1998, CARCINOGENESIS, V19, P2133, DOI 10.1093/carcin/19.12.2133; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLES B, 1985, CARCINOGENESIS, V6, P693, DOI 10.1093/carcin/6.5.693; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; DIILIO C, 1991, CARCINOGENESIS, V12, P1471; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON M, 1992, CLIN MICROBIOL REV, V5, P275, DOI 10.1128/CMR.5.3.275-301.1992; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; FERRY JA, 1997, CARCINOGENESIS, V18, P21113; Fotouhi-Ardakani N, 2000, MOL BIOL EVOL, V17, P331, DOI 10.1093/oxfordjournals.molbev.a026313; Galipeau J, 1999, CANCER RES, V59, P2384; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; HAYES JD, 1991, BIOCHEM J, V279, P385, DOI 10.1042/bj2790385; HAYES PC, 1991, GUT, V32, P1546, DOI 10.1136/gut.32.12.1546; HAYES PC, 1987, GLUTATHIONE S TRANSF, P175; HOWIE AF, 1990, CARCINOGENESIS, V11, P451, DOI 10.1093/carcin/11.3.451; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KENSLER TW, 1995, J CELL BIOCHEM, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Kessler FK, 1997, CARCINOGENESIS, V18, P107, DOI 10.1093/carcin/18.1.107; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kirby GM, 1996, TOXICOL PATHOL, V24, P458, DOI 10.1177/019262339602400408; KLONE A, 1990, CARCINOGENESIS, V11, P2179, DOI 10.1093/carcin/11.12.2179; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANGOUET S, 1995, CANCER RES, V55, P5574; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LIN JK, 1977, CANCER RES, V37, P4430; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MOREL F, 1993, CANCER RES, V53, P231; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; ODwyer PJ, 1997, CANCER RES, V57, P1050; Pulford DJ, 1996, BIOCHEM J, V318, P75, DOI 10.1042/bj3180075; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHECTER RL, 1993, CANCER RES, V53, P4900; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Sohn S, 2000, MUTAT RES-DNA REPAIR, V460, P17, DOI 10.1016/S0921-8777(00)00010-0; STALKER MJ, 1994, HEPATOLOGY, V20, P149, DOI 10.1016/0270-9139(94)90147-3; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; SUZUKI T, 1994, BIOCHEM BIOPH RES CO, V200, P1665, DOI 10.1006/bbrc.1994.1643; SWENSON DH, 1977, CANCER RES, V37, P172; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WARHOLM M, 1981, BIOCHEM BIOPH RES CO, V98, P512, DOI 10.1016/0006-291X(81)90870-6; WILD CP, 1993, ENVIRON HEALTH PERSP, V99, P115, DOI 10.2307/3431466; WOGAN GN, 1992, CANCER RES, V52, pS2114; WOLOSCHAK GE, 1995, MOL CARCINOGEN, V13, P44, DOI 10.1002/mc.2940130108; YAO KS, 1995, BIOCHEM PHARMACOL, V49, P275, DOI 10.1016/0006-2952(94)00544-V; ZHANG MH, 1991, HEPATOLOGY, V13, P316; Zhou TL, 1997, CANCER RES, V57, P2749; ZHU MH, 1993, INT J CANCER, V55, P571, DOI 10.1002/ijc.2910550409	71	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33395	33403		10.1074/jbc.M003754200	http://dx.doi.org/10.1074/jbc.M003754200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10934196	hybrid			2022-12-25	WOS:000090104600032
J	Kozak, KR; Rowlinson, SW; Marnett, LJ				Kozak, KR; Rowlinson, SW; Marnett, LJ			Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NEUROBLASTOMA-CELLS; TIME-DEPENDENT INHIBITION; NITRIC-OXIDE SYNTHASE; SELECTIVE-INHIBITION; ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; CANNABINOID RECEPTOR; ACTIVE-SITE; H SYNTHASES; BIOSYNTHESIS	Cyclooxygenases (COX) play an important role in lipid signaling by oxygenating arachidonic acid to endoperoxide precursors of prostaglandins and thromboxane. Two cyclooxygenases exist which differ in tissue distribution and regulation but otherwise carry out identical chemical functions. The neutral arachidonate derivative, 2-arachidonylglycerol (2-AG), is one of two described endocannabinoids and appears to be a ligand for both the central (CB1) and peripheral (CB2) cannabinoid receptors. Here we report that 2-AG is a substrate for COX-2 and that it is metabolized as effectively as arachidonic acid. COX-2-mediated 2-AG oxygenation provides the novel lipid, prostaglandin H-2 glycerol ester (PGH(2)-G), in vitro and in cultured macrophages. PGH(2)-G produced by macrophages is a substrate for cellular PGD synthase, affording PGD(2)-G. Pharmacological studies reveal that macrophage production of PGD(2)-G from endogenous sources of 2-AG is calcium-dependent and mediated by diacylglycerol Lipase and COX-2. These results identify a distinct function for COX-2 in endocannabinoid metabolism and in the generation of a new family of prostaglandins derived from diacylglycerol and 2-AG.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu			NATIONAL CANCER INSTITUTE [P01CA068484, R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479, CA68484] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Bisogno T, 1999, J NEUROCHEM, V72, P2113, DOI 10.1046/j.1471-4159.1999.0722113.x; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Burstein SH, 2000, PROSTAG OTH LIPID M, V61, P29, DOI 10.1016/S0090-6980(00)00053-8; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, CURR MED CHEM, V6, P721; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kalgutkar AS, 1998, J MED CHEM, V41, P4800, DOI 10.1021/jm980303s; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MacPherson JC, 1996, BBA-LIPID LIPID MET, V1303, P127, DOI 10.1016/0005-2760(96)00097-5; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARNETT LJ, 1997, BIOCHEMISTRY-US, V16, P4303; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Needleman P, 1997, J RHEUMATOL, V24, P6; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; PINTO JC, 1994, MOL PHARMACOL, V46, P516; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	46	306	315	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33744	33749		10.1074/jbc.M007088200	http://dx.doi.org/10.1074/jbc.M007088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931854	hybrid			2022-12-25	WOS:000090104600078
J	Marti, T; Hu, ZH; Pohl, NL; Shah, AN; Khosla, C				Marti, T; Hu, ZH; Pohl, NL; Shah, AN; Khosla, C			Cloning, nucleotide sequence, and heterologous expression of the biosynthetic gene cluster for R1128, a non-steroidal estrogen receptor antagonist - Insights into an unusual priming mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AROMATIC POLYKETIDE SYNTHASE; ACYL CARRIER PROTEIN; STREPTOMYCES-COELICOLOR A3(2); ENGINEERED BIOSYNTHESIS; BETA-KETOACYL; DEINOCOCCUS RADIODURANS; DEDUCED FUNCTIONS; ESCHERICHIA-COLI; PURIFICATION; STRAIN	R1128 substances are anthraquinone natural products that were previously reported as non-steroidal estrogen receptor antagonists with in vitro and in vivo potency approaching that of tamoxifen, From a biosynthetic viewpoint, these polyketides possess structurally interesting features such as an unusual primer unit that are absent in the well studied anthracyclic and tetracyclic natural products. The entire R1128 gene cluster was cloned and expressed in Streptomyces lividans, a genetically well developed heterologous host. In addition to R1128C, a novel optically active natural product, designated HU235, was isolated. Nucleotide sequence analysis of the biosynthetic gene cluster revealed genes encoding two ketosynthases, a chain length factor, an acyl transferase, three acetyl-CoA carboxylase subunits, two cyclases, two oxygenases, an amidase, and remarkably, two acyl carrier proteins. Feeding studies indicate that the unusual 4-methylvaleryl side chain of R1128C is derived from valine, Together with the absence of a dedicated ketoreductase, dehydratase, or enoylreductase within the R1128 gene cluster, this suggests a functional link between fatty acid biosynthesis and R1128 biosynthesis in the engineered host. Specifically, we propose that the R1128 synthase recruits four subunits from the endogenous fatty acid synthase during the biosynthesis of this family of pharmacologically significant natural products.	Stanford Univ, Dept Chem & Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Khosla, C (corresponding author), Stanford Univ, Dept Chem & Biochem, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu		Khosla, Chaitan/0000-0001-6529-495X	NCI NIH HHS [CA77248] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM19540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao WL, 1999, BIOCHEMISTRY-US, V38, P9752, DOI 10.1021/bi990751h; BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; DECKER H, 1995, J BACTERIOL, V177, P6126, DOI 10.1128/jb.177.21.6126-6136.1995; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Dreier J, 1999, J BIOL CHEM, V274, P25108, DOI 10.1074/jbc.274.35.25108; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Gokhale RS, 2000, CURR OPIN CHEM BIOL, V4, P22, DOI 10.1016/S1367-5931(99)00046-0; GORNICKI P, 1993, J BACTERIOL, V175, P5268, DOI 10.1128/JB.175.16.5268-5272.1993; Gould SJ, 1998, J ANTIBIOT, V51, P50, DOI 10.7164/antibiotics.51.50; GRIMM A, 1994, GENE, V151, P1, DOI 10.1016/0378-1119(94)90625-4; Han L, 2000, MICROBIOL-UK, V146, P903, DOI 10.1099/00221287-146-4-903; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; Hong ST, 1997, J BACTERIOL, V179, P470, DOI 10.1128/jb.179.2.470-476.1997; Hopwood D. A., 1985, GENETIC MANIPULATION; HORI Y, 1993, J ANTIBIOT, V46, P1055, DOI 10.7164/antibiotics.46.1055; HORI Y, 1993, J ANTIBIOT, V46, P1063, DOI 10.7164/antibiotics.46.1063; HORI Y, 1993, J ANTIBIOT, V46, P1069, DOI 10.7164/antibiotics.46.1069; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; LEGOUILL C, 1993, MOL GEN GENET, V240, P146, DOI 10.1007/BF00276894; Lomovskaya N, 1998, J BACTERIOL, V180, P2379, DOI 10.1128/JB.180.9.2379-2386.1998; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING LAB MANU; MAYAUX JF, 1991, J BACTERIOL, V173, P6694, DOI 10.1128/jb.173.21.6694-6704.1991; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; RICHARDSON MT, 1999, COMPREHENSIVE NATURA, V1, P473; STRAUCH E, 1991, MOL MICROBIOL, V5, P289, DOI 10.1111/j.1365-2958.1991.tb02109.x; TSAY JT, 1992, J BIOL CHEM, V267, P6807; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184; Zhang YX, 1999, MICROBIOL-SGM, V145, P2323, DOI 10.1099/00221287-145-9-2323; Ziermann R, 1999, BIOTECHNIQUES, V26, P106, DOI 10.2144/99261st05	46	80	84	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33443	33448		10.1074/jbc.M006766200	http://dx.doi.org/10.1074/jbc.M006766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931852	hybrid			2022-12-25	WOS:000090104600038
J	Beerli, RR; Schopfer, U; Dreier, B; Barbas, CF				Beerli, RR; Schopfer, U; Dreier, B; Barbas, CF			Chemically regulated zinc finger transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING GENE-EXPRESSION; RECEPTOR FUSION PROTEINS; MAMMALIAN-CELLS; ECDYSONE RECEPTOR; BINDING DOMAIN; LAC REPRESSOR; DNA; SYSTEM; COMPLEX; TRANSFORMATION	Ligand-dependent transcriptional regulators were generated by fusion of designed Cys(2)-His(2) zinc finger proteins and steroid hormone receptor ligand binding domains. To produce novel DNA binding domains, three-finger proteins binding specific 9-base pair sequences were constructed from modular building blocks. Fusion of these zinc finger proteins to a transcriptional activation domain and to modified ligand binding domains derived from either the estrogen or progesterone receptors yielded potent ligand-dependent transcriptional regulators. Together with optimized minimal promoters, these regulators provide 4-hydroxytamoxifen- or RU486-inducible expression systems with induction ratios of up to 3 orders of magnitude. These inducible expression systems are functionally independent, and each can be selectively switched on within the same cell. The potential use of zinc finger-steroid receptor fusion proteins for the regulation of natural promoters was also explored. A gene-specific six-finger protein binding an 18-base pair target sequence was converted into a ligand-dependent regulator by fusion with either two estrogen receptor ligand binding domains or one ecdysone receptor and one retinoid X receptor ligand binding domain. These single-chain receptor proteins undergo an intramolecular rearrangement, rather than intermolecular dimerization and are functional as monomers, Thus, the ability to engineer DNA binding specificities of zinc finger proteins enables the construction of ligand dependent transcriptional regulators with potential for the regulation of virtually any desired artificial or natural promoter. It is anticipated that the novel chemically regulated gene switches described herein will find many applications in applied and basic research, where the specific modulation of gene expression can be exploited.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Barbas, CF (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-550,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA086258] Funding Source: NIH RePORTER; NCI NIH HHS [CA86258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; NAKANISHI K, 1992, STEROIDS, V57, P649, DOI 10.1016/0039-128X(92)90018-5; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Whelan J, 1996, J STEROID BIOCHEM, V58, P3, DOI 10.1016/0960-0760(96)00010-6; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	47	100	117	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32617	32627		10.1074/jbc.M005108200	http://dx.doi.org/10.1074/jbc.M005108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924515	hybrid			2022-12-25	WOS:000090003800035
J	Okano, S; Kanno, S; Nakajima, S; Yasui, A				Okano, S; Kanno, S; Nakajima, S; Yasui, A			Cellular responses and repair of single-strand breaks introduced by UV damage endonuclease in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED HUMAN PROTEINS; BASE EXCISION-REPAIR; YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-REPAIR; APURINIC/APYRIMIDINIC SITES; PATHWAY; GENE; XRCC1; RECONSTITUTION; POLYMERASE	Although single-strand breaks (SSBs) occur frequently, the cellular responses and repair of SSB are not well understood. To address this, we established mammalian cell Lines expressing Neurospora crassa UV damage endonuclease (UVDE), which introduces a SSB with a 3'-OH immediately 5' to UV-induced cyclobutane pyrimidine dimers or 6-4 photoproducts and initiates an alternative excision repair process. Xeroderma pigmentosum group A cells expressing UVDE show UV resistance of almost the wild-type level. In these cells SSBs are produced upon UV irradiation and then efficiently repaired. The repair patch size is about seven nucleotides, and repair synthesis is decreased to 30% by aphidicolin, suggesting the involvement of a DNA polymerase delta/is an element of -dependent long-patch repair. Immediately after UV irradiation, cellular proteins are poly(ADP-ribosyl)ated. The UV resistance of the cells is decreased in the presence of 3-aminobenzamide, an inhibitor of poly(AI)P-ribose) polymerase. Expression of UVDE in XRCC1-defective EM9, a Chinese hamster ovary cell line, greatly sensitizes the host cells to UV, and addition of 3-aminobenzamide results in almost no further sensitization of the cells to UV. Thus, we show that XRCC1 and PARP are involved in the same pathway for the repair of SSBs.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan	Tohoku University	Yasui, A (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan.	ayasui@idac.tohoku.ac.jp	Kanno, Shin-ichiro/AAE-4549-2019					Alleva JL, 2000, BIOCHEMISTRY-US, V39, P2659, DOI 10.1021/bi992751n; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; BENHUR E, 1984, RADIAT RES, V97, P546, DOI 10.2307/3576146; BOORSTEIN RJ, 1984, J CELL PHYSIOL, V120, P345, DOI 10.1002/jcp.1041200313; Bowman KK, 1997, MUTAT RES-DNA REPAIR, V385, P95, DOI 10.1016/S0921-8777(97)00029-3; BOWMAN KK, 1994, NUCLEIC ACIDS RES, V22, P3026, DOI 10.1093/nar/22.15.3026; Chatterjee S, 1998, CONT CANC RES, P487; FREYER GA, 1995, MOL CELL BIOL, V15, P4572; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Kanno S, 1999, NUCLEIC ACIDS RES, V27, P3096, DOI 10.1093/nar/27.15.3096; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEHMAN AR, 1981, DNA REPAIR LAB MANUA, P471; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POVIRK LF, 1977, NUCLEIC ACIDS RES, V4, P3573, DOI 10.1093/nar/4.10.3573; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289; Takao M, 1996, NUCLEIC ACIDS RES, V24, P1267, DOI 10.1093/nar/24.7.1267; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; VALERIE K, 1987, CANCER RES, V47, P2967; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; Yasuhira S, 1999, J BIOL CHEM, V274, P26822, DOI 10.1074/jbc.274.38.26822; Yasui A, 1998, BIOESSAYS, V20, P291, DOI 10.1002/(SICI)1521-1878(199804)20:4<291::AID-BIES5>3.0.CO;2-T; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i	34	36	36	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32635	32641		10.1074/jbc.M004085200	http://dx.doi.org/10.1074/jbc.M004085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10924509	hybrid			2022-12-25	WOS:000090003800037
J	Baglia, FA; Badellino, KO; Ho, DH; Dasari, VR; Walsh, PN				Baglia, FA; Badellino, KO; Ho, DH; Dasari, VR; Walsh, PN			A binding site for the kringle II domain of prothrombin in the Apple 1 domain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XI; MOLECULAR-WEIGHT KININOGEN; BLOOD-COAGULATION; FUNCTIONAL-CHARACTERIZATION; HAGEMAN-FACTOR; HEAVY-CHAIN; ACTIVATION; THROMBIN; PLASMA; IDENTIFICATION	Previously we defined binding sites for high molecular weight kininogen (HK) and thrombin in the Apple 1 (Al) domain of factor XI (FM). Since prothrombin (and Ca2+) can bind FXI and can substitute for HK (and Zn2+) as a cofactor for FXI binding to platelets, we have attempted to identify a prothrombin-binding site in FXI. The recombinant Al domain (rAl, Glu(1)-Ser(90)) inhibited the saturable, specific and reversible binding of prothrombin to FXI, whereas neither the rA2 domain (Ser(90)-Ala(181)), rA3 domain (Ala(181)-Val(271)), nor rA4 domain (Phe(272)-Glu(361)) inhibited prothrombin binding to FXI. Kinetic binding studies using surface plasmon resonance showed binding of FXI (K-d similar to 71 nn) and the rAl domain (K-d similar to 239 nM) but not rA2, rA3, or rA4 to immobilized prothrombin. Reciprocal binding studies revealed that synthetic peptides (encompassing residues Ala(45)-Ser(86)) containing both HK- and thrombin-binding sites, inhibit I-125-rAl (Glu(1)-Ser(90)) binding to prothrombin, I-125-prothrombin binding to FXI, and 125I-prothrombin fragment 2 (Ser(156)-Arg(271)) binding to FXI. However, homologous prekallikrein-derived peptides (encompassing Pro(45)-Gly(86)) did not inhibit FXI rAl binding to prothrombin. The peptides Ala(45)-Arg(54), Phe(56)-Val(71), and Asp(72)-Ser(86), derived from sequences of the Al domain of FXI, acted synergistically to inhibit I-125-rAl binding to prothrombin. Mutant rAl peptides (V64A and I77A), which did not inhibit FXI binding to III, retained full capacity to inhibit rAl domain binding to prothrombin, and mutant rAl peptides Ala(45)-Ala(54) (D51A) and Val(59)-Arg(70) (E66A), which did not inhibit FXI binding to thrombin, retained full capacity to inhibit rAl domain binding to prothrombin. Thus, these experiments demonstrate that a prothrombin binding site exists in the Al domain of FXI spanning residues Ala(45)-Ser(86) that is contiguous with but separate and distinct from the HK- and thrombin-binding sites and that this interaction occurs through the kringle II domain of prothrombin.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@astro.ocis.temple.edu		Dasari, Venkat/0000-0001-9795-6567	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, R01HL046213, P01HL056914] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46213, HL56153, HL56914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAGLIA FA, 1999, THROMB DIATH HAEMO, V82, P428; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BRUNNEE T, 1993, BLOOD, V81, P580; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERWALD H, 1993, J BIOL CHEM, V268, P14527; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; Mann KG., 1994, HEMOSTASIS THROMBOSI, P184; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; NAITO K, 1991, J BIOL CHEM, V266, P7353; SCOTT CF, 1984, BLOOD, V63, P42; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715; SINHA D, 1985, J BIOL CHEM, V260, P714; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WALSH PN, 1993, METHOD ENZYMOL, V222, P65	33	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31954	31962		10.1074/jbc.M005465200	http://dx.doi.org/10.1074/jbc.M005465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924522	hybrid			2022-12-25	WOS:000089858900057
J	Balija, VS; Chakraborty, TR; Nikonov, AV; Morimoto, T; Haldar, D				Balija, VS; Chakraborty, TR; Nikonov, AV; Morimoto, T; Haldar, D			Identification of two transmembrane regions and a cytosolic domain of rat mitochondrial glycerophosphate acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; COA-BINDING PROTEIN; LIVER MITOCHONDRIA; ACYL-COA; MEMBRANE; TOPOGRAPHY; ACYLATION; SUBSTRATE; CLONING	The topography of rat glycerophosphate acyltransferase (GAT) in the transverse plane of the mitochondrial outer membrane (MOM) was investigated. Computer analysis of the amino acid (aa) sequence derived from rat mitochondrial GAT cDNA (GenBank(TM) accession nos. U36771 and AF021348) predicts the presence of two possible transmembrane domains (aa 473-493 and 574-594) separated by an 80-aa stretch (aa 494-573), To determine the actual orientation of the native protein, we prepared anti-peptide antibodies to three regions: one in between (aa 543-559) and the other two (aa 420-435 and 726-740) flanking the two putative transmembrane regions. Both immunoreaction and immunoprecipitation experiments employing intact and solubilized mitochondria indicate that regions on the N- and C-terminal sides of the transmembrane regions are sequestered on the inner surface of the MOM, while the region between the transmembrane domains is present on the cytosolic face of the MOM. Additionally, two green fluorescent protein (GFP) fusion proteins consisting of full-length GAT fused to GFP at either the C terminus or inserted 115 amino acids from the N terminus were also constructed to determine the orientation of the N and C termini. COS-l cells expressing these fusion proteins were fractionated to obtain mitochondria. Protease digestion of intact and solubilized COS-l cell mitochondria revealed that the GFP domains of these fusion proteins are sequestered on the inner side of the MOM. The present findings indicate that GAT is a dual-spanning, transmembrane protein adopting an inverted "U" conformation in the transverse plane of the MOM, where the N and C termini are sequestered on the inner surface of the MOM, while aa 494-573 are exposed on the cytosolic surface of the MOM.	St Johns Univ, Dept Biol Sci, Jamaica, NY 11432 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Saint John's University; New York University	Haldar, D (corresponding author), St Johns Univ, Dept Biol Sci, Jamaica, NY 11432 USA.				NIGMS NIH HHS [GM-46692, GM-57643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046692, R15GM057643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P12; Chakraborty TR, 1999, J BIOL CHEM, V274, P29786, DOI 10.1074/jbc.274.42.29786; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DAS SK, 1981, BIOCHEM BIOPH RES CO, V101, P237, DOI 10.1016/S0006-291X(81)80036-8; DAS SK, 1987, LIPIDS, V22, P757, DOI 10.1007/BF02533977; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V882, P1; FITZPATRICK SM, 1982, J NEUROCHEM, V39, P286, DOI 10.1111/j.1471-4159.1982.tb04738.x; GROSJEAN CD, 1982, FEBS LETT, V145, P281, DOI 10.1016/0014-5793(82)80183-X; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOFFMAN K, 1993, BIOL CHEM HOPPESEYLE, V347, P166; HOSTETLER KY, 1982, PHOSPHOLIPIDS, P481; KENNEDY EP, 1953, J BIOL CHEM, V201, P399; KENNEDY EP, 1961, FED PROC, V20, P934; KORNBERG A, 1953, J BIOL CHEM, V204, P345; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MONROY G, 1972, J BIOL CHEM, V247, P6884; MUDIO PM, 1999, BIOCHEM J, V338, P783; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; NIMO HG, 1979, FEBS LETT, V101, P262; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SHIN DH, 1991, J BIOL CHEM, V266, P23834; SHINDO Y, 1978, J BIOCHEM, V84, P1177, DOI 10.1093/oxfordjournals.jbchem.a132234; STERN W, 1978, J BIOL CHEM, V253, P8047; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C	32	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31668	31673		10.1074/jbc.M002963200	http://dx.doi.org/10.1074/jbc.M002963200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924502	hybrid			2022-12-25	WOS:000089858900019
J	Berenstein, D; Christensen, JF; Kristensen, T; Hofbauer, R; Munch-Petersen, B				Berenstein, D; Christensen, JF; Kristensen, T; Hofbauer, R; Munch-Petersen, B			Valine, not methionine, is amino acid 106 in human cytosolic thymidine kinase (TK1) - Impact on oligomerization, stability, and kinetic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; MAMMALIAN-CELLS; SEQUENCE; GENE; OVEREXPRESSION; PREDICTION; MUTATIONS; COMPLEX; CYCLE; POOL	Cytosolic thymidine kinase (TK1) cDNA from human lymphocytes was cloned, expressed in Escherichia coli, purified, and characterized with respect to the ATP effect on thymidine affinity and oligomerization, Sequence analysis of this lymphocyte TK1 cDNA and 21 other cDNAs or genomic TK1 DNAs from healthy cells or leukemic or transformed cell lines revealed a valine at amino acid position 106. The TK1 sequence in NCBI GenBank(TM) has methionine at this position. The recombinant lymphocyte TK1(Val-106) (rLy-TK1(Val-106)) has the same enzymatic and oligomerization properties as endogenous human lymphocyte TK1 (Ly-TK1); ATP exposure induces an enzyme concentration-dependent reversible transition from a dimer to a tetramer with 20-30-fold higher thymidine affinity (K-m about 15 and 0.5 mu M, respectively). Substitution of Val-106 with methionine to give rLy-TK1(Met-106) results in a permanent tetramer with the high thymidine affinity (K-m about 0.5 mu M), even without ATP exposure. Furthermore, rLy-TK1(Met-106) is considerably less stable than rLy-TK1(Val-106) (t(1/2) at 15 degrees C is 41 and 392 min, respectively). Because valine with high probability is the naturally occurring amino acid at position 106 in human TK1 and because this position has high impact on the enzyme properties, the Val-106 form should be used in future investigations of recombinant human TK1.	Roskilde Univ, Dept Life Sci & Chem, DK-4000 Roskilde, Denmark; Vienna Bioctr, Dept Mol Biol, Inst Med Biochem, A-1030 Vienna, Austria	Roskilde University; Vienna Biocenter (VBC)	Munch-Petersen, B (corresponding author), Roskilde Univ, Dept Life Sci & Chem, DK-4000 Roskilde, Denmark.							BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; FOLKERS G, 1991, J COMPUT AID MOL DES, V5, P385, DOI 10.1007/BF00125660; GIVER CR, 1995, CARCINOGENESIS, V16, P267, DOI 10.1093/carcin/16.2.267; GROSOVSKY AJ, 1993, MUTAT RES, V289, P231, DOI 10.1016/0027-5107(93)90074-P; HIRAGA S, 1967, BIOCHIM BIOPHYS ACTA, V145, P41, DOI 10.1016/0005-2787(67)90652-1; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; Kim CH, 1997, GENE, V199, P293, DOI 10.1016/S0378-1119(97)00384-3; KRISTENSEN T, 1994, LEUKEMIA RES, V18, P861, DOI 10.1016/0145-2126(94)90168-6; Lei HX, 1998, BIOMED ENVIRON SCI, V11, P354; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Munch-Petersen B, 2000, J BIOL CHEM, V275, P6673, DOI 10.1074/jbc.275.9.6673; MUNCHPETERSEN B, 1995, ADV ENZYME REGUL, V35, P69, DOI 10.1016/0065-2571(94)00014-T; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; MUNCHPETERSEN B, 1973, EXP CELL RES, V79, P249, DOI 10.1016/0014-4827(73)90442-4; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SAMBROOK J, 1989, MOL CLONING, V2, P9; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; Wild K, 1997, PROTEIN SCI, V6, P2097	27	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32187	32192		10.1074/jbc.M005325200	http://dx.doi.org/10.1074/jbc.M005325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10924519	hybrid			2022-12-25	WOS:000089858900087
J	Fogel, BL; McNally, MT				Fogel, BL; McNally, MT			A cellular protein, hnRNP H, binds to the negative regulator of splicing element from Rous sarcoma virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-H; MESSENGER-RNA; MASS-SPECTROMETRY; SR PROTEINS; IN-VITRO; 5'-SPLICE-SITE; SEQUENCES; GENE; U11; IDENTIFICATION	Incomplete RNA splicing is a key feature of the retroviral life cycle. This is in contrast to the processing of most cellular pre-mRNAs, which are usually spliced to completion. In Rous sarcoma virus, splicing control is achieved in part through a cis-acting RNA element termed the negative regulator of splicing (NRS). The NRS is functionally divided into two parts termed NRS5' and NRS3', which bind a number of splicing factors. The U1 and U11 small nuclear ribonucleoproteins interact with sequences in NRS3', whereas NRS5' binds several proteins including members of the family of proteins. Among the proteins that specifically bind NRS5' is a previously unidentified 55-kDa protein (p55), In this report we describe the isolation and identification of p55. The p55 binding site was localized by UV cross-linking to a 31-nucleotide segment, and a protein that binds specifically to it was isolated by RNA affinity selection and identified by mass spectrometry as hnRNP H. Antibodies against hnRNP H immunoprecipitated crosslinked p55 and induced a supershift of a p55-containing complex formed in HeLa nuclear extract. Furthermore, UV cross-linking and electrophoretic mobility shift assays indicated that recombinant hnRNP H specifically interacts with the p55 binding site, confirming that hnRNP H is p55, The possible roles of hnRNP H in NRS function are discussed.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	McNally, MT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mtm@mcw.edu			NCI NIH HHS [R01 CA78709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO S, 1988, MOL CELL BIOL, V8, P4858, DOI 10.1128/MCB.8.11.4858; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BECKLER GS, 1992, PROMEGA NOTES, V39, P12; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Coffin JM, 1996, FIELDS VIROLOGY, P1767; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1995, RNA, V1, P663; Ginisty H, 1999, J CELL SCI, V112, P761; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hibbert CS, 1999, RNA, V5, P333, DOI 10.1017/S1355838299981347; Holzmann K, 1997, EUR J BIOCHEM, V244, P479, DOI 10.1111/j.1432-1033.1997.00479.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kolossova I, 1997, RNA, V3, P227; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; McNally LM, 1996, J VIROL, V70, P1163, DOI 10.1128/JVI.70.2.1163-1172.1996; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; McNally LM, 1998, MOL CELL BIOL, V18, P3103, DOI 10.1128/MCB.18.6.3103; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERIC C, 1986, J VIROL, V60, P450; MILLER JT, 1992, J VIROL, V66, P4242, DOI 10.1128/JVI.66.7.4242-4251.1992; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Moore MJ, 1993, TNA WORLD, P303; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; STOLTZFUS CM, 1989, J VIROL, V63, P1669, DOI 10.1128/JVI.63.4.1669-1676.1989; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	41	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32371	32378		10.1074/jbc.M005000200	http://dx.doi.org/10.1074/jbc.M005000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10934202	hybrid			2022-12-25	WOS:000089858900111
J	Nathanson, L; Deutscher, MP				Nathanson, L; Deutscher, MP			Accelerated publication - Active aminoacyl-tRNA synthetases are present in nuclei as a high molecular weight multienzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN-PROTEIN INTERACTIONS; EXPORT; ORGANIZATION; COMPONENTS; EUKARYOTES; SYSTEM; CELLS; FORMS	Recent studies suggest that aminoacylation of tRNA may play an important role in the transport of these molecules from the nucleus to the cytoplasm. However, there is almost no information regarding the status of active aminoacyl-tRNA synthetases within the nuclei of eukaryotic cells. Here we show that at least 13 active aminoacyl-tRNA synthetases are present in purified nuclei of both Chinese hamster ovary and rabbit kidney cells, although their steady-state levels represent only a small percentage of those found in the cytoplasm. Most interestingly, all the nuclear aminoacyl-tRNA synthetases examined can be isolated as part of a multienzyme complex that is more stable, and consequently larger, than the comparable complex isolated from the cytoplasm. These data directly demonstrate the presence of active aminoacyl-tRNA synthetases in mammalian cell nuclei. Moreover, their unexpected structural organization raises important questions about the functional significance of these multienzyme complexes and whether they might play a more direct role in nuclear to cytoplasmic transport of tRNAs.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA.	mdeutsch@med.miami.edu	Nathanson, Lubov/ABC-2642-2021	Nathanson, Lubov/0000-0003-1038-9083	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARCOSTESEC A, 1989, BIOL CELL, V65, P21; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; BANDYOPADHYAY AK, 1971, J MOL BIOL, V60, P113, DOI 10.1016/0022-2836(71)90451-7; BARBARESE E, 1995, J CELL SCI, V108, P2781; DEUTSCHER MP, 1982, J BIOL CHEM, V257, P6003; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GREENBERG ME, 1997, CURRENT PROTOCOLS MO, V1; Grosshans H, 2000, GENE DEV, V14, P830; HAMPEL A, 1973, J MOL BIOL, V79, P285, DOI 10.1016/0022-2836(73)90006-5; Hopper AK, 1998, SCIENCE, V282, P2003, DOI 10.1126/science.282.5396.2003; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MURAMATSU M, 1963, CANCER RES, V23, P510; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; POPENKO VI, 1994, EUR J CELL BIOL, V65, P60; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Sanders J, 1996, J CELL SCI, V109, P1113; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Schimmel P, 1999, TRENDS BIOCHEM SCI, V24, P127, DOI 10.1016/S0968-0004(99)01369-9; SIVARAM P, 1990, P NATL ACAD SCI USA, V87, P3665, DOI 10.1073/pnas.87.10.3665; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	32	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31559	31562		10.1074/jbc.C000385200	http://dx.doi.org/10.1074/jbc.C000385200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930398	hybrid			2022-12-25	WOS:000089858900002
J	Ronchini, C; Capobianco, AJ				Ronchini, C; Capobianco, AJ			Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation	ONCOGENE			English	Article						notch; hormone inducible activity; phosphorylation; CBF-1; nuclear localization	HUMAN ESTROGEN-RECEPTOR; CELL-FATE; NEOPLASTIC TRANSFORMATION; DROSOPHILA NOTCH; IN-VIVO; CONDITIONAL TRANSFORMATION; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; FUSION PROTEINS	Notch genes encode a family of evolutionarily conserved transmembrane receptors that are involved in many distinct cellular processes such as differentiation, proliferation and apoptosis. Notch function has been shown to be required both during development and in adult life. Moreover, several studies on spontaneous human tumors and in experimental models demonstrate that three of the four mammalian Notch genes can act as oncogenes. The mechanism by which Notch proteins induce neoplastic transformation is not known. In order to determine the early signaling events mediated by Notch during cellular transformation we constructed several inducible alleles of Notch(ic) by fusing portions of Notch(ic) to the hormone-binding domain of the estrogen receptor. Here we show that Notch(ic)-ER chimeras are conditionally activated by 4-Hydroxytamoxifen (OHT) in a dose-dependent manner. Clonal RKE cell lines expressing Notch(ic)-ER chimeras display hormone-dependent transformation in vitro. Transformation mediated by Notch(ic)-ER is reversible and chronic stimulation is necessary for the maintenance of the transformed phenotype. In response to hormone activation Notch(ic)-ER chimeras become hyperphosphorylated and accumulate in the nuclear of the cell; indicating that both phosphorylation and nuclear localization are required for Notch transforming activity.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Capobianco, AJ (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Ronchini, Chiara/K-3935-2013	Ronchini, Chiara/0000-0003-3908-4021; Capobianco, Anthony/0000-0002-3706-6797	NATIONAL CANCER INSTITUTE [R01CA083736] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 83736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; ECCLES SA, 1994, INVAS METAST, V14, P337; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FuentesPanana EM, 1998, J VIROL, V72, P693; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Grignani F, 1998, CANCER RES, V58, P14; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lofts F J, 1992, Cancer Treat Res, V61, P161; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; NYE JS, 1994, DEVELOPMENT, V120, P2421; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; STIFANI S, 1992, NAT GENET, V2, P343, DOI 10.1038/ng1292-343a; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vigo E, 1999, MOL CELL BIOL, V19, P6379; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	57	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3914	3924		10.1038/sj.onc.1203719	http://dx.doi.org/10.1038/sj.onc.1203719			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951584				2022-12-25	WOS:000088614300010
J	Schulte, R; Grassl, GA; Preger, S; Fessele, S; Jacobi, CA; Schaller, M; Nelson, PJ; Autenrieth, IB				Schulte, R; Grassl, GA; Preger, S; Fessele, S; Jacobi, CA; Schaller, M; Nelson, PJ; Autenrieth, IB			Yersinia enterocolitica invasin protein triggers IL-8 production in epithelial cells via activation of Rel p65-p65 homodimers	FASEB JOURNAL			English	Article						bacteria; chemokine; transcription; NF-kappa B	NF-KAPPA-B; INTERLEUKIN-8 GENE-EXPRESSION; OUTER-MEMBRANE PROTEIN; PSEUDOTUBERCULOSIS INVASIN; TRANSCRIPTION FACTOR; HELICOBACTER-PYLORI; MAMMALIAN-CELLS; IN-VITRO; TYROSINE PHOSPHORYLATION; INFLAMMATORY CYTOKINES	Enteropathogenic Yersinia bacteria trigger the production of the proinflammatory chemokine IL-8, an important chemokine for the recruitment of polymorphonuclear leukocytes (PMN). Yersinia is resistant to phagocytosis by PMN, and the recruitment of these cells is thought to be part of a pathogenic strategy of Yersinia to establish infection by allowing the pathogen to gain access to, and disseminate within, host tissue. We report here that Yersinia expressing the outer membrane protein invasin triggers IL-8 production in epithelial cells. The 195 carboxyl-terminal amino acids of invasin when linked to latex beads are sufficient to trigger IL-8 production. By means of IL-8 promoter reporter gene assays and electrophoretic mobility shift assay experiments, the minimal optimal region of the IL-8 promoter responsive to invasin was identified and invasin-responsive control elements were characterized. Invasin-induced activation of the IL-8 promoter tvas found to be mediated through a previously identified NF-kappa B element. This NF-kappa B binding site preferentially binds Rel p65-p65 homodimers as well as some p50-p65 heterodimers in response to stimulation by invasin. Invasin-induced NF-kappa B activation col-related with degradation of I kappa B alpha. and the inhibition of NF-kappa B by specific inhibitors of I kappa B activation blocked invasin-induced IL-8 secretion. Invasin-triggered IL-8 production does not depend on invasin-triggered uptake of bacteria, and is independent of a functional PI3-kinase. This report is the first to demonstrate the molecular basis of IL-8 production triggered by enteropathogenic bacteria. Together, these data elucidate the possible early pathomechanisms operating in Yersinia infection and may have implications for the design of novel therapeutics directed against this enteropathogen.	Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; Univ Munich, Med Poliklin, D-80336 Munich, Germany; Univ Munich, Klin Dermatol & Allergol, D-80337 Munich, Germany	University of Munich; University of Munich; University of Munich	Autenrieth, IB (corresponding author), Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, Petterkoferstr 9A, D-80336 Munich, Germany.	Autenrieth@m304.mpk.med.uni-muenchen.de	Grassl, Guntram/B-3559-2010	Fessele, Sabine/0000-0002-5399-3574				Autenrieth IB, 1996, INFECT IMMUN, V64, P1357, DOI 10.1128/IAI.64.4.1357-1368.1996; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BLISKA JB, 1993, INFECT IMMUN, V61, P3914, DOI 10.1128/IAI.61.9.3914-3921.1993; BOTTONE EJ, 1977, CRC CR REV MICROBIOL, V5, P211, DOI 10.3109/10408417709102312; BRETT SJ, 1993, EUR J IMMUNOL, V23, P1608, DOI 10.1002/eji.1830230732; Clark MA, 1998, INFECT IMMUN, V66, P1237, DOI 10.1128/IAI.66.3.1237-1243.1998; Cornelis G R, 1994, Curr Top Microbiol Immunol, V192, P243; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; COVER TL, 1989, NEW ENGL J MED, V321, P16, DOI 10.1056/NEJM198907063210104; DELOR I, 1990, INFECT IMMUN, V58, P2983, DOI 10.1128/IAI.58.9.2983-2988.1990; Dersch P, 1999, EMBO J, V18, P1199, DOI 10.1093/emboj/18.5.1199; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Eckmann Lars, 1995, Trends in Microbiology, V3, P118, DOI 10.1016/S0966-842X(00)88894-0; Elewaut D, 1999, J IMMUNOL, V163, P1457; EMSDY L, 1989, J BACTERIOL, V171, P6674; Forsberg Ake, 1994, Trends in Microbiology, V2, P14, DOI 10.1016/0966-842X(94)90339-5; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V40, P37, DOI 10.1016/0378-1097(87)90512-X; HEESEMANN J, 1983, J BACTERIOL, V155, P761, DOI 10.1128/JB.155.2.761-767.1983; Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; ISBERG RR, 1989, MOL MICROBIOL, V3, P1449, DOI 10.1111/j.1365-2958.1989.tb00128.x; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEE WH, 1977, CAN J MICROBIOL, V23, P1714, DOI 10.1139/m77-247; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lundgren E, 1996, INFECT IMMUN, V64, P829, DOI 10.1128/IAI.64.3.829-835.1996; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McCormick BA, 1997, INFECT IMMUN, V65, P1414, DOI 10.1128/IAI.65.4.1414-1421.1997; MILLER VL, 1989, INFECT IMMUN, V57, P121, DOI 10.1128/IAI.57.1.121-131.1989; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, CURR TOP MICROBIOL, V138, P15; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PAI CH, 1978, INFECT IMMUN, V19, P908, DOI 10.1128/IAI.19.3.908-911.1978; PEPE JC, 1990, J BACTERIOL, V172, P3780, DOI 10.1128/jb.172.7.3780-3789.1990; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schulte R, 1998, MED MICROBIOL IMMUN, V187, P53, DOI 10.1007/s004300050074; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; Schulte R, 1998, INFECT IMMUN, V66, P1216, DOI 10.1128/IAI.66.3.1216-1224.1998; SCHULZ L, 1993, PAPIER, V47, P1; Sharma SA, 1998, J IMMUNOL, V160, P2401; SKURNIK M, 1989, MOL MICROBIOL, V3, P517, DOI 10.1111/j.1365-2958.1989.tb00198.x; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YOUNG VB, 1990, MOL MICROBIOL, V4, P1119, DOI 10.1111/j.1365-2958.1990.tb00686.x; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	70	55	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1471	1484		10.1096/fj.14.11.1471	http://dx.doi.org/10.1096/fj.14.11.1471			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928981				2022-12-25	WOS:000088627800001
J	Shakur, Y; Takeda, K; Kenan, Y; Yu, ZX; Rena, G; Brandt, D; Houslay, MD; Degerman, E; Ferrans, VJ; Manganiello, VC				Shakur, Y; Takeda, K; Kenan, Y; Yu, ZX; Rena, G; Brandt, D; Houslay, MD; Degerman, E; Ferrans, VJ; Manganiello, VC			Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDES) - Two N-terminal, domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; INHIBITED CAMP-PHOSPHODIESTERASE; PROTEIN-KINASE B; MICROSOMAL ALDEHYDE DEHYDROGENASE; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; SELECTIVE INHIBITOR; MOLECULAR-CLONING; RAT ADIPOCYTES	Subcellular localization of cyclic nucleotide phosphodiesterases (PDEs) may be important in compartmentalization of cAMP/cGMP signaling responses. In 3T3-L1 adipocytes, mouse (M) PDE3B was associated with the endoplasmic reticulum (ER) as indicated by its immunofluorescent colocalization with the ER protein BiP and subcellular fractionation studies. In transfected NIH 3006 or COS-7 cells, recombinant wild-type PDE3A and PDE3B isoforms were both found almost exclusively in the ER. The N-terminal portion of PDE3 can be arbitrarily divided into region 1 (aa 1-300), which contains a large hydrophobic domain with six predicted transmembrane helices, followed by region 2 (aa 301-500) containing a smaller hydrophobic domain (of similar to 50 aa). To investigate the role of regions 1 and 2 in membrane association, we examined the subcellular localization of a series of catalytically active, Flag-tagged N-terminal-truncated human (H) PDE3A and MPDE3B recombinants, as well as a series of fragments from regions 1 and 2 of MPDESB synthesized as enhanced green fluorescent (EGFP) fusion proteins in COS-7 cells. In COS-7 cells, the localization of a mutant HPDE3A, lacking the first 189 amino acids (aa) and therefore four of the six predicted transmembrane helices (H3A-Delta 189), was virtually identical to that of the wild type. R3B-Delta 302 (lacking region 1) and H3A-Delta 397 (lacking region 1 as well as part of region 2) retained, to different degrees, the ability to associate with membranes, albeit less efficiently than H3A-Delta 189. Proteins that lacked both regions I and 2, H3A-Delta 510 and M3B-Delta 604, did not associate with membranes. Consistent with these findings, region I EGFP-MPDE3B fusion proteins colocalized with the ER, whereas region 2 EGFP fusion proteins were diffusely distributed. Thus, some portion of the N-terminal hydrophobic domain in region 1 plus a second domain in region 2 are important for efficient membrane association/targeting of PDES.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; Otsuka Amer Pharmaceut Inc, Rockville, MD 20850 USA; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Glasgow G12 8Q0, Lanark, Scotland; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, S-22100 Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Glasgow; Lund University	Manganiello, VC (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N307,9000 Rockville Pike, Bethesda, MD 20892 USA.	manganiv@nhlbi.nih.gov	Rena, Graham/AAV-7985-2021; Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091; Rena, Graham/0000-0002-9121-1350	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000654, Z01HL002540, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Chini CCS, 1997, J BIOL CHEM, V272, P9854; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DEGERMAN E, 1994, BBA-PROTEIN STRUCT M, V1205, P189, DOI 10.1016/0167-4838(94)90233-X; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; DOENST T, 1998, ENDOCRINOL METAB, V275, pE558; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; FLEISCHER B, 1969, J CELL BIOL, V43, P59, DOI 10.1083/jcb.43.1.59; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Goransson O, 1998, BIOCHEM BIOPH RES CO, V246, P249, DOI 10.1006/bbrc.1998.8602; HEYWORTH CM, 1983, BIOCHEM J, V214, P99, DOI 10.1042/bj2140099; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KASUYA J, 1995, J BIOL CHEM, V270, P14305, DOI 10.1074/jbc.270.24.14305; KAUFFMAN RF, 1986, MOL PHARMACOL, V30, P609; KAWANO S, 1992, CIRC RES, V71, P585, DOI 10.1161/01.RES.71.3.585; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Komas N., 1996, PHOSPHODIESTERASE IN, P89, DOI [10.1016/b978-012210720-7/50008-3, DOI 10.1016/B978-012210720-7/50008-3]; KONO T, 1975, J BIOL CHEM, V250, P7826; Kurtz A, 1998, P NATL ACAD SCI USA, V95, P4743, DOI 10.1073/pnas.95.8.4743; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landstrom TR, 2000, BIOCHEM J, V346, P337, DOI 10.1042/bj3460337; Leroy MJ, 1996, BIOCHEMISTRY-US, V35, P10194, DOI 10.1021/bi952711t; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; Masaki R, 1996, J BIOL CHEM, V271, P16939, DOI 10.1074/jbc.271.28.16939; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Obeyesekere VR, 1997, MOL CELL ENDOCRINOL, V131, P173, DOI 10.1016/S0303-7207(97)00106-8; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SICHEL F, 1990, CLIN CHIM ACTA, V188, P49, DOI 10.1016/0009-8981(90)90145-I; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; TANAKA T, 1991, SEC MESS PHOSPHOPROT, V13, P87; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VOLPE P, 1994, BIOCHEM J, V301, P465, DOI 10.1042/bj3010465; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WEISHAAR RE, 1987, CIRC RES, V61, P539, DOI 10.1161/01.RES.61.4.539; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YANG Q, 1994, BIOCHEM BIOPH RES CO, V205, P1850, DOI 10.1006/bbrc.1994.2886; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	70	90	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38749	38761		10.1074/jbc.M001734200	http://dx.doi.org/10.1074/jbc.M001734200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952971	hybrid			2022-12-25	WOS:000165739800084
J	Zhou, B; Weigel, JA; Fauss, LA; Weigel, PH				Zhou, B; Weigel, JA; Fauss, LA; Weigel, PH			Identification of the hyaluronan receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; ISOLATED RAT HEPATOCYTES; BINDING PROTEINS; ACID; DISEASE; CD44; METABOLISM; OLIGOSACCHARIDES; INTERNALIZATION; MORPHOGENESIS	Rat liver sinusoidal endothelial cells (LECs) express two hyaluronan (HA) receptors, of 175 and 300 kDa, responsible for the endocytic clearance of HA. We have characterized eight monoclonal antibodies (mAbs) raised against the 175-kDa HA receptor partially purified from rat LECs. These mAbs also cross-react with the 300-kDa HA receptor. The 175-kDa HA receptor is a single protein, whereas the 300-kDa species contains three subunits, alpha, beta, and gamma at 260, 230, and 97 kDa, respectively (Zhou, B., Oka, J. A., and Weigel, P. H. (1999) J. Biol. Chem. 274, 35831-53834). The 97-kDa subunit was not recognized by any of the mAbs in Western blots. Based on their cross-reactivity with these mAbs, the 175-, 230-, and 260-kDa proteins appear to be related. Two of the mAbs inhibit I-125-HA binding and endocytosis by LECs at 37 degreesC. All of these results confirm that the mAbs recognize the bone fide LEC HA receptor. Indirect immunofluoresence shows high protein expression in liver sinusoids, the venous sinuses of the red pulp in spleen, and the medullary sinuses of lymph nodes. Because the tissue distribution for this endocytic HA receptor is not unique to liver, we propose the name HARE (HA receptor for endocytosis).	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar DJ, 1999, EXP CELL RES, V252, P292, DOI 10.1006/excr.1999.4641; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUMETTE WN, 1981, ANAL BIOCHEM, V112, P195; BURD DAR, 1991, BRIT J PLAST SURG, V44, P579, DOI 10.1016/0007-1226(91)90093-Y; Cantor JO, 1998, P SOC EXP BIOL MED, V217, P471; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; EVERED D, 1989, CIBA F SYMP, V143, P1; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; FROST SJ, 1990, BIOCHEMISTRY-US, V29, P10425, DOI 10.1021/bi00497a019; Fuxe K, 1996, BRAIN RES, V736, P329, DOI 10.1016/S0006-8993(96)00720-2; Gakunga P, 1997, DEVELOPMENT, V124, P3987; GHOSH P, 1994, CLIN EXP RHEUMATOL, V12, P75; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GUSTAFSON S, 1995, GLYCOCONJUGATE J, V12, P350, DOI 10.1007/BF00731337; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Hofmann M, 1998, J CELL SCI, V111, P1673; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; HUA Q, 1993, J CELL SCI, V106, P365; ILLUM L, 1994, J CONTROL RELEASE, V29, P133, DOI 10.1016/0168-3659(94)90129-5; Iocono JA, 1998, J SURG RES, V76, P111, DOI 10.1006/jsre.1998.5305; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; LAURENT C, 1988, ARCH OTOLARYNGOL, V114, P1435; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; McCourt PAG, 1997, INT J BIOCHEM CELL B, V29, P1179, DOI 10.1016/S1357-2725(97)00058-7; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; McCourt PAG, 1999, HEPATOLOGY, V30, P1276, DOI 10.1002/hep.510300521; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meyer K, 1934, J BIOL CHEM, V107, P629; MORALES TI, 1989, ARTHRITIS RHEUM-US, V32, P1197, DOI 10.1002/anr.1780321003; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; PELLETIER JP, 1993, J RHEUMATOL, V20, P19; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; SMEDSROD B, 1994, GUT, V35, P1509, DOI 10.1136/gut.35.11.1509; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1993, BLOOD, V81, P446; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; VERTEL BM, 1994, BIOCHEM J, V301, P211, DOI 10.1042/bj3010211; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451; Yaron I, 1997, J RHEUMATOL, V24, P2221; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831	62	213	218	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37733	37741		10.1074/jbc.M003030200	http://dx.doi.org/10.1074/jbc.M003030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10952975	hybrid			2022-12-25	WOS:000165618700059
J	Segerman, B; Larsson, N; Holmfeldt, P; Gullberg, M				Segerman, B; Larsson, N; Holmfeldt, P; Gullberg, M			Mutational analysis of Op18/stathmin-tubulin-interacting surfaces - Binding cooperativity controls tubulin GTP hydrolysis in the ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE DYNAMICS; PROTEIN-KINASE; ONCOPROTEIN-18; PHOSPHORYLATION; STATHMIN; TARGET	Oncoprotein 18 (Op18) is a microtubule regulator that forms a ternary complex with two tubulin heterodimers. Dispersed regions of Op18 are involved in two-site cooperative binding and subsequent modulation of tubulin GTPase activity. Here we have analyzed specific determinants of Op18 that govern both stoichiometry and positive cooperativity in tubulin binding and consequent stimulatory and inhibitory effects on tubulin GTPase activity. The data revealed that the central and C-terminal regions of Op18 contain overlapping binding-motifs contacting both tubulin heterodimers, suggesting that these regions of Op18 are wedged into the previously noted l-nm gap between the two longitudinally arranged tubulin heterodimers. Both the N- and C-terminal flanks adjacent to the central region are involved in stabilizing the ternary complex, but only the C-terminal flank does so by imposing positive binding cooperativity, Within the C-terminal flank, deletion of a 7-amino acid region attenuated positive binding cooperativity and resulted in a switch from stimulation to inhibition of tubulin GTP hydrolysis, This switch can be explained by attenuated binding cooperativity, because Op18 under these conditions may block longitudinal contact surfaces of single tubulins with consequent interference of tubulin-tubulin interaction-dependent GTP hydrolysis. Together, our results suggest that Op18 links two tubulin heterodimers via longitudinal contact surfaces to form a ternary GTPase productive complex.	Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden	Umea University	Gullberg, M (corresponding author), Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden.		Holmfeldt, Per/AAF-7940-2021	Gullberg, Martin/0000-0002-3984-4572				Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Carlier MF, 1997, BIOPHYS J, V73, P418, DOI 10.1016/S0006-3495(97)78081-0; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; McNally FJ, 1999, CURR BIOL, V9, pR274, DOI 10.1016/S0960-9822(99)80177-8; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Redeker V, 2000, J BIOL CHEM, V275, P6841, DOI 10.1074/jbc.275.10.6841; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	27	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35759	35766		10.1074/jbc.M005875200	http://dx.doi.org/10.1074/jbc.M005875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954719	hybrid			2022-12-25	WOS:000165382000019
J	Barbeyron, T; Michel, G; Potin, P; Henrissat, B; Kloareg, B				Barbeyron, T; Michel, G; Potin, P; Henrissat, B; Kloareg, B			iota-Carrageenases constitute a novel family of glycoside hydrolases, unrelated to that of kappa-carrageenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HYDROPHOBIC CLUSTER-ANALYSIS; ACID-SEQUENCE SIMILARITIES; BACILLUS-LICHENIFORMIS; CRYSTAL-STRUCTURE; ALTEROMONAS-CARRAGEENOVORA; CARBOXYLIC RESIDUES; MARINE BACTERIUM; CLEAVAGE SITES; ALPHA-AGARASE	i-Carrageenases are polysaccharide hydrolases that cleave the beta -1,4 linkages between the D-galactose-4-sulfate and 3,6-anhydro-D-galactose-2-sulfate residues in the red algal galactans known as i-carrageenans. We report here on the purification of i-carrageenase activity from the marine bacterium Zobeellia galactanovorans and on the characterization of L-carrageenase structural. genes. Genomic libraries from this latter bacterium as well as from Alteromonas fortis were functionally screened for the presence of i-carrageenase(+) clones. The Z. galactanovorans and a fortis L-carrageenase genes encode homologous proteins of 53.4 and 54.8 kDa, respectively. Based on hydrophobic cluster analysis and on the H-1 NMR monitoring of the products of the overexpressed A. fortis L-carrageenase, these enzymes appear to form a new family of glycoside hydrolases, unrelated to that of kappa -carrageenases and with an inverting mechanism of hydrolysis. They both feature a 45-amino acid-long N-terminal segment with sequence similarity to the N-terminal region of several other polysaccharidases, In those for which a three-dimensional structure is available, this conspicuous segment, also deemed "glycanase motif" (Chua, J, E, H,, Manning, P, A., and Morons, R, (1999) Microbiology (Reading) 145, 1649-1659), corresponds to a strand-helix-strand "cap" that covers the N-terminal end of a common, right-handed beta -helical fold.	CNRS, UMR 1931, Stn Biol Roscoff, F-29680 Roscoff, France; CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble 1, France; CNRS, IFR 1, F-13402 Marseille 20, Provence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Kloareg, B (corresponding author), CNRS, UMR 1931, Stn Biol Roscoff, Pl Georges Teissier, F-29680 Roscoff, France.	kloareg@sb-roscoff.fr	MICHEL, Gurvan/B-3490-2008; Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; MICHEL, Gurvan/0000-0002-3009-6205				Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARBEYRON T, 1994, GENE, V139, P105, DOI 10.1016/0378-1119(94)90531-2; Barbeyron T, 1998, MOL BIOL EVOL, V15, P528, DOI 10.1093/oxfordjournals.molbev.a025952; BUTTNER MJ, 1987, MOL GEN GENET, V209, P101, DOI 10.1007/BF00329843; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chua JEH, 1999, MICROBIOL-UK, V145, P1649, DOI 10.1099/13500872-145-7-1649; Craigie JS., 1990, BIOL RED ALGAE, P221; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; De Ruiter GA, 1997, TRENDS FOOD SCI TECH, V8, P389, DOI 10.1016/S0924-2244(97)01091-1; FIRPO MA, 1990, POSTTRANSCRIPTIONAL, P185; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GREER CW, 1984, CAN J MICROBIOL, V30, P1500, DOI 10.1139/m84-239; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KIDBY DK, 1973, ANAL BIOCHEM, V55, P321, DOI 10.1016/0003-2697(73)90323-0; KNUTSEN SH, 1992, CARBOHYD RES, V229, P233, DOI 10.1016/S0008-6215(00)90573-1; KNUTSEN SH, 1994, CARBOHYD POLYM, V19, P199; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; Krah M, 1998, EUR J BIOCHEM, V257, P101, DOI 10.1046/j.1432-1327.1998.2570101.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; Maniatis T, 1982, MOL CLONING LABORATO, P68; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Michel G, 1999, ACTA CRYSTALLOGR D, V55, P918, DOI 10.1107/S0907444998018526; Michel G, 2000, ACTA CRYSTALLOGR D, V56, P766, DOI 10.1107/S0907444900004844; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NISHITANI K, 1992, J BIOL CHEM, V267, P21058; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; POTIN P, 1995, EUR J BIOCHEM, V228, P971, DOI 10.1111/j.1432-1033.1995.0971m.x; POTIN P, 1991, EUR J BIOCHEM, V201, P241, DOI 10.1111/j.1432-1033.1991.tb16280.x; POTIN P, 1993, EUR J BIOCHEM, V214, P599, DOI 10.1111/j.1432-1033.1993.tb17959.x; Rees D A, 1969, Adv Carbohydr Chem Biochem, V24, P267; ROCHAS C, 1994, CARBOHYD RES, V253, P69, DOI 10.1016/0008-6215(94)80056-1; ROCHAS C, 1981, POLYM BULL, V5, P81; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; ZABLACKIS E, 1990, BOT MAR, V33, P273, DOI 10.1515/botm.1990.33.3.273; Zobell CE, 1941, J MAR RES, V4, P42	54	93	98	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35499	35505		10.1074/jbc.M003404200	http://dx.doi.org/10.1074/jbc.M003404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10934194	hybrid			2022-12-25	WOS:000165422800088
J	Dhar, SK; Dutta, A				Dhar, SK; Dutta, A			Identification and characterization of the human ORC6 homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA HOMOLOG; S-PHASE; XENOPUS; PROTEINS; CDC6P; PROLIFERATION; INITIATION	A new protein was cloned and identified as the sixth member of the human origin recognition complex (ORC). The newly identified 30-kDa protein hsORC6 is 28% identical and 49% similar to ORC6p from Drosophila melanogaster, which is consistent with the identities and similarities found among the other ORC members reported in the two species. The human ORC6 gene is located on chromosome 16q12. ORC6 protein level did not change through the cell cycle. Like ORC1, ORC6 did not co-immunoprecipitate with other ORC subunits but was localized in the nucleus along with the other ORC subunits. Several cellular proteins co-immunoprecipitated with ORC6, including a 65-kDa protein that was hyperphosphorylated in G(1) and dephosphorylated in mitosis, Therefore, unlike the tight stoichiometric association of six yeast ORC subunits in one hole-complex, only a small fraction of human ORC1 and ORC6 is likely to be associated with a subcomplex of ORC2, 3, 4, and 5, suggesting differences in the architecture and regulation of human ORC.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL CELL BIOL, V16, P741; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421	28	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34983	34988		10.1074/jbc.M006069200	http://dx.doi.org/10.1074/jbc.M006069200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945994	hybrid			2022-12-25	WOS:000165422800023
J	Kirsch, T; Harrison, G; Golub, EE; Nah, HD				Kirsch, T; Harrison, G; Golub, EE; Nah, HD			The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; CALCIUM-CHANNEL ACTIVITY; ANCHORIN-CII; CRYSTAL-STRUCTURE; BINDING-PROTEINS; MEMBRANE-PROTEIN; CALCIFICATION; CHONDROCYTES; RECOMBINANT; FAMILY	Annexins II, V, and VI are major components of matrix vesicles (MV), i.e. particles that have the critical role of initiating the mineralization process in skeletal tissues. Furthermore, types II and X collagen are associated with MV, and these interactions mediated by annexin V stimulate Ca2+ uptake and mineralization of MV. However, the exact roles of annexin II, V, and VI and the interaction between annexin V and types II and X collagen in MV function and initiation of mineralization are not well understood. In this study, we demonstrate that annexin II, V, or VI mediate Ca2+ influx into phosphatidylserine (PS)-enriched liposomes, liposomes containing lipids extracted from authentic MV, and intact authentic MV. The annexin Ca2+ channel blocker, K-201, not only inhibited Ca2+ influx into fura-2-loaded PS-enriched liposomes mediated by annexin II, V, or VI, but also inhibited Ca2+ uptake by authentic MV. Types II and X collagen only bound to liposomes in the presence of annexin V but not in the presence of annexin II or VI. Binding of these collagens to annexin V stimulated its Ca2+ channel activities, leading to an increased Ca2+ influx into the liposomes. These findings indicate that the formation of annexin II, V, and VI Ca2+ channels in MV together with stimulation of annexin V channel activity by collagen (types II and X) binding can explain how MV are able to rapidly take up Ca2+ and initiate the formation of the first crystal phase.	Univ Penn, Sch Dent Med, Dept Anat, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Histol, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Kirsch, T (corresponding author), Penn State Coll Med, Hershey Med Ctr, Dept Orthopaed Rehabil, H089,500 Univ Dr, Hershey, PA 17033 USA.				NIAMS NIH HHS [AR-43732, AR-46245] Funding Source: Medline; NIDCR NIH HHS [DE-06533] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043732, R01AR046245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006533] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI S Y, 1985, Scanning Electron Microscopy, P1555; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; Arias JL, 1997, CONNECT TISSUE RES, V36, P21, DOI 10.3109/03008209709160211; Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BERENDES R, 1993, FEBS LETT, V317, P131, DOI 10.1016/0014-5793(93)81507-V; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; Derfus B, 1998, CALCIFIED TISSUE INT, V63, P258, DOI 10.1007/s002239900523; DOYLE DV, 1982, J PATHOL, V136, P199, DOI 10.1002/path.1711360304; Geisow MJ, 1988, MOL MECH SECRETION, P598; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GERKE V, 1990, NUCLEIC ACIDS RES, V18, P4246, DOI 10.1093/nar/18.14.4246; HOHIMADAHL R, 1986, ARTHRITIS RHEUM, V29, P400; Hsu HHT, 1999, ATHEROSCLEROSIS, V143, P353, DOI 10.1016/S0021-9150(98)00322-0; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; Kaneko N, 1997, BBA-BIOMEMBRANES, V1330, P1, DOI 10.1016/S0005-2736(97)00132-6; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KANEKO N, 1994, DRUG DEVELOP RES, V33, P429, DOI 10.1002/ddr.430330406; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; Kirsch T, 2000, OSTEOARTHR CARTILAGE, V8, P294, DOI 10.1053/joca.1999.0304; Kirsch T, 2000, J BONE MINER RES, V15, P261, DOI 10.1359/jbmr.2000.15.2.261; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Matsuda R, 1997, BIOCHEM BIOPH RES CO, V237, P499, DOI 10.1006/bbrc.1997.7177; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; Nah HD, 2000, J BONE MINER RES, V15, P522, DOI 10.1359/jbmr.2000.15.3.522; PACIFICI M, 1991, EXP CELL RES, V192, P266, DOI 10.1016/0014-4827(91)90185-W; Paschalis EP, 1996, BONE, V19, P151, DOI 10.1016/8756-3282(96)00164-0; POOLE AR, 1989, J CELL BIOL, V109, P2547, DOI 10.1083/jcb.109.5.2547; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; Stehbens WE, 2000, CELL MOL BIOL, V46, P99; TURNAY J, 1995, J CELL BIOCHEM, V58, P208, DOI 10.1002/jcb.240580210; Worch KP, 1998, J DENT RES, V77, P927; WU LNY, 1991, J BIOL CHEM, V266, P1195; WUTHIER RE, 1982, CLIN ORTHOP RELAT R, P219	49	155	166	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35577	35583		10.1074/jbc.M005648200	http://dx.doi.org/10.1074/jbc.M005648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956650	hybrid			2022-12-25	WOS:000165422800098
J	Leonard, BJN; Clarke, BJ; Sridhara, S; Kelley, R; Ofosu, FA; Blajchman, MA				Leonard, BJN; Clarke, BJ; Sridhara, S; Kelley, R; Ofosu, FA; Blajchman, MA			Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human factor VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIIA; TISSUE FACTOR-BINDING; BLOOD-COAGULATION; PROTEASE DOMAIN; CA2+ BINDING; MONOCLONAL-ANTIBODY; CATALYTIC FUNCTION; CRYSTAL-STRUCTURE; FACTOR-XA; AFFINITY	The first epidermal growth factor-like domain (EGF-1) of factor VII (FVII) provides the region of greatest contact during the interaction of FVIIa with tissue factor. To understand this interaction better, the conformation-sensitive FVII EGF-l-specific monoclonal antibody (mAb) 231-7 was used to investigate the conformational effects occurring in this region upon both FVII activation and active site occupation. The binding affinity of mAb 231-7 was approximately 3-fold greater for the zymogen state than for the active state; a result affected by the presence of both calcium and the adjacent Gla domain. Once activated, active site inhibition of FVIIa with:a variety of chloromethyl ketone inhibitors resulted in a 10-fold range of affinities of FVIIai molecules to mAb 231-7. Gla domain removal eliminated this variation in affinity, suggesting the involvement of a Gla/EGF-I interaction in this conformational effect. In addition, the binding of mAb 231-7 to FVIIa EGF-1 stimulated the amidolytic activity of free FVIIa. Taken together, these results imply an allosteric interaction between the FVIIa active site and the EGF-1 domain that is sensitive to variation in active site occupant structure. Thus, these present studies indicate that the conformational change associated with FVII activation and active site occupation involves the EGF-1 domain and suggest potential functional consequences of these changes.	McMaster Univ, Med Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; Genentech Inc, San Francisco, CA 94080 USA	McMaster University; Roche Holding; Genentech	Blajchman, MA (corresponding author), McMaster Univ, Med Ctr, Dept Pathol & Mol Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ambrosini G, 1997, J BIOL CHEM, V272, P8340, DOI 10.1074/jbc.272.13.8340; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CERSKUS AL, 1985, BRIT J HAEMATOL, V61, P467, DOI 10.1111/j.1365-2141.1985.tb02850.x; CHANG JY, 1995, BIOCHEMISTRY-US, V34, P12227, DOI 10.1021/bi00038a017; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; Freskgard PO, 1998, BIOCHEMISTRY-US, V37, P7203, DOI 10.1021/bi972847m; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Leonard BJN, 1998, BLOOD, V91, P142, DOI 10.1182/blood.V91.1.142.142_142_148; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NICHOLAISEN EM, 1992, FEBS LETT, V306, P157; Persson E, 1997, J BIOL CHEM, V272, P19919, DOI 10.1074/jbc.272.32.19919; PERSSON E, 1995, EUR J BIOCHEM, V234, P293, DOI 10.1111/j.1432-1033.1995.293_c.x; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1986, BLOOD, V68, P685; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P7437, DOI 10.1021/bi962965u; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Ruiz SM, 2000, THROMB RES, V98, P203, DOI 10.1016/S0049-3848(99)00227-3; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Sridhara S, 1996, AM J HEMATOL, V53, P66; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	44	21	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34894	34900		10.1074/jbc.M001166200	http://dx.doi.org/10.1074/jbc.M001166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952970	hybrid			2022-12-25	WOS:000165422800012
J	Okado-Matsumoto, A; Fridovich, I				Okado-Matsumoto, A; Fridovich, I			The role of alpha,beta-dicarbonyl compounds in the toxicity of short chain sugars	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHYSIOLOGICAL CONDITIONS; GLYOXALASE-I; DNA-DAMAGE; METHYLGLYOXAL; SUPEROXIDE; IDENTIFICATION; AUTOXIDATION; PROTEINS; OXIDASE	The extent to which sugars serve as targets for superoxide was examined using glycolaldehyde as the simplest sugar and using superoxide dismutase (SOD)-replete and SOD-null strains growing under aerobic and anaerobic conditions. Glycolaldehyde was more toxic to the SOD-null strain than to its SOD replete parent, and this differential effect was oxygen-dependent. The product, glyoxal, could be trapped in the medium by 1,2-diaminobenzene and assayed as quinoxaline. The SOD-null strain produced more glyoxal and eliminated it more slowly than the SOD-replete parent strain. Glyoxal was similar to 10 times more toxic than glycolaldehyde and was more toxic to the SOD-null strain than to the parental strain. 1,2-Diaminobenzene protected against the toxicity of glycolaldehyde, These Escherichia coli strains contained the glutathione-dependent glyoxalases I and II, as well as the glutathione-independent glyoxalase III. Of these enzymes, glyoxalase III was most abundant, and it was inactivated within the aerobic SOD-null strain and also in extracts when exposed to the flux of superoxide and hydrogen peroxide imposed by the xanthine oxidase reaction. Thus, it appears that short chain sugars are oxidized by superoxide yielding toxic dicarbonyls, Moreover, the defensive glyoxalase III is also inactivated by the oxidative stress imposed by the lack of SOD, thereby exacerbating the deleterious effect of sugar oxidation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							Benov L, 1998, J BIOL CHEM, V273, P25741, DOI 10.1074/jbc.273.40.25741; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Cordeiro C, 1996, ANAL BIOCHEM, V234, P221, DOI 10.1006/abio.1996.0076; Deng YL, 1999, ANAL BIOCHEM, V270, P97, DOI 10.1006/abio.1999.4058; Ferguson GP, 1999, TRENDS MICROBIOL, V7, P242, DOI 10.1016/S0966-842X(99)01510-3; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; HIRSCH J, 1995, CARBOHYD RES, V267, P17, DOI 10.1016/0008-6215(94)00285-N; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LO TWC, 1994, J BIOL CHEM, V269, P32299; MacLean MJ, 1998, MOL MICROBIOL, V27, P563, DOI 10.1046/j.1365-2958.1998.00701.x; Maniatis T, 1982, MOL CLONING LABORATO, P68; MANNERVIK B, 1982, METHOD ENZYMOL, V90, P535; MASHINO T, 1987, ARCH BIOCHEM BIOPHYS, V254, P547, DOI 10.1016/0003-9861(87)90136-6; Meyer D, 1997, J BACTERIOL, V179, P1298, DOI 10.1128/jb.179.4.1298-1306.1997; MISRA K, 1995, BIOCHEM J, V305, P999, DOI 10.1042/bj3050999; ORAY B, 1982, METHOD ENZYMOL, V90, P547; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; ROBERTSON P, 1981, ARCH BIOCHEM BIOPHYS, V207, P282, DOI 10.1016/0003-9861(81)90035-7; Saadat D, 1998, BIOCHEMISTRY-US, V37, P10074, DOI 10.1021/bi980409p; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Totemeyer S, 1998, MOL MICROBIOL, V27, P553, DOI 10.1046/j.1365-2958.1998.00700.x	27	51	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34853	34857		10.1074/jbc.M005536200	http://dx.doi.org/10.1074/jbc.M005536200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10931845	hybrid			2022-12-25	WOS:000165422800006
J	Staropoli, I; Chanel, C; Girard, M; Altmeyer, R				Staropoli, I; Chanel, C; Girard, M; Altmeyer, R			Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HAMSTER OVARY CELLS; GP120 GLYCOPROTEIN; TRANSMEMBRANE GLYCOPROTEIN; DISULFIDE BONDS; CD4 RECEPTOR; TYPE-1; GP41; INHIBITION; PROTEIN	The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is thought to exist on the virion surface as a trimer of non-covalently associated gp120/gp41 molecules. We expressed trimeric envelope glycoprotein from three primary, macrophage tropic HIV-1 isolates in baby hamster kidney cells and analyzed the furin-mediated cleavage, stability, and receptor binding properties of the oligomers. The envelope glycoprotein was secreted in a soluble form deleted of its transmembrane anchor and the intracytoplasmic domain (gp140). A mixture of trimers, dimers, and monomers of gp140 as well as monomeric gp120 was detected on polyacrylamide gels. Analysis by sucrose gradient centrifugation revealed that trimers and dimers were essentially composed of uncleaved gp140, whereas most of the gp120 was found in the monomeric fraction. To analyze the effect of the cleavage of gp140 to gp120/Delta 41 on trimerization, we co-expressed the furin protease along with gp140. Surprisingly, furin expression changed the subcellular localization of the envelope glycoprotein, which became in majority sequestered in the major furin compartment, the trans-Golgi network, as judged by confocal laser microscopy. The envelope glycoprotein secreted from furin-co-expressing cells was almost completely cleaved to gp120 and Delta gp41, but gp120 was found exclusively in the monomeric fraction, with a few residual oligomers being composed of uncleaved gp140. Secreted uncleaved gp140 trimers were purified to homogeneity and analyzed for their capacity to interact with cellular receptors CD4 and CC chemokine receptor 5 (CCR5). Receptor binding was analyzed on CD4- and CCR5-expressing cells as well as on peripheral blood mononuclear cells. Trimers showed greatly reduced binding to CD4 as compared with monomers. Neither monomers nor trimers bound directly to CCR5. In conclusion, our results show that the cleaved form of the envelope glycoprotein does not form stable trimers, suggesting that gp120/gp41 oligomers on the virion surface might be stabilized by a yet to be identified mechanism and that the virion might attach to CD4 via a monomeric form of gp120. These results are relevant to the development of an envelope-based vaccine against AIDS.	Inst Pasteur, Unite Virol Mol, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Altmeyer, R (corresponding author), Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France.							Altmeyer R, 1999, VIROLOGY, V259, P314, DOI 10.1006/viro.1999.9780; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; BRITT WJ, 1994, VIROLOGY, V201, P294, DOI 10.1006/viro.1994.1294; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Center RJ, 2000, J VIROL, V74, P4448, DOI 10.1128/JVI.74.10.4448-4455.2000; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fischer PB, 1996, J VIROL, V70, P7153, DOI 10.1128/JVI.70.10.7153-7160.1996; Fouts TR, 1998, AIDS RES HUM RETROV, V14, P591, DOI 10.1089/aid.1998.14.591; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HALLENBERGER S, 1993, VIROLOGY, V193, P510, DOI 10.1006/viro.1993.1156; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Klimstra WB, 1999, J VIROL, V73, P6299, DOI 10.1128/JVI.73.8.6299-6306.1999; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LITTMAN DR, 1988, CELL, V55, P541, DOI 10.1016/0092-8674(88)90211-5; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCGINNES LW, 1994, VIROLOGY, V200, P470, DOI 10.1006/viro.1994.1210; McInerney TL, 1998, J VIROL, V72, P1523, DOI 10.1128/JVI.72.2.1523-1533.1998; Meanger J, 1997, BIOTECHNIQUES, V23, P432, DOI 10.2144/97233bm18; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; Moulard M, 1999, VIRUS RES, V60, P55, DOI 10.1016/S0168-1702(99)00002-7; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; TUCKER SP, 1991, VIROLOGY, V185, P710, DOI 10.1016/0042-6822(91)90542-J; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; VANCOTT TC, 1995, J IMMUNOL METHODS, V183, P103, DOI 10.1016/0022-1759(95)00038-C; Verrier FC, 1997, P NATL ACAD SCI USA, V94, P9326, DOI 10.1073/pnas.94.17.9326; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000; Zhang LQ, 1998, J VIROL, V72, P9307, DOI 10.1128/JVI.72.11.9307-9312.1998; Zhang YJ, 1998, J VIROL, V72, P9337, DOI 10.1128/JVI.72.11.9337-9344.1998; ZOLLAPAZNER S, 1995, J VIROL, V69, P3807, DOI 10.1128/JVI.69.6.3807-3815.1995	69	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35137	35145		10.1074/jbc.M003868200	http://dx.doi.org/10.1074/jbc.M003868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10926931	hybrid			2022-12-25	WOS:000165422800043
J	Polesskaya, A; Duquet, A; Naguibneva, I; Weise, C; Vervisch, A; Bengal, E; Hucho, F; Robin, P; Harel-Bellan, A				Polesskaya, A; Duquet, A; Naguibneva, I; Weise, C; Vervisch, A; Bengal, E; Hucho, F; Robin, P; Harel-Bellan, A			CREB-binding protein/p300 activates MyoD by acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL ACTIVATION; COACTIVATORS P300; DNA-BINDING; ONCOPROTEIN E1A; MUSCLE; CBP; DIFFERENTIATION; DOMAIN	The myogenic protein MyoD requires two nuclear histone acetyltransferases, CREB-binding protein (CBP)/p300 and PCAF, to transactivate muscle promoters. MyoD is acetylated by PCAF in vitro, which seems to increase its affinity for DNA We here show that MyoD is constitutively acetylated in muscle cells. In vitro, MyoD is acetylated both by CBP/p300 and by PCAF on two lysines located at the boundary of the DNA binding domain. MyoD acetylation by CBP/p300 (as well as by PCAF) increases its activity on a muscle-specific promoter, as assessed by microinjection experiments. MyoD mutants that cannot be acetylated in vitro are not activated in the functional assay, Our results provide direct evidence that MyoD acetylation functionally activates the protein and show that both PCAF and CBP/p300 are candidate enzymes for MyoD acetylation in vivo.	Inst Federat Andre Lwoff, CNRS UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, Villejuif, France; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; Inst Federat Andre Lwoff, Serv Commun Cytofluorometrie, Villejuif, France; Technion Israel Inst Technol, Dept Biochem, IL-31096 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); Free University of Berlin; Technion Israel Institute of Technology	Harel-Bellan, A (corresponding author), Inst Federat Andre Lwoff, CNRS UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, 7 Rue Guy Moquet, Villejuif, France.		Harel-Bellan, Annick/M-9795-2015	Harel-Bellan, Annick/0000-0002-2339-153X; Naguibneva, Irina/0000-0001-9566-6152				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WOLFFE AP, 1994, CURR BIOL, V4, P525, DOI 10.1016/S0960-9822(00)00114-7; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	38	105	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34359	34364		10.1074/jbc.M003815200	http://dx.doi.org/10.1074/jbc.M003815200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944526	hybrid			2022-12-25	WOS:000165095300050
J	Ray, K; Hauschild, BC				Ray, K; Hauschild, BC			Cys-140 is critical for metabotropic glutamate receptor-1 dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; HUMAN CALCIUM RECEPTOR; TERMINAL EXTRACELLULAR DOMAIN; CELL-SURFACE EXPRESSION; LIGAND-BINDING; SIGNAL-TRANSDUCTION; MULTIGENE FAMILY; CLONING; IDENTIFICATION; PURIFICATION	Metabotropic glutamate receptor 1 (mGluR1) expresses at the cell surface as disulfide-linked dimers and can be reduced to monomers with sulfhydryl reagents. To identify the dimerization domain, we transiently expressed in HEK-293 cells a truncated version of mGluR1 (RhodC-R1) devoid of the extracellular domain (ECD), RhodC-R1 was a monomer in the absence or presence of the reducing agents, suggesting that dimerization occurs via the ECD, To identify cysteine residues involved in dimerization within the ECD, cysteine to serine point mutations were made at three cysteines within the amino-terminal half of the ECD, A mutation at positions Cys-67, Cys-109, and Cys-140 all resulted in significant amounts of monomers in the absence of reducing agents. The monomeric C67S and C109S mutants were not properly glycosylated, failed to reach the cell surface, and showed no glutamate response, indicating that these mutant receptors were improperly folded and/or processed and thus retained intracellularly, In contrast, the monomeric C140S mutant was properly glycosylated, processed, and expressed at the cell surface. Phosphoinositide hydrolysis assay showed that the glutamate response of the C140S mutant receptor was similar to the wild type receptor. Substitution of a cysteine for Ser-129, Lys-134, Asp-143, and Thr-146 on the C140S mutant background restored receptor dimerization. Taken together, the results suggest that Cys-140 contributes to intermolecular disulfide linked dimerization of mGluR1.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ray, K (corresponding author), Natl Inst Deafness & Other Commun Disorders, Lab Signal Transduct, 5 Res Ct, Rockville, MD 20850 USA.							Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Copani A, 2000, BRAIN RES, V867, P165, DOI 10.1016/S0006-8993(00)02293-9; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Mary S, 1997, EUR J PHARMACOL, V335, P65, DOI 10.1016/S0014-2999(97)01155-2; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535	31	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34245	34251		10.1074/jbc.M005581200	http://dx.doi.org/10.1074/jbc.M005581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945991	hybrid			2022-12-25	WOS:000165095300035
J	Lefai, E; Fernandez-Moreno, MA; Alahari, A; Kaguni, LS; Garesse, R				Lefai, E; Fernandez-Moreno, MA; Alahari, A; Kaguni, LS; Garesse, R			Differential regulation of the catalytic and accessory subunit genes of Drosophila mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-RELATED ELEMENT; SYNTHASE BETA-SUBUNIT; SEA-URCHIN; TRANSCRIPTIONAL REGULATION; BINDING PROTEIN; MAMMALIAN-CELLS; NUCLEAR GENES; FACTOR DREF; EXPRESSION; CLONING	The developmental pattern of expression of the genes encoding the catalytic (alphay) and accessory (beta) subunits of mitochondrial DNA polymerase (pol gamma) has been examined in Drosophila melanogaster. The steady-state level of pol gamma-beta mRNA increases during the first hours of development, reaching its maximum value at the start of mtDNA replication in Drosophila embryos. In contrast, the steady-state level of pol gamma-alpha mRNA decreases as development proceeds and is low in stages of active mtDNA replication. This difference in mRNA abundance results at least in part from differences in the rates of mRNA synthesis. The pol gamma genes are located in a compact cluster of five genes that contains three promoter regions (P1-P3), The P1 region directs divergent transcription of the pol gamma-beta gene and the adjacent rpII33 gene. P1 contains a DNA replication-related element (DRE) that is essential for pol gamma-beta promoter activity, but not for rpII33 promoter activity in Schneider's cells. A second divergent promoter region (P2) controls the expression of the orc5 and sop2 genes. The P2 region contains two DREs that are essential for orc5 promoter activity, but not for sop2 promoter activity. The expression of the pol gamma-alpha gene is directed by P3, a weak promoter that does not contain DREs, Electrophoretic mobility shift experiments demonstrate that the DRE-binding factor (DREF) regulatory protein binds to the DREs in P1 and P2, DREF regulates the expression of several genes encoding key factors involved in nuclear DNA replication. Its role in controlling the expression of the pol gamma-beta and orc5 genes establishes a common regulatory mechanism linking nuclear and mitochondrial DNA replication. Overall, our results suggest that the accessory subunit of mtDNA polymerase plays an important role in the control of mtDNA replication in Drosophila.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, E-28029 Madrid, Spain; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Michigan State University	Garesse, R (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.	rafael.garesse@uam.es	Fernandez-Moreno, Miguel Angel/K-4425-2017; Garesse, Rafael/F-3836-2012; Lefai, Etienne/E-9615-2019; Lefai, Etienne/L-7961-2019	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726; Lefai, Etienne/0000-0002-3042-7801; Lefai, Etienne/0000-0002-3042-7801	NHLBI NIH HHS [HL59656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashburner M, 1999, GENETICS, V153, P179; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; de Mena IR, 2000, J BIOL CHEM, V275, P13628, DOI 10.1074/jbc.275.18.13628; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; FLEMING RJ, 1989, MOL CELL BIOL, V9, P719, DOI 10.1128/MCB.9.2.719; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lavia P, 1999, BIOESSAYS, V21, P221; Lefai E, 2000, INSECT MOL BIOL, V9, P315, DOI 10.1046/j.1365-2583.2000.00191.x; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; Moyes CD, 1997, AM J PHYSIOL-CELL PH, V272, pC1345, DOI 10.1152/ajpcell.1997.272.4.C1345; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; Pena P, 1995, BIOCHEM J, V312, P887, DOI 10.1042/bj3120887; POLLAK JK, 1980, TRENDS BIOCHEM SCI, V5, P23, DOI 10.1016/S0968-0004(80)80073-9; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; RUBENSTEIN JLR, 1977, CELL, V12, P471, DOI 10.1016/0092-8674(77)90123-4; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Talamillo A, 1998, MOL BIOL REP, V25, P87, DOI 10.1023/A:1006868306735; Vallejo CG, 1996, BIOCHEM J, V314, P505, DOI 10.1042/bj3140505; VEGANUNEZ E, 1995, J CLIN INVEST, V96, P893, DOI 10.1172/JCI118136; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wang YX, 1999, J BIOL CHEM, V274, P28972, DOI 10.1074/jbc.274.41.28972; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	54	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33123	33133		10.1074/jbc.M003024200	http://dx.doi.org/10.1074/jbc.M003024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10930405	hybrid			2022-12-25	WOS:000090003800101
J	Pasco, S; Monboisse, JC; Kieffer, N				Pasco, S; Monboisse, JC; Kieffer, N			The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta(3) subunit of integrin alpha(v)beta(3) and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; MELANOMA CELL-ADHESION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; ALPHA-3 CHAIN; PROTEIN; EXPRESSION; LIGAND; INVASION; ALPHA-V-BETA-3	We have recently identified integrin alpha (v)beta (3), and the associated CD47/integrin-associated protein (IAP) together with three other proteins as the potential tumor cell receptors for the ly, chain of basement membrane type IV collagen (Shahan, T.A., Ziaie, Z., Pasco, S., Fawzi, A., Bellon, G., Monboisse, J. C., and Kefalides, N. A. (1999) Cancer Res. 59, 4584-4590). Using different cell lines expressing alpha (v)beta (3), alpha (IIb)beta (3), and/or CD47 and a liquid phase receptor capture assay, we now provide direct evidence that the synthetic and biologically active alpha3(IV)185-206 peptide, derived from the alpha3(IV) chain, interacts with the beta (3) subunit of integrin alpha (v)beta (3), independently of CD47. Increased alpha3(IV) peptide binding was observed on transforming growth factor-beta (1)-stimulated HT-144 cells shown to up-regulate alpha (v)beta (3) independently of CD47. Also, incubation of HT-144 melanoma cells in suspension induced de novo exposure of ligand-induced binding site epitopes on the beta (3) subunit similar to those observed following Arg-Gly-Asp-Ser (RGDS) stimulation. However, RGDS did not prevent HT-144 cell attachment and spreading on the alpha3(TV) peptide, suggesting that the alpha3(TV) binding domain on the beta (3) subunit is distinct from the RGD recognition site. alpha3(IV) peptide binding to HT-144 cells in suspension stimulated time-dependent tyrosine phosphorylation, while the RGDS peptide did not. Two major phosphotyrosine proteins of 120-130 and 85 kDa were immunologically identified as focal adhesion kinase and phosphatidylinositol 3-kinase (PI3-kinase). A direct involvement of PI3-kinase in alpha3(IV)-dependent beta (3) integrin signaling could be documented, since pretreatment of HT-144 cells with wortmannin, a PI3-kinase inhibitor, reverted the known inhibitory effect of alpha3(IV) on HT-144 cell proliferation as well as membrane type 1-matrix metalloproteinase gene expression. These results provide evidence that the alpha3(TV)185-206 peptide, by directly interacting with the beta (3) subunit of alpha (v)beta (3), activates a signaling cascade involving focal adhesion kinase and PI3-kinase.	Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CNRS, CRP Sante, L-1511 Luxembourg, Luxembourg; Univ Reims Champagne Ardenne, Fac Med, CNRS UPRESA 6021, Lab Biochim Med & Biol Mol, F-51095 Reims, France	Luxembourg Institute of Health; University of Luxembourg; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Kieffer, N (corresponding author), Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CNRS, CRP Sante, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.			Brassart-Pasco, Sylvie/0000-0002-1340-7868				BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Edinger RS, 1999, AM J PHYSIOL-RENAL, V277, pF575, DOI 10.1152/ajprenal.1999.277.4.F575; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Juliano D, 1996, EXP CELL RES, V225, P132, DOI 10.1006/excr.1996.0164; Kieffer N, 1996, CELL ADHES COMMUN, V4, P25, DOI 10.3109/15419069609010761; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Pasco S, 2000, CANCER RES, V60, P467; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Polette M, 1997, J PATHOL, V182, P185, DOI 10.1002/(SICI)1096-9896(199706)182:2<185::AID-PATH828>3.0.CO;2-F; Sado Y, 1998, J BIOCHEM-TOKYO, V123, P767; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Yu M, 1998, CLIN EXP METASTAS, V16, P185; ZHOU J, 1994, J BIOL CHEM, V269, P13193	44	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32999	33007		10.1074/jbc.M005235200	http://dx.doi.org/10.1074/jbc.M005235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934203	hybrid			2022-12-25	WOS:000090003800085
J	Kim, IS; Kim, DH; Han, SM; Chin, MU; Nam, HJ; Cho, HP; Choi, SY; Song, BJ; Kim, ER; Bae, YS; Moon, YH				Kim, IS; Kim, DH; Han, SM; Chin, MU; Nam, HJ; Cho, HP; Choi, SY; Song, BJ; Kim, ER; Bae, YS; Moon, YH			Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; EXPORT SIGNAL; PORE COMPLEX; LOCALIZATION; GENE; MECHANISMS; MUTATIONS; SUBSTRATE; BINDING	Disruption of the function of tumor suppressor proteins occasionally can be dependent on their subcellular localization. In about 40% of the breast cancer tissues, p53 is found in the cytoplasm as opposed to the nucleus, where it resides in normal breast cells. This means that the regulation of subcellular location of p53 is an important mechanism in controlling its function. The transport factors required for the nuclear export of p53 and the mechanisms of their nuclear export have been extensively characterized. However, little is known about the mechanism of nuclear import of p53, p53 contains putative nuclear localization signals (NLSs) which would interact with a nuclear transport factor, importin alpha. In this report we demonstrate that importin a binds to NLSI in p53 and mediates the nuclear import of p53, Reverse transcriptase-polymerase chain reaction and sequencing analyses showed that a truncated importin alpha deleted the region encoding the putative NLS-binding domain of p53, suggesting that it could not bind to NLSs of p53 proteins. Binding of importin alpha to p53 was confirmed by using yeast two-hybrid assay. When expressed in CHO-K1 cells, the truncated importin alpha predominantly localized to the cytoplasm, In truncated importin alpha expressing cells, p53 preferentially localized to cytoplasmic sites as well, A significant increase in the p21(waf1/cip1) mRNA level and induction of apoptosis were also observed in importin alpha overexpressing cells. These results strongly suggest that importin alpha functions as a component of the NLS receptor for p53 and mediates nuclear import of p53.	Sung Ae Life Sci Res Inst, Kyeonggi 423030, South Korea; Hannam Univ, Dept Microbiol, Daeduk Gu, Taejon 306791, South Korea	Hannam University	Moon, YH (corresponding author), 389 Chulsan Kwangmyeong, Kyeonggi 423030, South Korea.	hjyhdjsj@sungae.co.kr						BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Boche I, 1997, J CELL BIOL, V139, P313, DOI 10.1083/jcb.139.2.313; BOSARI S, 1995, AM J PATHOL, V147, P790; DANG CV, 1989, J BIOL CHEM, V264, P18019; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lee MP, 1997, CANCER RES, V57, P3131; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; LIANG XH, 1993, ONCOGENE, V8, P2645; Lu ML, 1996, CANCER RES, V56, P4578; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; SaporitoIrwin SM, 1997, BIOTECHNIQUES, V23, P424, DOI 10.2144/97233bm16; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Smith HMS, 1998, PLANT CELL, V10, P1791, DOI 10.1105/tpc.10.11.1791; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUNDARESAN V, 1998, EMBO J, V17, P4657; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	36	101	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23139	23145		10.1074/jbc.M909256199	http://dx.doi.org/10.1074/jbc.M909256199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930427	hybrid			2022-12-25	WOS:000088419400073
J	Koundrioukoff, S; Jonsson, ZO; Hasan, S; de Jong, RN; van der Vliet, PC; Hottiger, MO; Hubscher, U				Koundrioukoff, S; Jonsson, ZO; Hasan, S; de Jong, RN; van der Vliet, PC; Hottiger, MO; Hubscher, U			A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; DNA-REPLICATION; BINDING-PROTEIN; REPAIR; SUBUNIT; CYCLINS; FEN-1; ALPHA; P21	Proliferating cell nuclear antigen is best known as a DNA polymerase accessory protein but has more recently also been shown to have different functions in important cellular processes such as DNA replication, DNA repair, and cell cycle control. PCNA has been found in quaternary complexes with the cyclin kinase inhibitor p21 and several pairs of cyclin-dependent protein kinases and their regulatory partner, the cyclins. Here we show a direct interaction between PCNA and Cdk2. This interaction involves the regions of the PCNA trimer close to the C termini. We found that PCNA and Cdk2 form a complex together with cyclin A. This ternary PCNA-Cdk2-cyclin A complex was able to phosphorylate the PCNA binding region of the large subunit of replication factor C as well as DNA ligase I. Furthermore, PCNA appears to be a connector between Cdk2 and DNA ligase I and to stimulate phosphorylation of DNA ligase I. Based on our results, we propose the model that PCNA brings Cdk2 to proteins involved in DNA replication and possibly might act as an "adaptor" for Cdk2-cyclin A to PCNA-binding DNA replication proteins.	Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	University of Zurich; Utrecht University	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hubscher@vetbio.unizh.ch	Jónsson, Zophonías/E-1960-2015; Jónsson, Zophonías Oddur/AAO-1354-2020; Hottiger, Michael O./J-7747-2013	Jónsson, Zophonías Oddur/0000-0001-5798-9647; Hottiger, Michael O./0000-0002-7323-2270; de Jong, Rob N./0000-0002-9300-6633				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Dekker J, 1998, J MOL BIOL, V277, P825, DOI 10.1006/jmbi.1998.1652; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	27	101	107	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22882	22887		10.1074/jbc.M001850200	http://dx.doi.org/10.1074/jbc.M001850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930425	hybrid, Green Accepted			2022-12-25	WOS:000088419400040
J	Reddy, TR; Tang, HL; Xu, WD; Wong-Staal, F				Reddy, TR; Tang, HL; Xu, WD; Wong-Staal, F			Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA	ONCOGENE			English	Article						nuclear export; RNA helicase A; Sam68; Tap; RRE; CTE	CONSTITUTIVE TRANSPORT ELEMENT; HIV-1 REV PROTEIN; MESSENGER-RNA; NUCLEAR EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; BINDING; IDENTIFICATION; EXPRESSION; SEQUENCES; SIGNAL	Unlike cellular mRNA, retroviral mRNA bypasses the tight coupling of the splicing and nuclear export steps to allow the export of intron-containing viral RNA transcripts to the cytoplasm. Two distinct nuclear export pathways for retroviral mRNA have been described: a CRM-1 dependent pathway mediated by the HIV-1 Rev protein and the Rev Response Element (RRE), and a CRM-1 independent pathway mediated by the Constitutive Transport Element (CTE) of type D retroviruses. Two CTE-binding proteins, RNA helicase A (RHA) and Tap, have been implicated in the nuclear export of CTE-containing RNA. Recently, we reported that expression of RRE-containing RNA could also be mediated by a cellular protein, Sam68, independently of Rev. Here we report evidence that Sam68, RHA and Tap cooperate in the nuclear export of both CTE- and RRE-containing RNA. RHA binds to Sam68 and to Tap both in vivo and in vitro. Over-expression of Sam68 activates both RRE-and CTE-regulated reporter gene expression in human cells and in quail cells in the presence of human lap. This activation was competitively inhibited by the nuclear transport domain (NTD) of RHA and a transdominant negative mutant of Tap. Conversely, the activation of CTE by Tap in quail cells was inhibited by a transdominant mutant of Sam68 and NTD. We propose that both HIV and type D retroviruses may access the same constitutive RNA nuclear export path tray involving RHA, Tap and Sam68, even though HIV also utilizes the Rev protein for more efficient nuclear export, it is likely that this constitutive export pathway is also used by cellular mRNA, but at a different interface with the splicing process.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Tang, Hengli/F-2085-2014		NIGMS NIH HHS [GM56089] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bear J, 1999, MOL CELL BIOL, V19, P6306; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; EMST RK, 1997, MOL CELL BIOL, V17, P135; Fornerod M, 1997, CELL, V90, P1051; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; SOLOMIN L, 1990, J VIROL, V64, P6010, DOI 10.1128/JVI.64.12.6010-6017.1990; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhang SS, 1999, J CELL SCI, V112, P1055; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	34	72	72	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3570	3575		10.1038/sj.onc.1203676	http://dx.doi.org/10.1038/sj.onc.1203676			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951562				2022-12-25	WOS:000088568300002
J	Wu, HJ; Xu, H; Miraglia, LJ; Crooke, ST				Wu, HJ; Xu, H; Miraglia, LJ; Crooke, ST			Human RNase III is a 160-kDa protein involved in preribosomal RNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; COLI RIBONUCLEASE-III; PRE-RIBOSOMAL-RNA; ESCHERICHIA-COLI; STRANDED-RNA; S-POMBE; GENE; SEQUENCE; SPLICEOSOME; SNRNA	A human RNase III gene encodes a protein of 160 kDa with multiple domains, a proline-rich, a serine- and arginine-rich, and an RNase III domain. The expressed purified RNase III domain cleaves double-strand RNA and does not cleave single-strand RNA. The gene is ubiquitously expressed in human tissues and cell lines, and the protein is localized in the nucleus of the cell, The levels of transcription and translation of the protein do not change during different phases of the cell cycle. However, a significant fraction of the protein in the nucleus is translocated to the nucleolus during the S phase of the cell cycle, That this human RNase III is involved in processing of pre-rRNA, but might cleave at sites different from those described for yeast RNase III, is shown by antisense inhibition of RNase III expression. Inhibition of human RNase III expression causes cell death, suggesting an essential role for human RNase III in the cell. The antisense inhibition technique used in this study provides an effective method for functional analysis of newly identified human genes.	ISIS Pharmaceut, Dept Biol Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut, Dept Biol Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	scrooke@isisph.com						AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ANASTASSOVAKRISTEVA M, 1977, J CELL SCI, V25, P103; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; ARRAIANO CM, 1993, WORLD J MICROB BIOT, V9, P421, DOI 10.1007/BF00328030; BRAM RJ, 1980, CELL, V19, P393, DOI 10.1016/0092-8674(80)90513-9; Chanfreau C, 2000, P NATL ACAD SCI USA, V97, P3142, DOI 10.1073/pnas.070043997; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Court D. L., 1993, CONTROL MESSENGER RN, P71; CROOKE ST, 1998, ANTISENSE RES APPL; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNN JJ, 1976, J BIOL CHEM, V251, P3807; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; FU XD, 1995, RNA, V1, P663; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; Harlow E., 1988, ANTIBODIES LAB MANUA; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KINGSTON R, 1997, CURRENT PROTOCOLS MO, V1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; NASHIMOTO H, 1985, MOL GEN GENET, V201, P25, DOI 10.1007/BF00397981; NAZAR RN, 1976, BIOCHEMISTRY-US, V15, P505, DOI 10.1021/bi00648a008; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; Qu LH, 1999, MOL CELL BIOL, V19, P1144; ROBERTSON HD, 1990, METHOD ENZYMOL, V181, P189; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Santos JM, 1997, FEMS MICROBIOL LETT, V157, P31, DOI 10.1111/j.1574-6968.1997.tb12749.x; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tollervey D, 1996, SCIENCE, V273, P1056, DOI 10.1126/science.273.5278.1056; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Wang W, 1997, J BACTERIOL, V179, P7379, DOI 10.1128/jb.179.23.7379-7385.1997; WATSON N, 1985, P NATL ACAD SCI USA, V82, P849, DOI 10.1073/pnas.82.3.849; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437	45	139	161	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36957	36965		10.1074/jbc.M005494200	http://dx.doi.org/10.1074/jbc.M005494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10948199	hybrid			2022-12-25	WOS:000165577700072
J	Hemmens, B; Goessler, W; Schmidt, K; Mayer, B				Hemmens, B; Goessler, W; Schmidt, K; Mayer, B			Role of bound zinc in dimer stabilization but not enzyme activity of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN BINDING; SUBUNIT DIMERIZATION; PTERIN-BINDING; HEME DOMAIN; BRAIN; SUBSTRATE; REQUIREMENT; CATALYSIS; REVEALS; OXYGEN	Nitric-oxide synthases (NOS) are homodimeric proteins and dan form an intersubunit Zn(4S) cluster. We have measured zinc bound to NOS purified from pig brain (0.6 mol/mol of NOS) and baculovirus-expressed rat neuronal NOS (nNOS) (0.49 +/- 0.13 mol/mol of NOS), by on-line gel-filtration/inductively coupled plasma mass spectrometry, Cobalt, manganese, molybdenum, nickel, and vanadium were all undetectable, Baculovirus-expressed nNOS also bound up to 2.00 +/- 0.58 mel of copper/mol of NOS. Diethylenetriaminepentaacetic acid (DTPA) reduced the bound zinc to 0.28 +/- 0.07 and the copper to 0.97 +/- 0.24 mol/mol of NOS. Desalting of samples into thiol-free buffer did not affect the zinc content but completely eliminated the bound copper (less than or equal to0.02 mol/mol of NOS). Most (greater than or equal to 75%) of the bound zinc was released from baculovirus-expressed rat nNOS by p-chloromercuriphenylsulfonic acid (PMPS), PMPS-treated nNOS was strongly (90 +/- 5%) inactivated. To isolate functional effects of zinc release from other effects of PMPS, PMPS-substituted thiols were unblocked by excess reduced thiol in the presence of DTPA, which hindered reincorporation of zinc. The resulting enzyme contained 0.12 +/- 0.05 mel of zinc but had a specific activity of 426 +/- 46 nmol of citrulline.mg(-1).min(-1), corresponding to 93 +/- 10% of non-PMPS-treated controls. PMPS also caused dissociation of nNOS dimers under native conditions, an effect that was blocked by the pteridine cofactor tetrahydrobiopterin (H-4 biopterin). H(4)biopterin did not affect zinc release. Even in the presence of H(4)biopterin, PMPS prevented conversion of NOS dimers to an SDS-resistant form. We conclude that zinc binding is a prerequisite for formation of SDS-resistant NOS dimers but is not essential for catalysis.	Graz Univ, Inst Pharmacol & Toxicol, A-8010 Graz, Austria; Graz Univ, Inst Chem, A-8010 Graz, Austria	University of Graz; University of Graz	Mayer, B (corresponding author), Graz Univ, Inst Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008; Goessler, Walter/A-1084-2016	Goessler, Walter/0000-0002-0142-9373; Mayer, Bernd/0000-0002-2921-3494				ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; CHENG KL, 1982, CRC HDB ORGANIC ANAL, P213; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Griep MA, 1996, BIOCHEMISTRY-US, V35, P8260, DOI 10.1021/bi952948p; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Miller RT, 1999, J BIOL CHEM, V274, P14537, DOI 10.1074/jbc.274.21.14537; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; QIU HW, 1994, J BIOL CHEM, V269, P2773; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; Rodriguez-Crespo I, 1999, J BIOL CHEM, V274, P21617, DOI 10.1074/jbc.274.31.21617; Sono M, 1999, BIOCHEMISTRY-US, V38, P15853, DOI 10.1021/bi991580j; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771	42	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35786	35791		10.1074/jbc.M005976200	http://dx.doi.org/10.1074/jbc.M005976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954720	hybrid			2022-12-25	WOS:000165382000022
J	Picard, V; Govoni, G; Jabado, N; Gros, P				Picard, V; Govoni, G; Jabado, N; Gros, P			Nramp 2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other divalent cations into a calcein-accessible cytoplasmic pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; NATURAL-RESISTANCE; TRANSMEMBRANE ORGANIZATION; FUNCTIONAL COMPLEMENTATION; EPITOPE INSERTION; P-GLYCOPROTEIN; PROTEIN; FAMILY; CELLS; GENE	Nrampa, also known as DMT1 and DCT1, is a la-transmembrane (TM) domain protein responsible for dietary iron uptake in the duodenum and iron acquisition from transferrin:in peripheral tissues. Nramp2/DMT1 produces by alternative splicing two isoforms differing at their C terminus (isoforms I and II). The subcellular localization, mechanism of action, and destination of divalent cations transported by the two Nrampa isoforms are not completely understood. Stable CHO transfectants expressing Nramp2 isoform II modified by addition of a hemaglutinin epitope in the loop defined by the TM7-TM8 interval were generated. Immunofluorescence with permeabilized and intact cells established that Nrampa isoform II is expressed at the plasma membrane and demonstrated the predicted extracytoplasmic location of the TM7-TR18 loop. Using the fluorescent, metal-sensitive dye calcein, and a combination of membrane-permeant and -impermeant iron chelators, Nrampa transport was measured and quantitated with respect to kinetic parameters and at steady state. Iron transport at the plasma membrane was time- and pH-dependent, saturable, and proportional to the amount of Nrampa expression. Iron uptake by Nrampa at the plasma membrane was into the nonferritin-bound, calcein-accessible so-called "labile iron pool." Ion selectivity experiments show that Nrampa isoform II can also transport Co2+ and Cd2+ but not Mg2+ into the calcein-accessible pool. Parallel experiments with transfectants expressing the lysosomal Nramp1 homolog do not show any divalent cation transport activity, establishing major functional differences between Nramp1 and Nramp2. Monitoring the effect of Nramp2 on the calcein-sensisitve labile iron pool allows a simple, rapid, and nonisotopic approach to the functional study of this protein.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond,Rm 907, Montreal, PQ H3G 1Y6, Canada.		Jabado, Nada/AAN-4026-2020	Govoni, Gregory/0000-0002-4664-0834	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035237] Funding Source: NIH RePORTER; NIAID NIH HHS [1 RO1 AI35237-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agranoff D, 1999, J EXP MED, V190, P717, DOI 10.1084/jem.190.5.717; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Curie C, 2000, BIOCHEM J, V347, P479; D'Souza J, 1999, J EXP BIOL, V202, P1909; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; EDWARDS JA, 1972, P SOC EXP BIOL MED, V141, P81; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Erdahl WL, 1996, BIOCHEMISTRY-US, V35, P13817, DOI 10.1021/bi961391q; Essodaigui M, 1998, BIOCHEMISTRY-US, V37, P2243, DOI 10.1021/bi9718043; FARCICH EA, 1992, AM J PHYSIOL, V262, pR220, DOI 10.1152/ajpregu.1992.262.2.R220; FARCICH EA, 1992, AM J HEMATOL, V39, P9, DOI 10.1002/ajh.2830390104; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Govoni G, 1999, INFECT IMMUN, V67, P2225, DOI 10.1128/IAI.67.5.2225-2232.1999; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; Moffett P, 1996, GENOMICS, V35, P144, DOI 10.1006/geno.1996.0333; Orgad S, 1998, J EXP BIOL, V201, P115; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ponka P, 1999, KIDNEY INT, V55, pS2, DOI 10.1046/j.1523-1755.1999.055Suppl.69002.x; RUSSELL ES, 1970, BLOOD-J HEMATOL, V35, P838, DOI 10.1182/blood.V35.6.838.838; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Tabuchi M, 1999, BIOCHEM J, V344, P211, DOI 10.1042/0264-6021:3440211; Tabuchi M, 2000, J BIOL CHEM, V275, P22220, DOI 10.1074/jbc.M001478200; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000	43	146	151	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35738	35745		10.1074/jbc.M005387200	http://dx.doi.org/10.1074/jbc.M005387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942769	hybrid			2022-12-25	WOS:000165382000016
J	Neaud, V; Hisaka, T; Monvoisin, A; Bedin, C; Balabaud, C; Foster, DC; Desmouliere, A; Kisiel, W; Rosenbaum, J				Neaud, V; Hisaka, T; Monvoisin, A; Bedin, C; Balabaud, C; Foster, DC; Desmouliere, A; Kisiel, W; Rosenbaum, J			Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; EXTRACELLULAR-MATRIX; PROTEASE INHIBITOR; STROMAL CELLS; MYOFIBROBLASTS; DEGRADATION; EXPRESSION; CULTURE; CLONING; LIVER	We have previously shown that human liver myofibroblasts promote in vitro invasion of human hepatocellular carcinoma (HCC) cells through a hepatocyte growth factor (HGF)/urokinase/plasmin-dependent mechanism. In this study, we demonstrate that myofibroblasts synthesize the serine proteinase inhibitor tissue factor pathway inhibitor-2 (TFPI-8). Despite the fact that recombinant TFPI-2 readily inhibits plasmin, we show that it potentiates HGF-induced invasion of HCC cells and is capable of inducing invasion on its own. Furthermore, HCC cells stably transfected with a TFPI-2 expression vector became spontaneously invasive. HCC cells express tissue factor and specifically factor VII, Addition of an antibody to factor VII abolished the pro-invasive effect of TFPI-2. We suggest that TFPI-2 induces invasion following binding to a tissue factor-factor VIIa complex preformed on HCC cells. Our data thus demonstrate an original mechanism of cell invasion that may be specific for liver tumor cells.	Univ Bordeaux 2, INSERM E9917, Grp Rech Etud Foie, F-33076 Bordeaux, France; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Zymogenet Inc.; University of New Mexico	Rosenbaum, J (corresponding author), Univ Bordeaux 2, INSERM E9917, Grp Rech Etud Foie, F-33076 Bordeaux, France.	jean.rosenbaum@gref.u-bordeaux2.fr	Rosenbaum, Jean/F-5547-2013	Rosenbaum, Jean/0000-0001-8585-5152; Monvoisin, Arnaud/0000-0002-9915-4872	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BAROUKI R, 1984, J BIOL CHEM, V259, P7970; Blazejewski S, 1997, AM J PATHOL, V151, P651; BLAZEJEWSKI S, 1995, HEPATOLOGY, V22, P788, DOI 10.1016/0270-9139(95)90298-8; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ENZAN H, 1994, HEPATOLOGY, V19, P895, DOI 10.1016/0270-9139(94)90289-5; Faouzi S, 1999, J HEPATOL, V30, P275, DOI 10.1016/S0168-8278(99)80074-9; Fischer EG, 1999, J CLIN INVEST, V104, P1213, DOI 10.1172/JCI7750; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Monvoisin A, 1999, J HEPATOL, V30, P511, DOI 10.1016/S0168-8278(99)80113-5; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Terada T, 1996, J HEPATOL, V24, P706; Toi M, 1998, BREAST CANCER RES TR, V52, P113, DOI 10.1023/A:1006167202856; WILDGOOSE P, 1989, BLOOD, V73, P1888; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121	25	44	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35565	35569		10.1074/jbc.M006101200	http://dx.doi.org/10.1074/jbc.M006101200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954721	hybrid			2022-12-25	WOS:000165422800096
J	Schumacher, MA; Goodman, RH; Brennan, RG				Schumacher, MA; Goodman, RH; Brennan, RG			The structure of a CREB bZIP center dot somatostatin CRE complex reveals the basis for selective dimerization and divalent cation-enhanced DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION LEUCINE-ZIPPER; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; TRANSCRIPTION; RECOGNITION; REPLACEMENT; REPRESSOR; MAGNESIUM; ANGSTROM	The cAMP responsive element-binding protein (CREB) is central to second messenger regulated transcription. To elucidate the structural mechanisms of DNA binding and selective dimerization of CREB, we determined to 3.0 Angstrom resolution, the structure of the CREB bZIP, (residues 283-341) bound to a 21-base pair deoxynucleotide that encompasses the canonical 8-base pair somatostatin cAMP response element (SSCRE), The CREB dimer is stabilized in part by ionic interactions from -Arg(314) to Glu(319') and Glu(328) to, Lys(333') as,,well as a hydrogen bond network that links the carboxamide side chains of Gln(322') -Asn(321)-Asn(321')-Gln(322). Critical to family selective dimerization are intersubunit hydrogen bonds between basic-region residue Tyr(307) and leucine zipper residue: Glu(312), which are conserved in all CREB/CREM/ ATF-1: family members. Strikingly, the structure reveals a hexahydrated Mg2+ ion bound in the cavity between the basic region and SSCRE that makes a water-mediated:DNA contact. DNA binding studies demonstrate that Mg2+ ions enhance CREB bZIP:SSCRE binding by more than 25-fold and suggest a possible physiological role for this ion in somatostatin cAMP response element and potentially other CRE-mediated gene expression.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Brennan, RG (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato H, 1998, BRAIN RES, V779, P329, DOI 10.1016/S0006-8993(97)01232-8; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SLITANI A, 1998, P NATL ACAD SCI USA, V95, P1404; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647	33	126	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35242	35247		10.1074/jbc.M007293200	http://dx.doi.org/10.1074/jbc.M007293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952992	hybrid			2022-12-25	WOS:000165422800056
J	Chen, LY; Lin, BC; Pan, CJ; Hiraiwa, H; Chou, JY				Chen, LY; Lin, BC; Pan, CJ; Hiraiwa, H; Chou, JY			Structural requirements for the stability and microsomal transport activity of the human glucose 6-phosphate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PUTATIVE GLUCOSE-6-PHOSPHATE TRANSLOCASE; TRANSMEMBRANE TOPOLOGY; CHROMOSOME 11Q23; GENE; IB; 1B; MUTATION; PROTEIN	Deficiencies in glucose 6-phosphate (G6P) transporter (G6PT), a 10-helical endoplasmic reticulum transmembrane protein of 429 amino acids, cause glycogen storage disease type Ib. To date, only three missense mutations in G6PT have been shown to abolish microsomal G6P transport activity. Here, we report the results of structure-function studies on human G6PT and demonstrate that 15 missense mutations and a codon deletion (Delta F93) mutation abolish microsomal G6P uptake activity and that two splicing mutations cause exon skipping. While most missense mutants support the synthesis of G6PT protein similar to that of the wild-type transporter, immunoblot analysis shows that G20D, Delta F93, and I278N mutations, located in helix 1, 2, and 6, respectively, destabilize the G6PT. Further, we demonstrate that G6PT mutants lacking an intact helix 10 are misfolded and undergo degradation within cells. Moreover, amino acids 415-417 in the cytoplasmic tail of the carboxyl-domain, extending from helix 10, also play a critical role in the correct folding of the transporter. However, the last 12 amino acids of the cytoplasmic tail play no essential role(s) in functional integrity of the G6PT. Our results, for the first time, elucidate the structural requirements for the stability and transport activity of the G6PT protein.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	chou@helix.nih.gov	Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; ARION WJ, 1980, J BIOL CHEM, V255, P396; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Galli L, 1999, FEBS LETT, V459, P255, DOI 10.1016/S0014-5793(99)01248-X; Gerin I, 1999, GENE, V227, P189, DOI 10.1016/S0378-1119(98)00614-3; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Hou DC, 1999, AM J MED GENET, V86, P253, DOI 10.1002/(SICI)1096-8628(19990917)86:3<253::AID-AJMG11>3.0.CO;2-7; Ihara K, 1998, HUM GENET, V103, P493, DOI 10.1007/s004390050856; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kure S, 1998, BIOCHEM BIOPH RES CO, V248, P426, DOI 10.1006/bbrc.1998.8985; Lam C W, 2000, Hum Mutat, V16, P94, DOI 10.1002/1098-1004(200007)16:1<94::AID-HUMU26>3.0.CO;2-Q; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Marcolongo P, 1998, FEBS LETT, V436, P247, DOI 10.1016/S0014-5793(98)01129-6; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Pan CJ, 1999, J BIOL CHEM, V274, P13865, DOI 10.1074/jbc.274.20.13865; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Veiga-Da-Cunha M, 1999, EUR J HUM GENET, V7, P717, DOI 10.1038/sj.ejhg.5200366; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888	30	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34280	34286		10.1074/jbc.M006439200	http://dx.doi.org/10.1074/jbc.M006439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940311	hybrid			2022-12-25	WOS:000165095300040
J	Delesque-Touchard, N; Park, SH; Waxman, DJ				Delesque-Touchard, N; Park, SH; Waxman, DJ			Synergistic action of hepatocyte nuclear factors 3 and 6 on CYP2C12 gene expression and suppression by growth hormone-activated - STAT5b proposed model for female-specific expression of CYP2C12 in adult rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; SEXUAL DIMORPHISM; BINDING-PROTEIN; RECEPTOR; IDENTIFICATION; INHIBITION; PROLACTIN; SECRETION; INSULIN	Growth hormone (GH) exerts sexually dimorphic effects on liver gene transcription through its sex-dependent temporal pattern of pituitary hormone secretion. CYP2C12 encodes a female-specific rat liver P450 steroid hydroxylase whose expression is activated by continuous GH stimulation of hepatocytes. Presently, we investigated the role of liver-enriched and GH-regulated transcription factors in the activation of CYP2C12 gene expression in GH-stimulated liver cells. Transcription of a CYP2C12 promoter-luciferase reporter gene in transfected HepG2 cells was activated 15-40-fold by the liver-enriched hepatocyte nuclear factor (HNF) 3 alpha, HNF3 beta, and HNF6. Synergistic interactions leading to an similar to 300-fold activation of the promoter by HNF3 beta in combination with HNF6 were observed. S'-Deletion analysis localized the HNF6 response to a single 5'-proximal 96-nucleotide segment. By contrast, the stimulatory effects of HNF3 alpha and HNF3 beta were attributable to five distinct regions within the 1.6-kilobase CYP2C12 proximal promoter. GH activation of the signal transducer and transcriptional activator STAT5b, which proceeds efficiently in male but not female rat liver, inhibited CYP2C12 promoter activation by HNF3 beta and HNF6, despite the absence of a classical STAT5-binding site. The female-specific pattern of CYP2C12 expression is thus proposed to reflect the positive synergistic action in female liver of liver-enriched and GH-regulated transcription factors, such as HNF3 beta and HNF6, coupled with a dominant inhibitory effect of GH-activated STAT5b that is manifest in males.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bio.bu.edu		Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Buggs C, 1998, MOL ENDOCRINOL, V12, P1294, DOI 10.1210/me.12.9.1294; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MACGEOCH C, 1984, J BIOL CHEM, V259, P5433; MODE A, 1992, ADV ENZYME REGUL, V32, P255; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Samadani U, 1996, GENE EXPRESSION, V6, P23; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sasaki Y, 1999, J BIOL CHEM, V274, P37117, DOI 10.1074/jbc.274.52.37117; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Sueyoshi T, 1999, MOL PHARMACOL, V56, P473, DOI 10.1124/mol.56.3.473; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Waxman David J., 1995, P391; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; WAXMAN DJ, 1984, J BIOL CHEM, V259, P5481; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672	51	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34173	34182		10.1074/jbc.M004027200	http://dx.doi.org/10.1074/jbc.M004027200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10931833	Green Submitted, hybrid			2022-12-25	WOS:000165095300026
J	Pedersen, LC; Tsuchida, K; Kitagawa, H; Sugahara, K; Darden, TA; Negishi, M				Pedersen, LC; Tsuchida, K; Kitagawa, H; Sugahara, K; Darden, TA; Negishi, M			Heparan/chondroitin sulfate biosynthesis - Structure and mechanism of human glucuronyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE-REGION; HEPARAN-SULFATE; N-ACETYLGALACTOSAMINE; MAST-CELLS; GLYCOSYLTRANSFERASES; DROSOPHILA; ENZYME; DOMAIN; PROTEOGLYCANS; ENCODES	Human beta1,3-glucuronyltransferase I (GlcAT-I) is a central enzyme in the initial steps of proteoglycan synthesis. GlcAT-I transfers a glucuronic acid moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to the common linkage region trisaccharide Gal beta1-3Gal beta1-4Xyl covalently bound to a Ser residue at the glycosaminylglycan attachment site of proteoglycans, We have now determined the crystal structure of GlcAT-I at 2.3 Angstrom in the presence of the donor substrate product UDP, the catalytic Mn2+ ion, and the acceptor substrate analog Gal beta1-3Gal beta1-4Xyl, The enzyme is a alpha/beta protein with two subdomains that constitute the donor and acceptor substrate binding site. The active site residues lie in a cleft extending across both subdomains in which the trisaccharide molecule is oriented perpendicular to the UDP. Residues Glu(227), Asp(252), and Glu(281) dictate the binding orientation of the terminal Gal-2 moiety. Residue Glu(281) is in position to function as a catalytic base by deprotonating the incoming 3-hydroxyl group of the acceptor. The conserved DXD motif (Asp(191), Asp(195), Asp(196)) has direct interaction with the ribose of the UDP molecule as well as with the Mn2+ ion. The key residues involved in substrate binding and catalysis are conserved in the glucuronyltransferase family as well as of her glycosyltransferases.	NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6858858, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kobe Pharmaceutical University	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Kitagawa, Hiroshi/AAJ-1344-2020; Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; *CCP4 SUIT, 1994, COMPUTATIONAL PROJ D, V50, P760; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DEANGELIS PL, 2000, IN PRESS J BIOL CHEM; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUZZINE M, 2000, IN PRESS J BIOL CHEM; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Tsuchida K, 1999, EUR J BIOCHEM, V264, P461, DOI 10.1046/j.1432-1327.1999.00635.x; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170	32	164	170	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34580	34585		10.1074/jbc.M007399200	http://dx.doi.org/10.1074/jbc.M007399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10946001	hybrid			2022-12-25	WOS:000165095300079
J	Yu, XF; Weissman, SM				Yu, XF; Weissman, SM			Characterization of the promoter of human leukocyte-specific transcript 1 - A small gene with a complex pattern of alternative transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; FACTOR PU.1; TNF REGION; ETS FAMILY; EXPRESSION; PROTEIN; BINDING; MEMBER; POLYMORPHISM; NF-IL6	The gene for the human leukocyte-specific transcript 1 (LST1) encodes a small protein that modulates immune responses and cellular morphogenesis. The LST1 transcripts are expressed at high levels in dendritic cells. Because of the complex splicing pattern, use of alternative 5'-untranslated exons, and a biologically interesting pattern of expression of LST1 mRNA, we studied the human LST1 gene promoter and regulatory elements. We identified an additional upstream 5'-untranslated exon in U937 monocytic cells. Transient transfection studies demonstrated that the combination of regions from -1363 to -621 with -112 to -54, relative to the translation start codon, produced the highest level of transcripts from among the various constructs tested, but the pattern of transcripts produced was only a subset of those produced from the endogenous gene. DNase I footprinting analysis and electrophoretic mobility shift assays showed that oligonucleotide probes corresponding to three regions, -1171 to -1142 (BI), -1136 to -1111 (BII), and -783 to -751 (BTV), bound proteins in U937 nuclear extracts. Competition and supershift electrophoretic mobility shift assay did not identify any known transcription factors responsible for BII probe binding. These studies suggest that a novel DNA-binding site and interaction of multiple regulatory elements may be involved in mediating the expression of the various forms of LST1 mRNA.	Yale Univ, Sch Med, Dept Genet, Boyer Ctr Mol Med, New Haven, CT 06510 USA	Yale University	Weissman, SM (corresponding author), Yale Univ, Sch Med, Dept Genet, Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06510 USA.				NHLBI NIH HHS [HL63357-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL063357] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Asano H, 1997, TISSUE ANTIGENS, V50, P484, DOI 10.1111/j.1399-0039.1997.tb02903.x; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CAMPBELL RD, 1997, IMMUNOL TODAY, V18, P43; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; De Baey A., 1996, Human Immunology, V47, P65, DOI 10.1016/0198-8859(96)85042-7; DEBAEY A, 1995, HUM IMMUNOL, V42, P9, DOI 10.1016/0198-8859(94)00070-7; deBaey A, 1997, GENOMICS, V45, P591, DOI 10.1006/geno.1997.4963; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gruen JR, 1997, BLOOD, V90, P4252; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLZINGER I, 1995, IMMUNOGENETICS, V42, P315, DOI 10.1007/BF00179392; HOLZINGER IR, 2000, J IMMUNOL, V164, P3169; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; LEE KAW, 1994, CELL BIOL LAB HDB, P668; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; McKercher SR, 1999, J LEUKOCYTE BIOL, V66, P727, DOI 10.1002/jlb.66.5.727; Middleton PG, 1998, BLOOD, V92, P3943, DOI 10.1182/blood.V92.10.3943.422k35_3943_3948; Nalabolu SR, 1996, GENOMICS, V31, P215, DOI 10.1006/geno.1996.0034; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; TSUGE I, 1987, IMMUNOGENETICS, V26, P378, DOI 10.1007/BF00343709; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P2; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34597	34608		10.1074/jbc.M004700200	http://dx.doi.org/10.1074/jbc.M004700200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944527	hybrid			2022-12-25	WOS:000165095300082
J	Mutucumarana, VP; Stafford, DW; Stanley, TB; Jin, DY; Solera, J; Brenner, B; Azerad, R; Wu, SM				Mutucumarana, VP; Stafford, DW; Stanley, TB; Jin, DY; Solera, J; Brenner, B; Azerad, R; Wu, SM			Expression and characterization of the naturally occurring mutation L394R in human gamma-glutamyl carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT CARBOXYLASE; BLOOD-COAGULATION FACTORS; FACTOR-IX; CONGENITAL DEFICIENCY; RECOGNITION SITE; CARBOXYGLUTAMIC ACID; PROPEPTIDE REGION; PEPTIDE-SUBSTRATE; ENZYME-ACTIVITY; PROTEIN-C	Patients with mutation L394R in gamma -glutamyl carboxylase have a severe bleeding disorder because of decreased biological activities of all vitamin K-dependent coagulation proteins. Vitamin K administration partially corrects this deficiency. To characterize L394R, we purified recombinant mutant L394R and wild-type carboxylase expressed in baculovirus-infected insect cells. By kinetic studies, we analyzed the catalytic activity of mutant L394R and its binding to factor M's propeptide and vitamin KM2. Mutant L394R differs from its wild-type counterpart as follows: 1) 110-fold higher K-i for Boc-mEEV, an active site-specific, competitive inhibitor of FLEEL; 2) 30-fold lower V-max/K-m toward the substrate FLEEL in the presence of the propeptide; 3) severely reduced activity toward FLEEL carboxylation in the absence of the propeptide; 4) 7-fold decreased affinity for the propeptide; 5) 9-fold higher K-m for FIXproGla, a substrate containing the propeptide and the Gla domain of human factor IX; and 6) B-fold higher K-m, for vitamin KH2. The primary defect in mutant L394R appears to be in its glutamate-binding site. To a lesser degree, the propeptide and KH2 binding properties are altered in the L394R mutant. Compared with its wildtype counterpart, the L394R mutant shows an augmented activation of FLEEL carboxylation by the propeptide.	Hosp Univ La Paz, Dept Mol Genet, Madrid 28046, Spain; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Rambam Med Ctr, Inst Hematol, Thrombosis & Hemostasis Unit, IL-31096 Haifa, Israel; Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, UFR Biomed St Peres, F-75270 Paris 06, France	Hospital Universitario La Paz; University of North Carolina; University of North Carolina Chapel Hill; Rambam Health Care Campus; Technion Israel Institute of Technology; UDICE-French Research Universities; Universite Paris Cite	Wu, SM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL48313] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048313] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZERAD R, 1988, CURRENT ADV VITAMIN, P17; BEGLEY GS, 2000, J BIOL CHEM     0712; BRENNER B, 1990, BRIT J HAEMATOL, V75, P537, DOI 10.1111/j.1365-2141.1990.tb07795.x; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; ESMON CT, 1975, J BIOL CHEM, V250, P4744; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; GOLDSMITH GH, 1982, J CLIN INVEST, V69, P1253, DOI 10.1172/JCI110564; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; JOHNSON CA, 1980, BRIT J HAEMATOL, V44, P461, DOI 10.1111/j.1365-2141.1980.tb05916.x; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MCMILLAN CW, 1966, NEW ENGL J MED, V274, P1313, DOI 10.1056/NEJM196606092742309; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; PAULI RM, 1987, AM J HUM GENET, V41, P566; PECHLANER C, 1992, THROMB HAEMOSTASIS, V68, P617; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; SOUTE BAM, 1990, BIOCHIM BIOPHYS ACTA, V1034, P11, DOI 10.1016/0304-4165(90)90146-N; SOUTE BAM, 1992, THROMB HAEMOSTASIS, V68, P521; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; THIJSSEN HHW, 1986, BIOCHEM PHARMACOL, V35, P3277, DOI 10.1016/0006-2952(86)90424-7; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VICENTE V, 1984, THROMB HAEMOSTASIS, V51, P343; WALLIN R, 1982, ARCH BIOCHEM BIOPHYS, V214, P155, DOI 10.1016/0003-9861(82)90017-0; WOOD GM, 1988, J BIOL CHEM, V263, P3234; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, METHOD ENZYMOL, V282, P346; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236	42	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32572	32577		10.1074/jbc.M006808200	http://dx.doi.org/10.1074/jbc.M006808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10934213	hybrid, Green Published			2022-12-25	WOS:000090003800028
J	Xie, YQ; Denison, C; Yang, SH; Fancy, DA; Kodadek, T				Xie, YQ; Denison, C; Yang, SH; Fancy, DA; Kodadek, T			Biochemical characterization of the TATA-binding protein-Gal4 activation domain complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; FUSION PROTEINS; BOX COMPLEX; YEAST; TBP; DNA; TRANSACTIVATION; DIMER; COACTIVATORS; AFFINITIES	It has been suggested that complexes between gene-specific activators and the TATA-binding protein (TBP) play an important role in the expression of many genes. However, few detailed studies of well defined activator-TBP complexes have been reported. An analysis of the biochemical properties of the complex formed by the acidic activation domain (AAD) of the yeast activator Gal4 and TBP is presented here. This is shown to be composed of two AAD and one TBP molecule. DNA binding experiments reveal that TATA-containing DNAs and the Gal4 AAD bind TBP competitively, suggesting that the AAD and TATA boxes recognize overlapping surfaces of TBP. The kinetics of the formation and dissociation of the AAD(2)-TBP complex is also probed. The impact of these findings on models for Gal4-mediated transcriptional activation is considered.	Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ryburn Ctr Mol Cardiol, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Fancy, David A./0000-0001-7786-936X; Kodadek, Thomas/0000-0003-1930-4795	NHLBI NIH HHS [HLO7360] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fancy DA, 1996, CHEM BIOL, V3, P551, DOI 10.1016/S1074-5521(96)90146-5; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; POON D, 1993, J BIOL CHEM, V268, P15325; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677	30	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31914	31920		10.1074/jbc.M003760200	http://dx.doi.org/10.1074/jbc.M003760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10931832	hybrid			2022-12-25	WOS:000089858900052
J	da Silva, EF; Reha-Krantz, LJ				da Silva, EF; Reha-Krantz, LJ			Dinucleotide repeat expansion catalyzed by bacteriophage T4 DNA polymerase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLE REPETITIVE DNA; SACCHAROMYCES-CEREVISIAE; REPLICATION ERRORS; OKAZAKI FRAGMENT; MISMATCH REPAIR; MUTATIONS; SEQUENCE; YEAST; DESTABILIZATION; EXONUCLEASE	DNA replication normally occurs with high fidelity, but certain "slippery" regions of DNA with tracts of mono-, di-, and trinucleotide repeats are frequently mutation hot spots. We have developed an in vitro assay to study the mechanism of dinucleotide repeat expansion. The primer-template resembles a base excision repair substrate with a single nucleotide gap centered opposite a tract of nine CA repeats; nonrepeat sequences flank the dinucleotide repeats. DNA polymerases are expected to repair the gap, but further extension is possible if the DNA polymerase can displace the downstream oligonucleotide. We report here that the wild type bacteriophage T4 DNA polymerase carries out gap and strand displacement replication and also catalyzes a dinucleotide expansion reaction. Repeat expansion was not detected for an exonuclease-deficient T4 DNA polymerase or for Escherichia coli DNA polymerase I. The dinucleotide repeat expansion reaction catalyzed by wild type T4 DNA polymerase required a downstream oligonucleotide to "stall" replication and 3' --> 5' exonuclease activity to remove the 3'-nonrepeat sequence adjacent to the repeat tract in the template strand. These results suggest that dinucleotide repeat expansion may be stimulated in vivo during DNA repair or during processing of Okazaki fragments.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Reha-Krantz, LJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	LREHA@gpu.srv.ualberta.ca	Reha-Krantz, Linda/A-3748-2014	Reha-Krantz, Linda/0000-0003-4497-423X; Fidalgo da Silva, Elizabeth/0000-0003-3540-9335				Beechem JM, 1998, BIOCHEMISTRY-US, V37, P10144, DOI 10.1021/bi980074b; BENZER S, 1960, GENETICS, V47, P403; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Fujii S, 1999, J MOL BIOL, V289, P835, DOI 10.1006/jmbi.1999.2802; GUPTA A, 1982, J BIOL CHEM, V257, P7689; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HADJIMARCON MI, 1999, CONSTRUCTION IN VIVO; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; KORNBERG A, 1964, P NATL ACAD SCI USA, V51, P315, DOI 10.1073/pnas.51.2.315; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Lyons-Darden T, 1999, NUCLEIC ACIDS RES, V27, P2235, DOI 10.1093/nar/27.11.2235; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2	29	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31528	31535		10.1074/jbc.M004594200	http://dx.doi.org/10.1074/jbc.M004594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10924513	hybrid			2022-12-25	WOS:000089762700108
J	Kawakami, Y; Kitamoto, M; Nakanishi, T; Yasui, W; Tahara, E; Nakayama, J; Ishikawa, F; Tahara, H; Ide, T; Kajiyama, G				Kawakami, Y; Kitamoto, M; Nakanishi, T; Yasui, W; Tahara, E; Nakayama, J; Ishikawa, F; Tahara, H; Ide, T; Kajiyama, G			Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues	ONCOGENE			English	Article						human telomerase reverse transcriptase; hepatocellular carcinoma; immunohistochemical detection	DISEASED PEDIATRIC LIVER; DNA POLYMERASE-ALPHA; MONOCLONAL-ANTIBODY; HEPATOCELLULAR-CARCINOMA; PROGENITOR CELLS; IMMUNOHISTOCHEMICAL DETECTION; PROLIFERATING HEPATOCYTES; DUCTULAR HEPATOCYTES; CATALYTIC COMPONENT; IMMORTAL CELLS	Although telomerase activity in hepatocellular carcinoma (HCC) increases in accordance with degree of histological undifferentiation, it is unknown whether the level of telomerase activity in HCC reflects of the degree of activity in individual cells or the frequency of telomerase-positive HCC cells. Non-cancerous liver tissues exhibit low but significant levels of telomerase activity, but the nature of telomerase-positive cells in these tissues is unclear, In this study, we performed immunohistochemical staining using specific antibody against telomerase reverse transcriptase (hTERT) protein in 15 HCC samples and 13 adjacent non-cancerous liver tissues, There were hTERT-positive hepatocytes, though very low frequency, in non-cancerous liver tissues. The frequencies in hTERT positive hepatocytes were very well correlated with clinicopathological parameters and telomerase activity levels: the average frequencies of chronic hepatitis was 0.2%, liver cirrhosis 0.2%, well-differentiated HCC 3.0%, moderately differentiated HCC 28%, and poorly differentiated HCC 95%, The intensity of staining varied among cells within a given specimen, and correlation with degree of histological undifferentiation was less obvious. Portions of migrating lymphocytes and biliary epithelial cells were also hTERT-positive. These findings indicate that the upregulation of telomerase activity with degree of undifferentiation of HCC is mainly due to the increase in frequency of hTERT positive HCC cells.	Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Minami Ku, Hiroshima 7348551, Japan; Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2260027, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Tokyo Institute of Technology	Ide, T (corresponding author), Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Ishikawa, Fuyuki/AAU-4056-2021; Nakayama, Jun-ichi/C-6003-2011	Ishikawa, Fuyuki/0000-0002-5580-2305; Nakayama, Jun-ichi/0000-0002-5597-8239				Baumann U, 1999, HEPATOLOGY, V30, P112, DOI 10.1002/hep.510300140; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crosby HA, 1998, AM J PATHOL, V152, P771; Crosby HA, 1998, HEPATOLOGY, V28, P980, DOI 10.1002/hep.510280412; Demetris AJ, 1996, AM J PATHOL, V149, P439; DEVOS R, 1992, AM J PATHOL, V140, P1441; DUNSFORD HA, 1985, AM J PATHOL, V118, P218; DUNSFORD HA, 1989, CANCER RES, V49, P4894; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; ELMORE LW, 1991, CANCER RES, V51, P5752; EVARTS RP, 1989, CANCER RES, V49, P1541; GOLDLUST A, 1995, EPILEPSY RES, V22, P1, DOI 10.1016/0920-1211(95)00028-9; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Haque S, 1996, LAB INVEST, V75, P699; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; KAWAKITA N, 1992, AM J PATHOL, V140, P513; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Nakamura Y, 1999, MOL CARCINOGEN, V26, P312, DOI 10.1002/(SICI)1098-2744(199912)26:4<312::AID-MC10>3.3.CO;2-1; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Novikoff PM, 1996, AM J PATHOL, V148, P1473; Ogami M, 1999, LAB INVEST, V79, P15; Ohyashiki K, 1997, CANCER RES, V57, P2100; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Roskams T, 1996, HISTOPATHOLOGY, V28, P291, DOI 10.1046/j.1365-2559.1996.d01-438.x; Ruck P, 1996, AM J PATHOL, V148, P321; SEKI S, 1990, HUM PATHOL, V21, P1020, DOI 10.1016/0046-8177(90)90251-Y; SEKI S, 1991, HEPATOLOGY, V14, P781, DOI 10.1002/hep.1840140507; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Takahashi S, 2000, EUR J CANCER, V36, P496, DOI 10.1016/S0959-8049(99)00284-1; Takaishi H, 2000, CANCER, V88, P312, DOI 10.1002/(SICI)1097-0142(20000115)88:2<312::AID-CNCR10>3.3.CO;2-I; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 1998, JPN J CANCER RES, V89, P1099, DOI 10.1111/j.1349-7006.1998.tb00502.x; Yasui W, 1996, J PATHOL, V180, P122, DOI 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	41	51	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3888	3893		10.1038/sj.onc.1203733	http://dx.doi.org/10.1038/sj.onc.1203733			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951582				2022-12-25	WOS:000088614300007
J	Gil, J; Esteban, M				Gil, J; Esteban, M			The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors	ONCOGENE			English	Article						PKR; apoptosis; FADD; caspases	TUMOR-SUPPRESSOR P53; EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; INFLUENZA-VIRUS INFECTION; NF-KAPPA-B; CELL-DEATH; DEPENDENT PATHWAY; ANTICANCER DRUGS; EXPRESSION; LIGAND; DOMAIN	The interferon-induced dsRNA-dependent protein kinase (PKR) induces apoptosis of mammalian cells. Apoptosis induction bq PKR involves phosphorylation of the translational factor eIF-2 alpha and activation of the transcriptional factor NF-kappa B, but caspase pathways activated by PKR are not known. Upregulation of Fas mRNA by PKR has been suggested to play a role in PKR-induced apoptosis. To learn how PKR induces apoptosis, we have analysed the role of molecules in death receptor pathways. We showed the involvement of the FADD-caspase 8 pathway on PKR-induced apoptosis based on four experimental findings: upregulation of caspase 8 activity during PKR-induced apoptosis, blocking of PKR-induced apoptosis by the use of a chemical inhibitor of caspase 8, and inhibition of PKR-induced apoptosis by expression of both a FADD dominant negative or a viral FLIP molecule. Significantly, despite the PKR-mediated upregulation of Fas mRSA expression, the Fas receptor-ligand pathway is not needed for PKR-induced apoptosis. Antibodies that inhibit TNF alpha-TNFR1 or Fas-FasL interactions were not able to block PKR-induced apoptosis. Taken together, our observations establish the involvement of caspase 8 in PKR-induced apoptosis and suggest that death receptors other than Fas or TNFR1 or, alternatively, a novel mechanism involving FADD independently of death receptors, are responsible for PKR-induced apoptosis.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Gil, Jesus/C-7739-2012; Esteban, Mariano/ABG-5375-2020	Gil, Jesus/0000-0002-4303-6260; Esteban, Mariano/0000-0003-0846-2827				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Brun A, 1996, VIROLOGY, V225, P227, DOI 10.1006/viro.1996.0592; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P715; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez A, 1996, J MED VIROL, V50, P342, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;342::AID-JMV10&gt;3.0.CO;2-K; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suarez P, 1996, J VIROL, V70, P2876; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vazquez MI, 1998, J VIROL, V72, P10126; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; WATANABE FR, 1992, NATURE, V356, P314; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	74	86	91	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3665	3674		10.1038/sj.onc.1203710	http://dx.doi.org/10.1038/sj.onc.1203710			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951573				2022-12-25	WOS:000088568300013
J	McPherson, RA; Taylor, MM; Hershey, ED; Sturgill, TW				McPherson, RA; Taylor, MM; Hershey, ED; Sturgill, TW			A different function for a critical tryptophan in c-Raf and Hck	ONCOGENE			English	Article						Raf; Ras; Src; kinase	PROTEIN-KINASE-C; SRC FAMILY; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; CELLS; C-RAF-1; PATHWAY; VIVO	The similarity of the catalytic domains of Raf and Src family members suggests that functions of homologous residues may be similar in both kinase families. A tryptophan residue, W260, in the WEI region of the Src family kinase Hck has an important role in regulating ATP binding. We tested the hypothesis that the tryptophan, W342, in the WEI region of c-Raf may have a similar role to the W260 of Hck. Mutation of W260 to A in Hck activates kinase activity, but me found that mutation of W342 to A in c-Raf inactivates the kinase activity. Mutating W342 to aspartate (D), lysine (K) or histidine (H) also inactivated c-Raf whether assayed as a purified immunoprecipitate or when recruited to the plasma membrane. A constitutively active c-Raf can be generated by mutating two regulatory tyrosines to aspartate. When placed into this active c-Raf mutant, mutation of W342 to D, K or H enabled phosphorylation and activation of the c-Raf substrate MEK at the plasma membrane but not in an immunoprecipitation assay. We conclude that (1) Tryptophan has a different role in the WEI regions of c-Raf and Hck, (2) W342 is not directly involved in MEK binding as both positive and negative residues at 342 are permissive for MEK activation at the membrane in a constitutively active c-Raf mutant, (3) Factors at the membrane are capable of potentiating activation of c-Raf containing mutated W342 in a hyperactivated c-Raf, but not in a wild type c-Raf and (4) There is a stringent structural requirement for W at residue 342 in c-Raf.	Univ Virginia, Hlth Sci Ctr, Dept Clin Pharmacol, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Howard Hughes Med Inst, Charlottesville, VA 22908 USA	University of Virginia; Howard Hughes Medical Institute; University of Virginia	McPherson, RA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Clin Pharmacol, Ctr Cell Signaling, Box 577, Charlottesville, VA 22908 USA.							Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dent P, 1997, CELL SIGNAL, V9, P539, DOI 10.1016/S0898-6568(97)00048-X; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Xia K, 1999, MOL CELL BIOL, V19, P4819; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	25	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3616	3622		10.1038/sj.onc.1203678	http://dx.doi.org/10.1038/sj.onc.1203678			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951567				2022-12-25	WOS:000088568300007
J	Guilherme, A; Emoto, M; Buxton, JM; Bose, S; Sabini, R; Theurkauf, WE; Leszyk, J; Czech, MP				Guilherme, A; Emoto, M; Buxton, JM; Bose, S; Sabini, R; Theurkauf, WE; Leszyk, J; Czech, MP			Perinuclear localization and insulin responsiveness of GLUT4 requires cytoskeletal integrity in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; ISOLATED RAT ADIPOCYTES; PLASMA-MEMBRANE; GLUT4-CONTAINING VESICLES; GOLGI-COMPLEX; CELL-SURFACE; INTERMEDIATE FILAMENTS; DEPENDENT TRAFFICKING; INTRACELLULAR GLUT4; ADIPOSE CONVERSION	The GLUT4 glucose transporter resides mostly in perinuclear membranes in unstimulated 3T3-L1 adipocytes and is acutely translocated to the cell surface in response to insulin. Using a novel method to purify intracellular GLUT4-enriched membranes, we identified by mass spectrometry the intermediate filament protein vimentin and the microtubule protein alpha -tubulin as components of these membranes. Immunoelectron microscopy of the GLUT4-containing membranes also revealed their association with these cytoskeletal proteins, Disruption of intermediate filaments and microtubules in 3T3-L1 adipocytes by microinjection of a vimentin-derived peptide of the helix initiation 1A domain caused marked dispersion of perinuclear GLUT4 to peripheral regions of the cells. Inhibition of the microtubule-based motor dynein by brief cytoplasmic acidification of cultured adipocytes also dispersed perinuclear GLUT4 and inhibited insulin-stimulated GLUT4 translocation to the cell surface. Insulin sensitivity was restored as GLUT4 was again concentrated near the nucleus upon recovery of cells in physiological buffer. These data suggest that GLUT4 trafficking to perinuclear membranes of cultured adipocytes is directed by dynein and is required for optimal GLUT4 regulation by insulin.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.			Sabini, Rosanna/0000-0002-9273-3855; Theurkauf, William/0000-0001-7342-1912	NIDDK NIH HHS [DK30898, DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898, P30DK032520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Lieber JG, 1996, J CELL SCI, V109, P3047; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROGERS SL, 2000, P NATL ACAD SCI USA, V12, P57; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; St-Denis Jean-Francois, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P153; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vaughan KT, 1999, J CELL SCI, V112, P1437; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	66	101	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38151	38159		10.1074/jbc.M003432200	http://dx.doi.org/10.1074/jbc.M003432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10950952	hybrid			2022-12-25	WOS:000165739800005
J	Kadoya, T; Kishida, S; Fukui, A; Hinoi, T; Michiue, T; Asashima, M; Kikuchi, A				Kadoya, T; Kishida, S; Fukui, A; Hinoi, T; Michiue, T; Asashima, M; Kikuchi, A			Inhibition of Wnt signaling pathway by a novel axin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; MOUSE FUSED LOCUS; F-BOX PROTEIN; BETA-CATENIN; NEGATIVE REGULATOR; DIRECTLY INTERACTS; GENE-EXPRESSION; MAMMALIAN-CELLS; XENOPUS EMBRYOS; PHOSPHATASE 2A	Axin forms a complex with adenomatous polyposis coli gene product, glycogen synthase kinase-3 beta (GSK-3 beta), beta -catenin, DvI, and protein phosphatase 2A and functions as a scaffold protein in the Wnt signaling pathway. In the Axin complex, GSK-3 beta efficiently phosphorylates beta -catenin, which is then ubiquitinated and degraded by proteasome. We isolated a novel protein that binds to Axin and named it Axam (for Axin associating molecule). Axam formed a complex with Axin in intact cells and bound directly to Axin. Axam inhibited the complex formation of DvI with Axin and the activity of DvI to suppress GSK-3 beta -dependent phosphorylation of Axin. Furthermore, Axam induced the degradation of beta -catenin in SW480 cells and inhibited Wnt-dependent axis duplication in Xenopus embryos. These results suggest that Axam regulates the Wnt signaling pathway negatively by inhibiting the binding of DvI to Axin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, PRESTO, Hiroshima 7348551, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, CREST Project, Meguro Ku, Tokyo 1538902, Japan	Hiroshima University; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hinoi, Takao/AAI-1443-2020; Fukui, Akimasa/F-5284-2011	Hinoi, Takao/0000-0003-0462-6177; kishida, shosei/0000-0003-0405-851X				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Maniatis T., 1982, MOL CLONING LAB MANU; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; PERRY WL, 1995, GENETICS, V141, P321; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Wagner U, 1997, FEBS LETT, V411, P369, DOI 10.1016/S0014-5793(97)00733-3; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	50	48	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37030	37037		10.1074/jbc.M005984200	http://dx.doi.org/10.1074/jbc.M005984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10944533	hybrid			2022-12-25	WOS:000165577700081
J	Barton, VA; Hall, MA; Hudson, KR; Heath, JK				Barton, VA; Hall, MA; Hudson, KR; Heath, JK			Interleukin-11 signals through the formation of a hexameric receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; BINDING SITES; ONCOSTATIN-M; ALPHA-CHAIN; 2 DISTINCT; GP130; IL-6	Interleukin-11 (IL-11) is a member of the gp130 family of cytokines. These cytokines drive the assembly of multisubunit receptor complexes, all of which contain at least one molecule of the transmembrane signaling receptor gp130. IL-11 has been shown to induce gp130-dependent signaling through the formation of a high affinity complex with the IL-11 receptor (IL-11R) and gp130. Site-directed mutagenesis studies have identified three distinct receptor binding sites of IL-11, which enable it to form this high affinity receptor complex. Here we present data from immunoprecipitation experiments, using differentially tagged forms of ligand and soluble receptor components, which show that multiple copies of IL-11, IL-11R, and gp130 are present in the receptor complex. Furthermore, it is demonstrated that sites II and III of IL-11 are independent gp130 binding epitopes and that both are essential for gp130 dimerization. We also show that a stable high affinity complex of IL-11, IL-11R, and gp130 can be resolved by nondenaturing polyacrylamide gel electrophoresis, and its composition verified by second dimension denaturing polyacrylamide gel electrophoresis. Results indicate that the three receptor binding sites of IL-11 and the Ig-like domain of gp130 are all essential for this stable receptor complex to be formed. We therefore propose that IL-11 forms a hexameric receptor complex composed of two molecules each of IL-11, IL-11R, and gp130.	Univ Birmingham, Sch Biosci, Canc Res Campaign Growth Factor Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Heath, JK (corresponding author), Univ Birmingham, Sch Biosci, Canc Res Campaign Growth Factor Grp, Birmingham B15 2TT, W Midlands, England.	j.k.heath@bham.ac.uk						ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BANK S, 1997, SHOCK, V7, P520; Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bilinski P, 1998, GENE DEV, V12, P2234, DOI 10.1101/gad.12.14.2234; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Harlow E., 1988, ANTIBODIES LAB MANUA; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermann JA, 1998, ARTHRITIS RHEUM, V41, P1388, DOI 10.1002/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Karow J, 1996, BIOCHEM J, V318, P489, DOI 10.1042/bj3180489; Kurth I, 1999, J IMMUNOL, V162, P1480; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Nandurkar HH, 1996, ONCOGENE, V12, P585; Neddermann P, 1996, J BIOL CHEM, V271, P30986, DOI 10.1074/jbc.271.48.30986; Olivier C, 2000, J BIOL CHEM, V275, P5648, DOI 10.1074/jbc.275.8.5648; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SONIS S, 1995, ORAL ONCOL, V31B, P261, DOI 10.1016/0964-1955(95)00015-A; Staunton D, 1998, PROTEIN ENG, V11, P1093, DOI 10.1093/protein/11.11.1093; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Timmermann A, 2000, FEBS LETT, V468, P120, DOI 10.1016/S0014-5793(00)01205-9; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; WANG XY, 1995, J BIOL CHEM, V270, P27999; WARD LD, 1994, J BIOL CHEM, V269, P23286; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1994, J BIOL CHEM, V269, P3731	50	66	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36197	36203		10.1074/jbc.M004648200	http://dx.doi.org/10.1074/jbc.M004648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948192	hybrid			2022-12-25	WOS:000165382000078
J	Zhou, Q; Melkoumian, ZK; Lucktong, A; Moniwa, M; Davie, JR; Strobl, JS				Zhou, Q; Melkoumian, ZK; Lucktong, A; Moniwa, M; Davie, JR; Strobl, JS			Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; INHIBITOR; GROWTH; CYCLE; P53; TRANSFORMATION; PROGRESSION; CARCINOMA	Quinidine inhibits proliferation and promotes cellular differentiation in human breast tumor epithelial cells. Previously we showed quinidine arrested MCF-7 cells in G(1) phase of the cell cycle and led to a G(1) to G(0) transition followed by apoptotic cell death, The present experiments demonstrated that MCF 7, MCF-7ras, T47D, MDA-MB-231, and MDA-MB-435 cells transiently differentiate before undergoing apoptosis in response to quinidine. The cells accumulated lipid droplets, and the cytokeratin 18 cytoskeleton was reorganized, Hyperacetylated histone H4 appeared within 2 h of the addition of quinidine to the medium, and levels Were maximal by 24 h, Quinidine-treated MCF-7 cells showed elevated p21(WAF1) hypophosphorylation and suppression of retinoblastoma protein, and down-regulation of cyclin D1, similar to the cell cycle response observed with cells induced to differentiate by histone deacetylase inhibitors, trichostatin A, and trapoxin. Quinidine did not show evidence for direct inhibition of histone deacetylase enzymatic activity in vitro. HDAC1 was undetectable in MCF-7 cells 30 min after addition of quinidine to the growth medium. The proteasome inhibitors MG-132 and lactacystin completely protected HDAC1 from the action of quinidine. We conclude that quinidine is a breast tumor cell differentiating agent that causes the loss of HDAC1 via a proteasomal sensitive mechanism.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	West Virginia University; University of Manitoba	Strobl, JS (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA.	jstrobl@hsc.wvu.edu		Davie, James/0000-0002-0420-6888				Ameyar M, 1999, ONCOGENE, V18, P5464, DOI 10.1038/sj.onc.1202919; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Davie JR, 1998, J CELL BIOCHEM, P203; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Fuqua SAW, 1999, CANCER RES, V59, P5425; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HALM HA, 1990, IN VITRO CELL DEV, V26, P803; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; ILIEV IG, 1993, CELL MOL BIOL RES, V39, P601; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Jing YK, 1996, DIFFERENTIATION, V60, P109, DOI 10.1046/j.1432-0436.1996.6020109.x; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Klimatcheva E, 1999, J MEMBRANE BIOL, V171, P35, DOI 10.1007/s002329900556; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Medina V, 1997, CANCER RES, V57, P3697; Mehta RR, 2000, INT J ONCOL, V16, P65; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakanishi M, 1999, BIOCHEM BIOPH RES CO, V263, P35, DOI 10.1006/bbrc.1999.1296; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Saunders N, 1999, CANCER RES, V59, P399; Schmidt K, 1999, ARCH PHARM, V332, P353, DOI 10.1002/(SICI)1521-4184(199910)332:10<353::AID-ARDP353>3.0.CO;2-X; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Sowa Y, 1999, CANCER RES, V59, P4266; STAMPFER MR, 1993, CANCER SURV, V18, P7; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Sun JM, 1999, BIOCHEMISTRY-US, V38, P5939, DOI 10.1021/bi982633k; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vladusic EA, 2000, ONCOL REP, V7, P157; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yeola SW, 1996, CIRC RES, V78, P1105, DOI 10.1161/01.RES.78.6.1105; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; ZHANG LS, 1995, CANCER RES, V55, P3890	54	83	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35256	35263		10.1074/jbc.M003106200	http://dx.doi.org/10.1074/jbc.M003106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10938272	hybrid			2022-12-25	WOS:000165422800058
J	Biere, AL; Wood, SJ; Wypych, J; Steavenson, S; Jiang, YJ; Anafi, D; Jacobsen, FW; Jarosinski, MA; Wu, GM; Louis, JC; Martin, F; Narhi, LO; Citron, M				Biere, AL; Wood, SJ; Wypych, J; Steavenson, S; Jiang, YJ; Anafi, D; Jacobsen, FW; Jarosinski, MA; Wu, GM; Louis, JC; Martin, F; Narhi, LO; Citron, M			Parkinson's disease-associated alpha-sylnuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY-BODY-DISEASE; NO PATHOGENIC MUTATIONS; NACP/ALPHA-SYNUCLEIN; IN-VITRO; CYTOPLASMIC INCLUSIONS; GENE; AGGREGATION; DEMENTIA; BODIES	Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies. Recently, two point mutations in alpha -synuclein were found to be associated with familial PD, but as of yet no mutations have been described in the homologous genes beta- and gamma -synuclein. alpha -Synuclein forms the major fibrillar component of Lewy bodies, but these do not stain for beta- or gamma -synuclein. This result is very surprising, given the extent of sequence conservation and the high similarity in expression and subcellular localization, in particular between alpha- and beta -synuclein, Here we compare in vitro fibrillogenesis of all three purified synucleins, We show that fresh solutions of alpha-, beta-, and gamma- synuclein show the same natively unfolded structure. While over time alpha -synuclein forms the previously described fibrils, no fibrils could be defected for beta- and gamma -synuclein under the same conditions. Most importantly, beta- and gamma -synuclein could not be cross-seeded with alpha -synuclein fibrils. How ever, under conditions that drastically accelerate aggregation, gamma -synuclein can form fibrils with a lag phase roughly three times longer than alpha -synuclein. These results indicate that beta- and gamma -synuclein are intrinsically less fibrillogenic than alpha -synuclein and cannot form mixed fibrils with alpha -synuclein, which mag explain why they do not appear in the pathological hallmarks of PD, although they are closely related to alpha -synuclein and are also abundant in brain.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Biere, AL (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Baba M, 1998, AM J PATHOL, V152, P879; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Ji HJ, 1997, CANCER RES, V57, P759; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, GENOMICS, V54, P173, DOI 10.1006/geno.1998.5556; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Lincoln S, 1999, NEUROSCI LETT, V259, P65, DOI 10.1016/S0304-3940(98)00901-X; Lincoln S, 1999, NEUROSCI LETT, V269, P107, DOI 10.1016/S0304-3940(99)00420-6; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	36	142	149	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34574	34579		10.1074/jbc.M005514200	http://dx.doi.org/10.1074/jbc.M005514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942772	hybrid			2022-12-25	WOS:000165095300078
J	Hicks-Berger, CA; Chadwick, BP; Frischauf, AM; Kirley, TL				Hicks-Berger, CA; Chadwick, BP; Frischauf, AM; Kirley, TL			Expression and characterization of soluble and membrane-bound human nucleoside triphosphate diphosphohydrolase 6 (CH39L2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN ECTO-APYRASE; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; FUNCTIONAL EXPRESSION; TRANSVERSE TUBULE; SKELETAL-MUSCLE; PURIFICATION; PROTEINS; GLYCOSYLATION; ATPASES	Ecto-nucleoside-triphosphate diphosphohydrolase-6 (eNTPDase6(1), also known as CD39L2) cDNA was expressed in mammalian COS-1 cells and characterized using nucleotidase assays as well as size exclusion, anion exchange, and cation exchange chromatography. The deduced amino acid sequence of eNTPDase6 is more homologous with the soluble E-type ATPase, eNTPDase5, than other E-type ATPases, suggesting it may also be soluble. To test this possibility, both the cell membranes and the growth media from eNTPDase6-transfected COS-1 cells were assayed for nucleotidase activities. Activity was found in both the membranes and the media. Soluble eNTPDase6 preferentially exhibits nucleoside diphosphatase activity, which is dependent on the presence of divalent cations. Western blot analysis of eNTPDase6 treated with PNGase-F indicated both soluble and membrane-bound forms are glycosylated. However, unlike some membrane-bound ecto-nucleotidases, the eNTPDase6 activity was not specifically inhibited by deglycosylation with peptide N-glycosidase F. Soluble eNTPDase6 hydrolyzed nucleoside triphosphates poorly and nucleoside monophosphates not at all. Analysis of the relative rates of hydrolysis of nucleoside diphosphates (GDP = IDP > UDP > CDP much greater than ADP) suggests that soluble eNTPDase6 is a diphosphatase most likely not involved in regulation of ADP levels important for circulatory hemostasis.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria	University System of Ohio; University of Cincinnati; Case Western Reserve University; Salzburg University	Kirley, TL (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA.			Kirley, Terence/0000-0002-6211-1414; Chadwick, Brian/0000-0001-5272-8384	NHLBI NIH HHS [HL59915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; AMESCH S, 1999, BIOCHEMISTRY-US, V38, P2248; Arca B, 1999, P NATL ACAD SCI USA, V96, P1516, DOI 10.1073/pnas.96.4.1516; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; CORITRAVERSO A, 1970, ARCH BIOCH BIPHYS, V137, P133; Dzhandzhugazyan KN, 2000, BBA-BIOMEMBRANES, V1466, P267, DOI 10.1016/S0005-2736(00)00169-3; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Hicks-Berger CA, 2000, IUBMB LIFE, V50, P43; KIRLEY TL, 1988, J BIOL CHEM, V263, P12682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LewisCarl S, 1997, J BIOL CHEM, V272, P23645, DOI 10.1074/jbc.272.38.23645; Mateo J, 1999, BRIT J PHARMACOL, V128, P396, DOI 10.1038/sj.bjp.0702805; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miles E W, 1977, Methods Enzymol, V47, P431; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; PLESNER L, 1995, INT REV CYTOL, V158, P141; SABORIDO A, 1991, J BIOL CHEM, V266, P23490; SARKIS J, 1986, BIOCHEM J, V223, P885; Smith TM, 1999, BIOCHEMISTRY-US, V38, P1509, DOI 10.1021/bi9821768; Smith TM, 1997, ARCH BIOCHEM BIOPHYS, V337, P351, DOI 10.1006/abbi.1996.9779; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; Smith TM, 1997, ECTO-ATPASES, P135; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	29	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34041	34045		10.1074/jbc.M004723200	http://dx.doi.org/10.1074/jbc.M004723200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10948193	hybrid			2022-12-25	WOS:000165095300008
J	Homma, K; Saito, J; Ikebe, R; Ikebe, M				Homma, K; Saito, J; Ikebe, R; Ikebe, M			Ca2+-dependent regulation of the motor activity of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; UNCONVENTIONAL MYOSINS; CALMODULIN-BINDING; 2-HEADED STRUCTURE; PEPTIDE COMPLEX; I-BETA; CLEAVAGE; KINETICS; BRAIN	Mouse myosin V constructs were produced that consisted of the myosin motor domain plus either one IQ motif (M5IQ1), two IQ motifs (M5IQ2), a complete set of six IQ motifs (SHM5), or the complete IQ motifs plus the coiled-coil domain (thus permitting formation of a double-headed structure,DHM5) and expressed in Sf9 cells. The actin-activated ATPase activity of all constructs except M5IQ1 was inhibited above pCa 5, but: this inhibition was completely reversed by addition of exogenous calmodulin, At the same Ca2+ concentration, 2 mol of calmodulin from SHM5 and DHM5 or 1 mol of calmodulin from M5IQ2 were dissociated, suggesting that the inhibition of the ATPase activity is due to dissociation of calmodulin from the heavy chain. However, the motility activity of DRM5 and M5IQ2 was completely inhibited at pCa 6, where no dissociation of calmodulin was detected. inhibition of the motility activity was not reversed by the addition of exogenous calmodulin. These results indicate that inhibition of the motility is due to conformational changes of calmodulin upon the Ca2+ binding to the high affinity site but is not due to dissociation of calmodulin from the heavy chain.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60381] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPINDOLA FS, 1996, MOL BIOL CELL, V7, P372; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; WHITE HD, 1993, J BIOL CHEM, V268, P10039; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	35	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34766	34771		10.1074/jbc.M003132200	http://dx.doi.org/10.1074/jbc.M003132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945977	hybrid			2022-12-25	WOS:000165095300102
J	Nagao, Y; Kitada, S; Kojima, K; Toh, H; Kuhara, S; Ogishima, T; Ito, A				Nagao, Y; Kitada, S; Kojima, K; Toh, H; Kuhara, S; Ogishima, T; Ito, A			Glycine-rich region of mitochondrial processing peptidase alpha-subunit is essential for binding and cleavage of the precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; BOVINE HEART-MITOCHONDRIA; RAT-LIVER; BETA-SUBUNIT; YEAST MITOCHONDRIA; SUBSTRATE RECOGNITION; SYNTHETIC PEPTIDE; PROTEASE; MATRIX; RESIDUES	Mitochondrial processing peptidase, a metalloendopeptidase consisting of alpha- and B -subunits, specifically recognizes a large variety of mitochondrial precursor proteins and cleaves off amino-terminal extension peptides. The alpha -subunit has a characteristic glycine-rich segment in the middle portion. To elucidate the role of the region in processing functions of the enzyme, deletion or site-directed mutations were introduced, and effects on kinetic parameters and substrate binding of the enzyme were analyzed. Deletion of three residues of the region, Phe(289) to Ala(291), led to a dramatic reduction in processing activity to practically zero. Mutation of Phe(289), Lys(296), and Met(298) to alanine resulted in a decrease in the activity, but these mutations had no apparent effect on interactions between the two subunits, indicating that reduction in processing activity is not due to structural disruption at the interface interacting with the beta -subunit, Although the mutant enzymes, Phe289Ala, Lys296Ala, and Met298Ala, had an approximate 10-fold less affinity for substrate peptides than did that of the wild type, the deletion mutant, Delta 289-291, showed an extremely low affinity. Thus, shortening of the glycine-rich stretch led to a dramatic reduction of interaction between the enzyme and substrate peptides and cleavage reaction, whereas mutation of each amino acid in this region seemed to affect primarily the cleavage reaction.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Genet Resources Technol, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.	a.itoscc@mbox.nc.kyushu-u.ac.jp						ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; Deng KP, 1998, J BIOL CHEM, V273, P20752, DOI 10.1074/jbc.273.33.20752; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; Luciano P, 1997, J MOL BIOL, V272, P213, DOI 10.1006/jmbi.1997.1231; MIURA S, 1986, BIOCHEM BIOPH RES CO, V134, P1151, DOI 10.1016/0006-291X(86)90371-2; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; ROHLEN DA, 1991, FEBS LETT, V278, P75, DOI 10.1016/0014-5793(91)80087-J; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Song MC, 1998, J BIOCHEM, V124, P1045, DOI 10.1093/oxfordjournals.jbchem.a022198; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	43	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34552	34556		10.1074/jbc.M003110200	http://dx.doi.org/10.1074/jbc.M003110200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942759	hybrid			2022-12-25	WOS:000165095300075
J	Draganov, DI; Stetson, PL; Watson, CE; Billecke, SS; La Du, BN				Draganov, DI; Stetson, PL; Watson, CE; Billecke, SS; La Du, BN			Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-LIPOPROTEINS; IDENTIFICATION; ARYLESTERASE; DISPOSITION; LOVASTATIN; SEQUENCE; ENZYMES; FAMILY; LIVER	The paraoxonase gene family contains at least three members: PON1, PON2, and PON3, The physiological roles of the corresponding gene products are still uncertain. Until recently, only the serum paraoxonase/arylesterase (PON1) had been purified and characterized. Here we report the purification, cloning, and characterization of rabbit serum PON3, PON3 is a 40-kDa protein associated with the high density lipoprotein fraction of serum. In contrast to PON1, PON3 has very limited arylesterase and no paraoxonase activities but rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin), These differences facilitated the complete separation of PON3 from PON1 during purification. PON3 hydrolyzes aromatic lactones and 5- or 6-member ring lactones with aliphatic substituents but not simple lactones or those with polar substituents. We cloned PON3 from total rabbit liver RNA and expressed it in mammalian 293T/17 cells, The recombinant PON3 has the same apparent molecular mass and substrate specificity as the enzyme purified from serum. Rabbit serum PON3 is more efficient than rabbit PON1 in protecting low density lipoprotein from copper-induced oxidation, This is the first report that identifies a second PON enzyme in mammalian serum and the first to describe an enzymatic activity for PON3.	Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Mil Med Acad, Lab Expt Toxicol, Sofia 1606, Bulgaria	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Military Medical Academy Sofia	Draganov, DI (corresponding author), Univ Michigan, Dept Anesthesiol, 7422 Med Sci 1 Bldg,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.							Aviram M, 1999, MOL MED TODAY, V5, P381, DOI 10.1016/S1357-4310(99)01546-4; Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BILLECKE S, 2000, IN PRESS DRUG METAB, V28; Billecke SS, 1999, FASEB J, V13, pA1013; Billecke SS, 1999, CHEM-BIOL INTERACT, V119, P251, DOI 10.1016/S0009-2797(99)00034-4; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; Doorn JA, 1999, CHEM-BIOL INTERACT, V119, P235, DOI 10.1016/S0009-2797(99)00032-0; DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Granjeaud S, 1999, IMMUNOGENETICS, V49, P964, DOI 10.1007/s002510050580; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Hatch F T, 1968, Adv Lipid Res, V6, P1; Josse D, 1999, CHEM-BIOL INTERACT, V119, P79, DOI 10.1016/S0009-2797(99)00016-2; Josse D, 1999, BIOCHEMISTRY-US, V38, P2816, DOI 10.1021/bi982281h; KANAGASUNDARAM V, 1992, BIOCHIM BIOPHYS ACTA, V1171, P198, DOI 10.1016/0167-4781(92)90120-O; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P284; KIEFT KA, 1991, J LIPID RES, V32, P859; Kobayashi M, 1998, P NATL ACAD SCI USA, V95, P12787, DOI 10.1073/pnas.95.22.12787; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P599, DOI 10.1016/S0009-2797(99)00075-7; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P379, DOI 10.1016/S0009-2797(99)00049-6; La Du BN, 1992, PHARMACOGENETICS DRU, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; Navab M, 1998, CURR OPIN LIPIDOL, V9, P449, DOI 10.1097/00041433-199810000-00009; Ozols J, 1999, BIOCHEM J, V338, P265, DOI 10.1042/0264-6021:3380265; PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; TANG BK, 1995, EUR J CLIN PHARMACOL, V47, P449; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VICKERS S, 1990, DRUG METAB DISPOS, V18, P138; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	40	254	269	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33435	33442		10.1074/jbc.M004543200	http://dx.doi.org/10.1074/jbc.M004543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931838	hybrid			2022-12-25	WOS:000090104600037
J	Oppegard, LM; Kabb, AL; Connell, GJ				Oppegard, LM; Kabb, AL; Connell, GJ			Activation of guide RNA-directed editing of a cytochrome b mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI MITOCHONDRIA; LEISHMANIA-TARENTOLAE; URIDINE INSERTION; MESSENGER-RNAS; IN-VITRO; TRANSCRIPTS; COMPLEXES; MECHANISM	The coding sequence of several mitochondrial mRNAs of the kinetoplastid protozoa is created only after the addition or deletion of specific uridines. Although in vitro systems have been valuable in characterizing the editing mechanism, only a limited number of mRNAs are accurately edited in vitro. We demonstrate here that in vitro editing of cytochrome b mRNA is inhibited by an A-U sequence present on both the 5'-untranslated sequence and on a cytochrome b guide RNA. Mutation of the sequence on the guide RNA stimulates directed editing and results in the loss of binding to at least one component within the editing extract. Mutation of the sequence on the mRNA increases the accuracy of the editing. Evidence is provided that suggests the A-U sequence interacts with the editing machinery both in vitro and in vivo.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Connell, GJ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	gconnell@lenti.med.umn.edu			NIAID NIH HHS [R29-AI41138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Brown LM, 1999, J BIOL CHEM, V274, P6295, DOI 10.1074/jbc.274.10.6295; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Connell GJ, 1997, J BIOL CHEM, V272, P4212, DOI 10.1074/jbc.272.7.4212; Cruz-Reyes J, 1998, NUCLEIC ACIDS RES, V26, P3634, DOI 10.1093/nar/26.16.3634; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Piller KJ, 1997, RNA, V3, P279; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8	23	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33911	33919		10.1074/jbc.M003002200	http://dx.doi.org/10.1074/jbc.M003002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940300	hybrid			2022-12-25	WOS:000090104600101
J	Pasolli, HA; Klemke, M; Kehlenbach, RH; Wang, YZ; Huttner, WB				Pasolli, HA; Klemke, M; Kehlenbach, RH; Wang, YZ; Huttner, WB			Characterization of the extra-large G protein alpha-subunit XL alpha s - I. Tissue distribution and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY VESICLES; SIGNAL-TRANSDUCTION; SECRETOGRANIN-I; CHROMOGRANIN-B; RECEPTOR; CELLS; EXPRESSION; GENE; MEMBRANE; GRANULES	Our group previously described a new type of G protein, the 78-kDa XL alphas (extra large as) (Kehlenbach, R. H., Matthey, J., and Huttner, W. B. (1994) Nature 372, 804-809 and (1995) Nature 375, 253). Upon subcellular fractionation, XLas labeled by ADP-ribosylation with cholera toxin was previously mainly detected in the bottom fractions of a velocity sucrose gradient that contained trans-Golgi network and was differentially distributed to G alphas, which also peaked in the top fractions containing plasma membrane. Here, we investigate, using a new antibody specific for the XL domain, the tissue distribution and subcellular localization of XL alphas and novel splice variants referred to as XLN1. Upon immunoblotting and immunofluorescence analysis of various adult rat tissues, XLas and XLN1 were found to be enriched in neuroendocrine tissues, with a particularly high level of expression in the pituitary, By both immunofluorescence and immunogold electron microscopy, endogenous as well as transfected XL alphas and XLN1 were found to be predominantly associated with the plasma membrane, with only little immunoreactivity on internal, perinuclear membranes. Upon subcellular fractionation, immunoreactive XL alphas behaved similarly to G alphas but was differentially distributed to ADP-ribosylated XL alphas. Moreover, the bottom fractions of the velocity sucrose gradient were found to contain not only trans-Golgi network membranes but also certain subdomains of the plasma membrane, which reconciles the present with the previous observations. To further investigate the molecular basis of the association of XL alphas with the plasma membrane, chimeric proteins consisting of the YL domain or portions thereof fused to green fluorescent protein were analyzed by fluorescence and subcellular fractionation, In both neuroendocrine and non-neuroendocrine cells, a fusion protein containing the entire XL domain, in contrast to one containing only the proline-rich and cysteine-rich regions, was exclusively localized at the plasma membrane. We conclude that the physiological role of XL alphas is at the plasma membrane, where it presumably is involved in signal transduction processes characteristic of neuroendocrine cells.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Ruprecht Karls University Heidelberg; Max Planck Society	Huttner, WB (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Huttner, Wieland B./P-4080-2018; Wang, Yanzhuang/AAE-5299-2019	Wang, Yanzhuang/0000-0002-1864-7094; Pasolli, Hilda Amalia/0000-0003-3899-3530; Kehlenbach, Ralph/0000-0003-4920-9916				AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD JA, 1993, J BIOL CHEM, V268, P9879; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; KEHLENBACH RH, 1995, NATURE, V375, P253, DOI 10.1038/375253b0; KEHLENBACH RH, 1994, NATURE, V372, P804; Klemke M, 2000, J BIOL CHEM, V275, P33633, DOI 10.1074/jbc.M006594200; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; Rodbell M, 1997, ADV ENZYME REGUL, V37, P427, DOI 10.1016/S0065-2571(96)00020-9; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; Weinstein LS, 1999, TRENDS ENDOCRIN MET, V10, P81, DOI 10.1016/S1043-2760(98)00124-6; Xie W.Q., 1991, BIOTECHNIQUES, V11, P326	32	88	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33622	33632		10.1074/jbc.M001335200	http://dx.doi.org/10.1074/jbc.M001335200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931823	hybrid			2022-12-25	WOS:000090104600063
J	Chong, NW; Bernard, M; Klein, DC				Chong, NW; Bernard, M; Klein, DC			Characterization of the chicken serotonin N-acetyltransferase gene - Activation via clock gene heterodimer/e box interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCADIAN CLOCK; PINEAL-GLAND; TRANSCRIPTION FACTOR; MELATONIN SYNTHESIS; MESSENGER-RNA; RETINA; EXPRESSION; PROTEIN; RHYTHMS; LOOP	The abundance of serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) mRNA in the chicken pineal gland exhibits a circadian rhythm, which is translated into a circadian rhythm in melatonin production. Here we have started to elucidate the molecular basis of the circadian rhythm in chicken AANAT (cAANAT), The 5'-flanking region of the cAANAT gene was isolated and found to contain an E box DNA element that confers strong luciferase reporter activity. In transfection experiments using chicken pineal cells, an E box mutation dramatically decreased reporter activity. Northern blot analysis indicated that several putative clock genes (bmal1, Clock, and MOP4) are co-expressed in the chicken pineal gland. bmal1 mRNA is expressed in a rhythmic manner in the chicken pineal gland, with peak levels at early subjective night, coincident with the increase in cAANAT expression. Co-transfection experiments in COS cells demonstrated that chicken BMAL1/CLOCK and human BMAL1/MOP4 heterodimers bound the AANAT E box element and enhanced transcription. These observations suggest that binding of clock gene heterodimers to the cAANAT E box is a critical element in the expression of the cAANAT gene in vitro.	NICHD, Sect Neuroendocrinol, Lab Dev Neurobiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Klein, DC (corresponding author), NICHD, Sect Neuroendocrinol, Lab Dev Neurobiol, NIH, Bldg 49,Rm 6A80, Bethesda, MD 20892 USA.	Klein@helix.nih.gov		Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000095, ZIAHD000095] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arendt J., 1995, MELATONIN MAMMALIAN; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; BARRETT RK, 1995, J NEUROSCI, V15, P5681; BARTNESS TJ, 1989, EXPERIENTIA, V45, P939, DOI 10.1007/BF01953051; Begay V, 1998, ENDOCRINOLOGY, V139, P905, DOI 10.1210/en.139.3.905; Bernard M, 1997, J NEUROCHEM, V68, P213; Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304; BINKLEY S, 1988, PINEAL ENDOCRINE NEU; BINKLEY SA, 1978, SCIENCE, V202, P1198, DOI 10.1126/science.214852; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Cahill GM, 1997, BIOL SIGNAL, V6, P191; Cahill GM, 1996, BRAIN RES, V708, P177, DOI 10.1016/0006-8993(95)01365-2; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; CHEN W, 2000, IN PRESS MOL BRAIN R; Chong NW, 1998, MOL BRAIN RES, V61, P243, DOI 10.1016/S0169-328X(98)00219-8; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Falcon J, 1999, PROG NEUROBIOL, V58, P121, DOI 10.1016/S0301-0082(98)00078-1; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GREEN CB, 1994, J NEUROCHEM, V62, P2420; Green CB, 1998, TRENDS CELL BIOL, V8, P342, DOI 10.1016/S0962-8924(98)01338-5; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Iuvone PM, 1996, RETINAL DEGENERATION AND REGENERATION, P3; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1998, HDB BEHAV STATE CONT, V4, P45; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Larkin P, 1999, MOL BRAIN RES, V70, P253, DOI 10.1016/S0169-328X(99)00154-0; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; Mani SS, 1999, J BIOL CHEM, V274, P15590, DOI 10.1074/jbc.274.22.15590; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Namihira M, 1999, NEUROSCI LETT, V271, P1, DOI 10.1016/S0304-3940(99)00407-3; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1980, P NATL ACAD SCI-BIOL, V77, P2319, DOI 10.1073/pnas.77.4.2319; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; UNDERWOOD H, 1989, EXPERIENTIA, V45, P914, DOI 10.1007/BF01953048; Wada-Kiyama Y, 1999, FEBS LETT, V444, P117, DOI 10.1016/S0014-5793(99)00041-1; WADAKIYAMA Y, 1995, J BIOL CHEM, V270, P12439, DOI 10.1074/jbc.270.21.12439; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zatz M, 1996, SEMIN CELL DEV BIOL, V7, P811, DOI 10.1006/scdb.1996.0099; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	66	124	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32991	32998		10.1074/jbc.M005671200	http://dx.doi.org/10.1074/jbc.M005671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931848	hybrid			2022-12-25	WOS:000090003800084
J	Dana, RR; Eigsti, C; Holmes, KL; Leto, TL				Dana, RR; Eigsti, C; Holmes, KL; Leto, TL			A regulatory role for ADP-ribosylation factor 6 (ARF6) in activation of the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; GTP-BINDING-PROTEIN; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; MAMMALIAN-CELLS; OXIDATIVE BURST; HL-60 CELLS; TRANSLOCATION; INVOLVEMENT; REQUIREMENT	In activated neutrophils NADPH oxidase is regulated through various signaling intermediates, including heterotrimeric G proteins, kinases, GTPases, and phospholipases, ADP-ribosylation factor (ARF) describes a family of GTPases associated with phospholipase D (PLD) activation. PLD is implicated in NADPH oxidase activation, although it is unclear whether activation of PLD by ARF is linked to receptor-mediated oxidase activation. We explored whether ARF participates in NADPH oxidase activation by formyl-methionine-leucine-phenylalanine (fMLP) and whether this involves PLD. Using multicolor forward angle light scattering analyses to measure superoxide production in differentiated neutrophil-like PLB-985 cells, we tested enhanced green fluorescent fusion proteins of wild-type ARF1 or ARF6, or their mutant counterparts. The ARF6(Q67L) mutant defective in GTP hydrolysis caused increased superoxide production, whereas the ARF6(T27N) mutant defective in GTP binding caused diminished responses to fMLP. The ARF1 mutants had no effect on fMLP responses, and none of the ARF proteins affected phorbol 12-myristate 13-acetate-elicited oxidase activity. PLD inhibitors 1-butanol and 2,3-diphosphoglycerate, or the ARF6(N48R) mutant assumed to be defective in PLD activation, blocked fMLP-elicited oxidase activity in transfected cells. The data suggest that ARF6 but not ARF1 modulates receptor-mediated NADPH oxidase activation in a PLD-dependent mechanism. Because PMA-elicited NADPH oxidase activation also appears to be PLD-dependent, but ARF-independent, ARF6 and protein kinase C may act through distinct pathways, both involving PLD.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIAID, Flow Cytometry Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, Z01AI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KANAHO Y, 1993, J BIOL CHEM, V268, P12492; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; Kusner DJ, 1996, J EXP MED, V184, P585, DOI 10.1084/jem.184.2.585; Leto TL., 1999, INFLAMMATION BASIC P, P769; MALY FE, 1994, J BIOL CHEM, V269, P18743; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Model MA, 1997, J IMMUNOL METHODS, V202, P105, DOI 10.1016/S0022-1759(96)00241-4; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Serrander L, 1996, INFLAMMATION, V20, P439, DOI 10.1007/BF01486745; Shome K, 2000, ENDOCRINOLOGY, V141, P2200, DOI 10.1210/en.141.6.2200; Shome K, 1998, J BIOL CHEM, V273, P30836, DOI 10.1074/jbc.273.46.30836; Song J, 1998, J CELL SCI, V111, P2257; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vasudevan C, 1998, J CELL SCI, V111, P1277; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	41	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32566	32571		10.1074/jbc.M005406200	http://dx.doi.org/10.1074/jbc.M005406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10931844	hybrid			2022-12-25	WOS:000090003800027
J	Sitte, N; Huber, M; Grune, T; Ladhoff, A; Doecke, WD; Von Zglinicki, T; Davies, KJA				Sitte, N; Huber, M; Grune, T; Ladhoff, A; Doecke, WD; Von Zglinicki, T; Davies, KJA			Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts	FASEB JOURNAL			English	Article						ceroid pigment; protein turnover; lysosome; oxidative stress; free radicals	MULTICATALYTIC PROTEINASE COMPLEX; OXIDATIVE STRESS; OXIDIZED PROTEINS; AMBIENT OXYGEN; CELLS; ACCUMULATION; DEGRADATION; LIPOFUSCINOGENESIS; PROTEOLYSIS; BRAIN	We have studied the effects of hyperoxia and of cell loading with artificial lipofuscin or ceroid pigment on the postmitotic aging of human lung fibroblast cell cultures. Normobaric hyperoxia (40% oxygen) caused an irreversible senescence-like growth arrest after about 4 wk and shortened postmitotic life span from 1-1/2 years down to 3 months, During the first 8 wk of hyperoxria-induced 'aging', overall protein degradation (breakdown of [S-35]methionine metabolically radiolabeled cell proteins increased somewhat, but by 12 wk and thereafter overall proteolysis was significantly depressed, in contrast, protein synthesis rates were unaffected by 12 wk of hyperoxia. Lysosomal cathepsin-specific activity (using the fluorogenic substrate z-FR-MCA) and cytoplasmic proteasome-specific activity (measured with suc-LLVY-MCA) both declined by 80% or more over 12 wk. Hyperoxia also caused a remarkable increase iu lipofuscin/ceroid formation and accumulation over 12 wk, as judged by both fluorescence measurements and FACscan methods. To test whether the association between lipofuscin/ceroid accumulation and decreased proteolysis might be causal, we next exposed cells to lipofuscin/ceroid loading under normoxic conditions. Lipofuscin/ceroid-loaded cells indeed exhibited a gradual decrease in overall protein degradation over 4 wk of treatment, whereas protein synthesis was unaffected. Proteasome specific activity decreased by 25% over this period, which is important since proteasome is normally responsible for degrading oxidized cell proteins. In contrast, an apparent increase in lysosomal cathepsin activity was actually caused by a large increase in the number of lysosomes per cell. To test whether Lipofuscin/ceroid could in fact directly inhibit proteasome activity, thus causing oxidized proteins to accumulate, we incubated purified proteasome with lipofuscin/ceroid preparations in vitro. We found that proteasome is directly inhibited by lipofuscin/ceroid. Our results indicate that an accumulation of oxidized proteins land lipids) such as lipofuscin/ceroid may actually cause further increases in damage accumulation during aging by inhibiting the proteasome.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Humboldt Univ, Inst Pathol, Bereich Med Charite, Berlin, Germany; Humboldt Univ, Clin Phys Med & Rehabil, Bereich Med Charite, Berlin, Germany; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003; von Zglinicki, Thomas/0000-0002-5939-0248; Grune, Tilman/0000-0003-4775-9973	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R23ES003598, R56ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BRUNK U, 1988, APMIS, V96, P3, DOI 10.1111/j.1699-0463.1988.tb05261.x; BRUNK UT, 1992, MUTAT RES, V275, P395, DOI 10.1016/0921-8734(92)90042-N; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P195, DOI 10.1006/abbi.1995.1359; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GAO GX, 1994, MECH AGEING DEV, V73, P79, DOI 10.1016/0047-6374(94)90040-X; GILLE JJP, 1992, MUTAT RES, V275, P405, DOI 10.1016/0921-8734(92)90043-O; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; IVY GO, 1991, MECH AGEING DEV, V57, P213, DOI 10.1016/0047-6374(91)90048-5; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MARZABADI MR, 1991, APMIS, V99, P416, DOI 10.1111/j.1699-0463.1991.tb05170.x; Nakano M, 1995, GERONTOLOGY, V41, P69; Nilsson E, 1997, MECH AGEING DEV, V99, P61, DOI 10.1016/S0047-6374(97)00091-2; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SOHAL RS, 1989, FREE RADICAL BIO MED, V6, P23, DOI 10.1016/0891-5849(89)90155-X; SOHAL RS, 1986, ADV FREE RADICAL BIO, V2, P117, DOI 10.1016/S8755-9668(86)80026-6; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STREHLER BERNARD L., 1964, ADVANCE GERONTOL RES, V1, P343; vonZglinicki T, 1995, GERONTOLOGY, V41, P95; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; VONZGLINICKI T, 1993, Z GERONTOL, V26, P215	40	270	277	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1490	1498		10.1096/fj.14.11.1490	http://dx.doi.org/10.1096/fj.14.11.1490			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928983				2022-12-25	WOS:000088627800003
J	Iwaki, S; Tamura, N; Kimura-Someya, T; Nada, S; Yamaguchi, A				Iwaki, S; Tamura, N; Kimura-Someya, T; Nada, S; Yamaguchi, A			Cysteine-scanning mutagenesis of transmembrane segments 4 and 5 of the Tn10-encoded metal tetracycline/H+ antiporter reveals a permeability barrier in the middle of a transmembrane water-filled channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT PROTEIN; SITE-DIRECTED MUTAGENESIS; DUAL AMBER METHOD; ESCHERICHIA-COLI; LACTOSE PERMEASE; ACTIVE EFFLUX; RESISTANCE PROTEIN; SEQUENCE MOTIF; TOPOLOGY; RESIDUES	Cysteine-scanning mutants as to putative transmembrane segments 4 and 5 and the flanking regions of Tn10-encoded metal-tetracycline/H+ antiporter (TetA (B)) were constructed. All mutants were normally expressed, Among the 57 mutants (L99C to I155C), nine conserved arginine-, aspartate-, and glycine-replaced ones exhibited greatly reduced tetracycline resistance and almost no transport activity, and five conserved glycine- and proline-replaced mutants exhibited greatly reduced tetracycline transport activity in inverted membrane vesicles despite their high or moderate drug resistance. All other cysteine-scanning mutants retained normal drug resistance and normal tetracycline transport activity except for the L142C and I143C mutants. The transmembrane (TM) regions TM4 and TM5 were determined to comprise 20 amino acid residues, Leu-99 to Ile-118, and 17 amino acid residues, Ala-136 to Ala-152, respectively, on the basis of N-[C-14]ethylmaleimide ([C-14]NEM) reactivity, The NEM reactivity patterns of the TM4 and TM5 mutants were quite different from each other. TM4 could be divided into two halves, that is, a NEM nonreactive periplasmic half and a periodically reactive cytoplasmic half, indicating that TM4 is tilted toward a water-filled transmembrane channel and that only its cytoplasmic half faces the channel. On the other hand, NEM-reactive mutations were observed periodically (every two residues) along the whole length of TM5, A permeability barrier for a membrane-impermeable sulfhydryl reagent, 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, was present in the middle of TM5 between Leu-142 and Gly-145, whereas all the NEM-reactive mutants as to TM4 were not accessible to 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, indicating that the channel-facing side of TM4 is located inside the permeability barrier. Tetracycline protected the G141C mutant from the NEM binding, whereas the other mutants in TM4 and TM5 were not protected by tetracycline.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST); Osaka University	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				COPUE JJ, 1993, EMBO J, V12, P631; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; ECKERT B, 1989, J BIOL CHEM, V264, P11663; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; HANSEN LM, 1993, ANTIMICROB AGENTS CH, V37, P2699, DOI 10.1128/AAC.37.12.2699; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; HashimotoGotoh T, 1995, GENE, V167, P333, DOI 10.1016/0378-1119(95)00705-9; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; Kimura T, 1998, BIOCHEMISTRY-US, V37, P5475, DOI 10.1021/bi973188g; Kimura T, 1997, J BIOL CHEM, V272, P580; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Konishi S, 1999, FEBS LETT, V461, P315, DOI 10.1016/S0014-5793(99)01490-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MENEZES ME, 1990, P NATL ACAD SCI USA, V87, P1638, DOI 10.1073/pnas.87.5.1638; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; TERCERO JA, 1993, EUR J BIOCHEM, V218, P963, DOI 10.1111/j.1432-1033.1993.tb18454.x; Varela MF, 1995, MOL MEMBR BIOL, V12, P313, DOI 10.3109/09687689509072433; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	39	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22704	22712		10.1074/jbc.M910354199	http://dx.doi.org/10.1074/jbc.M910354199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930423	hybrid			2022-12-25	WOS:000088419400017
J	Muimo, R; Hornickova, Z; Riemen, CE; Gerke, V; Matthews, H; Mehta, A				Muimo, R; Hornickova, Z; Riemen, CE; Gerke, V; Matthews, H; Mehta, A			Histidine phosphorylation of annexin I in airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; LIPOCORTIN-I; PHOSPHOLIPID-BINDING; CALCIUM-BINDING; CROSS-LINKING; PROTEIN; AGGREGATION; ACTIVATION; CELLS; ENHANCEMENT	Although [C1(-)](i) regulates many cellular functions including cell secretion, the mechanisms governing these actions are not known. me have previously shown that the apical membrane of airway epithelium contains a 37-kDa phosphoprotein (p37) whose phosphorylation is regulated by chloride concentration. Using metal affinity (chelating Fe3+-Sepharose) and anion exchange (POROS HQ 20) chromatography, we have purified p37 from ovine tracheal epithelia to electrophoretic homogeneity. Sequence analysis and immunoprecipitation using monoclonal and specific polyclonal antibodies identified p37 as annexin I, a member of a family of Ca2+-dependent phospholipid-binding proteins. Phosphate on [P-32]annexin I, phosphorylated using both [gamma-P-32]ATP and [gamma-P-32]GTP, was labile under acidic but not alkaline conditions. Phosphoamino acid analysis showed the presence of phosphohistidine. The site of phosphorylation was localized to a carboxyl-terminal fragment of annexin I. Our data suggest that cAMP andAMP (but not cGMP) may regulate annexin I histidine phosphorylation. me propose a role for annexin I in an intracellular signaling system involving histidine phosphorylation.	Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Munster, Inst Med Biochem, D-48149 Munster, Germany	University of Dundee; University of California System; University of California Davis; University of Munster	Muimo, R (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland.	r.muimo@dundee.ac.uk						AmsterChoder O, 1997, J BACTERIOL, V179, P5621, DOI 10.1128/jb.179.17.5621-5624.1997; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; ANDO Y, 1989, BIOCHEM BIOPH RES CO, V163, P944, DOI 10.1016/0006-291X(89)92313-9; ANDO Y, 1991, J BIOL CHEM, V266, P1101; ANDO Y, 1989, J BIOL CHEM, V264, P6948; Brown JM, 1998, CURR BIOL, V8, pR662, DOI 10.1016/S0960-9822(07)00417-4; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CHAP H, 1991, M S-MED SCI, V7, P8, DOI 10.4267/10608/4270; CHUAH SY, 1989, J BIOL CHEM, V264, P21160; Cohen BE, 1995, FEBS LETT, V377, P444, DOI 10.1016/0014-5793(95)01395-4; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; CORBIN JD, 1985, J BIOL CHEM, V260, P8731; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fuhrmann M, 1999, AM J RESP CELL MOL, V20, P292, DOI 10.1165/ajrcmb.20.2.3140; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HAYES JD, 1989, BIOCHEM J, V264, P437, DOI 10.1042/bj2640437; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; Jorgensen AJ, 1997, PFLUG ARCH EUR J PHY, V434, P261; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Marshall LJ, 1999, AM J PHYSIOL-CELL PH, V276, pC109, DOI 10.1152/ajpcell.1999.276.1.C109; Mizuno T, 1998, J BIOCHEM, V123, P555; Muimo R, 1998, AM J RESP CELL MOL, V18, P270, DOI 10.1165/ajrcmb.18.2.2850; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REGNOUF F, 1995, J BIOL CHEM, V270, P27143, DOI 10.1074/jbc.270.45.27143; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; Seemann J, 1997, FEBS LETT, V413, P185, DOI 10.1016/S0014-5793(97)00911-3; Seemann J, 1996, MOL BIOL CELL, V7, P1359, DOI 10.1091/mbc.7.9.1359; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEI W, 1992, BIOCHEMISTRY-US, V31, P9934, DOI 10.1021/bi00156a011; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WENG XW, 1993, PROTEIN SCI, V2, P448; WIELAND T, 1993, J BIOL CHEM, V268, P18111	47	74	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36632	36636		10.1074/jbc.M000829200	http://dx.doi.org/10.1074/jbc.M000829200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956639	hybrid			2022-12-25	WOS:000165577700026
J	De Leo, R; Miccadei, S; Zammarchi, E; Civitareale, D				De Leo, R; Miccadei, S; Zammarchi, E; Civitareale, D			Role for p300 in Pax 8 induction of thyroperoxidase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATORS; BINDING PROTEINS; THYROID-GLAND; CYCLIC-AMP; CBP; DIFFERENTIATION; E1A; MECHANISMS; PROMOTER; ENHANCER	The nuclear p300 protein functions as a co-activator of gene transcription. Here we show that p300 works as a ca-activator of the transcription factor Pax 8 on the thyroperoxidase gene promoter. Consistent with its role as co-activator, p300 potentiates Pax 8-activated transcription. Furthermore, we provide evidence supporting the formation of a complex between both factors in vitro and in vitro. This interaction involves the aminoterminal and CH3 domains of p300 and the trans-activation domain of Pax 8 at its carboxyl-terminal end. We show that the CH3 domain is crucial for the co-activator role of p300 on the thyroperoxidase gene promoter. In agreement with our finding and with the ability of the adenoviral protein E1A to bind p300, we show that EIA down-regulates Pax 8 activity.	Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; Univ Florence, Dept Pediat, Meyer Hosp, I-50100 Florence, Italy; CNR, Inst Expt Med, I-00100 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Consiglio Nazionale delle Ricerche (CNR)	Civitareale, D (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, Via Messi Oro 156, I-00158 Rome, Italy.	dciv@yahoo.com	Civitareale, Donato/B-4889-2015; , stefaniamiccadei/J-2640-2017	Civitareale, Donato/0000-0001-5719-9098; , stefaniamiccadei/0000-0001-8890-6998	Telethon [E.0254] Funding Source: Medline	Telethon(Fondazione Telethon)		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 1999, CANCER RES, V59, p1716S; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PASCA M, 1997, J ENDOCRINOL INVE S5, V20, P1; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Taurog A., 1996, WERNER INGBARS THYRO, V7th, P47; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34100	34105		10.1074/jbc.M003043200	http://dx.doi.org/10.1074/jbc.M003043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10924503	hybrid			2022-12-25	WOS:000165095300017
J	Read, EK; Gumport, RI; Gardner, JF				Read, EK; Gumport, RI; Gardner, JF			Specific recognition of DNA by integration host factor - Glutamic acid 44 of the beta-subunit specifies the discrimination of a T : A from an A : T base pair without directly contacting the DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITES; FACTOR IHF; PROTEIN; DEFICIENT; MUTANTS; MU	Integration host factor (IHF) is a protein that binds to the H' site of bacteriophage lambda with sequence specificity. Genetic experiments implicated amino acid residue Glu(44) of the beta -subunit of HH in discrimination against substitution of A for T at position 44 of the TTR submotif of the binding site (Lee, E, C,, Hales, L, M,, Gumport, R, I., Gardner, J, F, (1992) EMBO J,, 11, 305-313), We have extended this observation by generating all possible single-base substitutions at positions 43, 44, and 45 of the H' site. IHF failed to bind these H' site substitution mutants in vivo. The K-d(app) value for each H' site substitution, except for H'45A mutant, was reduced >2000-fold relative to the wild-type site. Substitution of amino acid beta -Glu(44) with alanine prevented IHF from discriminating against the H'44A variant but not the other H' site substitution mutants. Further analysis with other substitutions at position beta 44 demonstrated that both oxygens of the wild-type glutamic acid are necessary for discrimination of AT at position 44, Because the beta -Glu(44) residue does not contact the DNA, this residue probably enforces binding specificity indirectly through interaction with amino acids that themselves contact the DNA.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gardner, JF (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM28717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOOSEN N, 1984, GENE, V30, P41, DOI 10.1016/0378-1119(84)90103-3; GRANSTON AE, 1993, J MOL BIOL, V234, P45, DOI 10.1006/jmbi.1993.1562; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; KANO Y, 1993, GENE, V126, P93; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; LEE EC, 1991, J BACTERIOL, V173, P609, DOI 10.1128/jb.173.2.609-617.1991; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MENGERITSKY G, 1993, J MOL BIOL, V231, P646, DOI 10.1006/jmbi.1993.1316; NASH HA, 1981, J BIOL CHEM, V256, P9246; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZULIANELLO L, 1995, J BIOL CHEM, V270, P17902, DOI 10.1074/jbc.270.30.17902	19	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33759	33764		10.1074/jbc.M910381199	http://dx.doi.org/10.1074/jbc.M910381199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10930420	hybrid			2022-12-25	WOS:000090104600080
J	Seiser, RM; Nicchitta, CV				Seiser, RM; Nicchitta, CV			The fate of membrane-bound ribosomes following the termination of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN; ROUGH MICROSOMES; 2 STEPS; TRANSLOCATION; POLYSOMES; CELLS; SUBUNITS; INVITRO; IMPORT	Contemporary models for protein translocation in the mammalian endoplasmic reticulum (ER) identify the termination of protein synthesis as the signal for ribosome release from the ER membrane, We have utilized morphometric and biochemical methods to assess directly the fate of membrane-bound ribosomes following the termination of protein synthesis. In these studies, tissue culture cells were treated with cycloheximide to inhibit elongation, with pactamycin to inhibit initiation, or with puromycin to induce premature chain termination, and ribosome-membrane interactions were subsequently analyzed. It was found that following the termination of protein synthesis, the majority of ribosomal particles remained membrane-associated. Analysis of the subunit structure of the membrane-bound ribosomal particles remaining after termination was conducted by negative stain electron microscopy and sucrose gradient sedimentation. By both methods of analysis, the termination of protein synthesis on membrane-bound ribosomes was accompanied by the release of small ribosomal subunits from the ER membrane; the majority of the large subunits remained membrane-bound. On the basis of these results, we propose that large ribosomal subunit release from the ER membrane is regulated independently of protein translocation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, POB 3709, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47897] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BAGLIONI C, 1971, NATURE-NEW BIOL, V232, P8, DOI 10.1038/newbio232008a0; BALIGA BS, 1969, J BIOL CHEM, V244, P4480; BARBACID M, 1975, J ANTIBIOT, V28, P453, DOI 10.7164/antibiotics.28.453; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BORGESE D, 1973, J MOL BIOL, V74, P415, DOI 10.1016/0022-2836(73)90037-5; Christensen AK, 1999, ANAT REC, V255, P116, DOI 10.1002/(SICI)1097-0185(19990601)255:2<116::AID-AR2>3.0.CO;2-O; FALVEY AK, 1970, J MOL BIOL, V53, P21, DOI 10.1016/0022-2836(70)90043-4; FLORENDO NT, 1969, J CELL BIOL, V41, P335, DOI 10.1083/jcb.41.1.335; GAETANI S, 1983, METHOD ENZYMOL, V96, P3; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GOLDBERG IH, 1973, FED PROC, V32, P1688; KAEMPFER R, 1969, COLD SPRING HARB SYM, V34, P209, DOI 10.1101/SQB.1969.034.01.027; KAPPEN LS, 1976, BIOCHEMISTRY-US, V15, P811, DOI 10.1021/bi00649a013; LUTSCH G, 1986, EUR J CELL BIOL, V40, P257; MECHLER B, 1975, J CELL BIOL, V67, P1, DOI 10.1083/jcb.67.1.1; MECHLER B, 1975, J CELL BIOL, V67, P25, DOI 10.1083/jcb.67.1.25; MEECHLER B, 1975, J CELL BIOL, V75, P16; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MONRO RE, 1969, COLD SPRING HARB SYM, V34, P357, DOI 10.1101/SQB.1969.034.01.042; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NONOMURA Y, 1971, J MOL BIOL, V60, P303, DOI 10.1016/0022-2836(71)90296-8; PALADE GE, 1956, J BIOPHYS BIOCHEM CY, V2, P171, DOI 10.1083/jcb.2.2.171; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; SABATINI DD, 1966, J MOL BIOL, V19, P503, DOI 10.1016/S0022-2836(66)80019-0; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; UNWIN PNT, 1977, NATURE, V269, P118, DOI 10.1038/269118a0; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68	31	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33820	33827		10.1074/jbc.M004462200	http://dx.doi.org/10.1074/jbc.M004462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931837	hybrid			2022-12-25	WOS:000090104600089
J	Lopez-Borges, S; Lazo, PA				Lopez-Borges, S; Lazo, PA			The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein	ONCOGENE			English	Article						VRK1; p53; mdm-2; kinase; autophosphorylation; nuclear localization signal	DAMAGE-INDUCED PHOSPHORYLATION; DROSOPHILA CLOCK GENE; DNA-DAMAGE; MULTISITE PHOSPHORYLATION; SUBSTRATE DETERMINANTS; DOUBLE-TIME; IN-VITRO; ENCODES; DOMAIN; ACTIVATION	The tumour suppressor p53 protein integrates multiple signals regulating cell cycle progression and apoptosis, This regulation is mediated by several kinases that phosphorylate specific residues in the different functional domains of the p53 molecule. The human VRK1 protein is a new kinase related to a poxvirus kinase, and more distantly to the casein kinase 1 family. We have characterized the biochemical properties of human VRK1 from HeLa cells. VRK1 has a strong autophosphorylating activity in st several Ser and Thr residues. VRK-1 phosphorylates acidic proteins, such as phosvitin and casein, and basic proteins such as histone 2b and myelin basic protein. Because some transcription factors are regulated by phosphorylation, we tested as substrates the N-transactivation domains of p53 and c-Jun fused to GST. Human c-Jun is not phosphorylated by VRK1. VRK1 phosphorylates murine p53 in threonine 18. This threonine is within the p53 hydrophobic loop (residues 13-23) required for the interaction of p53 with the cleft of its inhibitor mdm-2. The VRK1 C-terminus domain (residues 268-396) that contains a nuclear localization signal targets the protein to the nucleus, as determined by using fusion proteins with the green fluorescent protein. We conclude that VRK1 is an upstream regulator of p53 that belongs to a nerv signalling pathway.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; Inst Salud Carlos III, CSIC, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel de Unamuno, Salamanca 37007, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025				BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAUD G, 1995, J VIROL, V69, P1819, DOI 10.1128/JVI.69.3.1819-1826.1995; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown JM, 1999, CANCER RES, V59, P1391; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Ferrer M, 1999, ONCOGENE, V18, P2253, DOI 10.1038/sj.onc.1202551; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN SQ, 1992, J VIROL, V66, P2717, DOI 10.1128/JVI.66.5.2717-2723.1992; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Prives C, 1999, J PATHOL, V187, P112; REMPEL RE, 1990, J VIROL, V64, P574, DOI 10.1128/JVI.64.2.574-583.1990; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRAKTMAN P, 1989, J BIOL CHEM, V264, P21458; TUAZON PT, 1991, ADV SEC MESS PHOSPHO, V23, P123; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657	61	109	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3656	3664		10.1038/sj.onc.1203709	http://dx.doi.org/10.1038/sj.onc.1203709			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951572	Bronze			2022-12-25	WOS:000088568300012
J	Carter, C; Thornburg, RW				Carter, C; Thornburg, RW			Tobacco nectarin I - Purification and characterization as a germin-like, manganese superoxide dismutase implicated in the defense of floral reproductive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY OXALATE OXIDASE; OXIDATIVE BURST; PROTEIN; EXPRESSION; ENZYMES; GLYCOPROTEIN; AFFINITY; EMBRYOS; CLONING; CDNA	Nectarin I, a protein that accumulates in the nectar of Nicotiana sp., was determined to contain superoxide dismutase activity by colorimetric and in-gel assays. This activity was found to be remarkably thermostable. Extended incubations at temperatures up to 90 degreesC did not diminish the superoxide dismutase activity of nectarin I. This attribute allowed nectarin I to be purified to homogeneity by heat denaturation of the other nectar proteins. By SDS-polyacrylamide gel electrophoresis, nectarin I appeared as a 29-kDa monomer. If the protein sample was not boiled prior to loading the gel, then nectarin I migrated as 165-kDa oligomeric protein. By matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, the protomer subunit was found to be a 22.5-kDa protein. Purified nectarin I contained 0.5 atoms of manganese/monomer, and the superoxide dismutase activity of nectarin I was not inhibited by either H2O2 or NaCN. Following denaturation, the superoxide dismutase activity was restored after Mn2+ addition. Addition of Fe2+, Cu2+, Zn2+ and Cu2+/Zn2+ did not restore superoxide dismutase activity. The quaternary structure of the reconstituted enzyme was examined, and only tetrameric and pentameric aggregates were enzymatically active, The reconstituted enzyme was also shown to generate H2O2,. Putative nectarin I homologues mere found in the nectars of several other plant species.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Thornburg, RW (corresponding author), Iowa State Univ, Dept Biochem & Biophys, 2212 Mol Biol Bldg, Ames, IA 50011 USA.	thorn@iastate.edu						AHMAD S, 1988, FREE RADICAL RES COM, V4, P403, DOI 10.3109/10715768809066908; Baker H.G., 1983, P126; BEARD ME, 1987, P NATL ACAD SCI USA, V84, P7433, DOI 10.1073/pnas.84.21.7433; BRYANT J, 1976, BIOCHEMISTRY-US, V15, P3418, DOI 10.1021/bi00661a004; Carter C, 1999, PLANT MOL BIOL, V41, P207, DOI 10.1023/A:1006363508648; Carter C, 1998, PLANT MOL BIOL, V38, P929, DOI 10.1023/A:1006038117130; Carter Clay, 1999, Journal of Plant Biology, V42, P97; COLLEN J, 1994, PHYSIOL PLANTARUM, V92, P417; de Azeredo-Oliveira MTV, 1998, CYTOBIOS, V93, P83; DOMON JM, 1995, PLANT PHYSIOL, V108, P141, DOI 10.1104/pp.108.1.141; DUMAS B, 1995, PLANT PHYSIOL, V107, P1091, DOI 10.1104/pp.107.4.1091; DUMAS B, 1993, CR ACAD SCI III-VIE, V316, P793; FELTON GW, 1995, ARCH INSECT BIOCHEM, V29, P187, DOI 10.1002/arch.940290208; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Gane PJ, 1998, J MOL EVOL, V46, P488, DOI 10.1007/PL00006329; GELLER BL, 1983, ANAL BIOCHEM, V128, P86, DOI 10.1016/0003-2697(83)90348-2; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HESLOPHARRISON Y, 1971, PLANTA, V96, P183, DOI 10.1007/BF00387439; HURKMAN WJ, 1991, PLANT PHYSIOL, V97, P366, DOI 10.1104/pp.97.1.366; Hurkman WJ, 1996, PLANT PHYSIOL, V111, P735, DOI 10.1104/pp.111.3.735; JAIKARAN ASI, 1990, J BIOL CHEM, V265, P12503; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KOSTER JF, 1980, BIOL CLIN ASPECTS SU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE BG, 1992, EUR J BIOCHEM, V209, P961, DOI 10.1111/j.1432-1033.1992.tb17369.x; LANE BG, 1993, J BIOL CHEM, V268, P12239; LANE BG, 1991, FASEB J, V5, P2893, DOI 10.1096/fasebj.5.14.1752357; LINDNER WA, 1988, PHYTOCHEMISTRY, V27, P2501, DOI 10.1016/0031-9422(88)87017-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUBBIN WC, 1987, BIOCHEM CELL BIOL, V65, P1039, DOI 10.1139/o87-136; McManaman JL, 1996, ARCH BIOCHEM BIOPHYS, V332, P135, DOI 10.1006/abbi.1996.0325; Neutelings G, 1998, PLANT MOL BIOL, V38, P1179, DOI 10.1023/A:1006033622928; Ohmiya A, 1998, PLANT CELL PHYSIOL, V39, P492, DOI 10.1093/oxfordjournals.pcp.a029396; Peumans WJ, 1997, PLANTA, V201, P298, DOI 10.1007/s004250050070; RAHMAN S, 1988, BIOCHEM CELL BIOL, V66, P100, DOI 10.1139/o88-013; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; SCALA J, 1969, PLANT PHYSIOL, V44, P367, DOI 10.1104/pp.44.3.367; Sommer U, 1999, GLYCOCONJUGATE J, V16, P425, DOI 10.1023/A:1007030627948; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; SUGIURA M, 1979, CHEM PHARM BULL, V27, P2003; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; Vallelian-Bindschedler L, 1998, PLANT MOL BIOL, V37, P297, DOI 10.1023/A:1005982715972; Wei YD, 1998, PLANT MOL BIOL, V36, P101, DOI 10.1023/A:1005955119326; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Woo EJ, 1998, FEBS LETT, V437, P87, DOI 10.1016/S0014-5793(98)01203-4; Yamahara T, 1999, J BIOL CHEM, V274, P33274, DOI 10.1074/jbc.274.47.33274; YOST FJ, 1973, J BIOL CHEM, V248, P4905; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; ZHANG ZG, 1995, PLANT J, V8, P139, DOI 10.1046/j.1365-313X.1995.08010139.x; Zhou L, 1999, INDUCIBLE GENE EXPRESSION IN PLANTS, P127	50	150	167	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36726	36733		10.1074/jbc.M006461200	http://dx.doi.org/10.1074/jbc.M006461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10952990	hybrid			2022-12-25	WOS:000165577700041
J	Li, HH; Lyles, DS; Thomas, MJ; Pan, W; Sorci-Thomas, MG				Li, HH; Lyles, DS; Thomas, MJ; Pan, W; Sorci-Thomas, MG			Structural determination of lipid-bound ApoA-I using fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; TRANSGENIC MICE; BELT MODEL; DEFICIENCY; CONFORMATION; PARTICLES; ATHEROSCLEROSIS	Based on the x-ray crystal structure of lipid-free Delta 43 apoA-1, two monomers of apoA-1 were suggested to bind to a phospholipid bilayer in an antiparallel paired dimer, or "belt orientation." This hypothesis challenges the currently held model in which each of the two apoA-I monomers fold as antiparallel alpha -helices or "pick-et fence orientation" When apoA-I is bound to a phospholipid disc, the first model predicts that the glutamine at position 132 on one apoA-I molecule lies within 16 Angstrom of glutamine 132 in the second monomer, whereas, the second model predicts glutamines at position 132 to be 104 Angstrom apart. To distinguish between these models, glutamine at position 132 was mutated to cysteine in wild-type apoA-I to produce Q132C apoA-I, which were labeled with thiol-reactive fluorescent probes. Q132C apoA-I was labeled with either fluorescein (donor probe) or tetramethylrhodamine (acceptor probe) and then used to make recombinant phospholipid discs (recombinant high density lipoprotein (rHDL)). The rHDL containing donor- and acceptor-labeled Q132C apoA-I were of similar size, composition, and lecithin:cholesterol acyltransferase reactivity when compared to rHDL- containing human plasma apoA-I. Analysis of donor probe fluorescence showed highly efficient quenching in rHDL containing one donor- and one acceptor-labeled Q132C apoA-I. rHDL containing only acceptor probe-labeled Q132C apoA-I showed rhodamine selfquenching. Both of these observations demonstrate that position 132 in two lipid-bound apoA-I monomers were in close proximity, supporting the ''belt conformation" hypothesis for apoA-I on rHDL.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sorci-Thomas, MG (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Sorci-Thomas, Mary/0000-0002-6464-5006; Lyles, Douglas/0000-0002-8401-3073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL060079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015892, R55AI015892] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49373, HL-60079] Funding Source: Medline; NIAID NIH HHS [AI15892] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJTAI K, 1992, BIOCHEMISTRY-US, V31, P12431, DOI 10.1021/bi00164a019; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROUILLETTE CG, 2000, IN PRESS BIOCH BIOPH; Frank PG, 2000, J LIPID RES, V41, P853; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Hughes SD, 1997, ARTERIOSCL THROM VAS, V17, P1725, DOI 10.1161/01.ATV.17.9.1725; Jonas A, 1998, PROG LIPID RES, V37, P209, DOI 10.1016/S0163-7827(98)00007-1; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; LI WH, 1988, J LIPID RES, V29, P245; LYLES DS, 1990, BIOCHEMISTRY-US, V29, P2442, DOI 10.1021/bi00462a002; LYLES DS, 1985, BIOCHEMISTRY-US, V24, P8121, DOI 10.1021/bi00348a043; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MILLER NE, 1975, LANCET, V1, P1033, DOI 10.1016/S0140-6736(75)91977-7; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Packard BZ, 1996, P NATL ACAD SCI USA, V93, P11640, DOI 10.1073/pnas.93.21.11640; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SorciThomas MG, 1996, J LIPID RES, V37, P673; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STANTON SG, 1984, BIOCHIM BIOPHYS ACTA, V776, P228, DOI 10.1016/0005-2736(84)90212-8; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TALL AR, 1977, J BIOL CHEM, V252, P4701; TALUSSOT C, 1994, J THEOR BIOL, V169, P143, DOI 10.1006/jtbi.1994.1136; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; WolffLong VL, 1995, J BIOL CHEM, V270, P31111, DOI 10.1074/jbc.270.52.31111	41	78	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37048	37054		10.1074/jbc.M005336200	http://dx.doi.org/10.1074/jbc.M005336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956648	hybrid			2022-12-25	WOS:000165577700083
J	Zhang, ZY; Baron, R; Horne, WC				Zhang, ZY; Baron, R; Horne, WC			Integrin engagement, the actin cytoskeleton, and c-Src are required for the calcitonin-induced tyrosine phosphorylation of paxillin and HEF1, but not for calcitonin-induced Erk1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; CRK-ASSOCIATED SUBSTRATE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; COUPLED RECEPTORS; EXTRACELLULAR-MATRIX	We have previously shown that in a HEK-293 cell line that overexpresses the Cia isoform of the calcitonin receptor (C1a-HEK), calcitonin induces the tyrosine phosphorylation of the focal adhesion-associated proteins HEF1 (a p130(CAS)-like docking protein), paxillin, and focal adhesion kinase and that it also stimulates the phosphorylation and activation of Erk1 and Erk2, We report here that cell attachment to the extracellular matrix, an intact actin cytoskeleton, and c-Src are absolutely required for the calcitonin-induced phosphorylation of focal adhesion-associated proteins, In contrast to the phosphorylation of paxillin and HEF1 in cells attached to fibronectin-coated dishes, calcitonin failed to stimulate the phosphorylation of paxillin and HEF1 in suspended cells, in cells attached to poly-D-lysine-coated dishes, and in attached cells pretreated with the RGD-containing peptide GRGDS, Overexpression of wild-type c-Src increased calcitonin-induced paxillin and HEF1 phosphorylation, whereas overexpression of kinase-dead Src or Src lacking a functional SH2 domain inhibited the calcitonin-stimulated tyrosine phosphorylation of these proteins, Overexpression of Src lacking the SH3 domain did not affect the calcitonin-induced phosphorylation of paxillin and HEF1. In contrast to the regulation of paxillin and HEF1 phosphorylation, the calcitonin-induced phosphorylation of Erk1 and Erk2 did not appear to involve c-Src and was only partially dependent on cell adhesion to the extracellular matrix and an intact actin cytoskeleton. Furthermore, inhibition of Erk1 and Erk2 phosphorylation had no effect on the calcitonin-induced phosphorylation of paxillin and HEF1, Thus, in C1a-HEK cells, the calcitonin receptor is coupled to the tyrosine phosphorylation of focal adhesion-associated proteins and to Erk1/2 phosphorylation by mechanisms that are in large part independent.	Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthopaed, POB 208044, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927, P30AR046032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-46032, AR-42927] Funding Source: Medline; NIDCR NIH HHS [DE-04724] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; deCurtis I, 1997, EXP CELL RES, V230, P233, DOI 10.1006/excr.1996.3423; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Grant RL, 1996, IN VITRO CELL DEV-AN, V32, P38, DOI 10.1007/BF02722992; Guo C, 1998, EUR J BIOCHEM, V257, P403, DOI 10.1046/j.1432-1327.1998.2570403.x; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Kanda H, 1999, IMMUNOLOGY, V97, P56; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDELY AJ, 1992, CELL, V70, P389; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TURNER CE, 1995, J CELL SCI, V108, P333; VAN BT, 1995, NATURE, V376, P781; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	54	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37219	37223		10.1074/jbc.M001818200	http://dx.doi.org/10.1074/jbc.M001818200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10954702	hybrid			2022-12-25	WOS:000165577700104
J	Boeke, J; Ammerpohl, O; Kegel, S; Moehren, U; Renkawitz, R				Boeke, J; Ammerpohl, O; Kegel, S; Moehren, U; Renkawitz, R			The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LYSOZYME DOWNSTREAM ENHANCER; RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL REPRESSOR; HISTONE DEACETYLASE; DNA METHYLATION; PROTEIN; DEMETHYLATION; CHROMATIN; COMPLEX	Different mechanisms mediating methylation-dependent repression have been demonstrated. Two of these mechanisms play a role in the context of the granulocyte/macrophage-specific lysozyme gene: direct interference with DNA binding of the transcription factor GA-binding protein and deacetylation of histones. Besides enhancement in the unmethylated state, and transcriptional repression upon DNA methylation, the lysozyme downstream enhancer confers tissue-specific demethylation, Because both demethylation activity and repression ability have been attributed to the methyl-CpG-binding domain-containing protein MBD2, we analyzed this protein. The short form MBD2b binds to the methylated lysozyme enhancer and mediates transcriptional repression. MBD2b is capable of binding to the transcriptional repressor Sin3A The interaction domain of Sin3A required for binding to MBD2b contains the paired amphipathic helix 3, We identified a minimal functional domain that confers both transcriptional repression as well as the interaction to Sin3A in contrast to the functionally related proteins MeCP2 and MBD1, the repression domain of MBD2b overlaps with the methyl-CpG-binding domain.	Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Justus Liebig University Giessen	Renkawitz, R (corresponding author), Univ Giessen, Genet Inst, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	Rainer.Renkawitz@gen.bio.uni-giessen.de	Ammerpohl, Ole/G-2691-2010					Ammerpohl O, 1998, NUCLEIC ACIDS RES, V26, P5256, DOI 10.1093/nar/26.23.5256; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; Baniahmad A, 1997, MOL CELL BIOL, V17, P4259, DOI 10.1128/MCB.17.8.4259; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Bergman Y, 1998, BIOL CHEM, V379, P401; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, CIBA F SYMP, V214, P6; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Schmitz A, 1997, J BIOL CHEM, V272, P20850, DOI 10.1074/jbc.272.33.20850; Short ML, 1996, CELL GROWTH DIFFER, V7, P1545; SIMPSON VJ, 1986, NUCLEIC ACIDS RES, V14, P6711, DOI 10.1093/nar/14.16.6711; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; YU F, 1908, NUCLEIC ACIDS RES, V28, P2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	38	83	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34963	34967		10.1074/jbc.M005929200	http://dx.doi.org/10.1074/jbc.M005929200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950960	hybrid			2022-12-25	WOS:000165422800020
J	Yan, ZJ; Jetten, AM				Yan, ZJ; Jetten, AM			Characterization of the repressor function of the nuclear orphan receptor retinoid receptor-related testis-associated receptor/germ cell nuclear factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RELATED RECEPTOR; DNA-BINDING; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL LOCALIZATION; DIFFERENTIAL EXPRESSION; SILENCING MEDIATOR; N-COR; GENE; COACTIVATOR	Retinoid receptor-related testis-associated receptor (RTR)/germ cell nuclear factor is a nuclear orphan receptor that plays an important role in the control of gene expression during early embryonic development and gametogenesis. It has been shown to repress transcriptional activation, In this study, we further characterize this repressor function. We demonstrate that RTR can suppress the transcriptional activation induced by the estrogen receptor related-receptor alpha1 through its response element. The latter is at least in part due to competition for binding to the same response element. In addition, RTR inhibits basal transcriptional activation, indicating that it functions as an active repressor. Mammalian two-hybrid analyses showed that RTR interacts with the co-repressor nuclear co-repressor (N-CoR) but is unable to interact with the co-repressor SMRT or RIP140. Pull-down analyses with glutathione S-transferase-RTR fusion protein demonstrated that RTR physically interacts with N-CoR in vitro, suggesting a potential role for N-CoR in the transcriptional repression by RTR. To identify the regions in RTR essential for the binding of RTR to N-CoR, the effect of various deletion and point mutations on this interaction was examined. This analysis revealed that this interaction requires the hinge domain, helix 3 as well as the helix 12 region of RTR. The residues Ser(246)-Tyr(247) in the hinge domain, Lys(318) in helix 3, and Lys(489)-Thr(490) in helix 12 are identified as being critical in this interaction. Our results demonstrate that RTR can function as an active transcriptional repressor and that this repression can be mediated through interactions with the corepressor N-CoR. We show that this interaction exhibits several characteristics unique to RTR. Through its repressor function, RTR can suppress the induction of transcriptional activation by other nuclear receptors. These repressor activities may provide important mechanisms by which RTR regulates gene expression during development and gametogenesis.	NIEHS, Pulm Pathobiol Lab, Cell Biol Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jetten, AM (corresponding author), NIEHS, Pulm Pathobiol Lab, Cell Biol Sect, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	jetten@niehs.nih.gov	Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025042] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agoulnik IY, 1998, FEBS LETT, V424, P73, DOI 10.1016/S0014-5793(98)00142-2; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; Bauer UM, 1997, EUR J BIOCHEM, V249, P826, DOI 10.1111/j.1432-1033.1997.t01-1-00826.x; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; Braat AK, 1999, MOL REPROD DEV, V53, P369, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;369::AID-MRD1&gt;3.0.CO;2-U; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cooney AJ, 1999, AM ZOOL, V39, P796; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Greschik H, 1998, J MOL MED-JMM, V76, P800, DOI 10.1007/s001090050284; Greschik H, 1999, MOL CELL BIOL, V19, P690; Heinzer C, 1998, BIOL CHEM, V379, P349, DOI 10.1515/bchm.1998.379.3.349; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; Joos TO, 1996, MECH DEVELOP, V60, P45, DOI 10.1016/S0925-4773(96)00599-0; Kapelle M, 1997, BBA-GENE STRUCT EXPR, V1352, P13, DOI 10.1016/S0167-4781(97)00043-2; Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364; KATZ D, 1998, KEYST S NUCL REC GEN; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shi HP, 1997, GENOMICS, V44, P52, DOI 10.1006/geno.1997.4850; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Susens U, 1996, BBA-GENE STRUCT EXPR, V1309, P179, DOI 10.1016/S0167-4781(96)00157-1; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; WILLY PJ, 1998, HORMONES SIGNALING, V1, P308; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z	56	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35077	35085		10.1074/jbc.M005566200	http://dx.doi.org/10.1074/jbc.M005566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10940306	hybrid			2022-12-25	WOS:000165422800035
J	Copeland, RA; Marcinkeviciene, J; Haque, TS; Kopcho, LM; Jiang, WJ; Wang, K; Ecret, LD; Sizemore, C; Amsler, KA; Foster, L; Tadesse, S; Combs, AP; Stern, AM; Trainor, GL; Slee, A; Rogers, MJ; Hobbs, F				Copeland, RA; Marcinkeviciene, J; Haque, TS; Kopcho, LM; Jiang, WJ; Wang, K; Ecret, LD; Sizemore, C; Amsler, KA; Foster, L; Tadesse, S; Combs, AP; Stern, AM; Trainor, GL; Slee, A; Rogers, MJ; Hobbs, F			Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROOROTATE DEHYDROGENASE; BREQUINAR SODIUM; ESCHERICHIA-COLI; SEQUENCE; MECHANISM; INVITRO; ACID	We report the discovery of a class of pyrazole-based compounds that are potent inhibitors of the dihydroorotate dehydrogenase of Helicobacter pylori but that do not inhibit the cognate enzymes from Gram-positive bacteria or humans. In culture these compounds inhibit the growth of H, pylori selectively, showing no effect on other Gram-negative or Gram-positive bacteria or human cell lines. These compounds represent the first examples of H, pylori-specific antibacterial agents. Cellular activity within this structural class appears to be due to dihydroorotate dehydrogenase inhibition. Minor structural changes that abrogate in vitro inhibition of the enzyme likewise eliminate cellular activity. Furthermore, the minimum inhibitory concentrations of these compounds increase upon addition of orotate to the culture medium in a concentration-dependent manner, consistent with dihydroorotate dehydrogenase inhibition as the mechanism of cellular inhibition, The data presented here suggest that targeted inhibition of de novo pyrimidine biosynthesis may be a valuable mechanism for the development of antimicrobial agents selective for H, pylori.	Dupont Merck Pharmaceut Co, Dept Chem Enzymol, Expt Stn, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Chem & Phys Sci, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Antimicrobials Grp, Wilmington, DE 19880 USA	DuPont; DuPont; DuPont	Copeland, RA (corresponding author), Dupont Merck Pharmaceut Co, Dept Chem Enzymol, Expt Stn, POB 80400, Wilmington, DE 19880 USA.			Sizemore, Christine/0000-0002-2807-471X; Stern, Andrew/0000-0002-8437-2957				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; Cleland W W, 1979, Methods Enzymol, V63, P103; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; Copeland RA., 2000, ENZYME PRACTICAL INT, P266, DOI 10.1002/0471220639.ch8; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; JAFFEE BD, 1993, TRANSPLANT P, V25, P19; Jensen KF, 1998, PATHS PYRIMIDINES, V6, P20; LAKASCHUS G, 1992, BIOCHEM PHARMACOL, V43, P1025, DOI 10.1016/0006-2952(92)90609-M; LARSEN JN, 1985, EUR J BIOCHEM, V151, P59, DOI 10.1111/j.1432-1033.1985.tb09068.x; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; Marcelli SW, 1996, FEMS MICROBIOL LETT, V138, P59; Marcinkeviciene J, 2000, BIOCHEM PHARMACOL, V60, P339, DOI 10.1016/S0006-2952(00)00348-8; Marcinkeviciene J, 1999, BIOCHEMISTRY-US, V38, P13129, DOI 10.1021/bi990674q; Marcinkeviciene J, 2000, ARCH BIOCHEM BIOPHYS, V377, P178, DOI 10.1006/abbi.2000.1769; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; MENDZ GL, 1994, J APPL BACTERIOL, V77, P1, DOI 10.1111/j.1365-2672.1994.tb03036.x; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSS CW, 1990, J CLIN MICROBIOL, V28, P395, DOI 10.1128/JCM.28.2.395-397.1990; Motulsky H., 1995, INTUITIVE BIOSTATIST, P155; Nair R., 1995, Journal of Heart and Lung Transplantation, V14, pS54; Neidhardt Edie A., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P183; PECK RM, 1999, CANCER RES, V59, P6124; Reynolds David J., 1997, P53; SIMON P, 1993, TRANSPLANT P, V25, P77; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	31	57	59	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33373	33378		10.1074/jbc.M004451200	http://dx.doi.org/10.1074/jbc.M004451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938275	hybrid			2022-12-25	WOS:000090104600029
J	Schmidt, PJ; Kunst, C; Culotta, VC				Schmidt, PJ; Kunst, C; Culotta, VC			Copper activation of superoxide dismutase 1 (SOD1) in vivo - Role for protein-protein interactions with the copper chaperone for SOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ATX1 GENE; IN-VIVO; METAL; COX17; HSP70; HOMEOSTASIS	Insertion of copper into superoxide dismutase 1 (SOD1) in vivo requires the copper chaperone for SOD1 (CCS). CCS encompasses three protein domains: copper binding Domains I and III at the amino and carboxyl termini, and a central Domain II homologous to SOD1, Using a yeast interaction mating system, yeast CCS was seen to physically interact with SOD1, and this interaction required sequences at the predicted dimer interface of CCS Domain II. Interactions with SOD1 also required sequences of Domain III, but not Domain I. Mutations were introduced at the dimer interface of yeast SOD1, and the corresponding mutant failed to interact with CCS. When loaded with copper independent of CCS, this mutant SOD1 exhibited superoxide scavenging activity, but was normally inactive in vivo because CCS failed to recognize the enzyme. Activation of SOD1 by CCS was also examined using an in vivo assay for copper incorporation into SOD1. Yeast CCS was observed to insert copper into a pre-existing pool of apoSOD1 without the need for new SOD1 synthesis or for protein unfolding by the major SSA cytosolic heat shock proteins. Our data are consistent with a model in which prefolded dimers of apoSOD1 serve as substrate for the CCS copper chaperone.	Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Eleanor Roosevelt Inst Canc Res, Denver, CO 80206 USA	Johns Hopkins University	Culotta, VC (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R37GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-07141] Funding Source: Medline; NIGMS NIH HHS [GM50016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Becker J, 1996, MOL CELL BIOL, V16, P4378; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P82292; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Falconi M, 1999, STRUCT FOLD DES, V7, P903, DOI 10.1016/S0969-2126(99)80117-8; Ferraroni M, 1999, J MOL BIOL, V288, P413, DOI 10.1006/jmbi.1999.2681; FINLEY RL, 1995, DNA CLONING, V2, P169; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lippard SJ, 1999, SCIENCE, V284, P748, DOI 10.1126/science.284.5415.748; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; LIU XF, 1992, J BIOL CHEM, V267, P18298; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sherman F., 1978, METHODS YEAST GENETI; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; Valentine J.S., 1981, COPPER PROTEINS, P291; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	42	100	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33771	33776		10.1074/jbc.M006254200	http://dx.doi.org/10.1074/jbc.M006254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944535	hybrid			2022-12-25	WOS:000090104600082
J	Shirakawa, R; Yoshioka, A; Horiuchi, H; Nishioka, H; Tabuchi, A; Kita, T				Shirakawa, R; Yoshioka, A; Horiuchi, H; Nishioka, H; Tabuchi, A; Kita, T			Small GTPase Rab4 regulates Ca2+-induced alpha-granule secretion in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; BINDING PROTEIN; PLASMA-MEMBRANE; GDP/GTP EXCHANGE; BOVINE BRAIN; ENDOCYTIC PATHWAY; TRANSPORT; FUSION; DOCKING; CELLS	Upon activation, platelets release many active substances stored in alpha- and dense-core granules. However, the molecular mechanisms governing regulated exocytosis are not yet fully understood. Here, we have established an assay system using permeabilized platelets to analyze the Ca2+-induced exocytosis of both types of granules, focusing on RabGTPases. Incubation with Rab GDP dissociation inhibitor, an inhibitory regulator of RabGTPases, reduced membrane-bound RabGTPases extensively, and caused strong inhibition of the Ca2+-induced secretion of von Willebrand factor (VWF) stored in alpha -granules, but not that of [H-3]5-hydroxytryptamine (5-HT) in dense-core granules, Specifically, Rab4 cofractionated with vWF and P-selectin (an alpha -granule marker) upon separation of platelet organelles by density gradient centrifugation. Incubation of the permeabilized platelets with cell extracts expressing the dominant negative mutant of His-tagged Rab4S22N, but not with those of similar mutant His-Rab3BT36N, inhibited the vWF secretion, whereas neither of the cell extracts affected the [H-3]5-HT secretion. Importantly, the inhibition of vWF secretion was rescued by depleting the cell extracts of the His-Rab4S22N crith nickel beads. Thus, in platelets, the regulatory mechanisms governing alpha- and dense-core granule secretions are distinct, and Rab4 is an essential regulator of the Ca2+-induced exocytosis of alpha -granules.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan	Kyoto University	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp						AKAYAMA M, 1986, CELL STRUCT FUNCT, V11, P259, DOI 10.1247/csf.11.259; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; CONNER GE, 1992, J BIOL CHEM, V267, P21738; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KARNIGUIAN A, 1993, P NATL ACAD SCI USA, V90, P7647, DOI 10.1073/pnas.90.16.7647; KNIGHT DE, 1982, NATURE, V296, P256, DOI 10.1038/296256a0; KREISEL W, 1994, ACTA HISTOCHEM, V96, P51, DOI 10.1016/S0065-1281(11)80009-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; NAGATA K, 1993, BIOCHEM BIOPH RES CO, V195, P1081, DOI 10.1006/bbrc.1993.2155; NAGATA K, 1992, BIOCHEM BIOPH RES CO, V189, P330, DOI 10.1016/0006-291X(92)91562-5; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Ohnishi H, 1999, GASTROENTEROLOGY, V116, P943, DOI 10.1016/S0016-5085(99)70078-8; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PLOW EF, 2000, HEMATOLOGY BASIC PRI, P1741; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	49	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33844	33849		10.1074/jbc.M002834200	http://dx.doi.org/10.1074/jbc.M002834200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10938270	hybrid			2022-12-25	WOS:000090104600092
J	Chappell, J; Golovchenko, I; Wall, K; Stjernholm, R; Leitner, JW; Goalstone, M; Draznin, B				Chappell, J; Golovchenko, I; Wall, K; Stjernholm, R; Leitner, JW; Goalstone, M; Draznin, B			Potentiation of Rho-A-mediated lysophosphatidic acid activity by hyperinsulinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SERINE/THREONINE KINASE; FAMILY GTPASES; KAPPA-B; RAS; PROTEIN; ACTIVATION; INSULIN; FARNESYLTRANSFERASE; CELLS	We have shown previously that insulin promotes phosphorylation and activation of farnesyltransferase and geranylgeranyltransferase (GGTase) II. We have now examined the effect of insulin on geranylgeranyltransferase I in MCF-7 breast cancer cells. Insulin increased GGTase I activity 3-fold and augmented the amounts of geranylgeranylated Rho-A by 18%. Both effects of the insulin were blocked by an inhibitor of GGTase I, GGTI-286. The insulin-induced increases in the amounts of geranylgeranylated Rho-A resulted in potentiation of the Rho-A-mediated effects of lysophosphatidic acid (LPA) on a serum response element-luciferase construct. Preincubation of cells with insulin augmented the LPA-stimulated serum response element-luciferase activation to la-fold, compared with just g-fold for LPA alone (p < 0.05). The potentiating effect of insulin was dose-dependent, inhibited by GGTI-286 and not mimicked by insulin-like growth factor-1. We conclude that insulin activates GGTase I, increases the amounts of geranylgeranylated Rho-A protein, and potentiates the Rho-A-dependent nuclear effects of LPA in MCF-7 breast cancer cells.	Univ Colorado, Hlth Sci Ctr, Dept Vet Affairs, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Draznin, B (corresponding author), Vet Affairs Hosp 151, 1055 Clermont St, Denver, CO 80220 USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; Goalstone ML, 1998, ENDOCRINOLOGY, V139, P4067, DOI 10.1210/en.139.10.4067; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1999, J BIOL CHEM, V274, P2880, DOI 10.1074/jbc.274.5.2880; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Katzung BG, 1989, BASIC CLIN PHARM; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YOSHIOKA K, 1995, FEBS LETT, V372, P25, DOI 10.1016/0014-5793(95)00937-5; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	35	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31792	31797		10.1074/jbc.M004798200	http://dx.doi.org/10.1074/jbc.M004798200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10930411	hybrid			2022-12-25	WOS:000089858900036
J	Attwell, S; Roskelley, C; Dedhar, S				Attwell, S; Roskelley, C; Dedhar, S			The integrin-linked kinase (ILK) suppresses anoikis	ONCOGENE			English	Article						apoptosis; protein kinase B; fibronectin; caspases	DEPENDENT CELL-SURVIVAL; FOCAL ADHESION KINASE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; APOPTOSIS; DEATH; B/AKT; AKT; PATHWAYS; GROWTH	Disruption of integrin-extracellular matrix interactions in normal epithelial cells induces apoptosis, a process termed anoikis, Reduced sensitivity to anoikis appears to be an important hallmark of oncogenic transformation, particularly in the process of metastasis, Several pathways have been implicated in the suppression of anoikis, however, the events which take place proximal to the integrin receptors remain unclear. Integrin-linked kinase (ILK) is an integrin-interacting protein kinase which has been identified as a potential PDK-2, as it is capable of phosphorylating PKB/Akt on Ser-473, and stimulating its activity, Here, we show that ILK activity is stimulated upon adhesion of SCP2 mouse mammary epithelial cells to fibronectin, and inhibited in suspended cells. Overexpression of ILK in the anoikis-sensitive SCP2 cells results in a profound inhibition of anoikis, as determined by annexin V binding and activation of caspases 8 and 3, This effect is reversible by the transfection and expression of a dominant-negative, kinase deficient ILK (ILK KD), as well as by a dominant negative PKB/Akt (PKB AAA). On the other hand, transfection of a dominant negative form of FAK (FRNK) failed to reverse the suppression of anoikis by ILK, Furthermore, inhibition of ILK activity induced anoikis in tno anoikis-resistant human breast cancer cell lines. These findings suggest that ILK plays a major role in the suppression of anoikis.	British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6P 6P2, Canada; Univ British Columbia, Dept Anat, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Agcy, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	28	199	210	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3811	3815		10.1038/sj.onc.1203711	http://dx.doi.org/10.1038/sj.onc.1203711			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949937				2022-12-25	WOS:000088568400015
J	Yang, TX; Huang, YN; Heasley, LE; Berl, T; Schnermann, JB; Briggs, JP				Yang, TX; Huang, YN; Heasley, LE; Berl, T; Schnermann, JB; Briggs, JP			MAPK mediation of hypertonicity-stimulated cyclooxygenase-2 expression in renal medullary collecting duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; OSMOTIC RESPONSE ELEMENT; CANINE KIDNEY-CELLS; N-TERMINAL KINASE; EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; MESANGIAL CELLS; MAMMALIAN-CELLS; P38 KINASE	We have previously shown that hypertonicity stimulates cyclooxygenase-2 (COX-2) expression in cultured medullary epithelial cells. The aims of the present study were (i) to examine the role of cytoplasmic signaling through MAPK pathways in tonicity regulation of COX-2 expression in collecting duct cells and (ii) to assess the possible contribution of COX-2 to the survival of inner medullary collecting duct (IMCD) cells under hypertonic conditions. In mIMCD-K2 cells, a cell line derived from mouse IMCDs, hypertonicity induced a marked increase in COX-2 protein expression, The stimulation was reduced significantly by inhibition of MEK1 (PD-98059, 5-50 mu M and p38 (SB-203580, 5-100 mu M) and was almost abolished by the combination of the two compounds. To study the role of JNK in tonicity-stimulated COX-2 expression, IMCD-3 cell lines stably transfected with dominant-negative mutants of three JNKs (JNK-1, -2, and -3) were used. Hypertonicity-stimulated COX-2 protein expression was significantly reduced in dominant-negative JNK-2-expressing cells and was unchanged in dominant-negative JNK-1- and JNK-3-expressing cells compared with controls. The reduction of COX-2 expression was associated with greatly reduced viability of dominant-negative JNK-2-expressing cells during hypertonicity treatment, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) (2-8 mu M), an inhibitor of Src kinases, reduced the tonicity-stimulated COX-2 expression in a dose-dependent manner, whereas PP3, an inactive analog of PP2, had no effect. Inhibition of COX-2 activity by NS-398 (30-90 mu M) and SC-58236 (10-20 mu M) significantly reduced viability of mIMCD-K2 cells subjected to prolonged hypertonic treatment. We conclude that 1) all three members of the MAPK family (ERK, JNK-2, and p38) as well as Src kinases are required for tonicity-stimulated COX-2 expression in mouse collecting duct cells and that 2) COX-2 may play a role in cell survival of medullary cells under hypertonic conditions.	NIDDK, NIH, Bethesda, MD 20892 USA; Univ Colorado, Dept Internal Med, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Colorado System; University of Colorado Denver	Briggs, JP (corresponding author), NIDDK, NIH, Bldg 31,Rm 9A17,31 Ctr Dr,MSC 2560, Bethesda, MD 20892 USA.	BriggsJ@hq.niddk.nih.gov	Briggs, Josephine P/B-9394-2009	Briggs, Josephine P/0000-0003-0798-1190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040042, P50DK039255, R01DK037448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40042, DK-39255, DK-37448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; Coroneos EJ, 1997, J AM SOC NEPHROL, V8, P1080; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KIZER ZL, 1995, AM J PHYSIOL, V37, pF347; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Zhang Z, 1997, AM J PHYSIOL-RENAL, V273, pF837, DOI 10.1152/ajprenal.1997.273.5.F837	37	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23281	23286		10.1074/jbc.M910237199	http://dx.doi.org/10.1074/jbc.M910237199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930430	hybrid			2022-12-25	WOS:000088419400094
J	del Arroyo, AG; Gil-Lamagniere, C; Lazaro, I; de Marco, MC; Layunta, I; Silva, A				del Arroyo, AG; Gil-Lamagniere, C; Lazaro, I; de Marco, MC; Layunta, I; Silva, A			Involvement of p53 and interleukin 3 in the up-regulation of CD95 (APO-1/Fas) by X-ray irradiation	ONCOGENE			English	Article						apoptosis; CD95 (Fas/Apo-1); IL-3; p53; X-ray irradiation	DRUG-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; BONE-MARROW CELLS; WILD-TYPE P53; RECEPTOR/LIGAND SYSTEM; DEATH DOMAIN; DIFFERENTIAL EXPRESSION; NEUROBLASTOMA-CELLS; ANTICANCER DRUGS; PERIPHERAL-BLOOD	Interleukin 3-dependent hone marrow and Ba/F3 cells present constitutive Fas expression. A dose dependent increase in Fas surface expression was induced in these cells by X-ray irradiation. Using primary cell cultures and established cell lines derived from p53-null mice (p53(-/-)), we demonstrated that the increase in Fas expression upon X-ray irradiation is dependent on the presence of at least one wild-type p53 allele. Fas induction by X-ray irradiation was negatively modulated by IL-3; an earlier Fas induction was observed in the absence of IL-3 or at low IL-3 concentrations. However, IL-3 withdrawal in non-irradiated cells did not induce an increase in Fas expression. X-ray irradiation of Ba/F3 cells induced the expression of functional Fas receptors. Therefore, in IL-3-dependent cells, IL-3 regulates the rate of Fas expression, which is correlated with the degree of apoptosis observed in X-irradiated cells. Finally, we demonstrate that IL-3 controls the degree of Fas expression induced by irradiation through a p53-mediated pathway.	CSIC, Ctr Invest Biol, Dept Immunol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Silva, A (corresponding author), CSIC, Ctr Invest Biol, Dept Immunol, Velazquez 144, E-28006 Madrid, Spain.		Gil-Lamaignere, Cristina/A-3866-2013					Akagi T, 1998, LEUKEMIA LYMPHOMA, V28, P483, DOI 10.3109/10428199809058355; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Booker JK, 1998, J IMMUNOL, V161, P4536; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; IWAI K, 1994, BLOOD, V84, P1201; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li T, 1996, CELL GROWTH DIFFER, V7, P107; MARVEL J, 1994, ONCOGENE, V9, P1117; MATSUE H, 1995, ARCH DERMATOL RES, V287, P315, DOI 10.1007/BF01105085; MIYASHITA T, 1995, CELL, V80, P293; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MULLNER EW, 1997, IMMUNOLOGY METHODS M; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; SATA M, 1988, NAT MED, V4, P415; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAMURA T, 1995, ONCOGENE, V11, P1939; WARASUKAMA H, 1988, EUR J IMMUNOL, V18, P97; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	49	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3647	3655		10.1038/sj.onc.1203662	http://dx.doi.org/10.1038/sj.onc.1203662			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951571				2022-12-25	WOS:000088568300011
J	Klausen, P; Pedersen, L; Jurlander, J; Baumann, H				Klausen, P; Pedersen, L; Jurlander, J; Baumann, H			Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells	ONCOGENE			English	Article						HepG3 cells; IL-6 type cytokines; IL-10; p27kip1; growth arrest	CYTOKINE RECEPTOR SUPERFAMILY; HEPATIC CELLS; RESPONSE ELEMENTS; DEPENDENT PHOSPHORYLATION; HEMATOPOIETIN RECEPTORS; GROWTH-INHIBITION; MELANOMA-CELLS; P27(KIP1); EXPRESSION; CANCER	We analysed the regulation of G1-phase progression in relation to cytokine receptor signalling in HepG2 hepatoma cells, stably transduced with the IL-10 receptor after stimulation with Oncostatin M (OSM), IL-6. Leukaemia Inhibitory Factor (LIF) and IL-10. All cytokines induced STAT3 phosphorylation to approximately the same level, but only OSM, and to a lesser extent IL-6, induced STAT5 phosphorylation. The cytokines also stimulated phosphorylation of ERK in the order of decreasing effectiveness: OSM>IL-6>LIF>IL-10. The same order of activity of the cytokines was observed on inhibition of DNA synthesis and accumulation of cells in the G1-phase of the cell cycle. These processes were accompanied by a decrease in cyclin A expression and CDK2 activity, and enhanced accumulation of p27kip1. The level of p27kip1 mRNA expression was unaffected by the cytokines, and maintenance of the elevated level of p27kip1 occurred independently of de novo protein synthesis. Furthermore, inhibition of proteasomal activity increased the level of p27kip1 in the unstimulated cells to the same level as in OSM-treated cells. Inhibition of MEK activation completely abrogated OSM and IL-6 induced p27kip1 accumulation, while expression of dominant negative STAT5 decreased the OSM and IL-6 mediated inhibition of DNA-synthesis and partially inhibited p27kip1 accumulation.	Rigshosp, Finsen Ctr, Leukemia & Lymphoma Marker Lab L4041, DK-2100 Copenhagen, Denmark; Roswell Pk Canc Inst, Dept Mol & Cell Biol, Buffalo, NY 14263 USA	Rigshospitalet; University of Copenhagen; Roswell Park Cancer Institute	Klausen, P (corresponding author), Rigshosp, Finsen Ctr, Leukemia & Lymphoma Marker Lab L4041, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.			Klausen, Pia/0000-0001-9386-9167	NCI NIH HHS [CA 26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TAKIZAWA H, 1993, CANCER RES, V53, P4175; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Wiznerowicz M, 1998, ADV EXP MED BIOL, V451, P441	33	55	56	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3675	3683		10.1038/sj.onc.1203707	http://dx.doi.org/10.1038/sj.onc.1203707			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951574				2022-12-25	WOS:000088568300014
J	Bennett, BD; Denis, P; Haniu, M; Teplow, DB; Kahn, S; Louis, JC; Citron, M; Vassar, R				Bennett, BD; Denis, P; Haniu, M; Teplow, DB; Kahn, S; Louis, JC; Citron, M; Vassar, R			A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PROCESSING ENZYME; HUMAN PRORENIN; DISEASE; ENDOPROTEOLYSIS; IDENTIFICATION; PURIFICATION; LOCALIZATION; CONVERSION; RECEPTOR	The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta -secretase that cleaves amyloid precursor protein to initiate beta -amyloid formation. As such, RACE is a prime therapeutic target for the treatment of Alzheimer's disease. BACE, like other aspartic proteases, has a propeptide domain that is removed to form the mature enzyme. RACE propeptide cleavage occurs at the sequence RLPR down arrow E, a potential furin recognition motif. Here, we explore the role of furin in BACE propeptide domain processing. BACE propeptide cleavage in cells does not appear to be autocatalytic, since an inactive D93A mutant of BACE is still cleaved appropriately. BACE and furin co-localize within the Golgis apparatus, and propeptide cleavage is inhibited by brefeldin A and monensin, drugs that disrupt trafficking through the Golgi. Treatment of cells with the calcium ionophore A23187, leading to inhibition of calcium-dependent proteases including furin, or transfection with the alpha (1)-antitrypsin variant alpha (1)-PDX, a potent furin inhibitor, dramatically reduces cleavage of the RACE propeptide. Moreover, the BACE propeptide is not processed in the furin-deficient LoVo cell line; however, processing is restored upon furin transfection. Finally, in vitro digestion of recombinant soluble RACE with recombinant furin results in complete cleavage only at the established E46 site. Taken together, our results strongly suggest that furin, or a furin-like proprotein convertase, is responsible for cleaving the RACE propeptide domain to form the mature enzyme.	Amgen Inc, Thousand Oaks, CA 91320 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Amgen; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Vassar, R (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,M-S 29-2-B, Thousand Oaks, CA 91320 USA.							ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Khan AR, 1998, PROTEIN SCI, V7, P815; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Mercure C, 1996, HYPERTENSION, V28, P840, DOI 10.1161/01.HYP.28.5.840; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TAKEDAEZAKI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P352, DOI 10.1006/abbi.1993.1361; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WANG PH, 1991, J BIOL CHEM, V266, P12633; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	32	225	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37712	37717		10.1074/jbc.M005339200	http://dx.doi.org/10.1074/jbc.M005339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956649	hybrid			2022-12-25	WOS:000165618700056
J	Stoeckelhuber, M; Dobner, P; Baumgartner, P; Ehlert, J; Brandt, E; Mentele, R; Adam, D; Engelmann, B				Stoeckelhuber, M; Dobner, P; Baumgartner, P; Ehlert, J; Brandt, E; Mentele, R; Adam, D; Engelmann, B			Stimulation of cellular sphingomyelin import by the chemokine connective tissue-activating peptide III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET BASIC-PROTEIN; LIPID TRANSFER PROTEINS; NECROSIS-FACTOR-ALPHA; NEUTRAL SPHINGOMYELINASE; BETA-THROMBOGLOBULIN; CRYSTAL-STRUCTURE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL	The selective import of phospholipids into cells could be mediated by proteins secreted from the cells into the extracellular compartment. We observed that the supernatants obtained from suspensions of thrombin-activated platelets stimulated the exchange of pyrene (py)labeled sphingomyelin between lipid vesicles in vitro. The proteins with sphingomyelin transfer activity were purified and identified as the chemokine connective tissue-activating peptide III (CTAP-III) and platelet basic protein. Isolated CTAP-III stimulated the exchange of py-sphingomyelin between lipid vesicles but did not affect the translocations of py-labeled phosphatidylcholine and phosphatidylethanolamine. CTAP-III rapidly increased the transfer of py-sphingomyelin from low density lipoproteins into peripheral blood lymphocytes, other immune cells, and fibroblasts, In the presence of heparin, CTAP-III was unable to insert sphingomyelin into the peripheral blood lymphocytes. The activation energy of the py sphingomyelin transfer suggested that the translocation proceeded entirely in a hydrophobic environment, [H-3]Sphingomyelin transferred to the cells by CTAP-III was hydrolyzed to [H-3]ceramide and [H-3]sphingosine after activation with tumor necrosis factor a. The generation of the [H-3]sphingolipid messengers was catalyzed by acid sphingomyelinase. Our results identify CTAP-III as the first mediator of the selective (endocytosis-independent) cellular import of sphingomyelin allowing the paracrine modulation of the sphingolipid signaling.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Forschungszentrum, Abt Immunol & Zellbiol, D-23845 Borstel, Germany; Univ Munich, Chirurg Klin, Abt Klin Chem & Biochem, D-80336 Munich, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany	University of Munich; University of Munich; University of Kiel	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.		Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Andrieu-Abadie N, 1998, BIOCHEM J, V333, P91, DOI 10.1042/bj3330091; Bligh E.G., 1959, CAN J BIOCHEM PHYSIO, V37, P912; BRANDT E, 1992, J IMMUNOL, V149, P1356; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN RE, 1991, SUBCELLULAR BIOCH, V16, P333; BRUCKDORFER KR, 1976, BIOLOGICAL MEMBRANES, V3, P103; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CASTOR CW, 1977, ARTHRITIS RHEUM-US, V20, P859, DOI 10.1002/art.1780200316; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; Ehlert JE, 1998, J IMMUNOL, V161, P4975; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; HOLT JC, 1988, EXP HEMATOL, V16, P303; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Ludwig A, 1997, BLOOD, V90, P4588; Malkowski MG, 1997, J MOL BIOL, V266, P367, DOI 10.1006/jmbi.1996.0796; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATHIAS S, 1968, BIOCHEM J, V335, P3596; Petersen F, 1996, J IMMUNOL, V156, P1954; Petersen F, 1998, J IMMUNOL, V161, P4347; Rajarathnam K, 1997, METHOD ENZYMOL, V287, P89; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; WALTZ A, 1990, J EXP MED, V171, P449; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; WENGER RH, 1989, BLOOD, V73, P1498; WIRTZ KWA, 1968, J BIOL CHEM, V243, P3596; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; YANG YQ, 1994, J BIOL CHEM, V269, P20110	48	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37365	37372		10.1074/jbc.M003709200	http://dx.doi.org/10.1074/jbc.M003709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956644	hybrid			2022-12-25	WOS:000165618700010
J	Detrich, HW; Parker, SK; Williams, RC; Nogales, E; Downing, KH				Detrich, HW; Parker, SK; Williams, RC; Nogales, E; Downing, KH			Cold adaptation of microtubule assembly and dynamics - Structural interpretation of primary sequence changes present in the alpha- and beta-tubulins of antarctic fishes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; LOW-TEMPERATURES; IN-VITRO; NOTOTHENIA-CORIICEPS; BRAIN TUBULIN; RNA ISOLATION; PROTEIN; EVOLUTION; ISOTYPES	The microtubules of Antarctic fishes, unlike those of homeotherms, assemble at very low temperatures (-1.8 degreesC). The adaptations that enhance assembly of these microtubules are intrinsic to the tubulin dimer and reduce its critical concentration for polymerization at 0 degreesC to similar to0.9 mg/ml (Williams, R, C., Jr., Correia, J. J., and DeVries, A. L. (1985) Biochemistry 24, 2790-2798). Here we demonstrate that microtubules formed by pure brain tubulins of Antarctic fishes exhibit slow dynamics at both low (5 degreesC) and high (25 degreesC) temperatures; the rates of polymer growth and shortening and the frequencies of interconversion between these states are small relative to those observed for mammalian microtubules (37 degreesC). To investigate the contribution of tubulin primary sequence variation to the functional properties of the microtubules of Antarctic fishes, we have sequenced brain cDNAs that encode 9 alpha -tubulins and 4 beta -tubulins from the yellowbelly rockcod Notothenia coriiceps and 4 alpha -tubulins and 2 beta -tubulins from the ocellated icefish Chionodraco rastrospinosus. The tubulins of these fishes mere found to contain small sets of unique or rare residue substitutions that mapped to the lateral, interprotofilament surfaces or to the interiors of the alpha- and beta -polypeptides; longitudinal interaction surfaces are not altered in the fish tubulins. Four changes (A278T and S287T in alpha; S280G and A285S in beta) were present in the S7-H9 interprotofilament ''M'' loops of some monomers and would be expected to increase the flexibility of these regions. A fifth lateral substitution specific to the alpha -chain (M302L or M302F) may increase the hydrophobicity of the interprotofilament interaction. Two hydrophobic substitutions (alpha :S187A in helix H5 and beta :Y202F in sheet S6) may act to stabilize the monomers in conformations favorable to polymerization. We propose that cold adaptation of microtubule assembly in Antarctic fishes has occurred in part by evolutionary restructuring of the lateral surfaces and the cores of the tubulin monomers.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Northeastern University; Vanderbilt University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Detrich, HW (corresponding author), Northeastern Univ, Dept Biol, 414 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46033, GM25638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BARGELLONI L, 1994, MOL BIOL EVOL, V11, P854; BILLGER M, 1994, CELL MOTIL CYTOSKEL, V28, P327, DOI 10.1002/cm.970280406; BINDER LI, 1975, P NATL ACAD SCI USA, V72, P1122, DOI 10.1073/pnas.72.3.1122; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE A, 1989, GEOLOGICAL SOC SPECI, V47, P253; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DETRICH HW, 1992, J BIOL CHEM, V267, P18766; Detrich HW, 1997, COMP BIOCHEM PHYS A, V118, P501, DOI 10.1016/S0300-9629(97)00012-1; DETRICH HW, 1986, J BIOL CHEM, V261, P922; DETRICH HW, 1987, J BIOL CHEM, V262, P8360; DETRICH HW, 1993, CELL MOTIL CYTOSKEL, V24, P156, DOI 10.1002/cm.970240303; DETRICH HW, 1989, BIOCHEMISTRY-US, V28, P10085, DOI 10.1021/bi00452a031; DEWITT HH, 1971, ANTARCTIC MAP FOLIO, P1; Eastman J. T, 1993, ANTARCTIC FISH BIOL; EASTMAN JT, 1989, GEOL SOC SPECIAL PUB, V47, P241; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; GAMBLIN TC, 1995, ANAL BIOCHEM, V232, P43; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; Greenwood P. H., 1966, Bulletin of the American Museum of Natural History, V131, P339; HERZOG W, 1977, P NATL ACAD SCI USA, V74, P1860, DOI 10.1073/pnas.74.5.1860; HIMES RH, 1989, BIOCHEMISTRY-US, V28, P5089, DOI 10.1021/bi00438a028; KENNETT JP, 1976, NATURE, V260, P513, DOI 10.1038/260513a0; KENNETT JP, 1977, J GEOPHYS RES-OC ATM, V82, P3843, DOI 10.1029/JC082i027p03843; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luduena RF, 1998, INT REV CYTOL, V178, P207; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MARTIN SR, 1993, BIOPHYS J, V65, P578, DOI 10.1016/S0006-3495(93)81091-9; Modig C, 1999, CELL MOTIL CYTOSKEL, V42, P315, DOI 10.1002/(SICI)1097-0169(1999)42:4<315::AID-CM5>3.0.CO;2-C; Modig C, 2000, BIOCHEM BIOPH RES CO, V269, P787, DOI 10.1006/bbrc.2000.2362; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; Parker SK, 1998, J BIOL CHEM, V273, P34358, DOI 10.1074/jbc.273.51.34358; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REIJO RA, 1994, MOL BIOL CELL, V5, P29, DOI 10.1091/mbc.5.1.29; Richards KL, 2000, MOL BIOL CELL, V11, P1887, DOI 10.1091/mbc.11.5.1887; SAGE CR, 1995, CELL MOTIL CYTOSKEL, V30, P285, DOI 10.1002/cm.970300406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shackleton N.J., 1975, INITIAL REPORTS DEEP, V29, P743, DOI [DOI 10.2973/DSDP.PROC.29.117.1975, 10.2973/DSDP.PROC.29.117.1975]; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; Wallin M, 1997, CELL MOTIL CYTOSKEL, V38, P297, DOI 10.1002/(SICI)1097-0169(1997)38:3<297::AID-CM8>3.0.CO;2-2; Willem S, 1999, EXTREMOPHILES, V3, P221, DOI 10.1007/s007920050119; WILLIAMS RC, 1985, BIOCHEMISTRY-US, V24, P2790, DOI 10.1021/bi00332a029	54	116	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37038	37047		10.1074/jbc.M005699200	http://dx.doi.org/10.1074/jbc.M005699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956651	hybrid			2022-12-25	WOS:000165577700082
J	Christiansen, J; Seefeldt, LC; Dean, DR				Christiansen, J; Seefeldt, LC; Dean, DR			Competitive substrate and inhibitor interactions at the physiologically relevant active site of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; AZOTOBACTER-VINELANDII NITROGENASE; Q-BAND ENDOR; FEMO-COFACTOR; MOFE PROTEIN; STATE NITROGENASE; BINDING; PROGRAM	Nitrogenase catalyzes the MgATP-dependent reduction of dinitrogen gas to ammonia. In addition to the physiological substrate, nitrogenase catalyzes reduction: of a variety of other multiply bonded substrates, such as acetylene, nitrous oxide, and azide, Although Carbon monoxide (CO) is not reduced by nitrogenase, it is a potent inhibitor of all nitrogenase catalyzed substrate: reductions except proton reduction. Here, we present kinetic parameters for an altered Azotobacter vinelandii MoFe protein for which the alpha Gly(69) residue was substituted by serine (Christiansen, J., Cash, V. L., Seefeldt, L. C., and Dean, D. R. (2000) J. Biol. Chem. 275, 11459-11464), For the wild type enzyme, CO and acetylene:are: both noncompetitive inhibitors of dinitrogen reduction. However, for the (alpha Ser(69) MoFe protein both CO and acetylene have become competitive inhibitors of dinitrogen reduction. CO is also converted from a noncompetitive inhibitor to a competitive inhibitor of acetylene, nitrous oxide, and azide reduction. These results are interpreted in terms of a two-site model. Site 1 is a high affinity acetylene-binding site to which CO also binds) but dinitrogen, azide, and nitrous oxide do not bind. This site is the one primarily accessed during typical:acetylene reduction assays. Site 2 is a low affinity acetylene-binding site to which CO, dinitrogen, azide, and nitrous oxide also bind. Site 1 and site 2 are proposed to be located in close proximity within a specific 4Fe-4S face of FeMo cofactor.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA	Utah System of Higher Education; Utah State University; Virginia Polytechnic Institute & State University	Seefeldt, LC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.			Seefeldt, Lance/0000-0002-6457-9504	NIGMS NIH HHS [R01-GM59087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Burgess B. K., 1985, MOLYBDENUM ENZYMES, P161; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Burris R. H., 1979, A treatise on dinitrogen fixation. Inorganic and physical chemistry and biochemistry, P569; Christiansen J, 2000, PROKARYOTIC NITROGEN FIXATION, P101; Christiansen J, 2000, J BIOL CHEM, V275, P11459, DOI 10.1074/jbc.275.15.11459; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; DAVIS LC, 1979, BIOCHEMISTRY-US, V18, P4860, DOI 10.1021/bi00589a014; DILWORTH MJ, 1992, ANAL BIOCHEM, V207, P6, DOI 10.1016/0003-2697(92)90491-O; DILWORTH MJ, 1981, BIOCHEM J, V193, P371; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee HI, 1997, J AM CHEM SOC, V119, P11395, DOI 10.1021/ja971508d; Lee HI, 1997, J AM CHEM SOC, V119, P10121, DOI 10.1021/ja9715096; LIANG JH, 1988, BIOCHEMISTRY-US, V27, P6726, DOI 10.1021/bi00418a013; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Segel IH, 1976, BIOCH CALCULATIONS; Shen J, 1997, BIOCHEMISTRY-US, V36, P4884, DOI 10.1021/bi9628578; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; YATES MG, 1991, BIOL NITROGEN FIXATI, P685	25	55	55	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36104	36107		10.1074/jbc.M004889200	http://dx.doi.org/10.1074/jbc.M004889200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948195	hybrid			2022-12-25	WOS:000165382000066
J	Zilkha-Falb, R; Barzilai, A; Djaldeti, R; Ziv, I; Melamed, E; Shirvan, A				Zilkha-Falb, R; Barzilai, A; Djaldeti, R; Ziv, I; Melamed, E; Shirvan, A			Involvement of T-complex protein-1 delta in dopamine triggered apoptosis in chick embryo sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; CELL-DEATH; MOLECULAR CHAPERONE; EUKARYOTIC CYTOSOL; MESSENGER-RNA; IDENTIFICATION; PROTEIN; SUBUNITS; DISEASE; HSP60	The neurotransmitter dopamine (DA) is capable of inducing: apoptosis in post-mitotic sympathetic neurons via its oxidative metabolites. The differential display method was applied to cultured sympathetic neurons in an effort to detect genes whose expression is transcriptionally regulated during the early stages of DA-triggered apoptosis. One of the up-regulated genes was identified as the chick homologue to T-complex polypeptida-1 delta (TCP-1 delta), a member of the molecular chaperone family of proteins. Each chaperone protein is a complex of seven to nine different subunits. A full-length clone of 1.9 kilobases-was isolated containing an open reading frame of 586 amino acids with a predicted molecular weight of 57,736, Comparison with the mouse TCP-1 delta revealed 78 and 91% homology on the DNA and protein levels, respectively. Northern blot analysis disclosed a steady and Significant increase in mRNA levels of TCP-1 delta after DA administration, reaching a peak between 4 and 9 h and declining thereafter. Induction of the TCP-1 delta protein levels was also observed as a function Of DA treatment, Overexpression of TCP-1 delta in sympathetic neurons accelerated DA-induced apoptosis; inhibition of TCP-1 delta expression in these neurons using antisense technology significantly reduced DA-induced neuronal death. These findings suggest a functional role fdr TCP-1 delta as a positive mediator of DA-induced neuronal apoptosis.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel	Tel Aviv University; Rabin Medical Center; Rabin Medical Center; Tel Aviv University	Barzilai, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chuang DM, 1996, NAT MED, V2, P609, DOI 10.1038/nm0696-609; Creagh EM, 1999, IMMUNOLOGY, V97, P36; Freyaldenhoven TE, 1996, BRAIN RES, V735, P42; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GREENE LA, 1977, DEV BIOL, V58, P96, DOI 10.1016/0012-1606(77)90076-8; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; HARLOW E, 1988, LAB MANUAL, P490; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JONSSON G, 1971, PROGR HISTOCHEM CYTO, V2, P299; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; KOPIN IJ, 1985, PHARMACOL REV, V37, P333; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Kuo YP, 1997, J BACTERIOL, V179, P6318, DOI 10.1128/jb.179.20.6318-6324.1997; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liang P, 1997, J CELL SCI, V110, P1431; LICHTENSTEIGER RM, 1970, PROG HISTOCHEM CYTOC, V1, P185; Lu KP, 1998, BIOCHEM BIOPH RES CO, V253, P828, DOI 10.1006/bbrc.1998.9866; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Offen D, 1997, CELL MOL NEUROBIOL, V17, P289, DOI 10.1023/A:1026390201168; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Punyiczki M, 1998, ANN NY ACAD SCI, V851, P67, DOI 10.1111/j.1749-6632.1998.tb08978.x; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Roobol A, 1999, J BIOL CHEM, V274, P2408, DOI 10.1074/jbc.274.4.2408; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Shirvan A, 1997, J NEUROCHEM, V69, P539; Shirvan A, 1997, J NEURAL TRANSM-SUPP, P67; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wu-Baer Foon, 1996, Journal of Biological Chemistry, V271, P4201, DOI 10.1074/jbc.271.8.4201; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yoda T, 1995, GENE, V166, P249, DOI 10.1016/0378-1119(95)00604-4; Zhang J, 1998, BIOCHEM BIOPH RES CO, V248, P812, DOI 10.1006/bbrc.1998.9044; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	55	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36380	36387		10.1074/jbc.M001692200	http://dx.doi.org/10.1074/jbc.M001692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954701	hybrid			2022-12-25	WOS:000165382000102
J	Dukuzumuremyi, JM; Rosqvist, R; Hallberg, B; Akerstrom, B; Wolf-Watz, H; Schesser, K				Dukuzumuremyi, JM; Rosqvist, R; Hallberg, B; Akerstrom, B; Wolf-Watz, H; Schesser, K			The Yersinia protein kinase A is a host factor inducible RhoA/Rac-binding virulence factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SECRETED PROTEIN; MAMMALIAN-CELLS; FOCAL ADHESIONS; RHO-GTPASES; PSEUDOTUBERCULOSIS; INHIBITION; MEMBRANE; EFFECTOR; PHOSPHORYLATION	The pathogenic yersiniae inject proteins directly into eukaryotic cells that interfere with a number of cellular processes including phagocytosis and inflammatory-associated host responses. One of these injected proteins, the Yersinia protein kinase A (YpktA), has previously been shown to affect the morphology of cultured eukaryotic cells as well as to localize to the plasma membrane following its injection into HeLa cells. Here it is shown that these activities are mediated by separable domains of YpkA. The amino terminus, which contains the kinase domain, is sufficient to localize YpkA to the plasma membrane while the carboxyl terminus of YpkA is required for YpkAs morphological effects. YpkAs carboxyl-terminal region was found to affect the levels of actin-Containing stress fibers as well as block the activation of the GTPase RhoA in Yersinia-infected cells. We show that the carboxyl-terminal region of YpkA, which contains sequences that bear similarity to the RhoA-binding domains of several eukaryotic RhoA-binding kinases, directly interacts with RhoA as well as Rac (but not Cdc42) and displays a slight but measurable binding preference for the GDP-bound form of RhoA, Surprisingly, YpkA binding to RhoA(GDP) affected neither the intrinsic nor guanine nucleotide exchange factor-mediated GDP/GTP exchange reaction suggesting that YpkA controls activated RhoA levels by a mechanism other than by simply blocking guanine nucleotide exchange factor activity. We go on to show that YpkAs kinase activity is neither dependent on nor promoted by its interaction with RhoA and Rac but is, however, entirely dependent on heat-sensitive eukaryotic factors present in HeLa cell extracts and fetal calf serum. Collectively, our data show that YpkA possesses both similarities and differences with the eukaryotic RhoA/Rac-binding kinases and suggest that the yersiniae utilize the Rho GTPases for unique activities during their interaction with eukaryotic cells.	Univ Lund, CMB, Immunol Sect, Dept Cell & Mol Biol, S-22362 Lund, Sweden; Umea Univ, Dept Cell & Mol Biol, SE-90187 Umea, Sweden; Univ Lund, Mol Signalling Sect, Dept Cell & Mol Biol, SE-22100 Lund, Sweden	Lund University; Umea University; Lund University	Schesser, K (corresponding author), Univ Lund, CMB, Immunol Sect, Dept Cell & Mol Biol, Solvegatan 21, S-22362 Lund, Sweden.							AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BEUSCHER HU, 1995, INFECT IMMUN, V63, P1270, DOI 10.1128/IAI.63.4.1270-1277.1995; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; BOLIN I, 1984, INFECT IMMUN, V43, P72; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GALYOV EE, 1994, J BACTERIOL, V176, P4543, DOI 10.1128/JB.176.15.4543-4548.1994; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Henriksson ML, 2000, BIOCHEM J, V349, P697, DOI 10.1042/bj3490697; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; James P, 1996, GENETICS, V144, P1425; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Viprey V, 1998, MOL MICROBIOL, V28, P1381, DOI 10.1046/j.1365-2958.1998.00920.x; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; YANG Y, 1997, SCIENCE, V284, P1322; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	49	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35281	35290		10.1074/jbc.M003009200	http://dx.doi.org/10.1074/jbc.M003009200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950948	hybrid			2022-12-25	WOS:000165422800061
J	Perrier, AL; Cousin, X; Boschetti, N; Haas, R; Chatel, JM; Bon, S; Roberts, WL; Pickett, SR; Massoulie, J; Rosenberry, TL; Krejci, E				Perrier, AL; Cousin, X; Boschetti, N; Haas, R; Chatel, JM; Bon, S; Roberts, WL; Pickett, SR; Massoulie, J; Rosenberry, TL; Krejci, E			Two distinct proteins are associated with tetrameric acetylcholinesterase on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; CAUDATE-NUCLEUS; QUATERNARY ASSOCIATIONS; ATTACHMENT DOMAIN; COLLAGEN TAIL; SUBUNIT; BRAIN; IDENTIFICATION; FORMS; TORPEDO	In mammalian brain, acetylcholinesterase (AChE) exists mostly as a tetramer of 70-kDa catalytic subunits that are linked through disulfide bonds to a hydrophobic subunit P of approximately 20 kDa. To characterize P, we reduced the disulfide bonds in purified bovine brain AChE and sequenced tryptic fragments from bands in the 80-kDa region. We obtained sequences belonging to at least two distinct proteins: the P protein and another protein that was not disulfide-linked to catalytic subunits. Both proteins were recognized in Western blots by antisera raised against specific peptides. We cloned cDNA encoding the second protein in a cDNA-library from bovine substantia nigra and obtained rat and human homologs. We call this protein mCutA because of its homology to a bacterial protein (CutA). We could not demonstrate a direct interaction between mCutA and AChE in vitro in transfected cells. However, in a mouse neuroblastoma cell line that produced membrane-bound AChE as an amphiphilic tetramer, the expression of mCutA antisense mRNA eliminated cell surface AChE and decreased the level of amphiphilic tetramer in cell extracts. mCutA therefore appears necessary for the localization of AChE at the cell surface; it may be part of a multicomponent complex that anchors AChE in membranes, together with the hydrophobic P protein.	Ecole Normale Super, CNRS, UMR 8544, Neurobiol Cellulaire & Mol Lab, F-75230 Paris 05, France; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Mayo Clin & Mayo Grad Sch Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin & Mayo Grad Sch Med, Mol Neurosci Program, Jacksonville, FL 32224 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Case Western Reserve University; Mayo Clinic; Mayo Clinic	Krejci, E (corresponding author), Ecole Normale Super, CNRS, UMR 8544, Neurobiol Cellulaire & Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.		Chatel, Jean-marc/ABB-9837-2020; Cousin, Xavier/E-2542-2013; Perrier, Anselme L/B-2272-2019; Chatel, Jean-Marc/F-9450-2013; Perrier, Anselme/E-3764-2010	Cousin, Xavier/0000-0002-8520-3610; Perrier, Anselme L/0000-0001-7915-1968; 	NINDS NIH HHS [NS-16577] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; Boschetti N, 1996, FEBS LETT, V380, P133, DOI 10.1016/0014-5793(96)00041-5; CHAN SL, 1972, J NEUROCHEM, V19, P2747, DOI 10.1111/j.1471-4159.1972.tb03812.x; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Fernandez HL, 1996, J NEUROCHEM, V66, P1335; FONG ST, 1995, MOL MICROBIOL, V15, P1127, DOI 10.1111/j.1365-2958.1995.tb02286.x; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; HAAS R, 1995, ANAL BIOCHEM, V224, P425, DOI 10.1006/abio.1995.1061; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; Hanner M, 1998, J BIOL CHEM, V273, P16289, DOI 10.1074/jbc.273.26.16289; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LIAO J, 1993, J NEUROCHEM, V61, P1127, DOI 10.1111/j.1471-4159.1993.tb03629.x; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; Navaratnam DS, 2000, J NEUROCHEM, V74, P2146, DOI 10.1046/j.1471-4159.2000.0742146.x; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3550, DOI 10.1021/bi00635a008; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROTUNDO RL, 1987, P NATL ACAD SCI USA, V84, P2063, DOI 10.1073/pnas.84.7.2063; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SORENSEN K, 1982, J NEUROCHEM, V39, P1050, DOI 10.1111/j.1471-4159.1982.tb11496.x; TAKAYUKI N, 1994, Patent No. 1994056895; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WENTHOLD RJ, 1974, J NEUROCHEM, V22, P945, DOI 10.1111/j.1471-4159.1974.tb04320.x	35	38	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34260	34265		10.1074/jbc.M004289200	http://dx.doi.org/10.1074/jbc.M004289200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10954708	hybrid, Green Published			2022-12-25	WOS:000165095300037
J	Xie, X; Rivier, AS; Zakrzewicz, A; Bernimoulin, M; Zeng, XL; Wessel, HP; Schapira, M; Spertini, O				Xie, X; Rivier, AS; Zakrzewicz, A; Bernimoulin, M; Zeng, XL; Wessel, HP; Schapira, M; Spertini, O			Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides - Studies with carboxyl-reduced and sulfated heparin and with trestatin A sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; ROLLING IN-VIVO; SIALYL-LEWIS-X; P-SELECTIN; GLYCOPROTEIN LIGAND-1; DEFICIENT MICE; MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING	Selectins play a major role in the inflammatory reaction by initiating neutrophil attachment to activated vascular endothelium, Some heparin preparations can interact with L- and P-selectin; however, the determinants required for inhibiting selectin-mediated cell adhesion have not yet been characterized. We now report that carboxyl-reduced and sulfated heparin (prepared by chemical modifications of porcine intestinal mucosal heparin leading to the replacement of carboxylates by O-sulfate groups) and trestatin A sulfate (obtained by sulfation of trestatin A, a non-uronic pseudo-nonasaccharide extracted from Streptomyces dimorphogenes) exhibit strong anti-P-selectin and anti-L-selectin activity while lacking antithrombin-mediated anticoagulant activity. In vitro experiments revealed that both compounds inhibited P-selectin- and L-selectin-mediated cell adhesion under laminar flow conditions. Moreover, carboxyl-reduced and sulfated heparin and trestatin A sulfate were also active in vivo, as assessed by experiments showing 1) that microinfusion of trestatin A sulfate reduced by 96% leukocyte rolling along rat mesenteric postcapillary venules and 2) that both compounds inhibited (by 58-81%) neutrophil migration into thioglycollate-inflamed peritoneum of BALB/c mice. These results indicate that nonanticoagulant sulfated saccharides targeted at P-selectin and L-selectin may have therapeutic potential in inflammatory disorders.	Univ Lausanne, Div Hematol, CHU Vaudois, CH-1011 Lausanne, Switzerland; Univ Lausanne, Cent Lab Hematol, CHU Vaudois, CH-1011 Lausanne, Switzerland; Free Univ Berlin, Inst Physiol, D-14195 Berlin, Germany; Hoffmann La Roche Ltd, Dept Pharmaceut Res, CH-4002 Basel, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Free University of Berlin; Roche Holding	Spertini, O (corresponding author), Univ Lausanne, Div Hematol, CHU Vaudois, BH 18-543,Bugnon 46, CH-1011 Lausanne, Switzerland.	olivier.spertini@chuv.hospvd.ch	Wessel, Hans Peter/E-9701-2015	Wessel, Hans Peter/0000-0002-2608-0657				ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; CASTELLOT JJ, 1984, J CELL PHYSIOL, V120, P315, DOI 10.1002/jcp.1041200309; Davenpeck KL, 1997, J IMMUNOL, V159, P1977; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; HARENBERG J, 1983, J CHROMATOGR, V261, P287, DOI 10.1016/S0021-9673(01)87952-8; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Jung U, 1996, AM J PHYSIOL-HEART C, V271, pH2740, DOI 10.1152/ajpheart.1996.271.6.H2740; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kirschfink M, 1997, J IMMUNOL, V158, P1324; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kouretas PC, 1998, ANN THORAC SURG, V66, P1210, DOI 10.1016/S0003-4975(98)00811-X; Kouretas PC, 1999, CIRCULATION, V99, P1062, DOI 10.1161/01.CIR.99.8.1062; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kunkel EJ, 1998, CIRC RES, V82, P30; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEFER AM, 1994, CARDIOVASC RES, V28, P289, DOI 10.1093/cvr/28.3.289; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1995, BLOOD, V85, P3727, DOI 10.1182/blood.V85.12.3727.bloodjournal85123727; LEY K, 1993, BLOOD, V82, P1632; LEY K, 1993, BLOOD, V81, P177; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIHELCIC D, 1994, BLOOD, V84, P2322; MOORE KL, 1994, J BIOL CHEM, V269, P23318; Nagashima M, 1998, CIRCULATION, V98, pII391; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH1865, DOI 10.1152/ajpheart.1998.275.5.H1865; Park JL, 1999, PHARMACOLOGY, V58, P120, DOI 10.1159/000028274; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramos CL, 1997, BLOOD, V89, P3009, DOI 10.1182/blood.V89.8.3009; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Scalia R, 1999, J EXP MED, V189, P931, DOI 10.1084/jem.189.6.931; SPERTINI O, 1991, J IMMUNOL, V147, P942; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; Tang MLK, 1997, J IMMUNOL, V158, P5191; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Toppila S, 1999, AM J PATHOL, V155, P1303, DOI 10.1016/S0002-9440(10)65232-7; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Tu LL, 1996, J IMMUNOL, V157, P3995; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Watanabe N, 1999, J BIOCHEM-TOKYO, V125, P826, DOI 10.1093/oxfordjournals.jbchem.a022355; WEILER JM, 1992, J IMMUNOL, V148, P3210; WESSEL HP, 1990, CARBOHYD RES, V204, P131, DOI 10.1016/0008-6215(90)84028-S; WESSEL HP, 1995, BIOORG MED CHEM LETT, V5, P437, DOI 10.1016/0960-894X(95)00051-T; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yadav SS, 1999, HEPATOLOGY, V29, P1494, DOI 10.1002/hep.510290505; Yanaka K, 1996, J NEUROSURG, V85, P1108, DOI 10.3171/jns.1996.85.6.1108; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	84	72	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34818	34825		10.1074/jbc.M001257200	http://dx.doi.org/10.1074/jbc.M001257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944519	hybrid			2022-12-25	WOS:000165095300109
J	Klemke, M; Pasolli, HA; Kehlenbach, RH; Offermanns, S; Schultz, G; Huttner, WB				Klemke, M; Pasolli, HA; Kehlenbach, RH; Offermanns, S; Schultz, G; Huttner, WB			Characterization of the extra-large G protein alpha-subunit XL alpha s - II. Signal transduction properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; ESCHERICHIA-COLI; ADP-RIBOSYLATION; TERMINAL DOMAIN; RECEPTOR; ACTIVATION; CELLS; RECONSTITUTION; IDENTIFICATION; HETEROTRIMER	In the preceding paper (Pasolli, H. A., Klemke, M., Kehlenbach, R. H., Wang, Y., and Huttner, W. B. (2000) J. Biol. Chem. 275, 33622-33632), we report on the tissue distribution and subcellular localization of XL alphas (extra large alphas), a neuroendocrine-specific, plasma membrane-associated protein consisting of a novel 37-kDa XL domain followed by a 41-kDa alphas domain encoded by exons 2-13 of the G alphas gene. Here, we have studied the signal transduction properties of XL alphas. Like G alphas, XL alphas undergoes a conformational change upon binding of GTP gammaS (guanosine 5'-O-(thio)triphosphate), as revealed by its partial resistance to tryptic digestion, which generated the same fragments as in the case of G alphas. Two approaches were used to analyze XL alphas-beta gamma interactions: (i) ADP-ribosylation by cholera toxin to detect even weak or transient XL alphas-beta gamma interactions and (ii) sucrose density gradient centrifugation to reveal stable heterotrimer formation. The addition of beta gamma subunits resulted in an increased ADP-ribosylation of XL alphas as well as an increased sedimentation rate of XL alphas in sucrose density gradients, indicating that XL alphas interacts with the beta gamma dimer. Surprisingly, however, XL alphas, in contrast to G alphas, was not activated by the beta2-adrenergic receptor upon reconstitution of S49cyc(-) membranes. Similarly, using photoaffinity labeling of pituitary membranes with azidoanilide-GTP, XL alphas was not activated upon stimulation of pituitary adenylyl cyclase-activating polypeptide (PACAP) receptors or other G alphas-coupled receptors known to be present in these membranes, whereas G alphas was. Despite the apparent inability of XL alphas to undergo receptor-mediated activation, XL alphas-GTP gammaS markedly stimulated adenylyl cyclase in S49cyc(-) membranes. Moreover, transfection of PC12 cells with a GTPase-deficient mutant of XL alphas, XL alphas-Q548L, resulted in a massive increase in adenylyl cyclase activity. Our results suggest that in neuroendocrine cells, the two related G proteins, G alphas and XL alphas, exhibit distinct properties with regard to receptor-mediated activation but converge onto the same effector system, adenylyl cyclase.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Huttner, WB (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Huttner, Wieland B./P-4080-2018; Offermanns, Stefan/L-3313-2017	Kehlenbach, Ralph/0000-0003-4920-9916; Offermanns, Stefan/0000-0001-8676-6805; Pasolli, Hilda Amalia/0000-0003-3899-3530				AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; AUDIGIER Y, 1994, METHOD ENZYMOL, V237, P239; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DENKER BM, 1992, J BIOL CHEM, V267, P6272; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; HIDE I, 1992, MOL PHARMACOL, V41, P352; JOHNSON GL, 1978, P NATL ACAD SCI USA, V75, P3113, DOI 10.1073/pnas.75.7.3113; JOHNSON GL, 1978, J BIOL CHEM, V253, P7120; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KEHLENBACH RH, 1995, NATURE, V375, P253, DOI 10.1038/375253b0; KEHLENBACH RH, 1994, NATURE, V372, P804; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; Pasolli HA, 2000, J BIOL CHEM, V275, P33622, DOI 10.1074/jbc.M001335200; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; ROSKOSKI R, 1989, J NEUROCHEM, V53, P1934, DOI 10.1111/j.1471-4159.1989.tb09264.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEST RE, 1985, J BIOL CHEM, V260, P4428	32	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33633	33640		10.1074/jbc.M006594200	http://dx.doi.org/10.1074/jbc.M006594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10931851	hybrid			2022-12-25	WOS:000090104600064
J	Lee, SK; Lee, B; Lee, JW				Lee, SK; Lee, B; Lee, JW			Mutations in retinoid X receptor that impair heterodimerization with specific nuclear hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; THYROID-HORMONE; DIRECT REPEATS; CO-REPRESSOR; GENE; RXR; TRANSACTIVATION; DETERMINANTS; RESISTANCE; BETA	Retinoid X receptor (RXR) serves as a promiscuous heterodimerization partner for many nuclear receptors through the identity box, a 40-amino acid subregion within the ligand binding domain. In this study, we randomly mutated two specific residues within the human RXR alpha identity box region previously identified as important determinants in heterodimerization (i.e. Ala(416) and Arg(421)). interestingly, most of these mutants still retained wild type interactions with thyroid hormone receptor (TR), retinoic acid receptor, peroxisome proliferator-activated receptor alpha, small heterodimer partner, and constitutive androstane receptor. However, RXR-A416D and R421L were specifically impaired for interactions with TR, whereas RXR-A416K lost both TR and retinoic acid receptor interactions. Accordingly, RXR-A416D did not support T3 transactivation in mammalian cells, whereas RXR-A416K was not supportive of transactivation by retinoids or T3. These results provide a basis upon which to further design mutant RXRs highly selective in heterodimerization, potentially useful tools to probe nuclear receptor function in vivo.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University; Chonnam National University	Lee, JW (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr						Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Kakizawa T, 1997, J BIOL CHEM, V272, P23799, DOI 10.1074/jbc.272.38.23799; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Pohlenz J, 1999, J CLIN ENDOCR METAB, V84, P3919, DOI 10.1210/jc.84.11.3919; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; QI JS, 1995, MOL CELL BIOL, V15, P1817; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1994, THYROID, V4, P345, DOI 10.1089/thy.1994.4.345; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; Weiss RE, 1996, J CLIN ENDOCR METAB, V81, P4196, DOI 10.1210/jc.81.12.4196; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	32	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33522	33526		10.1074/jbc.M006418200	http://dx.doi.org/10.1074/jbc.M006418200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10948200	hybrid			2022-12-25	WOS:000090104600049
J	Schlador, ML; Grubbs, RD; Nathanson, NM				Schlador, ML; Grubbs, RD; Nathanson, NM			Multiple topological domains mediate subtype-specific internalization of the M-2 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; DIFFERENTIAL REGULATION; INDEPENDENT MECHANISMS; ADENYLYL-CYCLASE; DOWN-REGULATION; M2; ENDOCYTOSIS; AGONIST	Endocytosis of agonist-activated G protein-coupled receptors (GPCRs) is required for both resensitization and recycling to the cell surface as well as lysosomal degradation. Thus, this process is crucial for regulation of receptor signaling and cellular responsiveness. Although many GPCRs internalize into clathrin-coated vesicles in a dynamin-dependent manner, some receptors, including the M-2 muscarinic acetylcholine receptor (mAChR), can also exhibit dynamin-independent internalization. We have identified five amino acids, located in the sixth and seventh transmembrane domains and the third intracellular loop, that are essential for agonist-induced M-2 mAChR internalization via a dynamin-independent mechanism in JEG-3 choriocarcinoma cells. Substitution of these residues into the M-1 mAChR, which does not internalize in these cells, is sufficient for conversion to the internalization-competent M-2 mAChR phenotype, whereas removal of these residues from the M-2 mAChR blocks internalization. Cotransfection of a dominant-negative isoform of dynamin has no effect on M-2 mAChR internalization. An internalization-incompetent M-2 mutant that lacks a subset of the necessary residues can still internalize via a G protein-coupled receptor kinase-2 and beta-arrestin-dependent pathway. Furthermore, internalization is independent of the signal transduction pathway that is activated. These results identify a novel motif that specifies structural requirements for subtype-specific dynamin-independent internalization of a GPCR.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Wright State Univ, Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA	University of Washington; University of Washington Seattle; Wright State University Dayton	Nathanson, NM (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Haasemann M, 1998, J CELL SCI, V111, P917; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NATHANSON NM, 1992, METHODS NEUROSCI, V9, P116; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Sambrook J., 2002, MOL CLONING LAB MANU; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SWANSON E, 1995, PSSHOW VERSION 4; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23295	23302		10.1074/jbc.M002380200	http://dx.doi.org/10.1074/jbc.M002380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10930431	hybrid			2022-12-25	WOS:000088419400096
J	Li, YH; Marzolo, MP; van Kerkhof, P; Strous, GJ; Bu, GJ				Li, YH; Marzolo, MP; van Kerkhof, P; Strous, GJ; Bu, GJ			The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEDIATED INTERNALIZATION; SORTING SIGNALS; BINDING-PROTEIN; VLDL RECEPTOR; APOE RECEPTOR; CELL-LINE; IN-VIVO; SYSTEM; LRP	All members of the low density lipoprotein (LDL) receptor family contain at least one copy of the NPXY sequence within their cytoplasmic tails. For the LDL receptor, it has been demonstrated that the NPXY motif serves as a signal for rapid endocytosis through coated pits. Thus, it is generally believed that the NPXY sequences function as endocytosis signals for an the LDL receptor family members. The primary aim of this study is to define the endocytosis signal(s) within the cytoplasmic tail of LDL receptor-related protein (LRP). By using LRP minireceptors, which mimic the function and trafficking of full-length endogenous LRP, we demonstrate that the YXXL motif, but not the two NPXY motifs, serves as the dominant signal for LRP endocytosis. We also found that the distal di-leucine motif within the LRP tail contributes to its endocytosis, and its function is independent of the YXXL motif. Although the proximal NPXY motif and the proximal di-leucine motif each play a limited role in LRP endocytosis in the context of the full-length tail, these motifs were functional within the truncated receptor tail. In addition, we show that LRP minireceptor mutants defective in endocytosis signal(s) accumulate at the cell surface and are less efficient in delivery of ligand for degradation.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Univ Chile, Dept Biol, Santiago, Chile; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Universidad de Chile; Utrecht University	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.		Eckhardt, Erik/G-1567-2010	van Kerkhof, Peter/0000-0002-8954-2230	NHLBI NIH HHS [R01 HL52753-07] Funding Source: Medline; NHLBI NIH HHS [HL59150] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li YH, 1997, BIOCHEM BIOPH RES CO, V240, P122, DOI 10.1006/bbrc.1997.7619; MORTON PA, 1990, J BIOL CHEM, V265, P14093; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Strous GJ, 1999, J CELL SCI, V112, P1417; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vilhardt F, 1999, MOL BIOL CELL, V10, P179, DOI 10.1091/mbc.10.1.179; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164; ZAGURSKY RJ, 1995, BIOTECHNIQUES, V18, P504; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	51	236	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17187	17194		10.1074/jbc.M000490200	http://dx.doi.org/10.1074/jbc.M000490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747918	hybrid			2022-12-25	WOS:000087392200111
J	Li, YS; Liu, JL; Zhan, X				Li, YS; Liu, JL; Zhan, X			Tyrosine phosphorylation of cortactin is required for H2O2-mediated injury of human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; OXIDANT INJURY; CROSS-LINKING; STRESS; SRC; RECEPTOR; H2O2; IDENTIFICATION; CYTOSKELETON; LOCOMOTION	Injury of endothelial cells induced by reactive oxygen species plays an important role in the development of early stages of vascular diseases such as hypertension and atherosclerosis. Exposure of human umbilical vein endothelial cells to hydrogen peroxide (H2O2), a common form of reaction oxygen species, triggers a series of intracellular events, including actin cytoskeletal reorganization, cytoplasm shrinkage, membrane blebbing and protein-tyrosine phosphorylation. The effect of H2O2 on endothelial cells is dramatically enhanced when a survival pathway involving extracellular signal-regulated kinase is blocked by PD098059. In contrast, the injury of endothelial cells mediated by H2O2, is inhibited by PP2, a selective specific inhibitor for protein-tyrosine kinase Src. Cortactin, a filamentous actin (F-actin)-associated protein, becomes phosphorylated at tyrosine residues upon stimulation by H2O2 in a manner dependent on the activity of Src. The level of tyrosine phosphorylation of cortactin is correlated with the formation of membrane blebs, Overexpression of wild-type cortactin tagged with green fluorescent protein in endothelial cells via a retroviral vector substantiates the H2O2,-induced morphological changes, whereas overexpression of a green fluorescent protein-cortactin mutant deficient in tyrosine phosphorylation renders endothelial cells resistant to H2O2. The functional role of cortactin in H2O2-mediated shape changes was also evaluated in NIH 3T3 cells. Stable 3T3 transfectants expressing wild-type cortactin in the presence of either H2O2/ PD098059 or H2O2 alone at 200 muM exhibited a dramatic shape change characterized by rounding up or aggregation, However, the similar changes were not detected with cells overexpressing a cortactin mutant deficient in tyrosine phosphorylation. These data demonstrate an important role of the Src/cortactin-dependent actin reorganization in the injury of endothelial cells mediated by reactive oxygen species.	Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA	American Red Cross	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	zhanx@usa.redcross.org	Eckhardt, Erik/G-1567-2010	van Kerkhof, Peter/0000-0002-8954-2230	NHLBI NIH HHS [R01 HL52753-07] Funding Source: Medline; NHLBI NIH HHS [HL59150] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810; Carbajal JM, 1998, BIOCHEM BIOPH RES CO, V249, P461, DOI 10.1006/bbrc.1998.9172; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hagmann J, 1999, J CELL BIOCHEM, V73, P488, DOI 10.1002/(SICI)1097-4644(19990615)73:4<488::AID-JCB7>3.0.CO;2-P; Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C; HINSHAW DB, 1986, AM J PATHOL, V123, P454; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HULL DS, 1984, INVEST OPHTH VIS SCI, V25, P1246; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; KURODA K, 1995, J IMMUNOL, V155, P4427; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEVYTOLEDANO S, 1995, THROMB HAEMOSTASIS, V73, P857; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Natarajan V, 1998, ENVIRON HEALTH PERSP, V106, P1205, DOI 10.2307/3433987; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SCHROR K, 1988, N-S ARCH PHARMACOL, V338, P268; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457	33	236	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37187	37193		10.1074/jbc.M000490200	http://dx.doi.org/10.1074/jbc.M000490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10747918	hybrid			2022-12-25	WOS:000165577700100
